hydrochlorothiazide has been researched along with Hypertension in 3353 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 9.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| "We evaluated whether combined oral hydrochlorothiazide and lisinopril therapy produced superior short-term blood pressure control when compared with nifedipine among postpartum individuals with hypertension requiring pharmacologic treatment." | 9.69 | Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial. ( Amro, F; Blackwell, SC; Chauhan, SP; Fishel Bartal, M; Lawal, D; Pedroza, C; Samuel, J; Sibai, BM, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 9.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension." | 9.30 | Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. ( Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019) |
| "The aim of the study was to establish the effect of valsartan and combination of valsartan and hydrochlorothiazide (HCTZ) on pulse wave velocity (PWV) and central blood pressure (CBP) in a large population of patients with mild to moderate arterial hypertension." | 9.27 | The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…. ( Accetto, R; Barbic Zagar, B; Sirenko, Y; Vincelj, J; Widimsky, J; Yevgenyevna, IC, 2018) |
| "Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ)." | 9.27 | Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Lloyd, E; Weber, MA; White, WB; Wu, J, 2018) |
| "A single-blind randomized clinical study was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 years) were recruited and divided into two groups: amlodipine or hydrochlorothiazide each comprising of 25 subjects." | 9.24 | Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes. ( Agu, PU; Aneke, EI; Azubike, NC; Eze, AA; Nwachukwu, DC; Nwachukwu, NZ; Obika, LF; Okoye, OI, 2017) |
| "The aim of the trial was to establish the efficacy and safety of Valsacor® (valsartan) and Valsacombi® (combination of valsartan and hydrochlorothiazide) in a wide variety of patient populations with mild to moderate arterial hypertension." | 9.24 | The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial. ( Accetto, R; Barbič-Žagar, B; Chazova, IY; Sirenko, Y; Vincelj, J; Widimsky, J, 2017) |
| "The objective of this article is to compare blood pressure (BP)-lowing effects of nitrendipine and hydrochlorothiazide and nitrendipine and metoprolol, and estimate the economic effect of these therapies on hypertension." | 9.24 | Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. ( Chen, Z; Hao, G; Li, Y; Ma, L; Wang, X; Wang, Z; Zhang, L; Zhao, X; Zhu, M, 2017) |
| "The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension." | 9.22 | Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. ( Hirata, K; Ishida, T; Kondo, K; Mori, K; Toh, R; Yasuda, T, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 9.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 9.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 9.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments." | 9.20 | Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. ( Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| " The purpose of this study was to compare the combination treatments of olmesartan/azelnidipine and olmesartan/diuretics on serum bone-related markers in patients with essential hypertension." | 9.19 | Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. ( Amaya, N; Arakawa, K; Fukuoka, Y; Ishida, K; Lee, JD; Morishita, T; Nakano, A; Tada, H; Uzui, H, 2014) |
| "To assess the efficacy and safety of once daily olmesartan medoxomil (OM)/amlodipine besylate (AM)/hydrochlorothiazide (HCTZ) 40/10/25 mg in patients with hypertension not at goal with mono, dual or triple drug therapy." | 9.19 | Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. ( Punzi, HA, 2014) |
| "Evaluate efficacy/safety of olmesartan medoxomil (OM)/amlodipine (AML)/ hydrochlorothiazide (HCTZ) in Hispanic/Latino adults with hypertension." | 9.19 | Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. ( Chrysant, SG; Fernandez, V; Izzo, JL; Kereiakes, DJ; Lee, J; Lewin, AJ; Melino, M; Oparil, S, 2014) |
| "An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension." | 9.19 | Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. ( Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 9.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
| "The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes." | 9.19 | The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. ( Cinteza, M; Ciobanu, AO; Dragoi Galrinho, R; Dulgheru, R; Florescu, M; Granger, C; Magda, S; Vinereanu, D, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 9.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "This prespecified subgroup analysis assessed the efficacy and safety of an olmesartan medoxomil (OM) 40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the 3 components as dual-combination treatments in participants with hypertension who were <65 and ≥ 65 years of age." | 9.17 | Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. ( Fernandez, V; Heyrman, R; Izzo, JL; Lee, J; Lewin, AJ; Melino, M, 2013) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 9.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 9.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "This study was designed to compare the efficacy and safety of 2 ramipril and hydrochlorothiazide (HCTZ) fixed-dose combinations in patients with hypertension stage 1 or 2." | 9.17 | Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM. ( Gomes, MA; Kohlmann, O; Nobre, F; Oigman, W; Pereira-Barretto, AC; Póvoa, R; Rocha, JC, 2013) |
| "To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension." | 9.17 | Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Jia, Y; Lacourcière, Y, 2013) |
| "Patients with grade 2/3 hypertension were randomized to receive telmisartan 40 mg (T40)/hydrochlorothiazide 12." | 9.17 | Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: a subgroup analysis of a randomized, double-blind, active-controlled trial. ( Birgit, V; Gao, PJ; Jeong, MH; Liu, SW; Mattheus, M; Zhu, DL, 2013) |
| "To observe the relationship between changes in renin-angiotensin-aldosterone system (RAAS) activity and blood plasma glucose after administration of hydrochlorothiazide (HCTZ) for one year in patients with hypertension." | 9.17 | The influence of long term hydrochlorothiazide administration on the relationship between renin-angiotensin-aldosterone system activity and plasma glucose in patients with hypertension. ( Du, HJ; Hu, WJ; Shaw, PX; Xiao, X, 2013) |
| " In this study the effects of fixed combination of valsartan with either amlodipine (V-A) or hydrochlorothiazide (V-H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed." | 9.17 | Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. ( Christogiannis, LG; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Tellis, CC; Tselepis, AD, 2013) |
| " The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy." | 9.17 | Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013) |
| "Adding hydrochlorothiazide to olmesartan provides more effective 24-hour blood pressure control versus olmesartan monotherapy in patients with moderate-to-severe hypertension." | 9.16 | Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. ( Girerd, X; Rosenbaum, D, 2012) |
| "Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy." | 9.16 | A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 9.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| " We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12." | 9.16 | Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2012) |
| "The Aichi Research on Combination therapy for Hypertension Study was a multicenter, open-label, prospective observational study that investigated the efficacy and safety of 1-year treatment with the losartan-hydrochlorothiazide (HCTZ) combination tablet in patients with hypertension uncontrolled by either ARB monotherapy or combination therapy with a calcium channel blocker (CCB)." | 9.16 | Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. ( Adachi, M; Kinoshita, A; Koh, N; Maeda, K; Miura, Y; Murohara, T, 2012) |
| "Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is also being developed in fixed-dose combinations with chlorthalidone, a potent, long-acting thiazide-like diuretic." | 9.16 | Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. ( Bakris, GL; Cushman, WC; Kupfer, S; Lloyd, E; Roberts, A; Sica, D; Weber, MA; White, WB, 2012) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "The objective of this study is to examine the effects of thiazide diuretics, plus medium-dose losartan versus maximal-dose angiotensin II receptor blockers (ARBs) on blood pressure (BP) in Japanese patients with uncontrolled hypertension despite the use of medium-dose ARBs." | 9.16 | Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. ( Emoto, N; Hirata, K; Inoue, Y; Ishida, T; Kitagawa, Y; Miki, T; Nishimura, K; Nonaka, H; Suematsu, M; Toh, R, 2012) |
| "To evaluate the clinic and ambulatory blood pressure (BP)-lowering efficacy and safety of an aliskiren/amlodipine/hydrochlorothiazide (HCT) triple combination compared with the component dual combinations, in patients with moderate-to-severe hypertension." | 9.16 | Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. ( Fang, H; Konis, G; Lacourcière, Y; Severin, T; Taddei, S; Zhang, J, 2012) |
| "There are limited data on the results of Russia's use of losartan in clinical practice for the treatment of patients with arterial hypertension (AH)." | 9.16 | [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. ( Glezer, MG; Saĭgitov, RT, 2012) |
| " This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in patients with moderate to severe hypertension." | 9.16 | Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. ( Garcia-Puig, J; Koenig, W; Murray, AV; Patel, S; Uddin, A; Zhang, J, 2012) |
| "The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study." | 9.15 | Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. ( Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset." | 9.15 | 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 9.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 9.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "This multicenter, double-blind, parallel-group, prompted-titration study of patients of at least 70 years of age with systolic hypertension compared the efficacy of valsartan, hydrochlorothiazide, and their combination on ambulatory blood pressure (ABP) reduction." | 9.15 | Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. ( Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, D, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 9.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| "In Korean adult patients with stage II hypertension, we evaluated the efficacy and tolerability of candesartan 16 mg/hydrochlorothiazide (HCT) 12." | 9.15 | Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. ( Ahn, YK; Choi, D; Chung, WJ; Hong, BK; Jeon, DW; Jung, HO; Kim, BO; Kim, D; Kim, SH; Lee, BK; Lee, HY; Lee, SH; Park, CK, 2011) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 9.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "In the 12-month core study, patients with hypertension (mean sitting diastolic BP ≥90 mmHg and <110 mmHg) were randomized in a 3 : 2 ratio to once-daily aliskiren 150 mg or 300 mg." | 9.15 | Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. ( Gradman, AH; Keefe, DL; Kolloch, RE; Lederballe, O; Sica, D; Zhang, J, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "The antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg, both combined with hydrochlorothiazide (HCTZ) 25 mg, were assessed in a pooled analysis from two large trials with identical study designs in patients with stage 1-2 hypertension." | 9.14 | Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. ( Davidai, G; Schumacher, H; White, WB, 2009) |
| "This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction." | 9.14 | Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2009) |
| "Patients with moderate-to-severe hypertension who were inadequately controlled with amlodipine 5 mg/day monotherapy and who subsequently completed 16 weeks of double-blind combination treatment with olmesartan and amlodipine entered a 28-week open-label phase in which all patients initially received olmesartan/amlodipine 40/5 mg/day." | 9.14 | Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. ( Haag, U; Miele, C; Volpe, M, 2009) |
| "To compare the long-term efficacy, safety and tolerability of the direct renin inhibitor aliskiren against the diuretic hydrochlorothiazide (HCTZ) in obese patients with hypertension." | 9.14 | Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. ( Bush, C; Gorostidi, M; Guerediaga, J; Keefe, DL; Philipp, T; Schmieder, RE, 2009) |
| "Data from 4632 men and women (sex ratio 1:1, mean age 54 years) with mild to moderate hypertension, who participated in one of seven randomized, double-blind, placebo-controlled studies with candesartan-HCT for 8-12 weeks, were entered in a common database." | 9.14 | A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. ( Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009) |
| " The primary objective of this randomized, multicenter, comparative, 3-month, open-label study was to evaluate the antihypertensive efficacy of losartan/chlorthalidone versus losartan/hydrochlorothiazide in mild-to-moderate essential hypertension." | 9.14 | A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. ( Basavanagowdappa, H; Chandurkar, N; Kumar, A; Pareek, A; Zawar, S, 2009) |
| "This study was designed to compare the efficacy and tolerability of a new generic formulation of ramipril (test) and the branded formulation of ramipril (reference) to satisfy regulatory requirements for marketing of the generic product for use in Korean patients with mild to moderate hypertension." | 9.14 | Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. ( Chae, IH; Chang, HJ; Cho, YS; Choi, DJ; Chung, WY; Gwak, JJ; Kang, HJ; Kim, HS; Kim, MA; Kim, SH; Kim, YJ; Lee, HY; Park, JS; Youn, TJ; Zo, JH, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 9.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline)." | 9.14 | Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S, 2009) |
| "This prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (HCTZ) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52." | 9.14 | Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. ( Calhoun, DA; Jamerson, KA; Palmer, BF; Purkayastha, D; Samuel, R; Zappe, DH, 2010) |
| "An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies." | 9.14 | Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. ( Calhoun, DA; Crikelair, NA; Glazer, RD; Yen, J, 2009) |
| "The BENIFICIARY (BENIcar safety and efFICacy evaluatIon: An open-label, single-ARm, titration study in patients with hypertension and tYpe 2 diabetes) study was conducted to evaluate the efficacy and safety of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes." | 9.14 | Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. ( Kereiakes, DJ; Neutel, JM; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J, 2010) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 9.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "To evaluate the therapeutic effects of combination administration of hydrochlorothiazide and nitrendipine at low dosage in the treatment of rural hypertension patients." | 9.14 | [Analysis of therapeutic effects of rural patients with hypertension by combination administration of low dosage of hydrochlorothiazide and nitrendipine]. ( Hu, DY; Li, J; Liu, SS; Sun, YX; Sun, ZQ; Xu, CL; Zhang, DY; Zhang, XG; Zhang, XZ; Zheng, LQ, 2010) |
| "To evaluate the safety and tolerability of a titrate-to-goal, olmesartan medoxomil-based therapy in patients with stage 1 hypertension (seated systolic BP [SeSBP] of 140-159 mmHg or seated diastolic BP [SeDBP] of 90-99 mmHg)." | 9.14 | Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. ( Chrysant, SG, 2010) |
| "To determine the efficacy of spironolactone (SPIRO) and hydrochlorothiazide (HCTZ) as monotherapy in older patients with hypertension in blood pressure (BP) control and measures of vascular stiffness." | 9.14 | Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. ( Kithas, PA; Supiano, MA, 2010) |
| "In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly." | 9.14 | Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). ( Ambrosioni, E; Bombelli, M; Cerasola, G; Cipollone, F; Ferri, C; Grazioli, I; Leprotti, C; Mancia, G; Melzi, G; Mugellini, A; Mulè, G; Palasciano, G; Salvetti, A; Trimarco, B, 2010) |
| "An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension." | 9.14 | Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. ( Dubiel, R; Kereiakes, DJ; Maa, JF; Shojaee, A, 2010) |
| "The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension." | 9.14 | Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. ( Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S, 2010) |
| "Secondary, prespecified analysis of a single-arm, open-label study evaluating the efficacy of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes." | 9.14 | Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. ( Kereiakes, DJ; Neutel, J, 2010) |
| " In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ." | 9.14 | 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2010) |
| "As of February 2007, 34,033 patients with essential hypertension and prescribed valsartan alone or with hydrochlorothiazide for BP management were enrolled across 2,125 Canadian sites." | 9.13 | Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4). ( Curnew, GP; Leclerc, JM; Rehel, B; Tardif, JC, 2008) |
| "Initial therapy with valsartan/HCTZ is effective and well tolerated in patients with severe hypertension." | 9.13 | Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. ( Calhoun, DA; Coenen, PD; Glazer, RD; Grosso, A; Pettyjohn, FS; Zhao, Y, 2008) |
| "This study examined the effects of increasing the thiazide diuretic dose in a fixed-dose ARB/diuretic combination in patients with uncontrolled hypertension despite 6 weeks' open-label treatment with the ARB/diuretic combination, telmisartan 80 mg/hydrochlorothiazide 12." | 9.13 | Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. ( Edwards, C; Neldam, S, 2008) |
| "The aim of this trial was to examine the effects of antihypertensive fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension." | 9.13 | Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. ( Alekseevna Andrievskaja, S; Baraković, F; Begović, B; Buksa, M; Eduardovich Bagrij, A; Georgievich Voronkov, L; Gerc, V; Hima, F; Iosifovna Tchelujko, V; Ivanovich Dyaduk, A; Knezević, B; Kusljugić, Z; Lazarević, A; Musić, L; Nikolaevich Polivoda, S; Vataman, E; Vehabović, M, 2008) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 9.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "This double-blind study compared long-term efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren and the angiotensin-converting enzyme inhibitor ramipril alone and combined with hydrochlorothiazide in patients with hypertension." | 9.13 | Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. ( Ali, MA; Andersen, K; Constance, CM; Egan, B; Jin, J; Keefe, DL; Weinberger, MH, 2008) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 9.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 9.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 9.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| " This controlled clinical trial investigated the calcium channel blocker lercanidipine versus hydrochlorothiazide (HCTZ) as add-on in diabetic patients with uncontrolled hypertension on enalapril monotherapy." | 9.12 | Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. ( Agrawal, R; Haller, H; Marx, A, 2006) |
| "Olmesartan medoxomil monotherapy at the recommended dosage of 20 mg once daily is effective and well tolerated in patients with mild-to-moderate hypertension." | 9.12 | Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. ( Böhm, M; Ewald, S, 2006) |
| " The aim of the present study was to determine the effect of hypotensive therapy with a diuretic (hydrochlorothiazide) and an angiotensin-converting enzyme inhibitor (perindopril) on selected oxidative stress parameters in the blood of elderly patients with essential hypertension." | 9.12 | Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension. ( Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Motyl, J; Pawluk, H; Szadujkis-Szadurski, L; Szewczyk-Golec, K, 2006) |
| " Thus, the authors evaluated the antihypertensive effects of telmisartan vs valsartan when combined with hydrochlorothiazide (HCTZ) 25 mg in a large (N=1066), placebo-controlled trial in patients with stage 1 or 2 hypertension." | 9.12 | Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. ( Davidai, G; Koval, SE; Murwin, D; Neutel, JM; Punzi, HA; White, WB, 2006) |
| "To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate essential hypertension." | 9.12 | [The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( Jiang, H; Ke, YN, 2006) |
| "This study investigated an aggressive treatment program for stage 2 systolic hypertension (pretreatment systolic blood pressure [SBP] > or = 160 mm Hg) using the angiotensin receptor blocker olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ)." | 9.12 | Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. ( Dubiel, R; Izzo, JL; Neutel, JM; Silfani, T; Walker, F, 2007) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 9.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| " The present study was aimed at assessing the effects of 1-year administration of the highly vasoselective calcium-channel blocker lercanidipine (10 mg/day) or the diuretic compound hydrochlorothiazide (25 mg/day) on hypertension-related vascular alterations." | 9.12 | Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. ( Cuspidi, C; Grassi, G; Mancia, G; Quarti-Trevano, F; Scopelliti, F; Seravalle, G, 2006) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 9.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "This study evaluated the overall safety profile of combination therapy with amlodipine plus valsartan compared with a combination of lisinopril plus hydrochlorothiazide (HCTZ) in patients with stage 2 hypertension (mean sitting diastolic BP [MSDBP] >or=110 and <120 mm Hg) over the short term (6 weeks)." | 9.12 | Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. ( Chiang, YT; Fomina, I; Gamboa, R; Glazes, R; Kaczor, J; Kargiannis, S; Poldermans, D; Wernsing, M; Yen, J, 2007) |
| "The prevalence of isolated systolic hypertension (ISH) is high in the elderly, and the objective of this study was to compare the antihypertensive efficacy of olmesartan medoxomil with that of nitrendipine in elderly (65-74 years) and very elderly (>/= 75 years) male and female patients with ISH." | 9.12 | Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. ( Heagerty, A; Laeis, P; Mallion, JM, 2007) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 9.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "The aim of this trial was to examine the efficacy and safety of antihypertensive fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension." | 9.12 | Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. ( Andrievskaja, SA; Bagrij, AE; Begović, B; Buksa, M; Dyaduk, AI; Ena, LM; Gerc, V; Hima, F; Ilyash, MG; Knezević, B; Kusljugić, Z; Musić, L; Tchelujko, VI; Vataman, E; Vehabović, A; Vehabović, M; Voronkov, LG, 2007) |
| "To evaluate the efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide in the 12 weeks treatment of mild to moderate essential hypertension in China." | 9.12 | [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China]. ( Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007) |
| "This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension." | 9.11 | Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. ( Punzi, CF; Punzi, HA, 2004) |
| "The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension." | 9.11 | Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). ( Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004) |
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 9.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 9.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "The results of this study suggest that delapril alone or combined with manidipine is well tolerated and as effective as enalapril alone or combined with HCTZ in lowering blood pressure in patients with mild to moderate essential hypertension." | 9.11 | Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. ( Cremonesi, G; Dobovisek, J; Fogari, R; Mugellini, A; Planinc, D, 2004) |
| "This study tested the effects on cardiovascular outcomes of treatments based on nifedipine gastrointestinal therapeutic system (GITS) compared with the diuretic combination co-amilozide in a pre-specified subset of patients with isolated systolic hypertension (ISH) enrolled in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) study." | 9.11 | Effects of nifedipine GITS and diuretics in isolated systolic hypertension--a subanalysis of the INSIGHT study. ( Brown, M; Castaigne, A; De Leeuw, P; Mancia, G; Palmer, C; Rosental, T; Ruilope, L; Wagener, G, 2004) |
| "We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)." | 9.11 | A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005) |
| "The purpose of this pilot study was to test whether carvedilol has a protective effect against oxidative deoxyribonucleic acid (DNA) damage in human hypertension in vivo." | 9.11 | Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study. ( Cheong, SS; Choi, YS; Kim, JU; Lee, J; Lee, M; Song, KI, 2005) |
| "To analyse the control rate of irbesartan/hydrochlorothiazide (HCTZ) combination tablets (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension." | 9.11 | [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. ( Chen, J; Jing, S; Sun, NL, 2005) |
| "This was a study of the effects on sitting systolic BP (SBP)of 2 combinations of valsartan and hydrochlorothiazide (HCTZ) compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension (SBP > or =160 mm Hg and < or =200 mm Hg) with or without other cardiovascular risk factors." | 9.11 | Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri ( Assouline, L; Hebert, D; Khder, Y; Lacourcière, Y; Poirier, L; Rehel, B; Stolt, P, 2005) |
| "To examine the effect of telmisartan or hydrochlorothiazide on the control of urinary albumin excretion (UAE) in patients with isolated systolic hypertension (ISH) unselected for albuminuria in a pre-planned substudy of a large, multicentre, double-blind, placebo-controlled, randomized study." | 9.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| "Combination of olmesartan 20 mg with HCTZ provides significantly better 24-h blood pressure reduction than olmesartan monotherapy in patients with mild-to-moderate hypertension." | 9.11 | Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. ( Laeis, P; Rump, LC; Sellin, L; Stegbauer, J, 2005) |
| " use of fixed dose combinations of enalapril (10 mg) with hydrochlorothiazide (25 mg) (Enap H) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 60 patients with I-II degree high and very high risk hypertension." | 9.11 | [Comparative efficacy of fixed dose combinations of enalapril with hydrochlorothiazide and captopril with hydrochlorothiazide in patients with high risk hypertension]. ( Nedogoda, SV, 2005) |
| "25 mg) (Noliprel forte) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 40 patients with I-II degree high and very high risk hypertension." | 9.11 | [Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension]. ( Brel', UA; Chaliabi, TA; Marchenko, IV; Nedogoda, SV; Prokhorova, EA; Tsoma, VV, 2005) |
| "Monotherapy with indapamide is associated with greater BP reduction and control and response rates than monotherapy with low-dose hydrochlorothiazide and may be an appropriate choice of antihypertensive diuretic therapy in black South African patients with mild to moderate hypertension." | 9.10 | Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension. ( Candy, GP; Ngcezula, T; Radevski, IV; Sareli, P; Valtchanova, ZP; Wald, AM, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension." | 9.10 | Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. ( Rizzoni, D; Rosei, EA, 2003) |
| "To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension." | 9.10 | Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). ( Brown, M; Castaigne, A; de Leeuw, P; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM; Wagener, G, 2003) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 9.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| " We aimed to clarify the effects of losartan and its combination with hydrochlorothiazide on 24-h blood pressures (BPs), central hemodynamics and microcirculation in essential hypertension (EH)." | 9.10 | Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. ( Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003) |
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 9.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| "The antihypertensive efficacy and tolerability of losartan/hydrochlorothiazide (HCTZ) and losartan monotherapy as initial treatment were compared in a double-blind trial in Chinese patients with mild to moderate essential hypertension." | 9.10 | A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. ( Chen, L; Gao, R; Jiang, B; Li, J; Li, Y; Liu, G; Su, L, 2003) |
| "This study compared the risk/benefit profiles of valsartan and amlodipine in elderly patients who have isolated systolic hypertension (ISH)." | 9.10 | A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. ( Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N, 2003) |
| "The goal of this study was to assess the effect of a once-daily fixed combination of irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg on the circadian blood pressure profile in patients with essential hypertension that was not controlled with full-dose single therapy or low-dose combined therapy." | 9.10 | Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. ( Bragulat, E; Calvo, C; Coca, A; de la Sierra, A; Gómez, E; López-Paz, JE; Sierra, C; Sobrino, J, 2003) |
| "Of the 310 randomized outpatients with uncomplicated mild-to-moderate primary hypertension, 259 (133 on valsartan/hydrochlorothiazide, 126 on amlodipine) were eligible for analysis." | 9.10 | Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. ( Bertocchi, F; Carretta, R; Di, SS; Dorigatti, F; Malacco, E; Mann, J; Palatini, P, 2002) |
| "The International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) showed, by means of office blood pressure measurements, that long-term treatment with nifedipine GITS is as effective as diuretics in preventing cardiovascular and cerebrovascular complications." | 9.10 | Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Mancia, G; Omboni, S; Parati, G, 2002) |
| "To assess the antihypertensive efficacy and safety of the novel AT1 receptor antagonist, telmisartan, compared with that of enalapril in elderly patients with mild to moderate hypertension." | 9.09 | Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. ( Hermansson, K; Karlberg, BE; Lins, LE, 1999) |
| "The efficacy of eprosartan, a highly selective, orally-active non-biphenyl, non-tetrazole, type 1 angiotensin II (AT1) receptor antagonist, was compared with that of the angiotensin-converting enzyme (ACE) inhibitor, enalapril, with the addition of hydrochlorothiazide (HCTZ) when necessary in patients with severe hypertension (sitting diastolic blood pressure [sitDBP] > or = 115 mmHg and < or = 125 mmHg)." | 9.09 | Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. ( Sega, R, 1999) |
| "The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 9.09 | Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. ( Guthrie, R; Kassler-Taub, K; Kochar, M; Reeves, RA; Triscari, J, 1999) |
| "The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-blind, placebo-controlled study." | 9.09 | Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Gradman, AH; Hardison, JD; Jones, DW; Levine, JH; Michelson, EL; Oparil, S; Prasad, R; Ripley, E; Zuschke, CA, 1999) |
| "The effectiveness as well as the metabolic effects of the combination of diuretics [hydrochlorothiazide (HCT) vs indapamide (IND)] and perindopril (P) in 14 patients (7 male, 7 female) aged 37-62 years with mild idiopathic hypertension were studied." | 9.09 | Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension. ( Elisaf, MS; Kalaitzidis, R; Katopodis, K; Papagalanis, N; Pappas, H; Siamopoulos, KC; Theodorou, J, 1999) |
| "This randomized, double-blind, placebo-controlled multicenter study was designed to evaluate the efficacy, tolerability, and safety of candesartan cilexetil in a diverse population of patients with severe systemic hypertension (diastolic blood pressure > or =110 mm Hg)." | 9.09 | Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. ( Oparil, S, 1999) |
| "To compare effectiveness, tolerance and safety of two inhibitors of angiotensin-converting enzyme--sinopril (lisinopril) and capoten (captopril)--in outpatient treatment of patients with mild and moderate hypertension." | 9.09 | [Antihypertensive efficacy, tolerance and safety of lisinopril (sinopril) and captopril (capoten) in patients with mild and moderate arterial hypertension]. ( Fitilev, SB; Ol'binskaia, LI; Potapova, GN; Pukhlianko, ME; Sergeeva, TE; Sizova, ZhM; Zheleznykh, EA, 1999) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 9.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 9.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "The objective of this randomised open, active controlled, cross-over study was to evaluate the effect of a fixed combination of verapamil SR/trandolapril compared to captopril/hydrochlorothiazide on serum lipids, lipoproteins, and other metabolic and electrolyte parameters in patients with essential hypertension." | 9.09 | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. ( Cifková, R; Compagnone, D; Hejl, Z; Nakov, R; Novozámská, E; Petrzílková, Z; Poledne, R; Stávek, P, 2000) |
| "In this case-control study in uncomplicated subjects with essential hypertension, losartan and enalapril, alone or combined with a diuretic, effectively and equally lowered office and ambulatory blood pressure and induced a significant reduction in left ventricular mass during long-term treatment." | 9.09 | Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. ( Benemio, G; Bruni, B; Porcellati, C; Reboldi, GP; Sacchi, N; Schillaci, G; Verdecchia, P, 2000) |
| " We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity in high-risk patients with hypertension." | 9.09 | Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM, 2000) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 9.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 9.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 9.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "Hydrochlorothiazide (HCTZ) is commonly used to treat black patients with hypertension." | 9.09 | Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. ( McGill, JB; Reilly, PA, 2001) |
| "This study was undertaken to compare the efficacy and tolerability of telmisartan, a novel antihypertensive agent, and atenolol, a well-established beta-blocker, in the treatment of mild to moderate hypertension." | 9.09 | Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. ( Deichsel, G; Freytag, F; Meinicke, T; Schelling, A, 2001) |
| "Monotherapy with caposide-50 (C-50) was compared to combined therapy C-50 + melatonin in 22 patients with essential hypertension stage II (mean age 60 years)." | 9.09 | [Capozide-50 alone and in combination with melatonin in therapy of hypertension]. ( Akhmetov, KZh; Biiasilov, NS; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 9.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 9.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| "This study was undertaken to identify combinations of telmisartan, a new oral angiotensin II type 1-receptor antagonist, and hydrochlorothiazide (HCTZ) that might provide greater antihypertensive efficacy than monotherapy with either agent in the treatment of mild to moderate hypertension." | 9.09 | Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. ( McGill, JB; Reilly, PA, 2001) |
| "The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in African American adults with mild to moderate hypertension." | 9.09 | Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. ( Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001) |
| "To compare the antihypertensive efficacy and tolerability of a once-daily fixed valsartan/hydrochlorothiazide (HCTZ) combination and amlodipine in subjects with mild-to-moderate hypertension." | 9.09 | A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. ( Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P, 2001) |
| "Fosinopril treatment with 10-40 mg/day was effective in monotherapy of hypertension in 85% patients and was well tolerated." | 9.09 | [Effectiveness and tolerance of fosinopril in the treatment of arterial hypertension of mild and medium severity]. ( Cech, J; Rosolová, H; Sefrna, F, 2001) |
| "To review the efficacy and safety of losartan and hydrochlorothiazide compared to losartan alone, hydrochlorothiazide alone or placebo in the treatment of mild to moderate hypertension in a clinical trial." | 9.08 | Losartan with hydrochlorothiazide in the treatment of hypertension. ( Schoenberger, JA, 1995) |
| "To compare the incidence of cough with the angiotensin II antagonist losartan, the angiotensin converting enzyme inhibitor lisinopril, and hydrochlorothiazide in hypertensive patients with previous angiotensin converting enzyme inhibitor cough." | 9.08 | Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. ( Ramsay, LE; Yeo, WW, 1995) |
| "A multicenter, controlled, open, randomized trial of antihypertensive and life quality (LQ) effects of monotherapy with captopril vs propranolol, hydrochlorothiazide and nifedipine included 345 males aged 35-60 years with mild and moderate hypertension." | 9.08 | [The effect of long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents on the quality of life in patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working ( Broer, M; Duda, SG; Filatova, NP; Metelitsa, VI; Mukhamedzhanova, GF; Ostrovskaia, TP; Siegrist, J; Vygodin, VA, 1995) |
| "5 mg hydrochlorothiazide (HCTZ) with each drug as monotherapy in patients with moderate to severe hypertension." | 9.08 | Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. ( Castellote, E; Ocón, J; Romero, R; Wagner, B, 1995) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 9.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "The efficacy and safety of the novel calcium antagonist Amlodipine (Pfizer Laboratories, New York, New York) and hydrochlorothiazide were evaluated and compared in a randomized, single-blind, parallel group study in black Africans with essential hypertension." | 9.08 | The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. ( Ajayi, AA; Akintomide, AO, 1995) |
| "This two-centre trial compared the efficacy of combinations of enalapril + hydrochlorothiazide (E + H) and captopril + hydrochlorothiazide (C + H) on mild-to-moderate hypertension, after a two-week placebo period, in 26 patients with mild-to-moderate HT (DBP between 95 and 114 mmHg) not controlled by previous treatment, randomized under double-blind conditions into two groups for two 4-week crossover treatment periods separated by a 4-week wash-out period." | 9.08 | [Comparison of the efficacy of enalapril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in mild-to-moderate arterial hypertension by ambulatory measurement of blood pressure]. ( Chanudet, X; Janin, G; Madonna, O; Mayaudon, H, 1995) |
| "25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effectiveness in patients with stage I and stage II (mild to moderate) systemic hypertension; and (2) assess whether this formulation was more effective or possessed a safety advantage over standard monotherapy with bisoprolol or 25 mg of HCTZ." | 9.08 | First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. ( Alemayehu, D; Bryzinski, BS; Burris, JF; Chen, SY; Frishman, WH; Mroczek, WJ; Simon, JS; Weir, MR, 1995) |
| "5 mg of hydrochlorothiazide on glucose metabolism insulin sensitivity and lipids was evaluated in hypertensive non-insulin-dependent diabetes." | 9.08 | The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1995) |
| "The aim of this 3-month double-blind study was to assess the antihypertensive effect and acceptability of perindopril in comparison with enalapril in patients with mild to moderate essential hypertension." | 9.08 | Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. ( Alcocer, L; Bahena, JH; Calvo, C; Campos, C; Lerebours, G; Mickalonis, L; Nacaud, A; Parra Carillo, J; Villahermosa, MT; Weber, C, 1995) |
| "To assess the efficacy and safety of several combinations of benazepril, an angiotensin-converting enzyme inhibitor, and hydrochlorothiazide, as compared with placebo, in the treatment of patients with essential hypertension." | 9.08 | Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. ( Chrysant, SG; Fagan, T; Glazer, R; Kriegman, A, 1996) |
| "To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension." | 9.08 | [Efficacy and tolerability of the captopril and hydrochlorothiazide combination in the treatment of mild to moderate hypertension. Multicenter study]. ( Franco, RJ; Martin, LC; Velasco-Cornejo, IF, 1995) |
| "This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension." | 9.08 | Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. ( Arcuri, KE; Goldberg, AI; MacKay, JH; Snapinn, SM; Sweet, CS, 1996) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 9.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "The purpose of this study was to evaluate the long-term safety and efficacy of moexipril, a non-sulphydryl angiotensin converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in older patients with hypertension." | 9.08 | Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. ( Stimpel, M; White, WB, 1995) |
| "One hundred and thirty five non-smoking hypertensive patients with ACE inhibitor cough confirmed by lisinopril rechallenge and placebo dechallenge were recruited into a double-blind random parallel-group comparison of losartan 50 mg, lisinopril 20 mg and hydrochlorothiazide 25 mg each given once daily for a maximum of 8 weeks." | 9.08 | ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. ( Ramsay, LE; Yeo, WW, 1995) |
| " In the present study, the drug was given in a short-term study in patients with essential hypertension, either as monotherapy or with added hydrochlorothiazide." | 9.08 | Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. ( Aurell, M; Bergbrant, A; Hansson, L; Himmelmann, A; Svensson, A, 1996) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood presssure and renal function were examined in patents with impaired renal function and moderate hypertension." | 9.08 | Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1996) |
| "To assess this possibility, the effects of five months' treatment with either hydrochlorothiazide (HCTZ) or the converting enzyme inhibitor captopril (CAPT) on lipoprotein lipid composition were compared in thirty normolipidaemic patients with essential hypertension (EH)." | 9.08 | Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension. ( Bagdade, JD; Buchanan, WF; Lithell, H; Pollare, T, 1996) |
| "Thirteen patients with mild hypertension (untreated diastolic blood pressure of 95 to 114 mmHg) received, in random order, three successive treatments of four weeks with placebo, spirapril (6 mg daily), or hydrochlorothiazide (HCT2) (24 mg daily)." | 9.08 | Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension. ( Gleerup, G; Mehlsen, J; Petersen, JR; Winther, K, 1996) |
| "This study provides clear evidence of the efficacy of combination therapy with diltiazem and hydrochlorothiazide in the management of patients with hypertension." | 9.08 | Double-blind, parallel, comparative multicentre study of a new combination of diltiazem and hydrochlorothiazide with individual components in patients with mild or moderate hypertension. ( Joy, A; Manning, G; Mathias, CJ; McDonald, CJ; Millar-Craig, MW, 1996) |
| "We conclude that the safety and efficacy of perindopril + indapamide, captopril + hydrochlorothiazide and enalapril + hydrochlorothiazide were equivalent after 8 weeks of treatment in patients with mild to moderate hypertension." | 9.08 | An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. ( Brault, Y; Chastang, C; Di Perri, T; Guez, D; Laurandin, I; Luccioni, R; Redon, J; Sever, PS, 1995) |
| " The objective of the present 32-week double-blind study was to compare the effects of hydrochlorothiazide (HCTZ) and amlodipine (AML) in elderly patients with confirmed ambulatory hypertension." | 9.08 | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. ( Archambault, F; Boileau, G; Cléroux, J; Lacourcière, Y; Lefebvre, J; Poirier, L, 1995) |
| " In this multicenter study, the efficacy and tolerability of perindopril added to continuing hydrochlorothiazide therapy were evaluated in patients with mild to moderate (stage I and II), essential hypertension." | 9.08 | Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. ( Chrysant, SG, 1997) |
| "The present study compares the occurrence of a dry, persistent cough with doses of 80 mg of valsartan, 10 mg of lisinopril, or 25 mg of hydrochlorothiazide in patients with a history of angiotensin-converting enzyme inhibitor-induced cough." | 9.08 | Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. ( Avery, C; Benz, J; Chiang, YT; Gatlin, M; Henry, D; Oshrain, C, 1997) |
| "In this double-blind study, 167 adult out-patients with mild-to-moderate essential hypertension were randomly allocated in equal number to receive valsartan 80 mg or HCTZ 25 mg for 12 weeks." | 9.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. ( Bodin, F; Faust, G; Freytag, F; Hegner, G; Meilenbrock, S; Sullivan, J, 1997) |
| "The blood pressure lowering effect and tolerability of the angiotensin-converting enzyme inhibitor enalapril combined with a very low dose of hydrochlorothiazide (HCTZ) were compared with the selective betareceptor blocker atenolol in patients with mild-to-moderate hypertension." | 9.08 | Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group. ( Dollerup, J; Hotnes, T; Mogensen, CE; Os, I, 1997) |
| "A multiple drug regimen consisting of trandolapril, verapamil and hydrochlorothiazide (HCTZ) were sequentially added in an open-label evaluation of patients with severe hypertension." | 9.08 | The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. ( Novrit, BA; Punzi, HA, 1997) |
| "To compare with placebo the efficacies of once-daily administrations of lacidipine and hydrochlorothiazide separately and in combination to elderly patients with systolic hypertension." | 9.08 | Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. ( Arnolda, LF; Bune, AJ; Chalmers, JP; Harvey, PJ; Molloy, D; Upton, J; Wing, LM, 1997) |
| "We compared, in a prospective double-blind randomized study, the effect of the angiotensin-converting enzyme inhibitor quinapril (QUI) with that of triamterene/hydrochlorothiazide (THCT) treatment on cardiovascular end-organ damage in subjects with untreated isolated systolic hypertension (ISH)." | 9.08 | Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. ( Beltman, FW; de Graeff, PA; Havinga, TK; Heesen, WF; Lie, KI; May, JF; Meyboom-de Jong, B; Schuurman, FH; Smit, AJ; van der Veur, E, 1998) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 9.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| "To compare 8 weeks of monotherapy using either felodipine extended release (ER) or a conventional diuretic therapy, triamterene/hydrochlorothiazide (HCTZ), in elderly patients with systolic hypertension." | 9.08 | Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. ( McClennen, W; Wilson, T, 1998) |
| "Since both agents were equally effective in reducing both SBP and DBP and reserpine is much cheaper than nifedipine, it is recommended that for a developing country like Zimbabwe, the combination of HCT and reserpine at the above doses should be used as the first step to treat mild to moderate hypertension without evidence of end organ damage." | 9.08 | A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. ( Manyemba, J, 1997) |
| "The aims of this study were to examine (1) the cardiac response to exercise in essential hypertension and (2) the effect of long-term enalapril treatment on cardiac reserve." | 9.08 | Divergent cardiac response to exercise in essential hypertension vs. normotension and the effect of enalapril. ( Gadsbøll, N; Giese, J; Høilund-Carlsen, PF; Jensen, BH; Leth, A; Rasmussen, S, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 9.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 9.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "At baseline, normoalbuminuria was found in 74 and 85 patients in the enalapril/hydrochlorothiazide and atenolol groups, respectively." | 9.08 | Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. ( Dollerup, J; Mogensen, CE; Nielsen, B; Nielsen, S, 1998) |
| "One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial." | 9.08 | [Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension]. ( Batlouni, M; Castro, I; Chaves Júnior, Hde C; da Rocha, JC; Feitosa, GS; God, EM; Luna, RL; Maia, LN; Mion, D; Oigman, W; Ortega, KC; Raineri, AM; Ramirez, JA, 1998) |
| "The association of captopril with hydrochlorothiazide is effective with good tolerance, being indicated as a once a day monotherapy for mild and moderate hypertension." | 9.08 | [Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study]. ( Mion Júnior, D; Santello, JL, 1998) |
| "The purpose of this study was to assess the efficacy and tolerability of the angiotensin-converting enzyme inhibitor moexipril alone and in combination with hydrochlorothiazide versus hydrochlorothiazide monotherapy in patients with stage II and III essential hypertension." | 9.08 | Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. ( Koch, B; Stimpel, M; White, WB, 1997) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 9.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "This parallel, double-blind trial was designed to evaluate the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide (HCTZ) in patients with uncomplicated moderate to severe hypertension." | 9.07 | Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. ( Aarsland, T; Dickstein, K; Ferrari, P; Stimpel, M; Todd, M, 1994) |
| "5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old." | 9.07 | Efficacy and tolerability of 5 mg of cilazapril plus 12.5 mg of hydrochlorothiazide in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. ( Bart, T; Gasser, P; Köhler, M; LeBloch, Y; Martina, B; Rhyner, K; Weinbacher, M; Wohler, D, 1994) |
| "To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic)." | 9.07 | Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. ( Brunner, H; Dobbins, TW; Faison, EP; Irwin, R; Karlberg, BE; Lacourcière, Y; Nelson, EB; Ramsay, LE; Snavely, DB, 1994) |
| "The purpose of this study was to assess the long-term efficacy and safety of moexipril, a new angiotensin-converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in patients with hypertension." | 9.07 | Long-term efficacy and safety of moexipril in the treatment of hypertension. ( Fox, AA; Stimpel, M; White, WB, 1994) |
| "6 years) with moderate to severe essential hypertension (DBP between 105 and 116 mmHg) were randomised to eight weeks of double-blind treatment with lisinopril (n = 56) or diltiazem SR (n = 54)." | 9.07 | Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension. ( Anzalone, D; Chrysant, S; Fagan, T; Flamenbaum, W; Kaihlanen, PM; Lueg, M; Weir, MR, 1994) |
| "Patients with a history of an ACE inhibitor-associated dry cough confirmed by a second challenge with lisinopril were enrolled into an international, multicenter, randomly allocated, double-blind, parallel-group, controlled trial, to be treated with losartan, lisinopril or hydrochlorothiazide." | 9.07 | Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. ( Faison, EP; Lacourcière, Y; Lefebvre, J; Nakhle, G; Nelson, EB; Snavely, DB, 1994) |
| "A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol (0, 2." | 9.07 | A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. ( Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994) |
| "5 to 10 mg) once daily was compared with that of hydrochlorothiazide (HCTZ) (25 to 100 mg) daily in 139 patients with mild-to-moderate hypertension." | 9.07 | Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension. ( Adolphe, AB; Brescia, D; Rofman, BA; Vlachakis, ND; Zellner, SR, 1993) |
| "The results of this study indicate that cilazapril, alone or with adjunctive hydrochlorothiazide, is effective and well tolerated as treatment for mild to moderate hypertension." | 9.07 | Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension. ( Chideckel, EW; Stevenson, JG, 1994) |
| "In a double-blind cross-over study, the arterial changes produced by hydrochlorothiazide were compared with those observed after the calcium antagonist felodipine in 16 patients with mild to moderate systemic hypertension." | 9.07 | Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. ( Asmar, RG; Benetos, A; Chaouche-Teyara, K; Raveau-Landon, CM; Safar, ME, 1993) |
| "This study used 24-h ambulatory blood pressure (BP) monitoring to investigate the effectiveness of a novel low-dose combination of bisoprolol/hydrochlorothiazide in adult patients with mild to moderate essential hypertension." | 9.07 | A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. ( Cardenas, P; Lewin, AJ; Lueg, MC; Targum, S, 1993) |
| "To identify appropriate dosages of ramipril and hydrochlorothiazide (HCT) when given in combination once a day for the treatment of essential hypertension." | 9.07 | Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. ( Bauer, B; Bender, N; Breitstadt, A; Cairns, V; Koch, G; Moreadith, C; Phillips, J; Priestley, C; Scholze, J; Vander Elst, E, 1993) |
| "Following a 2-week placebo period, 80 male and female patients with mild to moderate hypertension, aged 50 +/- 10 (mean +/- SD) years, were randomly allocated in a double-blind study to 4 weeks of treatment with the ACE inhibitor lisinopril at 20 mg once a day or the diuretic hydrochlorothiazide at 25 mg once a day." | 9.07 | Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. ( Bray-Desboscs, L; Donner, M; el Ghawi, R; Stoltz, JF; Thibout, E; Zannad, F, 1993) |
| "In an open, multicenter extension of a short-term study, 159 patients with mild to moderate hypertension were treated with either ramipril monotherapy or a combination of ramipril and hydrochlorothiazide for up to 1 year." | 9.07 | Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension--Part 2: An open long-term study of efficacy and safety. ( Bauer, B; Bender, N; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1993) |
| "The effects of the combination of captopril and hydrochlorothiazide at modest doses of plasma lipids, lipoproteins and apolipoproteins were investigated in 139 patients with mild to moderate primary hypertension." | 9.07 | Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension. ( Gagné, C; Lacourcière, Y, 1993) |
| "In an open two-month study with an initial placebo period, the effect of enalapril on glucose tolerance, insulin (IRI) sensitivity and lipid profile was evaluated in 20 patients with mild to moderate essential hypertension." | 9.07 | Metabolic effects of enalapril in the treatment of essential hypertension. ( Baculáková, V; Dzúrik, R; Fedelesová, V; Oksa, A; Spustová, V; Stefíková, K, 1992) |
| "Enalapril was significantly more effective than hydrochlorothiazide in reversing left ventricular hypertrophy without negatively affecting left ventricular function." | 9.07 | Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. ( Dahlöf, B; Hansson, L, 1992) |
| "A double-blind trial of hydrochlorothiazide, timolol and enalapril was carried out in Ethiopians with essential hypertension at the Tikur Anbessa Hospital, Addis Abeba, between 1987 and 1990." | 9.07 | The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. ( Habte, B, 1992) |
| "A controlled, randomized, single-blind, parallel-group study compared the effects of nicardipine hydrochloride/hydrochlorothiazide (HCTZ) with those of pindolol/HCTZ in treatment of essential hypertension." | 9.07 | A comparative study of nicardipine and pindolol as second-line treatments in essential hypertension. ( Huikko, M; Jounela, A; Kanniainen, E; Penttila, O, 1992) |
| "Nitrendipine (bypress) manufactured by Bayer Company in the form of 10 and 20 mg tablets and administered in a dose of 20-40 mg/day turned out an effective antihypertensive remedy in 65% of patients with arterial hypertension largely running a mild course." | 9.07 | [The efficacy of nitrendipine in patients with stable arterial hypertension. The data from a cooperative study in the USSR. The Working Group for the Cooperative Study of Nitrendipine]. ( Metelitsa, VI; Ostrovskaia, TP, 1992) |
| "In a parallel-group multicenter study, the efficacy and safety of combination therapy with ramipril 5 mg plus hydrochlorothiazide 25 mg were compared double-blind with those of 5 mg and 10 mg ramipril monotherapy in patients with mild to moderate hypertension who had not responded adequately to ramipril 5 mg alone." | 9.07 | Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1--A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy. ( Bender, N; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D; Langley, A, 1992) |
| "The effect of 10 oral doses of phenylpropanolamine hydrochloride 25 mg four times a day on blood pressure and heart rate in Korean patients with hypertension controlled by hydrochlorothiazide was studied." | 9.07 | Effect of phenylpropanolamine hydrochloride on blood pressure in Korean patients with hypertension controlled by hydrochlorothiazide. ( Jones, DW; Jung, KM; Kim, HJ; Sands, CD, 1992) |
| "To assess the short-term efficacy and safety of metoprolol in the treatment of hypertension in a large population of older patients." | 9.07 | Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. ( Glasser, S; LaPalio, L; Schork, A; Tifft, C, 1992) |
| "The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients less than or equal to 75 years of age, with borderline to moderate primary hypertension." | 9.07 | Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. ( Beck-Nielsen, H; Faergeman, O; Gall, MA; Gerdes, LU; Hommel, E; Lauritzen, M; Mathiesen, ER; Rossing, P; Skøtt, P; Vølund, A, 1992) |
| " After 1 month of receiving placebo, 165 patients with essential hypertension were randomised to perindopril 4 mg (n = 82) or to 50 mg hydrochlorothiazide + 5 mg amiloride (n = 83)." | 9.07 | A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension. ( Andrejak, M; Carré, A; Deruyttere, M; Gotzen, R; Magometschnigg, D; Santoni, JP; Stumpe, KO, 1991) |
| "The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients with mild to moderate hypertension." | 9.07 | Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1991) |
| "This multicenter study was designed to assess the clinical efficacy and safety of the new once-daily calcium antagonist lacidipine in the treatment of mild-to-moderate essential hypertension." | 9.07 | A double-blind comparison of the efficacy and safety of lacidipine and hydrochlorothiazide in essential hypertension. The Southern Italy Lacidipine Study Group. ( Chiariello, M, 1991) |
| "This 6-week, double-blind, parallel-group study compared the efficacy and safety of the angiotensin converting enzyme (ACE) inhibitors quinapril and captopril as initial monotherapies in patients with severe hypertension (diastolic blood pressure [DBP] greater than or equal to 115 and less than or equal to 130 mm Hg)." | 9.07 | Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril. ( Frishman, WH; Greenberg, S, 1991) |
| "Seventeen patients with mild to moderate hypertension, as indicated by a diastolic blood pressure (DPB) of 95-115 mmHg (WHO I), were treated in a randomized, double-blind, parallel study, with either 5 mg of fosinopril, a new phosphinic acid-containing angiotensin converting enzyme (ACE) inhibitor, or 25 mg of hydrochlorothiazide administered orally once daily for 4 weeks after a 4- to 6-week run-in period of placebo." | 9.07 | Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. ( Backman, R; Forslund, T; Franzén, P, 1991) |
| "Sixteen patients (mean age 68 years) with mild to moderate hypertension were treated with either diltiazem or hydrochlorothiazide for 6 weeks, followed by enalapril for a further 6 weeks." | 9.07 | Effects of hydrochlorothiazide, diltiazem and enalapril on mononuclear cell sodium and magnesium levels in systemic hypertension. ( Abraham, AS; Barchilon, E; Brooks, BA; Eylath, U; Grafstein, Y; Nubani, N; Shemesh, O, 1991) |
| " In a multicenter study, 206 patients with mild to moderate hypertension were randomized to receive benazepril at a dose of 2, 5, 10, or 20 mg, hydrochlorothiazide, 25 mg, or placebo once daily for 4 weeks." | 9.07 | The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. ( Abraham, PA; Bennett, WM; Brachfeld, N; Goodman, RP; Hollifield, JW; Kirkendall, WM; Lasseter, KC; Leon, AS; McKenney, JM; Moser, M, 1991) |
| "A double-blind, parallel-group study was performed to assess the antihypertensive effects and tolerability of felodipine and hydrochlorothiazide (HCT) in black patients with mild to moderate uncomplicated hypertension [entry supine diastolic blood pressure (DBP) of 96-116 mm Hg]." | 9.06 | Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans. ( Leary, WP; Maharaj, B, 1990) |
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 9.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "The efficacy and safety of enalapril and hydrochlorothiazide was investigated in a multicenter study of 81 patients with mild to moderate essential hypertension." | 9.06 | Treatment of hypertension by enalapril and hydrochlorothiazide separately and together: a multicenter study. ( Bernheim, J; Grossman, E; Levi, J; Rathaus, M; Rogel, S; Rosenthal, T; Weinstein, J; Zevin, D, 1990) |
| "We report the results of a randomized, double-blind, parallel group multicentre study in 120 patients with moderate to severe hypertension, comparing two different types of antihypertensive treatment: a) the standard 'triple therapy' with hydrochlorothiazide, propranolol and hydralazine, and b) the combination of an ACE inhibitor, enalapril with hydrochlorothiazide (HCTZ) and methyldopa." | 9.06 | Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. ( Ambrosioni, E; Cinotti, G; Cuspidi, C; Leonetti, G; Malini, PL; Morabito, S; Pessina, A; Rappelli, A; Sampieri, L; Semplicini, A, 1990) |
| "The effect of single dose (50 mg) Captopril (C) used either alone or associated to diuretics (50 mg hydrochlorothiazide -HCTI) in the treatment of mild-moderate essential arterial hypertension was studied in a multicentric study." | 9.06 | [Captopril in single doses in the treatment mild-moderated arterial hypertension]. ( Alcántara Nicolás, J; Cano Cano, E; Cano Cano, R; Contreras, C; García Galvis, JA; García Giralda, L; González Comeche, J; Madrid Conesa, A; Ramos La Torre, F; Sánchez Moreno, J, 1990) |
| "The efficacy of the calcium channel blocker nitrendipine alone and in combination with the beta blocking agent acebutolol or hydrochlorothiazide was tested in 34 patients with moderate essential hypertension." | 9.06 | [Therapy of moderate hypertension with the calcium antagonist nitrendipine in combination with beta receptor blocker or diuretic]. ( Kolloch, R; Müller, HM; Overlack, A; Stumpe, KO, 1990) |
| "A retrospective analysis was made from the charts of 53 patients with mild to moderate essential hypertension to determine the effects of pindolol (PIN) monotherapy, hydrochlorothiazide (HCTZ) added to PIN monotherapy, and PIN added to HCTZ monotherapy on serum lipids and blood pressure." | 9.06 | Long-term effects of pindolol and a thiazide diuretic on plasma lipids and blood pressure in patients with essential hypertension. ( Neusy, AJ; Valeri, A, 1990) |
| "The safety and efficacy of labetalol and hydrochlorothiazide (HCTZ) were compared in a group of 34 patients aged 65 years or older with mild to moderate essential hypertension." | 9.06 | Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring. ( Due, DL; Sirgo, MA; Toth, PD; Vidt, DG; Weidler, DJ, 1990) |
| "This multicenter, factorial-design trial assessed the safety and additive antihypertensive efficacy of a slow-release (SR) formulation of diltiazem hydrochloride given alone or in combination with hydrochlorothiazide for treatment of mild to moderate hypertension." | 9.06 | An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. ( Burris, JF; Cady, WJ; Oparil, S; Stewart, WH; Weber, M; Weir, MR, 1990) |
| "The antihypertensive effect and the influence on lipid metabolism of the alpha-receptor blocking drugs indoramin and prazosin given in combination with hydrochlorothiazide were investigated in patients with mild to moderate essential hypertension." | 9.06 | Comparison of the effect of indoramin and prazosin on blood pressure and lipid profiles in essential hypertension. ( Overlack, A; Stumpe, KO, 1986) |
| "Sixty patients with mild to moderate essential hypertension, uncontrolled with diuretics alone, were evaluated in a double-blind randomized study that compared the effect of indoramin plus hydrochlorothiazide with that of pindolol plus hydrochlorothiazide." | 9.06 | A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension. ( Hartikainen, M; Luomanmäki, K, 1986) |
| "Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months." | 9.06 | Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. ( Balás-Eltes, A; Farsang, C; Fehér, J; Péter, M, 1987) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with hydrochlorothiazie (HCTZ) in 145 patients with mild to moderate hypertension." | 9.06 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1988) |
| "Three hundred thirty-one patients with mild to moderate essential hypertension, 182 males and 149 females with a mean age of 54 (range, 17-87 years), were studied for 1 year in a clinical trial with ramipril, an angiotensin converting enzyme (ACE) inhibitor." | 9.06 | An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. ( Bauer, B; Lorenz, H; Zahlten, R, 1989) |
| "To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension." | 9.06 | Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1989) |
| " with light or moderate essential arterial hypertension were randomized double-blind into two subgroups of 20 subjects each, and submitted to daily combined drug treatment with either captopril 50 mg + hydrochlorothiazide 25 mg (group A) or amiloride 5 mg + hydrochlorothiazide 50 mg (group B)." | 9.06 | [Efficacy and tolerability of captopril-hydrochlorothiazide vs amiloride-hydrochlorothiazide combination in mild to moderate arterial hypertension]. ( Barlattani, M; Filippello, CP; Leone, G; Mammarella, A; Mariani, AR; Paoletti, V, 1989) |
| "5 or 5 mg once daily, was compared with that of hydrochlorothiazide 25 or 50 mg in 169 patients with mild to moderate hypertension." | 9.06 | Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Multicentre Study Group. ( Morgan, TO, 1989) |
| "A double-blind, parallel-group, multicentre study was carried out to compare the effects of once-daily treatment with lisinopril 20 mg and captopril 50 mg in 304 patients with mild to moderate hypertension." | 9.06 | ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group. ( Dallocchio, M; Gosse, P; Gourgon, R, 1989) |
| "Nitrendipine significantly reduces blood pressure with few side effects and no adverse metabolic effects, and offers a reasonable alternative for treating hypertension in the elderly." | 9.06 | Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine. ( Byyny, RL; LoVerde, M; Mitchell, W, 1989) |
| " Thirty-eight patients with mild to moderate essential hypertension (seated diastolic 95-110 mm Hg) were randomized double-blind to treatment with either zofenopril (n = 19) or hydrochlorothiazide (n = 19) over a period of 12 weeks." | 9.06 | Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. ( Lacourcière, Y; Provencher, P, 1989) |
| "This double-blind placebo controlled study investigated the antihypertensive and humoral effects of nifedipine capsules in patients with essential hypertension inadequately controlled (seated diastolic blood pressure greater than or equal to 95 mm Hg) by hydrochlorothiazide (HCTZ) alone." | 9.06 | Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone. ( Abraham, PA; Halstenson, CE; Opsahl, JA, 1989) |
| "The efficacy of captopril 25 mg/day as monotherapy or when necessary, in association with hydrochlorothiazide 25 mg/day, was studied during three months in 472 patients, average age 45 (17-59) years, 51% males with mild (73%) 95 less than PAD less than 104 mmHg, and moderate (27%) arterial hypertension 104 less than PAD less than 114 mmHg." | 9.06 | [Treatment of mild and moderate hypertension with the use of captopril alone or combined with hydrochlorothiazide. A multicenter study]. ( Lion, MF; Lion, R; Nascimento, LO; Pesquisadores, E, 1989) |
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 9.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "The efficacy of a new angiotensin converting enzyme inhibitor, lisinopril, used alone (group A) was compared with lisinopril plus hydrochlorothiazide (group B) in 26 patients with essential hypertension." | 9.06 | Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension. ( Lopez, LM; Mehta, J; Thorman, AD, 1988) |
| "Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderate essential hypertension." | 9.06 | Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. ( Frishman, WH; Goldberger, J; Sherman, D, 1987) |
| " To validate this principle, we studied 38 elderly males (aged greater than or equal to 65 years) with mild to moderate hypertension, comparing hemodynamic responses to and subjective impressions of enalapril or hydrochlorothiazide (HCTZ)." | 9.06 | Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension. ( Gums, JG; Lopez, LM; McCarley, DL; Quay, GP; Stein, GH, 1988) |
| "The antihypertensive efficacy and tolerability of lisinopril, a new long acting angiotensin converting enzyme inhibitor, and nifedipine, in a retard formulation, were compared in a randomized six month double-blind study, in 45 patients with essential hypertension." | 9.06 | Lisinopril in essential hypertension: a six month comparative study with nifedipine. ( Breckenridge, AM; Grimmer, SF; Johnston, GD; Kondowe, G; Meany, B; Richardson, PJ, 1987) |
| "The blood pressure of patients with hypertension who were aged between 60 and 75 years responded equally well to treatment with metoprolol (100 mg a day) or hydrochlorothiazide (25 mg a day) in a double-blind study which employed random allocation to two parallel groups." | 9.06 | Metoprolol or hydrochlorothiazide in patients with hypertension aged 60-75 years. With special reference to assessment of compliance. Hunter Hypertension Research Group. ( , 1986) |
| "9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84." | 9.06 | Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. ( Claessens, J; Nelemans, F; Riesen, W; Streulens, Y; Trost, BN; Weidmann, P, 1987) |
| "The safety and antihypertensive efficacy of PN 200-110 (isradipine), a novel calcium antagonist, are discussed in a preliminary report of double-blind, multicenter, controlled, phase III clinical trials for essential hypertension." | 9.06 | Treatment of essential hypertension with PN 200-110 (isradipine). ( Hamilton, BP, 1987) |
| "The effects of 10 weeks of treatment with isradipine (ISRP), a new dihydropyridine Ca antagonist, was evaluated in a prospective, randomized, double-blind, parallel group, hydrochlorothiazide (HCTZ) controlled study in patients with mild to moderate hypertension." | 9.06 | Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study. ( Gonasun, LM; Goodman, RP; Kirkendal, WM; Kontos, HA; Mohanty, PK; Samuel, P; Wright, JT, 1988) |
| "Patients with moderate to severe essential hypertension (mean untreated supine blood pressure 190/112 mm Hg) received once daily enalapril 20-40 mg or atenolol 50-100 mg, supplemented if required by hydrochlorothiazide 25-100 mg, in a randomized observer-blind trial." | 9.06 | Enalapril in moderate to severe hypertension: a comparison with atenolol. ( Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986) |
| "The hypotensive and hormonal effects of the angiotensin converting enzyme (ACE) inhibitor enalapril (10 mg twice daily) were compared with those of hydrochlorothiazide (25 mg twice daily), with the two drugs in combination and with placebo in 21 patients with essential hypertension." | 9.06 | Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. ( Bune, AJ; Cain, MD; Chalmers, JP; Elliott, JM; Graham, JR; Morris, MJ; Southgate, DO; West, MJ; Wing, LM, 1986) |
| "The effects of lisinopril (MK-521; MSD) and atenolol in the treatment of mild-to-moderate essential hypertension were compared in a double-blind, parallel, controlled study, with 24 patients randomly assigned to lisinopril and 12 to atenolol." | 9.06 | A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension. ( Parag, KB; Seedat, YK, 1987) |
| "One hundred fifty-nine patients with essential hypertension were randomly assigned to take 10 mg of tripamide or 50 mg of hydrochlorothiazide once a day for 12 weeks." | 9.06 | Multicenter private practice comparison of tripamide and hydrochlorothiazide in the treatment of hypertension. ( Adams, RC; Bope, ET; Brewer, SC; Cairns, CB; Fosnaugh, NR; Leidheiser, PC; Platt, CW; Polsley, JS; Romaker, RR; Scarbrough, SD, 1988) |
| "Eighty one patients with uncomplicated hypertension who required additional antihypertensive medication (diastolic Phase V [dBP] greater than or equal to 95 mm Hg) after 4 weeks treatment with hydrochlorothiazide (HCTZ) 25 mg o." | 9.06 | A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension. ( Carle, WK; Latta, D; Lees, CT; Lough, JR; Peers, EM; Pender, J; Richardson, PD; Ross, JR; Sefton, S, 1988) |
| "A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure." | 9.06 | Captopril-related (and -induced?) asthma. ( Popa, V, 1987) |
| "Twenty-nine subjects with mild to moderate essential hypertension completed this 13 week randomized, double-blind, placebo-controlled study comparing the antihypertensive effects of nifedipine GITS (N) (30-60 mg/day), hydrochlorothiazide (H) (25-50 mg/day) and placebo (P)." | 9.06 | Nifedipine GITS and hydrochlorothiazide in essential hypertension. ( Callender, K; Halperin, AK; Hashimoto, F; Jueng, C, 1987) |
| "Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment." | 9.06 | An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. ( Allman, S; Backhouse, CI; Crawford, RJ; Platt, J, 1988) |
| "The efficacy of diltiazem (DTZ) (Tilazem; Parke-Davis) 90-180 mg twice daily was compared with that of hydrochlorothiazide (HCT) 25-50 mg once daily in the monotherapy of mild-to-moderate essential hypertension using a double-blind, double-dummy technique." | 9.06 | Diltiazem compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. ( Leary, WP; van der Byl, K, 1988) |
| "A double-blind multicenter study compared oral acebutolol (n = 182) with hydrochlorothiazide (n = 178) in the treatment of mild to moderate essential hypertension (diastolic blood pressure 95 to 114 mm Hg)." | 9.06 | Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. ( Singh, BN; Thoden, WR; Wahl, J, 1986) |
| "The efficacy and tolerance of the loop diuretic muzolimine were compared with those of a fixed combination of hydrochlorothiazide and amiloride in patients with mild to moderate hypertension." | 9.06 | Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension. ( Clementy, J; Wicker, P, 1986) |
| "5 mg of amiloride with 25 mg of hydrochlorothiazide alone was conducted in 40 elderly patients with mild to moderate hypertension." | 9.06 | Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients. ( Juustila, H; Kinnunen, O; Koistinen, P; Salmela, PI, 1986) |
| "The safety and efficacy of captopril in geriatric patients with mild to moderate hypertension was examined in an eight-week multicenter study of 99 patients." | 9.06 | Low-dose captopril in mild to moderate geriatric hypertension. ( Katz, LA; Kirkendall, WM; Koeppe, PR; Ruoff, GE; Sapir, DG; Tuck, ML, 1986) |
| "The safety and efficacy of sustained-release diltiazem, 120 to 180 mg twice daily, was compared with those of hydrochlorothiazide, 25 to 50 mg twice daily, in 207 patients with mild-to-moderate hypertension (supine diastolic blood pressure [BP] 95 to 114 mm Hg) using a baseline, placebo, parallel-design study protocol." | 9.06 | Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension. ( Frishman, WH; Kirkendall, W; Lunn, J; McCarron, D; Moser, M; Schnaper, H; Smith, LK; Sowers, J; Swartz, SL; Zawada, ET, 1987) |
| "A multicentre controlled trial was carried out to determine the optimal dosage of a 2/1 combination of captopril plus hydrochlorothiazide (HCTZ) in mild hypertension at three doses against placebo in a 6 week double-blind trial." | 9.06 | Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension. ( Childs, M; Lancrenon, S; Languillat, JM; Mattei, A; Millet, B; Schwebig, A; Stephan, A; Steru, D, 1987) |
| "The hypotensive effect of captopril 50 mg twice daily and of captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily was studied in 12 patients with mild to moderate essential hypertension, whose blood pressure was not normalized by captopril 25 mg twice daily alone." | 9.06 | Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension. ( Ardesch, HG; De Bruijn, JH; Meijer, JL; Van Rooijen, JC, 1987) |
| "The purpose of our study was to determine the effects of treatment with hydrochlorothiazide (n = 10) or diltiazem (n = 8) on reflex humoral, hemodynamic, and vascular responses to graded lower body negative pressure in subjects with mild to moderate hypertension (supine diastolic pressure, 95-114 mm Hg)." | 9.06 | Effects of hydrochlorothiazide and diltiazem on reflex vasoconstriction in hypertension. ( Mohanty, PK; Sowers, JR; Thames, MD, 1987) |
| "The effects of 5 mg bendroflumethiazide plus 15 mmol potassium chloride versus 50 mg hydrochlorothiazide plus 5 mg amiloride on blood pressure and serum electrolytes were investigated in a 12-week, open, randomized study with parallel treatment groups." | 9.06 | The effects of bendroflumethiazide/potassium chloride versus hydrochlorothiazide/amiloride on blood pressure and serum electrolytes in patients with mild to moderate hypertension seen in general practice. ( Bredesgaard, P; Johansen, P; Jørgensen, F, 1986) |
| "The effect of a propranolol-hydrochlorothiazide combination tablet was compared with the effects of its two components alone in the twice-daily treatment of mild to moderate essential hypertension (100 to 125 mmHg diastolic blood pressure)." | 9.05 | Propranolol-hydrochlorothiazide combination in essential hypertension. ( Mullane, JF; Stevens, JD, 1982) |
| "Patients with mild to moderate essential hypertension were treated in four centers with hydrochlorothiazide (HCTZ) 25 mg daily for 4 weeks." | 9.05 | Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension. ( Glasser, SP; Leibowitz, DA; McMahon, SG; Ram, CV; Schoenberger, JA; Vanov, SK, 1984) |
| "When added to hydrochlorothiazide, enalapril is as effective as captopril in the treatment of moderate to severe hypertension." | 9.05 | The efficacy and safety of enalapril in moderate to severe essential hypertension. ( Kramsch, DM; Kulaga, SF; Walker, JF, 1984) |
| "Enalapril and enalapril/hydrochlorothiazide are effective in treating mild to moderate essential hypertension, and efficacy has been demonstrated for up to 48 weeks." | 9.05 | A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. ( Vidt, DG, 1984) |
| "Women with previously untreated arterial hypertension have been followed up during ten years of beta-blocker treatment, first for three years with alprenolol and then for seven years with the selective beta1-blocker metoprolol." | 9.05 | Seven years on a selective beta-blocker - metoprolol. A long-term study of women with arterial hypertension. ( Bengtsson, C, 1981) |
| " In 14 patients with mild to moderate essential hypertension, the effects of bucindolol, hydrochlorothiazide and their combination on blood pressure (BP), heart rate (HR) and parameters of the renin-aldosterone system were compared with those after placebo." | 9.05 | Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension. ( Fedder, IL; Ferguson, RK; Rocci, ML; Rotmensch, HH; Soyka, L; Swanson, BN; Vlasses, PH, 1984) |
| "We randomized 495 men with uncomplicated hypertension (diastolic BP, 92 to 109 mm Hg) to one of five captopril regimens at the following dosages: 12." | 9.05 | Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1984) |
| "The effect of low doses (25 mg three times a day) of captopril was evaluated in 16 patients with mild to moderate essential hypertension, previously uncontrolled by hydrochlorothiazide." | 9.05 | Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment. ( Ferguson, RK; Mojaverian, P; Rotmensch, HH; Swanson, BN; Vlasses, PH, 1982) |
| "Eight patients with essential hypertension completed a double-blind, randomly allocated crossover comparison of either 5 or 10 mg enalapril maleate, 50 mg hydrochlorothiazide, or their combination administered once daily during sequential two-week periods." | 9.05 | A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension. ( Ferguson, RK; Irvin, JD; Lee, RB; Swanson, BN; Vlasses, PH, 1982) |
| "Thirty-nine patients were entered into a 12-week, randomized, double-blind, parallel protocol to assess the safety and efficacy of enalapril (MK-421, 10 to 20 mg bid), hydrochlorothiazide (HCTZ, 25 to 50 mg bid), or combined drug therapy (MK-421 + HCTZ) for the treatment of primary hypertension." | 9.05 | Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. ( Bauer, JH; Jones, LB, 1984) |
| "In a multicenter randomized double-blind trial, we compared the antihypertensive effects of 12 weeks of therapy using timolol maleate, a new beta-adrenergic blocking agent, alone and in combination with hydrochlorothiazide, and hydrochlorothiazide alone in 70 outpatients with mild to moderate uncomplicated essential hypertension (61 of whom completed the study)." | 9.05 | A multiclinic double-blind comparison of timolol and hydrochlorothiazide alone and in combination in th e treatment of essential hypertension. ( Hunninghake, DB; Leon, AS, 1983) |
| "The effects on blood pressure, the renin-angiotensin-aldosterone and the kallikrein-kinin systems were investigated in 32 patients with primary hypertension WHO stage I-II treated with captopril." | 9.05 | Captopril, aldosterone and urinary kallikrein in primary hypertension. ( Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1983) |
| "A double-blind trial was carried out in 24 patients with mild hypertension to compare the efficacy and tolerability of indapamide with that of a standard thiazide diuretic, hydrochlorothiazide." | 9.05 | Indapamide in the treatment of essential arterial hypertension: results of a controlled study. ( Plante, GE; Robillard, C, 1983) |
| "An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker." | 9.05 | Indoramin as second step therapy in the management of benign essential hypertension. ( Gherardi, S; Manzoli, U; Mazzari, M; Montenero, AS; Schiavoni, G, 1983) |
| "The antihypertensive effects of oral labetalol, a new alpha- and beta-adrenergic blocking agent, and metoprolol, a relatively beta1 selective adrenergic blocker, were evaluated in 91 patients with mild to moderate hypertension (standing diastolic blood pressure of 90 to 115 mm Hg) in a double-blind parallel group multicenter clinical trial." | 9.05 | Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. ( Frishman, WH; Johnson, BF; Michelson, EL; Poland, MP, 1983) |
| "Labetalol, a new alpha- and beta-adrenergic blocking agent, was administered to 57 patients with essential hypertension whose standing diastolic blood pressure was 105 to 120 mm Hg after three and four weeks of placebo therapy and greater than 90 mm Hg after three to four weeks of therapy with hydrochlorothiazide, 25 mg twice a day." | 9.05 | Step II treatment with labetalol for essential hypertension. ( Bloomfield, SS; Gantt, CL; Lucas, CP; Medakovic, M; Poland, MP, 1983) |
| "We measured the first dosage effect and the long-term effect of lofexidine on blood pressure, heart rate, plasma catecholamines, and their major metabolites in 16 patients with primary hypertension who were receiving 50 mg hydrochlorothiazide twice a day while they were recumbent and upright and during isometric handgrip contraction." | 9.05 | Hemodynamic effect of lofexidine with a diuretic in hypertension. ( Alexander, N; Maronde, RF; Velasquez, M; Vlachakis, ND, 1983) |
| "Twenty-five patients with essential hypertension were randomly assigned to treatment with either captopril or atenolol." | 9.05 | Captopril or atenolol in essential hypertension. ( Andrén, L; Hansson, L; Svensson, A, 1983) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 119 patients with a diastolic pressure (DP) between 95 and 120 mmHg were randomised and treated either with 50 mg hydrochlorothiazide (n = 59) or 100 mg atenolol (n = 60)." | 9.05 | Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1984) |
| "One thousand four hundred and two patients with essential hypertension were treated by their general practitioners for 3 months with one tablet daily consisting of 200 mg acebutolol plus 12." | 9.05 | Treatment of essential hypertension with beta-blocker plus diuretic: a study of 1402 patients treated by general practitioners with acebutolol 200 mg combined with hydrochlorothiazide 12.5 mg ('Secadrex') once daily for 3 months. ( Baker, PG; McGowan, GK, 1984) |
| "The metabolic effects of piretanide (2 x 6 mg daily) were compared with those of hydrochlorothiazide, in doses of 2 x 25 mg or 2 x 50 mg daily, in a double-blind study consisting of three parallel groups totalling 15 patients with uncomplicated essential hypertension." | 9.05 | The effects of piretanide on catecholamine metabolism, plasma renin activity and serum aldosterone: a double-blind pilot comparison against hydrochlorothiazide in patients with essential hypertension. ( Bückert, C; Kirsten, R; Verho, M, 1984) |
| "41 patients (35 males and 6 females) with moderate hypertension were treated with a combination of methyldopa/hydrochlorothiazide/amiloride (M/HCT/A)." | 9.05 | [A combination of methyldopa, hydrochlorothiazide and amiloride in the treatment of essential hypertension]. ( Bolzano, K; Krempler, F; Sandhofer, F, 1984) |
| "Seventy-four patients from four short-term studies of captopril in mild-moderate essential hypertension continued in a cooperative long-term efficacy and tolerance program." | 9.05 | A long-term follow-up of patients with essential hypertension treated with captopril. ( Asplund, J; Aurell, M; Conradsson, T; Delin, K; Forslund, T; Frithz, G; Fyhrquist, F; Herlitz, H; Karlberg, B; Ohman, P, 1984) |
| "The results of an investigation to assess the clinical responses of patients with mild to moderate hypertension to a new combination formulation containing 75 mg triamterene and 50 mg hydrochlorothiazide are reported." | 9.05 | Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension. ( Blume, CD; Clark, T; Williams, RL, 1984) |
| "Seventeen patients with mild to moderate essential hypertension and controlled with antihypertensive drugs were treated with xipamid (40 mg) or hydrochlorothiazide (50 mg) in a double-blind cross-over randomized trial design." | 9.05 | A randomized double-blind clinical trial of xipamid and hydrochlorothiazide in essential hypertension. ( Kumar, S; Pandhi, P; Sharma, PL; Wahi, PL, 1984) |
| "Twenty patients with mild to moderate hypertension participated in a single-blind crossover comparison of treatment with 25 mg hydrochlorothiazide plus 50 mg triamterene and 50 mg hydrochlorothiazide plus 5 mg amiloride in once-daily dosage regimens." | 9.05 | Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension. ( Dean, S; Spencer-Mills, L, 1984) |
| "The efficacy and acceptability of a single half-tablet daily of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide was assessed in a study of 35 patients suffering from mild to moderate essential hypertension." | 9.05 | The efficacy and acceptability of the combination of acebutolol and hydrochlorothiazide in the treatment of essential hypertension. ( Sugeng, I; Suryaatmaja, M; Sutandar, H; Utama, H, 1984) |
| "The biochemical disturbance produced by thiazide diuretics and by amiloride during treatment of moderate hypertension were compared." | 9.05 | Comparison of thiazides and amiloride in treatment of moderate hypertension. ( Thomas, JP; Thomson, WH, 1983) |
| "5 mg) and timolol (10 mg) in the treatment of patients with mild to moderate hypertension, and to determine if there were any differences in response when medication was taken before or after food." | 9.05 | Efficacy and tolerance of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol, taken before or after food, in the treatment of hypertension. ( Arr, SM; Wight, L; Woollard, ML; Young, JH, 1984) |
| "A study of the effects of pindolol on potassium homeostasis was undertaken in 25 patients (19 women, 6 men) with essential hypertension." | 9.05 | Effect of pindolol on potassium homeostasis in patients with essential hypertension. ( Garrett, BN; Kaplan, NM; Ram, CV, 1984) |
| "We compared hydrochlorothiazide and propranolol hydrochloride for monotherapy of hypertension by a double-blind study of 683 men who were titrated to less than 90 mm Hg diastolic BP or to 640 mg of propranolol or 200 mg of hydrochlorothiazide." | 9.05 | Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. ( , 1982) |
| "1 A placebo-controlled, randomised double-blind comparison of captopril 25 mg three times a day, hydrochlorothiazide 15 mg three times a day, and the combination was conducted in 207 patients with essential hypertension with supine diastolic blood pressures of 92-110 mm Hg." | 9.05 | Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. ( Weinberger, MH, 1982) |
| "1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol." | 9.05 | Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. ( Andrén, L; Asplund, J; Hansson, L; Karlberg, B; Ohman, P; Svensson, A, 1982) |
| "An open study was carried out in 641 patients with mild to moderate hypertension seen in general practice to assess the effectiveness of treatment with a timolol/hydrochlorothiazide/amiloride preparation compared with cyclopenthiazide/potassium." | 9.05 | Comparison of timolol/hydrochlorothiazide/amiloride ('Moducren') with cyclopenthiazide/potassium in mild to moderate hypertension. ( Arr, S; Parry, EE; Young, J, 1982) |
| "Twenty-four patients with moderate to severe hypertension were treated for four weeks with captopril, an oral inhibitor of angiotensin-converting enzyme." | 9.05 | Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. ( Banks, RA; Bayliss, J; Jones, JC; MacGregor, GA; Markandu, ND; Roulston, JE, 1982) |
| "The effects of amiloride hydrochloride on thiazide-induced hypokalemia were evaluated." | 9.05 | Response of thiazide-induced hypokalemia to amiloride. ( Chan, L; Maronde, RF; Milgrom, M; Vlachakis, ND, 1983) |
| "The effect of a single dose of timolol, hydrochlorothiazide and amiloride in fixed combination (Moducren; MSD) in patients with mild to moderate essential hypertension was tested in an open study during 1978." | 9.05 | Combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A multicentre trial. ( Burns, DG; Pittaway, D, 1980) |
| "The effect of a single daily dose of timolol, hydrochlorothiazide and amiloride hydrochloride in fixed combination (Moducren; MDS) in patients with mild to moderate essential hypertension was tested during 1978 in an open study covering 10 weeks per patient." | 9.05 | Evaluation of a fixed combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A long-term multicentre trial. ( Pittaway, D, 1980) |
| "Fifty-five patients with primary hypertension, World Health Organization (WHO) stages I and II, were randomly allocated to a 9-mo multicenter, controlled, double-blind, crossover study with timolol, a nonselective beta adrenoceptor blocker, and hydrochlorothiazide combined with the potassium-sparing drug amiloride (AHCT)." | 9.05 | Timolol and hydrochlorothiazide-amiloride in primary hypertension. ( Andersson, PO; Henning, R; Karlberg, BE; Lins, LE; Nilsson, OR; Odar-Cederlöf, I; Tolagen, K, 1980) |
| "A randomized, double-blind, multicenter study comparing amiloride hydrochloride, amiloride hydrochloride plus hydrochlorothiazide, and hydrochlorothiazide was conducted in 179 patients with mild to moderate essential hypertension (diastolic pressure, 95 to 115 mm Hg)." | 9.05 | Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group. ( , 1981) |
| "Captopril (SQ 14 225), an orally active inhibitor of angiotensin converting enzyme, was evaluated in the treatment of primary (essential) hypertension in a placebo-controlled long-term study." | 9.05 | Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. A controlled long-term study with reference to initial plasma renin activity. ( Asplund, J; Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1981) |
| "Twenty-nine patients with mild to severe essential hypertension were treated with titrated doses of xipamide, before or after treatment with 50 and , if necessary, 100 mg hydrochlorothiazide in a 13- to 25-week open crossover study." | 9.05 | Hypotensive effects of xipamide in essential hypertension. Crossover comparison with hydrochlorothiazide. ( Pasquel, R; Simon, A; Tribble, PW, 1981) |
| "1 Captopril, an orally active angiotensin converting enzyme inhibitor, was compared with hydrochlorothiazide (HCT) in the treatment of mild and moderate essential hypertension." | 9.05 | Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor. ( el-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1981) |
| "In a double-blind study comprising 31 patients with essential hypertension not satisfactorily controlled on hydrochlorothiazide 25 mg o." | 9.05 | Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension. ( Dafgärd, T; Forsén, B; Lindahl, T, 1981) |
| "The efficacy, safety, and tolerability of lofexidine, a centrally acting imidazoline derivative, were compared to that of clonidine in a randomized double-blind trial in 28 patients with moderate essential hypertension." | 9.05 | Lofexidine and clonidine in moderate essential hypertension. ( Dustan, HP; Oparil, S; Smith, LR; Wilkins, LH; Winternitz, SR, 1981) |
| "The efficacy and acceptability of single daily doses of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide were assessed in an open study of 30 patients suffering from mild to moderate essential hypertension." | 9.05 | Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension. ( Harvard, CW; Nievel, JG, 1981) |
| "Captopril, a newly developed, orally active inhibitor of the angiotensin-converting enzyme, and hydrochlorothiazide were given alone or in combination to 39 patients with mild or moderate essential hypertension." | 9.05 | Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension. ( Aberg, H; Frithz, G; Mörlin, C, 1981) |
| "In a double-blind crossover study, the antihypertensive effect of hydrochlorothiazide alone and in combination with the beta blocker acebutolol was assessed in 18 patients suffering from mild to moderate hypertension." | 9.05 | Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension. ( Belleau, LJ; Brossard, JJ; Lebel, M, 1982) |
| "The antihypertensive effect of propranolol, in fixed combinations with two dosages of triamteren and hydrochlorothiazide (Dociteren), was evaluated in a double-blind test on 19 patients with uncomplicated essential hypertension." | 9.05 | [Propranolol, triamteren and hydrochlorothiazide in fixed combinations in the treatment of hypertension (author's transl)]. ( Herrmann, JM; Hiemstra, S; Hoenig, B, 1981) |
| "Forty patients completed a double-blind parallel group study comparing furosemide (FUR) and hydrochlorothiazide (HCT) when added to a stable dose of beta blocker in the treatment of mild to moderate hypertension." | 9.05 | Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension. ( Dombey, SL; Lawrence, J; Vander Elst, E; Vlassak, W, 1981) |
| "In a multicenter, double-blind comparison of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension (diastolic blood pressure, 95 to 114 mm Hg) in 182 and 178 patients, respectively, each agent reduced systolic and diastolic pressures to a similar significant degree: acebutolol, 15." | 9.05 | Comparison of acebutolol and hydrochlorothiazide in essential hypertension. ( Lewis, JE, 1985) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 9.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo." | 9.05 | Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension. ( Lucas, CP; Morledge, JH; Tessman, DK, 1985) |
| "This open randomised parallel trial compared the antihypertensive efficacy of enalapril and atenolol given alone once a day or with hydrochlorothiazide in 20 patients with moderate to severe hypertension." | 9.05 | Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension. ( Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985) |
| "The acute effects of 25 mg captopril on blood pressure, heart rate, components of the renin-angiotensin system and blood concentration of bradykinin were followed in a single-blind placebo study of untreated (group A, n = 15) and thiazide-treated (group B, n = 13) patients with mild or moderate essential hypertension." | 9.05 | Converting enzyme inhibition in mild and moderate essential hypertension. I. Acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril. ( Damkjaer Nielsen, M; Giese, J; Ibsen, H; Leth, A; Nielsen, F; Rasmussen, S, 1985) |
| "Effects of once-daily doses of 50 mg triamterene with 25 mg hydrochlorothiazide and 5 mg amiloride with 50 mg hydrochlorothiazide were compared in a randomized, multicenter study of 84 adult subjects with mild to moderate hypertension (diastolic blood pressure 90 to 114 mm Hg)." | 9.05 | Blood pressure lowering and potassium conservation by triamterene-hydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension. ( Brachfeld, J; Itskovitz, H; Lunn, JA; Maxwell, MH; Moser, M; Zawada, ET, 1985) |
| "The efficacy of captopril treatment was compared with that of propranolol in a single-blind crossover study in 14 patients with essential hypertension uncontrolled on diuretic alone." | 9.05 | Crossover comparison of captopril and propranolol as step 2 agents in hypertension. ( Ferguson, RK; Koplin, JR; Oren, A; Riley, LJ; Rotmensch, HH; Tadros, SS; Vlasses, PH, 1985) |
| "Control of hypertension (ie, reduction of blood pressure to less than or equal to 160/90 mmHg) in 40 mild to moderate hypertensives not responding adequately to hydrochlorothiazide was achieved by the addition of guanfacine (once daily) or methyldopa (twice daily) in a 16-week, double-blind, parallel-group trial." | 9.05 | Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension. ( Bouchard, S; Brookman, S; Farooki, MS; Farsky, K; Lalonde, Y, 1985) |
| "Fifty patients with mild or moderate essential hypertension were randomized (double-blindly) to treatment with either captopril (n = 26) or atenolol (n = 24)." | 9.05 | Long-term effects of captopril and atenolol in essential hypertension. ( Andrén, L; Hansson, L; Karlberg, BE; Nilsson, OR; Ohman, P; Svensson, A, 1985) |
| "Previous studies have shown that labetalol, a new alpha- and beta-adrenergic antagonist, is relatively safe for the treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD)." | 9.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. ( Burford, JG; Chetty, K; Conrad, SA; George, RB; Hudson, LD; Light, RW; Manocha, K, 1985) |
| "The safety and efficacy of sustained-release diltiazem 120 to 180 mg, 2 times a day, were compared with hydrochlorothiazide 25 to 50 mg, 2 times a day, and the combination of diltiazem and hydrochlorothiazide in 56 patients with mild to moderate hypertension (supine diastolic blood pressure between 95 and 114 mm Hg) using a placebo-controlled, parallel-design protocol." | 9.05 | Diuretics versus calcium-channel blockers in systemic hypertension: a preliminary multicenter experience with hydrochlorothiazide and sustained-release diltiazem. ( Frishman, WH; Kirkendall, W; Lunn, J; McCarron, D; Moser, M; Schnaper, H; Smith, LK; Sowers, J; Swartz, S; Zawada, E, 1985) |
| "In a randomised double blind study in patients with mild to moderate hypertension, piretanide 6 mg once and twice daily significantly reduced both supine and erect blood pressure." | 9.05 | Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: a double-blind comparison with a combination of hydrochlorothiazide and amiloride. ( Dols, W; Rangoonwala, B; Verho, M, 1985) |
| "To evaluate the efficacy of acebutolol, 400-600 mg/day in elderly hypertensive patients, and to compare it with hydrochlorothiazide 25-50 mg/day, 45 patients with mild-moderate uncomplicated hypertension were treated for 6 weeks in a multicentre, single-blind, randomized, crossover trial." | 9.05 | Multicentre comparison of the antihypertensive effect of acebutolol and hydrochlorothiazide in uncomplicated mild-moderate hypertension in the elderly. ( Airoldi, G; Cagianelli, MA; Cinotti, G; Cortese, R; Diamanti, G; Giuntoli, F; Lucchini, M; Pedrinelli, R; Pettinà, G; Salvetti, A, 1985) |
| "A randomized, double-blind, cross-over study comparing 50 mg hydrochlorothiazide plus 5 mg amiloride (HCTZ/A) with 50 mg hydrochlorothiazide plus 26 mmol potassium chloride (HCTZ/K) was conducted in 18 patients with mild essential hypertension (diastolic pressure 90-105 mmHg)." | 9.05 | Hydrochlorothiazide and potassium chloride in comparison with hydrochlorothiazide and amiloride in the treatment of mild hypertension. ( Andersen, B; Hardarson, T; Ragnarsson, J; Snorrason, SP, 1985) |
| "The antihypertensive mechanisms of single and combined therapy with a beta-adrenergic antagonist (propranolol) and a vasodilator (hydralazine) were investigated in 9 patients with moderately severe hypertension, who were receiving maintenance diuretic (hydrochlorothiazide) treatment." | 9.05 | Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action. ( Blomqvist, CG; Gaffney, FA; Graham, RM; Mulvihill-Wilson, J; Neal, WW; Pettinger, WA, 1985) |
| "Prazosin hydrochloride, a new antihypertensive agent, is said to be of mild-to-moderate potency when used as a sole agent in mild-to-moderate hypertension and when used in conjunction with other agents in severe hypertension." | 9.04 | Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension. ( Schirger, A; Sheps, SG, 1977) |
| "Captopril, an orally active angiotensin-converting enzyme (ACE) inhibitor, was effective in the long-term reduction of blood-pressure in 17 patients with essential hypertension." | 9.04 | Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. ( Johnston, CI; Matthews, PG; McGrath, BP; Millar, JA, 1979) |
| "The influence of hydrochlorothiazide (HCT) treatment on the plasma levels of triglycerides, total cholesterol and high density lipoprotein cholesterol (HDL-cholesterol) was studied in 10 patients with essential hypertension." | 9.04 | Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. ( Gevers Leuven, JA; van Brummelen, P; van Gent, CM, 1979) |
| " Captopril was shown to be as effective as hydrochlorothiazide in lowering the blood pressure in patients with moderately severe essential hypertension." | 9.04 | Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension. ( Johnston, CI; Matthews, PG; McGrath, BP, 1979) |
| "In a series of 450 patients with mild essential hypertension, propranolol alone (P), propranolol plus hydrochlorothiazide (P+T), propranolol plus hydralazine (P+H), and propranolol plus hydrochlorothiazide plus hydralazine (P+T+H) were compared to reserpine plus hydrochlorothiazide (R+T)." | 9.04 | Propranolol in the treatment of essential hypertension. ( , 1977) |
| "Eighteen patients with diastolic hypertension (100 to 120 mm Hg), in addition to propranolol, 160 mg daily, and hydrochlorothiazide, 100 mg daily, received progressively increased doses of either minoxidil or placebo in a double-blind crossover study." | 9.04 | Effect of minoxidil on blood pressure and hemodynamics in severe hypertension. ( Bryan, RK; Hoobler, SW; Purdy, JM; Rosenzweig, J; Weller, JM, 1977) |
| "Twenty-four patients with mild to moderate hypertension were treated for up to 60 weeks with hydrochlorothiazide and either placebo, timolol, or timolol and amiloride." | 9.04 | Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension. ( Castenfors, H, 1977) |
| "The effect on hypertension of hydrochlorothiazide 100 mg daily plus timolol 20-60 mg daily versus hydrochlorothiazide plus placebo and of hydrochlorothiazide plus timolol plus hydralazine 40-200 mg daily versus hydrochlorothiazide plus placebo plus hydralazine was evaluated in a double-blind, randomized, crossover study in 38 patients with hypertension." | 9.04 | Effect of timolol plus hydrochlorothiazide plus hydralazine on essential hypertension. ( Alimadadian, H; Aronow, WS; Burwell, D; Greenfield, R; Mann, W; Van Herick, R, 1978) |
| "In a double-blind study, 28 patients having mild to moderate essential hypertension were randomly assigned to a 6-week regimen of ticrynafen, hydrochlorothiazide, or placebo." | 9.04 | Ticrynafen and hydrochlorothiazide in hypertension. ( Beg, M; Okun, R, 1978) |
| "In a single blind crossover trial, spironolactone (50 mg twice a day), and hydrochlorothiazide (50 mg twice a day) were equally effective hypotensive agents in 16 patients with untreated essential hypertension." | 9.04 | A comparison between spironolactone and hydrochlorothiazide with and without alpha-methyldopa in the treatment of hypertension. ( Friedman, A; Johnston, CI; Suthers, MB; Walter, NM, 1978) |
| " A double-blind comparison of the effect of tienylic acid and hydrochlorothiazide on blood pressure was made in patients with moderate hypertension." | 9.04 | A double-blind comparison of the effects of hydrochlorothiazide and tienylic acid (a diuretic with uricosuric properties) in hypertension. ( Gillies, AH; Morgan, TO, 1978) |
| "A double-blind study of hydrochlorothiazide and spironolactone, alone and in combination, was conducted in 49 patients with mild-to-moderate essential hypertension after a 4-wk placebo washout period." | 9.04 | Hydrochlorothiazide and spironolactone in hypertension. ( Schrijver, G; Weinberger, MH, 1979) |
| "The efficacy of prazosin was assessed in 21 patients with essential hypertension who failed to respond adequately to a combination of methyldopa and hydrochlorothiazide." | 9.04 | Prazosin in hypertension with and without methyldopa. ( Itskovitz, HD; Kochar, MS; Zeller, JR, 1979) |
| "1 The antihypertensive effect and tolerability of MK-196 (10 mg and 15 mg daily) was compared to hydrochlorothiazide (HCT; 50 mg daily) in a 4-week multiclinic, double-blind study involving 42 patients with mild to moderate, essential hypertension." | 9.04 | A double-blind comparison of a novel indanone diuretic (MK-196) with hydrochlorothiazide in the treatment of essential hypertension. ( Bolognese, J; Cirillo, VJ; Enenkel, W; Lund-Johansen, P; Lutterbeck, PM; Moerlin, C; Tempero, KF; Vedin, JA; Vorburger, C; Wilhelmsson, CE, 1979) |
| "The effects of a single dose and of two equally divided doses of timolol were compared in a double-blind trial in 15 patients with essential hypertension." | 9.04 | Comparison of effectiveness of timolol administered once a day and twice a day in the control of blood pressure in essential hypertension. ( Bobik, A; Jennings, G; Korner, P, 1979) |
| "In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d)." | 9.04 | [Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)]. ( Ebel, H; Klaus, D; Lübke, H; Witzgall, H; Zehner, J, 1978) |
| "The relative benefits and risks of reserpine and guanethidine were compared in patients with thiazide-treated mild to moderate hypertension (diastolic pressure 95-115 mm Hg)." | 9.04 | Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine. ( Ferguson, RK; Nies, AS; Rothenberg, RJ, 1976) |
| "Debrisoquine, an antihypertensive agent, was compared with methyldopa in a double-blind trial in the treatment of hypertension in 20 patients." | 9.04 | A comparison of debrisoquine and methyldopa in hypertension. ( Pörsti, P, 1976) |
| "In a multicentre, double-blind, between-patient study the hypotensive effect of oxprenolol was investigated in 329 patients with mild to moderate hypertension." | 9.04 | Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study. ( Colombi, A; Motolese, M; Muiesan, G, 1975) |
| " The anti-hypertensive actions of timolol and hydrochlorothiazide were analysed in a double-blind 2 x 2 factorial trial in twenty patients with essential hypertension." | 9.04 | Quantitative effects of timolol and hydrochlorothiazide on blood pressure, heart rate and plasma renin activity: results of a double-blind factorial trial in patients with essential hypertension. ( Bune, AJ; Chalmers, JP; England, JD; Fletcher, PJ; Horvath, JS; Korner, PI; Tiller, DJ, 1976) |
| " The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a double-blind, controlled study in fifty-four patients with mild to moderate essential hypertension." | 9.04 | Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study. ( Agabiti-Rosei, E; Alicandri, C; Ambrosioni, E; Magnani, B; Miele, N; Muiesan, G, 1976) |
| "In 36 patients with essential hypertension the action and side effects of hydrochlorothiazide (25 mg/d), hydrochlorothiazide-triamterene (25 and 50 mg/d) and propranolol (160 mg/d) were investigated." | 9.04 | [Triamterene in the treatment of hypertension with hydrochlorothiazide and propranolol (author's transl)]. ( Düsing, R; Kramer, HJ, 1977) |
| "The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg)." | 8.98 | Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies. ( Bader, G; Brunel, P; Dayi, H; Sison, J; Vega, RMR, 2018) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 8.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| " The trials compared the metabolic effects of hydrochlorothiazide (HCTZ) versus no- HCTZ hypertension treatment in type 2 diabetes." | 8.93 | Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. ( Chang, HC; Chen, HY; Ku, CT; Lin, JJ, 2016) |
| "Aliskiren, a direct renin inhibitor, is effective for reducing blood pressure (BP) in patients with hypertension when combined with amlodipine or hydrochlorothiazide (HCTZ)." | 8.90 | Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. ( Cao, C; Dong, X; Gao, D; Liu, Y; Niu, X; Song, A; Wei, J; Yan, R, 2014) |
| "The article gives an overview of the risk factors for hypertension and the appropriate indication for using a fixed combination of telmisartan and hydrochlorothiazide." | 8.89 | [A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension]. ( Slíva, J; Vítovec, J, 2013) |
| " The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan medoxomil or angiotensin receptor blockers or renin angiotensin system or chlorthalidone and hypertension." | 8.89 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? ( Barrios, V; Escobar, C, 2013) |
| "This review summarizes the current data on the triple combination therapy of aliskiren with amlodipine and hydrochlorothiazide, and discusses the clinical use of single pill triple combination of aliskiren, amlodipine and hydrochlorothiazide in the treatment of hypertension and associated cardiovascular conditions." | 8.88 | The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. ( Huan, Y; Townsend, R, 2012) |
| "The combination of telmisartan/HCTZ is an effective and well-tolerated treatment option for patients with hypertension." | 8.86 | Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. ( Kjeldsen, SE; Mancia, G; Schmieder, RE; Unger, T, 2010) |
| "This was a systematic assessment of the efficacy and safety of telmisartan and valsartan for the management of blood pressure (BP) in patients with essential hypertension." | 8.86 | A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. ( Lin, S; Shi, H; Zheng, Z, 2010) |
| "Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infarction." | 8.85 | Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. ( Malacco, E; Omboni, S; Parati, G, 2009) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 8.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| "Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension." | 8.84 | Olmesartan medoxomil: a review of its use in the management of hypertension. ( McCormack, PL; Scott, LJ, 2008) |
| "Fixed-dose combinations of telmisartan and hydrochlorothiazide (HCTZ) [Micardis Plus, Micardis HCT, PritorPlus] are available in many countries for the treatment of patients with essential hypertension." | 8.84 | Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. ( Plosker, GL; White, WB, 2008) |
| "Telmisartan (Micardis, Pritor), a highly selective angiotensin II (AII) type 1 (AT1) receptor antagonist, is approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents." | 8.83 | Telmisartan: a review of its use in the management of hypertension. ( Battershill, AJ; Scott, LJ, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "Kinzalkomb marketed in Belgium by Bayer is a fixed combination of telmisartan 80 mg and hydrochlorothiazide 125 mg for the treatment of hypertension." | 8.82 | [Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension]. ( Kulbertus, H, 2003) |
| "Telmisartan is an angiotensin-II receptor blocker that has demonstrated efficacy in the reduction of blood pressure in patients with hypertension." | 8.82 | Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. ( Schmieder, RE, 2004) |
| " We also review outcome trials in patients with hypertension (such as LIFE [Losartan Intervention For Endpoint reduction in hypertension], VALUE [Valsartan Antihypertensive Long-term Use Evaluation], and SCOPE [Study on COgnition and Prognosis in the Elderly]), in which losartan, valsartan, and candesartan cilexetil were used in combination with hydrochlorothiazide." | 8.82 | Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. ( Beckey, K; Gleim, GW; Høieggen, A; Kjeldsen, SE; Oparil, S; Os, I, 2005) |
| "The combination of valsartan [an angiotensin II type 1 (AT(1)) receptor blocker] and hydrochlorothiazide (a thiazide diuretic), administered once daily, has been evaluated in the treatment of patients with hypertension in clinical trials ranging in duration from 8 weeks to 3 years." | 8.81 | Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. ( Faulds, DM; Wellington, K, 2002) |
| "The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension." | 8.81 | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. ( Jarvis, B; Melian, EB, 2002) |
| "Multiclinic controlled studies have shown that enalapril alone 10 to 40 mg/day orally is effective in lowering blood pressure in patients with essential hypertension." | 8.77 | Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. ( Davies, RO; Moncloa, F; Sromovsky, JA; Walker, JF, 1985) |
| "Hydrochlorothiazide is the most common thiazide diuretic used for hypertension in the US." | 8.31 | Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999-2018. ( Cheung, BMY; Li, HL; Lin, Z; Tsoi, MF, 2023) |
| "This study aimed to evaluate whether exercise training could contribute to a better modulation of the neurohumoral mechanisms linked to the pathophysiology of arterial hypertension (AH) in postmenopausal hypertensive rats treated with hydrochlorothiazide (HCTZ)." | 8.31 | Concurrent exercise training induces additional benefits to hydrochlorothiazide: Evidence for an improvement of autonomic control and oxidative stress in a model of hypertension and postmenopause. ( Bernardes, N; da Silva Dias, D; De Angelis, K; Ferreira, MJ; Irigoyen, MC; Santos Ferreira Silva, MPD, 2023) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 8.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "Thiazides are one of the most common antihypertensive drugs used for hypertension treatment and hydrochlorothiazide (HCTZ) is the most frequently used diuretic for hypertension treatment." | 8.02 | Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension. ( Araos, P; Jalil, JE; Mondaca-Ruff, D; Mora, IG; Novoa, UF; Ocaranza, MP; Yañez, CE, 2021) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 8.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits." | 7.96 | Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. ( Chen, R; Hripcsak, G; Krumholz, HM; Madigan, D; Pratt, N; Ryan, PB; Schuemie, MJ; Shea, S; Suchard, MA; You, SC, 2020) |
| "An innovative pediatric oral formulation of hydrochlorothiazide (HCT) (2mg/mL), endowed with improved bioavailability and sustained release properties and suitable for the hypertension treatment in pediatric patients, was developed by combining the drug-cyclodextrin complexation and the incorporation of the complex into Solid Lipid Nanoparticles (SLN)." | 7.85 | Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. ( Cirri, M; Di Cesare Mannelli, L; Ghelardini, C; Maestrelli, F; Mennini, N; Mura, P, 2017) |
| "Triamterene, because of its potassium-sparing properties, is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension." | 7.83 | Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension. ( Decker, BS; Eckert, GJ; Erdel, BL; He, Z; Hellman, RN; Murray, MD; Oates, JA; Pratt, JH; Tu, W, 2016) |
| "The aim of this study was to investigate the effects of aliskiren on vascular function and endothelial progenitor cells (EPCs) in patients with type 2 diabetes and essential hypertension." | 7.81 | Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. ( Dimitriadis, GD; Ikonomidis, I; Kotsifaki, EE; Lambadiari, VA; Lekakis, JP; Maratou, EP; Markakis, KP; Mazioti, MC; Raptis, AE; Raptis, SA; Tsirogianni, AG; Vlahakos, DV; Voumvourakis, AN, 2015) |
| "To compare adherence and persistence associated with nebivolol and hydrochlorothiazide (HCTZ) as add-on hypertension treatments." | 7.80 | Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension. ( Chen, S; Diener, M; Farooqui, S; Macaulay, D; Swallow, E; Wu, EQ; Xie, J, 2014) |
| "EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia." | 7.80 | Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. ( Abid, R; Afzal, J; Iktidar, S; Khan, W; Kumar, K; Maheshwary, N; Moin, N; Qadir, M; Sakrani, J; Siddiqi, A, 2014) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 7.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 7.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| "This study assessed the risk of new-onset gout following prescribing of hydrochlorothiazide (HCTZ) compared with chlorthalidone (CTD)." | 7.80 | Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. ( Nair, KV; Saseen, JJ; Wilson, L, 2014) |
| "Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension." | 7.79 | Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. ( Dhalla, IA; Gomes, T; Hellings, C; Juurlink, DN; Mamdani, MM; Nagge, J; Persaud, N; Yao, Z, 2013) |
| "In patients with hypertension already taking HCTZ, switching to chlorthalidone seems to further reduce systolic and diastolic blood pressures without any clinically significant changes in renal function or electrolyte levels." | 7.79 | Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. ( Brenner, AC; Brenner, MJ; Matthews, KA, 2013) |
| "Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension." | 7.78 | Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. ( Inoue, A; Mitsutake, R; Miura, S; Saku, K; Shiga, Y; Uehara, Y, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 7.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 7.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "The aim of the study was to estimate the efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in terms of alteration of the diurnal AP profile and heart rhythm in patients with essential hypertension (EH)." | 7.78 | [The efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in patients with essential hypertension]. ( Kakhramanova, SM, 2012) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 7.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| "The clinical course of losartan potassium/hydrochlorothiazide (Preminent(®))-induced hyponatremia has not been described." | 7.77 | Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients. ( Fujiki, K; Kinoshita, H; Kobayashi, K; Koga, N; Tomiyama, J; Yaguramaki, T; Yakushiji, F; Yasuda, M, 2011) |
| " We hypothesized that intergenic polymorphisms between OAT1 and OAT3 might be associated with adult hypertension and the antihypertensive effects of hydrochlorothiazide (HCTZ)." | 7.77 | Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. ( Chen, JZ; Fan, XH; Han, YF; Hui, R; Li, WJ; Sun, K; Wang, XJ; Wang, YB; Xue, H; Zhang, WL; Zhen, YS; Zhou, X, 2011) |
| "A total of 7567 Asian patients who were diagnosed with stage 1 or stage 2 essential hypertension and who took at least one dose of valsartan/hydrochlorothiazide single pill combination were included in the statistical analyses." | 7.77 | Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. ( Dongre, N; Lai, WT; Park, JE; Wang, J, 2011) |
| "Two WNK1 and one WNK4 polymorphisms were detected in two independent populations (n = 1592 and 602) for association with hypertension, and in two clinical trials of hydrochlorothiazide treatment (n = 542 and 274) for association with diuretics response." | 7.77 | Hypertension associated polymorphisms in WNK1/WNK4 are not associated with hydrochlorothiazide response. ( Chen, J; Fan, X; Han, Y; Hui, R; Sun, K; Wang, X; Wang, Y; Zhang, W; Zhen, Y, 2011) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 7.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| " In this case report, significant hyperkalemia and hyponatremia related to telmisartan/hydrochlorothiazide use in a diabetic patient has been presented." | 7.76 | Significant hyperkalemia and hyponatremia secondary to telmisartan/hydrochlorothiazide treatment. ( Cakir, M, 2010) |
| " We report the case of a 48-year-old woman with the presence of a sharply demarcated erythema of the inferior cervical folds, axillae, and gluteal area that started 4 days after the introduction of telmisartan-hydrochlorothiazide administration to treat hypertension." | 7.76 | Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. ( Azevedo, F; Cunha, AP; Ferreira, O; Morais, P; Mota, A, 2010) |
| "The aim of this analysis was to assess the efficacy and safety of the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil in elderly patients with either essential hypertension or isolated systolic hypertension." | 7.75 | Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. ( Heagerty, AM; Mallion, JM, 2009) |
| "In order to determine how both diuretics affect water metabolism, we here compare the effects of a rechallenge with either amiloride-hydrochlorothiazide fixed association (AmHTZ; amiloride chlorhydrate 5 mg+hydrochlorothiazide 50 mg; Moduretic) or furosemide (F; 40 mg; Lasix) on water excretion in a 79 year old woman who was previously admitted for severe symptomatic hyponatremia secondary to a 5 days course of AmHTZ for systolic hypertension." | 7.75 | Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatremia. ( Cogan, E; Fadel, S; Karmali, R, 2009) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| "The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals." | 7.74 | Based treatment algorithm for essencial hypertension with olmesartan medoxomil. ( Amodeo, C; Brandão, AA; Feitosa, AD; Gomes, MA; Moriguchi, EH; Oigman, W; Précoma, DB; Ribeiro, AB; Ribeiro, JM; Saraiva, JF, 2008) |
| "Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life." | 7.74 | [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]. ( Fimmers, R; Mengden, T; Uen, S; Un, I; Vetter, H, 2007) |
| " Here we report the results of a pre-planned 6-month interim analysis of a long-term, open-label study examining the safety, tolerability and efficacy of the aliskiren/valsartan 300/320-mg combination in patients with hypertension." | 7.74 | Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. ( Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J, 2008) |
| "Noncardiogenic pulmonary edema is a rare but potentially life-threatening complication of hydrochlorothiazide therapy." | 7.73 | Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. ( Binkley, K; Knowles, SR; Phillips, EJ; Rahim, SA; Shear, NH; Wong, GA, 2005) |
| " Nondiabetics with hypertension (N=30) were started on (or changed to) hydrochlorothiazide (HCTZ) 12." | 7.73 | Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. ( Falkner, B; Francos, G; Kushner, H, 2006) |
| "To investigate the chronic efficacy of low-dose hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 7.73 | [Chronic effects of low-dose hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( He, WC; Li, Y; Liu, FS; Liu, KJ; Sun, LX; Wang, GL; Wang, LG; Wu, SL; Zhao, HY, 2006) |
| "Patients (n=50) with essential hypertension were given either indapamide-retard (1." | 7.73 | [Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension]. ( Golevtsova, ZSh; Nazarov, AG; Potapov, VV; Pritykina, TV; Protskiĭ, IA; Semenkin, AA; Zhivilova, LA, 2006) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 7.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension." | 7.72 | Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians. ( Ofor, OO, 2004) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 7.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "After withdrawal of antihypertensive medications for at least four weeks (baseline) and stabilization on a diet approximating 150 mmol sodium per day, 225 African American and 280 Caucasian subjects with diagnosed essential hypertension were treated for four weeks with hydrochlorothiazide 25 mg per day." | 7.71 | Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. ( Boerwinkle, E; Chapman, AB; Schwartz, GL; Turner, ST, 2002) |
| "We examined the effect and safety of combination therapy with low-dose diuretics (hydrochlorothiazide: HCTZ) and angiotensin II receptor antagonist (losartan) in elderly cases of hypertension, using ambulatory blood pressure monitoring (ABPM)." | 7.71 | [Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension]. ( Abe, I; Eto, K; Iida, M; Tsuchihashi, T, 2002) |
| "The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in untreated patients with moderate-to-severe essential hypertension or patients with uncontrolled hypertension despite treatment with monotherapy or low-dose combination." | 7.71 | Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. ( Coca, A; de la Sierra, A; Felip, A; Mínguez, A; Pelegrí, A; Plana, J; Sobrino, J; Soler, J; Vila, J, 2002) |
| "Hydrochlorothiazide-induced pulmonary edema is an unusual but life-threatening adverse reaction." | 7.70 | Recurrent hydrochlorothiazide-induced pulmonary edema. ( Cervantes, M; Jordana, R; Mas, A; Vallés, J, 1998) |
| "A 74-year-old woman developed acute renal failure and granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride." | 7.69 | Granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride. ( Arenas, MD; Cabezuelo, JB; Enríquez, R; Fernández, J; González, C; Lacueva, J; Teruel, A, 1995) |
| "Effects of diazoxide, a benzothiadiazine derivative, on the blood pressure, excretion of Na+, K+, and Ca2+, and the levels of these electrolytes in serum, kidney, and aorta were studied in rats with deoxycorticosterone acetate (DOCA)-induced hypertension in comparison with rats treated with hydrochlorothiazide." | 7.69 | Effect of diazoxide on serum and tissue electrolyte levels in rats with deoxycorticosterone acetate-induced hypertension. ( Nakai, T, 1994) |
| "The efficacy, safety, tolerability and speed of onset of the hypotensive action of the combination of oral enalapril (10 mg) prazosin (1 mg) and hydrochlorothiazide (50 mg) has been assessed in 12 Nigerians with severe hypertension (Diastolic BP > or = 115 mmHg)." | 7.69 | Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. ( Adigun, AQ; Afolabi, MA; Ajayi, AA; Ajayi, OE; Akintomide, AO; Balogun, MO, 1996) |
| "Twenty five patients of mild to moderate uncomplicated essential hypertension and five with severe hypertension were treated with long acting converting enzyme inhibitor enalapril for six weeks." | 7.68 | Enalapril in hypertension. ( Misra, NP; Shah, JY; Verma, Y, 1992) |
| "In this study we evaluated in open the efficacy and tolerability of the preconstituted association Captopril 50 mg + Hydrochlorothiazide 25 mg, for a six-month period, in a population of 201 aged patients affected by isolated systolic hypertension." | 7.68 | [Efficacy and tolerability of a preconstituted combination of captopril 50 mg + hydrochlorothiazide 25 mg in aged subjects with isolated systolic hypertension]. ( Collatina, S; Ferroni, C; Salzano, E, 1992) |
| "In 78 patients with mild or moderate hypertension, effect of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen and plasma fibrinolysis time were investigated." | 7.68 | [Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?]. ( Karolko, B; Kopel, E; Kübler, G; Witkowska, M, 1991) |
| "Ten patients with arterial hypertension and chronic heart failure (stages NYHA I and II) were treated in a pilot study with a combination of 50 mg triamteren and 25 mg of hydrochlorothiazide for 20 days under clinical conditions." | 7.68 | [Arterial hypertension and hemorheology: the effects of triamterene and hydrochlorothiazide]. ( Angelkort, B; Gerlach, A; Spürk, P, 1990) |
| "The efficacy and safety of nitrendipine in oral doses of 5-40 mg twice daily, alone or in combination with hydrochlorothiazide (50-150 mg/day) and/or propranolol (40-120 mg/day), were evaluated in an open study of 50 patients with severe hypertension with supine diastolic blood pressure (BP) greater than 115 mm Hg." | 7.67 | Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study. ( Jain, AK; Maronde, R; McMahon, FG; Mroczek, W; Ryan, JR; Vlachakis, N, 1984) |
| "Thirteen patients developed syncope and a prolonged QTc interval while taking therapeutic doses of sotalol." | 7.67 | Sotalol, hypokalaemia, syncope, and torsade de pointes. ( Barlow, JB; McKibbin, JK; Millar, RN; Obel, IW; Pocock, WA, 1984) |
| "We observed the course of development of porokeratosis stimulated by benzylhydrochlorothiazide (BHCTh) in normal-appearing skin of a patient with long-standing stable porokeratosis of Mibelli." | 7.67 | Porokeratosis of Mibelli: benzylhydrochlorothiazide-induced new lesions accompanied by eosinophilic spongiosis. ( Inamoto, N; Nakamura, K; Watanabe, T, 1984) |
| " Therefore, a study was designed to compare the efficacy and the effects on left ventricular function of hydrochlorothiazide, propranolol and prazosin in 13 patients with mild to moderate hypertension." | 7.67 | Monotherapy in mild to moderate hypertension: comparison of hydrochlorothiazide, propranolol and prazosin. ( Benowitz, N; Inouye, I; Loge, D; Massie, B; Simpson, P; Topic, N, 1984) |
| "The time course of various doses of captopril (C) alone, hydrochlorothiazide (H) alone, and C with H was followed in 142 subjects with mild hypertension." | 7.67 | Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension. ( , 1984) |
| "The effect of verapamil on different metabolic parameters has been studied after changing the treatment of hypertension from hydrochlorothiazide to verapamil monotherapy." | 7.67 | Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. ( Gordin, A; Lehtonen, A, 1984) |
| "Captopril is an orally active converting enzyme inhibitor lowering blood pressure (BP) in different types of hypertension." | 7.67 | Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1984) |
| "An open-label study was conducted to determine the effectiveness and tolerability of methyldopa in the treatment of 20 older patients (mean age, 67 years) with isolated systolic hypertension." | 7.67 | Methyldopa: an agent for the treatment of older patients with isolated systolic hypertension. ( Vaicaitis, JS, 1984) |
| " Thirty subjects with hypertension on hydrochlorothiazide (HCTZ) were randomized to TIAM or CLON." | 7.67 | Withdrawal phenomena in subjects with essential hypertension on clonidine or tiamenidine. ( Hamilton, BP; Hamilton, J; Kuzbida, G; Levinson, P; Mersey, JH; Pavlis, R, 1984) |
| "An open-label clinical trail comparing the effectiveness of the combination of methyldopa with hydrochlorothiazide in low doses with that of hydrochlorothiazide therapy alone was conducted in 21 elderly patients with isolated systolic hypertension." | 7.67 | Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly. ( Boyles, PW, 1984) |
| "The comparative efficacy and safety of lofexidine and clonidine in patients with mild to moderate systemic hypertension were evaluated." | 7.67 | Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. ( Lopez, LM; Mehta, JL, 1984) |
| "This multicenter study evaluated nitrendipine, a dihydropyridine calcium antagonist, alone or in combination with hydrochlorothiazide and/or propranolol in severe essential hypertension (baseline supine diastolic BP greater than or equal to 115 mm Hg)." | 7.67 | Long-term efficacy and safety of nitrendipine in severe essential hypertension. ( Burris, JF; Mroczek, WJ; Nash, DT, 1988) |
| "In a group of elderly patients with systolic hypertension the hypotensive efficacy and adverse effects were studied of hydrochlorothiazide given in daily doses of 25 mg in a year." | 7.67 | [Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension]. ( Halawa, B, 1989) |
| "In 59 patients with mild or moderate essential hypertension effects of propranolol and hydrochlorothiazide on serum lipids, fibrynogen, glucose and uric acid concentrations as well as serum euglobulins fibrynolysis time were studied." | 7.67 | [Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension]. ( Karolko, B; Kawecka, M; Lukasik, S; Moszczyńska, J; Witkowska, M, 1989) |
| "We studied the effect of hydrochlorothiazide, 50 mg daily, on Na,K-adenosine triphosphatase (ATPase) activity in the red cells of 10 black men with hypertension." | 7.67 | Effect of treatment with hydrochlorothiazide on the red cell Na,K-adenosine triphosphatase in men with hypertension. ( Del Greco, F; Finn, M; Quintanilla, AP; Weffer, MI, 1987) |
| "A case of retroperitoneal fibrosis possibly associated with hydralazine, hydrochlorothiazide and ampicillin therapy is reported." | 7.67 | Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. ( Waters, VV, 1989) |
| "Enalapril (at a mean dose of 25 mg), a potent, long-acting angiotensin converting enzyme inhibitor, was prescribed in combination with hydrochlorothiazide (at a mean dose of 64 mg) for 96 weeks in 11 patients with essential hypertension who had pretreatment (placebo) glomerular filtration rates of less than 80 ml/minute/1." | 7.67 | Hemodynamic and renal function in essential hypertension during treatment with enalapril. ( Bauer, JH; Reams, GP, 1985) |
| "The effects of enalapril (10-20 mg twice daily), hydrochlorothiazide (25-50 mg twice daily), and combination enalapril-hydrochlorothiazide therapy (10-20 mg enalapril/25-50 mg hydrochlorothiazide in combination tablet twice daily) were evaluated and compared to no therapy (control) in eight patients with mild to moderate hypertension at rest and during treadmill exercise." | 7.67 | Rest and exercise hemodynamic and adrenergic responses to enalapril, hydrochlorothiazide, and combination treatment in patients with systemic hypertension. ( Charlap, S; Frishman, W; Saltzberg, S; Shamoon, H; Stroh, JA; Weinberg, P, 1985) |
| "Thirty-nine general practice patients with mild to moderate essential hypertension were treated with enalapril 10 to 40 mg once daily alone or in combination with hydrochlorothiazide 12." | 7.67 | Once daily enalapril in general practice patients with mild to moderate essential hypertension. ( Crombie, A; Manson, P; McVey, D; Smeeton, VJ; Smith, MW; Somerton, DT, 1986) |
| "Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean blood pressure, 172 +/- 6/111 +/- 4 mmHg) by the association of a converting enzyme inhibitor and a diuretic." | 7.67 | Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic. ( Mimran, A; Ribstein, J, 1986) |
| "In this open, titrated dose clinical trial, captopril, when used in small doses (up to 150 mg daily) for 8 weeks (n = 5) and 4 months (n = 13) in patients suffering from mild to moderate essential hypertension, produced a fall in blood pressure both systolic and diastolic." | 7.67 | Low-dose captopril alone and in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension. ( Mondal, S; Pandhi, P; Sharma, BK; Sharma, PL; Wahi, PL, 1986) |
| "7 years, with systemic systolic hypertension were studied before and after 1 month of therapy with oral hydrochlorothiazide, 50 mg/day." | 7.67 | Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, aldosterone, urinary metanephrines and response to thiazide therapy. ( Dunsky, MH; Hill, NE; Mookherjee, S; Smulyan, H; Vardan, S; Warner, RA, 1986) |
| "Penbutolol has proved particularly effective and suitable for the treatment, even on a long-term basis, of recently developed hypertension, especially in its hyperkinetic forms." | 7.67 | [Penbutolol and arterial hypertension]. ( Bravi, M; Broglia, M; Carisdeo, V; Giuffrè, G; Torriani, A, 1987) |
| "Effect of long-term oral administration of the converting enzyme inhibitor (2R, 4R)-2-(o-hydroxyphenyl)-3-(mercaptopropionyl)-4-thiazolidinecarboxylic acid (SA446) in combination with hydrochlorothiazide or propranolol on the development of hypertension was examined in spontaneously hypertensive rats (SHR)." | 7.67 | [Combined effect of (2R, 4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarbo xyl ic acid (SA446) with hydrochlorothiazide or propranolol on development of hypertension in spontaneously hypertensive rats (SHR) by long-term administration]. ( Iso, T; Nakata, K; Takada, T; Yamauchi, H, 1986) |
| "Captopril in low doses has been used recently with success in the treatment of mild to moderate hypertension." | 7.67 | Comparison of low-dose captopril and propranolol as second-line drugs in mild and moderate hypertension. ( Rosenfeld, JB; Traub, YM, 1985) |
| "Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 7.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
| "The antihypertensive effect and safety of hydrochlorothiazide administration as a single drug and together with medroxalol were determined in 20 patients with primary hypertension." | 7.66 | Medroxalol combined with hydrochlorothiazide in the treatment of hypertension. ( Alexander, N; Maronde, RF; Valasquez, M; Vlachakis, ND, 1983) |
| "The antihypertensive effects and side-effects of a clonidine transdermal therapeutic system (clonidine-TTS) were examined over 10 weeks in 22 patients with essential hypertension." | 7.66 | Clonidine through the skin in the treatment of essential hypertension: is it practical? ( Baumgart, P; Boerlin, HJ; Groth, H; Knüsel, J; Siegenthaler, W; Vetter, H; Vetter, W; Walger, P; Wehling, M, 1983) |
| "Twenty-seven patients with moderate to moderately severe hypertension who had not responded optimally to treatment with a standard step 2 regimen were treated with a three-drug regimen of hydrochlorothiazide, propranolol, and guanadrel." | 7.66 | Safety and efficacy of a three-drug regimen for the treatment of hypertension: hydrochlorothiazide, propranolol, and guanadrel. ( Gore, RD, 1983) |
| "5 mg clonidine (clonidine-TTS) was investigated in 21 patients with essential hypertension over a period of 10 weeks." | 7.66 | [Clonidine transdermal therapeutic system in essential hypertension: effect and tolerance]. ( Baumgart, P; Boerlin, HJ; Groth, H; Knüsel, J; Siegenthaler, W; Vetter, H; Vetter, W; Walger, P; Wehling, M, 1983) |
| "1 Forty-one patients with essential hypertension, stages I, II, and III, were treated with captopril alone or in combination with hydrochlorothiazide." | 7.66 | Captopril in essential hypertension. ( Alsina, J; Balcells Gorina, A; Ingelmo Morin, M; Martinez Amenos, A; Rabinad Estrada, E, 1982) |
| "1 Forty-one patients with primary (essential) hypertension were treated with captopril alone or in combination with hydrochlorothiazide for 12-36 months." | 7.66 | Long-term experience of captopril in the treatment of primary (essential) hypertension. ( Asplund, J; Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1982) |
| "Plasma volume (PV), extracellular fluid volume (ECV) serum electrolytes, renin and aldosterone were measured before and after 1 week and 4 months of hydrochlorothiazide (HCT) treatment, 50 mg twice daily, in nine male patients with uncomplicated essential hypertension." | 7.66 | Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. ( Schalekamp, MA; van Brummelen, P, 1980) |
| "26 patients with severe hypertension (10 essential, 9 renal parenchymatous, 7 renovascular) and a mean age of 42 years were treated with the new oral converting enzyme inhibitor captopril (SQ 14225)." | 7.66 | [Captopril in treatment-resistant hypertension (author's transl)]. ( Lüscher, T; Siegenthaler, W; Studer, A; Vetter, W, 1980) |
| "The angiotensin I-converting enzyme inhibitor, captopril (SQ 14225) was proposed as first treatment in 12 cases of uncomplicated essential hypertension maintained on unrestricted sodium intake (group I)." | 7.66 | [Effect of captopril in essential hypertension (author's transl)]. ( Laroche, B; Mimran, A; Targhetta, R, 1981) |
| "1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma." | 7.66 | Intravenous labetalol in severe hypertension. ( Dal Palu, C; Hlede, M; Morandin, F; Palatini, P; Pessina, AC; Rossi, GP; Semplicini, A; Sperti, G, 1982) |
| "The immediate and sustained circulatory effects of hydrochlorothiazide were evaluated at rest and during dynamic exercise in 24 patients with essential hypertension." | 7.66 | Circulatory dose-response effects of hydrochlorothiazide at rest and during dynamic exercise in essential hypertension. ( Ahuja, RC; Kumar, EB; Nelson, GI; Okoli, RC; Silke, B; Taylor, SH, 1982) |
| "Two fixed-combination drugs commonly used in the step 2 treatment of hypertension, chlorthalidone plus reserpine and hydrochlorothiazide plus methyldopa, were compared in an evaluation of efficacy and adverse reactions." | 7.66 | A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension. ( Adlin, EV; Channick, BJ; Kessler, WB; Marks, AD, 1981) |
| "The antihypertensive effect of acebutolol 400 mg and hydrochlorothiazide 25 mg in combination have been assessed in 22 patients with mild, moderate and severe hypertension." | 7.66 | The use of acebutolol with hydrochlorothiazide in hypertension. ( Darmadji, T; Pikir, BS; Saleh, M; Yogiarto, M, 1981) |
| "The antihypertensive effect and the tolerability of metoprolol Durules have been studied in fifty-five patients with mild to moderate hypertension." | 7.66 | Experiences with metoprolol Durules, a slow-release formulation in hypertension. ( Nissinen, A; Tuomilehto, J, 1980) |
| "The combination of hydrochlorothiazide and amiloride has been used in a group of patients diagnosed as having essential hypertension." | 7.66 | A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension. ( Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L, 1980) |
| "Acebutolol (ABL) and hydrochlorothiazide (HCT) were compared in patients with mild to moderate essential hypertension and low or normal peripheral renin activity." | 7.66 | Acebutolol and hydrochlorothiazide in essential hypertension. ( Brossard, JJ; Nadeau, J; Ogilvie, RI; Ruedy, J, 1980) |
| "1 The stepped care approach for the treatment of hypertension was adopted in a study at Ain Shams Hospital using hydrochlorothiazide (HCT) and a new beta-blocker, nadolol." | 7.66 | Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined. ( El-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1979) |
| ") before and during treatment with spironolactone (Sp, 75--100 mg/day) for at least 8 months was studied in 11 patients with essential hypertension." | 7.66 | Reduced response of plasma aldosterone to acute ACTH stimulation during long-term treatment with spironolactone in essential hypertension. ( Kim, KS; Miyamori, I; Miyamoto, M; Morimoto, S; Takeda, R; Uchida, K, 1979) |
| "Levels of serum lipids, uric acid and body weight are reported from a controlled trial of drug treatment of middle-aged men with uncomplicated mild hypertension." | 7.66 | Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study. ( Helgeland, A; Hjermann, I; Holme, I; Leren, P, 1978) |
| "The effect of long-term treatment of hypertension with propranolol, alone or in combination with hydrochlorothiazide and/or dihydralazine, was investigated in 93 patients with various types of hypertension." | 7.66 | [Long-term treatment of arterial hypertension with propranolol. Combination with diuretics and dihydrazinophthalazine]. ( Ambrosio, G; Corgnati, A; Dal Palù, C; Palatini, P; Pessina, AC, 1978) |
| "To determine the influence of dietary sodium intake on the effects of hydrochlorothiazide (HCT) on blood pressure (BP), serum electrolytes, renin and aldosterone, nine male patients with uncomplicated essential hypertension were studied during the following therapeutic regimes: 1) sodium restriction alone (50 mmol/day), 2) sodium restriction combined with HCT (50 MG TWICE DAILY), 3) HCT alone, and 4) sodium restriction combined with HCT." | 7.66 | Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. ( de Graeff, J; Schalekamp, M; van Brummelen, P, 1978) |
| "The therapeutic efficacy of four antihypertensive regimens (minoxidil, propranolol, and hydrochlorothiazide; propranolol and hydrochlorothiazide; methyldopa and hydroch-orothiazide; and hydrochlorothiazide alone) was evaluated in one child with systolic hypertension and in eight children with systolic and diastolic hypertension." | 7.65 | Management of severe childhood hypertension with minoxidil: a controlled clinical study. ( Mirkin, BL; Sinaiko, AR, 1977) |
| "The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension." | 7.65 | [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975) |
| " of spironolactone (SL) in 48 patients with essential hypertension." | 7.65 | Treatment of hypertension with hydrochlorothiazide and spironolactone. ( Ogilvie, RI; Ruedy, J, 1969) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 7.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 6.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| " Both drugs equally reduced SBP in the last 6 h of the dosing interval and homogeneously reduced SBP throughout the 24 h." | 6.82 | Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. ( Arca, M; Berra, S; Bucci, M; Calabrò, P; Fulgheri, PL; Ghione, S; Modesti, PA; Omboni, S; Pirvu, O; Popescu, E; Portaluppi, F; Pozzilli, P; Taddei, S; Velican, VG; Villani, GQ; Vladoianu, M; Volpe, M, 2016) |
| "Morning hypertension is an established risk factor for cardiovascular events." | 6.80 | Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study. ( Anegawa, T; Aoki, Y; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Uchiwa, H; Ueda, T, 2015) |
| " Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication." | 6.80 | A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). ( Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 6.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| " Safety and tolerability parameters included adverse events." | 6.79 | Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. ( Finck, A; Giles, TD; Li, H; Neutel, JM; Punzi, H; Weiss, RJ, 2014) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 6.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| " A potential reason for this is reduced nitric oxide bioavailability in African Americans, resulting in increased prevalence of factors that contribute to ventricular dysfunction." | 6.77 | Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. ( Bhaheetharan, S; Ferdinand, KC; Haque, T; Harris, J; Khan, BV; Merchant, N; Rahman, ST; Umar, K; Wahi, J, 2012) |
| " Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects." | 6.77 | Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. ( Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012) |
| " These differences were significant after 2 weeks at the higher dosage (P < 0." | 6.77 | Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. ( Bays, H; Gao, P; Mattheus, M; Ruilope, LM; Voelker, B; Zhu, DL, 2012) |
| "Many patients with hypertension have difficulty achieving their target blood pressure (BP)." | 6.77 | Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study. ( Inou, T; Kobayashi, K; Kubara, I; Meno, H; Nakamura, Y; Ota, T; Shiga, Y; Tanaka, M; Tsuchiya, Y, 2012) |
| " Aliskiren alone or in combination with HCT is safe and effective in Hispanic/Latino patients with stage 2 hypertension." | 6.77 | Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick ( Aguirre P, F; Alessi, T; Baschiera, F; Black, HR; Wright, M, 2012) |
| "An OM/HCTZ-based titration regimen enabled elderly patients with hypertension to safely reduce BP throughout the 24-hour dosing interval and allowed the majority of these patients to achieve a BP target of <140/90 mmHg or <140 mmHg." | 6.77 | Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. ( Chavanu, KJ; Dubiel, R; Germino, FW; Maa, JF; Neutel, JM, 2012) |
| " This study examined the practical efficacy of a combination therapy of ARB with thiazide diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy in patients with morning hypertension administered an ordinal dosage of ARB." | 6.77 | Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension. ( Hanayama, Y; Makino, H; Nakamura, Y; Uchida, HA, 2012) |
| " In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy." | 6.76 | Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. ( Girerd, X; Rump, LC; Sellin, L; Stegbauer, J, 2011) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 6.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| "Administration of angiotensin receptor blockers at bedtime results in greater reduction of nighttime blood pressure than dosing upon awakening, independent of the terminal half-life of each individual medication." | 6.76 | Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. ( Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2011) |
| " Clinical and laboratory adverse events were reported for 29 patients (11%), but serious abnormalities were not observed." | 6.75 | One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2010) |
| " Safety was assessed by monitoring and recording adverse events (AEs)." | 6.75 | Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. ( Chrysant, SG; Dattani, D; Hoppe, UC; Murray, AV; Patel, S; Ritter, S; Zhang, J, 2010) |
| " Dosing regimens are either not executed as prescribed (noncompliance) or patients stop taking the medication (nonpersistence)." | 6.74 | Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. ( Düsing, R; Handrock, R; Klebs, S; Tousset, E; Vrijens, B, 2009) |
| "High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality." | 6.74 | Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. ( Chandurkar, NB; Karnik, ND; Pareek, A; Salagre, SB; Zawar, SD, 2009) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 6.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| " This antiihypertensve effect was considerably potentiated, when kardos was administered in combination with enalapril." | 6.74 | Pharmacodynamics of kardos administered as monotherapy and in combination with hypothiazide and enalapril in grade I-II arterial hypertension. ( Bakumov, PA; Epshtein, OI; Kachanova, MV; Petrov, VI; Sabanov, LB; Sergeeva, SA; Zabolotneva, YA; Zernyukova, EA, 2009) |
| "Hypertension is most important risk factor in coronary heart disease and cerebrovascular accidents." | 6.74 | Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. ( Arif, AF; Joshi, C; Kadam, GG, 2009) |
| "As arterial hypertension is the most important risk factor for ischemic stroke, the relevant guidelines recommend rigorous treatment to normalize blood pressure." | 6.73 | [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)]. ( Bestehorn, K; Diener, HC; Haller, H; Jung, C; Lüders, S; Schmieder, RE; Schrader, J; Smolka, W; Wahle, K, 2008) |
| " In addition, a dose-response was observed with increasing dose of HCTZ with respect to MSSBP." | 6.73 | Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. ( Baumgart, P; Ferber, P; Le Breton, S; Reimund, B; Tuomilehto, J; Tykarski, A, 2008) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 6.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Treatment with olmesartan medoxomil 40 mg/day was associated with a lower frequency of adverse events than olmesartan medoxomil/hydrochlorothiazide combination therapy (21." | 6.73 | Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. ( Barrios, V; Boccanelli, A; Böhm, M; Ewald, S; Girerd, X; Heagerty, A; Krzesinski, JM; Lins, R; Rodicio, J; Stefenelli, T; Woittiez, A, 2007) |
| "Quinapril was an effective and safe treatment for achieving and maintaining recommended BP targets in this sample population." | 6.73 | Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies. ( Aran, S; Bahceci, M; Gultekin, F; Lowe, W; Ozdemir, K; Yener, G, 2007) |
| " There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group." | 6.73 | Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. ( Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007) |
| " Patients' dosing histories were compiled electronically (MEMS, AARDEX)." | 6.72 | Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. ( Mengden, T; Tousset, E; Uen, S; Vetter, H, 2006) |
| " During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12." | 6.71 | Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. ( Byrne, M; Gil-Extremera, B; Lacourcière, Y; Mueller, O; Williams, L, 2003) |
| " Both drugs provided effective control over the 24-h dosing interval." | 6.71 | Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. ( Kolloch, RE; Meinicke, TW; Neutel, JM; Plouin, PF; Schumacher, H, 2003) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 6.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "001) and the other periods of the 24-h interval compared with the levels achieved by the previous treatment, indicating a clear dose-response relationship." | 6.71 | Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. ( Lacourcière, Y; Poirier, L, 2003) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| " Incidence and severity of adverse events and physical examination and laboratory parameters were monitored for the safety evaluation." | 6.71 | Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. ( de Zeeuw, D; Köster, J; Manolis, AJ; Murphy, MB; Reid, JL; Seewaldt-Becker, E, 2004) |
| "The new guidelines for treatment of hypertension by the JNC VII in 2003 permit the initial use of a combination therapy, if blood pressure has to be lowered more than 20/10 mmHg." | 6.71 | Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. ( Bönner, G; Fuchs, W, 2004) |
| " Tolerability and safety were assessed by physical examination, laboratory parameters and evaluation of adverse events." | 6.71 | Assessment of efficacy, safety and tolerability of fixed dose combination of telmisartan 40mg and hydrochlorothiazide 12.5mg in adult Indian patients with mild to moderate hypertension. ( Chandrasekharan, S; Desai, A; Ganesan, R; Gawde, A; Jain, SD; Jayaram, S; Kadam, GS; Lahoti, S; Mishra, AB; Muralidharan, RS; Rajadhyaksha, GC; Sodhi, SS, 2004) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Control of hypertension is hindered by the incidence of adverse events associated with therapy, which can result in low patient compliance." | 6.70 | Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. ( Levine, B, 2001) |
| "Omapatrilat was effective and well tolerated when added to HCTZ in subjects whose blood pressure was not controlled with HCTZ alone." | 6.70 | Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. ( Barbosa, JA; Ferdinand, K; Kushnir, E; Lewin, A; Saini, R; Yellen, L, 2001) |
| " In conclusion, switching to V/HCTZ combination therapy provides an additional lowering of BP compared to dosage increase of the thiazide in patients with BP insufficiently controlled by HCTZ 12." | 6.70 | Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. ( Adam, SA; Handrock, R; Kolloch, R; Schmidt, A; Weidinger, G, 2001) |
| "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy." | 6.69 | Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. ( Cleary, EW; Dilzer, SC; Huffman, CS; Lasseter, KC; Smith, DA; Watkins, S, 1998) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| " At week 6, the dosage of irbesartan or placebo was doubled for seated diastolic blood pressure > or = 90 mmHg." | 6.69 | The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. ( Lin, CS; MacNeil, D; Osbakken, M; Rosenstock, J; Rossi, L, 1998) |
| " Dosage could be increased for both telmisartan (40 --> 80 --> 160 mg) and lisinopril (10 --> 20 --> 40 mg) at each of the first 2 monthly visits if DBP control (<90 mm Hg) had not been established." | 6.69 | Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. ( Frishman, WH; Guthrie, G; Neutel, JM; Oparil, S; Papademitriou, V, 1999) |
| "Losartan appears to be an effective anti-hypertensive agent in patients with mild to moderate hypertension." | 6.68 | Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. ( Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995) |
| " A dose-response relationship to losartan was observed in this patient population." | 6.68 | Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. ( Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " Based on the results obtained in these trials, both dose combinations of Fos/HCTZ taken once daily were safe and effective in the management of patients with mild-to-moderate hypertension." | 6.68 | Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators. ( Battikha, JP; Guthrie, R; Plesher, MM; Reggi, DR; Saini, RK, 1996) |
| "Both doxazosin and HCTZ were effective drugs over 1 year for treating hypertension." | 6.68 | Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. ( Flack, JM; Gonzalez, NM; Grimm, RH; Liebson, PR; Schoenberger, JA, 1996) |
| " Significant dose-response differences were observed between treatments." | 6.68 | Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. ( Anzalone, DA; Falkner, B; Hutchinson, HG; Reisin, E; Tuck, ML; Weir, MR, 1997) |
| " Withdrawals owing to adverse events were three from trandolapril and eight from the captopril group." | 6.67 | Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group. ( Pauly, NC; Safar, ME, 1994) |
| " The incidence of adverse events was similar in all three groups." | 6.67 | Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group. ( Meyer, BH; Pauly, NC, 1994) |
| "Essential hypertension is characterized by parallel and potentially reversible vascular and cardiac adaptations." | 6.67 | Nail fold capillaroscopy and echocardiography in mild-to-moderate hypertension treated with cilazapril plus hydrochlorothiazide: first results. ( Bart, T; Gasser, P; Köhler, M; Martina, B; Weinbacher, M, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 6.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| " The incidence of adverse events was lower in the combination group than in either of the monotherapy groups, and there were no serious clinically significant laboratory abnormalities in the combination group." | 6.67 | Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group. ( Genthon, R, 1994) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 6.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| "A factorial design method was applied in this multicentre trial of the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril) in combination with the diuretic hydrochlorothiazide (HCTZ) to assess the additive effects of the combination versus monotherapy, to characterise the dose-response relationship of each drug in the presence of the other and to determine if quinapril would attenuate the hypokalemic effect of HCTZ." | 6.67 | Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril Investigator Group. ( Canter, D; Frank, GJ; Knapp, LE; Phelps, M; Quade, M; Texter, M, 1994) |
| "Nitrendipine tablets were discontinued in nine patients on placebo and in 29 patients assigned to active treatment (P < 0." | 6.67 | Nitrendipine in older patients with isolated systolic hypertension: second progress report on the SYST-EUR trial. ( Bert, P; Bulpitt, C; De Cort, P; Fagard, R; Fletcher, A; Kivinen, P; Lehtomaki, E; Leonetti, G; O'Brien, E; Staessen, J, 1993) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 6.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| " L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ." | 6.67 | Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. ( Graham, RD, 1991) |
| "Treatment with felodipine ER over 2 weeks increased sympathetic outflow as indicated by elevated plasma norepinephrine levels, whereas plasma epinephrine was mainly unaffected, as were plasma renin and aldosterone levels." | 6.67 | Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. ( Binner, L; Gabrielsen, F; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "5 h after dosing with HCTZ, which was not significantly lower." | 6.67 | Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension. ( Binner, L; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "Hydrochlorothiazide treatment was accompanied by a decrease in serum potassium and an increase in serum uric acid." | 6.67 | The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group. ( Ibsen, H; Westberg, B, 1990) |
| " This combination is well tolerated, probably due to an adequate enalapril/HCTZ dosage ratio." | 6.67 | [Comparative study of enalapril, hydrochlorothiazide and their combination in the treatment of essential hypertension]. ( Delage, Y; Poggi, L; Souchet, T; Vaisse, B, 1991) |
| "Felodipine Er, 10 mg, was given once daily for 2 weeks, and after another wash-out period of 1 week, patients were switched to 25 mg HCTZ, once daily, and vice versa." | 6.67 | Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study. ( Binner, L; Ernst, E; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| " We concluded that enalapril in combination with hydrochlorothiazide is more effective and safe, and allows for lower dosing of enalapril than the drug as monotherapy in Korean hypertensives." | 6.67 | Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide. ( Jones, DW; Sands, CD, 1991) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 6.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| " The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)." | 6.66 | [Perindopril: first-line treatment of arterial hypertension]. ( Desche, P; Zanchetti, A, 1989) |
| " Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension." | 6.66 | Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. ( Chrysant, SG; Glasser, SP; Graves, J; Koehn, DK; Rofman, B, 1989) |
| "Nicardipine is an investigational dihydropyridine calcium channel blocking agent." | 6.66 | Nicardipine and hydrochlorothiazide in essential hypertension. ( Brown, R; Conrad, KA; Fagan, TC; Freedman, D; Lessem, J; Michelson, E; Montijo, M; Schnaper, H; Smolens, P, 1989) |
| "Treatment with amiloride + HCTZ led to elevations in serum levels of cholesterol, uric acid and urea, which were maintained at one year, whilst no abnormalities in blood biochemistry were seen in patients treated with nicardipine." | 6.66 | A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the General Practitioner Hypertension Study Group. ( Bradley, I; Davis, A; Ganvir, P; Gostick, NK; Hopwood, AM; MacKay, D; Mayhew, SR; Mukerji, D; Shepherd, F, 1989) |
| "Captopril appears to be a promising monotherapy for the elderly with mild to moderate hypertension." | 6.66 | A single-blind, randomized, cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly. ( Kin, T; Vallance-Owen, J; Woo, J; Woo, KS, 1987) |
| "Enalapril and atenolol were also equally effective, but in combination their hypotensive effects were less than fully additive, with attenuation of the potential additive response by 30-50%." | 6.66 | Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions. ( Bune, AJ; Chalmers, JP; Elliott, JM; Morris, MJ; Russell, AE; West, MJ; Wing, LM, 1987) |
| "Acebutolol was superior to placebo, propranolol, and hydrochlorothiazide in terms of response rate." | 6.66 | Effects of age and race on clinical response to acebutolol in essential hypertension. ( Boyles, PW, 1985) |
| "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension." | 6.66 | Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. ( Pool, JL, 1987) |
| "Hydrochlorothiazide was added for patients not achieving the treatment goal." | 6.66 | Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. ( Anderson, M; Bartels, D; Eidelson, BA; Labreche, DG; MacCarthy, EP; Massie, B; Ramanathan, KB; Tubau, JF; Ulep, D; Weiss, RJ, 1987) |
| "In recent years, hypertension has generally been treated with a step-care approach, the limitations of which are now becoming apparent." | 6.66 | Comparison and additivity of nitrendipine and hydrochlorothiazide in systemic hypertension. ( Massie, BM; Szlachcic, J; Tubau, JF; Vollmer, C, 1986) |
| " Previous medication was stopped and following a run-in period of 2 weeks on placebo, the initial dosage was C (25 mg)/HCT (12." | 6.66 | Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study. ( Baulac, L; Creisson, C; Lenfant, B, 1986) |
| " After 4 weeks the captopril dosage was doubled, whereas the hydrochlorothiazide dose remained at 25 mg for an additional 4 weeks." | 6.66 | Once-daily treatment of essential hypertension with captopril. ( Schoenberger, JA; Wilson, DJ, 1986) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 6.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| ", following the initial dose of active treatment) and on each visit when the dosage was increased." | 6.66 | The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. ( Blasucci, DJ; Falliers, CJ; Maloy, JW; Medakovic, M; Vrchota, J, 1985) |
| "Labetalol is a competitive, nonselective antagonist of both beta 1 and beta 2 adrenoceptors." | 6.66 | Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension. ( Kalbfleisch, JH; Kochar, MS; Tyson, J, 1985) |
| " These findings suggest that the long-term administration of this beta blocker combined with a diuretic results in serum lipid changes considered beneficial in the evaluation of risk factors for coronary artery disease." | 6.66 | Improvement of the lipid profile during long-term administration of pindolol and hydrochlorothiazide in patients with hypertension. ( Chin, B; Fenderson, RW; Gonasun, LM; Lieberman, S; Samuel, P; Schoenfeld, BH, 1986) |
| "Enalapril alone was not very effective in lowering blood pressure in these subjects, but the combination of enalapril with HCTZ was very effective." | 6.65 | Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension. ( Bain, RP; Douglas, MB; Freier, PA; Hall, WD; Unger, DJ; Wollam, GL, 1984) |
| "Indapamide was prescribed to replace hydrochlorothiazide, the other antihypertensive drugs being continued in those patients receiving combination therapy." | 6.65 | The treatment of hypertension with indapamide alone or in combination with other drugs. ( L'Homme, C; Lemieux, G, 1983) |
| "Captopril is an effective alternative in the treatment of hypertensive patients not readily controlled with conventional therapy." | 6.65 | The renin-angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment-resistant hypertension. ( Damkjaer Nielsen, M; Giese, J; Ibsen, H; Leth, A; Rasmussen, S, 1984) |
| " Apart from the hydrochlorothiazide dosage which was fixed, the dosage of the other active drugs was titrated incrementally until the target blood pressure level was achieved." | 6.65 | An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension. ( Fernandez, PG; Galway, AB; Kim, BK, 1984) |
| "Indapamide is a useful antihypertensive agent with good patient tolerance in mild or moderate hypertension and may offer advantages over traditional diuretics in view of its possible vasodilator and calcium-antagonist properties, once-a-day dosage, and good therapeutic effect with prolonged usage." | 6.65 | Clinical efficacy and safety of indapamide in essential hypertension. ( Morledge, JH, 1983) |
| " These studies range from single-dose experiences, through long-term administration for periods greater than 1 year, to hour-by-hour observation of effects following single doses." | 6.65 | Clinical hemodynamic profile of trimazosin in hypertension. ( Pool, PE; Salel, AF; Seagren, SC, 1983) |
| "An open, multi-centre study was carried out in general practice to compare the efficacy and tolerance of antihypertensive therapy with once-daily and twice-daily dosage of a fixed ratio combination of hydrochlorothiazide (25 mg), amiloride (2." | 6.65 | Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension. ( Currie, WJ; Isitt, VL; VandenBurg, MJ; Young, JH, 1984) |
| " The effect of twice the dosage was evaluated in subjects with unsatisfactory blood pressure (BP) on the lower dose." | 6.65 | Potassium sparing by amiloride during thiazide therapy in hypertension. ( Andersson, PO; H-Andersen, H; Hagman, A; Henning, R, 1984) |
| " Also during treatment, fewer patients receiving hydrochlorothiazide required termination as compared with those receiving propranolol; comparative dosage requirements were lower; additional titration during long-term treatment was required less often, and BP remained lower after withdrawal of the active drugs." | 6.65 | Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1982) |
| "Mepindolol was well tolerated: side effects were generally mild and inconsequential." | 6.65 | Multicenter evaluation of mepindolol and of mepindolol plus hydrochlorothiazide in essential hypertension. ( Galassi, A; Ginevrino, P; Libretti, A; Masoni, A; Morgagni, W; Rappelli, A; Tomasi, AM, 1982) |
| " It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed." | 6.65 | Long-term treatment of essential hypertension with Nadolol and Hydrochlorothiazide: a two-year follow-up. ( El-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1982) |
| " The results showed that the change in treatment led to a significant reduction in blood pressure in both groups, at a dosage of 1 tablet daily in over half the patients, and the majority (88%) preferred the new form of treatment." | 6.65 | A general practice study of timolol/hydrochlorothiazide/amiloride ('Moducren'), a new therapy for hypertension, and the doctor's influence on management. ( Arr, S; Parry, EE; Tait, D, 1983) |
| "1 The hypotensive effect of single daily dosing with 80 mg penbutolol was compared to 100 mg hydrochlorothiazide and placebo in a double-blind cross-over controlled trial with daily home measurements in ten hypertensive patients." | 6.65 | Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements. ( De Plaen, JF; Van Ypersele de Strihou, C; Vander Elst, E, 1981) |
| " Dosage was 2 tablets per day of the 5 mg amiloride plus 50 mg hydrochlorothiazide combination or of 50 mg hydrochlorothiazide alone." | 6.65 | Potassium conservation with amiloride/hydrochlorothiazide ("Moduret') in thiazide-induced hypokalaemia in hypertension. ( Campbell, N; Fernandez, PG; Galway, AB; Gill, V; Granter-Button, S; Kim, BK; MacDonald, J; Sharma, JN; Snedden, W, 1982) |
| " Data was pooled separately for the two T40 non-responder studies (T40 NR group, two T80 non-responder studies (T80 NR group), and the two factorial design dose-response studies (FD-DR group)." | 6.50 | Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. ( Kjeldsen, SE; Neldam, S; Neutel, JM; Schumacher, H, 2014) |
| "Hydrochlorothiazide doses were 12." | 6.49 | Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. ( Guthrie, RM; Kjeldsen, SE; Neldam, S; Schumacher, H, 2013) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality." | 6.47 | Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. ( Ram, CV, 2011) |
| "Hypertension is a major risk factor for cardiovascular, renal and stroke complications." | 6.47 | Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. ( Chrysant, SG, 2011) |
| "Olmesartan medoxomil (OM), an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability." | 6.46 | Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement. ( Wilford Germino, F, 2010) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 6.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Hypertension is a health threat which, so far, is not successfully managed, despite the availability of effective drug treatment." | 6.45 | Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. ( Bramlage, P, 2009) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 6.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Aliskiren is an orally effective direct renin inhibitor that blocks the generation of angiotensin I from angiotensinogen, the rate limiting step of RAAS activation." | 6.44 | Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. ( Sureshkumar, KK, 2008) |
| "Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure." | 6.44 | Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. ( Ruilope, LM, 2008) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 6.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| "Aliskiren is a direct inhibitor of renin, the rate-limiting enzyme for the production of angiotensin II, a powerful vasoconstrictive peptide." | 6.44 | Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. ( Chrysant, SG, 2008) |
| " The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval." | 6.43 | Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros ( Lacourcière, Y; Neutel, JM; Schumacher, H, 2005) |
| " In addition, combination therapy provided sustained and consistent BP control over the entire 24 hour dosing interval." | 6.43 | Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. ( Borghi, C; Cicero, AF, 2006) |
| " When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a beta-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor." | 6.43 | Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. ( Greathouse, M, 2006) |
| "Hypertension is a major risk factor for cardiovascular morbidity and mortality." | 6.42 | Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). ( Chrysant, SG, 2003) |
| "Control of high blood pressure has failed to reduce the risk of atherosclerotic coronary heart disease (CHD)." | 6.38 | Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. ( Nelson, EB; Pool, JL; Taylor, AA, 1989) |
| "Quinapril, when given as initial monotherapy or in addition to diuretics, was extensively evaluated in patients with moderate to severe hypertension, defined as sitting diastolic blood pressure (DBP) greater than or equal to 105 mm Hg with concomitant diuretic therapy or greater than or equal to 110 mm Hg during placebo baseline." | 6.16 | The treatment of moderate to severe hypertension with ACE inhibitors. ( Goldstein, RJ, 1990) |
| "Felodipine, a dihydropyridine calcium-channel antagonist, significantly reduces systolic and diastolic blood pressure (BP) in patients with hypertension and has been associated with beneficial hemodynamic effects in patients with chronic stable angina pectoris or congestive heart failure (CHF)." | 6.16 | Felodipine: a new dihydropyridine calcium-channel antagonist. ( Lopez, LM; Yedinak, KC, 1991) |
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 5.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| "We evaluated whether combined oral hydrochlorothiazide and lisinopril therapy produced superior short-term blood pressure control when compared with nifedipine among postpartum individuals with hypertension requiring pharmacologic treatment." | 5.69 | Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial. ( Amro, F; Blackwell, SC; Chauhan, SP; Fishel Bartal, M; Lawal, D; Pedroza, C; Samuel, J; Sibai, BM, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Recent US guidelines recommend chlorthalidone over other thiazide-type diuretics for the treatment of hypertension based on its long half-life and proven ability to reduce CVD events." | 5.51 | Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 5.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| " High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies." | 5.48 | Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. ( Anegawa, T; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Kajimoto, H; Uchiwa, H, 2018) |
| " Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)." | 5.37 | Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). ( Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011) |
| "Olmesartan treatment led to a decrease of cystatin C level." | 5.37 | Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension. ( Ahbap, E; Basturk, T; Borlu, F; Damar, AB; Koc, Y; Mazi, E; Sakaci, T; Unsal, A, 2011) |
| "High blood pressure is a major risk factor for cardiovascular disease worldwide." | 5.35 | Aliskiren for hypertension in adults. ( , 2008) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 5.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature." | 5.35 | Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension. ( Baldwin, CM; Plosker, GL, 2009) |
| "Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity." | 5.35 | Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. ( Deeks, ED, 2009) |
| "To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP in patients with CKD stage G3 or G4 and hypertension, we conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per day)." | 5.34 | A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. ( Bovée, DM; Danser, AHJ; De Mik-van Egmond, A; Greupink, R; Hoorn, EJ; Masereeuw, R; Middel, I; Russel, FGM; Visser, WJ; Zietse, R, 2020) |
| "Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents." | 5.33 | Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. ( Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006) |
| "We report a case of pulmonary edema induced by a common diuretic, hydrochlorothiazide." | 5.32 | [Acute non-cardiogenic pulmonary edema secondary to hydrochlorothiazide therapy]. ( de Miguel Díez, J; García Satue, JL; Jara Chinarro, B; Juretschke Moragues, MA; Serrano Iglesias, JA, 2003) |
| "This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension." | 5.30 | Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. ( Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019) |
| "In this randomized, single-blind, three-group trial conducted in six countries in sub-Saharan Africa, we randomly assigned 728 black patients with uncontrolled hypertension (≥140/90 mm Hg while the patient was not being treated or was taking only one antihypertensive drug) to receive a daily regimen of 5 mg of amlodipine plus 12." | 5.30 | Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. ( Badri, M; Barasa, F; Cornelius, V; Damasceno, A; Dzudie, A; Francis, V; Jones, E; Kramer, N; Mayosi, B; Mondo, C; Ogah, O; Ogola, E; Ojji, DB; Okpechi, IG; Poulter, N; Rayner, B; Sani, MU; Shedul, G; Shedul, GL; Sliwa, K; Smythe, W, 2019) |
| " The usual daily dosage was one tablet which was increased to two after eight weeks in case the DBP was not normalized, i." | 5.28 | The efficacy and tolerability of enalapril--hydrochlorothiazide combination as a first line therapy in black patients with mild to moderate arterial hypertension: a clinical study in Kenya. ( Lore, W; Muita, AK; Ogola, ES, 1992) |
| " For this reason we studied the influence of different dosing times on the antihypertensive effect over 24 h using ambulatory blood pressure monitoring (ABPM)." | 5.28 | Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing. ( Holzgreve, H; Klüglich, M; Middeke, M, 1991) |
| " It was found that in a part of patients the long-term administration of antihypertensive drugs led to an increased accumulation of kynurenine as a manifestation of pyridoxal-5-phosphate deficiency." | 5.28 | Increased blood kynurenine level as a factor inhibiting the therapeutic effect of antihypertensive agents in combined long-term treatment of essential hypertension. ( Liepinja, DJ; Rudzite, VK; Silava, AK; Vitols, AV, 1990) |
| "Hydrochlorothiazide was discontinued if the diastolic blood pressure remained less than or equal to 94 mm Hg after a 6-month period on the lower dose of hydrochlorothiazide." | 5.28 | Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension. ( Kochar, MS; Landry, KM; Ristow, SM, 1990) |
| "Hyperkalemia is known to occur with increased frequency in the patient with diabetes mellitus and in the elderly when agents that interfere with renal potassium excretion are employed, but the precise frequency has not been established." | 5.28 | Hyperkalemia in diabetes mellitus. Effect of a triamterene-hydrochlorothiazide combination. ( Hollenberg, NK; Mickiewicz, C, 1989) |
| "The aim of the study was to establish the effect of valsartan and combination of valsartan and hydrochlorothiazide (HCTZ) on pulse wave velocity (PWV) and central blood pressure (CBP) in a large population of patients with mild to moderate arterial hypertension." | 5.27 | The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…. ( Accetto, R; Barbic Zagar, B; Sirenko, Y; Vincelj, J; Widimsky, J; Yevgenyevna, IC, 2018) |
| "The authors tested the hypothesis that a valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension, defined as systolic BP (SBP) ≥135 mm Hg or diastolic BP ≥85 mm Hg assessed by a self-measuring information and communication technology-based home BP monitoring device more than three times before either combination's administration." | 5.27 | Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring. ( Fujiwara, T; Kanegae, H; Kario, K; Tomitani, N, 2018) |
| "Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ)." | 5.27 | Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Lloyd, E; Weber, MA; White, WB; Wu, J, 2018) |
| "Hemolysis was due to an immune process associated with antibody to thiazide." | 5.27 | Fatal intravascular immune hemolysis induced by hydrochlorothiazide. ( Beck, ML; Cline, JF; Davis, JW; Hardman, JT; Racela, LS, 1984) |
| "Spironolactone was prescribed at a mean dose of 98 mg, hydrochlorothiazide at 36 mg and cyclothiazide at 2 mg, during a mean follow-up of 20 months." | 5.27 | Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. ( Charru, A; Chatellier, G; Corvol, P; Degoulet, P; Jeunemaitre, X; Julien, J; Ménard, J; Plouin, PF, 1988) |
| "Pulmonary edema was evident clinically and radiographically." | 5.27 | Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion. ( Klein, MD, 1987) |
| "Hydrochlorothiazide and binazine treatment decreased systolic and diastolic blood pressure, the total electromechanical systolic time index (QS2I) and the left ventricular ejection time index (LVETI), and increased the PEP/LVET index at rest and after exercise." | 5.27 | Post-exertion changes in left ventricular systolic time intervals in patients with primary hypertension treated with hydrochlorothiazide, binazine, and propranolol. ( Cholewa, M; Górski, L; Markiewicz, K, 1985) |
| "Captopril was helpful in the management of refractory hypertension in most cases." | 5.26 | Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension. ( Julius, S; Nicholls, MG; Zweifler, AJ, 1981) |
| "Danazol is a semisynthetic androgen that is used in the treatment of endometriosis and hereditary angioedema." | 5.26 | Hypertension: a complication of danazol therapy. ( Bretza, JA; Novey, HS; Vaziri, ND; Warner, AS, 1980) |
| " The mean resting blood pressures were 168/108 mmHg, 151/98 mmHg and 150/96 mmHg at pre-trial, after the twice-daily dosage period and after the once-daily dosage period, respectively." | 5.26 | A fixed combination of metoprolol and hydrochlorothiazide for hypertension: a multi-centre study. ( Goodfellow, RM, 1979) |
| "To compare the blood pressure (BP)-lowering effects of telmisartan 40 mg/day and hydrochlorothiazide (HCTZ) 25 mg/day in high sodium intake patients with mild-to-moderate hypertension in China." | 5.24 | Telmisartan and hydrochlorothiazide antihypertensive treatment in high sodium intake population: a randomized double-blind trial. ( Li, X; Sun, L; Sun, N; Wang, H; Wu, Y; Xi, Y; Yan, LL; Zhang, J; Zhang, P, 2017) |
| "The ACE phenotype was determined in plasma of 14 patients with hypertension treated chronically for 4 weeks with 40 mg enalapril (E) or 20 mg E + 16 mg candesartan (EC) and in 20 patients with hypertension treated acutely with a single dose (20 mg) of E with or without pretreatment with hydrochlorothiazide." | 5.24 | ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors. ( Danilov, SM; Dull, RO; Schwartz, DE; Tovsky, SI, 2017) |
| "The aim of the study is to compare the effects of hydrochlorothiazide and indapamide on the kidney in patients with hypertension inadequately controlled with losartan." | 5.24 | Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan. ( Chen, X; Li, J; Liu, K; Meng, Q; Shi, D; Shi, R; Wang, S; Zhang, X; Zhou, X, 2017) |
| "A single-blind randomized clinical study was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 years) were recruited and divided into two groups: amlodipine or hydrochlorothiazide each comprising of 25 subjects." | 5.24 | Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes. ( Agu, PU; Aneke, EI; Azubike, NC; Eze, AA; Nwachukwu, DC; Nwachukwu, NZ; Obika, LF; Okoye, OI, 2017) |
| "The aim of the trial was to establish the efficacy and safety of Valsacor® (valsartan) and Valsacombi® (combination of valsartan and hydrochlorothiazide) in a wide variety of patient populations with mild to moderate arterial hypertension." | 5.24 | The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial. ( Accetto, R; Barbič-Žagar, B; Chazova, IY; Sirenko, Y; Vincelj, J; Widimsky, J, 2017) |
| "The present study was aimed at comparing the antihypertensive efficacy, tolerability, and side effects profile of nebivolol/hydrochlorothiazide (NH) vs irbesartan/hydrochlorothiazide (IH) combination in elderly patients with isolated systolic hypertension (ISH)." | 5.24 | Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. ( Brambilla, G; Dell'Oro, R; Fici, F; Grassi, G; Mancia, G; Seravalle, G; Trevano, FQ; van Bortel, L, 2017) |
| "In this randomized, open-label, controlled trial, we enrolled 175 Caucasian patients with essential hypertension not well controlled by concomitant ACE-I or ARBs and hydrochlorothiazide." | 5.24 | Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. ( Bestetti, A; D'Avino, M; Derosa, G; Felis, S; Gaudio, G; Guasti, L; Maffioli, P; Mugellini, A; Sala, C; Sarzani, R; Vanasia, M; Vulpis, V, 2017) |
| "The objective of this article is to compare blood pressure (BP)-lowing effects of nitrendipine and hydrochlorothiazide and nitrendipine and metoprolol, and estimate the economic effect of these therapies on hypertension." | 5.24 | Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. ( Chen, Z; Hao, G; Li, Y; Ma, L; Wang, X; Wang, Z; Zhang, L; Zhao, X; Zhu, M, 2017) |
| "BEAHIT (Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients with Hypertension) was approved by Changzheng Hospital Ethics Committee (CZ-20160504-16)." | 5.24 | Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. ( Dai, B; Lv, J; Mei, C; Wang, Y; Xue, C; Yang, B; Yu, S; Zhao, G; Zhou, C, 2017) |
| "We developed an mEDC to support an RCT called "Telmisartan and Hydrochlorothiazide Antihypertensive Treatment (THAT)" study, which was a multicenter, double-blinded, RCT, with the purpose of comparing the efficacy of telmisartan and hydrochlorothiazide (HCTZ) monotherapy in high-sodium-intake patients with mild to moderate hypertension during a 60 days follow-up." | 5.24 | Mobile Device-Based Electronic Data Capture System Used in a Clinical Randomized Controlled Trial: Advantages and Challenges. ( Liu, Y; Sun, L; Sun, N; Wang, H; Zhang, J; Zhang, P, 2017) |
| "The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug." | 5.22 | Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, G; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2016) |
| "The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension." | 5.22 | Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. ( Hirata, K; Ishida, T; Kondo, K; Mori, K; Toh, R; Yasuda, T, 2016) |
| "This 12-week comparative, double-blind, outpatient study randomized 54 patients with stage 1 hypertension to receive either chlorthalidone, 6." | 5.22 | Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. ( Agarwal, MA; Chandurkar, NB; Dharmadhikari, SK; Godbole, AV; Kshirsagar, PP; Kumbla, MM; Mathur, SL; Messerli, FH; Pareek, AK; Sharma, KH, 2016) |
| "The aim of the present study was to compare the effects of the combination of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on blood pressure, target organ damage and sympathetic activation in patients with grade 2 essential hypertension." | 5.22 | Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. ( Dimitriadis, K; Mani, I; Mantzouranis, E; Tousoulis, D; Tsioufis, C; Tsioufis, K, 2016) |
| "We performed a post hoc analysis of 1) a prospective saline infusion study with 12 patients with arterial hypertension who received 2 L of isotonic saline over 4 hours, and 2) a randomized controlled trial with 45 diabetic nephropathy (DN) patients on background angiotensin-converting enzyme -inhibition (ACEi), who underwent 4 6-week treatment periods with add-on hydrochlorothiazide (HCT) or placebo, combined with regular sodium (RS) or low sodium (LS) diet in a cross-over design." | 5.22 | Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. ( de Borst, MH; Fliser, D; Heine, GH; Humalda, JK; Kwakernaak, AJ; Navis, G; Seiler-Muler, S; Vervloet, MG, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 5.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events." | 5.20 | Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. ( Asp, J; Dahlöf, B; Jamerson, KA; Jia, Y; Kjeldsen, SE; Östergren, J; Skoglund, PH; Svensson, P; Weber, MA; Zappe, DH, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study." | 5.20 | TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. ( Argiolas, G; Barlassina, C; Boerwinkle, E; Braga, D; Carpini, SD; Chapman, AB; Chittani, M; Citterio, L; Condorelli, G; Cooper-Dehoff, RM; Cusi, D; Dominiczak, AF; Donner, KM; Frau, F; Fresu, G; Glorioso, N; Glorioso, V; Gong, Y; Hiltunen, TP; Johnson, JA; Kontula, KK; Lanzani, C; Manunta, P; Melander, O; Ortu, MF; Padmanabhan, S; Piras, DA; Pozzoli, S; Rivera, NV; Salvi, E; Simonini, M; Trimarco, B; Troffa, C; Turner, ST; Velayutham, D; Zaninello, R, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 5.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 5.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments." | 5.20 | Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. ( Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "Eighty-eight patients with hypertension (stage 1 or 2) were recruited and advised to receive perindopril (4mg), hydrochlorothiazide (25mg), or indapamide (1." | 5.20 | Antihypertensive therapy increases natural immunity response in hypertensive patients. ( Bianco, HT; Boschcov, P; Brandão, SA; Figueiredo-Neto, AM; Fonseca, FA; Fonseca, HA; Gidlund, M; Izar, MC; Juliano, L; Lins, LC; Monteiro, AM; Povoa, RM, 2015) |
| " This prospective randomized open-label study compared the efficacy and safety of a fixed-dose tablet of losartan (LST)-hydrochlorothiazide (HCTZ) (n = 99) and LST-amlodipine (AML) (n = 77) in Japanese patients whose hypertension was uncontrolled by ARB monotherapy." | 5.19 | Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. ( Hanaoka, K; Hasegawa, T; Kaizu, K; Kamata, K; Kimura, K; Kobayashi, S; Morita, S; Ohtake, T; Oshikawa, J; Sato, T; Taguri, M; Toya, Y; Umemura, S; Yasuda, G, 2014) |
| " The purpose of this study was to compare the combination treatments of olmesartan/azelnidipine and olmesartan/diuretics on serum bone-related markers in patients with essential hypertension." | 5.19 | Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. ( Amaya, N; Arakawa, K; Fukuoka, Y; Ishida, K; Lee, JD; Morishita, T; Nakano, A; Tada, H; Uzui, H, 2014) |
| "In previously monotherapy-treated, uncontrolled patients with hypertension, zofenopril 30-60 mg + HCTZ 12." | 5.19 | Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients. ( Agabiti-Rosei, E; Manolis, A; Omboni, S; Zava, D, 2014) |
| "To assess the efficacy and safety of once daily olmesartan medoxomil (OM)/amlodipine besylate (AM)/hydrochlorothiazide (HCTZ) 40/10/25 mg in patients with hypertension not at goal with mono, dual or triple drug therapy." | 5.19 | Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. ( Punzi, HA, 2014) |
| "Evaluate efficacy/safety of olmesartan medoxomil (OM)/amlodipine (AML)/ hydrochlorothiazide (HCTZ) in Hispanic/Latino adults with hypertension." | 5.19 | Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. ( Chrysant, SG; Fernandez, V; Izzo, JL; Kereiakes, DJ; Lee, J; Lewin, AJ; Melino, M; Oparil, S, 2014) |
| "An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension." | 5.19 | Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. ( Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "Male and female patients aged ≥ 18 years with hypertension despite 4-week, stable treatment with losartan 100-mg/d monotherapy were eligible for inclusion in this multicenter, randomized, double-blind study." | 5.19 | Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy. ( Ahn, T; Bae, JH; Han, KR; Hyon, MS; Kim, WH; Kim, YK; Lee, SU; Lim, DS; Park, HK; Suh, SY, 2014) |
| "This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 5.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
| "The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes." | 5.19 | The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. ( Cinteza, M; Ciobanu, AO; Dragoi Galrinho, R; Dulgheru, R; Florescu, M; Granger, C; Magda, S; Vinereanu, D, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 5.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "The aim of this research was the study of efficiency and endurance antihypertensive therapy on the basis of fixed combination of enalapril and hydrochlorothiazide (HCTZ) and enalapril and HCTZ in combination with amlodipine according to the twenty-four-hour (? day-and-night) monitoring of blood pressure (? 24H BPM) of patients with arterial hypertension (AH) 2-3 severity." | 5.19 | [Changes of twenty-four-hour profile blood pressure and its correction of patients with arterial hypertension on the background of combined antihypertensive therapy application]. ( Bedzaĭ, AO; Prots'ko, VV; Slaba, NA; Solomennchuk, TM, 2014) |
| "Our aim was to compare changes of vascular and metabolic parameters in patients with essential hypertension on treatment with combination of perindopril with either indapamide retard or hydrochlorothiazide." | 5.19 | [Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide]. ( Chindareva, OI; Nechaeva, GI; Pritykina, TV; Semenkin, AA; Stroeva, TV; Zhenatov, AB; Zhivilova, LA, 2014) |
| "Baseline low-grade inflammation in patients with hypertension was associated with a poor ambulatory BP response, especially with losartan/HCTZ treatment." | 5.17 | Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study. ( Eguchi, K; Fukutomi, M; Hoshide, S; Kario, K; Watanabe, T, 2013) |
| " The Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/hydrochlorothiazide (HCTZ) combination is superior to high-dose losartan in not only reducing morning systolic blood pressure (SBP) but also ameliorating urinary albumin excretion (UAE) after 3-month treatment." | 5.17 | Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. ( Adachi, H; Imaizumi, T; Kai, H; Kaneyuki, M; Kusaba, K; Mitsutake, Y; Shihara, M; Toyama, Y; Ueda, T; Umei, H, 2013) |
| "This prespecified subgroup analysis assessed the efficacy and safety of an olmesartan medoxomil (OM) 40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the 3 components as dual-combination treatments in participants with hypertension who were <65 and ≥ 65 years of age." | 5.17 | Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. ( Fernandez, V; Heyrman, R; Izzo, JL; Lee, J; Lewin, AJ; Melino, M, 2013) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 5.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 5.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "This study was designed to compare the efficacy and safety of 2 ramipril and hydrochlorothiazide (HCTZ) fixed-dose combinations in patients with hypertension stage 1 or 2." | 5.17 | Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM. ( Gomes, MA; Kohlmann, O; Nobre, F; Oigman, W; Pereira-Barretto, AC; Póvoa, R; Rocha, JC, 2013) |
| "Forty-four patients with hypertension and severe OSA (apnea/hypopnea index > 30) received stepped dose titration of antihypertensive treatment, consisting of valsartan 160 mg + amlodipine 5-10 mg + hydrochlorothiazide 25 mg." | 5.17 | Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. ( Aksenova, AV; Chazova, IE; Elfimova, EM; Galitsin, PV; Litvin, AY; Rogoza, AN; Sukmarova, ZN, 2013) |
| "To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension." | 5.17 | Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Jia, Y; Lacourcière, Y, 2013) |
| "Hydrochlorothiazide (HCTZ) is a thiazide diuretic used for the treatment of hypertension and edema associated with fluid overload conditions such as congestive heart failure (CHF)." | 5.17 | Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. ( Mager, DE; Mallikaarjun, S; Shoaf, SE; Van Wart, SA, 2013) |
| "Patients with grade 2/3 hypertension were randomized to receive telmisartan 40 mg (T40)/hydrochlorothiazide 12." | 5.17 | Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: a subgroup analysis of a randomized, double-blind, active-controlled trial. ( Birgit, V; Gao, PJ; Jeong, MH; Liu, SW; Mattheus, M; Zhu, DL, 2013) |
| "To observe the relationship between changes in renin-angiotensin-aldosterone system (RAAS) activity and blood plasma glucose after administration of hydrochlorothiazide (HCTZ) for one year in patients with hypertension." | 5.17 | The influence of long term hydrochlorothiazide administration on the relationship between renin-angiotensin-aldosterone system activity and plasma glucose in patients with hypertension. ( Du, HJ; Hu, WJ; Shaw, PX; Xiao, X, 2013) |
| "To evaluate the efficiency and safety of two treatment regimens using ramipril or losartan in combination with hydrochlorothiazide (HCT) and amlodipine in grade 1-2 arterial hypertension (AH)." | 5.17 | [Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial]. ( Chazova, IE; Martyniuk, TV, 2013) |
| " In this study the effects of fixed combination of valsartan with either amlodipine (V-A) or hydrochlorothiazide (V-H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed." | 5.17 | Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. ( Christogiannis, LG; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Tellis, CC; Tselepis, AD, 2013) |
| " The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy." | 5.17 | Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013) |
| "The ACCOMPLISH Trial investigated intensive antihypertensive combination treatment with benazepril + amlodipine (B+A) or benazepril + hydrochlorothiazide (B+H) on cardiovascular outcomes in patients with systolic hypertension." | 5.16 | Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. ( Bakris, GL; Dahlöf, B; Hester, A; Hua, TA; Ibsen, H; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Ostergren, J; Pitt, B; Tuomilehto, J; Velazquez, EJ; Weber, M; Zappe, D, 2012) |
| "Adding hydrochlorothiazide to olmesartan provides more effective 24-hour blood pressure control versus olmesartan monotherapy in patients with moderate-to-severe hypertension." | 5.16 | Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. ( Girerd, X; Rosenbaum, D, 2012) |
| "The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals." | 5.16 | Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012) |
| "Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy." | 5.16 | A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012) |
| "The study was a randomized, double-blind, placebo-controlled, three-period, four-treatment, balanced incomplete block, cross-over study in male patients assigned to treatment sequences consisting of placebo, cicletanine 50 mg, cicletanine 150 mg, and HCTZ 25 mg, doses used to treat hypertension." | 5.16 | A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. ( Beals, C; Carey, RM; De Lepeleire, I; Fernandez, R; Gildea, J; Greenwalt, DM; Johnson-Levonas, AO; Malice, MP; McGrath, HE; Mitta, S; Nunes, I; Sisk, CM; Van Dyck, K; Wagner, F; Wiegert, E, 2012) |
| "A 16-week, randomized, double-blind, prompted-titration trial evaluated initial valsartan (V)/hydrochlorothiazide (HCTZ) combination therapy versus initial HCTZ or V monotherapy in individuals aged ≥ 70 years with systolic hypertension." | 5.16 | Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. ( Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, DH, 2012) |
| "The objective of this study was to assess the effects of valsartan or olmesartan addition to dual therapy with amlodipine + hydrochlorothiazide (HCTZ) in the treatment of stage 2 hypertension." | 5.16 | Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "A total of 61 elderly patients with grade 2 or 3 hypertension were randomized into valsartan + amlodipine (the amlodipine group, n = 31) or valsartan + hydrochlorothiazide (the hydrochlorothiazide group, n = 30) group." | 5.16 | [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. ( Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 5.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| " We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12." | 5.16 | Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2012) |
| "The Aichi Research on Combination therapy for Hypertension Study was a multicenter, open-label, prospective observational study that investigated the efficacy and safety of 1-year treatment with the losartan-hydrochlorothiazide (HCTZ) combination tablet in patients with hypertension uncontrolled by either ARB monotherapy or combination therapy with a calcium channel blocker (CCB)." | 5.16 | Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. ( Adachi, M; Kinoshita, A; Koh, N; Maeda, K; Miura, Y; Murohara, T, 2012) |
| "Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is also being developed in fixed-dose combinations with chlorthalidone, a potent, long-acting thiazide-like diuretic." | 5.16 | Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. ( Bakris, GL; Cushman, WC; Kupfer, S; Lloyd, E; Roberts, A; Sica, D; Weber, MA; White, WB, 2012) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "The objective of this study is to examine the effects of thiazide diuretics, plus medium-dose losartan versus maximal-dose angiotensin II receptor blockers (ARBs) on blood pressure (BP) in Japanese patients with uncontrolled hypertension despite the use of medium-dose ARBs." | 5.16 | Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study. ( Emoto, N; Hirata, K; Inoue, Y; Ishida, T; Kitagawa, Y; Miki, T; Nishimura, K; Nonaka, H; Suematsu, M; Toh, R, 2012) |
| "To evaluate the clinic and ambulatory blood pressure (BP)-lowering efficacy and safety of an aliskiren/amlodipine/hydrochlorothiazide (HCT) triple combination compared with the component dual combinations, in patients with moderate-to-severe hypertension." | 5.16 | Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. ( Fang, H; Konis, G; Lacourcière, Y; Severin, T; Taddei, S; Zhang, J, 2012) |
| "We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively enrolled in the INternational VErapamil-Trandolapril STudy (INVEST)." | 5.16 | Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. ( Brumback, BA; Cooper-Dehoff, RM; Delaney, JA; Gerhard, T; Johnson, JA; Pepine, CJ; Shuster, J; Winterstein, AG, 2012) |
| "This study in patients with moderate-to-severe hypertension assessed the efficacy and safety of adding hydrochlorothiazide (HCTZ) 12." | 5.16 | Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. ( Ammentorp, B; Christian Rump, L; Laeis, P; Volpe, M, 2012) |
| "This is a randomized, double-blind, titrate-to-target blood pressure trial comparing the single-pill combination of azilsartan medoxomil and chlorthalidone versus co-administration of azilsartan medoxomil and hydrochlorothiazide in participants with stage 2 primary hypertension." | 5.16 | Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. ( Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012) |
| "These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring." | 5.16 | Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hou, W; Johnson, JA; Langaee, TY; McDonough, CW; Turner, ST; Wang, Z, 2012) |
| "There are limited data on the results of Russia's use of losartan in clinical practice for the treatment of patients with arterial hypertension (AH)." | 5.16 | [Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study]. ( Glezer, MG; Saĭgitov, RT, 2012) |
| " This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in patients with moderate to severe hypertension." | 5.16 | Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. ( Garcia-Puig, J; Koenig, W; Murray, AV; Patel, S; Uddin, A; Zhang, J, 2012) |
| "The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients." | 5.15 | The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. ( Deng, Q; Liu, L; Liu, M; Ma, L; Wang, W; Zhang, Y, 2011) |
| "The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study." | 5.15 | Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. ( Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "In this open-label, single-arm switch study reflecting clinical practice, patients with moderate hypertension not controlled by the free combination of CAN 32 + HCT 25 achieved a clinically and statistically significant reduction of blood pressure from the single pill combination of ALIS 300/HCT 25, and the optional addition of amlodipine." | 5.15 | Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. ( Benduhn, H; Klebs, S; Schweizer, J; Ulmer, HJ, 2011) |
| "To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset." | 5.15 | 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011) |
| "To valuate whether angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and aldosterone synthase (CYP11B2) gene -344T/C polymorphism are associated with individual response to hydrochlorothiazide (HCTZ) in the Han Chinese population with essential hypertension." | 5.15 | Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. ( Li, Y; Niu, JQ; Wu, SL; Wu, Y; Yang, P; Zhao, DD; Zhou, Y, 2011) |
| "The aim of the study was to evaluate the influence of allopurinol on blood pressure and aortic compliance in patients with arterial hypertension depending on hypotensive therapy with angiotensin-converting enzyme inhibitor (ACE-I) or thiazide diuretic, hypotensive drugs with distinct effects on serum uric acid levels and conversely, a positive influence on pulse wave velocity (PWV) in the aorta." | 5.15 | Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. ( Kostka-Jeziorny, K; Tykarski, A; Uruski, P, 2011) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 5.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 5.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "This multicenter, double-blind, parallel-group, prompted-titration study of patients of at least 70 years of age with systolic hypertension compared the efficacy of valsartan, hydrochlorothiazide, and their combination on ambulatory blood pressure (ABP) reduction." | 5.15 | Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. ( Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, D, 2011) |
| "The aim of this study was to present the results of a prespecified analysis of key secondary endpoints from a 12-week, open-label, single-arm study evaluating the efficacy and safety of olmesartan medoxomil plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes." | 5.15 | Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus. ( Kereiakes, DJ; Neutel, JM, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 5.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| "In Korean adult patients with stage II hypertension, we evaluated the efficacy and tolerability of candesartan 16 mg/hydrochlorothiazide (HCT) 12." | 5.15 | Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. ( Ahn, YK; Choi, D; Chung, WJ; Hong, BK; Jeon, DW; Jung, HO; Kim, BO; Kim, D; Kim, SH; Lee, BK; Lee, HY; Lee, SH; Park, CK, 2011) |
| "The precise relationship of Hyperuricemia found in hypertensive patients is still obscure; this study is a urinary uric acid lowering intervention with Losartan in hypertensive patients induced by Thiazide diuretics." | 5.15 | To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. ( Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J, 2011) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 5.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "In the 12-month core study, patients with hypertension (mean sitting diastolic BP ≥90 mmHg and <110 mmHg) were randomized in a 3 : 2 ratio to once-daily aliskiren 150 mg or 300 mg." | 5.15 | Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. ( Gradman, AH; Keefe, DL; Kolloch, RE; Lederballe, O; Sica, D; Zhang, J, 2011) |
| "This 12-week, multicenter, randomized, double-blinded, 4-arm study in 440 patients with moderate to severe hypertension compared ambulatory blood pressure (ABP) responses with a triple-combination regimen (olmesartan medoxomil [OM] 40 mg, amlodipine besylate [AML] 10 mg, and hydrochlorothiazide [HCTZ] 25 mg) and its component dual-combination regimens at similar doses." | 5.15 | 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. ( Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn Iii, T; Melino, M; Oparil, S, 2011) |
| "The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36)." | 5.15 | Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. ( Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011) |
| " High-risk patients aged ≥18 years with previously uncontrolled hypertension were started on candesartan 32 mg in a fixed-dose combination with either 12." | 5.15 | Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon. ( Bramlage, P; Hübner, R; Mengden, T, 2011) |
| "Thiazide diuretics such as hydrochlorothiazide (HCT) are a widely used first-line treatment for hypertension, but most patients will not achieve blood pressure (BP) control with HCT alone and so will require combination therapy." | 5.14 | Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. ( Andersen, K; Blumenstein, M; Calderón, A; Ibram, G; Liu, Z; Romaszko, J; Zhang, J, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "The antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg, both combined with hydrochlorothiazide (HCTZ) 25 mg, were assessed in a pooled analysis from two large trials with identical study designs in patients with stage 1-2 hypertension." | 5.14 | Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. ( Davidai, G; Schumacher, H; White, WB, 2009) |
| "This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction." | 5.14 | Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2009) |
| "Patients with moderate-to-severe hypertension who were inadequately controlled with amlodipine 5 mg/day monotherapy and who subsequently completed 16 weeks of double-blind combination treatment with olmesartan and amlodipine entered a 28-week open-label phase in which all patients initially received olmesartan/amlodipine 40/5 mg/day." | 5.14 | Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. ( Haag, U; Miele, C; Volpe, M, 2009) |
| "To compare the long-term efficacy, safety and tolerability of the direct renin inhibitor aliskiren against the diuretic hydrochlorothiazide (HCTZ) in obese patients with hypertension." | 5.14 | Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. ( Bush, C; Gorostidi, M; Guerediaga, J; Keefe, DL; Philipp, T; Schmieder, RE, 2009) |
| "Data from 4632 men and women (sex ratio 1:1, mean age 54 years) with mild to moderate hypertension, who participated in one of seven randomized, double-blind, placebo-controlled studies with candesartan-HCT for 8-12 weeks, were entered in a common database." | 5.14 | A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. ( Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009) |
| " The primary objective of this randomized, multicenter, comparative, 3-month, open-label study was to evaluate the antihypertensive efficacy of losartan/chlorthalidone versus losartan/hydrochlorothiazide in mild-to-moderate essential hypertension." | 5.14 | A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. ( Basavanagowdappa, H; Chandurkar, N; Kumar, A; Pareek, A; Zawar, S, 2009) |
| "This study was designed to compare the efficacy and tolerability of a new generic formulation of ramipril (test) and the branded formulation of ramipril (reference) to satisfy regulatory requirements for marketing of the generic product for use in Korean patients with mild to moderate hypertension." | 5.14 | Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. ( Chae, IH; Chang, HJ; Cho, YS; Choi, DJ; Chung, WY; Gwak, JJ; Kang, HJ; Kim, HS; Kim, MA; Kim, SH; Kim, YJ; Lee, HY; Park, JS; Youn, TJ; Zo, JH, 2009) |
| " Patients with uncomplicated hypertension were randomized to receive either hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by addition of the alternative drug." | 5.14 | Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Campbell, K; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Johnson, JA; Schmidt, S; Schwartz, GL; Turner, ST, 2009) |
| "The combination of olmesartan medoxomil and hydrochlorothiazide (HCTZ) [olmesartan medoxomil/HCTZ] has previously been shown to produce significantly greater SBP/DBP reductions than monotherapy with either agent alone in a randomized, double-blind, factorial study in patients with stage 2 hypertension." | 5.14 | Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. ( Chavanu, KJ; Chrysant, SG; Xu, J, 2009) |
| "Patients with essential hypertension (DBP > or = 90 mmHg and <110 mmHg) received open-label olmesartan medoxomil 20 mg/day (n = 2306)." | 5.14 | Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. ( Barrios, V; Böhm, M; Calderon, A; Escobar, C, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 5.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline)." | 5.14 | Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S, 2009) |
| "This randomized, double-blind, 14-week study was conducted to compare the efficacy and tolerability of various doses of valsartan +/- hydrochlorothiazide (HCTZ) versus amlodipine +/- HCTZ for maximizing BP control in 1,285 patients with uncontrolled hypertension." | 5.14 | Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. ( Ferber, P; Papst, CC; Zappe, D, 2009) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| "This prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (HCTZ) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52." | 5.14 | Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. ( Calhoun, DA; Jamerson, KA; Palmer, BF; Purkayastha, D; Samuel, R; Zappe, DH, 2010) |
| "An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies." | 5.14 | Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. ( Calhoun, DA; Crikelair, NA; Glazer, RD; Yen, J, 2009) |
| "The BENIFICIARY (BENIcar safety and efFICacy evaluatIon: An open-label, single-ARm, titration study in patients with hypertension and tYpe 2 diabetes) study was conducted to evaluate the efficacy and safety of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes." | 5.14 | Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. ( Kereiakes, DJ; Neutel, JM; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J, 2010) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 5.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "The benefits of valsartan (Val)/hydrochlorothiazide (HCTZ) combination as initial treatment for hypertension were evaluated in a post hoc analysis of an 8-week, double-blind, placebo-controlled, parallel-group trial." | 5.14 | Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. ( Chiang, YT; Crikelair, NA; Glazer, RD; Weinberger, MH, 2010) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "To evaluate the therapeutic effects of combination administration of hydrochlorothiazide and nitrendipine at low dosage in the treatment of rural hypertension patients." | 5.14 | [Analysis of therapeutic effects of rural patients with hypertension by combination administration of low dosage of hydrochlorothiazide and nitrendipine]. ( Hu, DY; Li, J; Liu, SS; Sun, YX; Sun, ZQ; Xu, CL; Zhang, DY; Zhang, XG; Zhang, XZ; Zheng, LQ, 2010) |
| "To evaluate the safety and tolerability of a titrate-to-goal, olmesartan medoxomil-based therapy in patients with stage 1 hypertension (seated systolic BP [SeSBP] of 140-159 mmHg or seated diastolic BP [SeDBP] of 90-99 mmHg)." | 5.14 | Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. ( Chrysant, SG, 2010) |
| "To determine the efficacy of spironolactone (SPIRO) and hydrochlorothiazide (HCTZ) as monotherapy in older patients with hypertension in blood pressure (BP) control and measures of vascular stiffness." | 5.14 | Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. ( Kithas, PA; Supiano, MA, 2010) |
| "In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly." | 5.14 | Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). ( Ambrosioni, E; Bombelli, M; Cerasola, G; Cipollone, F; Ferri, C; Grazioli, I; Leprotti, C; Mancia, G; Melzi, G; Mugellini, A; Mulè, G; Palasciano, G; Salvetti, A; Trimarco, B, 2010) |
| "The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H)." | 5.14 | Cardiovascular events during differing hypertension therapies in patients with diabetes. ( Bakris, GL; Dahlöf, B; Devereux, RB; Hester, A; Hua, TA; Jamerson, K; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, EJ; Weber, MA; Weir, M, 2010) |
| "This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk." | 5.14 | Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. ( Franklin, SS; Neutel, JM, 2010) |
| "An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension." | 5.14 | Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. ( Dubiel, R; Kereiakes, DJ; Maa, JF; Shojaee, A, 2010) |
| "The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension." | 5.14 | Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. ( Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S, 2010) |
| " The aim of the study was to evaluate the efficacy of nebivolol alone and in association with hydrochlorothiazide (HCT) in reducing BP in hypertensive patients with new-onset, mild-to-moderate hypertension, and to assess the effect of combination therapy on glucose and lipid metabolism." | 5.14 | Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. ( Cacciotti, L; Caminiti, G; Iaia, L; Marazzi, G; Massaro, R; Mercuro, G; Rosano, G; Sposato, B; Vitale, C; Volterrani, M, 2010) |
| "Combined treatment with an angiotensin II receptor blocker and hydrochlorothiazide (HCT) is advocated to control hypertension (HT)." | 5.14 | Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. ( Hu, ZP; Qian, HY; Wang, BN; Wang, Y; Wei, W; Zhou, Q, 2010) |
| "Secondary, prespecified analysis of a single-arm, open-label study evaluating the efficacy of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes." | 5.14 | Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. ( Kereiakes, DJ; Neutel, J, 2010) |
| " In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ." | 5.14 | 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2010) |
| "As of February 2007, 34,033 patients with essential hypertension and prescribed valsartan alone or with hydrochlorothiazide for BP management were enrolled across 2,125 Canadian sites." | 5.13 | Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4). ( Curnew, GP; Leclerc, JM; Rehel, B; Tardif, JC, 2008) |
| " Patients with stage 1 and 2 hypertension were randomized to treatment with valsartan/HCTZ (160/12." | 5.13 | Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT ( Calhoun, DA; Purkayastha, D; Samuel, R; Taylor, AA; White, WB; Zappe, DH, 2008) |
| "Initial therapy with valsartan/HCTZ is effective and well tolerated in patients with severe hypertension." | 5.13 | Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. ( Calhoun, DA; Coenen, PD; Glazer, RD; Grosso, A; Pettyjohn, FS; Zhao, Y, 2008) |
| "This study examined the effects of increasing the thiazide diuretic dose in a fixed-dose ARB/diuretic combination in patients with uncontrolled hypertension despite 6 weeks' open-label treatment with the ARB/diuretic combination, telmisartan 80 mg/hydrochlorothiazide 12." | 5.13 | Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. ( Edwards, C; Neldam, S, 2008) |
| "The aim of this trial was to examine the effects of antihypertensive fixed combination of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd, Bosnia and Herzegovina) on regression of left ventricular hypertrophy in patients with essential arterial hypertension." | 5.13 | Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. ( Alekseevna Andrievskaja, S; Baraković, F; Begović, B; Buksa, M; Eduardovich Bagrij, A; Georgievich Voronkov, L; Gerc, V; Hima, F; Iosifovna Tchelujko, V; Ivanovich Dyaduk, A; Knezević, B; Kusljugić, Z; Lazarević, A; Musić, L; Nikolaevich Polivoda, S; Vataman, E; Vehabović, M, 2008) |
| "The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial is the first cardiovascular outcome trial designed to compare initial use of 2 different fixed-dose antihypertensive regimens, benazepril plus hydrochlorothiazide vs benazepril plus amlodipine, on cardiovascular end points in hypertensive patients at high cardiovascular risk secondary to previous major events or presence of diabetes mellitus (DM)." | 5.13 | The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. ( Bakris, G; Dahlof, B; Hester, A; Jamerson, K; Pitt, B; Shi, V; Staikos-Byrne, L; Velasquez, E; Weber, M, 2008) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 5.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "The efficacy and safety of an olmesartan medoxomil (OM)-based treatment algorithm was tested in a double-blind, randomized, placebo-controlled titration study in 276 patients with stage 1 or 2 hypertension." | 5.13 | Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. ( Chavanu, KJ; Chrysant, SG; Dubiel, R; Kereiakes, D; Oparil, S; Waverczak, W; Xu, J, 2008) |
| "A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks)." | 5.13 | Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. ( Bönner, G, 2008) |
| "To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean sitting diastolic BP [msDBP] > 90 and < or = 110 mmHg following 4 weeks of aliskiren 300 mg)." | 5.13 | Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. ( Lembo, G; Nickenig, G; Ritter, S; Rodriguez, P; Salko, T; Simanenkov, V; Zhang, J, 2008) |
| "This prospective, double-blind, parallel-group study randomized patients with moderate hypertension (seated systolic blood pressure (SeSBP) 160-179 mm Hg when seated diastolic blood pressure (SeDBP) <110 mm Hg; or SeDBP 100-109 mm Hg when SeSBP <180 mm Hg) 3:1:1 to treatment with irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg combination therapy (n=328), irbesartan 300 mg monotherapy (n=106) or HCTZ monotherapy 25 mg (n=104)." | 5.13 | A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Ptaszynska, A, 2008) |
| "In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan." | 5.13 | Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. ( Chrysant, SG; Davidai, G; Guthrie, R; Koval, SE; Murwin, D; White, WB, 2008) |
| "This double-blind study compared long-term efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren and the angiotensin-converting enzyme inhibitor ramipril alone and combined with hydrochlorothiazide in patients with hypertension." | 5.13 | Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. ( Ali, MA; Andersen, K; Constance, CM; Egan, B; Jin, J; Keefe, DL; Weinberger, MH, 2008) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 5.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 5.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension." | 5.13 | A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. ( Abate, N; Chen, E; Creager, MA; Galet, V; Jia, G; Julius, S; Lerman, A; Lyle, PA; Oparil, S; Pool, J; Tershakovec, AM, 2008) |
| "In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension used amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order." | 5.13 | Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. ( Donner, K; Hannila-Handelberg, T; Hiltunen, TP; Kontula, K; Miettinen, HE; Paavonen, KJ; Pentikäinen, PJ; Strandberg, T; Suonsyrjä, T; Tikkanen, I; Tilvis, R, 2008) |
| "This was a prespecified subgroup analysis of one of the primary efficacy end points-mean change in systolic blood pressure (SBP) at 6 weeks -in a previously published community-based, randomized, open-label trial comparing valsartan monotherapy with valsartan/hydrochlorothiazide (HCTZ) combination therapy as initial treatment for high-risk patients with stage 2 hypertension." | 5.13 | Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. ( Danielson, E; Everett, BM; Glynn, RJ; Ridker, PM, 2008) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| " This controlled clinical trial investigated the calcium channel blocker lercanidipine versus hydrochlorothiazide (HCTZ) as add-on in diabetic patients with uncontrolled hypertension on enalapril monotherapy." | 5.12 | Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. ( Agrawal, R; Haller, H; Marx, A, 2006) |
| "Olmesartan medoxomil monotherapy at the recommended dosage of 20 mg once daily is effective and well tolerated in patients with mild-to-moderate hypertension." | 5.12 | Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. ( Böhm, M; Ewald, S, 2006) |
| " The aim of the present study was to determine the effect of hypotensive therapy with a diuretic (hydrochlorothiazide) and an angiotensin-converting enzyme inhibitor (perindopril) on selected oxidative stress parameters in the blood of elderly patients with essential hypertension." | 5.12 | Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension. ( Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Motyl, J; Pawluk, H; Szadujkis-Szadurski, L; Szewczyk-Golec, K, 2006) |
| " Thus, the authors evaluated the antihypertensive effects of telmisartan vs valsartan when combined with hydrochlorothiazide (HCTZ) 25 mg in a large (N=1066), placebo-controlled trial in patients with stage 1 or 2 hypertension." | 5.12 | Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. ( Davidai, G; Koval, SE; Murwin, D; Neutel, JM; Punzi, HA; White, WB, 2006) |
| "To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate essential hypertension." | 5.12 | [The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( Jiang, H; Ke, YN, 2006) |
| " In 3 open-label studies in which blood pressure was assessed with ambulatory measurement, aliskiren was administered to patients with mild-to-moderate hypertension in combination with hydrochlorothiazide (n=23), ramipril (n=21), or irbesartan (n=23)." | 5.12 | Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. ( Barton, J; Dicker, P; Jensen, C; Mulcahy, D; Nussberger, J; O'Brien, E; Stanton, A, 2007) |
| "In this multicenter, randomized, placebo-controlled, 8-week trial, 1123 patients with mild-to-moderate hypertension underwent a 3 to 4 week single-blind placebo run-in and were then randomized in a modified factorial study design to receive once-daily, double-blind oral treatment with placebo, aliskiren monotherapy (75, 150, or 300 mg), valsartan monotherapy (80, 160, or 320 mg), aliskiren and valsartan in combination, or valsartan/hydrochlorothiazide (160/12." | 5.12 | Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. ( Aldigier, JC; Azizi, M; Chiang, Y; Januszewicz, A; Pool, JL; Satlin, A; Schmieder, RE; Zidek, W, 2007) |
| "The authors studied the combination of hydrochlorothiazide (HCTZ) 50 mg/d plus olmesartan medoxomil (OM) 40 mg/d in stage 2 systolic hypertension during an extension phase of an open-label 12-week dose titration study." | 5.12 | Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. ( Dubiel, R; Izzo, JL; Neutel, JM; Silfani, T; Walker, F, 2007) |
| "This study investigated an aggressive treatment program for stage 2 systolic hypertension (pretreatment systolic blood pressure [SBP] > or = 160 mm Hg) using the angiotensin receptor blocker olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ)." | 5.12 | Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. ( Dubiel, R; Izzo, JL; Neutel, JM; Silfani, T; Walker, F, 2007) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 5.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| "This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension." | 5.12 | Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. ( Alvarado, R; Glazer, R; Graff, A; Huang, J; Pool, JL; Weinberger, M, 2007) |
| " The present study was aimed at assessing the effects of 1-year administration of the highly vasoselective calcium-channel blocker lercanidipine (10 mg/day) or the diuretic compound hydrochlorothiazide (25 mg/day) on hypertension-related vascular alterations." | 5.12 | Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. ( Cuspidi, C; Grassi, G; Mancia, G; Quarti-Trevano, F; Scopelliti, F; Seravalle, G, 2006) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 5.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "The present study investigated whether initiating therapy with a combination of losartan (L) and hydrochlorothiazide (HCTZ) allows for faster blood pressure (BP) control and fewer medications than the usual stepped-care approach in patients with stage 2 or 3 hypertension and ambulatory systolic hypertension." | 5.12 | Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. ( Lacourcière, Y; Lefebvre, J; Poirier, L, 2007) |
| "This study evaluated the overall safety profile of combination therapy with amlodipine plus valsartan compared with a combination of lisinopril plus hydrochlorothiazide (HCTZ) in patients with stage 2 hypertension (mean sitting diastolic BP [MSDBP] >or=110 and <120 mm Hg) over the short term (6 weeks)." | 5.12 | Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. ( Chiang, YT; Fomina, I; Gamboa, R; Glazes, R; Kaczor, J; Kargiannis, S; Poldermans, D; Wernsing, M; Yen, J, 2007) |
| "We analyzed 5017 Hispanic and 4710 non-Hispanic white hypertensive women with coronary artery disease (CAD) in the INternational VErapamil SR/Trandolapril STudy (INVEST) to determine the impact of baseline characteristics and BP control on CV outcomes." | 5.12 | Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. ( Cangiano, JL; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Handberg, E; Pepine, CJ; Zhou, Q, 2007) |
| "The prevalence of isolated systolic hypertension (ISH) is high in the elderly, and the objective of this study was to compare the antihypertensive efficacy of olmesartan medoxomil with that of nitrendipine in elderly (65-74 years) and very elderly (>/= 75 years) male and female patients with ISH." | 5.12 | Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. ( Heagerty, A; Laeis, P; Mallion, JM, 2007) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 5.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "The aim of this randomized, double-blind, multicenter 12-week study was to compare the efficacy, safety, and tolerability of a combination of olmesartan medoxomil/hydrochlorothiazide (HCTZ) with that of benazepril plus amlodipine besylate in patients with stage 2 hypertension." | 5.12 | Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. ( Dubiel, R; Kereiakes, DJ; Lipka, LJ; Neutel, JM; Punzi, HA; Xu, J, 2007) |
| "The aim of this trial was to examine the efficacy and safety of antihypertensive fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension." | 5.12 | Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. ( Andrievskaja, SA; Bagrij, AE; Begović, B; Buksa, M; Dyaduk, AI; Ena, LM; Gerc, V; Hima, F; Ilyash, MG; Knezević, B; Kusljugić, Z; Musić, L; Tchelujko, VI; Vataman, E; Vehabović, A; Vehabović, M; Voronkov, LG, 2007) |
| "A post hoc pooled analysis of 2 multicenter, randomized, double-blind, active-controlled force-titration studies assessed the antihypertensive efficacy and tolerability of 7 to 8 weeks' once-daily fixed-dose irbesartan/hydrochlorothiazide (HCTZ) 300/25 mg in 796 stage 1 or 2 hypertensive patients according to age (65 years or older or younger than 65) (n=121 or 675) and presence or absence of obesity (n=378 or 414), type 2 diabetes (n=99 or 697), and high World Health Organization-defined cardiovascular risk (n=593 or 202)." | 5.12 | The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. ( Bhaumik, A; De Obaldia, ME; Lapuerta, P; Neutel, JM; Weir, MR, 2007) |
| "To evaluate the efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide in the 12 weeks treatment of mild to moderate essential hypertension in China." | 5.12 | [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China]. ( Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007) |
| "The Study on COgnition and Prognosis in the Elderly (SCOPE) was a multinational, randomised, double-blind study to assess the effects of candesartan 8-16 mg daily on cardiovascular events and cognitive function in elderly patients (aged 70-89 years) with mild to moderate hypertension." | 5.11 | Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). ( Degl'Innocenti, A; Elmfeldt, D; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Wiklund, I; Zanchetti, A, 2004) |
| "This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension." | 5.11 | Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. ( Punzi, CF; Punzi, HA, 2004) |
| "The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension." | 5.11 | Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). ( Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004) |
| "Forty patients with hypertension were allocated randomly to groups to receive either irbesartan, an inhibitor of angiotensin II type 1 (AT1) receptors (n = 20), or a diuretic (hydrochlorothiazide) (n = 20)." | 5.11 | Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. ( Caccese, D; Germanò, G; Lauro, R; Lenti, L; Pignatelli, P; Ragazzo, M; Sanguigni, V; Violi, F, 2004) |
| "15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine." | 5.11 | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. ( Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Weber, M; Zanchetti, A, 2004) |
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 5.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 5.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) tested whether (1) the angiotensin-converting enzyme (ACE) inhibitor fosinopril (20 mg per day) was more effective on carotid atherosclerosis progression than the diuretic hydrochlorothiazide (25 mg per day), (2) pravastatin (40 mg per day) was more effective than placebo when added to either hydrochlorothiazide or fosinopril, and (3) there were additive effects of ACE inhibitor and lipid-lowering therapies." | 5.11 | Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. ( Baggio, G; Bond, MG; Crepaldi, G; Gallus, G; Magni, A; Mancia, G; Rubba, P; Sampieri, L; Sperti, G; Veglia, F; Ventura, A; Zanchetti, A, 2004) |
| "The results of this study suggest that delapril alone or combined with manidipine is well tolerated and as effective as enalapril alone or combined with HCTZ in lowering blood pressure in patients with mild to moderate essential hypertension." | 5.11 | Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. ( Cremonesi, G; Dobovisek, J; Fogari, R; Mugellini, A; Planinc, D, 2004) |
| "This study tested the effects on cardiovascular outcomes of treatments based on nifedipine gastrointestinal therapeutic system (GITS) compared with the diuretic combination co-amilozide in a pre-specified subset of patients with isolated systolic hypertension (ISH) enrolled in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) study." | 5.11 | Effects of nifedipine GITS and diuretics in isolated systolic hypertension--a subanalysis of the INSIGHT study. ( Brown, M; Castaigne, A; De Leeuw, P; Mancia, G; Palmer, C; Rosental, T; Ruilope, L; Wagener, G, 2004) |
| "We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)." | 5.11 | A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005) |
| "To assess efficacy and tolerability of candesartan cilexetil (CC) plus hydrochlorothiazide (HCTZ) fixed combination vs previous monotherapy (PM) plus HCTZ in hypertension." | 5.11 | Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. ( Mancia, G; Omboni, S, 2004) |
| "Treatment with losartan causes an increase in urinary Zn excretion and induces Zn deficiency in patients with hypertension." | 5.11 | The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. ( Berman, S; Dishy, V; Golik, A; Koren-Michowitz, M; Weissgarten, J; Yona, O; Zaidenstein, R, 2005) |
| "The OBP and ABPM responses to hydrochlorothiazide (25 mg/d, for 4 weeks) were measured in 228 subjects with essential hypertension, and mean responses were compared between methods using the Student paired t test." | 5.11 | Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. ( Boerwinkle, E; Chapman, AB; Finkielman, JD; Schwartz, GL; Turner, ST, 2005) |
| "The purpose of this pilot study was to test whether carvedilol has a protective effect against oxidative deoxyribonucleic acid (DNA) damage in human hypertension in vivo." | 5.11 | Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study. ( Cheong, SS; Choi, YS; Kim, JU; Lee, J; Lee, M; Song, KI, 2005) |
| "Over the course of the long-term, 12-month follow-up study, indapamide SR was shown to be an effective and well tolerated antihypertensive therapy, even after a switch from amlodipine or hydrochlorothiazide, in patients aged 65 years-80 years with systolo-diastolic hypertension (SDH) or ISH." | 5.11 | Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. ( Abate, G; Calvo-Gomez, C; Emeriau, JP; Knauf, H; Leonetti, G; Pujadas, JO, 2005) |
| "This study compares the effects of telmisartan hydrochlorothiazide (HCTZ) combination versus nifedipine GITS on ambulatory blood pressure (BP) and sympathetic activity, in patients with mild-to-moderate hypertension." | 5.11 | Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. ( Corradi, L; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "Patients with hypertension, either untreated or currently on treatment, were started on, or switched to, the angiotensin receptor blocker telmisartan 40 mg daily; after 2 weeks, if office blood pressure (BP) remained > or =140/85 mmHg, the dose was increased to 80 mg; and if necessary, hydrochlorothiazide 12." | 5.11 | Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. ( Bakris, GL; Davidai, G; Giles, T; Neutel, JM; Weber, MA; White, WB, 2005) |
| "The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
| "To compare clinical efficacy and tolerance of fixed combinations of perindopril and indapamide (noliprel), capoten+hydrochlorotiaside (caposide) in arterial hypertension stage I-II of high and very high risk which failed prior monotherapy." | 5.11 | [Comparison of noliprel and caposide efficacy in patients with arterial hypertension of high risk]. ( Brel', UA; Chaliabi, TA; Kapustin, IO; Marchenko, IV; Nedogoda, SV; Prokhorova, EA; Tsoma, VA, 2005) |
| "To analyse the control rate of irbesartan/hydrochlorothiazide (HCTZ) combination tablets (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension." | 5.11 | [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. ( Chen, J; Jing, S; Sun, NL, 2005) |
| "A community-based sample of 585 adults with essential hypertension (291 African Americans [150 women and 141 men] and 294 non-Hispanic whites [126 women and 168 men]) underwent monotherapy with hydrochlorothiazide for 4 weeks." | 5.11 | Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. ( Boerwinkle, E; Chapman, AB; Klungel, OH; Maitland-van der Zee, AH; Schwartz, GL; Turner, ST, 2005) |
| "This was a study of the effects on sitting systolic BP (SBP)of 2 combinations of valsartan and hydrochlorothiazide (HCTZ) compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension (SBP > or =160 mm Hg and < or =200 mm Hg) with or without other cardiovascular risk factors." | 5.11 | Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri ( Assouline, L; Hebert, D; Khder, Y; Lacourcière, Y; Poirier, L; Rehel, B; Stolt, P, 2005) |
| "To examine the effect of telmisartan or hydrochlorothiazide on the control of urinary albumin excretion (UAE) in patients with isolated systolic hypertension (ISH) unselected for albuminuria in a pre-planned substudy of a large, multicentre, double-blind, placebo-controlled, randomized study." | 5.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| "Combination of olmesartan 20 mg with HCTZ provides significantly better 24-h blood pressure reduction than olmesartan monotherapy in patients with mild-to-moderate hypertension." | 5.11 | Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. ( Laeis, P; Rump, LC; Sellin, L; Stegbauer, J, 2005) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| " use of fixed dose combinations of enalapril (10 mg) with hydrochlorothiazide (25 mg) (Enap H) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 60 patients with I-II degree high and very high risk hypertension." | 5.11 | [Comparative efficacy of fixed dose combinations of enalapril with hydrochlorothiazide and captopril with hydrochlorothiazide in patients with high risk hypertension]. ( Nedogoda, SV, 2005) |
| "25 mg) (Noliprel forte) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 40 patients with I-II degree high and very high risk hypertension." | 5.11 | [Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension]. ( Brel', UA; Chaliabi, TA; Marchenko, IV; Nedogoda, SV; Prokhorova, EA; Tsoma, VV, 2005) |
| "Eprosartan alone or in combination with hydrochlorothiazide was highly effective and safe in lowering blood pressure, notably SBP, in older subjects with mild to moderate hypertension." | 5.11 | Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting. ( Conter, HS; McKay, DW; Reiz, RJ, 2004) |
| " Patients > or = 21 years of age with moderate-to-severe essential hypertension, defined as a mean trough sitting diastolic blood pressure (SiDBP) of 105 to 115 mm Hg, were randomly assigned in a 2:2:1 ratio to receive losartan 100 mg/hydrochlorothiazide 25 mg (L100/25), losartan 50 mg/hydrochlorothiazide 12." | 5.10 | A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essent ( Brady, WE; Gazdick, LP; Gradman, AH; Lyle, P; Zeldin, RK, 2002) |
| "Monotherapy with indapamide is associated with greater BP reduction and control and response rates than monotherapy with low-dose hydrochlorothiazide and may be an appropriate choice of antihypertensive diuretic therapy in black South African patients with mild to moderate hypertension." | 5.10 | Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension. ( Candy, GP; Ngcezula, T; Radevski, IV; Sareli, P; Valtchanova, ZP; Wald, AM, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| " Of the 690 patients with mild-to-moderate hypertension completing the preceding 6-week, randomized trial (comparing telmisartan 80 mg with losartan 50 mg/HCTZ 12." | 5.10 | Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. ( Klein, C; Meinicke, TW; Neutel, JM; Schumacher, H, 2002) |
| "A total of 60 patients (53 +/- 10 years) with essential hypertension mean [blood pressure (BP) 173 +/- 9/102 +/- 3 mmHg] were randomized to 6 weeks double-blind therapy with either valsartan 80 mg, hydrochlorothiazide (HCTZ) 25 mg or placebo once daily." | 5.10 | AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. ( Jacobi, J; John, S; Klingbeil, AU; Schmieder, RE; Schneider, MP; Weidinger, G, 2002) |
| "Sixty patients (53 +/- 10 years) with essential hypertension were randomized to 6 weeks of double-blind therapy with either valsartan (80 mg), hydrochlorothiazide (HCTZ) (25 mg), or placebo once daily." | 5.10 | Effect of AT1 receptor blockade on endothelial function in essential hypertension. ( Handrock, R; Jacobi, J; John, S; Klingbeil, AU; Schmieder, RE; Schneider, MP, 2003) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| "The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension." | 5.10 | Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. ( Rizzoni, D; Rosei, EA, 2003) |
| "Renin-angiotensin system reactivity and the constitutive capacity of the renal tubule to reabsorb sodium play a role in the individual response to diuretic therapy; therefore we evaluated the blood pressure (BP) response to hydrochlorothiazide in 87 never-treated individuals with mild essential hypertension, according to ACE gene I/D and alpha-adducin Gly460Trp polymorphism." | 5.10 | ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. ( Barlassina, C; Bianchi, G; Cusi, D; Lanzani, C; Manunta, P; Sciarrone, MT; Stella, P, 2003) |
| "To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension." | 5.10 | Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). ( Brown, M; Castaigne, A; de Leeuw, P; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM; Wagener, G, 2003) |
| "To assess whether candesartan-based antihypertensive treatment in elderly patients with mildly to moderately elevated blood pressure confers a reduction in cardiovascular events, cognitive decline and dementia." | 5.10 | The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. ( Elmfeldt, D; Hansson, L; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Zanchetti, A, 2003) |
| "The aim of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study was to compare the long-term effect of the commonly used inexpensive medication with a low-dose diuretic (hydrochlorothiazide), alone or in combination with a beta-adrenoceptor (atenolol), with that of more modern but also more expensive antihypertensive treatment with an angiotensin-II-receptor blocker (candesartan), alone or in combination with a calcium antagonist (felodipine), and to do so in newly diagnosed patients with primary hypertension." | 5.10 | Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). ( Alaupovic, P; Carlberg, B; Lindholm, LH; Persson, M; Samuelsson, O; Svensson, A, 2003) |
| "We conducted a prospective, randomized, open-label, blinded endpoint crossover study comparing the metabolic responses to the addition of either hydrochlorothiazide (HCTZ) or indapamide, in 18 diabetic hypertensive patients receiving ACE inhibitor monotherapy for hypertension." | 5.10 | Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. ( Gilbert, RE; Krum, H; Skiba, M, 2003) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 5.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| "To evaluate efficacy and tolerance of a compound drug co-renitec combining an ACE inhibitor enalapril maleate and diuretic hydrochlorothiazide co-renitec taken for 16 weeks in essential hypertension (EH)." | 5.10 | [Co-renitek treatment of patients with moderate and severe forms of hypertensive disease]. ( Chazova, IE; Dmitriev, VV; Khanbalaeva, MN; Kotkina, TI; Ratova, LG, 2003) |
| " We aimed to clarify the effects of losartan and its combination with hydrochlorothiazide on 24-h blood pressures (BPs), central hemodynamics and microcirculation in essential hypertension (EH)." | 5.10 | Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. ( Bulatov, VA; Os, I; Podzolkov, VI; Son, EA, 2003) |
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 5.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| "The antihypertensive efficacy and tolerability of losartan/hydrochlorothiazide (HCTZ) and losartan monotherapy as initial treatment were compared in a double-blind trial in Chinese patients with mild to moderate essential hypertension." | 5.10 | A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. ( Chen, L; Gao, R; Jiang, B; Li, J; Li, Y; Liu, G; Su, L, 2003) |
| "This study compared the risk/benefit profiles of valsartan and amlodipine in elderly patients who have isolated systolic hypertension (ISH)." | 5.10 | A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. ( Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N, 2003) |
| "The goal of this study was to assess the effect of a once-daily fixed combination of irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg on the circadian blood pressure profile in patients with essential hypertension that was not controlled with full-dose single therapy or low-dose combined therapy." | 5.10 | Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. ( Bragulat, E; Calvo, C; Coca, A; de la Sierra, A; Gómez, E; López-Paz, JE; Sierra, C; Sobrino, J, 2003) |
| " We investigated the effects on 24-h ambulatory blood pressure (ABP) of the angiotensin-receptor blocker, valsartan, in combination with hydrochlorothiazide (HCTZ), compared with the calcium-channel blocker amlodipine in a Brazilian population in a multicentre, double-blind, double-dummy, parallel group, controlled study in 373 patients with essential hypertension." | 5.10 | Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. ( Franco, RJ; Goldflus, S; McQuitty, M; Oigman, W, 2003) |
| "Of the 310 randomized outpatients with uncomplicated mild-to-moderate primary hypertension, 259 (133 on valsartan/hydrochlorothiazide, 126 on amlodipine) were eligible for analysis." | 5.10 | Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. ( Bertocchi, F; Carretta, R; Di, SS; Dorigatti, F; Malacco, E; Mann, J; Palatini, P, 2002) |
| "The International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) showed, by means of office blood pressure measurements, that long-term treatment with nifedipine GITS is as effective as diuretics in preventing cardiovascular and cerebrovascular complications." | 5.10 | Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Mancia, G; Omboni, S; Parati, G, 2002) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "To assess the antihypertensive efficacy and safety of the novel AT1 receptor antagonist, telmisartan, compared with that of enalapril in elderly patients with mild to moderate hypertension." | 5.09 | Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. ( Hermansson, K; Karlberg, BE; Lins, LE, 1999) |
| "The short-term treatment with atenolol in patients with arterial hypertension and sleep apnea syndrome is associated with normalization of autonomic nervous control judged by heart rate and blood pressure variability." | 5.09 | The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. ( Kantola, I; Pelttari, L; Salo, TM; Viikari, JS; Voipio-Pulkki, LM, 1999) |
| "In 34 out-patients with essential hypertension, the antihypertensive effect and the trough-to-peak ratios of once-daily enalapril or lisinopril were compared by ambulatory blood pressure monitoring (ABPM) according to a crossover design." | 5.09 | Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring. ( Diamant, M; Vincent, HH, 1999) |
| "The efficacy of eprosartan, a highly selective, orally-active non-biphenyl, non-tetrazole, type 1 angiotensin II (AT1) receptor antagonist, was compared with that of the angiotensin-converting enzyme (ACE) inhibitor, enalapril, with the addition of hydrochlorothiazide (HCTZ) when necessary in patients with severe hypertension (sitting diastolic blood pressure [sitDBP] > or = 115 mmHg and < or = 125 mmHg)." | 5.09 | Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. ( Sega, R, 1999) |
| "The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 5.09 | Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. ( Guthrie, R; Kassler-Taub, K; Kochar, M; Reeves, RA; Triscari, J, 1999) |
| "The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCTZ) in a 4-week, multicenter, randomized, double-blind, placebo-controlled study." | 5.09 | Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. ( Cushing, DJ; Gradman, AH; Hardison, JD; Jones, DW; Levine, JH; Michelson, EL; Oparil, S; Prasad, R; Ripley, E; Zuschke, CA, 1999) |
| " We studied 17 women with arthritis and hypertension who were receiving fosinopril and HCTZ, and administered sequentially in random order ibuprofen, sulindac, and nabumetone for 1 month each, with an intervening 2-week washout period between each treatment period." | 5.09 | Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. ( Cook, ME; Thakur, V; Wallin, JD, 1999) |
| "We studied 21 patients with essential hypertension during both a baseline period and a period of treatment with hydrochlorothiazide (25 mg daily)." | 5.09 | Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. ( Kimura, G; Uzu, T, 1999) |
| "The effectiveness as well as the metabolic effects of the combination of diuretics [hydrochlorothiazide (HCT) vs indapamide (IND)] and perindopril (P) in 14 patients (7 male, 7 female) aged 37-62 years with mild idiopathic hypertension were studied." | 5.09 | Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension. ( Elisaf, MS; Kalaitzidis, R; Katopodis, K; Papagalanis, N; Pappas, H; Siamopoulos, KC; Theodorou, J, 1999) |
| "This randomized, double-blind, placebo-controlled multicenter study was designed to evaluate the efficacy, tolerability, and safety of candesartan cilexetil in a diverse population of patients with severe systemic hypertension (diastolic blood pressure > or =110 mm Hg)." | 5.09 | Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. ( Oparil, S, 1999) |
| "To compare effectiveness, tolerance and safety of two inhibitors of angiotensin-converting enzyme--sinopril (lisinopril) and capoten (captopril)--in outpatient treatment of patients with mild and moderate hypertension." | 5.09 | [Antihypertensive efficacy, tolerance and safety of lisinopril (sinopril) and captopril (capoten) in patients with mild and moderate arterial hypertension]. ( Fitilev, SB; Ol'binskaia, LI; Potapova, GN; Pukhlianko, ME; Sergeeva, TE; Sizova, ZhM; Zheleznykh, EA, 1999) |
| "In elderly Chinese patients with isolated systolic hypertension, stepwise antihypertensive drug treatment, starting with the dihydropyridine calcium channel blocker nitrendipine, improved prognosis." | 5.09 | Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. ( Gong, L; Liu, L; Staessen, JA; Wang, JG, 2000) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 5.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "Losartan is an angiotensin II receptor blocker indicated for treatment of hypertension." | 5.09 | Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial. ( Fitzgerald, D; Kelly, L; Nallen, R; O'Brien, E; Owens, P; Ryan, D, 2000) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 5.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "The objective of this randomised open, active controlled, cross-over study was to evaluate the effect of a fixed combination of verapamil SR/trandolapril compared to captopril/hydrochlorothiazide on serum lipids, lipoproteins, and other metabolic and electrolyte parameters in patients with essential hypertension." | 5.09 | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. ( Cifková, R; Compagnone, D; Hejl, Z; Nakov, R; Novozámská, E; Petrzílková, Z; Poledne, R; Stávek, P, 2000) |
| "In this case-control study in uncomplicated subjects with essential hypertension, losartan and enalapril, alone or combined with a diuretic, effectively and equally lowered office and ambulatory blood pressure and induced a significant reduction in left ventricular mass during long-term treatment." | 5.09 | Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. ( Benemio, G; Bruni, B; Porcellati, C; Reboldi, GP; Sacchi, N; Schillaci, G; Verdecchia, P, 2000) |
| " We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity in high-risk patients with hypertension." | 5.09 | Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM, 2000) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 5.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 5.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 5.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "Hydrochlorothiazide (HCTZ) is commonly used to treat black patients with hypertension." | 5.09 | Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. ( McGill, JB; Reilly, PA, 2001) |
| "5 mg shows similar antihypertensive efficacy to amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients, while in patients with isolated systolic hypertension, indapamide SR 1." | 5.09 | A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. ( Abate, G; Calvo-Gomez, C; Chastang, C; Emeriau, JP; Knauf, H; Leonetti, G; Pujadas, JO, 2001) |
| "This study was undertaken to compare the efficacy and tolerability of telmisartan, a novel antihypertensive agent, and atenolol, a well-established beta-blocker, in the treatment of mild to moderate hypertension." | 5.09 | Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. ( Deichsel, G; Freytag, F; Meinicke, T; Schelling, A, 2001) |
| "The objective of this study was to compare the long-term efficacy and safety of 6 months' treatment with barnidipine and hydrochlorothiazide (HCTZ) as monotherapy in patients aged > or = 75 years with mild to moderate essential hypertension." | 5.09 | Treatment of hypertension in the very old. ( Otterstad, JE; Ruilope, LM, 2000) |
| "Monotherapy with caposide-50 (C-50) was compared to combined therapy C-50 + melatonin in 22 patients with essential hypertension stage II (mean age 60 years)." | 5.09 | [Capozide-50 alone and in combination with melatonin in therapy of hypertension]. ( Akhmetov, KZh; Biiasilov, NS; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 5.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| "In older patients with isolated systolic hypertension, antihypertensive treatment starting with the dihydropyridine calcium-channel blocker, nitrendipine, did not decrease blood pressure at the expense of renal function and prevented the development of proteinuria, especially in diabetic patients." | 5.09 | Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. ( Birkenhäger, WH; de Leeuw, PW; Efstratopoulos, AD; Fagard, R; Leonetti, G; Nachev, C; Rodicio, JL; Staessen, JA; Thijs, L; Tuomilehto, J; Voyaki, SM; Wang, JG, 2001) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 5.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| " The study was designed as a side arm of INSIGHT (International Nifedipine Study: Intervention as Goal for Hypertension Therapy), aimed to show the efficacy of nifedipine once daily versus co-amilozide (hydrochlorothiazide 25 mg, amiloride 2." | 5.09 | Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. ( Motro, M; Shemesh, J, 2001) |
| "This study, ancillary to the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), involved nifedipine 30 mg or co-amilozide (hydrochlorothiazide 25 mg and amiloride 2." | 5.09 | Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. ( Gariépy, J; Levenson, J; Moyse, D; Simon, A, 2001) |
| "This study was undertaken to identify combinations of telmisartan, a new oral angiotensin II type 1-receptor antagonist, and hydrochlorothiazide (HCTZ) that might provide greater antihypertensive efficacy than monotherapy with either agent in the treatment of mild to moderate hypertension." | 5.09 | Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. ( McGill, JB; Reilly, PA, 2001) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "The purpose of this study was to assess the antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide (HCTZ) in African American adults with mild to moderate hypertension." | 5.09 | Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. ( Alderman, M; Alexander, J; Ceesay, P; Espenshade, M; Flack, JM; Goldberg, A; Gradman, A; Green, S; Kraus, WE; Lester, FM; Pratt, JH; Saunders, E; Vargas, R, 2001) |
| "To compare the antihypertensive efficacy and tolerability of a once-daily fixed valsartan/hydrochlorothiazide (HCTZ) combination and amlodipine in subjects with mild-to-moderate hypertension." | 5.09 | A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. ( Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P, 2001) |
| " In retrospective analyses of the Veterans Affairs Single-Drug Therapy for Hypertension Study, we compared changes in pulse pressure with 6 classes of antihypertensive agents: 1292 men with diastolic blood pressure of 95 to 109 mm Hg on placebo were randomized to receive hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem, prazosin, or placebo." | 5.09 | Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. ( Cushman, WC; Materson, BJ; Reda, DJ; Williams, DW, 2001) |
| "5 mg/day) for 4 weeks in patients with mild to moderate essential hypertension having been treated for 4 weeks by an angiotensin II antagonist (valsartan, 80 mg/day) but still having a diastolic blood pressure (BP) > 90 mmHg on this medication given alone." | 5.09 | Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. ( Aschwanden, R; Ferber, P; Sadecky, L; Waeber, B, 2001) |
| "Fosinopril treatment with 10-40 mg/day was effective in monotherapy of hypertension in 85% patients and was well tolerated." | 5.09 | [Effectiveness and tolerance of fosinopril in the treatment of arterial hypertension of mild and medium severity]. ( Cech, J; Rosolová, H; Sefrna, F, 2001) |
| "Fifteen women with arthritis and hypertension who were receiving lisinopril and HCT, and administered sequentially in random order ibuprofen, sulindac, and diclofenac for one month each, with an intervening two-week washout period between each treatment period." | 5.09 | Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. ( Bhagat, K, 2001) |
| "To review the efficacy and safety of losartan and hydrochlorothiazide compared to losartan alone, hydrochlorothiazide alone or placebo in the treatment of mild to moderate hypertension in a clinical trial." | 5.08 | Losartan with hydrochlorothiazide in the treatment of hypertension. ( Schoenberger, JA, 1995) |
| "To compare the incidence of cough with the angiotensin II antagonist losartan, the angiotensin converting enzyme inhibitor lisinopril, and hydrochlorothiazide in hypertensive patients with previous angiotensin converting enzyme inhibitor cough." | 5.08 | Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. ( Ramsay, LE; Yeo, WW, 1995) |
| "A multicenter, controlled, open, randomized trial of antihypertensive and life quality (LQ) effects of monotherapy with captopril vs propranolol, hydrochlorothiazide and nifedipine included 345 males aged 35-60 years with mild and moderate hypertension." | 5.08 | [The effect of long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents on the quality of life in patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working ( Broer, M; Duda, SG; Filatova, NP; Metelitsa, VI; Mukhamedzhanova, GF; Ostrovskaia, TP; Siegrist, J; Vygodin, VA, 1995) |
| "5 mg hydrochlorothiazide (HCTZ) with each drug as monotherapy in patients with moderate to severe hypertension." | 5.08 | Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. ( Castellote, E; Ocón, J; Romero, R; Wagner, B, 1995) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood pressure and renal function were examined in patients with impaired renal function and moderate hypertension." | 5.08 | Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1995) |
| "The antihypertensive effects of moexipril, a new angiotensin converting enzyme inhibitor, and verapamil-SR as add-on therapy to hydrochlorothiazide (HCTZ) were investigated in patients with moderate to severe (stages II and III) essential hypertension." | 5.08 | Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. ( Chrysant, SG; Fox, AA; Stimpel, M, 1995) |
| "The efficacy and safety of the novel calcium antagonist Amlodipine (Pfizer Laboratories, New York, New York) and hydrochlorothiazide were evaluated and compared in a randomized, single-blind, parallel group study in black Africans with essential hypertension." | 5.08 | The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. ( Ajayi, AA; Akintomide, AO, 1995) |
| "This two-centre trial compared the efficacy of combinations of enalapril + hydrochlorothiazide (E + H) and captopril + hydrochlorothiazide (C + H) on mild-to-moderate hypertension, after a two-week placebo period, in 26 patients with mild-to-moderate HT (DBP between 95 and 114 mmHg) not controlled by previous treatment, randomized under double-blind conditions into two groups for two 4-week crossover treatment periods separated by a 4-week wash-out period." | 5.08 | [Comparison of the efficacy of enalapril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in mild-to-moderate arterial hypertension by ambulatory measurement of blood pressure]. ( Chanudet, X; Janin, G; Madonna, O; Mayaudon, H, 1995) |
| " Since these metabolic defects are accentuated by obesity, we thought it important to compare the effects of 3 months' treatment with either lisinopril (20 mg/day) or low dose hydrochlorothiazide (12." | 5.08 | Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. ( Chen, YD; Clinkingbeard, C; Foote, J; Hollenbeck, CB; Jeppesen, J; Maheux, P; Pei, D; Reaven, GM, 1995) |
| "25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effectiveness in patients with stage I and stage II (mild to moderate) systemic hypertension; and (2) assess whether this formulation was more effective or possessed a safety advantage over standard monotherapy with bisoprolol or 25 mg of HCTZ." | 5.08 | First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. ( Alemayehu, D; Bryzinski, BS; Burris, JF; Chen, SY; Frishman, WH; Mroczek, WJ; Simon, JS; Weir, MR, 1995) |
| "5 mg of hydrochlorothiazide on glucose metabolism insulin sensitivity and lipids was evaluated in hypertensive non-insulin-dependent diabetes." | 5.08 | The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1995) |
| "The aim of this 3-month double-blind study was to assess the antihypertensive effect and acceptability of perindopril in comparison with enalapril in patients with mild to moderate essential hypertension." | 5.08 | Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. ( Alcocer, L; Bahena, JH; Calvo, C; Campos, C; Lerebours, G; Mickalonis, L; Nacaud, A; Parra Carillo, J; Villahermosa, MT; Weber, C, 1995) |
| "To assess the efficacy and safety of several combinations of benazepril, an angiotensin-converting enzyme inhibitor, and hydrochlorothiazide, as compared with placebo, in the treatment of patients with essential hypertension." | 5.08 | Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. ( Chrysant, SG; Fagan, T; Glazer, R; Kriegman, A, 1996) |
| "To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension." | 5.08 | [Efficacy and tolerability of the captopril and hydrochlorothiazide combination in the treatment of mild to moderate hypertension. Multicenter study]. ( Franco, RJ; Martin, LC; Velasco-Cornejo, IF, 1995) |
| "This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension." | 5.08 | Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. ( Arcuri, KE; Goldberg, AI; MacKay, JH; Snapinn, SM; Sweet, CS, 1996) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 5.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "The purpose of this study was to evaluate the long-term safety and efficacy of moexipril, a non-sulphydryl angiotensin converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in older patients with hypertension." | 5.08 | Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. ( Stimpel, M; White, WB, 1995) |
| "One hundred and thirty five non-smoking hypertensive patients with ACE inhibitor cough confirmed by lisinopril rechallenge and placebo dechallenge were recruited into a double-blind random parallel-group comparison of losartan 50 mg, lisinopril 20 mg and hydrochlorothiazide 25 mg each given once daily for a maximum of 8 weeks." | 5.08 | ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. ( Ramsay, LE; Yeo, WW, 1995) |
| "Eighty-one adult Nigerians with essential hypertension were randomly allocated to receive doxazosin, hydrochlorothiazide/amloride, or amlodipine." | 5.08 | Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients. ( Agbedana, OE; Ahaneku, JE; Taylor, OG, 1995) |
| "We performed a randomized, double-blind, two-period crossover trial of ibuprofen (1800 mg per day) vs placebo treatment in patients older than 60 years of age with hypertension controlled with hydrochlorothiazide." | 5.08 | The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. ( Avorn, J; Beaudet, MP; Choodnovskiy, I; Everitt, DE; Glynn, RJ; Gurwitz, JH; Monane, M, 1996) |
| " Older patients (> or = 60 years, n=337) with isolated systolic hypertension by conventional sphygmomanometry at the clinic were randomized to placebo or active treatment consisting of nitrendipine (10 to 40 mg/d), with the possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12." | 5.08 | Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. ( Bieniaszewski, L; Davidson, C; Dobovisek, J; Fagard, R; Jääskivi, M; Laks, T; Lehtonen, A; O'Brien, ET; Palatini, P; Staessen, JA; Thijs, L; Vanhanen, H; Webster, J, 1996) |
| "To support the use of a combination of losartan, a highly specific and selective AT1 angiotensin II receptor antagonist, and hydrochlorothiazide for treatment of hypertension, a pharmacokinetic drug interaction study was conducted." | 5.08 | Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. ( Capra, NL; Goldberg, MR; Hsieh, JY; Lin, CC; Lo, MW; McCrea, JB; Tomasko, L, 1995) |
| " In the present study, the drug was given in a short-term study in patients with essential hypertension, either as monotherapy or with added hydrochlorothiazide." | 5.08 | Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. ( Aurell, M; Bergbrant, A; Hansson, L; Himmelmann, A; Svensson, A, 1996) |
| "Moexipril is well tolerated and is at least as effective as HCTZ in elderly patients with essential hypertension." | 5.08 | Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. ( Persson, B; Stimpel, M, 1996) |
| "The long-term effects of indapamide or hydrochlorothiazide on blood presssure and renal function were examined in patents with impaired renal function and moderate hypertension." | 5.08 | Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. ( Gadallah, M; Madkour, H; Massry, SG; Plante, GE; Riveline, B, 1996) |
| "To assess this possibility, the effects of five months' treatment with either hydrochlorothiazide (HCTZ) or the converting enzyme inhibitor captopril (CAPT) on lipoprotein lipid composition were compared in thirty normolipidaemic patients with essential hypertension (EH)." | 5.08 | Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension. ( Bagdade, JD; Buchanan, WF; Lithell, H; Pollare, T, 1996) |
| "Thirteen patients with mild hypertension (untreated diastolic blood pressure of 95 to 114 mmHg) received, in random order, three successive treatments of four weeks with placebo, spirapril (6 mg daily), or hydrochlorothiazide (HCT2) (24 mg daily)." | 5.08 | Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension. ( Gleerup, G; Mehlsen, J; Petersen, JR; Winther, K, 1996) |
| "The antihypertensive effectiveness of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, and sustained-release verapamil (verapamil SR) in combination with low-dose hydrochlorothiazide was investigated in patients with moderate to severe (Stages II and III) essential hypertension." | 5.08 | A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. ( Chrysant, SG; Stimpel, M, 1996) |
| "This study provides clear evidence of the efficacy of combination therapy with diltiazem and hydrochlorothiazide in the management of patients with hypertension." | 5.08 | Double-blind, parallel, comparative multicentre study of a new combination of diltiazem and hydrochlorothiazide with individual components in patients with mild or moderate hypertension. ( Joy, A; Manning, G; Mathias, CJ; McDonald, CJ; Millar-Craig, MW, 1996) |
| " A placebo-controlled investigation was carried out in 22 patients with essential arterial hypertension, to ascertain whether this was the case with once daily administration of ramipril." | 5.08 | Monitoring antihypertensive therapy through blood pressure measurements taken casually, at rest, during exercise, and under outpatient conditions. ( Hammerschmidt, R; Lohmann, FW; Schaaf, D, 1996) |
| "We conclude that the safety and efficacy of perindopril + indapamide, captopril + hydrochlorothiazide and enalapril + hydrochlorothiazide were equivalent after 8 weeks of treatment in patients with mild to moderate hypertension." | 5.08 | An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. ( Brault, Y; Chastang, C; Di Perri, T; Guez, D; Laurandin, I; Luccioni, R; Redon, J; Sever, PS, 1995) |
| " The objective of the present 32-week double-blind study was to compare the effects of hydrochlorothiazide (HCTZ) and amlodipine (AML) in elderly patients with confirmed ambulatory hypertension." | 5.08 | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. ( Archambault, F; Boileau, G; Cléroux, J; Lacourcière, Y; Lefebvre, J; Poirier, L, 1995) |
| " In this multicenter study, the efficacy and tolerability of perindopril added to continuing hydrochlorothiazide therapy were evaluated in patients with mild to moderate (stage I and II), essential hypertension." | 5.08 | Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. ( Chrysant, SG, 1997) |
| "5 mg lisinopril/hydrochlorothiazide and placebo in patients with essential hypertension." | 5.08 | Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. ( de Leeuw, PW; Notter, T; Zilles, P, 1997) |
| "The present study compares the occurrence of a dry, persistent cough with doses of 80 mg of valsartan, 10 mg of lisinopril, or 25 mg of hydrochlorothiazide in patients with a history of angiotensin-converting enzyme inhibitor-induced cough." | 5.08 | Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. ( Avery, C; Benz, J; Chiang, YT; Gatlin, M; Henry, D; Oshrain, C, 1997) |
| "Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial." | 5.08 | Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Anderson, RJ; Gottdiener, JS; Massie, BM; Materson, BJ; Reda, DJ; Williams, DW, 1997) |
| " Since combinations of different antihypertensive drugs are often necessary and frequently used, we performed a randomized study comparing the effects of a fixed combination of hydrochlorothiazide and sotalol (group A), or hydrochlorothiazide and captopril (group B) on blood pressure and on lipid and glucose metabolism in 40 men with essential hypertension over 1 year." | 5.08 | The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. ( Holzgreve, H; Middeke, M; Richter, WO; Schwandt, P, 1997) |
| "In this double-blind study, 167 adult out-patients with mild-to-moderate essential hypertension were randomly allocated in equal number to receive valsartan 80 mg or HCTZ 25 mg for 12 weeks." | 5.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. ( Bodin, F; Faust, G; Freytag, F; Hegner, G; Meilenbrock, S; Sullivan, J, 1997) |
| "To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension." | 5.08 | Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. ( Anlauf, M; Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1997) |
| "The blood pressure lowering effect and tolerability of the angiotensin-converting enzyme inhibitor enalapril combined with a very low dose of hydrochlorothiazide (HCTZ) were compared with the selective betareceptor blocker atenolol in patients with mild-to-moderate hypertension." | 5.08 | Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group. ( Dollerup, J; Hotnes, T; Mogensen, CE; Os, I, 1997) |
| "Three hundred and seven patients whose mild-to-moderate essential hypertension remained uncontrolled after 4 weeks of treatment with hydrochlorothiazide (HCTZ) 25 mg/day and placebo were randomised to receive combined treatment with HCTZ and once-daily doses of 12." | 5.08 | The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. ( Carney, S; Kallwellis, R; Kobrin, I; Mion, D; Ribeiro, A; Viskoper, RJ; Wing, L; Zimlichman, R, 1997) |
| "Among elderly patients with isolated systolic hypertension, antihypertensive drug treatment starting with nitrendipine reduces the rate of cardiovascular complications." | 5.08 | Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. ( Arabidze, GG; Birkenhäger, WH; Bulpitt, CJ; Celis, H; de Leeuw, PW; Dollery, CT; Fagard, R; Fletcher, AE; Forette, F; Leonetti, G; Nachev, C; O'Brien, ET; Rodicio, JL; Rosenfeld, J; Staessen, JA; Thijs, L; Tuomilehto, J; Zanchetti, A, 1997) |
| "A multiple drug regimen consisting of trandolapril, verapamil and hydrochlorothiazide (HCTZ) were sequentially added in an open-label evaluation of patients with severe hypertension." | 5.08 | The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. ( Novrit, BA; Punzi, HA, 1997) |
| "The complementary action of angiotensin converting enzyme inhibitors and diuretics in the treatment of hypertension has been demonstrated in a number of studies of fosinopril and hydrochlorothiazide (HCTZ)." | 5.08 | Management of hypertension: the role of combination therapy. ( Plat, F; Saini, R, 1997) |
| "The authors made an open-comparative trial of fosinopril (Fosinorm) efficacy and tolerability in 20 patients (9 males and 11 females) with stage II mild and moderate essential hypertension accompanied with disturbed glucose tolerance and dyslipidemia." | 5.08 | [Fosinorm in the treatment of essential hypertension with a metabolic syndrome]. ( Drozdov, VN; Ivleva, AIa; Kobalava, ZhD; Kotovskaia, IuV; Moiseev, VS; Moryleva, ON, 1997) |
| "Patients with mild to moderate diastolic hypertension and LV mass in excess of 1 SD of normal values were randomized to isradipine (n = 89) or hydrochlorothiazide therapy (n = 45)." | 5.08 | Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. ( Chase, GA; Cushman, WG; Gottdiener, JS; Gottdiener, PS; Narayan, P; Papademetriou, V; Zachariah, PK, 1997) |
| "To compare with placebo the efficacies of once-daily administrations of lacidipine and hydrochlorothiazide separately and in combination to elderly patients with systolic hypertension." | 5.08 | Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. ( Arnolda, LF; Bune, AJ; Chalmers, JP; Harvey, PJ; Molloy, D; Upton, J; Wing, LM, 1997) |
| "We compared, in a prospective double-blind randomized study, the effect of the angiotensin-converting enzyme inhibitor quinapril (QUI) with that of triamterene/hydrochlorothiazide (THCT) treatment on cardiovascular end-organ damage in subjects with untreated isolated systolic hypertension (ISH)." | 5.08 | Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. ( Beltman, FW; de Graeff, PA; Havinga, TK; Heesen, WF; Lie, KI; May, JF; Meyboom-de Jong, B; Schuurman, FH; Smit, AJ; van der Veur, E, 1998) |
| "To compare the effect of four drug groups on the ambulatory circadian blood pressure (BP) pattern, amiloride hydrochlorothiazide, atenolol, nifedipine, and perindopril (5/50 mg/d, 100 mg/d, 40 mg/d, and 4 mg/d respectively, for 14 days) were alternated in each of 20 essential hypertension patients." | 5.08 | Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study. ( Moulopoulos, S; Stamatelopoulos, S; Zakopoulos, N, 1997) |
| "The antihypertensive and metabolic effects of a fixed combination of very low dose of moexipril (MO), an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide (HCTZ) were tested in a multicenter, placebo (PBO) controlled, double-blind, parallel study of men (M) and women (W) with mild to moderate essential hypertension." | 5.08 | Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. ( Chrysant, SG; Stimpel, M, 1998) |
| "The purpose of our study was to evaluate the antihypertensive efficacy, tolerability and effects on left ventricular mass of losartan over 10 months in patients with essential hypertension." | 5.08 | [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension]. ( Acitorio, M; Aquino, D; Caccavale, A; Coppolino, P; Cosimi, R; Iacono, A; Iarussi, D; Ratti, G; Rocereto, A; Tedesco, MA, 1998) |
| "The effects of two antihypertensive regimens (isradipine and hydrochlorothiazide-amiloride) on the ratio between media thickness and lumen diameter of subcutaneous arteries and on left ventricular mass in essential hypertension were compared." | 5.08 | Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. ( Aalkjaer, C; Lederballe, O; Mulvany, MJ; Schroeder, AP; Sihm, I; Thygesen, K, 1998) |
| "5 mg; diuretic, hydrochlorothiazide [HCTZ] 25 mg; and angiotension converting enzyme-inhibitor, spirapril 6 mg) on obese patients with sleep disordered breathing and hypertension were compared by the ambulatory blood pressure measurement (ABPM)." | 5.08 | Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. ( Hietanen, EK; Kantola, IM; Kataja, MJ; Pelttari, LH; Salo, TT, 1998) |
| "To compare 8 weeks of monotherapy using either felodipine extended release (ER) or a conventional diuretic therapy, triamterene/hydrochlorothiazide (HCTZ), in elderly patients with systolic hypertension." | 5.08 | Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. ( McClennen, W; Wilson, T, 1998) |
| "Since both agents were equally effective in reducing both SBP and DBP and reserpine is much cheaper than nifedipine, it is recommended that for a developing country like Zimbabwe, the combination of HCT and reserpine at the above doses should be used as the first step to treat mild to moderate hypertension without evidence of end organ damage." | 5.08 | A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. ( Manyemba, J, 1997) |
| "The present study was designed to compare the safety and efficacy of the new angiotensin-converting enzyme inhibitor moexipril with that of hydrochlorothiazide (HCTZ) in postmenopausal women with mild-to-moderate hypertension." | 5.08 | Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). ( Koch, B; Oparil, S; Stimpel, M, 1998) |
| "The aims of this study were to examine (1) the cardiac response to exercise in essential hypertension and (2) the effect of long-term enalapril treatment on cardiac reserve." | 5.08 | Divergent cardiac response to exercise in essential hypertension vs. normotension and the effect of enalapril. ( Gadsbøll, N; Giese, J; Høilund-Carlsen, PF; Jensen, BH; Leth, A; Rasmussen, S, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 5.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "During a 12-week, multicenter study to evaluate the efficacy and safety of lisinopril and hydrochlorothiazide (HCTZ) for the treatment of obesity-related hypertension, ambulatory blood pressure (ABP) monitoring was performed both at baseline and at study completion in 124 patients." | 5.08 | Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. ( Falkner, B; Hutchinson, HG; Reisin, E; Sha, L; Tuck, ML; Weir, MR, 1998) |
| "In the double-blind Systolic Hypertension in Europe (Syst-Eur) Trial, active treatment was initiated with nitrendipine (10 to 40 mg/d) with the possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12." | 5.08 | Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. ( Arabidze, G; Babeanu, S; Birkenhäger, WH; Bulpitt, CJ; Davidson, C; de Leeuw, PW; Efstratopoulos, AD; Fagard, RH; Fletcher, AE; Fogari, R; Gil-Extremera, B; Jääskivi, M; Kawecka-Jaszcz, K; Nachev, C; Petrie, JC; Seux, ML; Staessen, JA; Thijs, L; Tuomilehto, J; Webster, J; Yodfat, Y, 1998) |
| " The study included 175 (mean+/-SD age, 51+/-9 years) subjects with mild-moderate essential hypertension who had echocardiographic evidence of left ventricular (LV) hypertrophy taken from the SAMPLE study (Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation), an open-label multicenter study." | 5.08 | Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study. ( Fogari, R; Mancia, G; Omboni, S; Palatini, P; Rappelli, A, 1998) |
| "The aim of this study was to evaluate the effect of the calcium antagonist Nifedipine GITS in a double-blind, randomized comparison with the diuretic hydrochlorothiazide (HCTZ) on reduction of left ventricular (LV) mass and minimal vascular resistance in a group of essential hypertensives with left ventricular hypertrophy (LVH)." | 5.08 | Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. ( Agabiti-Rosei, E; Corbellini, C; Monteduro, C; Muiesan, ML; Rizzoni, D; Salvetti, M; Zulli, R, 1998) |
| "This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension." | 5.08 | Effects of losartan on hypertension and left ventricular mass: a long-term study. ( Aquino, D; di Salvo, G; Galzerano, D; Iacono, A; Iarussi, D; Limongelli, G; Mennella, S; Ratti, G; Tedesco, MA, 1998) |
| "At baseline, normoalbuminuria was found in 74 and 85 patients in the enalapril/hydrochlorothiazide and atenolol groups, respectively." | 5.08 | Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. ( Dollerup, J; Mogensen, CE; Nielsen, B; Nielsen, S, 1998) |
| "In 174 patients with essential hypertension and left ventricular hypertrophy, enrolled in the Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation (SAMPLE), aged 20-65 years, we measured clinic blood pressure, 24 h ambulatory blood pressure and the left ventricular mass index (echocardiography) before and after treatment with lisinopril at 20 mg with the addition of 12." | 5.08 | The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. ( Agabiti-Rosei, E; Mancia, G; Omboni, S; Parati, G; Rizzoni, D, 1998) |
| "This study compared the antihypertensive efficacy and tolerability of a combination tablet containing the vascular-selective calcium antagonist felodipine and the beta1-selective adrenergic antagonist metoprolol, with a combination tablet of captopril-hydrochlorothiazide in a randomized, double-blind trial involving 109 patients with mild to moderate hypertension." | 5.08 | Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group. ( Klein, G, 1998) |
| "One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial." | 5.08 | [Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension]. ( Batlouni, M; Castro, I; Chaves Júnior, Hde C; da Rocha, JC; Feitosa, GS; God, EM; Luna, RL; Maia, LN; Mion, D; Oigman, W; Ortega, KC; Raineri, AM; Ramirez, JA, 1998) |
| "The association of captopril with hydrochlorothiazide is effective with good tolerance, being indicated as a once a day monotherapy for mild and moderate hypertension." | 5.08 | [Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study]. ( Mion Júnior, D; Santello, JL, 1998) |
| "The purpose of this study was to assess the efficacy and tolerability of the angiotensin-converting enzyme inhibitor moexipril alone and in combination with hydrochlorothiazide versus hydrochlorothiazide monotherapy in patients with stage II and III essential hypertension." | 5.08 | Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. ( Koch, B; Stimpel, M; White, WB, 1997) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 5.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "This parallel, double-blind trial was designed to evaluate the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide (HCTZ) in patients with uncomplicated moderate to severe hypertension." | 5.07 | Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. ( Aarsland, T; Dickstein, K; Ferrari, P; Stimpel, M; Todd, M, 1994) |
| "5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old." | 5.07 | Efficacy and tolerability of 5 mg of cilazapril plus 12.5 mg of hydrochlorothiazide in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. ( Bart, T; Gasser, P; Köhler, M; LeBloch, Y; Martina, B; Rhyner, K; Weinbacher, M; Wohler, D, 1994) |
| "To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic)." | 5.07 | Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. ( Brunner, H; Dobbins, TW; Faison, EP; Irwin, R; Karlberg, BE; Lacourcière, Y; Nelson, EB; Ramsay, LE; Snavely, DB, 1994) |
| "To investigate the effects of enalapril and hydrochlorothiazide on erythrocyte sodium and potassium in relation to their effects on BP, 28 men (mean age 46 years, range 22-64 years) with previously untreated essential hypertension (casual DBP > or = 95 mmHg) were randomised to enalapril (n = 14) or hydrochlorothiazide (n = 14) treatment." | 5.07 | Relationship between change in erythrocyte sodium and antihypertensive response to enalapril. ( Dahlöf, B; Hansson, L; Herlitz, H; Jonsson, O, 1994) |
| "In a double-blind, placebo-controlled, three-period cross-over, randomized study we evaluated the efficacy and tolerability of a fixed combination of benazepril 20 mg and hydrochlorothiazide 25 mg (BN + HCT) as compared with the fixed combination of captopril 50 mg and hydrochlorothiazide 25 mg (CP + HCT) by ambulatory blood pressure monitoring (ABPM) in patients with mild to moderate hypertension." | 5.07 | Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of benazepril 20 mg plus hydrochlorothiazide 25 mg fixed combination as compared to captopril 50 mg [corrected] plus hydrochlorothiazide 25 mg fixed combination in treating mild to mod ( Fogari, R; Lusardi, P; Motolese, M; Tettamanti, F; Tettamanzi, D; Zoppi, A, 1994) |
| "This is the first report of long-term use (one year) of isradipine, a new dihydropyridine calcium channel blocker, in the treatment of elderly patients with essential hypertension." | 5.07 | One year experience of elderly hypertensive patients with isradipine therapy. ( Abrams, A; Culter, R; Hamilton, BP; Hamilton, JH; Holtzman, JL; Kirkendall, WM; Matthews, K; Neri, G; Stein, GH, 1994) |
| "The purpose of this study was to assess the long-term efficacy and safety of moexipril, a new angiotensin-converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in patients with hypertension." | 5.07 | Long-term efficacy and safety of moexipril in the treatment of hypertension. ( Fox, AA; Stimpel, M; White, WB, 1994) |
| " We assessed pharmacokinetic and pharmacodynamic interactions of the ACE inhibitor cilazapril and the beta-blocker propranolol in healthy volunteers and patients with essential hypertension." | 5.07 | Review of studies on the clinical pharmacodynamics of cilazapril. ( Belz, GG; Breithaupt, K; Erb, K, 1994) |
| "6 years) with moderate to severe essential hypertension (DBP between 105 and 116 mmHg) were randomised to eight weeks of double-blind treatment with lisinopril (n = 56) or diltiazem SR (n = 54)." | 5.07 | Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension. ( Anzalone, D; Chrysant, S; Fagan, T; Flamenbaum, W; Kaihlanen, PM; Lueg, M; Weir, MR, 1994) |
| "Patients with a history of an ACE inhibitor-associated dry cough confirmed by a second challenge with lisinopril were enrolled into an international, multicenter, randomly allocated, double-blind, parallel-group, controlled trial, to be treated with losartan, lisinopril or hydrochlorothiazide." | 5.07 | Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. ( Faison, EP; Lacourcière, Y; Lefebvre, J; Nakhle, G; Nelson, EB; Snavely, DB, 1994) |
| "In short-term studies (4 to 6 months) we have reported that antihypertensive treatment with beta-adrenergic blockade and thiazide diuretics induced insulin resistance, hyperinsulinemia, and a deranged lipid profile; the ACE inhibitor captopril increased insulin sensitivity without affecting serum lipids." | 5.07 | Long-term metabolic effects of antihypertensive drugs. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1994) |
| "The aim of this trial was to study the treatment of hypertension in the elderly, comparing a new oxazoline antihypertensive agent, rilmenidine, with the diuretic hydrochlorothiazide (HCZ)." | 5.07 | Efficacy and safety of rilmenidine in elderly patients--comparison with hydrochlorothiazide. The Belgian Multicentre Study Group. ( Corcoran, C; Coupez, G; Creytens, G; Opsomer, M; Pelemans, W; Van Dessel, A; Verhaeghe, J, 1994) |
| "A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol (0, 2." | 5.07 | A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. ( Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994) |
| "5 to 10 mg) once daily was compared with that of hydrochlorothiazide (HCTZ) (25 to 100 mg) daily in 139 patients with mild-to-moderate hypertension." | 5.07 | Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension. ( Adolphe, AB; Brescia, D; Rofman, BA; Vlachakis, ND; Zellner, SR, 1993) |
| "The results of this study indicate that cilazapril, alone or with adjunctive hydrochlorothiazide, is effective and well tolerated as treatment for mild to moderate hypertension." | 5.07 | Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension. ( Chideckel, EW; Stevenson, JG, 1994) |
| "1062 patients with moderate to severe hypertension were enrolled in an open-label multicenter trial investigating the antihypertensive efficacy and safety of the preconstituted formulation enalapril (20 mg) and hydrochlorothiazide (12." | 5.07 | [Antihypertensive effectiveness of enalapril and hydrochlorothiazide as a combination drug]. ( Banyai, M; Pirich, C, 1993) |
| "In a double-blind cross-over study, the arterial changes produced by hydrochlorothiazide were compared with those observed after the calcium antagonist felodipine in 16 patients with mild to moderate systemic hypertension." | 5.07 | Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. ( Asmar, RG; Benetos, A; Chaouche-Teyara, K; Raveau-Landon, CM; Safar, ME, 1993) |
| "This study used 24-h ambulatory blood pressure (BP) monitoring to investigate the effectiveness of a novel low-dose combination of bisoprolol/hydrochlorothiazide in adult patients with mild to moderate essential hypertension." | 5.07 | A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. ( Cardenas, P; Lewin, AJ; Lueg, MC; Targum, S, 1993) |
| "Various aspects of carbohydrate and lipid metabolism were studied in two groups of patients with mild hypertension before and after 6 months' treatment with either lisinopril (n = 10) or hydrochlorothiazide (n = 10)." | 5.07 | Glucose and lipid metabolism in essential hypertension: effects of diuretics and ACE-inhibitors. ( Andriani, A; De Cesaris, R; Filitti, V; Lamontanara, G; Ranieri, G, 1993) |
| "To identify appropriate dosages of ramipril and hydrochlorothiazide (HCT) when given in combination once a day for the treatment of essential hypertension." | 5.07 | Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. ( Bauer, B; Bender, N; Breitstadt, A; Cairns, V; Koch, G; Moreadith, C; Phillips, J; Priestley, C; Scholze, J; Vander Elst, E, 1993) |
| "Following a 2-week placebo period, 80 male and female patients with mild to moderate hypertension, aged 50 +/- 10 (mean +/- SD) years, were randomly allocated in a double-blind study to 4 weeks of treatment with the ACE inhibitor lisinopril at 20 mg once a day or the diuretic hydrochlorothiazide at 25 mg once a day." | 5.07 | Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. ( Bray-Desboscs, L; Donner, M; el Ghawi, R; Stoltz, JF; Thibout, E; Zannad, F, 1993) |
| "In an open, multicenter extension of a short-term study, 159 patients with mild to moderate hypertension were treated with either ramipril monotherapy or a combination of ramipril and hydrochlorothiazide for up to 1 year." | 5.07 | Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension--Part 2: An open long-term study of efficacy and safety. ( Bauer, B; Bender, N; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1993) |
| " Forty patients with moderate to severe hypertension and daytime ambulatory diastolic blood pressure > or = 90 mm Hg were randomized double-blind to once-daily treatment with either quinapril up to 20 mg (n = 20) or atenolol up to 100 mg (n = 20) as single drugs or in combination with hydrochlorothiazide 25 mg over a period of 12 weeks." | 5.07 | Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring. ( Lacourcière, Y; Lefebvre, J; Poirier, L; Provencher, P, 1993) |
| "The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine." | 5.07 | Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. ( Lacourcière, Y; Nadeau, A; Poirier, L; Tancrède, G, 1993) |
| "The effects of the combination of captopril and hydrochlorothiazide at modest doses of plasma lipids, lipoproteins and apolipoproteins were investigated in 139 patients with mild to moderate primary hypertension." | 5.07 | Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension. ( Gagné, C; Lacourcière, Y, 1993) |
| "We tried to assess the antihypertensive effectivity of a betablocker, celiprolol, in the control of mild to moderate essential arterial hypertension." | 5.07 | [Double blind comparative randomized study of the efficacy of celiprolol versus amiloride-hydrochlorothiazide in mild to moderate AHT]. ( Hoyos Jiménez, M; Justo Alpañés, E; Miranda García, MJ; Oliván Martínez, J; Pérez Cano, R, 1993) |
| "The effects of the calcium antagonist nitrendipine and the diuretic hydrochlorothiazide on plasma calciotropic hormone concentrations and lumbar bone density were compared during the treatment of hypertension in a randomized, double-blind, 8 week parallel study, followed by a 52 week open label study." | 5.07 | Comparative effects of nitrendipine and hydrochlorothiazide on calciotropic hormones and bone density in hypertensive patients. ( Giles, TD; Mazzu, AL; Quiroz, AC; Roffidal, LE; Sander, GE, 1992) |
| "In an open two-month study with an initial placebo period, the effect of enalapril on glucose tolerance, insulin (IRI) sensitivity and lipid profile was evaluated in 20 patients with mild to moderate essential hypertension." | 5.07 | Metabolic effects of enalapril in the treatment of essential hypertension. ( Baculáková, V; Dzúrik, R; Fedelesová, V; Oksa, A; Spustová, V; Stefíková, K, 1992) |
| "Enalapril was significantly more effective than hydrochlorothiazide in reversing left ventricular hypertrophy without negatively affecting left ventricular function." | 5.07 | Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. ( Dahlöf, B; Hansson, L, 1992) |
| "A double-blind trial of hydrochlorothiazide, timolol and enalapril was carried out in Ethiopians with essential hypertension at the Tikur Anbessa Hospital, Addis Abeba, between 1987 and 1990." | 5.07 | The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. ( Habte, B, 1992) |
| "A controlled, randomized, single-blind, parallel-group study compared the effects of nicardipine hydrochloride/hydrochlorothiazide (HCTZ) with those of pindolol/HCTZ in treatment of essential hypertension." | 5.07 | A comparative study of nicardipine and pindolol as second-line treatments in essential hypertension. ( Huikko, M; Jounela, A; Kanniainen, E; Penttila, O, 1992) |
| "Nitrendipine (bypress) manufactured by Bayer Company in the form of 10 and 20 mg tablets and administered in a dose of 20-40 mg/day turned out an effective antihypertensive remedy in 65% of patients with arterial hypertension largely running a mild course." | 5.07 | [The efficacy of nitrendipine in patients with stable arterial hypertension. The data from a cooperative study in the USSR. The Working Group for the Cooperative Study of Nitrendipine]. ( Metelitsa, VI; Ostrovskaia, TP, 1992) |
| "The effect of hydrochlorothiazide 50 mg, amiloride 5 mg (HCTZ-A) (Moduretic; MSD) and its combination with pindolol and nadolol on renal function were compared in patients with mild to moderate essential hypertension (mean untreated supine blood pressure 179 +/- 5." | 5.07 | Effects of therapy on renal impairment in essential hypertension. ( Byrne, MJ; Jennings, AA; Opie, LH; van Zyl, A, 1992) |
| "In a parallel-group multicenter study, the efficacy and safety of combination therapy with ramipril 5 mg plus hydrochlorothiazide 25 mg were compared double-blind with those of 5 mg and 10 mg ramipril monotherapy in patients with mild to moderate hypertension who had not responded adequately to ramipril 5 mg alone." | 5.07 | Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1--A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy. ( Bender, N; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D; Langley, A, 1992) |
| "The effect of 10 oral doses of phenylpropanolamine hydrochloride 25 mg four times a day on blood pressure and heart rate in Korean patients with hypertension controlled by hydrochlorothiazide was studied." | 5.07 | Effect of phenylpropanolamine hydrochloride on blood pressure in Korean patients with hypertension controlled by hydrochlorothiazide. ( Jones, DW; Jung, KM; Kim, HJ; Sands, CD, 1992) |
| "To assess the short-term efficacy and safety of metoprolol in the treatment of hypertension in a large population of older patients." | 5.07 | Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. ( Glasser, S; LaPalio, L; Schork, A; Tifft, C, 1992) |
| "The efficacy and safety of once-daily administration of the new angiotensin-converting enzyme inhibitor quinapril or quinapril plus hydrochlorothiazide (HCTZ) were assessed in 64 older (greater than 65 years) patients with mild to moderate hypertension in an uncontrolled, open-label study." | 5.07 | Efficacy and safety of quinapril in the elderly hypertensive patient. ( Forette, B; Koen, R; Vicaut, E, 1992) |
| "The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients less than or equal to 75 years of age, with borderline to moderate primary hypertension." | 5.07 | Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. ( Beck-Nielsen, H; Faergeman, O; Gall, MA; Gerdes, LU; Hommel, E; Lauritzen, M; Mathiesen, ER; Rossing, P; Skøtt, P; Vølund, A, 1992) |
| " After 1 month of receiving placebo, 165 patients with essential hypertension were randomised to perindopril 4 mg (n = 82) or to 50 mg hydrochlorothiazide + 5 mg amiloride (n = 83)." | 5.07 | A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension. ( Andrejak, M; Carré, A; Deruyttere, M; Gotzen, R; Magometschnigg, D; Santoni, JP; Stumpe, KO, 1991) |
| "The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients with mild to moderate hypertension." | 5.07 | Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1991) |
| "This multicenter study was designed to assess the clinical efficacy and safety of the new once-daily calcium antagonist lacidipine in the treatment of mild-to-moderate essential hypertension." | 5.07 | A double-blind comparison of the efficacy and safety of lacidipine and hydrochlorothiazide in essential hypertension. The Southern Italy Lacidipine Study Group. ( Chiariello, M, 1991) |
| "In the majority of hypertensive patients, treatment with 50 mg/d of hydrochlorothiazide does not cause marked hypokalemia or ventricular arrhythmias." | 5.07 | Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. ( Black, DM; Cheitlin, MD; Fine, R; Hearst, N; Hulley, SB; Sebastian, A; Seeley, DG; Siegel, D, 1992) |
| "The antihypertensive and metabolic effects of placebo (PL), a fixed combination of hydrochlorothiazide (25 mg) and triamterene (50 mg) (HCTZ/TRI), atenolol (25 mg) (Atc-25), atenolol (50 mg) (Ate-50) and their combination with HCTZ/TRI given once daily, were tested on 256 patients with mild-to-moderate essential-hypertension." | 5.07 | Antihypertensive and metabolic effects of single and combined atenolol regimens. ( Chappel, C; Chrysant, SG; Farnham, DJ; Levin, B; Lueg, M; McCluskey, D; Steiner, C, 1992) |
| "This 6-week, double-blind, parallel-group study compared the efficacy and safety of the angiotensin converting enzyme (ACE) inhibitors quinapril and captopril as initial monotherapies in patients with severe hypertension (diastolic blood pressure [DBP] greater than or equal to 115 and less than or equal to 130 mm Hg)." | 5.07 | Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril. ( Frishman, WH; Greenberg, S, 1991) |
| "Labetalol and hydrochlorothiazide (HCTZ) were compared for their efficacy in controlling hypertension of blacks in a prospective, double-blind study." | 5.07 | The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients. ( Due, D; Forbes, WP; Jenkins, P; Lucas, C; Mendels, J; Sirgo, MA, 1991) |
| "The Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) is a randomized, double-blind, active-control trial to compare the effectiveness of two treatment regimens for the control of hypertension in reducing the rate of progression of early extracranial carotid artery atherosclerosis in hypertensive patients." | 5.07 | MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data. ( Applegate, WB; Byington, RP, 1991) |
| "Seventeen patients with mild to moderate hypertension, as indicated by a diastolic blood pressure (DPB) of 95-115 mmHg (WHO I), were treated in a randomized, double-blind, parallel study, with either 5 mg of fosinopril, a new phosphinic acid-containing angiotensin converting enzyme (ACE) inhibitor, or 25 mg of hydrochlorothiazide administered orally once daily for 4 weeks after a 4- to 6-week run-in period of placebo." | 5.07 | Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. ( Backman, R; Forslund, T; Franzén, P, 1991) |
| "Sixteen patients (mean age 68 years) with mild to moderate hypertension were treated with either diltiazem or hydrochlorothiazide for 6 weeks, followed by enalapril for a further 6 weeks." | 5.07 | Effects of hydrochlorothiazide, diltiazem and enalapril on mononuclear cell sodium and magnesium levels in systemic hypertension. ( Abraham, AS; Barchilon, E; Brooks, BA; Eylath, U; Grafstein, Y; Nubani, N; Shemesh, O, 1991) |
| " In a multicenter study, 206 patients with mild to moderate hypertension were randomized to receive benazepril at a dose of 2, 5, 10, or 20 mg, hydrochlorothiazide, 25 mg, or placebo once daily for 4 weeks." | 5.07 | The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. ( Abraham, PA; Bennett, WM; Brachfeld, N; Goodman, RP; Hollifield, JW; Kirkendall, WM; Lasseter, KC; Leon, AS; McKenney, JM; Moser, M, 1991) |
| "In a randomized primary prevention trial including 3,234 men with mild to moderate uncomplicated hypertension, the effect of the beta-blocker metoprolol or a thiazide diuretic as an initial antihypertensive therapy was compared regarding the risk of sudden cardiovascular death during a follow-up ranging from 2." | 5.07 | Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. ( Barber, H; Berglund, G; Eliasson, K; Elmfeldt, D; Jastrup, B; Karatzas, N; Leer, J; Olsson, G; Tuomilehto, J; Warnold, I, 1991) |
| " To investigate the effect of an exercise training programme on antihypertensive drug requirements, 19 sedentary subjects (14 men and five women) with mild essential hypertension (systolic blood pressure greater than 140 mmHg but less than 180 mmHg), aged 29-55 years, were randomly assigned to 16 weeks of moderate intensity exercise or light intensity exercise (control), and titrated on antihypertensive drug therapy (captopril and hydrochlorothiazide) until resting systolic blood pressure (sitting) of less than 140 mmHg was achieved." | 5.07 | A controlled study of the effects of aerobic exercise on antihypertensive drug requirements of essential hypertensive patients in the general practice setting. ( Allen, DH; Beilin, LJ; Morton, AR; Puddey, IB, 1991) |
| "A double-blind, parallel-group study was performed to assess the antihypertensive effects and tolerability of felodipine and hydrochlorothiazide (HCT) in black patients with mild to moderate uncomplicated hypertension [entry supine diastolic blood pressure (DBP) of 96-116 mm Hg]." | 5.06 | Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans. ( Leary, WP; Maharaj, B, 1990) |
| "Sixty-one patients (41 men, 20 women) aged 29-73 years, with moderate to severe hypertension, were enrolled in a multicentre study to compare the efficacy, safety, and tolerability of dilevalol (D) and captopril (C)." | 5.06 | Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. ( Fraser, I; Howes, L; Kincaid-Smith, PS; Louis, W; MacDonald, G; Matthews, PG; McGrath, BP; Rallings, M; Scheinkestel, C; Whitworth, JA, 1990) |
| "Carvedilol has been shown to be effective and safe in patients with essential hypertension when given as monotherapy." | 5.06 | Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L, 1990) |
| ") as an adjunct to pre-existing hydrochlorothiazide (HCTZ) monotherapy in patients with mild to moderate hypertension [diastolic blood pressure (DBP), 100-115 mm Hg]." | 5.06 | Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; Stienen, U; Uberbacher, HJ; van der Does, R; Widmann, L, 1990) |
| "To define the efficacy and tolerability of urapidil as a monotherapy in ambulatory patients with hypertension, we compared urapidil with a standard first-line antihypertensive agent, hydrochlorothiazide (HCT), in a multicentre general practice trial." | 5.06 | Clinical aspects of antihypertensive therapy with urapidil. Comparison with hydrochlorothiazide. ( Distler, A; Haerlin, R; Hilgenstock, G; Passfall, J, 1990) |
| "The efficacy and safety of enalapril and hydrochlorothiazide was investigated in a multicenter study of 81 patients with mild to moderate essential hypertension." | 5.06 | Treatment of hypertension by enalapril and hydrochlorothiazide separately and together: a multicenter study. ( Bernheim, J; Grossman, E; Levi, J; Rathaus, M; Rogel, S; Rosenthal, T; Weinstein, J; Zevin, D, 1990) |
| "We report the results of a randomized, double-blind, parallel group multicentre study in 120 patients with moderate to severe hypertension, comparing two different types of antihypertensive treatment: a) the standard 'triple therapy' with hydrochlorothiazide, propranolol and hydralazine, and b) the combination of an ACE inhibitor, enalapril with hydrochlorothiazide (HCTZ) and methyldopa." | 5.06 | Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. ( Ambrosioni, E; Cinotti, G; Cuspidi, C; Leonetti, G; Malini, PL; Morabito, S; Pessina, A; Rappelli, A; Sampieri, L; Semplicini, A, 1990) |
| "The effect of single dose (50 mg) Captopril (C) used either alone or associated to diuretics (50 mg hydrochlorothiazide -HCTI) in the treatment of mild-moderate essential arterial hypertension was studied in a multicentric study." | 5.06 | [Captopril in single doses in the treatment mild-moderated arterial hypertension]. ( Alcántara Nicolás, J; Cano Cano, E; Cano Cano, R; Contreras, C; García Galvis, JA; García Giralda, L; González Comeche, J; Madrid Conesa, A; Ramos La Torre, F; Sánchez Moreno, J, 1990) |
| "The purpose of the study was to evaluate the effect of 6 weeks treatment with hydrochlorothiazide or propranolol on gastric acid and gastrin secretion in essential hypertension." | 5.06 | [Effect of adrenergic beta receptor blockaders and thiazide diuretics on gastric acid and gastrin secretion in patients with essential hypertension]. ( Grzeszczak, W; Kokot, F; Zukowska-Szczechowska, E, 1990) |
| "To examine the need for antihypertensive therapy and its timing, a 46 year-old woman with a 10-year history of "mild to moderate hypertension," treated for that span with 50 mg of hydrochlorothiazide per day, usually taken before retiring, carried out a study in a series of stages." | 5.06 | Longitudinal chronobiologic blood pressure monitoring for assessing the need and timing of antihypertensive treatment. ( Abramowitz, P; Cornélissen, G; Halberg, F; Little, J; Sánchez de la Peña, S; Tuna, N, 1990) |
| " We studied 13 patients with mild essential hypertension in a randomized, double-blind design to assess the effects of indomethacin on hydrochlorothiazide's ability to lower blood pressure, alter body weight, stimulate plasma renin activity, and modulate vascular prostacyclin biosynthesis as assessed by the urinary excretion of the major enzymatically produced metabolite of prostacyclin, 2,3-dinor-6-keto-prostaglandin F1 alpha (PGF1 alpha), measured by GC/MS." | 5.06 | The antihypertensive efficacy of hydrochlorothiazide is not prostacyclin dependent. ( Byyny, RL; Gerber, JG; LoVerde, M; Nies, AS, 1990) |
| "The cardioselective beta-blocker atenolol and the angiotensin-converting enzyme inhibitor enalapril were compared for efficacy, safety, and quality-of-life factors in 30 patients with hypertension whose hypertension was inadequately controlled with diuretic alone." | 5.06 | Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. ( Blumenthal, JA; Ekelund, LG; Emery, CF, 1990) |
| "A comparative study was undertaken to examine antihypertensive effects and impact of hydrochlorothiazide (HCT) alone or in combination with triamterene or amiloride on the hemodynamics of 79 patients with Stage II hypertension." | 5.06 | [Comparative study of the hypotensive action of monotherapy using hydrochlorothiazide and its combination with triamterene and amiloride and their effect on hemodynamics at rest and during exercise therapy]. ( Glezer, GA; Levinzon, AM; Lipko, DS, 1990) |
| "The efficacy of the calcium channel blocker nitrendipine alone and in combination with the beta blocking agent acebutolol or hydrochlorothiazide was tested in 34 patients with moderate essential hypertension." | 5.06 | [Therapy of moderate hypertension with the calcium antagonist nitrendipine in combination with beta receptor blocker or diuretic]. ( Kolloch, R; Müller, HM; Overlack, A; Stumpe, KO, 1990) |
| "A retrospective analysis was made from the charts of 53 patients with mild to moderate essential hypertension to determine the effects of pindolol (PIN) monotherapy, hydrochlorothiazide (HCTZ) added to PIN monotherapy, and PIN added to HCTZ monotherapy on serum lipids and blood pressure." | 5.06 | Long-term effects of pindolol and a thiazide diuretic on plasma lipids and blood pressure in patients with essential hypertension. ( Neusy, AJ; Valeri, A, 1990) |
| "The safety and efficacy of labetalol and hydrochlorothiazide (HCTZ) were compared in a group of 34 patients aged 65 years or older with mild to moderate essential hypertension." | 5.06 | Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring. ( Due, DL; Sirgo, MA; Toth, PD; Vidt, DG; Weidler, DJ, 1990) |
| "This multicenter, factorial-design trial assessed the safety and additive antihypertensive efficacy of a slow-release (SR) formulation of diltiazem hydrochloride given alone or in combination with hydrochlorothiazide for treatment of mild to moderate hypertension." | 5.06 | An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. ( Burris, JF; Cady, WJ; Oparil, S; Stewart, WH; Weber, M; Weir, MR, 1990) |
| "The antihypertensive effect and the influence on lipid metabolism of the alpha-receptor blocking drugs indoramin and prazosin given in combination with hydrochlorothiazide were investigated in patients with mild to moderate essential hypertension." | 5.06 | Comparison of the effect of indoramin and prazosin on blood pressure and lipid profiles in essential hypertension. ( Overlack, A; Stumpe, KO, 1986) |
| "The safety and efficacy of indoramin and prazosin added to hydrochlorothiazide (HCTZ) were compared in a double-blind trial involving 209 patients with mild to moderately severe essential hypertension." | 5.06 | Antihypertensive effects of indoramin and prazosin in combination with hydrochlorothiazide. ( Solomon, R, 1986) |
| "Sixty patients with mild to moderate essential hypertension, uncontrolled with diuretics alone, were evaluated in a double-blind randomized study that compared the effect of indoramin plus hydrochlorothiazide with that of pindolol plus hydrochlorothiazide." | 5.06 | A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension. ( Hartikainen, M; Luomanmäki, K, 1986) |
| "Forty patients (aged 28-66 years) with essential hypertension were randomized to 14 weeks of treatment with diltiazem or hydrochlorothiazide (HCTZ) in a double-blind, parallel study design." | 5.06 | Endocrine and vascular responses in hypertensive patients to long-term treatment with diltiazem. ( Swartz, SL, 1987) |
| "The antihypertensive effect of the combination of ketanserin, a new antiserotonergic agent, and thiazide has been evaluated in 35 patients with arterial hypertension of mild to moderate degree in the greater than 50-year-old age group." | 5.06 | Antihypertensive efficacy of the combination of ketanserin + thiazide in hypertensives older than 50 years. ( Fasano, ML; Ferrara, LA; Mancini, M; Pasanisi, F; Soro, S, 1987) |
| "The effects of monotherapy with once-daily ketanserin (40 mg) were compared to those of ketanserin (40 mg) plus hydrochlorothiazide (25 mg) once daily in 21 patients with mild essential hypertension." | 5.06 | Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily. ( Leary, WP; Maharaj, B; Reyes, AJ; van der Byl, K, 1987) |
| "Forty-four patients with uncomplicated systemic hypertension underwent 48-hour electrocardiographic monitoring before and after four weeks of treatment with hydrochlorothiazide, 100 mg daily." | 5.06 | Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. ( Burris, JF; Fletcher, RD; Freis, ED; Notargiacomo, A; Papademetriou, V, 1988) |
| "Twenty-three patients with essential hypertension were treated consecutively with prazosin or dihydrochlorothiazide or the combination of the two, each treatment period lasting for three months." | 5.06 | Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. ( Balás-Eltes, A; Farsang, C; Fehér, J; Péter, M, 1987) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with hydrochlorothiazie (HCTZ) in 145 patients with mild to moderate hypertension." | 5.06 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1988) |
| "Three hundred thirty-one patients with mild to moderate essential hypertension, 182 males and 149 females with a mean age of 54 (range, 17-87 years), were studied for 1 year in a clinical trial with ramipril, an angiotensin converting enzyme (ACE) inhibitor." | 5.06 | An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. ( Bauer, B; Lorenz, H; Zahlten, R, 1989) |
| "To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension." | 5.06 | Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1989) |
| "The efficacy and acceptability of Rilmenidine (RIL) were assessed in a multicentre, controlled, double-blind trial versus hydrochlorothiazide (HCZ) in patients with mild to moderate hypertension." | 5.06 | [Multicenter, double-blind study comparing rilmenidine 1 mg and hydrochlorothiazide 25 mg in 244 patients]. ( Fiorentini, C; Guazzi, M; Guillet, C, 1989) |
| " with light or moderate essential arterial hypertension were randomized double-blind into two subgroups of 20 subjects each, and submitted to daily combined drug treatment with either captopril 50 mg + hydrochlorothiazide 25 mg (group A) or amiloride 5 mg + hydrochlorothiazide 50 mg (group B)." | 5.06 | [Efficacy and tolerability of captopril-hydrochlorothiazide vs amiloride-hydrochlorothiazide combination in mild to moderate arterial hypertension]. ( Barlattani, M; Filippello, CP; Leone, G; Mammarella, A; Mariani, AR; Paoletti, V, 1989) |
| "5 or 5 mg once daily, was compared with that of hydrochlorothiazide 25 or 50 mg in 169 patients with mild to moderate hypertension." | 5.06 | Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Multicentre Study Group. ( Morgan, TO, 1989) |
| "Twenty patients with uncomplicated systemic hypertension underwent treadmill testing twice during placebo treatment and twice during hydrochlorothiazide treatment." | 5.06 | Diuretic therapy and exercise in patients with systemic hypertension. ( Freis, ED; Notargiacomo, A; Papademetriou, V, 1989) |
| " In a double-blind, placebo-controlled, double-dummy, randomized, parallel-group preliminary study, the antihypertensive efficacy and tolerability of the ACE inhibitor enalapril (20 mg day-1) and hydrochlorothiazide (50 mg day-1) were evaluated and compared for 4 weeks in 20 African patients with essential hypertension." | 5.06 | Enalapril and hydrochlorothiazide in hypertensive Africans. ( Ajayi, AA; Akinsola, A; Ladipo, GO; Oyewo, EA, 1989) |
| "A double-blind, parallel-group, multicentre study was carried out to compare the effects of once-daily treatment with lisinopril 20 mg and captopril 50 mg in 304 patients with mild to moderate hypertension." | 5.06 | ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group. ( Dallocchio, M; Gosse, P; Gourgon, R, 1989) |
| "Among 447 hypertensive patients, most with a history of diuretic-induced hypokalemia, 252 developed diuretic-induced hypokalemia while receiving hydrochlorothiazide, 50 mg/d." | 5.06 | Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. ( Freis, ED; Friedman, RG; Garland, WT; Hall, WD; Hollifield, J; Jain, AK; Jenkins, P; Marks, A; McMahon, FG; Schnaper, HW, 1989) |
| "Nitrendipine significantly reduces blood pressure with few side effects and no adverse metabolic effects, and offers a reasonable alternative for treating hypertension in the elderly." | 5.06 | Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine. ( Byyny, RL; LoVerde, M; Mitchell, W, 1989) |
| "This study evaluated the overall efficacy and safety of two specific vasodilators--the alpha-blocker prazosin and the angiotensin-converting enzyme inhibitor captopril--in the treatment of mild-to-moderate essential hypertension." | 5.06 | Selective alpha-blockade versus angiotensin-converting enzyme inhibition as initial antihypertensive therapy. Effects on circulating lipoproteins. ( Cervenka, JH; Dinh, T; O'Connor, DT; Takiyyuddin, MA; Witztum, JL, 1989) |
| "A randomized, drug-controlled trial was conducted to evaluate the comparative efficacy of hydrochlorothiazide versus prazosin in controlling mild diastolic hypertension in black and white patients." | 5.06 | Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients. ( Batey, DM; Jeffrey, SS; Lasser, NL; Lasser, VI; Nicolich, MJ, 1989) |
| "M-mode echocardiography was used in 80 patients with essential hypertension to study changes in the index of left ventricular mass during treatment over 3 years with reserpine, prazosin, indapamide and atenolol, separately or in combination." | 5.06 | The effect of chronic antihypertensive therapy on the index of left ventricular mass in patients with essential hypertension. ( Duman, EL; Komsuoğlu, B; Komsuoğlu, SS; Ozgür, O, 1989) |
| " Thirty-eight patients with mild to moderate essential hypertension (seated diastolic 95-110 mm Hg) were randomized double-blind to treatment with either zofenopril (n = 19) or hydrochlorothiazide (n = 19) over a period of 12 weeks." | 5.06 | Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. ( Lacourcière, Y; Provencher, P, 1989) |
| "Nineteen men with mild to moderate hypertension and without a history of cardiac arrhythmias were randomized (double-blind) into groups to receive hydrochlorothiazide (HCTZ) at a dose of 25 mg/day, HCTZ at 50 mg/day, or HCTZ (25 mg) plus triamterene (50 mg) for a six-month period after a three-week (single-blind) placebo period." | 5.06 | Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension. ( Hamilton, BP; Hamilton, J; Peters, RW, 1989) |
| "In this double blind study we have evaluated the efficacy and tolerability of the association Captopril 50 mg + hydrochlorothiazide 15 mg/die vs hydrochlorothiazide 25 mg/die in aged patients with hypertension." | 5.06 | [Evaluation of the efficacy and tolerability of a fixed dose combination of captopril (CPT) 50 mg and hydrochlorothiazide (HCTZ) 15 mg in the elderly]. ( Antonicelli, R; Bossini, A; Botta, GF; Paciaroni, E; Raffaelli, S; Zingaretti, P, 1989) |
| "A comparative study of the antihypertensive effects of hydrochlorothiazide (HCT) monotherapy and of its combinations with triamterene (T), carried out in 57 patients with Stage II noncomplicated essential hypertension, have shown the best antihypertensive effect of 2 tablets of triampur (TP), containing 12." | 5.06 | [Hypotensive effect of hydrochlorothiazide and its combination with triamterene]. ( Glezer, GA; Levinzon, AM, 1989) |
| "This double-blind placebo controlled study investigated the antihypertensive and humoral effects of nifedipine capsules in patients with essential hypertension inadequately controlled (seated diastolic blood pressure greater than or equal to 95 mm Hg) by hydrochlorothiazide (HCTZ) alone." | 5.06 | Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone. ( Abraham, PA; Halstenson, CE; Opsahl, JA, 1989) |
| "The efficacy of captopril 25 mg/day as monotherapy or when necessary, in association with hydrochlorothiazide 25 mg/day, was studied during three months in 472 patients, average age 45 (17-59) years, 51% males with mild (73%) 95 less than PAD less than 104 mmHg, and moderate (27%) arterial hypertension 104 less than PAD less than 114 mmHg." | 5.06 | [Treatment of mild and moderate hypertension with the use of captopril alone or combined with hydrochlorothiazide. A multicenter study]. ( Lion, MF; Lion, R; Nascimento, LO; Pesquisadores, E, 1989) |
| "The antihypertensive efficacy and tolerability of the 5HT2-receptor antagonist ketanserin was investigated in 188 patients aged 41 to 82 years with mild to moderate essential hypertension." | 5.06 | [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy]. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Reutter, F; Vallotton, MB, 1989) |
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 5.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "In 30 patients with mild hypertension (diastolic blood pressure, 95 to 105 mmHg), the antihypertensive effect of rilmenidine 1 mg was compared in a double-blind study, with the effect of hydrochlorothiazide 25 mg." | 5.06 | Effort blood pressure control in the course of antihypertensive treatment. ( Ausiello, M; Brignoli, M; de Divitiis, O; Di Somma, S; Galderisi, M; Liguori, V; Magnotta, C; Natale, N; Petitto, M, 1989) |
| " Twelve middle-aged black women with essential hypertension, controlled with 50 mg hydrochlorothiazide per day, randomly received 3200 mg ibuprofen and a placebo for 8 days." | 5.06 | The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide. ( Bryan, DL; Cooper, LW; Lambert, CM; Lehany, AM; McKenney, JM; Wright, JT, 1989) |
| "The efficacy of a new angiotensin converting enzyme inhibitor, lisinopril, used alone (group A) was compared with lisinopril plus hydrochlorothiazide (group B) in 26 patients with essential hypertension." | 5.06 | Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension. ( Lopez, LM; Mehta, J; Thorman, AD, 1988) |
| "In a multicenter, multinational study, 200 patients with essential hypertension were treated with a fixed dose of Enalapril (E) 20 mg/day after a 2- to 4-week placebo period." | 5.06 | Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. ( Acosta, JH; Bolzano, K; Dahlöf, B; Fairhurst, G; Ferreira, C; Hansson, L; Kaarsalo, E; Silva, MC; Simone, A, 1988) |
| "Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderate essential hypertension." | 5.06 | Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. ( Frishman, WH; Goldberger, J; Sherman, D, 1987) |
| " To validate this principle, we studied 38 elderly males (aged greater than or equal to 65 years) with mild to moderate hypertension, comparing hemodynamic responses to and subjective impressions of enalapril or hydrochlorothiazide (HCTZ)." | 5.06 | Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension. ( Gums, JG; Lopez, LM; McCarley, DL; Quay, GP; Stein, GH, 1988) |
| "The antihypertensive efficacy and tolerability of lisinopril, a new long acting angiotensin converting enzyme inhibitor, and nifedipine, in a retard formulation, were compared in a randomized six month double-blind study, in 45 patients with essential hypertension." | 5.06 | Lisinopril in essential hypertension: a six month comparative study with nifedipine. ( Breckenridge, AM; Grimmer, SF; Johnston, GD; Kondowe, G; Meany, B; Richardson, PJ, 1987) |
| "The effect of sulindac on renal function and blood pressure was compared with those of placebo, piroxicam, and naproxen in 20 patients with primary hypertension being treated with a diuretic and a beta-blocker." | 5.06 | Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. ( Freeman, D; Lamki, L; McDonald, JW; Spence, JD; Wong, DG, 1986) |
| "The efficacy and safety of terazosin were compared with those of other antihypertensive drugs in three parallel-group, randomized, double-blind studies in which 133 patients with mild to moderate hypertension participated." | 5.06 | Comparative trials of terazosin with other antihypertensive agents. ( Ruoff, G, 1986) |
| "The blood pressure of patients with hypertension who were aged between 60 and 75 years responded equally well to treatment with metoprolol (100 mg a day) or hydrochlorothiazide (25 mg a day) in a double-blind study which employed random allocation to two parallel groups." | 5.06 | Metoprolol or hydrochlorothiazide in patients with hypertension aged 60-75 years. With special reference to assessment of compliance. Hunter Hypertension Research Group. ( , 1986) |
| "9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84." | 5.06 | Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. ( Claessens, J; Nelemans, F; Riesen, W; Streulens, Y; Trost, BN; Weidmann, P, 1987) |
| "The efficacy and tolerability of the alpha-blocker prazosin was compared with that of atenolol, a beta-blocker, in the long-term treatment of uncomplicated, essential hypertension." | 5.06 | The long-term antihypertensive effects of prazosin and atenolol. ( Itskovitz, HD; Khoury, S; Krug, K; Mollura, JL, 1989) |
| "Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist which has been shown to be effective and well tolerated in the treatment of hypertension given in once-daily doses as monotherapy for up to 1 year or as an adjunct to thiazide or beta-adrenoceptor blockers." | 5.06 | The antihypertensive effects of doxazosin: a clinical overview. ( Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986) |
| "The safety and antihypertensive efficacy of PN 200-110 (isradipine), a novel calcium antagonist, are discussed in a preliminary report of double-blind, multicenter, controlled, phase III clinical trials for essential hypertension." | 5.06 | Treatment of essential hypertension with PN 200-110 (isradipine). ( Hamilton, BP, 1987) |
| "The effects of 10 weeks of treatment with isradipine (ISRP), a new dihydropyridine Ca antagonist, was evaluated in a prospective, randomized, double-blind, parallel group, hydrochlorothiazide (HCTZ) controlled study in patients with mild to moderate hypertension." | 5.06 | Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study. ( Gonasun, LM; Goodman, RP; Kirkendal, WM; Kontos, HA; Mohanty, PK; Samuel, P; Wright, JT, 1988) |
| "In 24 patients with mild/moderate essential hypertension, we studied the effects of captopril with/without hydrochlorothiazide (Htz) on blood pressure, the renin-angiotensin system, blood bradykinin concentration (BBK), plasma volume, exchangeable sodium and glomerular filtration." | 5.06 | Converting enzyme inhibition in mild and moderate essential hypertension. II. ( Damkjaer Nielsen, M; Giese, J; Ibsen, H; Leth, A; Nielsen, F; Rasmussen, S, 1986) |
| "Twenty-seven subjects with essential hypertension were prospectively followed for a minimum of 100 weeks, receiving either enalapril monotherapy or enalapril and hydrochlorothiazide combination therapy." | 5.06 | Humoral effects of long-term oral enalapril therapy. ( Bauer, JH; Reams, GP, 1986) |
| "Patients with moderate to severe essential hypertension (mean untreated supine blood pressure 190/112 mm Hg) received once daily enalapril 20-40 mg or atenolol 50-100 mg, supplemented if required by hydrochlorothiazide 25-100 mg, in a randomized observer-blind trial." | 5.06 | Enalapril in moderate to severe hypertension: a comparison with atenolol. ( Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986) |
| "The hypotensive and hormonal effects of the angiotensin converting enzyme (ACE) inhibitor enalapril (10 mg twice daily) were compared with those of hydrochlorothiazide (25 mg twice daily), with the two drugs in combination and with placebo in 21 patients with essential hypertension." | 5.06 | Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. ( Bune, AJ; Cain, MD; Chalmers, JP; Elliott, JM; Graham, JR; Morris, MJ; Southgate, DO; West, MJ; Wing, LM, 1986) |
| "The effects of lisinopril (MK-521; MSD) and atenolol in the treatment of mild-to-moderate essential hypertension were compared in a double-blind, parallel, controlled study, with 24 patients randomly assigned to lisinopril and 12 to atenolol." | 5.06 | A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension. ( Parag, KB; Seedat, YK, 1987) |
| "The pharmacokinetics of free unchanged captopril, total captopril and hydrochlorothiazide (HCTZ) were investigated in three groups of patients with moderate essential hypertension and normal renal function on the first and on the 45th days of an oral treatment with either captopril (50 mg once daily, n = 7) or HCTZ (25 mg once daily, n = 10) or their combination captopril 50 mg + HCTZ 25 mg once daily, n = 8." | 5.06 | Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ( Giudicelli, JF; Mattei, A; Richer, C, 1987) |
| "Twenty-four black men with mild to moderate essential hypertension were enrolled in an open-label trial comparing the efficacy of two doses of Capozide (captopril and hydrochlorothiazide)." | 5.06 | Treating black hypertensives with capozide. ( Cobbol, C; Katz, LA, 1988) |
| "The effects of hydrochlorothiazide (HCTZ) and guanabenz monotherapy on blood pressure and serum lipoprotein levels were compared in a 14-week, randomized, parallel, double-blind multicenter study of 218 outpatients with mild hypertension." | 5.06 | Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. ( Grundy, S; Kaplan, NM, 1988) |
| "We compared the effect on serum lipids of an alpha-blocker (prazosin) and a diuretic (hydrochlorothiazide) used as initial antihypertensive drug treatment for 102 men and women with less severe hypertension (average entry blood pressure, 148/97 mm Hg, with no major organ system damage)." | 5.06 | Initial antihypertensive drug therapy. Final report of a randomized, controlled trial comparing alpha-blocker and diuretic. ( Berkson, DM; Dyer, AR; Gosch, FC; Hershinow, P; Stamler, J; Stamler, R, 1988) |
| "One hundred fifty-nine patients with essential hypertension were randomly assigned to take 10 mg of tripamide or 50 mg of hydrochlorothiazide once a day for 12 weeks." | 5.06 | Multicenter private practice comparison of tripamide and hydrochlorothiazide in the treatment of hypertension. ( Adams, RC; Bope, ET; Brewer, SC; Cairns, CB; Fosnaugh, NR; Leidheiser, PC; Platt, CW; Polsley, JS; Romaker, RR; Scarbrough, SD, 1988) |
| "A randomized controlled, single-blind trial was conducted to compare the effectiveness of a high-dose diuretic with a combination of a diuretic and metoprolol in black adults with hypertension." | 5.06 | Diuretics and hypertension in black adults. ( Dieckmann, MR; Hawkins, DW; Horner, RD, 1988) |
| "In a double-blind parallel group study carried out on 47 patients with mild to moderate essential hypertension, the effects of 6 mg piretanide once or twice daily on serum selenium levels were compared with 50 mg hydrochlorothiazide plus 5 mg amiloride before treatment and after 6 and 12 weeks of treatment." | 5.06 | Serum selenium levels in diuretic-treated hypertensives: a double-blind trial of piretanide against hydrochlorothiazide plus amiloride. ( Bossaller, W; Malerczyk, V; Verho, M, 1988) |
| "Eighty one patients with uncomplicated hypertension who required additional antihypertensive medication (diastolic Phase V [dBP] greater than or equal to 95 mm Hg) after 4 weeks treatment with hydrochlorothiazide (HCTZ) 25 mg o." | 5.06 | A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension. ( Carle, WK; Latta, D; Lees, CT; Lough, JR; Peers, EM; Pender, J; Richardson, PD; Ross, JR; Sefton, S, 1988) |
| "A double-blind parallel group study was carried out in patients with mild to moderate hypertension to assess the effects of 6 mg piretanide once or twice daily, in comparison to 50 mg hydrochlorothiazide plus 5 mg amiloride once daily, on serum trace-element levels over a period of three months." | 5.06 | Serum trace-element levels in piretanide-treated hypertensives: a double-blind trial against hydrochlorothiazide plus amiloride. ( Bossaller, W; Heinen, B; Verho, M, 1987) |
| "A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure." | 5.06 | Captopril-related (and -induced?) asthma. ( Popa, V, 1987) |
| "A double-blind parallel group study was conducted to examine the effects of oral labetalol, in doses from 100 to 800 mg BID, and propranolol, 40 to 320 mg, in patients with mild to moderate hypertension." | 5.06 | Labetalol compared with propranolol in the treatment of black hypertensive patients. ( Curry, C; Hinds, J; Kong, BW; Medakovic, M; Poland, M; Roper, K; Saunders, E, 1987) |
| "In a double-blind parallel-group study 133 patients with mild to moderate essential hypertension were randomised to felodipine 5mg twice daily or Moduretic mite every morning after a run-in placebo period of 1 to 2 weeks." | 5.06 | Felodipine versus Moduretic. A double-blind parallel-group multicentre study. ( Flygt, G; Krönig, B, 1987) |
| "Twenty-nine subjects with mild to moderate essential hypertension completed this 13 week randomized, double-blind, placebo-controlled study comparing the antihypertensive effects of nifedipine GITS (N) (30-60 mg/day), hydrochlorothiazide (H) (25-50 mg/day) and placebo (P)." | 5.06 | Nifedipine GITS and hydrochlorothiazide in essential hypertension. ( Callender, K; Halperin, AK; Hashimoto, F; Jueng, C, 1987) |
| "The results of a multicenter trial conducted in order to determine the therapeutic efficacy of the gastrointestinal therapeutic system (GITS) formulation of nifedipine in comparison with hydrochlorothiazide and placebo in the management of mild to moderate essential hypertension are presented." | 5.06 | Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. ( Crook, J; Garrett, B; Gavras, H; Gavras, I; Halperin, AK; Higgins, JT; Mulinari, R; Reeves, RL; Zawada, ET, 1987) |
| "Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment." | 5.06 | An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. ( Allman, S; Backhouse, CI; Crawford, RJ; Platt, J, 1988) |
| "The efficacy of diltiazem (DTZ) (Tilazem; Parke-Davis) 90-180 mg twice daily was compared with that of hydrochlorothiazide (HCT) 25-50 mg once daily in the monotherapy of mild-to-moderate essential hypertension using a double-blind, double-dummy technique." | 5.06 | Diltiazem compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. ( Leary, WP; van der Byl, K, 1988) |
| "To study the effect of a combination of amiloride, 5 mg, and hydrochlorothiazide, 50 mg (Moduretic), on plasma and skeletal muscle electrolytes in patients on long-term diuretic therapy (greater than 1 year) for arterial hypertension and/or congestive heart failure, 58 patients were recruited." | 5.06 | Amiloride prevents thiazide-induced intracellular potassium and magnesium losses. ( Dyckner, T; Wester, PO; Widman, L, 1988) |
| "The antihypertensive effectiveness of a combination of ketanserin 20 mg plus hydrochlorothiazide 25 mg has been evaluated in 20 patients with arterial hypertension of mild to moderate degree in the age group over 50 years (age range 50-78 years)." | 5.06 | Blood pressure during a combination of ketanserin and hydrochlorothiazide. ( Celentano, E; Farinaro, E; Fasano, ML; Ferrara, LA; Mancini, M; Soro, S, 1987) |
| "A double-blind multicenter study compared oral acebutolol (n = 182) with hydrochlorothiazide (n = 178) in the treatment of mild to moderate essential hypertension (diastolic blood pressure 95 to 114 mm Hg)." | 5.06 | Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. ( Singh, BN; Thoden, WR; Wahl, J, 1986) |
| "The efficacy and tolerance of the loop diuretic muzolimine were compared with those of a fixed combination of hydrochlorothiazide and amiloride in patients with mild to moderate hypertension." | 5.06 | Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension. ( Clementy, J; Wicker, P, 1986) |
| "After three weeks' administration of placebo, three groups of eight patients with moderate hypertension were randomly assigned to single daily dose, double-blind treatment with either pindolol 15 mg, hydrochlorothiazide 50 mg, or a combination of both for eight weeks." | 5.06 | The influence of pindolol and hydrochlorothiazide on blood pressure, and plasma renin and plasma lipid levels. ( Johnson, BF; Johnson, J; Marwaha, R; Weiner, B, 1986) |
| "After a run-in period of 8 weeks on a regimen of hydrochlorothiazide (HCT, median dosage 75 mg/day), patients with essential hypertension were randomly allocated to continued hydrochlorothiazide therapy (Group I) or additional treatment with amiloride (Group II, median dosage 15 mg/day, or 5 mg per 25 mg hydrochlorothiazide) for the following 12 weeks." | 5.06 | Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients. ( Dige-Petersen, H; Giese, J; Ibsen, H; Leth, A; Nielsen, MD; Rasmussen, S; Svendsen, UG, 1986) |
| "We conducted a multicenter randomized double-blind clinical trial among 626 men with mild to moderate hypertension to determine the effects of captopril, methyldopa, and propranolol on their quality of life." | 5.06 | The effects of antihypertensive therapy on the quality of life. ( Brown, B; Bulpitt, CJ; Croog, SH; Jenkins, CD; Klerman, GL; Levine, S; Testa, MA; Williams, GH, 1986) |
| "5 mg of amiloride with 25 mg of hydrochlorothiazide alone was conducted in 40 elderly patients with mild to moderate hypertension." | 5.06 | Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients. ( Juustila, H; Kinnunen, O; Koistinen, P; Salmela, PI, 1986) |
| "The safety and efficacy of captopril in geriatric patients with mild to moderate hypertension was examined in an eight-week multicenter study of 99 patients." | 5.06 | Low-dose captopril in mild to moderate geriatric hypertension. ( Katz, LA; Kirkendall, WM; Koeppe, PR; Ruoff, GE; Sapir, DG; Tuck, ML, 1986) |
| "In order to assess the neurohormonal responses to oral administration of two drugs with different antihypertensive mechanisms, and their implications for long-term efficacy, we studied the changes in plasma renin activity, aldosterone, catecholamines and blood pressure after two cross-over periods of treatment with captopril and hydrochlorothiazide for three months in 14 patients with moderate essential hypertension." | 5.06 | Neurohormonal responses to antihypertensive treatment with captopril or hydrochlorothiazide. ( Balcells, A; Gaya, J; Ingelmo, M; Rabinad, E; Rivera, F, 1986) |
| "The influence of hydrochlorothiazide and atenolol on serum lipoproteins was investigated in a randomized, prospective study on 68 men with essential hypertension." | 5.06 | Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial. ( Holzgreve, H; Middeke, M; Schwandt, P; Weisweiler, P, 1987) |
| "The safety and efficacy of sustained-release diltiazem, 120 to 180 mg twice daily, was compared with those of hydrochlorothiazide, 25 to 50 mg twice daily, in 207 patients with mild-to-moderate hypertension (supine diastolic blood pressure [BP] 95 to 114 mm Hg) using a baseline, placebo, parallel-design study protocol." | 5.06 | Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension. ( Frishman, WH; Kirkendall, W; Lunn, J; McCarron, D; Moser, M; Schnaper, H; Smith, LK; Sowers, J; Swartz, SL; Zawada, ET, 1987) |
| "In an open triple crossover study in 8 patients with essential hypertension, the possibility has been investigated of whether the blood pressure lowering effect of hydrochlorothiazide 50 mg once daily was attenuated by co-administration for 4 weeks of ibuprofen 400 mg t." | 5.06 | The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. ( Gribnau, FW; Koopmans, PP; Thien, T, 1987) |
| "A multicentre controlled trial was carried out to determine the optimal dosage of a 2/1 combination of captopril plus hydrochlorothiazide (HCTZ) in mild hypertension at three doses against placebo in a 6 week double-blind trial." | 5.06 | Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension. ( Childs, M; Lancrenon, S; Languillat, JM; Mattei, A; Millet, B; Schwebig, A; Stephan, A; Steru, D, 1987) |
| "The hypotensive effect of captopril 50 mg twice daily and of captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily was studied in 12 patients with mild to moderate essential hypertension, whose blood pressure was not normalized by captopril 25 mg twice daily alone." | 5.06 | Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension. ( Ardesch, HG; De Bruijn, JH; Meijer, JL; Van Rooijen, JC, 1987) |
| "An open, randomized, multicentre, comparative trial on 2128 patients with mild-to-moderate hypertension, treated with so-called perceived best therapy or a combination of captopril plus hydrochlorothiazide (HCTZ), was conducted over a period of 10 weeks." | 5.06 | Captopril in combination with hydrochlorothiazide: comparative efficacy vs perceived best therapy. ( Holzgreve, H; Osterkorn, K; Runge, J, 1987) |
| "The purpose of our study was to determine the effects of treatment with hydrochlorothiazide (n = 10) or diltiazem (n = 8) on reflex humoral, hemodynamic, and vascular responses to graded lower body negative pressure in subjects with mild to moderate hypertension (supine diastolic pressure, 95-114 mm Hg)." | 5.06 | Effects of hydrochlorothiazide and diltiazem on reflex vasoconstriction in hypertension. ( Mohanty, PK; Sowers, JR; Thames, MD, 1987) |
| "The effects of 5 mg bendroflumethiazide plus 15 mmol potassium chloride versus 50 mg hydrochlorothiazide plus 5 mg amiloride on blood pressure and serum electrolytes were investigated in a 12-week, open, randomized study with parallel treatment groups." | 5.06 | The effects of bendroflumethiazide/potassium chloride versus hydrochlorothiazide/amiloride on blood pressure and serum electrolytes in patients with mild to moderate hypertension seen in general practice. ( Bredesgaard, P; Johansen, P; Jørgensen, F, 1986) |
| "The effect of a propranolol-hydrochlorothiazide combination tablet was compared with the effects of its two components alone in the twice-daily treatment of mild to moderate essential hypertension (100 to 125 mmHg diastolic blood pressure)." | 5.05 | Propranolol-hydrochlorothiazide combination in essential hypertension. ( Mullane, JF; Stevens, JD, 1982) |
| "eu in July 2020 to identify studies that investigate the effect of the combination of angiotensin receptor blocker with chlorthalidone or hydrochlorothiazide on the systolic and diastolic blood pressure in patients with hypertension." | 5.05 | Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2020) |
| "Patients with mild to moderate essential hypertension were treated in four centers with hydrochlorothiazide (HCTZ) 25 mg daily for 4 weeks." | 5.05 | Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension. ( Glasser, SP; Leibowitz, DA; McMahon, SG; Ram, CV; Schoenberger, JA; Vanov, SK, 1984) |
| "Fifty-three patients with mild to moderate essential hypertension were treated with enalapril (10-40 mg q." | 5.05 | Long-term antihypertensive, metabolic and cellular effects of enalapril. ( Ambrosioni, E; Magnani, B; Malini, PL; Strocchi, E, 1984) |
| "When added to hydrochlorothiazide, enalapril is as effective as captopril in the treatment of moderate to severe hypertension." | 5.05 | The efficacy and safety of enalapril in moderate to severe essential hypertension. ( Kramsch, DM; Kulaga, SF; Walker, JF, 1984) |
| " In controlled trials, 2249 subjects, who included normal volunteers and patients with hypertension and congestive heart failure, have received enalapril alone or concomitantly with hydrochlorothiazide or other antihypertensive agents." | 5.05 | Overall tolerance and safety of enalapril. ( Kulaga, SF; McFate Smith, W; Moncloa, F; Pingeon, R; Walker, JF, 1984) |
| " Patients with uncomplicated essential hypertension were randomly allocated to one of two stepped-care treatment groups: enalapril 20 mg once-a-day, or placebo as the first step, followed when necessary by the successive addition of hydrochlorothiazide (25 and 50 mg), oxprenolol (160 and 320 mg) and dihydralazine (50 and 100 mg)." | 5.05 | A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension. ( Alhenc-Gelas, F; Amiot, AM; Chatellier, G; Corvol, P; Ménard, J; Sassano, P, 1984) |
| "Enalapril and enalapril/hydrochlorothiazide are effective in treating mild to moderate essential hypertension, and efficacy has been demonstrated for up to 48 weeks." | 5.05 | A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. ( Vidt, DG, 1984) |
| "Women with previously untreated arterial hypertension have been followed up during ten years of beta-blocker treatment, first for three years with alprenolol and then for seven years with the selective beta1-blocker metoprolol." | 5.05 | Seven years on a selective beta-blocker - metoprolol. A long-term study of women with arterial hypertension. ( Bengtsson, C, 1981) |
| " In 14 patients with mild to moderate essential hypertension, the effects of bucindolol, hydrochlorothiazide and their combination on blood pressure (BP), heart rate (HR) and parameters of the renin-aldosterone system were compared with those after placebo." | 5.05 | Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension. ( Fedder, IL; Ferguson, RK; Rocci, ML; Rotmensch, HH; Soyka, L; Swanson, BN; Vlasses, PH, 1984) |
| "We randomized 495 men with uncomplicated hypertension (diastolic BP, 92 to 109 mm Hg) to one of five captopril regimens at the following dosages: 12." | 5.05 | Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1984) |
| "The effect of low doses (25 mg three times a day) of captopril was evaluated in 16 patients with mild to moderate essential hypertension, previously uncontrolled by hydrochlorothiazide." | 5.05 | Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment. ( Ferguson, RK; Mojaverian, P; Rotmensch, HH; Swanson, BN; Vlasses, PH, 1982) |
| "Eight patients with essential hypertension completed a double-blind, randomly allocated crossover comparison of either 5 or 10 mg enalapril maleate, 50 mg hydrochlorothiazide, or their combination administered once daily during sequential two-week periods." | 5.05 | A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension. ( Ferguson, RK; Irvin, JD; Lee, RB; Swanson, BN; Vlasses, PH, 1982) |
| " We studied the effect of the ACEI captopril (CAP) on the urinary excretion of 6-keto-PGF2 alpha (6-KF), the major metabolite of the vasodilatory prostaglandin, prostacyclin, and thromboxane B2 (TxB2), the stable metabolite of the vasoconstrictor TxA2, in 8 patients with essential hypertension after placebo, two weeks of CAP 25 mg t." | 5.05 | Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients. ( Ferguson, RK; Rotmensch, HH; Smith, JB; Swanson, BN; Vlasses, PH, 1983) |
| "Thirty-nine patients were entered into a 12-week, randomized, double-blind, parallel protocol to assess the safety and efficacy of enalapril (MK-421, 10 to 20 mg bid), hydrochlorothiazide (HCTZ, 25 to 50 mg bid), or combined drug therapy (MK-421 + HCTZ) for the treatment of primary hypertension." | 5.05 | Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. ( Bauer, JH; Jones, LB, 1984) |
| "Twenty-five patients with essential hypertension were given 50 mg of hydrochlorothiazide twice daily." | 5.05 | Double-blind study of guanabenz acetate in hypertensive patients. ( Grenfell, RF, 1983) |
| "In a multicenter randomized double-blind trial, we compared the antihypertensive effects of 12 weeks of therapy using timolol maleate, a new beta-adrenergic blocking agent, alone and in combination with hydrochlorothiazide, and hydrochlorothiazide alone in 70 outpatients with mild to moderate uncomplicated essential hypertension (61 of whom completed the study)." | 5.05 | A multiclinic double-blind comparison of timolol and hydrochlorothiazide alone and in combination in th e treatment of essential hypertension. ( Hunninghake, DB; Leon, AS, 1983) |
| "The effects on blood pressure, the renin-angiotensin-aldosterone and the kallikrein-kinin systems were investigated in 32 patients with primary hypertension WHO stage I-II treated with captopril." | 5.05 | Captopril, aldosterone and urinary kallikrein in primary hypertension. ( Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1983) |
| "A double-blind trial was carried out in 24 patients with mild hypertension to compare the efficacy and tolerability of indapamide with that of a standard thiazide diuretic, hydrochlorothiazide." | 5.05 | Indapamide in the treatment of essential arterial hypertension: results of a controlled study. ( Plante, GE; Robillard, C, 1983) |
| "An open study was carried out to assess the efficacy of indoramin used as second step therapy in 30 patients with moderate to severe hypertension who had failed to respond adequately to monotherapy with a thiazide or beta-blocker." | 5.05 | Indoramin as second step therapy in the management of benign essential hypertension. ( Gherardi, S; Manzoli, U; Mazzari, M; Montenero, AS; Schiavoni, G, 1983) |
| " The effects of labetalol and hydrochlorothiazide on the hypertension and ventilatory function of patients with both hypertension and mild reversible chronic pulmonary disease were compared." | 5.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. ( Chetty, KG; Light, RW; Stansbury, DW, 1983) |
| "The antihypertensive effects of oral labetalol, a new alpha- and beta-adrenergic blocking agent, and metoprolol, a relatively beta1 selective adrenergic blocker, were evaluated in 91 patients with mild to moderate hypertension (standing diastolic blood pressure of 90 to 115 mm Hg) in a double-blind parallel group multicenter clinical trial." | 5.05 | Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. ( Frishman, WH; Johnson, BF; Michelson, EL; Poland, MP, 1983) |
| "Labetalol, a new alpha- and beta-adrenergic blocking agent, was administered to 57 patients with essential hypertension whose standing diastolic blood pressure was 105 to 120 mm Hg after three and four weeks of placebo therapy and greater than 90 mm Hg after three to four weeks of therapy with hydrochlorothiazide, 25 mg twice a day." | 5.05 | Step II treatment with labetalol for essential hypertension. ( Bloomfield, SS; Gantt, CL; Lucas, CP; Medakovic, M; Poland, MP, 1983) |
| "We measured the first dosage effect and the long-term effect of lofexidine on blood pressure, heart rate, plasma catecholamines, and their major metabolites in 16 patients with primary hypertension who were receiving 50 mg hydrochlorothiazide twice a day while they were recumbent and upright and during isometric handgrip contraction." | 5.05 | Hemodynamic effect of lofexidine with a diuretic in hypertension. ( Alexander, N; Maronde, RF; Velasquez, M; Vlachakis, ND, 1983) |
| "The effects of clonidine, naloxone, and their combination on arterial blood pressure (BP), heart rate (HR), and hemodynamic and biochemical parameters were examined in 29 patients with essential hypertension." | 5.05 | Reversal by naloxone of the antihypertensive action of clonidine: involvement of the sympathetic nervous system. ( Farsang, C; Fekete, M; Kapocsi, J; Kunos, G; Malisak, Z; Vajda, L; Varga, K, 1984) |
| "Twenty-five patients with essential hypertension were randomly assigned to treatment with either captopril or atenolol." | 5.05 | Captopril or atenolol in essential hypertension. ( Andrén, L; Hansson, L; Svensson, A, 1983) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 119 patients with a diastolic pressure (DP) between 95 and 120 mmHg were randomised and treated either with 50 mg hydrochlorothiazide (n = 59) or 100 mg atenolol (n = 60)." | 5.05 | Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1984) |
| "One thousand four hundred and two patients with essential hypertension were treated by their general practitioners for 3 months with one tablet daily consisting of 200 mg acebutolol plus 12." | 5.05 | Treatment of essential hypertension with beta-blocker plus diuretic: a study of 1402 patients treated by general practitioners with acebutolol 200 mg combined with hydrochlorothiazide 12.5 mg ('Secadrex') once daily for 3 months. ( Baker, PG; McGowan, GK, 1984) |
| "The metabolic effects of piretanide (2 x 6 mg daily) were compared with those of hydrochlorothiazide, in doses of 2 x 25 mg or 2 x 50 mg daily, in a double-blind study consisting of three parallel groups totalling 15 patients with uncomplicated essential hypertension." | 5.05 | The effects of piretanide on catecholamine metabolism, plasma renin activity and serum aldosterone: a double-blind pilot comparison against hydrochlorothiazide in patients with essential hypertension. ( Bückert, C; Kirsten, R; Verho, M, 1984) |
| "Fifty patients (25 Blacks and 25 Indians) suffering from mild-to-moderate hypertension (supine diastolic blood pressure 100 - 105 mmHg) were studied in order to compare the antihypertensive effect of a combination of a beta-blocker (sotalol hydrochloride 160 mg/d) plus a thiazide derivative (hydrochlorothiazide 25 mg/d) ( Sotazide ; B-M) with that of a combination of reserpine 0,1 mg/d ( Serpasil ; Ciba) plus hydrochlorothiazide 25 mg/d ( Dichlotride ; Frosst MSD)." | 5.05 | Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients. ( Bhigjee, AI; Hoosen, S; Seedat, YK, 1984) |
| "The efficacy of transdermal clonidine, alone and in combination with diuretics, has been demonstrated in several studies involving patients with mild to moderate essential hypertension." | 5.05 | Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system. ( Drayer, JI; Weber, MA, 1984) |
| "41 patients (35 males and 6 females) with moderate hypertension were treated with a combination of methyldopa/hydrochlorothiazide/amiloride (M/HCT/A)." | 5.05 | [A combination of methyldopa, hydrochlorothiazide and amiloride in the treatment of essential hypertension]. ( Bolzano, K; Krempler, F; Sandhofer, F, 1984) |
| "Seventy-four patients from four short-term studies of captopril in mild-moderate essential hypertension continued in a cooperative long-term efficacy and tolerance program." | 5.05 | A long-term follow-up of patients with essential hypertension treated with captopril. ( Asplund, J; Aurell, M; Conradsson, T; Delin, K; Forslund, T; Frithz, G; Fyhrquist, F; Herlitz, H; Karlberg, B; Ohman, P, 1984) |
| "The results of an investigation to assess the clinical responses of patients with mild to moderate hypertension to a new combination formulation containing 75 mg triamterene and 50 mg hydrochlorothiazide are reported." | 5.05 | Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension. ( Blume, CD; Clark, T; Williams, RL, 1984) |
| "Seventeen patients with mild to moderate essential hypertension and controlled with antihypertensive drugs were treated with xipamid (40 mg) or hydrochlorothiazide (50 mg) in a double-blind cross-over randomized trial design." | 5.05 | A randomized double-blind clinical trial of xipamid and hydrochlorothiazide in essential hypertension. ( Kumar, S; Pandhi, P; Sharma, PL; Wahi, PL, 1984) |
| "Twenty patients with mild to moderate hypertension participated in a single-blind crossover comparison of treatment with 25 mg hydrochlorothiazide plus 50 mg triamterene and 50 mg hydrochlorothiazide plus 5 mg amiloride in once-daily dosage regimens." | 5.05 | Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension. ( Dean, S; Spencer-Mills, L, 1984) |
| "The efficacy and acceptability of a single half-tablet daily of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide was assessed in a study of 35 patients suffering from mild to moderate essential hypertension." | 5.05 | The efficacy and acceptability of the combination of acebutolol and hydrochlorothiazide in the treatment of essential hypertension. ( Sugeng, I; Suryaatmaja, M; Sutandar, H; Utama, H, 1984) |
| "The biochemical disturbance produced by thiazide diuretics and by amiloride during treatment of moderate hypertension were compared." | 5.05 | Comparison of thiazides and amiloride in treatment of moderate hypertension. ( Thomas, JP; Thomson, WH, 1983) |
| "In an open triple crossover study in 10 patients with mild to moderate essential hypertension the influence was investigated of adding indomethacin 50 mg, naproxen 250 mg, or sulindac 200 mg, each twice daily for four weeks, to diuretic treatment with hydrochlorothiazide 50 mg a day." | 5.05 | Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. ( Gribnau, FW; Koopmans, PP; Thien, T, 1984) |
| "Twenty patients aged 33 to 69 years with uncomplicated hypertension, no heart disease, and normal stress test results underwent ambulatory ECG monitoring a month after receiving placebo and two and four weeks after hydrochlorothiazide therapy." | 5.05 | Nonarrhythmogenicity of diuretic-induced hypokalemia. Its evidence in patients with uncomplicated hypertension. ( Gavras, HP; Madias, JE; Madias, NE, 1984) |
| "5 mg) and timolol (10 mg) in the treatment of patients with mild to moderate hypertension, and to determine if there were any differences in response when medication was taken before or after food." | 5.05 | Efficacy and tolerance of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol, taken before or after food, in the treatment of hypertension. ( Arr, SM; Wight, L; Woollard, ML; Young, JH, 1984) |
| "A study of the effects of pindolol on potassium homeostasis was undertaken in 25 patients (19 women, 6 men) with essential hypertension." | 5.05 | Effect of pindolol on potassium homeostasis in patients with essential hypertension. ( Garrett, BN; Kaplan, NM; Ram, CV, 1984) |
| "Total body potassium content, plasma potassium concentration, blood pressure, and plasma concentrations of renin, angiotensin II, and aldosterone were measured in patients with essential hypertension after a run-in period of 8 wk on a regimen of hydrochlorothiazide (median dosage 75 mg/day)." | 5.05 | Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients. ( Dige-Petersen, H; Giese, J; Ibsen, H; Leth, A; Nielsen, MD; Rasmussen, S; Svendsen, UG, 1983) |
| " They had simultaneously started therapy with, or increased the dosage of, chlorthalidone or hydrochlorothiazide for the treatment of hypertension." | 5.05 | Serum cholesterol during treatment of hypertension with diuretic drugs. ( Ames, RP; Peacock, PB, 1984) |
| "We compared hydrochlorothiazide and propranolol hydrochloride for monotherapy of hypertension by a double-blind study of 683 men who were titrated to less than 90 mm Hg diastolic BP or to 640 mg of propranolol or 200 mg of hydrochlorothiazide." | 5.05 | Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. ( , 1982) |
| "1 A placebo-controlled, randomised double-blind comparison of captopril 25 mg three times a day, hydrochlorothiazide 15 mg three times a day, and the combination was conducted in 207 patients with essential hypertension with supine diastolic blood pressures of 92-110 mm Hg." | 5.05 | Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. ( Weinberger, MH, 1982) |
| "1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol." | 5.05 | Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. ( Andrén, L; Asplund, J; Hansson, L; Karlberg, B; Ohman, P; Svensson, A, 1982) |
| "An open study was carried out in 641 patients with mild to moderate hypertension seen in general practice to assess the effectiveness of treatment with a timolol/hydrochlorothiazide/amiloride preparation compared with cyclopenthiazide/potassium." | 5.05 | Comparison of timolol/hydrochlorothiazide/amiloride ('Moducren') with cyclopenthiazide/potassium in mild to moderate hypertension. ( Arr, S; Parry, EE; Young, J, 1982) |
| "Twenty-four patients with moderate to severe hypertension were treated for four weeks with captopril, an oral inhibitor of angiotensin-converting enzyme." | 5.05 | Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. ( Banks, RA; Bayliss, J; Jones, JC; MacGregor, GA; Markandu, ND; Roulston, JE, 1982) |
| "The effects of amiloride hydrochloride on thiazide-induced hypokalemia were evaluated." | 5.05 | Response of thiazide-induced hypokalemia to amiloride. ( Chan, L; Maronde, RF; Milgrom, M; Vlachakis, ND, 1983) |
| "Eighteen patients with idiopathic hypertension were studied to assess the anti-hypertensive control, both at rest and during exercise of increasing doses of hydrochlorothiazide, metoprolol and a combination of hydrochlorothiazide and metoprolol." | 5.05 | An evaluation of the effect on resting and exercise blood pressure of some first line treatments in hypertension. ( Barbour, MB; Lawrie, TD; Lorimer, AR, 1983) |
| "Blood pressure, cardiac output, plasma volume, renin, and aldosterone were measured in 13 patients with essential hypertension on placebo and after 1, 4, and 12 wk on hydrochlorothiazide 100 mg daily." | 5.05 | Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. ( Man in 't Veld, AJ; Schalekamp, MA; van Brummelen, P, 1980) |
| "In an open two-period crossover study hydrochlorothiazide/amiloride and chlorthalidone were compared with regard to their anti-hypertensive and biochemical properties in ambulatory patients with mild to moderate hypertension." | 5.05 | The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone. ( van Soeren, F, 1980) |
| " Sixteen patients with essential hypertension were treated with guanfacine and with clonidine for 5 weeks each in a double-blind, placebo-controlled, cross-over trial." | 5.05 | Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine. ( Distler, A; Kirch, W; Lüth, B, 1980) |
| "The effect of a single dose of timolol, hydrochlorothiazide and amiloride in fixed combination (Moducren; MSD) in patients with mild to moderate essential hypertension was tested in an open study during 1978." | 5.05 | Combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A multicentre trial. ( Burns, DG; Pittaway, D, 1980) |
| "The effect of a single daily dose of timolol, hydrochlorothiazide and amiloride hydrochloride in fixed combination (Moducren; MDS) in patients with mild to moderate essential hypertension was tested during 1978 in an open study covering 10 weeks per patient." | 5.05 | Evaluation of a fixed combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A long-term multicentre trial. ( Pittaway, D, 1980) |
| "Fifty-five patients with primary hypertension, World Health Organization (WHO) stages I and II, were randomly allocated to a 9-mo multicenter, controlled, double-blind, crossover study with timolol, a nonselective beta adrenoceptor blocker, and hydrochlorothiazide combined with the potassium-sparing drug amiloride (AHCT)." | 5.05 | Timolol and hydrochlorothiazide-amiloride in primary hypertension. ( Andersson, PO; Henning, R; Karlberg, BE; Lins, LE; Nilsson, OR; Odar-Cederlöf, I; Tolagen, K, 1980) |
| "One hundred nineteen patients with essential hypertension (96 completing six months and 92 a one year study period) were randomized into four parallel groups and treated with one of four programs: 200 mg of metoprolol plus placebo; 200 mg of metoprolol plus 25 mg of hydrochlorothiazide; 200 mg of metoprolol plus 50 mg hydrochlorothiazide, or; 200 mg metoprolol plus 50 mg of hydralazine." | 5.05 | Clinical evaluation of the antihypertensive effect of metoprolol in combination with hydrochlorothiazide and hydralazine in an unselected hypertensive population. ( Honkavaara, M; Nissinen, A; Tuomilehto, J, 1980) |
| "A randomized, double-blind, multicenter study comparing amiloride hydrochloride, amiloride hydrochloride plus hydrochlorothiazide, and hydrochlorothiazide was conducted in 179 patients with mild to moderate essential hypertension (diastolic pressure, 95 to 115 mm Hg)." | 5.05 | Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group. ( , 1981) |
| "Captopril (SQ 14 225), an orally active inhibitor of angiotensin converting enzyme, was evaluated in the treatment of primary (essential) hypertension in a placebo-controlled long-term study." | 5.05 | Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. A controlled long-term study with reference to initial plasma renin activity. ( Asplund, J; Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1981) |
| "Patients with mild to moderate essential hypertension were treated with guanabenz plus placebo (26 patients) or guanabenz plus hydrochlorothiazide (26 patients) for one year." | 5.05 | Effect of guanabenz and hydrochlorothiazide on blood pressure and plasma renin activity. ( Fairchild, C; Gomez-Sanchez, CE; Holland, OB, 1981) |
| "Twenty-nine patients with mild to severe essential hypertension were treated with titrated doses of xipamide, before or after treatment with 50 and , if necessary, 100 mg hydrochlorothiazide in a 13- to 25-week open crossover study." | 5.05 | Hypotensive effects of xipamide in essential hypertension. Crossover comparison with hydrochlorothiazide. ( Pasquel, R; Simon, A; Tribble, PW, 1981) |
| "1 Captopril, an orally active angiotensin converting enzyme inhibitor, was compared with hydrochlorothiazide (HCT) in the treatment of mild and moderate essential hypertension." | 5.05 | Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor. ( el-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1981) |
| "In a double-blind study comprising 31 patients with essential hypertension not satisfactorily controlled on hydrochlorothiazide 25 mg o." | 5.05 | Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension. ( Dafgärd, T; Forsén, B; Lindahl, T, 1981) |
| " 55 patients with essential hypertension grade WHO I and II were randomly allocated to a fixed combination of metoprolol 100 mg and hydrochlorothiazide 12." | 5.05 | Antihypertensive effect and tolerability of two fixed combination of metoprolol and hydrochlorothiazide followed by a long-term tolerance study with one combination. ( Liedholm, H; Ursing, D, 1981) |
| "The efficacy, safety, and tolerability of lofexidine, a centrally acting imidazoline derivative, were compared to that of clonidine in a randomized double-blind trial in 28 patients with moderate essential hypertension." | 5.05 | Lofexidine and clonidine in moderate essential hypertension. ( Dustan, HP; Oparil, S; Smith, LR; Wilkins, LH; Winternitz, SR, 1981) |
| "The efficacy and acceptability of single daily doses of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide were assessed in an open study of 30 patients suffering from mild to moderate essential hypertension." | 5.05 | Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension. ( Harvard, CW; Nievel, JG, 1981) |
| "Captopril, a newly developed, orally active inhibitor of the angiotensin-converting enzyme, and hydrochlorothiazide were given alone or in combination to 39 patients with mild or moderate essential hypertension." | 5.05 | Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension. ( Aberg, H; Frithz, G; Mörlin, C, 1981) |
| "In a double-blind crossover study, the antihypertensive effect of hydrochlorothiazide alone and in combination with the beta blocker acebutolol was assessed in 18 patients suffering from mild to moderate hypertension." | 5.05 | Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension. ( Belleau, LJ; Brossard, JJ; Lebel, M, 1982) |
| "More than 1200 patients who received pindolol for the treatment of hypertension, angina pectoris, and various arrhythmias in studies conducted in the United States were included in the New Drug Application submitted to the FDA." | 5.05 | Adverse reactions to pindolol administration. ( Gonasun, LM; Langrall, H, 1982) |
| "The antihypertensive effects of hydrochlorothiazide and spironolactone when added to treatment with metoprolol were compared in a double-blind trial comprising 55 previously untreated patients with essential hypertension." | 5.05 | A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol. ( Hansson, L; Lavenius, B, 1982) |
| "1 In a placebo-controlled study, the respective anti-hypertensive effects of hydrochlorothiazide and hydrochlorothiazide plus the beta-adrenoceptor blocker acebutolol were assessed in 18 patients with moderately severe essential hypertension." | 5.05 | Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide. ( Brossard, JJ; McKenzie, JK; Mitenko, PA, 1982) |
| "An open parallel study was carried out in general practice on 70 patients with uncomplicated mild to moderate hypertension to compare the hypotensive efficacy of hydrochlorothiazide/amiloride with that of cyclopenthiazide/potassium." | 5.05 | Do all diuretics have equal hypotensive efficacy? ( Gay, J; Grimshaw, JJ; Hossain, M; Jaffe, G, 1982) |
| "The effectiveness and tolerance of a centrally acting antihypertensive agent (clonidine) was compared to that of a diuretic (hydrochlorothiazide) in treatment of adolescents with essential hypertension." | 5.05 | Effectiveness of centrally acting drugs and diuretics in adolescent hypertension. ( Affrime, MB; Falkner, B; Lowenthal, DT; Onesti, G, 1982) |
| "The antihypertensive effect of propranolol, in fixed combinations with two dosages of triamteren and hydrochlorothiazide (Dociteren), was evaluated in a double-blind test on 19 patients with uncomplicated essential hypertension." | 5.05 | [Propranolol, triamteren and hydrochlorothiazide in fixed combinations in the treatment of hypertension (author's transl)]. ( Herrmann, JM; Hiemstra, S; Hoenig, B, 1981) |
| "The efficacy and safety of timolol maleate combined with hydrochlorothiazide given once daily compared with hydrochlorothiazide given once daily to patients with hypertension was investigated in a double-blind, randomized study." | 5.05 | Antihypertensive effect of oral timolol maleate and hydrochlorothiazide once daily compared with hydrochlorothiazide once daily. ( Cubberley, RB; Durley, Y; Thomas, S, 1981) |
| "Forty patients completed a double-blind parallel group study comparing furosemide (FUR) and hydrochlorothiazide (HCT) when added to a stable dose of beta blocker in the treatment of mild to moderate hypertension." | 5.05 | Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension. ( Dombey, SL; Lawrence, J; Vander Elst, E; Vlassak, W, 1981) |
| "Because captopril alone does not control blood pressure in all patients with essential hypertension, studies were performed to assess the effect of sodium intake and of captopril combined with hydrochlorothiazide, propranolol, and nifedipine." | 5.05 | Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. ( MacGregor, GA; Markandu, ND; Sagnella, GA; Smith, SJ, 1985) |
| "The antihypertensive efficacy of combination therapy with the angiotensin-converting enzyme inhibitor captopril and a diuretic or a calcium antagonist was compared in 16 patients with essential hypertension with a blood pressure of over 160/95 mm Hg having triple drug therapy." | 5.05 | Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. ( Bolli, P; Brouwer, RM; Bühler, FR; Conen, D; Erné, P; Kiowski, W, 1985) |
| "5 or 25 mg once daily when added in a placebo-controlled double-blind randomized study of patients with essential hypertension, whose diastolic blood pressure (DBP) was not adequately controlled (DBP > 90 mmHg) following 6 weeks of single-blind treatment with the angiotensin converting enzyme (ACE) inhibitor enalapril, 20 mg once daily." | 5.05 | Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Svensson, A, 1985) |
| "In a multicenter, double-blind comparison of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension (diastolic blood pressure, 95 to 114 mm Hg) in 182 and 178 patients, respectively, each agent reduced systolic and diastolic pressures to a similar significant degree: acebutolol, 15." | 5.05 | Comparison of acebutolol and hydrochlorothiazide in essential hypertension. ( Lewis, JE, 1985) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 5.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo." | 5.05 | Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension. ( Lucas, CP; Morledge, JH; Tessman, DK, 1985) |
| " A study was conducted on 19 black South Africans with mild or moderate essential hypertension; enalapril was compared with propranolol as monotherapy or together with hydrochlorothiazide in a 1-year randomized, double-blind, parallel study." | 5.05 | Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans. ( Coull, A; Goodman, C; Rosendorff, C, 1985) |
| " Thirty-nine patients with primary hypertension were entered into a randomized, double-blind protocol to assess the efficacy of enalapril (10 to 20 mg bid), hydrochlorothiazide (25 to 50 mg bid), or combined drug therapy." | 5.05 | Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition. ( Bauer, JH; Gaddy, P, 1985) |
| "This open randomised parallel trial compared the antihypertensive efficacy of enalapril and atenolol given alone once a day or with hydrochlorothiazide in 20 patients with moderate to severe hypertension." | 5.05 | Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension. ( Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985) |
| "The acute effects of 25 mg captopril on blood pressure, heart rate, components of the renin-angiotensin system and blood concentration of bradykinin were followed in a single-blind placebo study of untreated (group A, n = 15) and thiazide-treated (group B, n = 13) patients with mild or moderate essential hypertension." | 5.05 | Converting enzyme inhibition in mild and moderate essential hypertension. I. Acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril. ( Damkjaer Nielsen, M; Giese, J; Ibsen, H; Leth, A; Nielsen, F; Rasmussen, S, 1985) |
| "Effects of once-daily doses of 50 mg triamterene with 25 mg hydrochlorothiazide and 5 mg amiloride with 50 mg hydrochlorothiazide were compared in a randomized, multicenter study of 84 adult subjects with mild to moderate hypertension (diastolic blood pressure 90 to 114 mm Hg)." | 5.05 | Blood pressure lowering and potassium conservation by triamterene-hydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension. ( Brachfeld, J; Itskovitz, H; Lunn, JA; Maxwell, MH; Moser, M; Zawada, ET, 1985) |
| "The efficacy of captopril treatment was compared with that of propranolol in a single-blind crossover study in 14 patients with essential hypertension uncontrolled on diuretic alone." | 5.05 | Crossover comparison of captopril and propranolol as step 2 agents in hypertension. ( Ferguson, RK; Koplin, JR; Oren, A; Riley, LJ; Rotmensch, HH; Tadros, SS; Vlasses, PH, 1985) |
| "Control of hypertension (ie, reduction of blood pressure to less than or equal to 160/90 mmHg) in 40 mild to moderate hypertensives not responding adequately to hydrochlorothiazide was achieved by the addition of guanfacine (once daily) or methyldopa (twice daily) in a 16-week, double-blind, parallel-group trial." | 5.05 | Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension. ( Bouchard, S; Brookman, S; Farooki, MS; Farsky, K; Lalonde, Y, 1985) |
| "Fifty patients with mild or moderate essential hypertension were randomized (double-blindly) to treatment with either captopril (n = 26) or atenolol (n = 24)." | 5.05 | Long-term effects of captopril and atenolol in essential hypertension. ( Andrén, L; Hansson, L; Karlberg, BE; Nilsson, OR; Ohman, P; Svensson, A, 1985) |
| "Previous studies have shown that labetalol, a new alpha- and beta-adrenergic antagonist, is relatively safe for the treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD)." | 5.05 | Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. ( Burford, JG; Chetty, K; Conrad, SA; George, RB; Hudson, LD; Light, RW; Manocha, K, 1985) |
| "The safety and efficacy of sustained-release diltiazem 120 to 180 mg, 2 times a day, were compared with hydrochlorothiazide 25 to 50 mg, 2 times a day, and the combination of diltiazem and hydrochlorothiazide in 56 patients with mild to moderate hypertension (supine diastolic blood pressure between 95 and 114 mm Hg) using a placebo-controlled, parallel-design protocol." | 5.05 | Diuretics versus calcium-channel blockers in systemic hypertension: a preliminary multicenter experience with hydrochlorothiazide and sustained-release diltiazem. ( Frishman, WH; Kirkendall, W; Lunn, J; McCarron, D; Moser, M; Schnaper, H; Smith, LK; Sowers, J; Swartz, S; Zawada, E, 1985) |
| "Twelve patients with essential hypertension (diastolic blood pressure, greater than 90 mmHg) after four weeks of treatment with captopril (50 mg BID) were randomly divided into two groups and treated with 12." | 5.05 | Antihypertensive efficacy of two low dosages of hydrochlorothiazide in patients treated with captopril. ( Ambrosioni, E; Borghi, C; Costa, FV; Mussi, A, 1985) |
| "In a randomised double blind study in patients with mild to moderate hypertension, piretanide 6 mg once and twice daily significantly reduced both supine and erect blood pressure." | 5.05 | Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: a double-blind comparison with a combination of hydrochlorothiazide and amiloride. ( Dols, W; Rangoonwala, B; Verho, M, 1985) |
| "To evaluate the efficacy of acebutolol, 400-600 mg/day in elderly hypertensive patients, and to compare it with hydrochlorothiazide 25-50 mg/day, 45 patients with mild-moderate uncomplicated hypertension were treated for 6 weeks in a multicentre, single-blind, randomized, crossover trial." | 5.05 | Multicentre comparison of the antihypertensive effect of acebutolol and hydrochlorothiazide in uncomplicated mild-moderate hypertension in the elderly. ( Airoldi, G; Cagianelli, MA; Cinotti, G; Cortese, R; Diamanti, G; Giuntoli, F; Lucchini, M; Pedrinelli, R; Pettinà, G; Salvetti, A, 1985) |
| "A randomized, double-blind, cross-over study comparing 50 mg hydrochlorothiazide plus 5 mg amiloride (HCTZ/A) with 50 mg hydrochlorothiazide plus 26 mmol potassium chloride (HCTZ/K) was conducted in 18 patients with mild essential hypertension (diastolic pressure 90-105 mmHg)." | 5.05 | Hydrochlorothiazide and potassium chloride in comparison with hydrochlorothiazide and amiloride in the treatment of mild hypertension. ( Andersen, B; Hardarson, T; Ragnarsson, J; Snorrason, SP, 1985) |
| "In 20 patients with long-standing essential hypertension, a comparison was made in a randomized cross-over study of the effect of once and twice daily prazosin administration on blood pressure levels." | 5.05 | Prazosin once or twice daily? ( Hengeveld, WL; Schouten, JA; Westerman, RF, 1985) |
| "The antihypertensive mechanisms of single and combined therapy with a beta-adrenergic antagonist (propranolol) and a vasodilator (hydralazine) were investigated in 9 patients with moderately severe hypertension, who were receiving maintenance diuretic (hydrochlorothiazide) treatment." | 5.05 | Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action. ( Blomqvist, CG; Gaffney, FA; Graham, RM; Mulvihill-Wilson, J; Neal, WW; Pettinger, WA, 1985) |
| "A comparative study of changes in plasma lipids, apo-A1 and apo-B under the effect of 2-week, 2-month and 6-month treatments with hydrochlorothiazide and pratsiol was conducted in 48 patients with arterial hypertension." | 5.05 | [Change in the spectrum of lipids and apoproteins A1 and B as affected by hypothiazide and pratsiol in patients with hypertension]. ( Metel'skaia, VA; Mustafaev, II; Oganov, RG; Perova, NV; Postol'nikov, SF, 1985) |
| "Prazosin hydrochloride, a new antihypertensive agent, is said to be of mild-to-moderate potency when used as a sole agent in mild-to-moderate hypertension and when used in conjunction with other agents in severe hypertension." | 5.04 | Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension. ( Schirger, A; Sheps, SG, 1977) |
| " Nineteen patients with moderate arterial hypertension were treated for 5 consecutive weeks in a randomized fashion in a double-blind study with either tienilic acid or hydrochlorothiazide." | 5.04 | Treatment of arterial hypertension with tienilic acid, a new diuretic with uricosuric properties. ( Beauchemin, M; Gougoux, A; Lemieux, G; Vinay, P, 1978) |
| "The effects of timolol (10 mg thrice daily) and hydrochlorothiazide (50 mg/day) have been compared in a double-blind factorial trial in 20 patients with essential hypertension." | 5.04 | Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. ( Bune, A; Chalmers, J; Horvath, J; Tiller, D, 1976) |
| "Captopril, an orally active angiotensin-converting enzyme (ACE) inhibitor, was effective in the long-term reduction of blood-pressure in 17 patients with essential hypertension." | 5.04 | Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. ( Johnston, CI; Matthews, PG; McGrath, BP; Millar, JA, 1979) |
| "The influence of hydrochlorothiazide (HCT) treatment on the plasma levels of triglycerides, total cholesterol and high density lipoprotein cholesterol (HDL-cholesterol) was studied in 10 patients with essential hypertension." | 5.04 | Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. ( Gevers Leuven, JA; van Brummelen, P; van Gent, CM, 1979) |
| " Captopril was shown to be as effective as hydrochlorothiazide in lowering the blood pressure in patients with moderately severe essential hypertension." | 5.04 | Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension. ( Johnston, CI; Matthews, PG; McGrath, BP, 1979) |
| "In a series of 450 patients with mild essential hypertension, propranolol alone (P), propranolol plus hydrochlorothiazide (P+T), propranolol plus hydralazine (P+H), and propranolol plus hydrochlorothiazide plus hydralazine (P+T+H) were compared to reserpine plus hydrochlorothiazide (R+T)." | 5.04 | Propranolol in the treatment of essential hypertension. ( , 1977) |
| "Eighteen patients with diastolic hypertension (100 to 120 mm Hg), in addition to propranolol, 160 mg daily, and hydrochlorothiazide, 100 mg daily, received progressively increased doses of either minoxidil or placebo in a double-blind crossover study." | 5.04 | Effect of minoxidil on blood pressure and hemodynamics in severe hypertension. ( Bryan, RK; Hoobler, SW; Purdy, JM; Rosenzweig, J; Weller, JM, 1977) |
| "This study was designed to compare the effectiveness of spironolactone, hydrochlorothiazide, and combined spironolactone-hydrochlorothiazide therapy in patients with low renin and those with normal renin essential hypertension." | 5.04 | Diuretic therapies in low renin and normal renin essential hypertension. ( Brooks, CS; Johnson, CA; Kotchen, JM; Kotchen, TA, 1977) |
| "Twenty-four patients with mild to moderate hypertension were treated for up to 60 weeks with hydrochlorothiazide and either placebo, timolol, or timolol and amiloride." | 5.04 | Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension. ( Castenfors, H, 1977) |
| "Hydrochlorothiazide (HCT) and spironolactone (SP), alone and in combination, were utilized in the treatment of 79 adult men with mild to moderate essential hypertension." | 5.04 | Antihypertensive effect and serum potassium homeostasis: comparison of hydrochlorothiazide and spironolactone alone and in combination. ( Nash, DT, 1977) |
| "The effect on hypertension of hydrochlorothiazide 100 mg daily plus timolol 20-60 mg daily versus hydrochlorothiazide plus placebo and of hydrochlorothiazide plus timolol plus hydralazine 40-200 mg daily versus hydrochlorothiazide plus placebo plus hydralazine was evaluated in a double-blind, randomized, crossover study in 38 patients with hypertension." | 5.04 | Effect of timolol plus hydrochlorothiazide plus hydralazine on essential hypertension. ( Alimadadian, H; Aronow, WS; Burwell, D; Greenfield, R; Mann, W; Van Herick, R, 1978) |
| "In a double-blind study, 28 patients having mild to moderate essential hypertension were randomly assigned to a 6-week regimen of ticrynafen, hydrochlorothiazide, or placebo." | 5.04 | Ticrynafen and hydrochlorothiazide in hypertension. ( Beg, M; Okun, R, 1978) |
| "Sixteen patients with essential hypertension were treated with N-Amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride (BS 100--141) and clonidine for five weeks each in a double-blind cross-over trial." | 5.04 | Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. ( Distler, A; Kirch, W, 1978) |
| "In a single blind crossover trial, spironolactone (50 mg twice a day), and hydrochlorothiazide (50 mg twice a day) were equally effective hypotensive agents in 16 patients with untreated essential hypertension." | 5.04 | A comparison between spironolactone and hydrochlorothiazide with and without alpha-methyldopa in the treatment of hypertension. ( Friedman, A; Johnston, CI; Suthers, MB; Walter, NM, 1978) |
| "Fourty-six men and 6 women aged 45 years and having arterial hypertension newly diagnosed at routine medical examinations were given out-patient antihypertensive treatment with prazosin, prazosin + hydrochlorothiazide, or prazosin + hydrochlorothiazide + clonidine." | 5.04 | Antihypertensive drug combinations: prazosin, hydrochlorothiazide and clonidine. ( Kontro, J; Kyöstilä, S; Mattila, MJ; Pitkäjärvi, T, 1977) |
| " A double-blind comparison of the effect of tienylic acid and hydrochlorothiazide on blood pressure was made in patients with moderate hypertension." | 5.04 | A double-blind comparison of the effects of hydrochlorothiazide and tienylic acid (a diuretic with uricosuric properties) in hypertension. ( Gillies, AH; Morgan, TO, 1978) |
| "A double-blind study of hydrochlorothiazide and spironolactone, alone and in combination, was conducted in 49 patients with mild-to-moderate essential hypertension after a 4-wk placebo washout period." | 5.04 | Hydrochlorothiazide and spironolactone in hypertension. ( Schrijver, G; Weinberger, MH, 1979) |
| "The efficacy of prazosin was assessed in 21 patients with essential hypertension who failed to respond adequately to a combination of methyldopa and hydrochlorothiazide." | 5.04 | Prazosin in hypertension with and without methyldopa. ( Itskovitz, HD; Kochar, MS; Zeller, JR, 1979) |
| "A new hypouricemic diuretic (tienilic acid) was compared with hydrochlorothiazide in a double-blind study in 8 patients with mild essential hypertension." | 5.04 | [Experiences with a new hypouricemic diuretic (tienilic acid): comparison with hydrochlorothiazide]. ( Furrer, J; Siegenthaler, W; Vetter, W, 1978) |
| "The relative efficacies of potassium chloride, amiloride, triamterene and spironolactone in maintaining potassium balance were studied in 40 patients with essential hypertension receiving diuretic therapy." | 5.04 | Maintenance of potassium balance during diuretic therapy. ( Eisalo, A; Kohvakka, A; Manninen, V, 1979) |
| "Timolol, 10 to 40 mg daily, given to 103 patients with uncomplicated arterial hypertension induced significant increments of serum potassium at all dose levels (p less than 0." | 5.04 | Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic. ( Mikkelsen, E; Pedersen, OL, 1979) |
| "526 patients with essential hypertension or congestive cardiac failure were treated with ticrynafen (250--500 mg/day) or hydrochlorothiazide (50--100 mg/day) for 6 weeks to 6 months." | 5.04 | Renal function during ticrynafen therapy. ( Beg, MA; Donikian, MA; Ragland, R; Ziv, DS; Zuccarello, W, 1979) |
| "Furosemide and hydrochlorothiazide were compared for treatment of black patients with mild to moderate hypertension in a randomized, open-label, crossover study design." | 5.04 | Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. ( Gomez-Sanchez, CE; Holland, OB; Kuhnert, LV; Pak, CY; Poindexter, C, 1979) |
| "1 The antihypertensive effect and tolerability of MK-196 (10 mg and 15 mg daily) was compared to hydrochlorothiazide (HCT; 50 mg daily) in a 4-week multiclinic, double-blind study involving 42 patients with mild to moderate, essential hypertension." | 5.04 | A double-blind comparison of a novel indanone diuretic (MK-196) with hydrochlorothiazide in the treatment of essential hypertension. ( Bolognese, J; Cirillo, VJ; Enenkel, W; Lund-Johansen, P; Lutterbeck, PM; Moerlin, C; Tempero, KF; Vedin, JA; Vorburger, C; Wilhelmsson, CE, 1979) |
| "In a double-blind study, thirty patients having mild to moderate essential hypertension were randomly assigned to a six week regimen of either tienilic acid, hydrochlorothiazide, or placebo." | 5.04 | A double-blind study of tienilic acid with two year follow-up of patients with mild to moderate essential hypertension. ( Beg, MA; Okun, R, 1979) |
| "The purpose of this double-blind study was to compare the effects on blood pressure of tienilic acid and hydrochlorothiazide in patients with essential hypertension." | 5.04 | Long-term usage of tienilic acid in essential hypertension. ( Beg, MA; Noble, RE, 1979) |
| " These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout." | 5.04 | Safety of tienilic acid. ( Beg, MA; Ragland, R, 1979) |
| "The effects of a single dose and of two equally divided doses of timolol were compared in a double-blind trial in 15 patients with essential hypertension." | 5.04 | Comparison of effectiveness of timolol administered once a day and twice a day in the control of blood pressure in essential hypertension. ( Bobik, A; Jennings, G; Korner, P, 1979) |
| "103 patients with arterial hypertension were treated with timolol + placebo for 7 weeks in a multicentre trial, and with timolol + hydrochlorothiazide and amiloride for a further 7-week period." | 5.04 | Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension. ( Mikkelsen, E; Pedersen, OL, 1979) |
| "Comparative treatments of 14 patients suffering from arterial hypertension of the stages II to IV with haemiton and haemiton compositum (haemiton, triamteren and hydrochlorothiazide) lasting three weeks each showed that under influence of haemiton compositum the systolic blood pressure was lower in which case particularly reactions of orthostasis were practically absent." | 5.04 | [Haemiton compositum in the ambulatory therapy of hypertension]. ( Eckermann, P; Jung, D; Schröder, K; Teichmann, G, 1978) |
| "In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d)." | 5.04 | [Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)]. ( Ebel, H; Klaus, D; Lübke, H; Witzgall, H; Zehner, J, 1978) |
| "The relative benefits and risks of reserpine and guanethidine were compared in patients with thiazide-treated mild to moderate hypertension (diastolic pressure 95-115 mm Hg)." | 5.04 | Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine. ( Ferguson, RK; Nies, AS; Rothenberg, RJ, 1976) |
| "Debrisoquine, an antihypertensive agent, was compared with methyldopa in a double-blind trial in the treatment of hypertension in 20 patients." | 5.04 | A comparison of debrisoquine and methyldopa in hypertension. ( Pörsti, P, 1976) |
| "In a multicentre, double-blind, between-patient study the hypotensive effect of oxprenolol was investigated in 329 patients with mild to moderate hypertension." | 5.04 | Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study. ( Colombi, A; Motolese, M; Muiesan, G, 1975) |
| "A crossover comparison of metoprolol and hydrochlorothiazide has been performed in 20 patients with mild hypertension." | 5.04 | Comparison of metoprolol as hydrochlorothiazide and antihypertensive agents. ( Pedersen, OL, 1976) |
| " The anti-hypertensive actions of timolol and hydrochlorothiazide were analysed in a double-blind 2 x 2 factorial trial in twenty patients with essential hypertension." | 5.04 | Quantitative effects of timolol and hydrochlorothiazide on blood pressure, heart rate and plasma renin activity: results of a double-blind factorial trial in patients with essential hypertension. ( Bune, AJ; Chalmers, JP; England, JD; Fletcher, PJ; Horvath, JS; Korner, PI; Tiller, DJ, 1976) |
| " The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a double-blind, controlled study in fifty-four patients with mild to moderate essential hypertension." | 5.04 | Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study. ( Agabiti-Rosei, E; Alicandri, C; Ambrosioni, E; Magnani, B; Miele, N; Muiesan, G, 1976) |
| "In 36 patients with essential hypertension the action and side effects of hydrochlorothiazide (25 mg/d), hydrochlorothiazide-triamterene (25 and 50 mg/d) and propranolol (160 mg/d) were investigated." | 5.04 | [Triamterene in the treatment of hypertension with hydrochlorothiazide and propranolol (author's transl)]. ( Düsing, R; Kramer, HJ, 1977) |
| "The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg)." | 4.98 | Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies. ( Bader, G; Brunel, P; Dayi, H; Sison, J; Vega, RMR, 2018) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 4.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| " The trials compared the metabolic effects of hydrochlorothiazide (HCTZ) versus no- HCTZ hypertension treatment in type 2 diabetes." | 4.93 | Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. ( Chang, HC; Chen, HY; Ku, CT; Lin, JJ, 2016) |
| "To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension." | 4.91 | Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. ( Vongpatanasin, W, 2015) |
| "Aliskiren, a direct renin inhibitor, is effective for reducing blood pressure (BP) in patients with hypertension when combined with amlodipine or hydrochlorothiazide (HCTZ)." | 4.90 | Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. ( Cao, C; Dong, X; Gao, D; Liu, Y; Niu, X; Song, A; Wei, J; Yan, R, 2014) |
| "The article gives an overview of the risk factors for hypertension and the appropriate indication for using a fixed combination of telmisartan and hydrochlorothiazide." | 4.89 | [A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension]. ( Slíva, J; Vítovec, J, 2013) |
| " The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan medoxomil or angiotensin receptor blockers or renin angiotensin system or chlorthalidone and hypertension." | 4.89 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? ( Barrios, V; Escobar, C, 2013) |
| "The aim of this review was to compare telmisartan and valsartan in the treatment of hypertension." | 4.89 | Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review. ( Lacourcière, Y, 2013) |
| "Chlorthalidone's safety and efficacy in the management of hypertension has been demonstrated in landmark trials." | 4.88 | Chlorthalidone: the forgotten diuretic. ( Ezer, M; Goldman, A; Kountz, DS; Mikhail, J, 2012) |
| "Pooled data from seven randomized controlled trials (3,654 patients with stage 1-2 hypertension) were analyzed to investigate the BP-lowering efficacy of telmisartan 40 or 80 mg (T40 or T80) in combination with hydrochlorothiazide 12." | 4.88 | Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures. ( Guthrie, R; Neldam, S; Schumacher, H, 2012) |
| "Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys." | 4.88 | Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. ( Guddati, AK; Holford, TR; Roush, GC, 2012) |
| "Thiazide and thiazide-like diuretics are widely used in the management of hypertension, but recently the equivalence of hydrochlorothiazide and chlorthalidone for blood pressure (BP) lowering and prevention of cardiovascular disease has been questioned." | 4.88 | Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. ( Chaturvedi, N; Hardy, R; Hughes, AD; Peterzan, MA, 2012) |
| "This review summarizes the current data on the triple combination therapy of aliskiren with amlodipine and hydrochlorothiazide, and discusses the clinical use of single pill triple combination of aliskiren, amlodipine and hydrochlorothiazide in the treatment of hypertension and associated cardiovascular conditions." | 4.88 | The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. ( Huan, Y; Townsend, R, 2012) |
| "The authors analyze the importance of the combination therapy of candesartan cilexetil plus hydrochlorothiazide in the treatment of hypertension." | 4.88 | Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. ( Mugellini, A; Nieswandt, V, 2012) |
| "This review focuses on the role of the fixed-dose combination (FDC) drug valsartan/hydrochlorothiazide (HCTZ) in the treatment of hypertension." | 4.87 | Valsartan plus hydrochlorothiazide: a review of its use since its introduction. ( Bains, J; Smith, WB, 2011) |
| "The combination of telmisartan/HCTZ is an effective and well-tolerated treatment option for patients with hypertension." | 4.86 | Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. ( Kjeldsen, SE; Mancia, G; Schmieder, RE; Unger, T, 2010) |
| "This was a systematic assessment of the efficacy and safety of telmisartan and valsartan for the management of blood pressure (BP) in patients with essential hypertension." | 4.86 | A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. ( Lin, S; Shi, H; Zheng, Z, 2010) |
| "To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes." | 4.85 | Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. ( Kondrack, R; Mohiuddin, S, 2009) |
| "Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infarction." | 4.85 | Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. ( Malacco, E; Omboni, S; Parati, G, 2009) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 4.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| "Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension." | 4.84 | Olmesartan medoxomil: a review of its use in the management of hypertension. ( McCormack, PL; Scott, LJ, 2008) |
| "Fixed-dose combinations of telmisartan and hydrochlorothiazide (HCTZ) [Micardis Plus, Micardis HCT, PritorPlus] are available in many countries for the treatment of patients with essential hypertension." | 4.84 | Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. ( Plosker, GL; White, WB, 2008) |
| "Our objective was to assess time to achieve blood-pressure (BP) goal with incremental doses of valsartan alone, and together with hydrochlorothiazide (HCTZ), in patients with uncomplicated hypertension." | 4.84 | Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. ( Crikelair, N; Glazer, R; Levy, D; Meng, X; Rocha, R; Weir, MR, 2007) |
| "Telmisartan (Micardis, Pritor), a highly selective angiotensin II (AII) type 1 (AT1) receptor antagonist, is approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents." | 4.83 | Telmisartan: a review of its use in the management of hypertension. ( Battershill, AJ; Scott, LJ, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "Kinzalkomb marketed in Belgium by Bayer is a fixed combination of telmisartan 80 mg and hydrochlorothiazide 125 mg for the treatment of hypertension." | 4.82 | [Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension]. ( Kulbertus, H, 2003) |
| "Telmisartan is an angiotensin-II receptor blocker that has demonstrated efficacy in the reduction of blood pressure in patients with hypertension." | 4.82 | Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. ( Schmieder, RE, 2004) |
| " We also review outcome trials in patients with hypertension (such as LIFE [Losartan Intervention For Endpoint reduction in hypertension], VALUE [Valsartan Antihypertensive Long-term Use Evaluation], and SCOPE [Study on COgnition and Prognosis in the Elderly]), in which losartan, valsartan, and candesartan cilexetil were used in combination with hydrochlorothiazide." | 4.82 | Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. ( Beckey, K; Gleim, GW; Høieggen, A; Kjeldsen, SE; Oparil, S; Os, I, 2005) |
| "The combination of valsartan [an angiotensin II type 1 (AT(1)) receptor blocker] and hydrochlorothiazide (a thiazide diuretic), administered once daily, has been evaluated in the treatment of patients with hypertension in clinical trials ranging in duration from 8 weeks to 3 years." | 4.81 | Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. ( Faulds, DM; Wellington, K, 2002) |
| "The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension." | 4.81 | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. ( Jarvis, B; Melian, EB, 2002) |
| " The International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) is the first, large, randomized, double-blind study undertaken exclusively in high-risk hypertensive patients, with CV events as a prospectively defined primary end-point." | 4.81 | Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS? ( Ruilope, LM, 2002) |
| "Experience is presented from clinical trials conducted during the development of cilazapril (CLZ) for the treatment of hypertension, in which hydrochlorothiazide (HCTZ) was added to the treatment regimen in patients whose blood pressures did not normalize [sitting diastolic blood pressure (SDBP) < or = 90 mm Hg] in response to CLZ alone." | 4.79 | Cilazapril with adjunctive hydrochlorothiazide. Analysis of safety and efficacy in hypertensive patients not responding to cilazapril alone. ( Pordy, RC, 1995) |
| "Multiclinic controlled studies have shown that enalapril alone 10 to 40 mg/day orally is effective in lowering blood pressure in patients with essential hypertension." | 4.77 | Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. ( Davies, RO; Moncloa, F; Sromovsky, JA; Walker, JF, 1985) |
| "Sustained-release diltiazem (D-SR) and sustained-release verapamil (V-SR) when given twice a day have been successfully used to treat both essential hypertension and angina pectoris." | 4.77 | Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs. ( Klein, MD; Weiner, DA, 1987) |
| "Hydrochlorothiazide is the most common thiazide diuretic used for hypertension in the US." | 4.31 | Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999-2018. ( Cheung, BMY; Li, HL; Lin, Z; Tsoi, MF, 2023) |
| " In the present analysis, we investigated seasonal variation in the antihypertensive treatment effect of the irbesartan/hydrochlorothiazide combination in patients with stage 2 and 3 hypertension." | 4.31 | Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Ye, XF, 2023) |
| "This study aimed to evaluate whether exercise training could contribute to a better modulation of the neurohumoral mechanisms linked to the pathophysiology of arterial hypertension (AH) in postmenopausal hypertensive rats treated with hydrochlorothiazide (HCTZ)." | 4.31 | Concurrent exercise training induces additional benefits to hydrochlorothiazide: Evidence for an improvement of autonomic control and oxidative stress in a model of hypertension and postmenopause. ( Bernardes, N; da Silva Dias, D; De Angelis, K; Ferreira, MJ; Irigoyen, MC; Santos Ferreira Silva, MPD, 2023) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 4.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "Thiazides are one of the most common antihypertensive drugs used for hypertension treatment and hydrochlorothiazide (HCTZ) is the most frequently used diuretic for hypertension treatment." | 4.02 | Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension. ( Araos, P; Jalil, JE; Mondaca-Ruff, D; Mora, IG; Novoa, UF; Ocaranza, MP; Yañez, CE, 2021) |
| "Hydrochlorothiazide (HCTZ) is a thiazide diuretic used in adults and children for the treatment of hypertension and edema." | 4.02 | Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation. ( Al-Uzri, A; Boakye-Agyeman, F; Cohen-Wolkowiez, M; Commander, SJ; Harper, B; Hornik, CD; Hornik, CP; Melloni, C; Mendley, SR; Wu, H; Zimmerman, K, 2021) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 4.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits." | 3.96 | Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. ( Chen, R; Hripcsak, G; Krumholz, HM; Madigan, D; Pratt, N; Ryan, PB; Schuemie, MJ; Shea, S; Suchard, MA; You, SC, 2020) |
| " She had a known case of hypertension and was recently started on hydrochlorothiazide." | 3.96 | Sequential Drug-Induced Severe Hyponatremia in a Minimally Symptomatic, 81-Year-Old Patient. ( Akeely, Y; Lin, LC; Vilke, GM, 2020) |
| "Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners." | 3.94 | Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. ( Atkins, E; Bennett, A; Burke, M; Chalmers, J; Chou, M; Chow, CK; Dehbi, HM; Hillis, G; Hilmer, S; Krum, H; Neal, B; Nelson, M; Patel, A; Peiris, D; Reid, CM; Rodgers, A; Rogers, K; Salam, A; Thakkar, J; Thom, S; Usherwood, T; Vo, K; Webster, R; Woodward, M, 2017) |
| "Hydrochlorothiazide (HCTZ) belongs to the thiazide diuretics family that is used for the treatment of hypertension." | 3.91 | Enalapril protect human lymphocytes from genotoxicity of Hydrochlorothiazide. ( Alzoubi, KH; Khabour, OF; Laham, HZ; Sadiq, MF, 2019) |
| "The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided greater cardiovascular risk reduction among high-risk hypertensive patients." | 3.88 | Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. ( Bakris, G; Brook, RD; Dahlöf, B; Hau, T; Jamerson, KA; Kaciroti, N; Pitt, B; Velazquez, E; Weber, M; Zappe, DH, 2018) |
| "An innovative pediatric oral formulation of hydrochlorothiazide (HCT) (2mg/mL), endowed with improved bioavailability and sustained release properties and suitable for the hypertension treatment in pediatric patients, was developed by combining the drug-cyclodextrin complexation and the incorporation of the complex into Solid Lipid Nanoparticles (SLN)." | 3.85 | Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. ( Cirri, M; Di Cesare Mannelli, L; Ghelardini, C; Maestrelli, F; Mennini, N; Mura, P, 2017) |
| "Triamterene, because of its potassium-sparing properties, is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension." | 3.83 | Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension. ( Decker, BS; Eckert, GJ; Erdel, BL; He, Z; Hellman, RN; Murray, MD; Oates, JA; Pratt, JH; Tu, W, 2016) |
| "We have previously shown that an association of losartan and hydrochlorothiazide, initiated 1 mo after 5/6 nephrectomy (Nx), reversed hypertension and albuminuria and promoted lasting renoprotection." | 3.83 | An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. ( Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016) |
| "The characteristics of the Asian hypertensive patients with diastolic hypertension can present a favourable metabolic response to the short-term hydrochlorothiazide treatment." | 3.83 | Hypertension subtypes modify metabolic response to thiazide diuretics. ( Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC, 2016) |
| "Telmisartan (TL), Hydrochlorothiazide (HZ) and Amlodipine besylate (AM) are co-formulated together for hypertension management." | 3.83 | Application and validation of superior spectrophotometric methods for simultaneous determination of ternary mixture used for hypertension management. ( Lamie, NT; Mohamed, HM, 2016) |
| "Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp)." | 3.83 | Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. ( Fujisawa, Y; Hitomi, H; Kittikulsuth, W; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sohara, E; Sufiun, A; Uchida, S, 2016) |
| "Objective To compare 1-year treatment adherence of ramipril + amlodipine and ramipril +hydroclorothiazide fixed-dose combination therapies in patients with hypertension." | 3.83 | Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. ( Alföldi, S; Farsang, C; Ferenci, T; Simonyi, G, 2016) |
| "5 mg/day, and amlodipine 5 mg/day (baseline), 166 patients were classified as having resistant hypertension (n = 140) or CBP (n = 26) by ambulatory BP monitoring." | 3.83 | Copeptin is increased in resistant hypertension. ( Azizi, M; Bergerot, D; Blanchard, A; Bobrie, G; Courand, PY; Dubourg, J; Forni, V; Frank, M; Menard, J; Mendes, M, 2016) |
| "The aim of this study was to investigate the effects of aliskiren on vascular function and endothelial progenitor cells (EPCs) in patients with type 2 diabetes and essential hypertension." | 3.81 | Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. ( Dimitriadis, GD; Ikonomidis, I; Kotsifaki, EE; Lambadiari, VA; Lekakis, JP; Maratou, EP; Markakis, KP; Mazioti, MC; Raptis, AE; Raptis, SA; Tsirogianni, AG; Vlahakos, DV; Voumvourakis, AN, 2015) |
| " The aim of this study was to document the safety and effectiveness of the FDC olmesartan/amlodipine/hydrochlorothiazide in patients with essential hypertension in clinical practice." | 3.81 | Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. ( Bramlage, P; Fronk, EM; Schmieder, RE; Smolnik, R; Sutton, G; Wolf, WP, 2015) |
| "The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations." | 3.81 | Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. ( Assaad-Khalil, SH; Cho, B; DiTommaso, S; Kitchlew, AR; Najem, R; Shete, A; Sison, J; Ueng, KC, 2015) |
| "To compare adherence and persistence associated with nebivolol and hydrochlorothiazide (HCTZ) as add-on hypertension treatments." | 3.80 | Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension. ( Chen, S; Diener, M; Farooqui, S; Macaulay, D; Swallow, E; Wu, EQ; Xie, J, 2014) |
| "Lercanidipine both in monotherapy and in combination with enalapril, was able to improve microvascular structure and to decrease central blood pressure, being thus a useful approach for both reducing blood pressure and improving vascular alterations in hypertension." | 3.80 | Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. ( Caimi, L; Cancarini, A; De Ciuceis, C; Duse, S; La Boria, E; Muiesan, ML; Paini, A; Ricotta, D; Rizzoni, D; Rosei, CA; Rosei, EA; Rossini, C; Ruggeri, G; Salvetti, M; Sarkar, A; Semeraro, F, 2014) |
| "EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia." | 3.80 | Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. ( Abid, R; Afzal, J; Iktidar, S; Khan, W; Kumar, K; Maheshwary, N; Moin, N; Qadir, M; Sakrani, J; Siddiqi, A, 2014) |
| "A European multi-center, prospective, 24-week, non-interventional study was conducted including 14,979 patients with essential hypertension and new treatment with olmesartan, amlodipine and hydrochlorothiazide as an FDC." | 3.80 | Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. ( Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Smolnik, R; Wolf, WP; Zemmrich, C, 2014) |
| "In a study conducted on 82 patients with a history of heart failure and hypertension who had been treated with an ARB but failed to reach the target blood pressure, ongoing oral ARB treatment was switched to a drug combination of losartan and hydrochlorothiazide (HCTZ)." | 3.80 | Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure. ( Aizawa, T; Amino, M; Deguchi, Y; Ikari, Y; Kanda, S; Tanabe, T; Yoshioka, K, 2014) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 3.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| "This study assessed the risk of new-onset gout following prescribing of hydrochlorothiazide (HCTZ) compared with chlorthalidone (CTD)." | 3.80 | Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. ( Nair, KV; Saseen, JJ; Wilson, L, 2014) |
| " The patient had been treated with amlodipine (Amlor(®)) and a combination of bisoprolol and hydrochlorothiazide (Lodoz(®)) for 5years for essential hypertension." | 3.79 | [Telangiectasia during amlodipine therapy]. ( Dussouil, AS; Gaudy-Marqueste, C; Grob, JJ; Mallet, S; Monestier, S; Richard, MA; Tasei, AM, 2013) |
| "Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension." | 3.79 | Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. ( Dhalla, IA; Gomes, T; Hellings, C; Juurlink, DN; Mamdani, MM; Nagge, J; Persaud, N; Yao, Z, 2013) |
| " Adult patients with essential hypertension showing therapy resistance to angiotensin receptor blocker (ARB) as a monotherapy or in combination with Ca channel blockers (CCB) were enrolled, and their previously administered ARBs were replaced with the combination tablet containing losartan (50 mg per day) and hydrochlorothiazide (12." | 3.79 | Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance. ( Asakura, J; Fukada, H; Hasegawa, H; Kanozawa, K; Kogure, H; Komuro, O; Matsuzawa, M; Mitarai, T; Takayanagi, K; Tokushima, H, 2013) |
| "In patients with hypertension already taking HCTZ, switching to chlorthalidone seems to further reduce systolic and diastolic blood pressures without any clinically significant changes in renal function or electrolyte levels." | 3.79 | Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. ( Brenner, AC; Brenner, MJ; Matthews, KA, 2013) |
| "Adult patients with angiotensin receptor blocker (ARB)-resistant essential hypertension (n = 104) were enrolled and switched to combination therapy with losartan (50 mg/day) and hydrochlorothiazide (12." | 3.79 | Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension. ( Asakura, J; Hasegawa, H; Iwashita, T; Kawashima, K; Matsuda, A; Mitarai, T; Nakamura, T; Ogawa, T; Shimizu, T; Takayanagi, K; Tayama, Y, 2013) |
| "Numerous randomized clinical trials have demonstrated the efficacy and tolerability of aliskiren and aliskiren hydrochlorothiazide (aliskiren HCT) single-pill combination therapy in patients with hypertension." | 3.79 | Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting. ( Echtay, A; Go, L; Gulzar, T; Haque, KM; Hristoskova, S; Kadwa, M; Maddury, SR; Pande, A, 2013) |
| "Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension." | 3.78 | Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. ( Inoue, A; Mitsutake, R; Miura, S; Saku, K; Shiga, Y; Uehara, Y, 2012) |
| "This retrospective patient data analysis was initiated to describe current treatment patterns of patients in Germany with arterial hypertension, with a special focus on compliance, persistence, and medication costs of fixed-dose and unfixed combinations of angiotensin receptor blockers (ARBs), amlodipine (AML) and hydrochlorothiazide (HCT) in Germany." | 3.78 | Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. ( Breitscheidel, L; Ehlken, B; Kostev, K; Oberdiek, MS; Sandberg, A; Schmieder, RE, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 3.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "25 mg of hydrochlorothiazide, the clinical condition, the daily profile of blood pressure, body adrenoreactivity structural and functional parameters of the left ventricle in 28 pregnant women with preeclampsia in the background chronic hypertension (hypertension stage II, 2 nd degree) and 28 pregnant women with preeclampsia and mild to moderate severity in terms of 22-28 weeks of pregnancy." | 3.78 | [Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia]. ( Manukhin, IB; Markova, EV; Markova, LI; Striuk, RI, 2012) |
| "To evaluate the effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system (RAAS) activity and blood pressure in response to hydrochlorothiazide (HCTZ) treatment in Han Chinese patients with essential hypertension." | 3.78 | [Effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide]. ( Chu, LM; Li, Y; Lu, DS; Sun, MJ; Wu, SL; Wu, Y; Xu, S; Yang, P; Yuan, JX; Zhao, DD; Zhao, LP, 2012) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 3.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| " 1D11, diltiazem, and hydrochlorothiazide (HCT) attenuated the development of hypertension, proteinuria, and glomerular injury." | 3.78 | Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats. ( Chen, CC; Dahly-Vernon, AJ; Dunn, KM; Ledbetter, SR; Murphy, SR; Roman, RJ; Williams, JM, 2012) |
| "Switching to a fixed-dose combination of AML/OM ± hydrochlorothiazide provided significant BP lowering and effectively controlled BP in a large proportion of Hispanic and non-Hispanic patients with hypertension uncontrolled on previous monotherapy." | 3.78 | Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy. ( Maa, JF; Punzi, H; Shojaee, A, 2012) |
| "The aim of the study was to estimate the efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in terms of alteration of the diurnal AP profile and heart rhythm in patients with essential hypertension (EH)." | 3.78 | [The efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in patients with essential hypertension]. ( Kakhramanova, SM, 2012) |
| " We investigated the effect of switching from an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) to a combination of losartan and hydrochlorothiazide on left ventricular (LV) relaxation in patients with hypertension and diastolic dysfunction." | 3.78 | Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Shimada, K; Takami, T; Watanabe, H; Yoshikawa, J, 2012) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 3.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| "The clinical course of losartan potassium/hydrochlorothiazide (Preminent(®))-induced hyponatremia has not been described." | 3.77 | Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients. ( Fujiki, K; Kinoshita, H; Kobayashi, K; Koga, N; Tomiyama, J; Yaguramaki, T; Yakushiji, F; Yasuda, M, 2011) |
| " We hypothesized that intergenic polymorphisms between OAT1 and OAT3 might be associated with adult hypertension and the antihypertensive effects of hydrochlorothiazide (HCTZ)." | 3.77 | Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. ( Chen, JZ; Fan, XH; Han, YF; Hui, R; Li, WJ; Sun, K; Wang, XJ; Wang, YB; Xue, H; Zhang, WL; Zhen, YS; Zhou, X, 2011) |
| "There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
| " Patients with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination of candesartan cilexetil 16 mg and HCTZ 12." | 3.77 | Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). ( Bönner, G; Bramlage, P; Landers, B, 2011) |
| "A total of 7567 Asian patients who were diagnosed with stage 1 or stage 2 essential hypertension and who took at least one dose of valsartan/hydrochlorothiazide single pill combination were included in the statistical analyses." | 3.77 | Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. ( Dongre, N; Lai, WT; Park, JE; Wang, J, 2011) |
| "Two WNK1 and one WNK4 polymorphisms were detected in two independent populations (n = 1592 and 602) for association with hypertension, and in two clinical trials of hydrochlorothiazide treatment (n = 542 and 274) for association with diuretics response." | 3.77 | Hypertension associated polymorphisms in WNK1/WNK4 are not associated with hydrochlorothiazide response. ( Chen, J; Fan, X; Han, Y; Hui, R; Sun, K; Wang, X; Wang, Y; Zhang, W; Zhen, Y, 2011) |
| "1." | 3.77 | Angiotensin-converting enzyme inhibition as first-line treatment for hypertension. ( Thurston, H, 1992) |
| " In a clinical real-life setting we evaluated BP impact and tolerability of the angiotensin-II receptor blocker telmisartan in patients with essential hypertension." | 3.76 | Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care. ( Arnesen, Ø; Bye, A; Johansen, OE; Kontny, F; Risanger, T, 2010) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 3.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| " In this case report, significant hyperkalemia and hyponatremia related to telmisartan/hydrochlorothiazide use in a diabetic patient has been presented." | 3.76 | Significant hyperkalemia and hyponatremia secondary to telmisartan/hydrochlorothiazide treatment. ( Cakir, M, 2010) |
| " We report the case of a 48-year-old woman with the presence of a sharply demarcated erythema of the inferior cervical folds, axillae, and gluteal area that started 4 days after the introduction of telmisartan-hydrochlorothiazide administration to treat hypertension." | 3.76 | Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. ( Azevedo, F; Cunha, AP; Ferreira, O; Morais, P; Mota, A, 2010) |
| "The aim of this analysis was to assess the efficacy and safety of the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil in elderly patients with either essential hypertension or isolated systolic hypertension." | 3.75 | Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. ( Heagerty, AM; Mallion, JM, 2009) |
| "In order to determine how both diuretics affect water metabolism, we here compare the effects of a rechallenge with either amiloride-hydrochlorothiazide fixed association (AmHTZ; amiloride chlorhydrate 5 mg+hydrochlorothiazide 50 mg; Moduretic) or furosemide (F; 40 mg; Lasix) on water excretion in a 79 year old woman who was previously admitted for severe symptomatic hyponatremia secondary to a 5 days course of AmHTZ for systolic hypertension." | 3.75 | Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatremia. ( Cogan, E; Fadel, S; Karmali, R, 2009) |
| " Thus, we characterized the antihypertensive effect of the combination of telmisartan and low-dose hydrochlorothiazide in patients with hypertension that was not controlled by amlodipine, which is the most common CCB." | 3.75 | Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. ( Ando, K; Isshiki, M; Takahashi, K, 2009) |
| " To determine whether the variant rs4149601 A allele is a risk factor for hypertension, has an impact on the antihypertensive response to hydrochlorothiazide, and is associated with orthostatic hypotension, we performed a case-control study of hypertension (n=1686), a 4-week clinical trial (n=542), and a case-control study of orthostatic hypotension (n=793) in Chinese subjects." | 3.75 | A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. ( Hui, R; Luo, F; Sun, K; Wang, X; Wang, Y; Zhou, X, 2009) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| "Changes in serum potassium and serum glucose levels were not correlated in individuals receiving hydrochlorothiazide monotherapy; thus maintenance of normal potassium levels may not attenuate the risk of thiazide diuretic-induced hyperglycemia." | 3.75 | Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. ( Anderson, SD; Bailey, K; Boerwinkle, E; Chapman, A; Cooper-Dehoff, RM; Feng, H; Gong, Y; Gums, JG; Hall, KL; Johnson, JA; Schwartz, GL; Smith, SM; Turner, ST; Wen, S, 2009) |
| "A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12." | 3.75 | [Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program]. ( Bubnova, MG; Oganov, RG, 2009) |
| "This was a double-blind, placebo-controlled clinical trial (n = 1329) in patients with essential hypertension (mean sitting diastolic BP [DBP] > or = 95 mmHg and <110 mmHg) who were randomized to placebo, valsartan 160 mg, valsartan 320 mg, hydrochlorothiazide (HCTZ) 12." | 3.75 | The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. ( Crikelair, N; Glazer, R; Levy, D; Pool, JL, 2009) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| "The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals." | 3.74 | Based treatment algorithm for essencial hypertension with olmesartan medoxomil. ( Amodeo, C; Brandão, AA; Feitosa, AD; Gomes, MA; Moriguchi, EH; Oigman, W; Précoma, DB; Ribeiro, AB; Ribeiro, JM; Saraiva, JF, 2008) |
| " Patients with previously uncontrolled hypertension with at least one further risk factor in which physicians deemed a treatment with 16 mg Candesartan/12." | 3.74 | Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. ( Bramlage, P; Odoj, P; Schönrock, E, 2008) |
| "Replacing candesartan + hydrochlorothiazide for previously ineffective antihypertensive drugs in patients with uncontrolled arterial hypertension significantly reduced both blood pressure and ST-segment depression during daily life." | 3.74 | [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]. ( Fimmers, R; Mengden, T; Uen, S; Un, I; Vetter, H, 2007) |
| "Fifty-four patients with essential hypertension received hydrochlorothiazide (12." | 3.74 | Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. ( Cheng, YL; Huang, J; Jiang, X; Li, J; Lin, G; Lu, XZ; Sheng, HH; Xiao, HS; Zhan, YY, 2007) |
| " The authors investigated the effects of varying doses of hydrochlorothiazide (HCTZ) on arterial elasticity and metabolic parameters in patients with hypertension (HTN), HTN and impaired fasting glucose (HTN+IFG), and HTN and type 2 diabetes mellitus (HTN+DM)." | 3.74 | Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. ( Asherov, J; Boaz, M; Davidovitz, I; Gavish, D; Shargorodsky, M; Zimlichman, R, 2007) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| "A multicentre, prospective, post-marketing surveillance study was conducted over 9 months in 14 200 patients aged > or =18 years with previously uncontrolled hypertension (either receiving therapy or newly diagnosed), paying particular attention to a subgroup of patients receiving irbesartan/hydrochlorothiazide as first-line combination therapy." | 3.74 | BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan. ( Bramlage, P; Lüders, S; Paar, DW; Schirmer, A; Schrader, J; Thoenes, M, 2007) |
| " Here we report the results of a pre-planned 6-month interim analysis of a long-term, open-label study examining the safety, tolerability and efficacy of the aliskiren/valsartan 300/320-mg combination in patients with hypertension." | 3.74 | Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. ( Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J, 2008) |
| "Low-renin hypertension responsive to amiloride-thiazide therapy in a 4-year-old Afro-Haitian girl suggested Liddle syndrome." | 3.73 | A novel epithelial sodium channel beta-subunit mutation associated with hypertensive Liddle syndrome. ( Freundlich, M; Ludwig, M, 2005) |
| " The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial compares regimens of benazepril plus amlodipine versus benazepril plus hydrochlorothiazide, force-titrated to 40/10 and 40/25mg, respectively." | 3.73 | The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. ( Weder, AB, 2005) |
| " To control hypertension and chronic heart failure he had been treated with 5 mg ramipril and 12." | 3.73 | [A patient with severe hyperkalaemia -- an emergency after RALES]. ( Daul, A; Nürnberger, J; Philipp, T, 2005) |
| "Noncardiogenic pulmonary edema is a rare but potentially life-threatening complication of hydrochlorothiazide therapy." | 3.73 | Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. ( Binkley, K; Knowles, SR; Phillips, EJ; Rahim, SA; Shear, NH; Wong, GA, 2005) |
| "To understand the effects of single- and multiple-drug combinations for hypertension on the risk of adverse clinical outcomes, the authors analyzed data from the International Verapamil SR/Trandolapril Study (INVEST)." | 3.73 | A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. ( Cooper-DeHoff, R; Elliott, WJ; Hewkin, AC; Kupfer, S; Pepine, CJ, 2005) |
| " Nondiabetics with hypertension (N=30) were started on (or changed to) hydrochlorothiazide (HCTZ) 12." | 3.73 | Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. ( Falkner, B; Francos, G; Kushner, H, 2006) |
| "To investigate the chronic efficacy of low-dose hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 3.73 | [Chronic effects of low-dose hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( He, WC; Li, Y; Liu, FS; Liu, KJ; Sun, LX; Wang, GL; Wang, LG; Wu, SL; Zhao, HY, 2006) |
| "Patients (n=50) with essential hypertension were given either indapamide-retard (1." | 3.73 | [Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension]. ( Golevtsova, ZSh; Nazarov, AG; Potapov, VV; Pritykina, TV; Protskiĭ, IA; Semenkin, AA; Zhivilova, LA, 2006) |
| "To characterize changes in erythrocytic membranes (ErM) structure and function in patients with essential hypertension (EH) due to combined therapy with enalapril maleate (EM) and hypothiazide." | 3.72 | [Effect of combined therapy with enalapril maleate and hypothiazide on the structuro-functional status of erythrocyte membranes in hypertensive patients]. ( Geĭchenko, VP; Kuriato, AV, 2003) |
| "Twenty four hour blood pressure (BP) monitoring was carried out and structural state of left ventricular myocardium assessed in 20 patients with mild and moderate hypertension before and after 24 weeks of therapy with Hyzaar - fixed dose combination of losartan (50 mg) and hydrochlorothiazide (12." | 3.72 | [Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy]. ( Chazova, IE; Dmitriev, VV; Ratova, LG; Sinitsin, VE; Stukalova, OV, 2003) |
| "A combination of low-dose oral enalapril, methyldopa and hydrochlorothiazide was evaluated in the acute treatment of severe hypertension." | 3.72 | Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians. ( Ofor, OO, 2004) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 3.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "These studies determined the ability of AT1 receptor blockade or 'triple therapy', to reverse angiotensin II-induced hypertension and improve autoregulatory behavior." | 3.72 | Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. ( Cook, AK; Imig, JD; Inscho, EW; Murzynowski, JB, 2004) |
| "Hydrochlorothiazide and other thiazide-like diuretics are considered as a first-line drug for initial therapy in uncomplicated arterial hypertension [1]." | 3.72 | Hydrochlorothiazide induced hepato-cholestatic liver injury. ( Alexander, P; Arinzon, Z; Berner, Y, 2004) |
| " A second combination compound including verapamil 180 mg and trandolapril 2 mg daily was added 5 days prior to hospitalisation due to insufficient control of arterial hypertension." | 3.72 | [Lethal polypharmacy in a patient with arterial hypertension]. ( Diethelm, M; Joerger, M, 2004) |
| " After the addition of hydrochlorothiazide (HCT) to the combination, she developed hypokalaemia with muscle cramps and weakness." | 3.71 | ['Licorice hypertension' also caused by licorice tea]. ( Brouwers, AJ; van der Meulen, J, 2001) |
| "After withdrawal of antihypertensive medications for at least four weeks (baseline) and stabilization on a diet approximating 150 mmol sodium per day, 225 African American and 280 Caucasian subjects with diagnosed essential hypertension were treated for four weeks with hydrochlorothiazide 25 mg per day." | 3.71 | Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. ( Boerwinkle, E; Chapman, AB; Schwartz, GL; Turner, ST, 2002) |
| "We examined the effect and safety of combination therapy with low-dose diuretics (hydrochlorothiazide: HCTZ) and angiotensin II receptor antagonist (losartan) in elderly cases of hypertension, using ambulatory blood pressure monitoring (ABPM)." | 3.71 | [Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension]. ( Abe, I; Eto, K; Iida, M; Tsuchihashi, T, 2002) |
| "The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in untreated patients with moderate-to-severe essential hypertension or patients with uncontrolled hypertension despite treatment with monotherapy or low-dose combination." | 3.71 | Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. ( Coca, A; de la Sierra, A; Felip, A; Mínguez, A; Pelegrí, A; Plana, J; Sobrino, J; Soler, J; Vila, J, 2002) |
| "Hydrochlorothiazide-induced pulmonary edema is an unusual but life-threatening adverse reaction." | 3.70 | Recurrent hydrochlorothiazide-induced pulmonary edema. ( Cervantes, M; Jordana, R; Mas, A; Vallés, J, 1998) |
| "Addition of hydrochlorothiazide can overcome the blunting of the therapeutic efficacy of ACE inhibition on proteinuria and blood pressure by a high sodium intake." | 3.70 | The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. ( Buter, H; de Jong, PE; de Zeeuw, D; Hemmelder, MH; Navis, G, 1998) |
| " Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated in patients with essential hypertension." | 3.70 | Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. ( Sever, PS, 1999) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| "To compare the efficacy of increasing doses of losartan or the addition of hydrochlorothiazide to achieve adequate blood pressure levels in patients with hypertension." | 3.70 | [Antihypertensive efficacy of monotherapy in increasing doses versus therapy associated in low doses]. ( Fasce, E; Wagemann, H, 1999) |
| "To investigate the effects of perindopril, propranolol, and dihydrochlorothiazide on artery wall thickening, left ventricular hypertrophy, and cardiac fibrosis in spontaneously hypertensive rats (SHR)." | 3.70 | Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats. ( Chen, DG; Chen, SC; Rui, HB; Su, JZ; Wang, HJ; Wang, XY; Wu, KG, 1999) |
| "A 74-year-old woman developed acute renal failure and granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride." | 3.69 | Granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride. ( Arenas, MD; Cabezuelo, JB; Enríquez, R; Fernández, J; González, C; Lacueva, J; Teruel, A, 1995) |
| "Forty-two patients with mild-to-moderate hypertension between the ages of 35 and 65 (23 men, 19 women) were studied to determine whether psychological characteristics can help differentiate between responders and nonresponders to diuretic (hydrochlorothiazide 25 mg and triamterene 50 mg)." | 3.69 | Hostility and the response to diuretic in mild-to-moderate hypertension. ( Hui, KK; Jamner, LD; Pasic, J; Shapiro, D, 1994) |
| "To determine the effect of hydrochlorothiazide on total cholesterol, baseline total cholesterol and blood pressure were determined in 618 hypertensive subjects in a hypertension clinic in Pusan, Korea." | 3.69 | Lack of effect of hydrocholorthiazide on total cholesterol. ( Jones, DW; Sands, CD, 1994) |
| "Effects of diazoxide, a benzothiadiazine derivative, on the blood pressure, excretion of Na+, K+, and Ca2+, and the levels of these electrolytes in serum, kidney, and aorta were studied in rats with deoxycorticosterone acetate (DOCA)-induced hypertension in comparison with rats treated with hydrochlorothiazide." | 3.69 | Effect of diazoxide on serum and tissue electrolyte levels in rats with deoxycorticosterone acetate-induced hypertension. ( Nakai, T, 1994) |
| "The efficacy, safety, tolerability and speed of onset of the hypotensive action of the combination of oral enalapril (10 mg) prazosin (1 mg) and hydrochlorothiazide (50 mg) has been assessed in 12 Nigerians with severe hypertension (Diastolic BP > or = 115 mmHg)." | 3.69 | Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. ( Adigun, AQ; Afolabi, MA; Ajayi, AA; Ajayi, OE; Akintomide, AO; Balogun, MO, 1996) |
| "Effects of benidipine hydrochloride or triple therapy (hydralazine, reserpine, and hydrochlorothiazide) on renal cortical and medullary intrinsic antioxidant enzyme (AOE) activity were evaluated in stroke-prone spontaneously hypertensive rats (SHR-SP) as an animal model for human essential hypertension with cerebral stroke." | 3.69 | Effects of benidipine hydrochloride on antioxidant enzyme activity in stroke-prone spontaneous hypertensive rats (SHR-SP). ( Fukui, M; Shou, I; Takahashi, Y; Tomino, Y; Wang, LN, 1997) |
| "We compared the effects of long-term treatment with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydrochlorothiazide, reserpine, and hydralazine) on the metabolic and renal features in the SHR/N-corpulent (cp) rat, a genetic model of non-insulin-dependent diabetes mellitus and hypertension." | 3.69 | Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. ( Abraham, AA; Michaelis, OE; Scalbert, E; Striffler, JS; Thibault, N; Velasquez, MT, 1997) |
| "Twenty patients with essential hypertension aged 39-70 years, underwent 20 weeks (short-term) and 30 weeks (long-term) lipid and lipoprotein assessment following moduretic (combination of hydrochlorothiazide and amloride) therapy." | 3.68 | Effects of moduretic on plasma lipid and lipoprotein levels in hypertensive African patients. ( Agbedana, OE; Ahaneku, JE; Salako, LA; Taylor, GO; Walker, O, 1993) |
| "The hemodynamic effects of orthostatic stress in elderly subjects with systolic hypertension were studied before and after long-term hydrochlorothiazide therapy (50 mg daily)." | 3.68 | Hemodynamic response to orthostatic stress in the elderly with systolic systemic hypertension before and after long-term thiazide therapy. ( Hill, NE; Mehrotra, KG; Mookherjee, S; Smulyan, H; Vardan, S, 1993) |
| "The aim was to compare the effects of two diuretics, indapamide and hydrochlorothiazide, on cardiac hypertrophy in stroke prone spontaneously hypertensive rats (SHR-SP)." | 3.68 | Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat. ( Contard, F; Glukhova, M; Guez, D; Marotte, F; Narcisse, G; Rappaport, L; Samuel, JL; Schatz, C; Swynghedauw, B, 1993) |
| " Several observations support the hypothesis that in rats of the Milan hypertensive strain elevated levels of a circulating ouabain-like factor might normalize the elevated Na+ reabsorption, but, on the other hand, might contribute to the development of hypertension." | 3.68 | Differences in ouabain-induced natriuresis between isolated kidneys of Milan hypertensive and normotensive rats. ( Bianchi, G; Ferrario, RG; Foulkes, R; Salvati, P, 1992) |
| "Twenty five patients of mild to moderate uncomplicated essential hypertension and five with severe hypertension were treated with long acting converting enzyme inhibitor enalapril for six weeks." | 3.68 | Enalapril in hypertension. ( Misra, NP; Shah, JY; Verma, Y, 1992) |
| "We have compared the effects of the angiotensin converting enzyme inhibitor, perindopril, and a conventional antihypertensive regimen (triple therapy: hydralazine, reserpine and hydrochlorothiazide) on kidney function and albuminuria in hypertensive diabetic rats." | 3.68 | Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. ( Allen, TJ; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Rumble, JR, 1992) |
| "In this study we evaluated in open the efficacy and tolerability of the preconstituted association Captopril 50 mg + Hydrochlorothiazide 25 mg, for a six-month period, in a population of 201 aged patients affected by isolated systolic hypertension." | 3.68 | [Efficacy and tolerability of a preconstituted combination of captopril 50 mg + hydrochlorothiazide 25 mg in aged subjects with isolated systolic hypertension]. ( Collatina, S; Ferroni, C; Salzano, E, 1992) |
| "Lipid profiles were determined in 56 elderly patients with benign essential hypertension during an open-label 1-year study of the safety and efficacy of isradipine, a new calcium antagonist, in controlling blood pressure." | 3.68 | Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. ( Bannatyne, RE; Lopez, L; Matthews, K; McCarley, D; Quay, G; Stein, GH, 1990) |
| "To assess whether therapy with hydrochlorothiazide (HCTZ) or the calcium antagonist nitrendipine influences silent ischemia or arrhythmias, we studied 10 asymptomatic hypertensive male patients with positive Tl-201 scintigraphy in a double-blind, crossover protocol." | 3.68 | Influence of therapy on silent ischemia and ventricular arrhythmias in hypertensive patients. ( Ammon, S; Massie, BM; O'Kelly, B; Szlachcic, J; Tubau, JF, 1991) |
| "In 78 patients with mild or moderate hypertension, effect of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen and plasma fibrinolysis time were investigated." | 3.68 | [Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?]. ( Karolko, B; Kopel, E; Kübler, G; Witkowska, M, 1991) |
| "The temporal blood pressure course and the diurnal profile of the renin-angiotensin system were examined in 13 patients with essential hypertension receiving hydrochlorothiazide and enalapril once daily." | 3.68 | Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition. ( Damkjaer Nielsen, M; Gadsbøll, N; Giese, J; Leth, A; Lønborg-Jensen, H, 1990) |
| "To evaluate the participation of the renin-angiotensin system in sustaining hypertension, we administered the specific dipeptide renin inhibitor enalkiren (A-64662) to 18 patients with essential hypertension." | 3.68 | Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. ( Boger, RS; Essinger, I; Glassman, HN; Luther, R; Neutel, JM; Weber, MA, 1990) |
| "Ten patients with arterial hypertension and chronic heart failure (stages NYHA I and II) were treated in a pilot study with a combination of 50 mg triamteren and 25 mg of hydrochlorothiazide for 20 days under clinical conditions." | 3.68 | [Arterial hypertension and hemorheology: the effects of triamterene and hydrochlorothiazide]. ( Angelkort, B; Gerlach, A; Spürk, P, 1990) |
| "The efficacy and safety of nitrendipine in oral doses of 5-40 mg twice daily, alone or in combination with hydrochlorothiazide (50-150 mg/day) and/or propranolol (40-120 mg/day), were evaluated in an open study of 50 patients with severe hypertension with supine diastolic blood pressure (BP) greater than 115 mm Hg." | 3.67 | Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study. ( Jain, AK; Maronde, R; McMahon, FG; Mroczek, W; Ryan, JR; Vlachakis, N, 1984) |
| " Enalapril maleate (MK421) and hydrochlorothiazide (HTZ) were used to assess the control of hypertension, and reversal of left ventricular hypertrophy in Dahl sensitive (DS) and Dahl resistant (DR) rats given either a high (8% NaCl), or a low (0." | 3.67 | The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension. ( Fernandez, D; Fernandez, PG; Idikio, H; Kim, BK; Snedden, W; Triggle, CR, 1984) |
| "A new experimental model is presented for determining the optimum dose of 3 different doses (13 mg, 25 mg, 37 mg per day) of hydrochlorothiazide employed to enhance hypotensive effect of 200 mg/day of metoprolol in human hypertension." | 3.67 | Assessment of optimal dose of diuretic associated with fixed dose of beta-blocking: a new experimental model based on multiple sampling of blood pressure performed by self-measurements. ( Bigioli, F; Corti, C; Croppi, E; Imperiale, P; Livi, R; Romano, S; Scarpelli, L; Scarpelli, PT; Stinchetti, A, 1984) |
| "Thirteen patients developed syncope and a prolonged QTc interval while taking therapeutic doses of sotalol." | 3.67 | Sotalol, hypokalaemia, syncope, and torsade de pointes. ( Barlow, JB; McKibbin, JK; Millar, RN; Obel, IW; Pocock, WA, 1984) |
| "Treatment of hypertension with diuretics and beta-blockers is often associated with changes in lipids and uric acid levels." | 3.67 | The impact on serum lipids of combinations of diuretics and beta-blockers and of beta-blockers alone. ( Helgeland, A, 1984) |
| "The effect of a single daily dose of 500 mg of methyldopa with 50 mg of hydrochlorothiazide and 5 mg of amiloride hydrochloride was studied in 21 patients with mild to moderate hypertension." | 3.67 | The effect of single-dose methyldopa and diuretic on BP and left ventricular mass. ( Hilewitz, H; Rogel, S; Weinstein, M, 1984) |
| "We observed the course of development of porokeratosis stimulated by benzylhydrochlorothiazide (BHCTh) in normal-appearing skin of a patient with long-standing stable porokeratosis of Mibelli." | 3.67 | Porokeratosis of Mibelli: benzylhydrochlorothiazide-induced new lesions accompanied by eosinophilic spongiosis. ( Inamoto, N; Nakamura, K; Watanabe, T, 1984) |
| " Therefore, a study was designed to compare the efficacy and the effects on left ventricular function of hydrochlorothiazide, propranolol and prazosin in 13 patients with mild to moderate hypertension." | 3.67 | Monotherapy in mild to moderate hypertension: comparison of hydrochlorothiazide, propranolol and prazosin. ( Benowitz, N; Inouye, I; Loge, D; Massie, B; Simpson, P; Topic, N, 1984) |
| "Potassium balance was followed in 12 subjects with hypertension during treatment either with timolol and hydrochlorothiazide or with timolol, hydrochlorothiazide, and amiloride." | 3.67 | Thiazide-induced potassium loss not prevented by beta blockade. ( Steiness, E, 1984) |
| "The time course of various doses of captopril (C) alone, hydrochlorothiazide (H) alone, and C with H was followed in 142 subjects with mild hypertension." | 3.67 | Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension. ( , 1984) |
| "The effect of verapamil on different metabolic parameters has been studied after changing the treatment of hypertension from hydrochlorothiazide to verapamil monotherapy." | 3.67 | Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. ( Gordin, A; Lehtonen, A, 1984) |
| "Captopril is an orally active converting enzyme inhibitor lowering blood pressure (BP) in different types of hypertension." | 3.67 | Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1984) |
| "An open-label study was conducted to determine the effectiveness and tolerability of methyldopa in the treatment of 20 older patients (mean age, 67 years) with isolated systolic hypertension." | 3.67 | Methyldopa: an agent for the treatment of older patients with isolated systolic hypertension. ( Vaicaitis, JS, 1984) |
| "To compare the effect of amiloride with that of oral potassium chloride (KCl) in hypokalemia, metabolic balance studies were carried out in hospitalized subjects with mild hypertension without edema who developed negative potassium balance after 4 days on hydrochlorothiazide (HCTZ)." | 3.67 | Oral potassium chloride and amiloride in hydrochlorothiazide-induced potassium loss. ( Barr, J; Chan, L; Maronde, RF; Spencer, CA; Vlachakis, ND, 1984) |
| "We have presented five episodes of hydrochlorothiazide-induced hyponatremia in three elderly nursing home patients." | 3.67 | Hyponatremia induced by thiazide-like diuretics in the elderly. ( Denham, JW; Oles, KS, 1984) |
| " Thirty subjects with hypertension on hydrochlorothiazide (HCTZ) were randomized to TIAM or CLON." | 3.67 | Withdrawal phenomena in subjects with essential hypertension on clonidine or tiamenidine. ( Hamilton, BP; Hamilton, J; Kuzbida, G; Levinson, P; Mersey, JH; Pavlis, R, 1984) |
| " Thirty-eight patients (22 low renin, 16 normal renin) with moderate diastolic hypertension were treated with hydrochlorothiazide administered twice a day." | 3.67 | Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. ( Hollifield, JW, 1984) |
| "An open-label clinical trail comparing the effectiveness of the combination of methyldopa with hydrochlorothiazide in low doses with that of hydrochlorothiazide therapy alone was conducted in 21 elderly patients with isolated systolic hypertension." | 3.67 | Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly. ( Boyles, PW, 1984) |
| "The antihypertensive efficacy of prazosin was compared with that of a combination of prazosin and propranolol in 14 patients with essential hypertension." | 3.67 | Prazosin versus propranolol plus prazosin: a comparison in diuretic-treated hypertensive patients. ( Blumenthal, SS; Kalbfleisch, JH; Kochar, MS; Maierhofer, WJ, 1984) |
| "The comparative efficacy and safety of lofexidine and clonidine in patients with mild to moderate systemic hypertension were evaluated." | 3.67 | Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. ( Lopez, LM; Mehta, JL, 1984) |
| " Thirty-one patients with uncomplicated hypertension underwent 48-hour ambulatory ECG monitoring both before any treatment and after 4 weeks of hydrochlorothiazide, (HCTZ), 100 mg daily." | 3.67 | Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy. ( Fletcher, RD; Freis, ED; Gottdiener, J; Notargiacomo, A; Papademetriou, V; Price, M, 1985) |
| "This multicenter study evaluated nitrendipine, a dihydropyridine calcium antagonist, alone or in combination with hydrochlorothiazide and/or propranolol in severe essential hypertension (baseline supine diastolic BP greater than or equal to 115 mm Hg)." | 3.67 | Long-term efficacy and safety of nitrendipine in severe essential hypertension. ( Burris, JF; Mroczek, WJ; Nash, DT, 1988) |
| "In stroke-prone spontaneously hypertensive rats, oral long-term treatment with verapamil, propranolol, hydrochlorothiazide, and dihydralazine attenuated the development of hypertension." | 3.67 | Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. ( Gries, J; Kretzschmar, R; Neumann, BW, 1989) |
| "We studied 14 patients to determine whether sustained-release diltiazem is a satisfactory long-term substitute for the combination of propranolol plus hydrochlorothiazide (HCTZ), control phase, in the treatment of systemic hypertension with coexisting chronic stable angina pectoris." | 3.67 | Response of blood pressure, cardiac output, peripheral resistance, and exercise performance to substitution of calcium blocker for beta-blocker plus thiazide diuretic therapy in patients with both systemic hypertension and mild stable angina. ( Gonzales, A; Kawanishi, DT; O'Rourke, RA; Rahimtoola, SH; Reid, CL, 1989) |
| "Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean arterial pressure 132 +/- 4 4 mm Hg) by the combination of a converting enzyme inhibitor and a diuretic." | 3.67 | Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic. ( Mimran, A; Ribstein, J, 1985) |
| "In a group of elderly patients with systolic hypertension the hypotensive efficacy and adverse effects were studied of hydrochlorothiazide given in daily doses of 25 mg in a year." | 3.67 | [Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension]. ( Halawa, B, 1989) |
| "In 59 patients with mild or moderate essential hypertension effects of propranolol and hydrochlorothiazide on serum lipids, fibrynogen, glucose and uric acid concentrations as well as serum euglobulins fibrynolysis time were studied." | 3.67 | [Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension]. ( Karolko, B; Kawecka, M; Lukasik, S; Moszczyńska, J; Witkowska, M, 1989) |
| "The whole-day blood pressure response to once-daily and twice-daily administration of a combination of captopril and hydrochlorothiazide was measured in a study of elderly patients (aged 59 to 78 years) with mild to moderate hypertension." | 3.67 | Assessing duration of antihypertensive effects with whole-day blood pressure monitoring. ( Cheung, DG; Gasster, JL; Weber, MA, 1989) |
| "Sixteen of 22 elderly male patients (aged 60-74 years) who had previously taken only hydrochlorothiazide 50 mg completed a study evaluating the safety, efficacy, and tolerability of 12-20 weeks of transdermal clonidine (Catapres TTS) as monotherapy for mild hypertension." | 3.67 | Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males. ( Goodfriend, TL; Schmidt, GR; Schuna, AA, 1989) |
| "We studied the effect of hydrochlorothiazide, 50 mg daily, on Na,K-adenosine triphosphatase (ATPase) activity in the red cells of 10 black men with hypertension." | 3.67 | Effect of treatment with hydrochlorothiazide on the red cell Na,K-adenosine triphosphatase in men with hypertension. ( Del Greco, F; Finn, M; Quintanilla, AP; Weffer, MI, 1987) |
| "The effect on plasma lipids of a new beta-blocker bucindolol, which possesses weak alpha-adrenergic blocking property and intrinsic sympathomimetic activity, given orally over a 3-month period as a monotherapy or with a thiazide diuretic to 44 patients with essential hypertension was studied." | 3.67 | Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients. ( Lehtonen, A; Tanskanen, A; Temmerman, J, 1987) |
| "A case of retroperitoneal fibrosis possibly associated with hydralazine, hydrochlorothiazide and ampicillin therapy is reported." | 3.67 | Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report. ( Waters, VV, 1989) |
| "The long-term effect of hydrochlorothiazide on beta 2-adrenoceptor density on mononuclear cells was investigated in 10 male patients with essential hypertension." | 3.67 | Adrenergic hyposensitivity during long-term diuretic therapy--a possible explanation for the antihypertensive effect of diuretics? ( Holzgreve, H; Kirzinger, S; Middeke, M; Remien, J, 1985) |
| "Enalapril (at a mean dose of 25 mg), a potent, long-acting angiotensin converting enzyme inhibitor, was prescribed in combination with hydrochlorothiazide (at a mean dose of 64 mg) for 96 weeks in 11 patients with essential hypertension who had pretreatment (placebo) glomerular filtration rates of less than 80 ml/minute/1." | 3.67 | Hemodynamic and renal function in essential hypertension during treatment with enalapril. ( Bauer, JH; Reams, GP, 1985) |
| "The effects of enalapril (10-20 mg twice daily), hydrochlorothiazide (25-50 mg twice daily), and combination enalapril-hydrochlorothiazide therapy (10-20 mg enalapril/25-50 mg hydrochlorothiazide in combination tablet twice daily) were evaluated and compared to no therapy (control) in eight patients with mild to moderate hypertension at rest and during treadmill exercise." | 3.67 | Rest and exercise hemodynamic and adrenergic responses to enalapril, hydrochlorothiazide, and combination treatment in patients with systemic hypertension. ( Charlap, S; Frishman, W; Saltzberg, S; Shamoon, H; Stroh, JA; Weinberg, P, 1985) |
| "Thirty-nine general practice patients with mild to moderate essential hypertension were treated with enalapril 10 to 40 mg once daily alone or in combination with hydrochlorothiazide 12." | 3.67 | Once daily enalapril in general practice patients with mild to moderate essential hypertension. ( Crombie, A; Manson, P; McVey, D; Smeeton, VJ; Smith, MW; Somerton, DT, 1986) |
| "Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean blood pressure, 172 +/- 6/111 +/- 4 mmHg) by the association of a converting enzyme inhibitor and a diuretic." | 3.67 | Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic. ( Mimran, A; Ribstein, J, 1986) |
| "Initial plasma renin activity (PRA) was measured in 213 patients with untreated hypertension before beginning thiazide (chlorothiazide and hydrochlorothiazide) therapy alone to test whether patients with low-renin hypertension exhibited a greater response to diuretic therapy." | 3.67 | Influence of renin levels on the treatment of essential hypertension with thiazide diuretics. ( Gimenez, L; Russell, RP; Walker, WG; Whelton, PK; Wyndham, RN, 1987) |
| "The effect of short-term diuretic treatment on the action of clonidine was evaluated in eight subjects with mild, uncomplicated hypertension." | 3.67 | Diuretic treatment alters clonidine suppression of plasma norepinephrine. ( Felton, K; Hui, TP; Krakoff, LR; Yeager, K, 1986) |
| "In this open, titrated dose clinical trial, captopril, when used in small doses (up to 150 mg daily) for 8 weeks (n = 5) and 4 months (n = 13) in patients suffering from mild to moderate essential hypertension, produced a fall in blood pressure both systolic and diastolic." | 3.67 | Low-dose captopril alone and in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension. ( Mondal, S; Pandhi, P; Sharma, BK; Sharma, PL; Wahi, PL, 1986) |
| "The aim of this study was to evaluate the effect of captopril on carbohydrate metabolism in diabetic patients with essential arterial hypertension." | 3.67 | Effect of converting enzyme inhibitors in hypertensive patients with non-insulin-dependent diabetes mellitus. ( de la Calle, H; Dominguez, JR; Hurtado, A; Robles, RG; Sancho-Rof, J, 1986) |
| "7 years, with systemic systolic hypertension were studied before and after 1 month of therapy with oral hydrochlorothiazide, 50 mg/day." | 3.67 | Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, aldosterone, urinary metanephrines and response to thiazide therapy. ( Dunsky, MH; Hill, NE; Mookherjee, S; Smulyan, H; Vardan, S; Warner, RA, 1986) |
| "The purpose of this study was to evaluate over a 24 h period the antihypertensive effect of captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once a day in mild to moderate hypertension." | 3.67 | Captopril + hydrochlorothiazide 24 h ambulatory monitoring effects. ( Asmar, RG; Hugue, CJ; Laurent, S; Pannier, BM; Safar, ME; Safavian, A, 1987) |
| "Serum zinc levels and urinary zinc excretion were compared in 15 patients with essential hypertension taking chronically a combination of hydrochlorothiazide and amiloride as monotherapy, eight patients maintained with hydrochlorothiazide alone, and eight control subjects." | 3.67 | Hydrochlorothiazide-amiloride causes excessive urinary zinc excretion. ( Averbukh, Z; Cohen, N; Golik, A; Modai, D; Shaked, U; Sigler, E; Weissgarten, J; Zaidenstein, R, 1987) |
| "Penbutolol has proved particularly effective and suitable for the treatment, even on a long-term basis, of recently developed hypertension, especially in its hyperkinetic forms." | 3.67 | [Penbutolol and arterial hypertension]. ( Bravi, M; Broglia, M; Carisdeo, V; Giuffrè, G; Torriani, A, 1987) |
| "Effect of long-term oral administration of the converting enzyme inhibitor (2R, 4R)-2-(o-hydroxyphenyl)-3-(mercaptopropionyl)-4-thiazolidinecarboxylic acid (SA446) in combination with hydrochlorothiazide or propranolol on the development of hypertension was examined in spontaneously hypertensive rats (SHR)." | 3.67 | [Combined effect of (2R, 4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarbo xyl ic acid (SA446) with hydrochlorothiazide or propranolol on development of hypertension in spontaneously hypertensive rats (SHR) by long-term administration]. ( Iso, T; Nakata, K; Takada, T; Yamauchi, H, 1986) |
| "In this study we compared the absorption and disposition of two commonly used combination formulations of hydrochlorothiazide and triamterene (Dyazide and Maxzide) in 48 patients with essential hypertension after dosing with each formulation to steady state." | 3.67 | Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. ( Benet, LZ; Blume, C; Clark, TS; Lin, E; Thornhill, MD; Upton, RA; Williams, RL, 1986) |
| "The purpose of this study was to identify the most accurate indirect measure of medication compliance in primary hypertension through comparison with a recently developed direct measure of the antihypertensive agent, hydrochlorothiazide." | 3.67 | Accuracy of indirect measures of medication compliance in hypertension. ( Craig, HM, 1985) |
| "Captopril in low doses has been used recently with success in the treatment of mild to moderate hypertension." | 3.67 | Comparison of low-dose captopril and propranolol as second-line drugs in mild and moderate hypertension. ( Rosenfeld, JB; Traub, YM, 1985) |
| "As part of the Veterans Administration cooperative studies on antihypertensive agents, systolic time intervals (STIs) were recorded before and after 2 or 4 weeks of treatment with hydrochlorothiazide (HCTZ) alone in 320 asymptomatic patients with mild to moderate hypertension." | 3.67 | Serial measurements of systolic time intervals during treatment with hydrochlorothiazide alone and combined with other antihypertensive agents. ( Freis, ED; Kyle, MC, 1985) |
| "Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 3.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
| "A group of 8 patients with essential hypertension and 12 patients with recurrent renal calcium stones were treated with 50 mg hydrochlorothiazide daily for a period of 3-10 years." | 3.67 | The myth of long-term thiazide-induced magnesium deficiency. ( Cohen, L; Kitzes, R; Shnaider, H, 1985) |
| "Enalapril maleate (MK 421), and hydrochlorothiazide were used to evaluate the control of hypertension and reversal of myocardial hypertrophy in Dahl sensitive (DS) and Dahl resistant (DR) rats given either a high (8% NaCl) or a low salt (0." | 3.66 | Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide. ( Fernandez, PG; Idikio, H; Kim, BK; Sharma, JN; Triggle, CR, 1983) |
| "The blood presure abilities of the beta receptor antagonist acebutolol and the fixed diuretic combination of hydrochlorothiazide/amiloride hydrochloride to reduce exercise-induced increases in blood presure durng and after standardized ergometric work were compared in a within-patient study of patients with uncomplicated essential hypertension." | 3.66 | Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients. ( Franz, IW, 1980) |
| "Sixteen patients (11 M, 5 F), median age 41 years, with essential hypertension insufficiently controlled on hydrochlorothiazide 75 mg/day (DBP greater than or equal to 100 mmHg) were investigated." | 3.66 | Angiotensin II blockade during combined thiazide-beta-blocker treatment. ( Christensen, NJ; Giese, J; Ibsen, H; Leth, A; McNair, A, 1980) |
| "Twelve patients with hypertension who did not become normotensive after treatment with hydrochlorothiazide alone were studied." | 3.66 | Treadmill exercise testing in hypertensive patients treated with hydrochlorothiazide and beta-blocking drugs. ( Abrams, DL; Grais, IM; Kaplan, BM; Miller, AJ; Upton, MT, 1983) |
| "Heart rate (HR), blood pressure and systolic time intervals (STI), including total electromechanical systole (QS2), left ventricular ejection time (LVETc), pre-ejection period (PEPc), the PEP/LVET index and the time to the peak of carotid upstroke (Ut), were measured in 24 patients with moderate essential hypertension after 15 days of treatment with oral furosemide (F), hydrochlorothiazide (H), propranolol (P), atenolol (A), furosemide + propranolol (F + P) and hydrochlorothiazide + propranolol (H + P)." | 3.66 | Modification of blood pressure and systolic time intervals by diuretics and beta-blockers in essential hypertension. ( Gamio Capestany, F; García-Barreto, D; González-Gómez, A; Hernández-Cañero, A, 1983) |
| "The antihypertensive effect and safety of hydrochlorothiazide administration as a single drug and together with medroxalol were determined in 20 patients with primary hypertension." | 3.66 | Medroxalol combined with hydrochlorothiazide in the treatment of hypertension. ( Alexander, N; Maronde, RF; Valasquez, M; Vlachakis, ND, 1983) |
| " This possibility was investigated by studying the influence of hydrochlorothiazide on blood pressure and urinary kallikrein excretion in patients with essential hypertension." | 3.66 | Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems. ( Higuchi, M; Kolloch, R; Müller, HM; Overlack, A; Stumpe, KO, 1982) |
| "During 12-week hydrochlorothiazide treatment 16 men suffering from uncomplicated essential hypertension were examined." | 3.66 | [Hemodynamic mechanism of the hypotensive action of diuretics and their effect on myocardial hypertrophy in the process of long-term treatment of hypertension]. ( D'iakonova, EG; Iurenev, AP, 1982) |
| "M-mode echocardiography was used in 12 patients with essential hypertension to study changes in cardiac anatomy during long-term therapy with hydrochlorothiazide (50 to 100 mg) and alpha-methyldopa (500 to 1,750 mg)." | 3.66 | Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension. ( Drayer, JI; Gardin, JM; Lipson, JL; Weber, MA, 1983) |
| "The antihypertensive effects and side-effects of a clonidine transdermal therapeutic system (clonidine-TTS) were examined over 10 weeks in 22 patients with essential hypertension." | 3.66 | Clonidine through the skin in the treatment of essential hypertension: is it practical? ( Baumgart, P; Boerlin, HJ; Groth, H; Knüsel, J; Siegenthaler, W; Vetter, H; Vetter, W; Walger, P; Wehling, M, 1983) |
| "The effects of metoprolol, propranolol and hydrochlorothiazide on lipoprotein metabolism were studied in three different but comparable groups of middle-aged men with previously untreated hypertension (n=10, n=10, and n=11, respectively)." | 3.66 | Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide. ( Berglund, G; Bondjers, G; Elmfeldt, D; Fager, G; Lager, I; Olofsson, SO; Smith, U; Wiklund, O, 1983) |
| "Twenty-seven patients with moderate to moderately severe hypertension who had not responded optimally to treatment with a standard step 2 regimen were treated with a three-drug regimen of hydrochlorothiazide, propranolol, and guanadrel." | 3.66 | Safety and efficacy of a three-drug regimen for the treatment of hypertension: hydrochlorothiazide, propranolol, and guanadrel. ( Gore, RD, 1983) |
| "5 mg clonidine (clonidine-TTS) was investigated in 21 patients with essential hypertension over a period of 10 weeks." | 3.66 | [Clonidine transdermal therapeutic system in essential hypertension: effect and tolerance]. ( Baumgart, P; Boerlin, HJ; Groth, H; Knüsel, J; Siegenthaler, W; Vetter, H; Vetter, W; Walger, P; Wehling, M, 1983) |
| "1 Forty-one patients with essential hypertension, stages I, II, and III, were treated with captopril alone or in combination with hydrochlorothiazide." | 3.66 | Captopril in essential hypertension. ( Alsina, J; Balcells Gorina, A; Ingelmo Morin, M; Martinez Amenos, A; Rabinad Estrada, E, 1982) |
| "1 Forty-one patients with primary (essential) hypertension were treated with captopril alone or in combination with hydrochlorothiazide for 12-36 months." | 3.66 | Long-term experience of captopril in the treatment of primary (essential) hypertension. ( Asplund, J; Karlberg, BE; Nilsson, OR; Ohman, KP; Wettre, S, 1982) |
| "The interrelationship between PRA, urinary aldosterone excretion, and blood pressure was studied in 11 patients with essential hypertension while receiving a diuretic (1st week) and subsequently a diuretic + oxprenolol (2nd week)." | 3.66 | The renin-angiotensin-aldosterone system and blood pressure during oxprenolol treatment in hypertensive patients pretreated with diuretics. ( Pedrinelli, R; Salvetti, A; Simonini, N, 1982) |
| " Ventilatory support must be available if apnea occurs." | 3.66 | Clonidine poisoning. A complex problem. ( Artman, M; Boerth, RC, 1983) |
| " We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule." | 3.66 | Thiazide diuretics, hypokalemia and cardiac arrhythmias. ( Hollifield, JW; Slaton, PE, 1981) |
| "Plasma volume (PV), extracellular fluid volume (ECV) serum electrolytes, renin and aldosterone were measured before and after 1 week and 4 months of hydrochlorothiazide (HCT) treatment, 50 mg twice daily, in nine male patients with uncomplicated essential hypertension." | 3.66 | Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. ( Schalekamp, MA; van Brummelen, P, 1980) |
| " We have measured plasma concentrations of renin, renin substrate and angiotensins I and II as well as plasma renin activity in nine patients with severe or malignant hypertension during treatment with captopril, hydrochlorothiazide and propranolol." | 3.66 | Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays. ( Damkjaer Nielsen, M; Giese, J; Rasmussen, S, 1981) |
| "26 patients with severe hypertension (10 essential, 9 renal parenchymatous, 7 renovascular) and a mean age of 42 years were treated with the new oral converting enzyme inhibitor captopril (SQ 14225)." | 3.66 | [Captopril in treatment-resistant hypertension (author's transl)]. ( Lüscher, T; Siegenthaler, W; Studer, A; Vetter, W, 1980) |
| "The angiotensin I-converting enzyme inhibitor, captopril (SQ 14225) was proposed as first treatment in 12 cases of uncomplicated essential hypertension maintained on unrestricted sodium intake (group I)." | 3.66 | [Effect of captopril in essential hypertension (author's transl)]. ( Laroche, B; Mimran, A; Targhetta, R, 1981) |
| "One hundred fifty eight patients with essential hypertension (both in- and out-patients) at stages IIA and IIB were treated with diuretics: furosemide (120 mg/day) during three days followed by hydrochlorothiazide in the doses that allow maintaining the renal sodium and water transport of the changed level." | 3.66 | [Continuous long-term treatment with diuretics of hypertension and the status of the renin-angiotensin-aldosterone system]. ( Konstantinov, EN; Mergenbaeva, TK; Nekrasova, AA; Ostapenko, TV; Suvorov, IuI, 1982) |
| "1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma." | 3.66 | Intravenous labetalol in severe hypertension. ( Dal Palu, C; Hlede, M; Morandin, F; Palatini, P; Pessina, AC; Rossi, GP; Semplicini, A; Sperti, G, 1982) |
| " To determine the effects of antihypertensive drugs on heart rate and blood velocity 15 patients with hypertension were treated with placebo, hydrochlorothiazide, nadolol, propranolol and hydralazine in sequence." | 3.66 | Effects of antihypertensive agents on blood velocity: implications for atherogenesis. ( Spence, JD, 1982) |
| "The immediate and sustained circulatory effects of hydrochlorothiazide were evaluated at rest and during dynamic exercise in 24 patients with essential hypertension." | 3.66 | Circulatory dose-response effects of hydrochlorothiazide at rest and during dynamic exercise in essential hypertension. ( Ahuja, RC; Kumar, EB; Nelson, GI; Okoli, RC; Silke, B; Taylor, SH, 1982) |
| " Eighteen patients, aged between 37 and 67 years, with moderate arterial hypertension underwent a double-blind, within-patient, crossover study to compare the effects of tienilic acid (TNCF) and hydrochlorothiazide (HCTZ) on blood pressure, renal function, serum levels of uric acid and electrolytes, and liver function." | 3.66 | Comparison of the metabolic and antihypertensive properties of tienilic acid and hydrochlorothiazide. ( Tse, TF; Wong, CM, 1981) |
| "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension." | 3.66 | Triamterene nephrolithiasis complicating dyazide therapy. ( Patel, KM, 1981) |
| "Two patients on long-term lithium therapy for manic-depressive psychosis developed serious toxicity within days of being prescribed a combination of triamterene (50 mg) and hydrochlorothiazide (25 mg) for mild symptomless hypertension." | 3.66 | Lithium toxicity induced by triamterene-hydrochlorothiazide. ( Mehta, BR; Robinson, BH, 1980) |
| "Two fixed-combination drugs commonly used in the step 2 treatment of hypertension, chlorthalidone plus reserpine and hydrochlorothiazide plus methyldopa, were compared in an evaluation of efficacy and adverse reactions." | 3.66 | A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension. ( Adlin, EV; Channick, BJ; Kessler, WB; Marks, AD, 1981) |
| "5 mg hydrochlorothiazide in the treatment of mild to moderate hypertension, with particular reference to elderly patients." | 3.66 | The treatment of high blood pressure in the elderly: a multi-centre evaluation of a fixed combination of metoprolol and hydrochlorothiazide ("Co-Betaloc") in general practice. ( Goodfellow, RM; Westberg, B, 1981) |
| "The antihypertensive effect of acebutolol 400 mg and hydrochlorothiazide 25 mg in combination have been assessed in 22 patients with mild, moderate and severe hypertension." | 3.66 | The use of acebutolol with hydrochlorothiazide in hypertension. ( Darmadji, T; Pikir, BS; Saleh, M; Yogiarto, M, 1981) |
| "The antihypertensive effect and the tolerability of metoprolol Durules have been studied in fifty-five patients with mild to moderate hypertension." | 3.66 | Experiences with metoprolol Durules, a slow-release formulation in hypertension. ( Nissinen, A; Tuomilehto, J, 1980) |
| "In a study of 50 patients with uncomplicated arterial hypertension the administration of hydrochlorothiazide, 50 to 100 mg daily or every other day, with or without reserpine, 0." | 3.66 | Hypokalemia during the treatment of arterial hypertension with diuretics. ( Beauchemin, M; Gougoux, A; Lemieux, G; Vinay, P, 1980) |
| "Hydrochlorothiazide, a drug which is often initially prescribed for mild to moderate hypertension, failed to lower blood pressures in 9 of 43 patients but concomitantly elevated plasma norepinephrine (NE) levels in all patients with hypertension." | 3.66 | Fenfluramine potentiation of antihypertensive effects of thiazides. ( Coleman, MD; Kopin, IJ; Lake, CR; Ziegler, MG, 1980) |
| "Among 54 patients attending a hospital hypertension clinic and receiving the fixed-combination diuretic Moduretic (hydrochlorothiazide 50 mg, amiloride 5 mg), there was a 44." | 3.66 | Plasma potassium levels in hypertensive patients receiving fixed-combination diuretic therapy. ( Frewin, DB; Penhall, RK, 1980) |
| "The combination of hydrochlorothiazide and amiloride has been used in a group of patients diagnosed as having essential hypertension." | 3.66 | A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension. ( Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L, 1980) |
| "Acebutolol (ABL) and hydrochlorothiazide (HCT) were compared in patients with mild to moderate essential hypertension and low or normal peripheral renin activity." | 3.66 | Acebutolol and hydrochlorothiazide in essential hypertension. ( Brossard, JJ; Nadeau, J; Ogilvie, RI; Ruedy, J, 1980) |
| "27 patients with essential hypertension received placebo for 2 weeks, then 1 Moduretic tablet (50 mg hydrochlorothiazide and 5 mg amiloride) daily for 4 weeks, followed by 2 Moduretic tablets daily for a further 10 weeks." | 3.66 | [Comparative evaluation of the anti-hypertensive effect of moduretic and thiazides]. ( Rosenfeld, JB, 1980) |
| "In 23 patients with essential hypertension of stage I and II according to the WHO, the effects of a fixed combination of a beta-receptor-blocker plus saluretic composed of 20 mg of metipranolol (Disorat 20) and 2." | 3.66 | [Metabolic effects of a fixed combination (betablocker plus saluretic) in long-term treatment of arterial hypertension (author's transl)]. ( Faupel, RP; Gotzen, R, 1979) |
| "1 The stepped care approach for the treatment of hypertension was adopted in a study at Ain Shams Hospital using hydrochlorothiazide (HCT) and a new beta-blocker, nadolol." | 3.66 | Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined. ( El-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1979) |
| "Peripheral beta-adrenergic receptor sensitivity was characterized in 24 patients with essential hypertension and in 13 age-matched normotensive subjects using an isoproterenol hydrochloride bolus dose-response technique." | 3.66 | Peripheral beta-receptor responsiveness in patients with essential hypertension. ( Dominic, JA; Guthrie, GP; Kotchen, TA; Love, DW; McAllister, RG, 1979) |
| ") before and during treatment with spironolactone (Sp, 75--100 mg/day) for at least 8 months was studied in 11 patients with essential hypertension." | 3.66 | Reduced response of plasma aldosterone to acute ACTH stimulation during long-term treatment with spironolactone in essential hypertension. ( Kim, KS; Miyamori, I; Miyamoto, M; Morimoto, S; Takeda, R; Uchida, K, 1979) |
| " Sixteen patients (11 male, five female), median age 41 years, with essential hypertension insufficiently controlled by hydrochlorothiazide (75 mg/day; diastolic blood pressure greater than or equal to 100 mmHg), were studied." | 3.66 | Angiotensin II blockade during combined thiazide-beta-adrenoreceptor-blocker treatment. ( Giese, J; Ibsen, H; Leth, A; McNair, A, 1979) |
| " Blood pressure, systemic haemodynamics, plasma volume, renin and aldosterone were measured during placebo treatment and after 1, 4 and 12 weeks of hydrochlorothiazide in 13 patients with uncomplicated essential hypertension." | 3.66 | Haemodynamics during long-term thiazide treatment in essential hypertension: differences between responders and non-responders. ( Man in't Veld, A; Schalekamp, MA; Van Brummelen, P, 1979) |
| "The potassium sparing effect of 5 mg of amiloride (A) given either alone, or in combination with 50 mg of hydrochlorothiazide (HCTH) was evaluated in 23 patients with essential hypertension on a daily diet containing 70 mEq of K and 130 mEq of Na." | 3.66 | Total body potassium and long-term treatment with amiloride HCL and/or hydrochlorothiazide. ( Ambrosioni, E; Magnani, B; Melandri, G; Pasetti, L; Tartagni, F, 1979) |
| "Levels of serum lipids, uric acid and body weight are reported from a controlled trial of drug treatment of middle-aged men with uncomplicated mild hypertension." | 3.66 | Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study. ( Helgeland, A; Hjermann, I; Holme, I; Leren, P, 1978) |
| "The effect of long-term treatment of hypertension with propranolol, alone or in combination with hydrochlorothiazide and/or dihydralazine, was investigated in 93 patients with various types of hypertension." | 3.66 | [Long-term treatment of arterial hypertension with propranolol. Combination with diuretics and dihydrazinophthalazine]. ( Ambrosio, G; Corgnati, A; Dal Palù, C; Palatini, P; Pessina, AC, 1978) |
| "Thirty-two USAF aircrewmen with mild or moderate, uncomplicated essential hypertension were treated with Aldactazide (spironolactone and hydrochlorothiazide)." | 3.66 | Treatment of hypertension in aviators: a clinical trial with Aldactazide. ( Hull, DH; McAfoose, DA; Triebwasser, JH; Wolthuis, RA, 1978) |
| "To determine the influence of dietary sodium intake on the effects of hydrochlorothiazide (HCT) on blood pressure (BP), serum electrolytes, renin and aldosterone, nine male patients with uncomplicated essential hypertension were studied during the following therapeutic regimes: 1) sodium restriction alone (50 mmol/day), 2) sodium restriction combined with HCT (50 MG TWICE DAILY), 3) HCT alone, and 4) sodium restriction combined with HCT." | 3.66 | Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. ( de Graeff, J; Schalekamp, M; van Brummelen, P, 1978) |
| "Eleven patients with hypertension secondary to renal disease were treated with hydrochlorothiazide or furosemide plus other drugs to normalize blood pressure." | 3.66 | Use of diuretics in treatment of hypertension secondary to renal disease. ( Bank, N; Lief, PD; Piczon, O, 1978) |
| "Iodine metabolism and thyroid hormones in blood were studied in 19 men and 11 women who had been treated with thiazides for arterial hypertension from 1 month to 15 years." | 3.66 | Influence of thiazides on thyroid parameters in man. ( Bech, K; Hansen, JM; Siersbaek-Nielsen, K; Skovsted, L, 1978) |
| "The therapeutic efficacy of four antihypertensive regimens (minoxidil, propranolol, and hydrochlorothiazide; propranolol and hydrochlorothiazide; methyldopa and hydroch-orothiazide; and hydrochlorothiazide alone) was evaluated in one child with systolic hypertension and in eight children with systolic and diastolic hypertension." | 3.65 | Management of severe childhood hypertension with minoxidil: a controlled clinical study. ( Mirkin, BL; Sinaiko, AR, 1977) |
| "1 The effect of pindolol administered to twenty-six patients with hypertension of unknown origin was compared with respect to blood pressure and plasma renin activity change after increase of the dose over a period of 6 weeks." | 3.65 | The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients. ( Goodwin, TJ; Lancaster, R; Peart, WS, 1976) |
| "The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension." | 3.65 | [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975) |
| "This study was designed to obtain information under general practice conditions on the efficacy and tolerability of a fixed combination of the beta-blocking agent oxprenolol 80 mg (Trasicor 80) and hydrochlorothiazide + KCl (Esidrex-K) in the treatment of moderate essential hypertension." | 3.65 | [Treatment of essential hypertension with Transicor 80 and Esidrex K under medical practice conditions]. ( Mauracher, EH; Rivier, JL, 1976) |
| " of spironolactone (SL) in 48 patients with essential hypertension." | 3.65 | Treatment of hypertension with hydrochlorothiazide and spironolactone. ( Ogilvie, RI; Ruedy, J, 1969) |
| "Hypertension is the leading risk factor for premature death worldwide." | 3.30 | Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. ( Hagström, E; Held, C; Lind, L; Lytsy, P; Marttala, K; Neal, B; Nowrouzi, S; Östlund, O; Sundström, J, 2023) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 3.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| "We found no increased skin cancer risk when analyzing cohort studies or studies that corrected for important covariates." | 3.01 | The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis. ( Daams, JG; de Rie, MA; Heisel, AGU; Olde Engberink, RHG; van den Born, BH; Vogt, L; Vuurboom, MD, 2023) |
| "Hydrochlorothiazide-based therapy was associated with a lower number of endothelial microparticles throughout the study, whereas a higher number of platelet microparticles was observed after rosuvastatin withdrawal in the amlodipine arm." | 2.90 | Circulating microparticles and central blood pressure according to antihypertensive strategy. ( Bianco, HT; Ferreira, CES; Figueiredo Neto, AM; Fonseca, FAH; França, CN; Izar, MCO; Kato, JT; Massunaga, ND; Póvoa, RMS, 2019) |
| "The Precision HYpertenSIon Care (PHYSIC) study aims to investigate if there is a consistent between-person variation in blood pressure response to the common blood pressure-lowering drug classes of a clinically relevant magnitude, given the within-person variation in blood pressure." | 2.90 | The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study. ( Ekman, I; Lind, L; Lytsy, P; Marttala, K; Nowrouzi, S; Öhagen, P; Östlund, O; Sundström, J, 2019) |
| "Forty hypertensive patients with type 2 diabetes were randomly assigned to 4-week treatment with dapagliflozin 10 mg or hydrochlorothiazide (HCT) 12." | 2.90 | The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature. ( Biancalana, E; Bruno, RM; Dardano, A; Ghiadoni, L; Giannini, L; Parolini, F; Rossi, C; Seghieri, M; Solini, A; Taddei, S, 2019) |
| " AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ." | 2.87 | Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. ( Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018) |
| "Spironolactone or HCTZ was randomly prescribed for 4 weeks." | 2.87 | Spironolactone is superior to hydrochlorothiazide for blood pressure control and arterial stiffness improvement: A prospective study. ( Dai, S; Liao, H; Liu, L; Liu, Y; Xiao, C, 2018) |
| "To observe and analyze the clinical efficacy and ultrasound detection results of treatment of hypertensive patients with heart disease with valsartan combined with hydrochlorothiazide." | 2.87 | Clinical efficacy and ultrasound inspection of the treatment of hypertensive heart patients with Valsartan combined with hydrochlorothiazide. ( Dai, M; Qian, D; Tao, H; Zhang, C, 2018) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 2.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| " Long-term use of hydrochlorothiazide has been linked to an increased dose-dependent risk of certain types of skin cancer in recent years." | 2.82 | What Dermatologists Should Know About Thiazides. ( Llamas-Molina, JM; Navarro-Triviño, FJ; Ruiz-Villaverde, R, 2022) |
| "Hypertension affects approximately 116 million adults in the US and more than 1 billion adults worldwide and is a leading cause of CVD morbidity and mortality." | 2.82 | Treatment of Hypertension: A Review. ( Carey, RM; Moran, AE; Whelton, PK, 2022) |
| " Both drugs equally reduced SBP in the last 6 h of the dosing interval and homogeneously reduced SBP throughout the 24 h." | 2.82 | Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. ( Arca, M; Berra, S; Bucci, M; Calabrò, P; Fulgheri, PL; Ghione, S; Modesti, PA; Omboni, S; Pirvu, O; Popescu, E; Portaluppi, F; Pozzilli, P; Taddei, S; Velican, VG; Villani, GQ; Vladoianu, M; Volpe, M, 2016) |
| "Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks." | 2.82 | Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. ( Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016) |
| " Adverse events (AEs) were reported in 75." | 2.82 | Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. ( Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016) |
| "Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction." | 2.80 | Time of administration important? Morning versus evening dosing of valsartan. ( Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015) |
| "Morning hypertension is an established risk factor for cardiovascular events." | 2.80 | Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study. ( Anegawa, T; Aoki, Y; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Uchiwa, H; Ueda, T, 2015) |
| " Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication." | 2.80 | A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). ( Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015) |
| "The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6." | 2.80 | Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. ( Ahn, Y; Baek, SH; Chae, JK; Doh, JH; Ha, JW; Kim, CH; Kim, JJ; Kim, SH; Kim, SK; Kim, W; Oh, BH; Park, CG; Park, JB; Park, SW; Rhee, MY; Rim, SJ; Shin, JH; Yoo, BS, 2015) |
| "Hypertension is associated with dyslipidemia." | 2.79 | A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide. ( Akinpelu, AO; Maruf, FA; Salako, BL, 2014) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 2.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| " Safety and tolerability parameters included adverse events." | 2.79 | Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. ( Finck, A; Giles, TD; Li, H; Neutel, JM; Punzi, H; Weiss, RJ, 2014) |
| " An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill." | 2.79 | The evening versus morning polypill utilization study: the TEMPUS rationale and design. ( Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014) |
| "Test and reference formulations gave a mean Cmax of 5." | 2.78 | A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ( Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013) |
| "5 mg) (ARB+D; n = 72) or a combination of amlodipine (5 mg) and the typical dosage of ARBs (ARB+C; n = 68) to evaluate the change in the BP, laboratory values and cognitive function." | 2.78 | Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. ( Hasebe, N; Kikuchi, K; Koyama, S; Maruyama, J; Morimoto, H; Morita, K; Saijo, Y; Sano, H; Sasagawa, Y; Sato, N; Sumitomo, K; Takehara, N; Takeuchi, T, 2013) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| " Hypertensive patients (clinic blood pressure [BP] ≥ 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12." | 2.78 | The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study. ( Bilo, G; Parati, G; Redon, J, 2013) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 2.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| " A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles." | 2.78 | Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. ( Fujiwara, W; Ishii, J; Izawa, H; Kinoshita, K; Morimoto, S; Mukaide, D; Nomura, M; Ozaki, Y; Ukai, G; Yokoi, H, 2013) |
| "Hypertension is associated with an increased risk of diastolic dysfunction." | 2.77 | Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Kasayuki, N; Kihara, H; Nakamura, F; Shimada, K; Yoshikawa, J, 2012) |
| "Arterial hypertension affects endothelial function and arterial stiffness." | 2.77 | Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. ( Dall'Armi, V; Fini, M; Iellamo, F; Marazzi, G; Spoletini, I; Vitale, C; Volterrani, M, 2012) |
| "Antihypertensive therapy is effective in reducing the risk of major adverse cardiovascular events." | 2.77 | Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. ( Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012) |
| " A potential reason for this is reduced nitric oxide bioavailability in African Americans, resulting in increased prevalence of factors that contribute to ventricular dysfunction." | 2.77 | Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. ( Bhaheetharan, S; Ferdinand, KC; Haque, T; Harris, J; Khan, BV; Merchant, N; Rahman, ST; Umar, K; Wahi, J, 2012) |
| " Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects." | 2.77 | Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. ( Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y, 2012) |
| "Hydrochlorothiazide was added when need to achieve blood pressure control." | 2.77 | Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals. ( Armendaris, MK; Beck, AL; D'Avila, LB; Netto, FM; Otto, ME; Sposito, AC, 2012) |
| " These differences were significant after 2 weeks at the higher dosage (P < 0." | 2.77 | Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. ( Bays, H; Gao, P; Mattheus, M; Ruilope, LM; Voelker, B; Zhu, DL, 2012) |
| "Many patients with hypertension have difficulty achieving their target blood pressure (BP)." | 2.77 | Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study. ( Inou, T; Kobayashi, K; Kubara, I; Meno, H; Nakamura, Y; Ota, T; Shiga, Y; Tanaka, M; Tsuchiya, Y, 2012) |
| " Aliskiren alone or in combination with HCT is safe and effective in Hispanic/Latino patients with stage 2 hypertension." | 2.77 | Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick ( Aguirre P, F; Alessi, T; Baschiera, F; Black, HR; Wright, M, 2012) |
| "An OM/HCTZ-based titration regimen enabled elderly patients with hypertension to safely reduce BP throughout the 24-hour dosing interval and allowed the majority of these patients to achieve a BP target of <140/90 mmHg or <140 mmHg." | 2.77 | Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. ( Chavanu, KJ; Dubiel, R; Germino, FW; Maa, JF; Neutel, JM, 2012) |
| "When felodipine was compared to placebo, the benefit of a lower SBP/DBP caused by felodipine was evident in the no-add-on patients (hazard ratio 0." | 2.77 | Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial? ( Liu, L; Tang, X; Wang, Y; Zanchetti, A; Zhang, X; Zhang, Y, 2012) |
| " This study examined the practical efficacy of a combination therapy of ARB with thiazide diuretics for lowering morning home blood pressure (MHBP) in comparison to high-dose ARB therapy in patients with morning hypertension administered an ordinal dosage of ARB." | 2.77 | Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension. ( Hanayama, Y; Makino, H; Nakamura, Y; Uchida, HA, 2012) |
| " In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy." | 2.76 | Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. ( Girerd, X; Rump, LC; Sellin, L; Stegbauer, J, 2011) |
| " This study included 15 subjects whose therapy was changed from a usual dosage of ARB to losartan 50mg/HCTZ 12." | 2.76 | Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. ( Hirose, H; Kawabe, H; Saito, I, 2011) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 2.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| "Administration of angiotensin receptor blockers at bedtime results in greater reduction of nighttime blood pressure than dosing upon awakening, independent of the terminal half-life of each individual medication." | 2.76 | Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. ( Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2011) |
| "Aliskiren was then force-titrated to 300 mg once daily for another 6 weeks." | 2.76 | Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. ( Baek, I; Drummond, W; Keefe, DL; Ramos, E; Sirenko, YM, 2011) |
| " Serious adverse events were more frequent in E (2." | 2.76 | Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study. ( Aoun, J; Girerd, X; Rosenbaum, D, 2011) |
| " Clinical and laboratory adverse events were reported for 29 patients (11%), but serious abnormalities were not observed." | 2.75 | One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. ( Ayabe, T; Eto, T; Etoh, T; Ichiki, Y; Kato, J; Kita, T; Kitamura, K; Tamaki, N; Yokota, N, 2010) |
| " It compares the bioavailability of these two study drugs from a TDDS with conventional immediate release oral tablets in healthy volunteers." | 2.75 | Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ( Aggarwal, A; Agrawal, SS, 2010) |
| " Safety was assessed by monitoring and recording adverse events (AEs)." | 2.75 | Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. ( Chrysant, SG; Dattani, D; Hoppe, UC; Murray, AV; Patel, S; Ritter, S; Zhang, J, 2010) |
| "Aliskiren treatment, both as monotherapy and with optional addition of amlodipine, provided significantly greater BP reductions than the respective hydrochlorothiazide regimens." | 2.74 | Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. ( Botha, J; Gorostidi, M; Guerediaga, J; Maboudian, M; Philipp, T; Schmieder, RE; Smith, B; van Ingen, H; Weissbach, N, 2009) |
| " T80/H25 FDC was well tolerated; drug-related adverse events occurred in 29 (4." | 2.74 | Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication. ( Edwards, C; Neldam, S, 2009) |
| " Dosing regimens are either not executed as prescribed (noncompliance) or patients stop taking the medication (nonpersistence)." | 2.74 | Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. ( Düsing, R; Handrock, R; Klebs, S; Tousset, E; Vrijens, B, 2009) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality." | 2.74 | Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. ( Chandurkar, NB; Karnik, ND; Pareek, A; Salagre, SB; Zawar, SD, 2009) |
| "The aim of this study was to compare the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker on aortic systolic blood pressure (BP) and brachial ambulatory systolic BP." | 2.74 | Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. ( Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Miyashita, H; O'Rourke, MF; Shimada, K, 2009) |
| "The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5." | 2.74 | Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. ( Devereux, RB; Hall, D; Hilkert, R; Pitt, B; Purkayastha, D; Reichek, N; Rocha, RA, 2009) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 2.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| " This antiihypertensve effect was considerably potentiated, when kardos was administered in combination with enalapril." | 2.74 | Pharmacodynamics of kardos administered as monotherapy and in combination with hypothiazide and enalapril in grade I-II arterial hypertension. ( Bakumov, PA; Epshtein, OI; Kachanova, MV; Petrov, VI; Sabanov, LB; Sergeeva, SA; Zabolotneva, YA; Zernyukova, EA, 2009) |
| "Hypertension is most important risk factor in coronary heart disease and cerebrovascular accidents." | 2.74 | Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. ( Arif, AF; Joshi, C; Kadam, GG, 2009) |
| "As arterial hypertension is the most important risk factor for ischemic stroke, the relevant guidelines recommend rigorous treatment to normalize blood pressure." | 2.73 | [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)]. ( Bestehorn, K; Diener, HC; Haller, H; Jung, C; Lüders, S; Schmieder, RE; Schrader, J; Smolka, W; Wahle, K, 2008) |
| " In addition, a dose-response was observed with increasing dose of HCTZ with respect to MSSBP." | 2.73 | Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. ( Baumgart, P; Ferber, P; Le Breton, S; Reimund, B; Tuomilehto, J; Tykarski, A, 2008) |
| " The incidence and causality of all adverse events (AEs) and laboratory abnormalities occurring during treatment were recorded." | 2.73 | The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. ( Mancia, G; Schumacher, H, 2008) |
| "Hypertensive patients with the cardiometabolic syndrome (CMS) are at increased risk for type 2 diabetes and cardiovascular disease." | 2.73 | Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. ( Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH, 2008) |
| "Aliskiren is a novel, orally active renin inhibitor." | 2.73 | Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. ( Calhoun, D; Chrysant, SG; Hsu, H; Matrisciano-Dimichino, L; Schober, B; Villamil, A; Zhang, J, 2007) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 2.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Indapamide retard was metabolically neutral whereas hydrochlorothiazide increased the blood levels of triglycerides and glucose by 15." | 2.73 | [Possibilities of using indices of vascular wall function as markers of negative metabolic effects of treatment with thiazide diuretics in patients with essential hypertension]. ( Semenkin, AA, 2007) |
| "Treatment with olmesartan medoxomil 40 mg/day was associated with a lower frequency of adverse events than olmesartan medoxomil/hydrochlorothiazide combination therapy (21." | 2.73 | Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. ( Barrios, V; Boccanelli, A; Böhm, M; Ewald, S; Girerd, X; Heagerty, A; Krzesinski, JM; Lins, R; Rodicio, J; Stefenelli, T; Woittiez, A, 2007) |
| "Hypertension is one of the most common cardiovascular risk factors." | 2.73 | [Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study]. ( Abts, M; Kastrati, D; Schühlen, H, 2007) |
| "Quinapril was an effective and safe treatment for achieving and maintaining recommended BP targets in this sample population." | 2.73 | Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies. ( Aran, S; Bahceci, M; Gultekin, F; Lowe, W; Ozdemir, K; Yener, G, 2007) |
| " There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group." | 2.73 | Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. ( Hirayama, Y; Matsuoka, H; Nonaka, K; Ogihara, T; Saruta, T; Suzuki, H; Takahashi, K; Toki, M, 2007) |
| "Hypertension is a chronic condition leading to increased stress on the heart and blood vessels, a critical risk factor for clinically significant events such as myocardial infarction heart failure, stroke and death." | 2.72 | Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2021) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "Chlorthalidone has significantly reduced stroke and cardiovascular end points in several landmark trials; however, hydrochlorothiazide remains favored in practice." | 2.72 | Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. ( Bergus, GR; Carter, BL; Ernst, ME; Goerdt, CJ; Phillips, BB; Steffensmeier, JJ; Zimmerman, MB, 2006) |
| " Patients' dosing histories were compiled electronically (MEMS, AARDEX)." | 2.72 | Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. ( Mengden, T; Tousset, E; Uen, S; Vetter, H, 2006) |
| "Severe hypertension is difficult to control." | 2.72 | Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S; Ptaszynska, A, 2006) |
| "Treatment with valsartan alone or combined with hydrochlorothiazide provides effective blood pressure reduction and is well tolerated." | 2.71 | [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives]. ( Mengden, T; Vetter, H; Weisser, B, 2003) |
| " Irbesartan therapy at a dosage of 150300 mg was instituted as monotherapy or associated with hydrochlorothiazide, 12." | 2.71 | [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk]. ( Aranda, P; Calvo, C; Coca, A; de la Sierra, A; Luque, M; Marín-Iranzo, R; Ruilope, LM, 2003) |
| " During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12." | 2.71 | Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. ( Byrne, M; Gil-Extremera, B; Lacourcière, Y; Mueller, O; Williams, L, 2003) |
| " Safety was assessed in both studies by the incidence of adverse experiences." | 2.71 | Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. ( Dickson, TZ; Lin, CC; Lo, MW; Ramjit, D; Ritter, MA; Shahinfar, S; Snavely, D; Zagrobelny, J, 2003) |
| " Both drugs provided effective control over the 24-h dosing interval." | 2.71 | Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. ( Kolloch, RE; Meinicke, TW; Neutel, JM; Plouin, PF; Schumacher, H, 2003) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 2.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "001) and the other periods of the 24-h interval compared with the levels achieved by the previous treatment, indicating a clear dose-response relationship." | 2.71 | Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. ( Lacourcière, Y; Poirier, L, 2003) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it." | 2.71 | Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Preti, P; Zoppi, A, 2004) |
| " Incidence and severity of adverse events and physical examination and laboratory parameters were monitored for the safety evaluation." | 2.71 | Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. ( de Zeeuw, D; Köster, J; Manolis, AJ; Murphy, MB; Reid, JL; Seewaldt-Becker, E, 2004) |
| "The new guidelines for treatment of hypertension by the JNC VII in 2003 permit the initial use of a combination therapy, if blood pressure has to be lowered more than 20/10 mmHg." | 2.71 | Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. ( Bönner, G; Fuchs, W, 2004) |
| "Hypertension is often poorly controlled, despite its importance and despite the availability of very effective treatments." | 2.71 | Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. ( Burnier, M; Ferrari, P; Hess, L; Muggli, F; Pechere-Bertschi, A, 2004) |
| "Because hypertension is associated with potentially reversible structural and functional alterations in the cerebral circulation that may improve with treatment, we investigated whether long-term pharmacological reduction of systolic blood pressure will improve, rather than worsen, cerebral blood flow and its regulation." | 2.71 | Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. ( Babikian, V; Cheng, DM; Cupples, LA; Gagnon, M; Iloputaife, I; Kiely, DK; Lipsitz, LA; Serrador, J; Sorond, F; Vyas, M, 2005) |
| " Tolerability and safety were assessed by physical examination, laboratory parameters and evaluation of adverse events." | 2.71 | Assessment of efficacy, safety and tolerability of fixed dose combination of telmisartan 40mg and hydrochlorothiazide 12.5mg in adult Indian patients with mild to moderate hypertension. ( Chandrasekharan, S; Desai, A; Ganesan, R; Gawde, A; Jain, SD; Jayaram, S; Kadam, GS; Lahoti, S; Mishra, AB; Muralidharan, RS; Rajadhyaksha, GC; Sodhi, SS, 2004) |
| "Treatment with hydrochlorothiazide diminished the delipidation rate value whereas propranolol mildly increased the removal rate of the remnant particle." | 2.71 | Effects of hydrochlorothiazide and propranolol treatment on chylomicron metabolism in hypertensive objects. ( Bernik, MM; Cazita, PM; Heimann, JC; Nakandakare, ER; Neves, MQ; Nunes, VS; Quintão, EC; Rocha, JC, 2005) |
| "Thirty percent had type 2 diabetes mellitus, 46% had metabolic syndrome, and baseline blood pressure was 154." | 2.71 | The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Neutel, JM; Ofili, EO; Saunders, E; Sowers, JR; Weber, MA, 2005) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| " Most adverse events were of mild-to-moderate intensity and unrelated to treatment." | 2.70 | Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. ( Freytag, F; Holwerda, NJ; Karlberg, BE; Meinicke, TW; Schumacher, H, 2002) |
| "Hypertension is twice as common in postmenopausal than in premenopausal women." | 2.70 | Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. ( Abellán, J; de Castro, SS; De Vinuesa, SG; Fernández-Vega, F; Luño, J; Maceira, B; Nicolás, RR; Rodríguez, JC; Vegazo, O, 2002) |
| " In both treatment groups the dosage could be doubled after > or =2 weeks [according to blood pressure (BP) response] and, if necessary, subsequently decreased if the higher dosage was poorly tolerated." | 2.70 | Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. ( Forsén, B; Neldam, S, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Control of hypertension is hindered by the incidence of adverse events associated with therapy, which can result in low patient compliance." | 2.70 | Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. ( Levine, B, 2001) |
| "Omapatrilat was effective and well tolerated when added to HCTZ in subjects whose blood pressure was not controlled with HCTZ alone." | 2.70 | Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. ( Barbosa, JA; Ferdinand, K; Kushnir, E; Lewin, A; Saini, R; Yellen, L, 2001) |
| "The fixed combination V + H used for treatment of hypertension, after failure of monotherapy, is very effective in reducing pulse pressure, systolic and diastolic blood pressure, over 24 hours, homogeneously, and is as well tolerated as placebo." | 2.70 | [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring]. ( Asmar, R; Ghobrial, H; Herpin, D; Mallion, JM; Poncelet, P; Vaïsse, B; Vaur, L, 2001) |
| " In conclusion, switching to V/HCTZ combination therapy provides an additional lowering of BP compared to dosage increase of the thiazide in patients with BP insufficiently controlled by HCTZ 12." | 2.70 | Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. ( Adam, SA; Handrock, R; Kolloch, R; Schmidt, A; Weidinger, G, 2001) |
| "Hypertension is a risk factor for dementia, particularly vascular dementia." | 2.69 | [Antihypertensive treatment and prevention of dementia]. ( Seux, ML, 1999) |
| " The cardinal questions to be answered were: (1) the relationship between three targeted diastolic pressures (< or = 90, < or = 85 and < or = 80 mm Hg, respectively) and cardiovascular morbidity and mortality rates among hypertensives; and (2) the effect of low dosage aspirin (75 mg daily) on morbidity and mortality rates, compared with a placebo." | 2.69 | [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age]. ( Kolloch, RE; Rahn, KH, 1998) |
| "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy." | 2.69 | Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. ( Cleary, EW; Dilzer, SC; Huffman, CS; Lasseter, KC; Smith, DA; Watkins, S, 1998) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| " At week 6, the dosage of irbesartan or placebo was doubled for seated diastolic blood pressure > or = 90 mmHg." | 2.69 | The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. ( Lin, CS; MacNeil, D; Osbakken, M; Rosenstock, J; Rossi, L, 1998) |
| "Concern based on the reported short-term adverse effects of antihypertensive agents on plasma lipid and lipoprotein profiles (PLPPs) has complicated the therapy for hypertension." | 2.69 | Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Cushman, WC; Freis, ED; Lakshman, MR; Materson, BJ; Reda, DJ, 1999) |
| " Dosage could be increased for both telmisartan (40 --> 80 --> 160 mg) and lisinopril (10 --> 20 --> 40 mg) at each of the first 2 monthly visits if DBP control (<90 mm Hg) had not been established." | 2.69 | Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. ( Frishman, WH; Guthrie, G; Neutel, JM; Oparil, S; Papademitriou, V, 1999) |
| "To compare candesartan cilexetil and lisinopril in fixed combination with hydrochlorothiazide with respect to antihypertensive efficacy and tolerability." | 2.69 | Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. ( Istad, H; Keinänen-Kiukaanniemi, S; McInnes, GT; O'Kane, KP; Van Mierlo, HF, 2000) |
| "Losartan appears to be an effective anti-hypertensive agent in patients with mild to moderate hypertension." | 2.68 | Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. ( Bauer, IH; Lau-Sieckman, A; Reams, GP; Wu, Z, 1995) |
| " A dose-response relationship to losartan was observed in this patient population." | 2.68 | Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. ( Goldberg, AI; Pratt, JH; Soffer, BA; Sweet, CS; Wiens, B; Wright, JT, 1995) |
| "01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent." | 2.68 | Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. ( Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " Although plasma inactive renin concentrations did not change acutely after losartan dosing on day 1 or 42 they did increase from 27." | 2.68 | Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. ( Goldberg, MR; Katz, SA; Opsahl, JA, 1995) |
| " We conclude that although the pharmacokinetics of both enalaprilat and HCTZ are related to renal function, HCTZ has no significant effect on the pharmacokinetics of enalaprilat and that dosage adjustment for both regimens should be based on renal function." | 2.68 | Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. ( Carmody, M; Doyle, GD; Hersh, AD; Kelly, JG; Laher, MS, 1996) |
| "Hypertension is a constituent of the metabolic syndrome, although the rise of the blood sugar does not directly correlate with manifestation of type 2 diabetes, it is a warning that insulin resistance can influence the effectiveness of provisions of the therapeutic regimen, and last not least, also the development of type 2 diabetes." | 2.68 | [Glycemia increases during treatment of hypertension. 13 years' experience in the treatment of middle-aged men, randomized for treatment with beta blockers and diuretics]. ( Storková, H; Válek, J; Válková, L, 1996) |
| " Based on the results obtained in these trials, both dose combinations of Fos/HCTZ taken once daily were safe and effective in the management of patients with mild-to-moderate hypertension." | 2.68 | Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators. ( Battikha, JP; Guthrie, R; Plesher, MM; Reggi, DR; Saini, RK, 1996) |
| "Nitrendipine tablets were discontinued in 10 patients on placebo and in 21 patients assigned to active treatment (P < 0." | 2.68 | Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators. ( Celis, H; Clement, D; Cozic, J; De Cort, P; Fagard, R; Forette, F; Grégoire, M; Heyrman, J; Staessen, J; Stibbe, G; Thijs, L; Van den Haute, M; Yodfat, Y, 1996) |
| "Both doxazosin and HCTZ were effective drugs over 1 year for treating hypertension." | 2.68 | Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. ( Flack, JM; Gonzalez, NM; Grimm, RH; Liebson, PR; Schoenberger, JA, 1996) |
| "Hydrochlorothiazide, 25 mg/day, was added after 4 weeks if required." | 2.68 | Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. ( Darioli, R; Greminger, P; Riesen, W; Simeon-Dubach, D; Waeber, B; Wunderlin, R, 1995) |
| "The captopril treated patients exhibited favorable changes in several aspects of quality of life: sleep-related, gastrointestinal, and physical activity-related symptoms improved from baseline to end of follow-up." | 2.68 | The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. ( Anson, O; Neumann, L; Paran, E, 1996) |
| "Doxazosin therapy was characterized by significant increase in the levels of mean plasma total protein and albumin, while moduretic therapy showed significant reduction in the mean values of plasma creatinine and calcium." | 2.68 | Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. ( Agbedana, EO; Ahaneku, JE; Salako, LA; Sowunmi, A; Taylor, GO; Walker, O, 1996) |
| "Antihypertensive drug combinations have two major advantages: First, dosage of the single components can be reduced, and second, putative side effects can be minimized." | 2.68 | [Combination antihypertensive therapy in patients with an increased risk profile]. ( Bartens, W; Nauck, M; Wanner, C, 1996) |
| " Significant dose-response differences were observed between treatments." | 2.68 | Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. ( Anzalone, DA; Falkner, B; Hutchinson, HG; Reisin, E; Tuck, ML; Weir, MR, 1997) |
| "Reversal of left ventricular hypertrophy has been shown to improve left ventricular diastolic function in elderly patients with hypertension, but little is known about whether this affects physical performance." | 2.68 | Physical performance is preserved after regression of left ventricular hypertrophy. ( Cléroux, J; Lacourcière, Y; Poirier, L, 1997) |
| " Withdrawals owing to adverse events were three from trandolapril and eight from the captopril group." | 2.67 | Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group. ( Pauly, NC; Safar, ME, 1994) |
| " The incidence of adverse events was similar in all three groups." | 2.67 | Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group. ( Meyer, BH; Pauly, NC, 1994) |
| "Moxonidine 0." | 2.67 | Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. ( Frei, M; Gardosch von Krosigk, PP; Koch, HF; Küppers, H; Küster, L, 1994) |
| "Essential hypertension is characterized by parallel and potentially reversible vascular and cardiac adaptations." | 2.67 | Nail fold capillaroscopy and echocardiography in mild-to-moderate hypertension treated with cilazapril plus hydrochlorothiazide: first results. ( Bart, T; Gasser, P; Köhler, M; Martina, B; Weinbacher, M, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 2.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| " At the end of both periods, sphygmomanometric blood pressure was assessed 24 hours after dosing and 24-hour ambulatory blood pressure was performed, taking blood pressure readings every 15 minutes during day- and night-time." | 2.67 | [The antihypertensive effects of the lisinopril-hydrochlorothiazide combination (Zestoretic) in elderly hypertensive patients. The results of a multicenter study. The Italian Zestoretic Study Group]. ( Mancia, G, 1994) |
| " The incidence of adverse events was lower in the combination group than in either of the monotherapy groups, and there were no serious clinically significant laboratory abnormalities in the combination group." | 2.67 | Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group. ( Genthon, R, 1994) |
| "Thiazide diuretics are widely used in the drug treatment of hypertension but their dose-response curves for the antihypertensive and adverse metabolic effects differ." | 2.67 | Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. ( Borrild, NJ; Hoyem, A; Jounela, AJ; Lilja, M; Lumme, J; Mörlin, C; Wessel-Aas, T, 1994) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 2.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| " After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached." | 2.67 | Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. ( Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994) |
| "A factorial design method was applied in this multicentre trial of the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril) in combination with the diuretic hydrochlorothiazide (HCTZ) to assess the additive effects of the combination versus monotherapy, to characterise the dose-response relationship of each drug in the presence of the other and to determine if quinapril would attenuate the hypokalemic effect of HCTZ." | 2.67 | Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril Investigator Group. ( Canter, D; Frank, GJ; Knapp, LE; Phelps, M; Quade, M; Texter, M, 1994) |
| "Hydrochlorothiazide treatment decreased diastolic blood pressure to 83." | 2.67 | Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. ( Goodfriend, TL; Klassen, D; Peterson, CA; Schuna, AA; Young, DY, 1993) |
| "and felodipine PT b." | 2.67 | Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group. ( Carruthers, SG; Vint-Reed, C, 1993) |
| " During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study." | 2.67 | Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. ( Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994) |
| "Nitrendipine tablets were discontinued in nine patients on placebo and in 29 patients assigned to active treatment (P < 0." | 2.67 | Nitrendipine in older patients with isolated systolic hypertension: second progress report on the SYST-EUR trial. ( Bert, P; Bulpitt, C; De Cort, P; Fagard, R; Fletcher, A; Kivinen, P; Lehtomaki, E; Leonetti, G; O'Brien, E; Staessen, J, 1993) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 2.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent)." | 2.67 | Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Cushman, WC; Freis, ED; Fye, C; Gottdiener, J; Hamburger, RJ; Kochar, MS; Lakshman, R; Massie, BM; Materson, BJ; Reda, DJ, 1993) |
| " One capsule was taken for three days and then the dosage was doubled for the remainder of a four-week period." | 2.67 | Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. ( Annett, MP; Culbert, JP; McCorvey, E; McKenney, JM; Proctor, JD; Wright, JT, 1993) |
| " for K-Can: dosing was doubled after 1 month if seated diastolic BP was > or = 95 mmHg." | 2.67 | Different sensitivity to hydrochlorothiazide and to potassium-canrenoate among essential hypertensive patients. ( Cusi, D; Glorioso, N; Madeddu, P; Manunta, P; Melis, MG; Pala, F; Pazzola, A; Soro, A; Tonolo, G; Troffa, C, 1993) |
| "Renal hemodynamics, albuminuria and metabolic parameters were evaluated for a period of one year." | 2.67 | Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. ( Bakris, GL; Barnhill, BW; Sadler, R, 1992) |
| "Treatment with Enalapril decreased the reflection of the retinal arterial wall significantly and reduced the narrowing of arteries and arterio-venous crossing phenomena non-significantly." | 2.67 | Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. ( Dahlöf, B; Hansson, L; Stenkula, S, 1992) |
| " This suggests that some were apparent non-responders due to too low dosing of atenolol rather than true non-responders." | 2.67 | Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men. ( Erikssen, J; Froeland, G; Otterstad, JE; Saltvedt, E; Soeyland, AK, 1992) |
| " L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ." | 2.67 | Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. ( Graham, RD, 1991) |
| "Co-administration of drugs with complementary action is a rational approach to the treatment of hypertension provided that the drugs are free of mutual pharmacokinetic interactions." | 2.67 | The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ( Swaisland, AJ, 1991) |
| " Similar differences have been reported for such patient groups when the drugs were administered separately, indicating an absence of pharmacokinetic interaction." | 2.67 | The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ( Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991) |
| "Hypertension is a risk factor for the development of atherosclerosis and its complications, which are among the major causes of morbidity and mortality." | 2.67 | The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group. ( Bond, MG; Borhani, NO; Buckalew, V; Canossa-Terris, M; Gibbons, ME; Sowers, JR; Worthy, AJ, 1991) |
| "Treatment with felodipine ER over 2 weeks increased sympathetic outflow as indicated by elevated plasma norepinephrine levels, whereas plasma epinephrine was mainly unaffected, as were plasma renin and aldosterone levels." | 2.67 | Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. ( Binner, L; Gabrielsen, F; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| " Adverse events were reported in 11 of the 38 patients in the ramipril group, in 22 of 83 patients treated with the combination for more than 50 weeks, and in 9 of 38 patients treated with the combination for 50 weeks or less." | 2.67 | Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study. ( Bauer, B; Breitstadt, A; Cairns, V; Froer, KL; Heidbreder, D, 1991) |
| "Perindopril (4 mg) was compared to atenolol (50 mg), captopril (25 mg b." | 2.67 | Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs. ( Desche, P; Thurston, H, 1991) |
| "5 h after dosing with HCTZ, which was not significantly lower." | 2.67 | Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension. ( Binner, L; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| " Nine patients experienced adverse events during combination treatment." | 2.67 | The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. ( Dupont, AG; Schoors, DF; Venuti, RP, 1990) |
| "Hydrochlorothiazide treatment was accompanied by a decrease in serum potassium and an increase in serum uric acid." | 2.67 | The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group. ( Ibsen, H; Westberg, B, 1990) |
| " This combination is well tolerated, probably due to an adequate enalapril/HCTZ dosage ratio." | 2.67 | [Comparative study of enalapril, hydrochlorothiazide and their combination in the treatment of essential hypertension]. ( Delage, Y; Poggi, L; Souchet, T; Vaisse, B, 1991) |
| "Felodipine Er, 10 mg, was given once daily for 2 weeks, and after another wash-out period of 1 week, patients were switched to 25 mg HCTZ, once daily, and vice versa." | 2.67 | Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study. ( Binner, L; Ernst, E; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| " We concluded that enalapril in combination with hydrochlorothiazide is more effective and safe, and allows for lower dosing of enalapril than the drug as monotherapy in Korean hypertensives." | 2.67 | Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide. ( Jones, DW; Sands, CD, 1991) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 2.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| "We studied the dose-response relationship for hydrochlorothiazide + triameterene and verapamil, comparing monotherapy with combined treatment in 216 hypertensive patients over 3 weeks of active treatment following a 2-week washout period with placebo." | 2.67 | Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial. ( Bluemner, E; Letzel, H, 1990) |
| "5 mg of triamterene) to one capsule of Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene) to determine if the difference in bioavailability would be reflected in differences in blood pressure control and metabolic changes." | 2.67 | A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide. ( Casner, PR; Dillon, KR, 1990) |
| "Propranolol treated patients had increased "trouble getting breath," bradycardia, shortness of breath or wheezing, and blurred vision." | 2.67 | Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. ( Baume, RM; Croog, SH; Levine, S; Schoenberger, JA; Sudilovsky, A, 1990) |
| "Non-melanoma skin cancer is the most prevalent malignancy in fair-skinned people and its incidence is increasing." | 2.66 | Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. ( Borges-Costa, J; Garrido, PM, 2020) |
| " After at least 6 months of treatment, the mean daily dosage of indoramin was higher among patients who received indoramin alone (122 mg/day) than among those who received indoramin plus a diuretic (92 mg/day)." | 2.66 | Antihypertensive therapy with indoramin in the elderly. ( Allen, IE; Deitch, MW; Pascucci, VL, 1986) |
| "Nitrendipine is a second-generation dihydropyridine derivative that, though not yet approved in the United States, has been extensively evaluated both there and abroad." | 2.66 | Antihypertensive therapy with nitrendipine: comparison with hydrochlorothiazide and propranolol. ( Massie, BM, 1988) |
| "There was no difference in ventricular extrasystoles between the two supplementation groups." | 2.66 | The effect of potassium and potassium plus magnesium supplementation on ventricular extrasystoles in mild hypertensives treated with hydrochlorothiazide. ( Jounela, AJ; Lumme, JA, 1989) |
| " The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)." | 2.66 | [Perindopril: first-line treatment of arterial hypertension]. ( Desche, P; Zanchetti, A, 1989) |
| " Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension." | 2.66 | Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. ( Chrysant, SG; Glasser, SP; Graves, J; Koehn, DK; Rofman, B, 1989) |
| "Amlodipine treated patients had lower arterial pressures in both the supine and upright positions (P less than ." | 2.66 | Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. ( Chrysant, C; Chrysant, SG; Hitchcock, A; Trus, J, 1989) |
| " No significant pharmacokinetic interaction was found between cilazapril and hydrochlorothiazide." | 2.66 | Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients. ( Grynne, B; Kleinbloesem, CH; Nilsen, OG; Romfo, OS; Sellevold, OF; Smedsrud, A; Williams, PE, 1989) |
| "More metoprolol-treated patients withdrew because of depression (6 vs less than 1%; p = 0." | 2.66 | Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol. ( Ahmad, S; Glasser, SP; Lucas, C; Lutz, LJ; Materson, BJ; Morledge, JH; Ramanathan, KB; Saunders, E; Schnaper, HW; Vlachakis, ND, 1989) |
| "Amlodipine treatment was associated with a slightly higher incidence of side effects compared with placebo, but most of this difference was the result of edema, which was usually well tolerated." | 2.66 | The safety of amlodipine. ( Osterloh, I, 1989) |
| "When captopril was added to hydrochlorothiazide, a significant attenuation of the diuretic effect on potassium and uric acid was observed, and the significant change in blood sugar and cholesterol seen with the diuretic alone was prevented." | 2.66 | Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. ( Weinberger, MH, 1985) |
| " A very flat dose-response curve in high dosages and the expectation of fewer side effects made us combine low-dose captopril with enhanced stimulation of the renin-angiotensin-aldosterone (RAA) system." | 2.66 | Captopril and hydrochlorothiazide in the fixed combination multicenter trial. ( Lederle, RM, 1985) |
| "Benazepril was shown in preclinical studies to be a potent and specific inhibitor of angiotensin-converting enzyme with a benign toxicologic profile." | 2.66 | Definition of the effective dose of the converting-enzyme inhibitor benazepril. ( Whalen, JJ, 1989) |
| " Although some patients remained normotensive after discontinuation of step II drugs, a greater proportion returned to elevated BP than when step II dosage was unchanged." | 2.66 | Effects of reduction in drugs or dosage after long-term control of systemic hypertension. ( Borreson, RE; Fisher, SG; Freis, ED; Hamburger, R; Mezey, KC; Mukherji, B; Neal, WW; Perry, HM; Taguchi, JT; Thomas, JR, 1989) |
| "Nicardipine is an investigational dihydropyridine calcium channel blocking agent." | 2.66 | Nicardipine and hydrochlorothiazide in essential hypertension. ( Brown, R; Conrad, KA; Fagan, TC; Freedman, D; Lessem, J; Michelson, E; Montijo, M; Schnaper, H; Smolens, P, 1989) |
| "Treatment with amiloride + HCTZ led to elevations in serum levels of cholesterol, uric acid and urea, which were maintained at one year, whilst no abnormalities in blood biochemistry were seen in patients treated with nicardipine." | 2.66 | A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the General Practitioner Hypertension Study Group. ( Bradley, I; Davis, A; Ganvir, P; Gostick, NK; Hopwood, AM; MacKay, D; Mayhew, SR; Mukerji, D; Shepherd, F, 1989) |
| "Hydrochlorothiazide was assayed in 24-hour urine samples." | 2.66 | Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product. ( Cane, RC; Costello, K; Goodwin, P; Perkal, M; Sharoky, M; Tabatznik, B, 1989) |
| "Captopril appears to be a promising monotherapy for the elderly with mild to moderate hypertension." | 2.66 | A single-blind, randomized, cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly. ( Kin, T; Vallance-Owen, J; Woo, J; Woo, KS, 1987) |
| "Enalapril and atenolol were also equally effective, but in combination their hypotensive effects were less than fully additive, with attenuation of the potential additive response by 30-50%." | 2.66 | Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions. ( Bune, AJ; Chalmers, JP; Elliott, JM; Morris, MJ; Russell, AE; West, MJ; Wing, LM, 1987) |
| "Enalapril monotherapy was associated with a slight, but not significant, fall in fasting blood glucose levels and with a significant fall in hemoglobin A1c levels." | 2.66 | Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. ( Bandi, Z; Holland, OB; Padia, M; Prince, MJ; Stuart, CA, 1988) |
| "Acebutolol was superior to placebo, propranolol, and hydrochlorothiazide in terms of response rate." | 2.66 | Effects of age and race on clinical response to acebutolol in essential hypertension. ( Boyles, PW, 1985) |
| "Hydrochlorothiazide was used alone in 36 percent of patients, in combination with propranolol in 26 percent, and with methyldopa in 20 percent." | 2.66 | Coronary heart disease and treatment of hypertension. Some Oslo Study data. ( Helgeland, A; Leren, P, 1986) |
| "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension." | 2.66 | Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. ( Pool, JL, 1987) |
| "Captopril was associated with a significantly (P less than 0." | 2.66 | Angiotensin converting enzyme inhibitors and quality of life: the European trial. ( Bulpitt, CJ; Fletcher, AE; Hill, JF, 1985) |
| " There was no evidence of a flat dose-response curve in the daily dose range of 12." | 2.66 | Is low-dose hydrochlorothiazide effective? ( Freis, ED; Magee, PF, 1986) |
| "5mg bid, respectively, with significant attenuation of these effects at both hydrochlorothiazide dosage levels." | 2.66 | Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study. ( Goldberg, MR; Offen, WW, 1988) |
| "The propranolol-treated smokers tended to be younger, taller, thinner, and wre more likely to be black." | 2.66 | Cigarette smoking interferes with treatment of hypertension. ( Freis, ED; Henderson, WG; Materson, BJ; Reda, D, 1988) |
| "The patients with complex arrhythmias were older (p less than 0." | 2.66 | Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker. ( Hardarson, T; Ragnarsson, J; Snorrason, SP, 1987) |
| "Hydrochlorothiazide was added for patients not achieving the treatment goal." | 2.66 | Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. ( Anderson, M; Bartels, D; Eidelson, BA; Labreche, DG; MacCarthy, EP; Massie, B; Ramanathan, KB; Tubau, JF; Ulep, D; Weiss, RJ, 1987) |
| " Eumagnesaemia and eupotassaemia were preserved at all dosage of the piretanide monosubstance." | 2.66 | Lack of effect of piretanide (a potassium-stable diuretic) on serum magnesium. ( de Looze, S; Irmisch, R; Rangoonwala, B; Verho, M, 1987) |
| "Prazosin-treated patients whose initial fasting blood glucose was less than 110 mg/dl had 3." | 2.66 | Initial antihypertensive therapy. Comparison of prazosin and hydrochlorothiazide. ( Alderman, MH; Carroll, L; Davis, TK, 1986) |
| "The antihypertensive and biochemical effects of 25 mg hydrochlorothiazide alone or 50 mg hydrochlorothiazide alone or in combination with triamterene (either 37." | 2.66 | Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. ( Eisalo, A; Gordin, A; Kohvakka, A; Salo, H, 1986) |
| "Amiloride hydrochloride has now been recognized as a safe and effective potassium-sparing diuretic alternative to triamterene with a similar mechanism of pharmacologic activity." | 2.66 | Antihypertensive therapy with triamterene-hydrochlorothiazide vs amiloride-hydrochlorothiazide. Comparison of effects on urinary prostaglandin E2 excretion. ( Zawada, ET, 1986) |
| "In recent years, hypertension has generally been treated with a step-care approach, the limitations of which are now becoming apparent." | 2.66 | Comparison and additivity of nitrendipine and hydrochlorothiazide in systemic hypertension. ( Massie, BM; Szlachcic, J; Tubau, JF; Vollmer, C, 1986) |
| " Previous medication was stopped and following a run-in period of 2 weeks on placebo, the initial dosage was C (25 mg)/HCT (12." | 2.66 | Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study. ( Baulac, L; Creisson, C; Lenfant, B, 1986) |
| "Treatment with captopril induced a decrease in Nai, no change in Ke and an increase in Ki and Ki/Ke." | 2.66 | Influence of captopril on intracellular ions--a possible mode of action. ( Ambrosioni, E; Borghi, C; Costa, FV; Mussi, A, 1986) |
| " After 4 weeks the captopril dosage was doubled, whereas the hydrochlorothiazide dose remained at 25 mg for an additional 4 weeks." | 2.66 | Once-daily treatment of essential hypertension with captopril. ( Schoenberger, JA; Wilson, DJ, 1986) |
| " Furthermore, no adverse effects were noted with either potassium chloride formulation, and patient acceptance, tolerability, and compliance to prescribed dosing regimens were similar for both products." | 2.66 | Therapeutic assessment of Slow-K and K-tab potassium chloride formulations in hypertensive patients treated with thiazide diuretics. ( Acchiardo, SR; Carter, CA; Skoutakis, VA, 1987) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 2.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| ", following the initial dose of active treatment) and on each visit when the dosage was increased." | 2.66 | The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. ( Blasucci, DJ; Falliers, CJ; Maloy, JW; Medakovic, M; Vrchota, J, 1985) |
| "Labetalol is a competitive, nonselective antagonist of both beta 1 and beta 2 adrenoceptors." | 2.66 | Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension. ( Kalbfleisch, JH; Kochar, MS; Tyson, J, 1985) |
| " These findings suggest that the long-term administration of this beta blocker combined with a diuretic results in serum lipid changes considered beneficial in the evaluation of risk factors for coronary artery disease." | 2.66 | Improvement of the lipid profile during long-term administration of pindolol and hydrochlorothiazide in patients with hypertension. ( Chin, B; Fenderson, RW; Gonasun, LM; Lieberman, S; Samuel, P; Schoenfeld, BH, 1986) |
| "Enalapril alone was not very effective in lowering blood pressure in these subjects, but the combination of enalapril with HCTZ was very effective." | 2.65 | Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension. ( Bain, RP; Douglas, MB; Freier, PA; Hall, WD; Unger, DJ; Wollam, GL, 1984) |
| "Indapamide was prescribed to replace hydrochlorothiazide, the other antihypertensive drugs being continued in those patients receiving combination therapy." | 2.65 | The treatment of hypertension with indapamide alone or in combination with other drugs. ( L'Homme, C; Lemieux, G, 1983) |
| "Captopril is an effective alternative in the treatment of hypertensive patients not readily controlled with conventional therapy." | 2.65 | The renin-angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment-resistant hypertension. ( Damkjaer Nielsen, M; Giese, J; Ibsen, H; Leth, A; Rasmussen, S, 1984) |
| " Apart from the hydrochlorothiazide dosage which was fixed, the dosage of the other active drugs was titrated incrementally until the target blood pressure level was achieved." | 2.65 | An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension. ( Fernandez, PG; Galway, AB; Kim, BK, 1984) |
| "Labetalol is a new adrenergic antagonist with both alpha- and beta-blocking effects." | 2.65 | Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. ( Burford, JG; Conrad, SA; George, RB; Kinasewitz, GT; Manocha, K, 1983) |
| "Oxprenolol (OX) is a nonselective, beta-adrenergic blocking agent with intrinsic sympathomimetic activity." | 2.65 | Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial. ( Friedman, BA; Glazer, N; Gray, JM; Gross, S; Hla, KM; Materson, BJ; Neidorf, BS, 1983) |
| "Indapamide is a useful antihypertensive agent with good patient tolerance in mild or moderate hypertension and may offer advantages over traditional diuretics in view of its possible vasodilator and calcium-antagonist properties, once-a-day dosage, and good therapeutic effect with prolonged usage." | 2.65 | Clinical efficacy and safety of indapamide in essential hypertension. ( Morledge, JH, 1983) |
| "Indapamide has been the subject of a long-term safety study in which over 100 hypertensive patients have been followed up for 2 years or longer." | 2.65 | Multi-centre clinical investigation of indapamide in the United States: a review. ( Barton, J; Bronstein, R; Caruso, F; Eff, J; Losi, M; Neiss, ES; Schotz, WE; Vukovich, RA; Webb, E; Zisblatt, M, 1983) |
| " These studies range from single-dose experiences, through long-term administration for periods greater than 1 year, to hour-by-hour observation of effects following single doses." | 2.65 | Clinical hemodynamic profile of trimazosin in hypertension. ( Pool, PE; Salel, AF; Seagren, SC, 1983) |
| "Oxprenolol was well tolerated in the elderly; it produced a low incidence of typical beta-blocker side effects even when given in a once-daily regimen." | 2.65 | Clinical responses to oxprenolol in the elderly. ( Ellis, RA, 1983) |
| " This reduced bioavailability may reduce its effectiveness in hypertensive patients who change from optimally bioavailable hydrochlorothiazide tablets to Dyazide capsules in an effort to correct hypokalemia." | 2.65 | A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide). ( Blume, CD; Williams, RL, 1984) |
| "5 mg, 25 mg, and 50 mg hydrochlorothiazide combined with 400 mg acebutolol was assessed." | 2.65 | Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. ( Banks, RA; Bayliss, J; MacGregor, GA; Markandu, ND; Roulston, J, 1983) |
| "An open, multi-centre study was carried out in general practice to compare the efficacy and tolerance of antihypertensive therapy with once-daily and twice-daily dosage of a fixed ratio combination of hydrochlorothiazide (25 mg), amiloride (2." | 2.65 | Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension. ( Currie, WJ; Isitt, VL; VandenBurg, MJ; Young, JH, 1984) |
| " All groups had mean diastolic pressure controlled at or below the 90 mmHg criterion during the period of constant methyldopa dosage for those patients who required Step 2 therapy." | 2.65 | Indapamide in the stepped-care treatment of obese hypertensive patients. ( Godfrey, JC; Neiss, ES; Noble, RE; Vukovich, RA; Webb, EL; Zisblatt, M, 1983) |
| " The effect of twice the dosage was evaluated in subjects with unsatisfactory blood pressure (BP) on the lower dose." | 2.65 | Potassium sparing by amiloride during thiazide therapy in hypertension. ( Andersson, PO; H-Andersen, H; Hagman, A; Henning, R, 1984) |
| " Also during treatment, fewer patients receiving hydrochlorothiazide required termination as compared with those receiving propranolol; comparative dosage requirements were lower; additional titration during long-term treatment was required less often, and BP remained lower after withdrawal of the active drugs." | 2.65 | Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. ( , 1982) |
| "Mepindolol was well tolerated: side effects were generally mild and inconsequential." | 2.65 | Multicenter evaluation of mepindolol and of mepindolol plus hydrochlorothiazide in essential hypertension. ( Galassi, A; Ginevrino, P; Libretti, A; Masoni, A; Morgagni, W; Rappelli, A; Tomasi, AM, 1982) |
| " It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed." | 2.65 | Long-term treatment of essential hypertension with Nadolol and Hydrochlorothiazide: a two-year follow-up. ( El-Mehairy, MM; Hamza, S; Ramadan, M; Shaker, A; Tadros, SS, 1982) |
| " The results showed that the change in treatment led to a significant reduction in blood pressure in both groups, at a dosage of 1 tablet daily in over half the patients, and the majority (88%) preferred the new form of treatment." | 2.65 | A general practice study of timolol/hydrochlorothiazide/amiloride ('Moducren'), a new therapy for hypertension, and the doctor's influence on management. ( Arr, S; Parry, EE; Tait, D, 1983) |
| " The dosage problem with HTZ + AMl is discussed." | 2.65 | Antihypertensive and metabolic effects of a combination of hydrochlorothiazide and amiloride. ( Leary, WP; Reyes, AJ, 1981) |
| "1 The hypotensive effect of single daily dosing with 80 mg penbutolol was compared to 100 mg hydrochlorothiazide and placebo in a double-blind cross-over controlled trial with daily home measurements in ten hypertensive patients." | 2.65 | Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements. ( De Plaen, JF; Van Ypersele de Strihou, C; Vander Elst, E, 1981) |
| " Dosage was 2 tablets per day of the 5 mg amiloride plus 50 mg hydrochlorothiazide combination or of 50 mg hydrochlorothiazide alone." | 2.65 | Potassium conservation with amiloride/hydrochlorothiazide ("Moduret') in thiazide-induced hypokalaemia in hypertension. ( Campbell, N; Fernandez, PG; Galway, AB; Gill, V; Granter-Button, S; Kim, BK; MacDonald, J; Sharma, JN; Snedden, W, 1982) |
| "Cyclothiazide tended to cause hypokalaemia, apparently due to increased potassium loss, but with the present dosage none of the 13 patients developed marked hypokalaemia (serum potassium less than 3." | 2.65 | Antihypertensive, saluretic and hypokalaemic effects of cyclothiazide in comparison with hydrochlorthiazide with amiloride supplement. ( Salonen, JT; Ylitalo, P, 1982) |
| "Ten patients with congestive heart failure, on full digitalis treatment, were given TA (dose range 250-1000 mg/die): in each patient a prompt diuretic effect was observed, associated to a significant reduction of body weight and to a marked improvement of the clinical signs of heart failure." | 2.65 | [Tienilic acid in the treatment of arterial hypertension and congestive cardiac insufficiency]. ( Agabiti-Rosei, E; Alicandri, C; Corea, L; Fariello, R; Muiesan, G; Oldoni, T, 1979) |
| " Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily." | 2.64 | Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent. ( Freis, ED; Kyle, MC; Nemati, M, 1977) |
| "With propranolol, findings were 138 +/- 3/106 +/- 2 to 123 +/- 3/89 +/- 3; in 7 of 12 to less than 91 mm Hg and from 91 to 95 in 4 subjects." | 2.64 | Antihypertensive effects of oxprenolol and propranolol. ( Materson, BJ; Michael, UF; Oster, JR; Perez-Stable, EC, 1976) |
| "The goals of treatment in hypertension are to optimally control high blood pressure and to reduce associated cardiovascular morbidity and mortality using the most suitable therapy available." | 2.61 | Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2019) |
| "Hydrochlorothiazide and skin cancer Hydrochlorothiazide is a frequently prescribed diuretic with known photosensitizing properties." | 2.61 | [Hydrochlorothiazide and skin cancer]. ( Olde Engberink, RHG; van den Born, BH; van der Hoeven, NV; Zwinderman, AH, 2019) |
| "Hydrochlorothiazide has less effect on blood pressure, a high risk of metabolic side effects, and may not have pleiotropic effects." | 2.55 | [All diuretics used in the treatment of hypertension are not the same]. ( Asil, S; Atalar, E, 2017) |
| "Hypokalemia is a recognized adverse effect of thiazide diuretic treatment." | 2.52 | Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. ( Bailey, K; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Del-Aguila, JL; Gums, JG; Johnson, JA; Turner, ST, 2015) |
| "Hypertension is a powerful risk factor strongly linked to adverse cardiovascular outcomes." | 2.52 | Misconceptions and facts about treating hypertension. ( Argulian, E; Grossman, E; Messerli, FH, 2015) |
| "Hydrochlorothiazide (HCTZ) has often been contrasted with chlorthalidone, but relatively little is known about HCTZ versus indapamide (INDAP)." | 2.52 | Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. ( Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Tandon, S, 2015) |
| " Data was pooled separately for the two T40 non-responder studies (T40 NR group, two T80 non-responder studies (T80 NR group), and the two factorial design dose-response studies (FD-DR group)." | 2.50 | Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. ( Kjeldsen, SE; Neldam, S; Neutel, JM; Schumacher, H, 2014) |
| "Hypertension is a modifiable cardiovascular risk factor." | 2.50 | Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. ( Bassett, K; Musini, VM; Nazer, M; Wright, JM, 2014) |
| "Hydrochlorothiazide doses were 12." | 2.49 | Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. ( Guthrie, RM; Kjeldsen, SE; Neldam, S; Schumacher, H, 2013) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "Effective treatment of hypertension is a key strategy for preventing and reducing the burden of hypertension-related cardiovascular diseases." | 2.48 | Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. ( Paneni, F; Passerini, J; Tocci, G; Volpe, M, 2012) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality." | 2.47 | Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. ( Ram, CV, 2011) |
| "Hypertension is a major risk factor for cardiovascular, renal and stroke complications." | 2.47 | Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. ( Chrysant, SG, 2011) |
| "Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US." | 2.47 | Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. ( Bangalore, S; Messerli, FH, 2011) |
| " We sought to describe their comparative dose-response relationships for changes in systolic blood pressure (SBP) and potassium." | 2.46 | Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. ( Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010) |
| "Olmesartan medoxomil (OM), an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability." | 2.46 | Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement. ( Wilford Germino, F, 2010) |
| "Triple therapy is recommended in the treatment of hypertension in those patients not adequately controlled with two antihypertensive drugs." | 2.46 | Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination? ( Barrios, V; Escobar, C, 2010) |
| " Additionally, the increased efficacy resulting from the combination with hydrochlorothiazide does not appear to significantly affect the tolerability profile of olmesartan medoxomil." | 2.45 | Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. ( Punzi, HA, 2009) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 2.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Hypertension is a health threat which, so far, is not successfully managed, despite the availability of effective drug treatment." | 2.45 | Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. ( Bramlage, P, 2009) |
| "Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding of angiotensin II to the angiotensin II type 1 receptor." | 2.45 | Valsartan: more than a decade of experience. ( Bailey, J; Black, HR; Samuel, R; Zappe, D, 2009) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 2.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| " Likewise, few studies have directly compared more than two agents or ARB/hydrochlorothiazide fixed-dose combinations, and most ARBs have not been compared across their full recommended dosage ranges." | 2.44 | Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. ( Smith, DH, 2008) |
| "Aliskiren is an orally effective direct renin inhibitor that blocks the generation of angiotensin I from angiotensinogen, the rate limiting step of RAAS activation." | 2.44 | Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. ( Sureshkumar, KK, 2008) |
| "Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure." | 2.44 | Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. ( Ruilope, LM, 2008) |
| "Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker." | 2.44 | Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide? ( Fornoni, A; Lenz, O; Materson, BJ; Tejada, T, 2007) |
| "Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule." | 2.44 | Metoprolol succinate extended release/hydrochlorothiazide combination tablets. ( Hainer, JW; Sugg, J, 2007) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 2.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| "Aliskiren is a direct inhibitor of renin, the rate-limiting enzyme for the production of angiotensin II, a powerful vasoconstrictive peptide." | 2.44 | Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. ( Chrysant, SG, 2008) |
| "Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years." | 2.44 | Beta-blockers in the management of hypertension: focus on nebivolol. ( Papademetriou, V; Wojciechowski, D, 2008) |
| " The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval." | 2.43 | Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros ( Lacourcière, Y; Neutel, JM; Schumacher, H, 2005) |
| " In addition, combination therapy provided sustained and consistent BP control over the entire 24 hour dosing interval." | 2.43 | Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. ( Borghi, C; Cicero, AF, 2006) |
| " When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a beta-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor." | 2.43 | Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. ( Greathouse, M, 2006) |
| "Hypertension is a major risk factor for cardiovascular morbidity and mortality." | 2.42 | Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). ( Chrysant, SG, 2003) |
| "Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective." | 2.42 | Pharmacological and clinical profile of moexipril: a concise review. ( Chrysant, GS; Chrysant, SG, 2004) |
| "Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile." | 2.41 | Safety and tolerability of eprosartan in combination with hydrochlorothiazide. ( Böhm, M; Sachse, A, 2002) |
| "Candesartan cilexetil has also been shown to be effective and well tolerated in combination with hydrochlorothiazide in those hypertensive patients who require more than one agent to reach their target blood pressure." | 2.41 | Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade. ( Ruilope, L, 2000) |
| "Hyperlipidemia is a widely acknowledged side effect of thiazide diuretic therapy, but it is often dismissed as a short-term effect of high-dose therapy." | 2.40 | Hyperlipidemia of diuretic therapy. ( Ames, R, 1998) |
| "Valsartan/HCTZ was well tolerated in both short and long term trials." | 2.40 | Valsartan/hydrochlorothiazide. ( Langtry, HD; McClellan, KJ, 1999) |
| "Thiazide diuretics are commonly used to treat hypertension because of their demonstrated efficacy, favorable safety profile, low acquisition cost, and their proven ability to reduce blood pressure-related morbidity and mortality." | 2.39 | Evidence for the efficacy of low-dose diuretic monotherapy. ( Cushman, WC; Flack, JM, 1996) |
| "Insulin resistance is associated with a number of risk factors for atherosclerosis, including glucose intolerance, hypertension, and dyslipidemia." | 2.38 | Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. ( Bell, DS, 1993) |
| " On the fourth day of once-daily dosing with hydrochlorothiazide 25 mg, 24-hour natriuresis and chloriuresis are no longer augmented, but the elevation in 24-hour kaliuresis that follows the first dose remains unchanged." | 2.38 | Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations. ( Leary, WP; Reyes, AJ, 1993) |
| " The results of comparative trials of benazepril with propranolol and nifedipine suggest that benazepril, administered alone or with the diuretic hydrochlorothiazide, is as effective as the other antihypertensive agents alone or in combination with hydrochlorothiazide." | 2.38 | Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide. ( DeQuattro, V, 1991) |
| "Control of high blood pressure has failed to reduce the risk of atherosclerotic coronary heart disease (CHD)." | 2.38 | Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. ( Nelson, EB; Pool, JL; Taylor, AA, 1989) |
| "Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the active converting enzyme inhibitor enalaprilat." | 2.37 | An overview of the clinical pharmacology of enalapril. ( Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF, 1984) |
| "Hypertension is the leading single preventable risk factor for cardiovascular disease." | 1.91 | The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020. ( Bhargava, B; Durgad, K; Gupta, S; Kaur, P; Kunwar, A; Sharma, M, 2023) |
| "Hydrochlorothiazide (HCT) has been suggested to induce photosensitivity, thereby increasing the incidence of skin cancers." | 1.91 | Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study. ( Böhm, M; Götzinger, F; Hardtstock, F; Krieger, J; Kunz, M; Lauder, L; Mahfoud, F; Maywald, U; Schulz, M; Wilke, T, 2023) |
| "We evaluated melanoma and nonmelanoma skin cancer among hydrochlorothiazide users with 3 different cohorts as each allows assessment of different potential cofounders/effect modifiers, including race/ethnicity." | 1.91 | Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity. ( Abrahamowicz, M; Bernatsky, S; Birck, MG; Liu, JL; Machado, MAA; Moura, CS; Pilote, L, 2023) |
| " To conclude, beta-glucan alone and in combination with hydrochlorothiazide may be a promising a strategy for managing hypertension and related cardiac complications." | 1.91 | Oat Beta-Glucan Alone and in Combination with Hydrochlorothiazide Lowers High Blood Pressure in Male but Not Female Spontaneously Hypertensive Rats. ( Malunga, L; Netticadan, T; Raj, P; Sabra, A; Sayfee, K; Thandapilly, SJ; Wijekoon, C; Yu, L, 2023) |
| "Uncontrolled hypertension is an important cardiovascular risk factor and therefore requires effective approaches to patient management." | 1.72 | Management of American Heart Association/American College of Cardiology-Defined Stage 2 Hypertension by Cardiologists in India. ( Abdullakutty, J; Abhyankar, M; Dalal, J; Das, MK; Fulwani, M; Guha, S; Gupta, R; Kahali, D; Mohan, JC; Mohanan, PP; Nair, T; Narasimhan, C; Ram, CVS; Ray, S; Revankar, S; Roy, DG, 2022) |
| "Hypertension is a chronic disease associated with chronic inflammation involving activated macrophages." | 1.62 | Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response. ( Bryniarski, P; Marcinkiewicz, J; Nazimek, K, 2021) |
| " In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers." | 1.62 | Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats. ( Balavoine, F; De Mota, N; Hmazzou, R; Llorens-Cortes, C; Marc, Y, 2021) |
| " Repeat dose pharmacokinetic and pharmacodynamic study of the nano-fixed dose combination (FDC) was done in dexamethasone-induced animal model." | 1.56 | Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ( Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020) |
| "Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma." | 1.51 | Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. ( Friis, S; Gaist, D; Hölmich, LR; Johannesdottir Schmidt, SA; Pedersen, SA; Pottegård, A, 2019) |
| " This article also discusses the new guidelines for the prevention and treatment of orthostatic hypotension and the recently published papers on the risk of skin cancers associated with the long-term use of hydrochlorothiazide (> 5 years)." | 1.51 | [Arterial hypertension : novelties in 2018]. ( Burnier, M; Wuerzner, G, 2019) |
| " High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies." | 1.48 | Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. ( Anegawa, T; Fukuda, K; Fukumoto, Y; Imaizumi, T; Iwamoto, Y; Kai, H; Kajimoto, H; Uchiwa, H, 2018) |
| "Once hypertension is established, increased mechanical stretch stress becomes a leading cause of vascular remodeling." | 1.46 | Role of nifedipine and hydrochlorothiazide in MAPK activation and vascular smooth muscle cell proliferation and apoptosis. ( Bardeesi, ASA; Deng, L; Guo, Y; Li, C; Li, Y; Li, Z; Liu, K; Liu, S; Pei, T; Ping, S; Sheng, P; Wang, H; Wang, J; Zhou, Y, 2017) |
| "Hypertension was induced in uninephrectomized control rats (UNx) by subcutaneous implantation of a DOCA pellet plus administration of 1% NaCl in the drinking water (DOCA-salt) for 3 wk." | 1.43 | Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats. ( Cha, H; Cook, AK; Guan, Z; Inscho, EW; Pollock, DM; Pollock, JS; Singletary, ST; Van Beusecum, JP, 2016) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| " Night-time dosing of thiazides may be particularly beneficial in patients with modest glucocorticoid excess." | 1.43 | Glucocorticoids Induce Nondipping Blood Pressure by Activating the Thiazide-Sensitive Cotransporter. ( Al-Dujaili, EA; Bailey, MA; Dear, JW; Dhaun, N; Flatman, PW; Howarth, AR; Hunter, RW; Ivy, JR; Oosthuyzen, W; Peltz, TS; Webb, DJ, 2016) |
| "Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema." | 1.42 | Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. ( Hirai, K; Hoshino, T; Ito, K; Kaku, Y; Miyazawa, H; Mori, H; Ookawara, S; Tabei, K; Ueda, Y; Yoshida, I, 2015) |
| " The synergistic antihypertensive pharmacodynamic interaction between telmisartan and hydrochlorothiazide was observed, which was simulated by the inhibitory function of telmisartan and stimulatory function of hydrochlorothiazide after co-administration of the two drugs." | 1.42 | The pharmacokinetic-pharmacodynamic model of telmisartan and hydrochlorothiazide on blood pressure and plasma potassium after long-term administration in spontaneously hypertensive rats. ( Chen, Y; Hao, K; Yu, D, 2015) |
| "Hypertension is a major modifiable risk for the development of cardiovascular, cerebrovascular and renal diseases." | 1.40 | ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. ( de la Sierra, A; Kreutz, R; Laurent, S; Manolis, AJ; Volpe, M, 2014) |
| " The current pharmacokinetic-pharmacodynamic model was based on the non-competitive pharmacodynamic interaction of two drugs acting on different physiological processes." | 1.40 | Pharmacokinetic-pharmacodynamic model of the antihypertensive interaction between telmisartan and hydrochlorothiazide in spontaneously hypertensive rats. ( Chen, Y; Hao, K; Liu, X; Zhao, X, 2014) |
| " The research comprised various studies which includes solubility studies in various vehicles, pseudoternary phase diagram construction, and preparation and characterization of SNEDDS along with in vitro dissolution and in vivo pharmacodynamic profiling." | 1.40 | Development, characterization, and pharmacodynamic evaluation of hydrochlorothiazide loaded self-nanoemulsifying drug delivery systems. ( Amin, S; Verma, A; Yadav, E; Yadav, PS, 2014) |
| "Chlorthalidone, 12." | 1.39 | Obesity and hypertension: It's about more than the numbers. ( Ferdinand, KC, 2013) |
| "Hypertension is a condition which in many cases is treated with more than one drug." | 1.39 | Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study. ( Freytag, S; Hagendorff, A; Klebs, S; Müller, A, 2013) |
| "Aliskiren is a novel direct renin inhibitor that reduces both angiotensin I and II blood levels." | 1.39 | Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS). ( Benitez, FN; Cedenio, H; Giorgi, M; Jaramillo, N; Molina, N; Volman, S; Zilberman, J, 2013) |
| " Adverse drug reactions were rare (n = 19), and no serious adverse drug reactions occurred." | 1.39 | Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. ( Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Wolf, WP; Zemmrich, C, 2013) |
| "Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability." | 1.39 | Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. ( de la Sierra, A; Volpe, M, 2013) |
| "Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase." | 1.38 | An economic evaluation of antihypertensive therapies based on clinical trials. ( Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL, 2012) |
| "Hypertension was evident by the second day of treatment, being preceded by reduced renal sodium excretion due to activation of the thiazide-sensitive sodium-chloride co-transporter." | 1.38 | Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. ( Ashek, A; Bailey, MA; Bellamy, CO; Flatman, PW; Harmar, AJ; Kenyon, CJ; Menzies, RI; Mullins, JJ; Mullins, LJ, 2012) |
| "Hypertension is also related to poor performance in tests that assess cognitive functions." | 1.37 | The influence of cognition, anxiety and psychiatric disorders over treatment adherence in uncontrolled hypertensive patients. ( De Castro, MS; Ferreira, MB; Fuchs, FD; Jacobs, Ú, 2011) |
| " Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)." | 1.37 | Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). ( Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011) |
| "Olmesartan treatment led to a decrease of cystatin C level." | 1.37 | Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension. ( Ahbap, E; Basturk, T; Borlu, F; Damar, AB; Koc, Y; Mazi, E; Sakaci, T; Unsal, A, 2011) |
| "Obesity is a risk factor for stroke, but the determinants of increased stroke risk in obesity are unknown." | 1.36 | Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. ( Mintz, JD; Osmond, JM; Stepp, DW, 2010) |
| "High blood pressure is a major risk factor for cardiovascular disease worldwide." | 1.35 | Aliskiren for hypertension in adults. ( , 2008) |
| "Hypertension is associated with cerebrovascular remodeling and endothelial dysfunction, which may reduce cerebral vasomotor reactivity to CO2." | 1.35 | Cerebral vasomotor reactivity before and after blood pressure reduction in hypertensive patients. ( Claassen, JA; Levine, BD; Zhang, R, 2009) |
| " Main outcome parameters were the systolic (SBP) and diastolic (DBP) blood pressure reduction, the rate of normalized patients at study end compared to baseline, and the number and type of adverse events (AEs)." | 1.35 | Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care. ( Bestehorn, K; Bönner, G; Jung, C; Smolka, W, 2009) |
| "Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature." | 1.35 | Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension. ( Baldwin, CM; Plosker, GL, 2009) |
| "Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity." | 1.35 | Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. ( Deeks, ED, 2009) |
| "A 2 s pause with presyncope and a hypotension (blood pressure values were 80/70 mm Hg) were observed after 2 min in the provocation phase." | 1.35 | Pharmacological washout for the correct evaluation of the head-up tilt testing. ( Coglitore, S; Di Bella, G; Patanè, S; Pugliatti, P; Recupero, A, 2008) |
| "Nondiabetic patients with treated or untreated hypertension were evaluated if they did not take diuretics and their office systolic BP (SBP) >140 mm Hg or diastolic BP (DBP) >90 mm Hg." | 1.35 | Clinical predictors of the response to short-term thiazide treatment in nondiabetic essential hypertensives. ( Chen, JW; Huang, CC; Leu, HB; Lin, SJ; Wu, TC, 2008) |
| "The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality." | 1.34 | Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. ( Bramlage, P; Kintscher, U; Paar, WD; Thoenes, M; Unger, T, 2007) |
| "Hypertension is an important risk factor associated with development and progression of diabetic retinopathy (DR)." | 1.34 | Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. ( Biswas, SK; de Faria, JB; de Faria, JM; Pinto, CC; Silva, KC; Souza, DS, 2007) |
| "The present study investigates the effects of chronic administration of ACEIs (angiotensin-converting-enzyme inhibitors; either zofenopril or enalapril) in combination with a diruetic (hydrochlorothiazide) on BP (blood pressure) increase and renal injury induced by L-NAME (NG-nitro-L-arginine methyl ester), an inhibitor of NO (nitric oxide) synthesis." | 1.33 | Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. ( Alcaraz, A; Atucha, NM; Evangelista, S; García-Estañ, J; Navarro, EG; O'Valle, F; Ortiz, MC; Vargas, F, 2006) |
| " The low adverse event rates confirm the good tolerability profile and suitability for chronic use of antihypertensive regimens containing valsartan." | 1.33 | Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: the MACHT Observational Study. ( Abts, M; Claus, V; Lataster, M, 2006) |
| "Atenolol presented lower LF and higher HF of PI." | 1.33 | Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. ( Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC, 2006) |
| "Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents." | 1.33 | Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. ( Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "We report a case of pulmonary edema induced by a common diuretic, hydrochlorothiazide." | 1.32 | [Acute non-cardiogenic pulmonary edema secondary to hydrochlorothiazide therapy]. ( de Miguel Díez, J; García Satue, JL; Jara Chinarro, B; Juretschke Moragues, MA; Serrano Iglesias, JA, 2003) |
| "Fifteen patients with untreated arterial hypertension were enrolled." | 1.32 | Effect of cilazapril with or without low dose thiazide on LDL peroxidation in [correction of peroxidationin] hypertensive patients. ( Hussein, O; Radan, A; Reuven, V, 2003) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| " We compared the efficacy of an endothelin-receptor antagonist (darusentan), an angiotensin-receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide, HCTZ) to prevent and regress pulse pressure (PP) elevation and remodeling of large and small arteries, in a rat model of ISH obtained by the chronic administration of warfarin and vitamin K1 (WK)." | 1.31 | Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. ( Dao, HH; De Champlain, J; Essalihi, R; Graillon, JF; Larivière, R; Moreau, P, 2002) |
| "Aldosterone excretion was also lower in blacks and without its normal circadian pattern which may, in part, explain their altered potassium excretion pattern." | 1.31 | Racial differences in response to acute dosing with hydrochlorothiazide. ( King, K; Ripley, E; Sica, DA, 2000) |
| "5 mg/kg/day) combined with indapamide (0." | 1.31 | Protective effects of delapril combined with indapamide or hydrochlorothiazide in spontaneously hypertensive stroke-prone rats: a comparative dose-response analysis. ( Agnati, LF; Biagini, G; Boschi, S; Torri, C; Vantaggiato, G; Zini, I; Zoli, M, 2000) |
| "Hydrochlorothiazide treatment did not prevent the hyperuricemia or arteriolopathy despite controlling blood pressure." | 1.31 | Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. ( Chen, Q; Feng, L; Gordon, KL; Han, L; Johnson, RJ; Kanellis, J; Kang, DH; Lan, HY; Mazzali, M; Nakagawa, T; Watanabe, S; Xia, YY, 2002) |
| " Dose-response curves were repeated after local tetraethylammonium (TEA) administration to determine the role of potassium channel activation and, in patients with the Gitelman syndrome, to determine the role of the thiazide-sensitive Na-Cl cotransporter in the vasodilator effect of hydrochlorothiazide." | 1.30 | Thiazide-induced vasodilation in humans is mediated by potassium channel activation. ( Hughes, AD; Pickkers, P; Russel, FG; Smits, P; Thien, T, 1998) |
| "Vascular and cardiac hypertrophy were significantly attenuated with losartan or perindopril, but were unchanged with other treatments." | 1.30 | Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. ( Anderson, NH; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; Morton, JJ; Reid, JL; Schork, NJ, 1999) |
| "Perindopril treatment also effectively prevented the development of vascular hypertrophy; however, treatment with hydralazine and hydrochlorothiazide was not as effective despite equivalent blood pressure reduction." | 1.30 | Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. ( Brosnan, MJ; Clark, JS; Devlin, AM; Dominiczak, AF; Mullins, JJ, 1999) |
| "Treatment with ramipril reduced blood pressure and force development in response to Bay K8644 in adult SHRSP, although not to levels of WKY rats, whereas WKY rats were unaffected by treatment." | 1.29 | Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats. ( Traub, O; Webb, RC, 1993) |
| "The patient discussed developed severe acute renal failure after strenuous exercise and therapeutic doses of ibuprofen and hydrochlorothiazide-triamterene." | 1.29 | Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene. ( Sanders, LR, 1995) |
| "Renal cell carcinoma has been linked to hypertension and antihypertensive medications." | 1.29 | Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). ( Hiatt, RA; Quesenberry, CP; Tolan, K, 1994) |
| "Type II pseudohypoaldosteronism is a rare tubulopathy defined by abnormal renal potassium excretion." | 1.29 | [Dwarfism, arterial hypertension and hyperkalemic acidosis corrected with thiazides. A case of type II pseudohypoaldosteronism]. ( Brusquet, Y; Cornus, P; Cournelle, MA; Frayssinet, R; Poujol, A; Rimet, Y; Zarrouk, F, 1993) |
| "Enalapril treatment significantly reduced proteinuria (731 +/- 23 vs." | 1.29 | Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| "To discover whether in hypertensives with left ventricular hypertrophy (LVH) the increased muscle mass will completely regress under antihypertensive treatment and drug dosage can in consequence be reduced." | 1.29 | [Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy]. ( Behr, U; Franz, IW; Ketelhut, R; Tönnesmann, U, 1996) |
| "Atenolol was initiated in 7." | 1.29 | Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system. ( Aron, DC; Aucott, JN; Dombrowski, R; Fuehrer, SM; Laich, J; Pelecanos, E, 1996) |
| " Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia." | 1.29 | [The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension]. ( Chil'tsov, VV; Ignat'ev, VG; Kukes, VG; Pavlov, SS; Pavlova, LI; Privalov, AN; Rumiantsev, AS, 1996) |
| " An exploratory procedure based on RSM modeling is used to build a segmented linear model and a stairstep linear model to describe dose-response relationships." | 1.28 | The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology. ( Cairns, V; Koch, GG; Phillips, JA, 1992) |
| " Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)." | 1.28 | Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992) |
| "Spontaneous motor activity was measured in six baboons during chronic oral dosing with a diuretic (hydrochlorothiazide/triamterene), a calcium channel blocker (verapamil), and a combination of the two drugs." | 1.28 | Chronic hydrochlorothiazide and verapamil effects on motor activity in hypertensive baboons. ( Allen, RP; Hienz, RD; Turkkan, JS, 1992) |
| " The usual daily dosage was one tablet which was increased to two after eight weeks in case the DBP was not normalized, i." | 1.28 | The efficacy and tolerability of enalapril--hydrochlorothiazide combination as a first line therapy in black patients with mild to moderate arterial hypertension: a clinical study in Kenya. ( Lore, W; Muita, AK; Ogola, ES, 1992) |
| " In clinical trials, adverse experiences in patients treated with a lisinopril-hydrochlorothiazide combination were dizziness (7." | 1.28 | Review of international safety data for lisinopril-hydrochlorothiazide combination treatment. ( Murray, NH, 1991) |
| " For this reason we studied the influence of different dosing times on the antihypertensive effect over 24 h using ambulatory blood pressure monitoring (ABPM)." | 1.28 | Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing. ( Holzgreve, H; Klüglich, M; Middeke, M, 1991) |
| " It was found that in a part of patients the long-term administration of antihypertensive drugs led to an increased accumulation of kynurenine as a manifestation of pyridoxal-5-phosphate deficiency." | 1.28 | Increased blood kynurenine level as a factor inhibiting the therapeutic effect of antihypertensive agents in combined long-term treatment of essential hypertension. ( Liepinja, DJ; Rudzite, VK; Silava, AK; Vitols, AV, 1990) |
| "Hydrochlorothiazide was discontinued if the diastolic blood pressure remained less than or equal to 94 mm Hg after a 6-month period on the lower dose of hydrochlorothiazide." | 1.28 | Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension. ( Kochar, MS; Landry, KM; Ristow, SM, 1990) |
| "Hyperkalemia is known to occur with increased frequency in the patient with diabetes mellitus and in the elderly when agents that interfere with renal potassium excretion are employed, but the precise frequency has not been established." | 1.28 | Hyperkalemia in diabetes mellitus. Effect of a triamterene-hydrochlorothiazide combination. ( Hollenberg, NK; Mickiewicz, C, 1989) |
| " Compound 9d, which lowered arterial blood pressure 37 mmHg in SHR when dosed at 100 mg/kg, was further evaluated in chronic hypertensive dogs because of apparent minimal CNS effects." | 1.27 | N2-(4-Substituted-2,6-dichlorophenyl)-N1,N1-dimethylformamidines as antihypertensive and diuretic agents. ( Chan, PS; Emma, JE; Meyer, WE; Tomcufcik, AS, 1984) |
| "Oral treatment with enalapril (15-100 mg X kg-1 X day-1) and HTZ (60-400 mg X kg-1 X day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P less than 0." | 1.27 | Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats. ( Fernandez, PG; Kim, BK; Sharma, JN; Triggle, CR, 1984) |
| "In spontaneously hypertensive rats (SHR), after 1 day of dosing with an angiotensin-converting enzyme (ACE) inhibitor (captopril or enalapril) plus a diuretic (hydrochlorothiazide), a synergistic antihypertensive effect was observed when a second dose of the combination or ACE inhibitor alone but not the diuretic alone was given the next day." | 1.27 | Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics. ( Cervoni, P; Chan, PS; Ronsberg, MA, 1984) |
| " Very slight accumulation of sotalol and hydrochlorothiazide was observed, so it appears unnecessary to reduce the dosage in patients with a creatinine clearance of 30 ml/min or more." | 1.27 | Pharmacokinetics of a fixed combination of sotalol and hydrochlorothiazide in hypertensive patients with moderate renal insufficiency. ( Fillastre, JP; Fourtillan, JB; Ingrand, I; Kher, A; Lefebvre, MA, 1984) |
| "A 54-year-old woman had seizures and a focal neurologic deficit associated with hyponatremia induced by a thiazide diuretic." | 1.27 | Thiazide-induced hyponatremia. ( Johnson, JE; Wright, LF, 1983) |
| " In these patients, the doubling of diuretic dose (hydrochlorothiazide 50 mg + amiloride 5 mg) in combination with atenolol resulted in a further drop in systolic pressure (to 142." | 1.27 | Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients. ( Bentivoglio, M; Corea, L; Verdecchia, P, 1983) |
| "Care must be taken in treating hypertension in diabetic patients because the choice of antihypertensive agent may worsen the diabetic state or its complications or cause additional health problems for the patient." | 1.27 | Treatment of hypertension in diabetic men: problems with sexual dysfunction. ( Lipson, LG, 1984) |
| "Hemolysis was due to an immune process associated with antibody to thiazide." | 1.27 | Fatal intravascular immune hemolysis induced by hydrochlorothiazide. ( Beck, ML; Cline, JF; Davis, JW; Hardman, JT; Racela, LS, 1984) |
| "Hydrochlorothiazide did not produce a statistically significant increase in urinary amylase excretion but did reduce the ratio of salivary amylase/creatinine clearance in a two-hour urine collection." | 1.27 | The influence of hydrochlorothiazide and tripamide on serum and urinary amylase. ( Conrad, KA; Fagan, TC; Simons, JA, 1988) |
| "Renal hypertrophy was also decreased significantly by cicletanine at a dose of 100 mg/kg." | 1.27 | Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. ( Braquet, P; Clostre, F; Le Hegarat, M; Malherbe, E, 1988) |
| "Spironolactone was prescribed at a mean dose of 98 mg, hydrochlorothiazide at 36 mg and cyclothiazide at 2 mg, during a mean follow-up of 20 months." | 1.27 | Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. ( Charru, A; Chatellier, G; Corvol, P; Degoulet, P; Jeunemaitre, X; Julien, J; Ménard, J; Plouin, PF, 1988) |
| "Captopril was well tolerated in all patients and no adverse reactions were observed." | 1.27 | Glucose metabolism during captopril mono- and combination therapy in diabetic hypertensive patients: a multiclinic trial. ( Iino, S; Inoue, S; Shionoiri, H, 1987) |
| " No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects." | 1.27 | A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. ( Adam, HK; Castleden, CM; Fitzsimons, TJ; Ryan, J; Sabanathan, K, 1987) |
| "Pulmonary edema was evident clinically and radiographically." | 1.27 | Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion. ( Klein, MD, 1987) |
| " Triamterin pharmacokinetic studies may be used for the screening of hypertensive patients as potential candidates for triampur treatment." | 1.27 | [Relation between the hypotensive effect of triampur and its pharmacokinetics in patients with hypertension]. ( Kuznetsov, GP; Lebedev, PA, 1986) |
| "A total of 127 patients with bronchial asthma of infectious-allergic genesis and chronic obstructive bronchitis were examined for the central and regional hemodynamics as well as for the blood levels of serotonin and monoamine oxidase." | 1.27 | [Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]. ( Bobrov, VA; Fushteĭ, IM; Ianushevskaia, TA; Polipova, SN, 1985) |
| "Sixteen patients were being treated for hypertension and three for fluid retention; five hypertensive patients were also taking non-steroidal anti-inflammatory drugs (NSAID)." | 1.27 | Renal failure with potassium-sparing diuretics. ( Bailey, RR; Low, WI; Lynn, KL; Sainsbury, R; Swainson, CP, 1985) |
| "Now that the benefits of treating diastolic hypertension in the elderly have been convincingly proved, attention is turning to the need for, and the choice of, treatment of isolated systolic hypertension in this age group." | 1.27 | Management of isolated systolic hypertension in the elderly. ( Gifford, RW, 1986) |
| "Hydrochlorothiazide and binazine treatment decreased systolic and diastolic blood pressure, the total electromechanical systolic time index (QS2I) and the left ventricular ejection time index (LVETI), and increased the PEP/LVET index at rest and after exercise." | 1.27 | Post-exertion changes in left ventricular systolic time intervals in patients with primary hypertension treated with hydrochlorothiazide, binazine, and propranolol. ( Cholewa, M; Górski, L; Markiewicz, K, 1985) |
| "Captopril was helpful in the management of refractory hypertension in most cases." | 1.26 | Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension. ( Julius, S; Nicholls, MG; Zweifler, AJ, 1981) |
| " The dosage of guanabenz was adjusted upward from 16 mg/day until blood pressure normalized or side effects intervened." | 1.26 | Preliminary clinical trial with a new hypotensive, guanabenz, in a group of hypertensive patients. ( De Ridder, JH; Marchandise, P, 1980) |
| "Criteria for the choice of drug dosage are established." | 1.26 | [Determination of the criteria for selecting the optimal obsidan and hypothiazide treatment regimen in hypertension based on mathematical modelling data]. ( Churnosov, EV; Katiukhin, VN; Temirov, AA, 1981) |
| "Danazol is a semisynthetic androgen that is used in the treatment of endometriosis and hereditary angioedema." | 1.26 | Hypertension: a complication of danazol therapy. ( Bretza, JA; Novey, HS; Vaziri, ND; Warner, AS, 1980) |
| " The measure was used to survey compliance with 20 common drugs prescribed to 419 outpatients for long-term administration on regular schedules." | 1.26 | Variations in patient compliance with common long-term drugs. ( Carter, WB; Dohan, JJ; Inui, TS; Pearlman, RA; Pecoraro, RE, 1980) |
| "The art of treatment of hypertension therefore appears to be in a healthy state and we should expect more advances in the future." | 1.26 | Treatment of hypertension: state of the art in 1979. ( Freis, ED, 1979) |
| " The mean resting blood pressures were 168/108 mmHg, 151/98 mmHg and 150/96 mmHg at pre-trial, after the twice-daily dosage period and after the once-daily dosage period, respectively." | 1.26 | A fixed combination of metoprolol and hydrochlorothiazide for hypertension: a multi-centre study. ( Goodfellow, RM, 1979) |
| "Hypertension was defined as supine diastolic blood pressure repeatedly above 90 mm Hg." | 1.26 | Essential hypertension in childhood. ( Aschinberg, LC; Chan, LL; John, EG; Miller, RA; Zeis, PM, 1977) |
| "The biguanides were a therapeutic enrichment particularly in the treatment of adipose elderly diabetics with obligatory diet." | 1.26 | [Indications and results of an additional differentiated pharmacotherapy of obesity]. ( Kucher, E, 1978) |
| " During another two-week period, a 50 mg/day dosage of hydrochlorothiazide did cause a significant rise in serum lithium levels." | 1.26 | Serum lithium levels and long-term diuretic use. ( Jefferson, JW; Kalin, NH, 1979) |
| "The treatment of both hyperlipidemia and hypertension appeared to be more effective than the treatment of hyperlipidemia, alone." | 1.26 | Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta. ( Hollander, W; Kirkpatrick, B; Madoff, I; Paddock, J, 1976) |
| "DOC hypertension was associated with increased 42K turnover (rate constant for DOC = 0." | 1.26 | The effect of norepinephrine on aortic 42K turnover during deoxycorticosterone acetate hypertension and antihypertensive therapy in the rat. ( Jones, AW; Kampschmidt, DL; Sander, PD, 1977) |
| "A study was carried out of plasma electrolyte estimations made before and after long-term use of a combination of amiloride and hydrochlorothiazide in 23 patients." | 1.26 | Long-term effects of an amiloride/hydrochlorothiazide combination ('Moduretic') on electrolyte balance. ( Burge, PS; Montuschi, E, 1976) |
| "14C-hydrochlorothiazide (hct) was administered orally (n=4) and iv (n = 2 to healthy subjects." | 1.26 | Absorption, metabolism, and excretion of hydrochlorothiazide. ( Beermann, B; Groschinsky-Grind, M; Rosén, A, 1976) |
| " From the third week of treatment onwards, the Esidrix dosage was maintained; the dosage of Trasicor 80 was either maintained, increased, or later decreased, according to the results obtained." | 1.25 | [Ambulatory treatment of arterial hypertension urinary the new combination "saluretic and beta-sympatholytic"]. ( Dannhorn, R; Müller, AA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1494 (44.56) | 18.7374 |
| 1990's | 574 (17.12) | 18.2507 |
| 2000's | 584 (17.42) | 29.6817 |
| 2010's | 618 (18.43) | 24.3611 |
| 2020's | 83 (2.48) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, WE | 1 |
| Tomcufcik, AS | 1 |
| Chan, PS | 4 |
| Emma, JE | 1 |
| Stokker, GE | 1 |
| Smith, RL | 1 |
| Cragoe, EJ | 1 |
| Ludden, CT | 2 |
| Russo, HF | 1 |
| Sweet, CS | 7 |
| Watson, LS | 1 |
| Dong, S | 1 |
| VanGelder, K | 1 |
| Shi, ZC | 1 |
| Yu, Y | 1 |
| Wu, Z | 2 |
| Ferguson, R | 1 |
| Guo, ZZ | 1 |
| Tang, H | 2 |
| Frie, J | 1 |
| Fu, Q | 4 |
| Gu, X | 1 |
| Priest, BT | 1 |
| Thomas-Fowlkes, B | 1 |
| Weinglass, A | 1 |
| Margulis, M | 1 |
| Liu, J | 1 |
| Pai, LY | 1 |
| Hampton, C | 1 |
| Haimbach, RE | 1 |
| Owens, K | 1 |
| Tong, V | 1 |
| Xu, S | 2 |
| Hu, M | 1 |
| Zingaro, GJ | 1 |
| Morissette, P | 1 |
| Ehrhart, J | 1 |
| Roy, S | 2 |
| Sullivan, K | 1 |
| Pasternak, A | 1 |
| Cechinel-Zanchett, CC | 1 |
| Bolda Mariano, LN | 1 |
| Boeing, T | 4 |
| da Costa, JC | 1 |
| Da Silva, LM | 3 |
| Bastos, JK | 1 |
| Cechinel-Filho, V | 4 |
| de Souza, P | 4 |
| Stevens, JD | 1 |
| Mullane, JF | 1 |
| Qin, L | 1 |
| Zhang, N | 1 |
| Ishigami, J | 1 |
| Miller, ER | 1 |
| Pfister, M | 1 |
| Moran, AE | 3 |
| Cox, E | 1 |
| Mondaca-Ruff, D | 1 |
| Araos, P | 1 |
| Yañez, CE | 1 |
| Novoa, UF | 1 |
| Mora, IG | 1 |
| Ocaranza, MP | 1 |
| Jalil, JE | 1 |
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Huang, CC | 4 |
| Huang, YL | 1 |
| Lin, CH | 1 |
| Chen, JW | 4 |
| Bryniarski, P | 1 |
| Nazimek, K | 1 |
| Marcinkiewicz, J | 1 |
| Ram, CVS | 1 |
| Dalal, J | 1 |
| Kahali, D | 1 |
| Mohanan, PP | 1 |
| Das, MK | 1 |
| Guha, S | 1 |
| Nair, T | 1 |
| Narasimhan, C | 1 |
| Roy, DG | 1 |
| Abdullakutty, J | 1 |
| Ray, S | 1 |
| Fulwani, M | 1 |
| Mohan, JC | 1 |
| Gupta, R | 1 |
| Abhyankar, M | 1 |
| Revankar, S | 1 |
| Preston, RA | 2 |
| Afshartous, D | 1 |
| Caizapanta, EV | 1 |
| Materson, BJ | 17 |
| Rodco, R | 1 |
| Alonso, E | 1 |
| Alonso, AB | 1 |
| Ojji, DB | 4 |
| Shedul, GL | 3 |
| Sani, M | 1 |
| Ogah, OS | 1 |
| Dzudie, A | 4 |
| Barasa, F | 4 |
| Mondo, C | 4 |
| Ingabire, PM | 2 |
| Jones, ESW | 1 |
| Rayner, B | 3 |
| Albertino, D | 1 |
| Ogola, E | 3 |
| Smythe, W | 4 |
| Hickman, N | 2 |
| Francis, V | 4 |
| Shahiemah, P | 1 |
| Shedul, G | 5 |
| Aje, A | 2 |
| Sliwa, K | 6 |
| Stewart, S | 1 |
| Mahfoud, F | 4 |
| Kieble, M | 2 |
| Enners, S | 2 |
| Kintscher, U | 4 |
| Laufs, U | 3 |
| Böhm, M | 9 |
| Schulz, M | 3 |
| Bao, M | 1 |
| Song, Y | 1 |
| Wu, S | 2 |
| Li, J | 5 |
| Ishani, A | 4 |
| Leatherman, SM | 4 |
| Woods, P | 3 |
| Hau, C | 3 |
| Klint, A | 3 |
| Lew, RA | 3 |
| Taylor, AA | 6 |
| Glassman, PA | 3 |
| Brophy, MT | 4 |
| Fiore, LD | 3 |
| Ferguson, RE | 4 |
| Cushman, WC | 27 |
| Ernst, ME | 12 |
| Fravel, MA | 2 |
| Lin, Z | 1 |
| Li, HL | 1 |
| Tsoi, MF | 1 |
| Cheung, BMY | 1 |
| Llamas-Molina, JM | 1 |
| Navarro-Triviño, FJ | 1 |
| Ruiz-Villaverde, R | 1 |
| El-Hanboushy, S | 1 |
| Marzouk, HM | 1 |
| Fayez, YM | 1 |
| Abdelkawy, M | 1 |
| Lotfy, HM | 1 |
| Kaur, P | 1 |
| Kunwar, A | 1 |
| Sharma, M | 1 |
| Durgad, K | 1 |
| Gupta, S | 1 |
| Bhargava, B | 1 |
| Ding, P | 1 |
| Pan, Y | 1 |
| Wang, Q | 1 |
| Xu, R | 1 |
| Cornelius, V | 2 |
| Partington, G | 1 |
| Pandie, S | 1 |
| Damasceno, A | 4 |
| Jones, E | 3 |
| Ogah, O | 3 |
| Sani, MU | 3 |
| Poulter, N | 3 |
| Bashir, K | 1 |
| Burns, T | 1 |
| Pirruccello, SJ | 1 |
| Aurit, SJ | 1 |
| Hilleman, DE | 1 |
| Abdelwahab, R | 1 |
| Tangalos, EG | 1 |
| Matulis, J | 1 |
| Agarwal, R | 2 |
| Chekka, LMS | 1 |
| Cooper-DeHoff, RM | 29 |
| Gums, JG | 20 |
| Chapman, AB | 27 |
| Johnson, JA | 24 |
| Carey, RM | 2 |
| Whelton, PK | 6 |
| Schumacher, B | 1 |
| Ye, XF | 3 |
| Huang, QF | 5 |
| Li, Y | 14 |
| Wang, JG | 12 |
| Huang, GD | 2 |
| Yan, P | 1 |
| Luo, Y | 1 |
| Zhang, J | 15 |
| Liu, H | 1 |
| Chen, J | 5 |
| Wang, J | 6 |
| Dong, G | 1 |
| Ge, M | 1 |
| Burnier, M | 9 |
| Redon, J | 7 |
| Volpe, M | 9 |
| Bard, JT | 1 |
| Kornmehl, HA | 1 |
| Smith, RJ | 1 |
| Liuzzo, G | 1 |
| Fishel Bartal, M | 1 |
| Blackwell, SC | 1 |
| Pedroza, C | 2 |
| Lawal, D | 1 |
| Amro, F | 1 |
| Samuel, J | 1 |
| Chauhan, SP | 1 |
| Sibai, BM | 1 |
| Götzinger, F | 2 |
| Wilke, T | 1 |
| Hardtstock, F | 1 |
| Krieger, J | 1 |
| Maywald, U | 1 |
| Kunz, M | 1 |
| Lauder, L | 2 |
| Hohl, M | 1 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 1 |
| Bavishi, C | 1 |
| Krämer, BK | 1 |
| Hausberg, M | 1 |
| Kreutz, R | 5 |
| Wenzel, U | 1 |
| Messerli, FH | 15 |
| Sundström, J | 2 |
| Lind, L | 5 |
| Nowrouzi, S | 2 |
| Hagström, E | 1 |
| Held, C | 3 |
| Lytsy, P | 2 |
| Neal, B | 3 |
| Marttala, K | 2 |
| Östlund, O | 2 |
| Heisel, AGU | 1 |
| Vuurboom, MD | 1 |
| Daams, JG | 1 |
| de Rie, MA | 1 |
| Vogt, L | 3 |
| van den Born, BH | 2 |
| Olde Engberink, RHG | 2 |
| Azoulay, L | 1 |
| St-Jean, A | 1 |
| Dahl, M | 2 |
| Quail, J | 1 |
| Aibibula, W | 1 |
| Brophy, JM | 1 |
| Chan, AW | 1 |
| Bresee, L | 1 |
| Carney, G | 1 |
| Eltonsy, S | 1 |
| Tamim, H | 1 |
| Paterson, JM | 1 |
| Platt, RW | 1 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Birck, MG | 1 |
| Moura, CS | 2 |
| Machado, MAA | 1 |
| Liu, JL | 1 |
| Abrahamowicz, M | 2 |
| Pilote, L | 2 |
| Bernatsky, S | 2 |
| Raj, P | 1 |
| Sayfee, K | 1 |
| Yu, L | 2 |
| Sabra, A | 1 |
| Wijekoon, C | 1 |
| Malunga, L | 1 |
| Thandapilly, SJ | 1 |
| Netticadan, T | 2 |
| Danieli, C | 1 |
| Ferreira, MJ | 1 |
| Santos Ferreira Silva, MPD | 1 |
| da Silva Dias, D | 1 |
| Bernardes, N | 1 |
| Irigoyen, MC | 1 |
| De Angelis, K | 1 |
| Oh, J | 1 |
| Kim, W | 2 |
| Kim, GH | 1 |
| Kim, HL | 1 |
| Park, SD | 1 |
| Min, KW | 1 |
| Hyun, D | 1 |
| Hong, JH | 1 |
| Lim, S | 1 |
| Shin, J | 3 |
| Ebell, MH | 1 |
| Steurer, J | 1 |
| Cunha, MR | 1 |
| Cunha, AR | 1 |
| Marques, BCAA | 1 |
| Mattos, SS | 1 |
| D'El-Rei, J | 1 |
| França, NM | 1 |
| Oigman, W | 7 |
| Neves, MF | 1 |
| Wei, J | 2 |
| Ma, W | 1 |
| Yao, G | 1 |
| Jia, Q | 1 |
| Cheng, X | 1 |
| Ouyang, H | 1 |
| Chang, Y | 1 |
| Chen, X | 3 |
| He, J | 1 |
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 1 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 1 |
| Dineva, S | 3 |
| Uzunova, K | 3 |
| Pavlova, V | 3 |
| Filipova, E | 3 |
| Kalinov, K | 3 |
| Vekov, T | 3 |
| Onakpoya, I | 1 |
| Massunaga, ND | 1 |
| França, CN | 1 |
| Bianco, HT | 2 |
| Ferreira, CES | 1 |
| Kato, JT | 1 |
| Póvoa, RMS | 1 |
| Figueiredo Neto, AM | 1 |
| Izar, MCO | 1 |
| Fonseca, FAH | 1 |
| Martins, VM | 2 |
| Helal, L | 1 |
| Ferrari, F | 1 |
| Bottino, LG | 1 |
| Fuchs, SC | 2 |
| Fuchs, FD | 3 |
| Laham, HZ | 1 |
| Khabour, OF | 1 |
| Alzoubi, KH | 1 |
| Sadiq, MF | 1 |
| Bovée, DM | 1 |
| Visser, WJ | 1 |
| Middel, I | 1 |
| De Mik-van Egmond, A | 1 |
| Greupink, R | 1 |
| Masereeuw, R | 1 |
| Russel, FGM | 1 |
| Danser, AHJ | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 2 |
| O'Neill, B | 1 |
| Moe, S | 1 |
| Korownyk, C | 1 |
| Hripcsak, G | 2 |
| Suchard, MA | 1 |
| Shea, S | 2 |
| Chen, R | 1 |
| You, SC | 1 |
| Pratt, N | 1 |
| Madigan, D | 1 |
| Krumholz, HM | 1 |
| Ryan, PB | 1 |
| Schuemie, MJ | 2 |
| Taherifard, E | 1 |
| Vilke, GM | 1 |
| Akeely, Y | 1 |
| Lin, LC | 1 |
| Pottegård, A | 2 |
| Morales, D | 1 |
| Bossoni, S | 1 |
| Chiesa, L | 1 |
| Giustina, A | 1 |
| Garrido, PM | 1 |
| Borges-Costa, J | 1 |
| Pandey, AK | 1 |
| Shafiq, N | 2 |
| Bhandari, RK | 1 |
| Rather, IIG | 1 |
| Kaur, N | 1 |
| Bhatia, A | 1 |
| Sharma, S | 2 |
| Malhotra, S | 2 |
| Roush, GC | 8 |
| Oparil, S | 26 |
| Frieden, TR | 1 |
| Park, E | 1 |
| Lee, Y | 2 |
| Jue, MS | 1 |
| Umair, M | 1 |
| Ahmad, M | 1 |
| Saeed, H | 1 |
| Saleem, Z | 1 |
| Tauqeer, F | 1 |
| Adalsteinsson, JA | 1 |
| Muzumdar, S | 1 |
| Waldman, R | 1 |
| Hu, C | 1 |
| Wu, R | 1 |
| Ratner, D | 1 |
| Ungar, J | 1 |
| Silverberg, JI | 1 |
| Olafsdottir, GH | 1 |
| Kristjansson, AK | 1 |
| Tryggvadottir, L | 1 |
| Jonasson, JG | 1 |
| Aloud, BM | 1 |
| Petkau, JC | 1 |
| McCallum, J | 1 |
| Kirby, C | 1 |
| Blewett, H | 1 |
| Commander, SJ | 1 |
| Wu, H | 3 |
| Boakye-Agyeman, F | 1 |
| Melloni, C | 1 |
| Hornik, CD | 1 |
| Zimmerman, K | 1 |
| Al-Uzri, A | 1 |
| Mendley, SR | 1 |
| Harper, B | 1 |
| Cohen-Wolkowiez, M | 1 |
| Hornik, CP | 1 |
| Aschenbrenner, DS | 1 |
| Groenland, EH | 1 |
| van Kleef, MEAM | 1 |
| Bots, ML | 2 |
| Visseren, FLJ | 1 |
| van der Elst, KCM | 1 |
| Spiering, W | 3 |
| Werning, J | 1 |
| Millenaar, D | 1 |
| Langeard, A | 1 |
| Cloutier, SO | 1 |
| Olmand, M | 1 |
| Saillant, K | 1 |
| Gagnon, C | 1 |
| Grégoire, CA | 1 |
| Fortier, A | 1 |
| Lacroix, M | 1 |
| Lalongé, J | 1 |
| Gayda, M | 1 |
| Besnier, F | 1 |
| Gagnon, D | 1 |
| Bherer, L | 1 |
| Nigam, A | 1 |
| Fujiwara, T | 2 |
| Hoshide, S | 5 |
| Tomitani, N | 2 |
| Kanegae, H | 2 |
| Kario, K | 8 |
| Sung, J | 1 |
| Ahn, KT | 1 |
| Cho, BR | 1 |
| Lee, SY | 1 |
| Kim, BJ | 1 |
| Kim, DK | 1 |
| Park, JI | 1 |
| Lee, WS | 1 |
| Hu, LX | 1 |
| Wang, D | 2 |
| Liu, HL | 2 |
| Zhang, QT | 1 |
| Sun, DS | 1 |
| Zhang, L | 3 |
| Chang, GL | 1 |
| Chrysant, SG | 34 |
| Chrysant, GS | 3 |
| Dasa, O | 1 |
| Smith, SM | 4 |
| Howard, G | 1 |
| Gong, Y | 21 |
| Handberg, E | 2 |
| Pepine, CJ | 11 |
| Marc, Y | 1 |
| Hmazzou, R | 1 |
| De Mota, N | 1 |
| Balavoine, F | 1 |
| Llorens-Cortes, C | 1 |
| Cheung, DWS | 1 |
| Koon, JCM | 1 |
| Wong, PH | 1 |
| Yau, KC | 1 |
| Wat, ECL | 1 |
| Chan, JYW | 1 |
| Lau, VKM | 1 |
| Ko, ECH | 1 |
| Waye, MMY | 1 |
| Fung, KP | 1 |
| Zhang, D | 2 |
| Wei, SY | 1 |
| Wang, YX | 1 |
| Zhang, QF | 1 |
| Zhao, SL | 1 |
| Diao, TT | 1 |
| Li, JS | 1 |
| Qi, WR | 1 |
| He, YX | 1 |
| Guo, XY | 1 |
| Zhang, MZ | 2 |
| Chen, JY | 1 |
| Wang, XT | 1 |
| Wei, QJ | 1 |
| Wang, Y | 8 |
| Li, B | 1 |
| Chen, KC | 1 |
| Chu, P | 1 |
| Jenner, R | 1 |
| Fatureto-Borges, F | 1 |
| Costa-Hong, V | 1 |
| Lopes, HF | 1 |
| Teixeira, SH | 1 |
| Marum, E | 1 |
| Giorgi, DAM | 1 |
| Consolim-Colombo, FM | 1 |
| Bortolotto, LA | 1 |
| Lorenzi-Filho, G | 1 |
| Krieger, EM | 1 |
| Drager, LF | 1 |
| Zhang, P | 2 |
| Wang, H | 9 |
| Sun, L | 2 |
| Xi, Y | 1 |
| Wu, Y | 5 |
| Yan, LL | 1 |
| Li, X | 1 |
| Sun, N | 3 |
| Danilov, SM | 1 |
| Tovsky, SI | 1 |
| Schwartz, DE | 1 |
| Dull, RO | 1 |
| Liang, W | 1 |
| Ma, H | 1 |
| Cao, L | 1 |
| Yan, W | 1 |
| Yang, J | 1 |
| De Ciuceis, C | 4 |
| Salvetti, M | 6 |
| Paini, A | 4 |
| Rossini, C | 2 |
| Muiesan, ML | 8 |
| Duse, S | 2 |
| Caletti, S | 1 |
| Coschignano, MA | 1 |
| Semeraro, F | 2 |
| Trapletti, V | 1 |
| Bertacchini, F | 1 |
| Brami, V | 1 |
| Petelca, A | 1 |
| Agabiti Rosei, E | 1 |
| Rizzoni, D | 9 |
| Agabiti Rosei, C | 1 |
| Wang, S | 1 |
| Zhou, X | 4 |
| Liu, K | 2 |
| Zhang, X | 5 |
| Meng, Q | 1 |
| Shi, R | 1 |
| Shi, D | 1 |
| Schlickmann, F | 1 |
| Mariano, LNB | 2 |
| Steimbach, VMB | 1 |
| Krueger, CMA | 1 |
| de Andrade, SF | 1 |
| Scholze, J | 5 |
| Douros, A | 2 |
| Nwachukwu, DC | 1 |
| Eze, AA | 1 |
| Nwachukwu, NZ | 1 |
| Aneke, EI | 1 |
| Agu, PU | 1 |
| Azubike, NC | 1 |
| Obika, LF | 1 |
| Okoye, OI | 1 |
| van der Wel, MC | 1 |
| Biermans, M | 1 |
| Akkermans, R | 1 |
| Lenders, JWM | 1 |
| van Weel, C | 1 |
| Deinum, J | 1 |
| Thomopoulos, C | 2 |
| Uchiwa, H | 2 |
| Kai, H | 5 |
| Iwamoto, Y | 2 |
| Anegawa, T | 2 |
| Kajimoto, H | 1 |
| Fukuda, K | 2 |
| Imaizumi, T | 5 |
| Fukumoto, Y | 2 |
| Magvanjav, O | 1 |
| McDonough, CW | 8 |
| Turner, ST | 30 |
| Bailey, KR | 12 |
| Boerwinkle, E | 30 |
| Beitelshees, AL | 15 |
| Tanaka, T | 1 |
| Kubo, M | 1 |
| MacDonald, TM | 4 |
| Williams, B | 5 |
| Webb, DJ | 5 |
| Morant, S | 3 |
| Caulfield, M | 3 |
| Cruickshank, JK | 5 |
| Ford, I | 4 |
| Sever, P | 4 |
| Mackenzie, IS | 3 |
| Padmanabhan, S | 6 |
| McCann, GP | 1 |
| Salsbury, J | 4 |
| McInnes, G | 4 |
| Brown, MJ | 7 |
| Accetto, R | 2 |
| Widimsky, J | 2 |
| Vincelj, J | 2 |
| Sirenko, Y | 2 |
| Yevgenyevna, IC | 1 |
| Barbic Zagar, B | 1 |
| de Almeida, CLB | 1 |
| Silva, LMD | 1 |
| Andrade, SF | 2 |
| Sison, J | 3 |
| Vega, RMR | 1 |
| Dayi, H | 1 |
| Bader, G | 1 |
| Brunel, P | 3 |
| Witte, J | 1 |
| Lampe, J | 1 |
| Koenen, A | 1 |
| Urbaneck, I | 1 |
| Steinbach, A | 1 |
| Rettig, R | 1 |
| Grisk, O | 1 |
| Brook, RD | 1 |
| Kaciroti, N | 1 |
| Bakris, G | 5 |
| Dahlöf, B | 29 |
| Pitt, B | 14 |
| Velazquez, E | 4 |
| Weber, M | 7 |
| Zappe, DH | 13 |
| Hau, T | 1 |
| Jamerson, KA | 8 |
| Bakris, GL | 29 |
| White, WB | 17 |
| Weber, MA | 37 |
| Sica, D | 5 |
| Roberts, A | 3 |
| Lloyd, E | 5 |
| Kupfer, S | 6 |
| Schmutz, JL | 1 |
| Abdelfattah, R | 2 |
| Song, S | 2 |
| Kostis, JB | 4 |
| Sica, DA | 7 |
| van der Merwe, WM | 1 |
| Zhao, L | 2 |
| Juhasz, A | 1 |
| Hisada, M | 1 |
| Ala-Mutka, EM | 1 |
| Rimpelä, JM | 1 |
| Fyhrquist, F | 5 |
| Kontula, KK | 4 |
| Hiltunen, TP | 10 |
| Liu, Y | 4 |
| Dai, S | 1 |
| Liu, L | 13 |
| Liao, H | 1 |
| Xiao, C | 1 |
| Kramer, N | 2 |
| Badri, M | 2 |
| Kana, SS | 1 |
| Mntla, P | 1 |
| Ogola, EN | 1 |
| Ogunbanjo, G | 1 |
| Okpechi, I | 1 |
| Mayosi, BM | 1 |
| Ayyagari, R | 1 |
| Xie, J | 2 |
| Cheng, D | 1 |
| Wu, EQ | 2 |
| Huang, XY | 1 |
| Chen, S | 3 |
| Mira, FS | 1 |
| Temido, H | 1 |
| Gaspar, E | 1 |
| Pedersen, SA | 1 |
| Johannesdottir Schmidt, SA | 1 |
| Hölmich, LR | 1 |
| Friis, S | 1 |
| Gaist, D | 1 |
| de Moura Leão, MF | 1 |
| Duarte, JA | 1 |
| Sauzen, PD | 1 |
| Piccoli, JDCE | 1 |
| de Oliveira, LFS | 1 |
| Machado, MM | 1 |
| Qian, D | 1 |
| Tao, H | 1 |
| Dai, M | 1 |
| Zhang, C | 1 |
| Mengesha, HG | 1 |
| Welegerima, AH | 1 |
| Hadgu, A | 1 |
| Temesgen, H | 1 |
| Otieno, MG | 1 |
| Tsegay, K | 1 |
| Fisseha, T | 1 |
| Getachew, S | 1 |
| Merha, Z | 1 |
| Tewodros, H | 1 |
| Dabessa, J | 1 |
| Gebreegzabher, B | 1 |
| Petrucka, P | 1 |
| Ferdinand, KC | 10 |
| Wu, J | 1 |
| Tadic, M | 1 |
| Cuspidi, C | 4 |
| Ekman, I | 1 |
| Öhagen, P | 1 |
| Meadows, C | 1 |
| Khitan, ZJ | 1 |
| Kazemi Korayem, A | 1 |
| Ghamami, S | 1 |
| Bahrami, Z | 1 |
| Johannsen, JO | 1 |
| Reuter, H | 1 |
| Hoffmann, F | 1 |
| Blaich, C | 1 |
| Wiesen, MHJ | 1 |
| Streichert, T | 1 |
| Müller, C | 1 |
| Donato, A | 2 |
| Kuusela, PJ | 1 |
| Heymann, WR | 1 |
| Pais, P | 5 |
| Jung, H | 4 |
| Dans, A | 4 |
| Zhu, J | 3 |
| Kamath, D | 1 |
| Bosch, J | 4 |
| Lonn, E | 2 |
| Yusuf, S | 5 |
| Wuerzner, G | 1 |
| Johnson, R | 1 |
| Dludla, P | 1 |
| Mabhida, S | 1 |
| Benjeddou, M | 1 |
| Louw, J | 1 |
| February, F | 1 |
| Williams, CR | 1 |
| Mistry, M | 1 |
| Cheriyan, AM | 1 |
| Williams, JM | 2 |
| Naraine, MK | 1 |
| Ellis, CL | 1 |
| Mallick, R | 1 |
| Mistry, AC | 1 |
| Gooch, JL | 1 |
| Ko, B | 1 |
| Cai, H | 1 |
| Hoover, RS | 1 |
| Samuel, JP | 1 |
| Tyson, JE | 1 |
| Green, C | 1 |
| Bell, CS | 1 |
| Molony, D | 1 |
| Samuels, J | 1 |
| Faconti, L | 2 |
| Ferro, A | 1 |
| Webb, AJ | 1 |
| Chowienczyk, PJ | 1 |
| Mayosi, B | 1 |
| Okpechi, IG | 1 |
| Georgianos, PI | 1 |
| Fan, P | 1 |
| Zhao, YM | 1 |
| Liao, Y | 1 |
| Yang, KQ | 1 |
| Tian, T | 1 |
| Lou, Y | 1 |
| Luo, F | 2 |
| Ma, WJ | 1 |
| Zhang, HM | 1 |
| Song, L | 1 |
| Cai, J | 1 |
| Liu, YX | 1 |
| Zhou, XL | 1 |
| Kaabi, W | 1 |
| Aouinti, I | 1 |
| Charfi, O | 1 |
| Zaiem, A | 1 |
| Lakhoua, G | 1 |
| Hamza, I | 1 |
| Daghfous, R | 1 |
| Kastalli, S | 1 |
| El Aidli, S | 1 |
| Cho, EJ | 3 |
| Lee, HY | 4 |
| Sung, KC | 2 |
| Park, S | 2 |
| Sohn, IS | 3 |
| Park, CG | 5 |
| Choi, DJ | 3 |
| Ha, JW | 3 |
| Ahn, YK | 3 |
| Hong, SJ | 2 |
| Kim, SK | 3 |
| Chung, WJ | 3 |
| Yoo, BS | 3 |
| Hong, TJ | 3 |
| Youn, HJ | 3 |
| Cho, MC | 2 |
| Chae, SC | 2 |
| Kim, YJ | 3 |
| Kim, CJ | 3 |
| van der Hoeven, NV | 1 |
| Zwinderman, AH | 1 |
| Algharably, EAH | 1 |
| Solini, A | 1 |
| Seghieri, M | 1 |
| Giannini, L | 1 |
| Biancalana, E | 1 |
| Parolini, F | 1 |
| Rossi, C | 1 |
| Dardano, A | 1 |
| Taddei, S | 5 |
| Ghiadoni, L | 2 |
| Bruno, RM | 2 |
| Brown, K | 1 |
| Iniesta, R | 1 |
| Campbell, D | 1 |
| Venturini, C | 1 |
| Singh, S | 1 |
| Irvin, MR | 1 |
| Arnett, DK | 1 |
| Weale, ME | 1 |
| Warren, H | 1 |
| Munroe, PB | 1 |
| Cruickshank, K | 1 |
| Lewis, C | 1 |
| Chowienczyk, P | 1 |
| Okura, T | 1 |
| Miyoshi, K | 1 |
| Irita, J | 1 |
| Enomoto, D | 1 |
| Jotoku, M | 1 |
| Nagao, T | 2 |
| Watanabe, K | 1 |
| Matsuoka, H | 6 |
| Ashihara, T | 1 |
| Higaki, J | 4 |
| Arias, SC | 2 |
| Valente, CP | 1 |
| Machado, FG | 1 |
| Fanelli, C | 2 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Malheiros, DM | 2 |
| Zatz, R | 2 |
| Fujihara, CK | 2 |
| Fukutomi, M | 2 |
| Eguchi, K | 4 |
| Watanabe, T | 3 |
| Kaneyuki, M | 1 |
| Shihara, M | 1 |
| Toyama, Y | 1 |
| Mitsutake, Y | 1 |
| Umei, H | 1 |
| Kusaba, K | 1 |
| Ueda, T | 3 |
| Adachi, H | 1 |
| Dussouil, AS | 1 |
| Gaudy-Marqueste, C | 1 |
| Tasei, AM | 1 |
| Monestier, S | 1 |
| Mallet, S | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| Kubota, Y | 1 |
| Takahashi, H | 3 |
| Asai, K | 1 |
| Yasutake, M | 1 |
| Mizuno, K | 1 |
| Gorain, B | 1 |
| Choudhury, H | 1 |
| Halder, D | 1 |
| Sarkar, AK | 1 |
| Sarkar, P | 1 |
| Biswas, E | 1 |
| Ghosh, B | 1 |
| Pal, TK | 1 |
| Sato, N | 2 |
| Saijo, Y | 2 |
| Sasagawa, Y | 2 |
| Morimoto, H | 2 |
| Takeuchi, T | 2 |
| Sano, H | 2 |
| Koyama, S | 2 |
| Takehara, N | 2 |
| Morita, K | 2 |
| Sumitomo, K | 2 |
| Maruyama, J | 2 |
| Kikuchi, K | 2 |
| Hasebe, N | 2 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 2 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Iyalomhe, GB | 1 |
| Omogbai, EK | 1 |
| Isah, AO | 1 |
| Iyalomhe, OO | 1 |
| Dada, FL | 1 |
| Iyalomhe, SI | 1 |
| Hagendorff, A | 1 |
| Freytag, S | 1 |
| Müller, A | 1 |
| Klebs, S | 4 |
| Watanabe, Y | 1 |
| Halberg, F | 3 |
| Otsuka, K | 1 |
| Cornelissen, G | 2 |
| Lewin, AJ | 6 |
| Izzo, JL | 14 |
| Melino, M | 9 |
| Lee, J | 10 |
| Fernandez, V | 8 |
| Heyrman, R | 8 |
| Dhalla, IA | 2 |
| Gomes, T | 1 |
| Yao, Z | 1 |
| Nagge, J | 1 |
| Persaud, N | 1 |
| Hellings, C | 1 |
| Mamdani, MM | 2 |
| Juurlink, DN | 2 |
| Briasoulis, A | 1 |
| Jamerson, K | 9 |
| Kelly, RY | 5 |
| Hester, A | 8 |
| Hua, T | 2 |
| Zappe, D | 10 |
| Okin, PM | 4 |
| Hille, DA | 3 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 19 |
| Lindholm, LH | 7 |
| Devereux, RB | 11 |
| Schwartz, GL | 14 |
| Bailey, K | 6 |
| Sheng, CS | 1 |
| Ma, GS | 1 |
| Dai, QY | 1 |
| Hasegawa, H | 2 |
| Kanozawa, K | 1 |
| Asakura, J | 2 |
| Takayanagi, K | 2 |
| Komuro, O | 1 |
| Fukada, H | 1 |
| Tokushima, H | 1 |
| Kogure, H | 1 |
| Matsuzawa, M | 1 |
| Mitarai, T | 2 |
| Gomes, MA | 2 |
| Pereira-Barretto, AC | 1 |
| Póvoa, R | 1 |
| Kohlmann, O | 5 |
| Rocha, JC | 3 |
| Nobre, F | 2 |
| Maruf, FA | 3 |
| Akinpelu, AO | 3 |
| Salako, BL | 3 |
| Evangelista, S | 3 |
| Zhang, MS | 1 |
| Litvin, AY | 1 |
| Sukmarova, ZN | 1 |
| Elfimova, EM | 1 |
| Aksenova, AV | 1 |
| Galitsin, PV | 1 |
| Rogoza, AN | 1 |
| Chazova, IE | 5 |
| Matsumura, K | 4 |
| Arima, H | 3 |
| Tominaga, M | 3 |
| Ohtsubo, T | 3 |
| Sasaguri, T | 3 |
| Fujii, K | 4 |
| Fukuhara, M | 3 |
| Uezono, K | 3 |
| Morinaga, Y | 3 |
| Ohta, Y | 3 |
| Otonari, T | 3 |
| Kawasaki, J | 3 |
| Kato, I | 3 |
| Tsuchihashi, T | 8 |
| Calhoun, DA | 8 |
| Lacourcière, Y | 28 |
| Crikelair, N | 9 |
| Jia, Y | 4 |
| Glazer, RD | 6 |
| Volman, S | 1 |
| Benitez, FN | 1 |
| Cedenio, H | 1 |
| Giorgi, M | 1 |
| Jaramillo, N | 1 |
| Molina, N | 1 |
| Zilberman, J | 1 |
| Schumacher, H | 11 |
| Neldam, S | 6 |
| Guthrie, RM | 2 |
| Buddharaju, V | 1 |
| Kjeldsen, S | 2 |
| Mancia, G | 26 |
| Schmieder, R | 3 |
| Mattheus, M | 3 |
| Unger, T | 6 |
| O'Connell, JR | 2 |
| Citterio, L | 4 |
| Donner, KM | 4 |
| Hedner, T | 2 |
| Lanzani, C | 7 |
| Melander, O | 3 |
| Saarela, J | 2 |
| Ripatti, S | 2 |
| Wahlstrand, B | 1 |
| Manunta, P | 9 |
| Kontula, K | 6 |
| Dominiczak, AF | 7 |
| Vítovec, J | 1 |
| Slíva, J | 1 |
| Holford, TR | 2 |
| Guddati, AK | 2 |
| DiNicolantonio, JJ | 2 |
| O'Keefe, JH | 2 |
| Lavie, CJ | 2 |
| Badgett, RG | 1 |
| Donzelli, A | 1 |
| Einhorn, PT | 1 |
| M'Buyamba-Kabangu, JR | 3 |
| Anisiuba, BC | 3 |
| Ndiaye, MB | 3 |
| Lemogoum, D | 3 |
| Jacobs, L | 1 |
| Ijoma, CK | 3 |
| Thijs, L | 15 |
| Boombhi, HJ | 3 |
| Kaptue, J | 3 |
| Kolo, PM | 3 |
| Mipinda, JB | 2 |
| Osakwe, CE | 1 |
| Odili, A | 1 |
| Ezeala-Adikaibe, B | 2 |
| Kingue, S | 3 |
| Omotoso, BA | 3 |
| Ba, SA | 3 |
| Ulasi, II | 3 |
| Staessen, JA | 17 |
| Weir, MR | 25 |
| Shojaee, A | 9 |
| Maa, JF | 7 |
| Oshikawa, J | 1 |
| Toya, Y | 2 |
| Morita, S | 1 |
| Taguri, M | 1 |
| Hanaoka, K | 2 |
| Hasegawa, T | 2 |
| Kaizu, K | 1 |
| Kamata, K | 1 |
| Kobayashi, S | 2 |
| Ohtake, T | 1 |
| Sato, T | 2 |
| Yasuda, G | 1 |
| Kimura, K | 1 |
| Umemura, S | 3 |
| Farinde, A | 1 |
| Hamada, T | 1 |
| Kuwabara, M | 1 |
| Watanabe, A | 1 |
| Mizuta, E | 1 |
| Ohtahara, A | 1 |
| Omodani, H | 1 |
| Watanabe, M | 1 |
| Nakamura, H | 1 |
| Hirota, Y | 1 |
| Miyazaki, S | 1 |
| Kato, M | 1 |
| Ogino, K | 1 |
| Kosaka, H | 1 |
| Haruaki, N | 1 |
| Taniguchi, S | 1 |
| Yamamoto, K | 2 |
| Kotake, H | 1 |
| Hisatome, I | 1 |
| Cotsonis, G | 1 |
| Parekh, V | 2 |
| Cooper-DeHoff, R | 2 |
| Roth, EM | 1 |
| Karalliedde, J | 2 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 2 |
| Gnudi, L | 1 |
| Bilo, G | 4 |
| Parati, G | 11 |
| Matthews, KA | 1 |
| Brenner, MJ | 1 |
| Brenner, AC | 1 |
| Conde, D | 1 |
| Castro, F | 1 |
| Caro, M | 1 |
| Bramlage, P | 19 |
| Zemmrich, C | 2 |
| Ketelhut, R | 5 |
| Wolf, WP | 5 |
| Fronk, EM | 3 |
| Schmieder, RE | 19 |
| Okada, Y | 2 |
| Jarvis, SS | 1 |
| Best, SA | 1 |
| Bivens, TB | 1 |
| Adams-Huet, B | 1 |
| Levine, BD | 4 |
| Barrios, V | 6 |
| Escobar, C | 4 |
| Segura, J | 3 |
| Ruilope, LM | 17 |
| Radchenko, GD | 1 |
| Sirenko, YM | 2 |
| Kushnir, SM | 1 |
| Torbas, OO | 1 |
| Dobrokhod, AS | 1 |
| Karnes, JH | 3 |
| Van Wart, SA | 1 |
| Shoaf, SE | 1 |
| Mallikaarjun, S | 1 |
| Mager, DE | 1 |
| Pacanowski, MA | 1 |
| Arwood, MJ | 2 |
| Langaee, TY | 5 |
| Zhu, DL | 3 |
| Gao, PJ | 1 |
| Liu, SW | 1 |
| Jeong, MH | 1 |
| Birgit, V | 1 |
| Macaulay, D | 1 |
| Swallow, E | 1 |
| Diener, M | 1 |
| Farooqui, S | 1 |
| Antonio, PR | 1 |
| Marta, PS | 1 |
| Luís, DD | 1 |
| Antonio, DP | 1 |
| Manuel, ST | 1 |
| Rafael, MS | 1 |
| Sonia, GV | 1 |
| Manuel, GP | 1 |
| Isabel, MN | 1 |
| Carlos, EN | 1 |
| Gabriel, CT | 1 |
| Francisco, GU | 1 |
| Tayama, Y | 1 |
| Nakamura, T | 1 |
| Kawashima, K | 1 |
| Shimizu, T | 2 |
| Iwashita, T | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Uzui, H | 1 |
| Morishita, T | 1 |
| Nakano, A | 1 |
| Amaya, N | 1 |
| Fukuoka, Y | 1 |
| Ishida, K | 1 |
| Arakawa, K | 2 |
| Lee, JD | 1 |
| Tada, H | 1 |
| Handler, J | 6 |
| Yan, R | 1 |
| Song, A | 1 |
| Niu, X | 1 |
| Cao, C | 1 |
| Dong, X | 1 |
| Gao, D | 1 |
| Lederle, FA | 2 |
| Xiao, X | 1 |
| Du, HJ | 1 |
| Hu, WJ | 1 |
| Shaw, PX | 1 |
| La Boria, E | 1 |
| Cancarini, A | 1 |
| Rosei, CA | 3 |
| Sarkar, A | 1 |
| Ruggeri, G | 1 |
| Caimi, L | 1 |
| Ricotta, D | 1 |
| Rosei, EA | 4 |
| Fogari, R | 22 |
| Derosa, G | 10 |
| Zoppi, A | 12 |
| Lazzari, P | 5 |
| D'Angelo, A | 2 |
| Mugellini, A | 17 |
| Agabiti-Rosei, E | 9 |
| Manolis, A | 2 |
| Zava, D | 1 |
| Omboni, S | 10 |
| Martyniuk, TV | 1 |
| Salam, A | 2 |
| Webster, R | 4 |
| Singh, K | 1 |
| Kallakuri, S | 1 |
| Rodgers, A | 4 |
| Prabhakaran, D | 1 |
| Maulik, PK | 1 |
| Jan, S | 2 |
| Thom, S | 3 |
| Naik, N | 1 |
| Guggilla, R | 1 |
| Selak, V | 1 |
| Patel, A | 3 |
| Andreadis, EA | 1 |
| Angelopoulos, ET | 1 |
| Kolyvas, GN | 1 |
| Agaliotis, GD | 1 |
| Mousoulis, CG | 1 |
| Mousoulis, GP | 1 |
| Byrd, JB | 1 |
| Punzi, HA | 6 |
| Bays, H | 2 |
| Zhu, D | 1 |
| de la Sierra, A | 9 |
| Laurent, S | 4 |
| Manolis, AJ | 4 |
| Stevanović, J | 1 |
| O'Prinsen, AC | 1 |
| Verheggen, BG | 1 |
| Schuiling-Veninga, N | 1 |
| Postma, MJ | 1 |
| Pechlivanoglou, P | 1 |
| BARE, WW | 3 |
| Khan, W | 1 |
| Moin, N | 1 |
| Iktidar, S | 1 |
| Sakrani, J | 1 |
| Abid, R | 1 |
| Afzal, J | 1 |
| Maheshwary, N | 1 |
| Kumar, K | 1 |
| Siddiqi, A | 1 |
| Qadir, M | 1 |
| Vandell, AG | 2 |
| Lucas, AM | 1 |
| Johnson, RJ | 3 |
| Teo, KK | 2 |
| Pfeffer, M | 1 |
| O'Donnell, M | 1 |
| Dagenais, G | 3 |
| Diaz, R | 3 |
| Joseph, P | 1 |
| Copland, I | 1 |
| Pogue, J | 3 |
| Kereiakes, DJ | 10 |
| Hao, K | 2 |
| Chen, Y | 3 |
| Zhao, X | 4 |
| Liu, X | 1 |
| Cass, A | 1 |
| Peiris, D | 2 |
| Usherwood, T | 2 |
| Brown, A | 1 |
| Hillis, GS | 1 |
| Rafter, N | 1 |
| Tonkin, A | 1 |
| Billot, L | 1 |
| Bompoint, S | 1 |
| Burch, C | 1 |
| Burke, H | 1 |
| Hayman, N | 1 |
| Molanus, B | 1 |
| Reid, CM | 5 |
| Shiel, L | 1 |
| Togni, S | 1 |
| Wang, W | 4 |
| Zhou, W | 1 |
| Wang, X | 7 |
| Tang, J | 1 |
| Zhao, Y | 5 |
| Lu, X | 1 |
| Wang, L | 2 |
| Shen, C | 2 |
| Yang, S | 1 |
| Chung, CM | 1 |
| Hung, SI | 1 |
| Leu, HB | 3 |
| Lin, LY | 2 |
| Huang, PH | 2 |
| Wu, TC | 3 |
| Lin, SJ | 3 |
| Pan, WH | 1 |
| Smolnik, R | 2 |
| Kanda, S | 1 |
| Yoshioka, K | 1 |
| Amino, M | 1 |
| Deguchi, Y | 1 |
| Aizawa, T | 1 |
| Tanabe, T | 1 |
| Ikari, Y | 1 |
| Chadha, R | 1 |
| Bhandari, S | 1 |
| Khullar, S | 1 |
| Mandal, SK | 1 |
| Jain, DV | 1 |
| Ammentorp, B | 4 |
| Laeis, P | 6 |
| Hall, KL | 2 |
| Limacher, MC | 1 |
| Hoshino, T | 1 |
| Ookawara, S | 1 |
| Miyazawa, H | 1 |
| Ito, K | 1 |
| Ueda, Y | 2 |
| Kaku, Y | 1 |
| Hirai, K | 1 |
| Mori, H | 2 |
| Yoshida, I | 1 |
| Tabei, K | 1 |
| Neutel, JM | 33 |
| Musini, VM | 1 |
| Nazer, M | 1 |
| Bassett, K | 1 |
| Wright, JM | 1 |
| Tarlovskaia, EI | 1 |
| Balandina, IuA | 1 |
| Maksimchuk-Kolobova, NS | 1 |
| Kildare, L | 1 |
| Jones, T | 1 |
| Neher, JO | 1 |
| St Anna, L | 1 |
| Tipton, AJ | 1 |
| Baban, B | 1 |
| Sullivan, JC | 2 |
| Yamamoto, S | 1 |
| Nishida, K | 1 |
| Uriu, K | 1 |
| Tanaka, Y | 1 |
| Griffin, KA | 1 |
| Polichnowski, A | 1 |
| Litbarg, N | 1 |
| Picken, M | 1 |
| Venkatachalam, MA | 1 |
| Bidani, AK | 1 |
| Schilders, JE | 1 |
| Boomsma, F | 2 |
| van den Meiracker, AH | 2 |
| Danser, AH | 2 |
| Snelder, N | 1 |
| Ploeger, BA | 1 |
| Luttringer, O | 1 |
| Rigel, DF | 1 |
| Fu, F | 1 |
| Beil, M | 1 |
| Stanski, DR | 1 |
| Danhof, M | 1 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 2 |
| Rakugi, H | 4 |
| Shimada, K | 10 |
| Numaguchi, H | 3 |
| Nishida, C | 3 |
| Yamaguchi, H | 3 |
| Fujimoto, G | 1 |
| Azuma, K | 4 |
| Shirakawa, M | 3 |
| Hanson, ME | 1 |
| Fujita, KP | 3 |
| Raptis, AE | 1 |
| Markakis, KP | 1 |
| Mazioti, MC | 1 |
| Ikonomidis, I | 1 |
| Maratou, EP | 1 |
| Vlahakos, DV | 1 |
| Kotsifaki, EE | 1 |
| Voumvourakis, AN | 1 |
| Tsirogianni, AG | 1 |
| Lambadiari, VA | 1 |
| Lekakis, JP | 1 |
| Raptis, SA | 1 |
| Dimitriadis, GD | 1 |
| Assaad-Khalil, SH | 2 |
| Najem, R | 2 |
| Kitchlew, AR | 2 |
| Cho, B | 2 |
| Ueng, KC | 2 |
| Shete, A | 2 |
| Knap, D | 1 |
| Ando, K | 2 |
| Nitta, K | 1 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 1 |
| Tomita, K | 1 |
| Nangaku, M | 1 |
| Takahashi, K | 3 |
| Isshiki, M | 2 |
| Shimosawa, T | 2 |
| Fujita, T | 2 |
| Gangadhariah, MH | 1 |
| Luther, JM | 1 |
| Garcia, V | 1 |
| Paueksakon, P | 1 |
| Hayward, SW | 1 |
| Love, HD | 1 |
| Falck, JR | 1 |
| Manthati, VL | 1 |
| Imig, JD | 2 |
| Schwartzman, ML | 1 |
| Zent, R | 1 |
| Capdevila, JH | 1 |
| Pozzi, A | 1 |
| Borghi, C | 12 |
| O'Brien, E | 6 |
| Shiga, Y | 6 |
| Miura, S | 6 |
| Norimatsu, K | 2 |
| Hitaka, Y | 1 |
| Nagata, I | 2 |
| Koyoshi, R | 1 |
| Morii, J | 3 |
| Kuwano, T | 3 |
| Uehara, Y | 5 |
| Inoue, A | 4 |
| Shirotani, T | 2 |
| Fujisawa, K | 2 |
| Matsunaga, E | 2 |
| Saku, K | 6 |
| Suh, SY | 1 |
| Ahn, T | 1 |
| Bae, JH | 2 |
| Lim, DS | 1 |
| Lee, SU | 1 |
| Kim, YK | 1 |
| Hyon, MS | 1 |
| Kim, WH | 1 |
| Han, KR | 1 |
| Park, HK | 1 |
| Kobalava, ZhD | 3 |
| Kotovskaia, IuV | 2 |
| Lobzhanidze, TV | 1 |
| Kravtsova, OA | 1 |
| Tamura, K | 2 |
| Ohki, K | 1 |
| Kobayashi, R | 1 |
| Uneda, K | 1 |
| Azushima, K | 1 |
| Ohsawa, M | 1 |
| Wakui, H | 1 |
| Sakai, M | 1 |
| Tokita, Y | 1 |
| Del-Aguila, JL | 2 |
| Moore, MJ | 1 |
| Hou, W | 2 |
| Hall, K | 2 |
| Schmidt, SO | 1 |
| Curry, RW | 1 |
| Chapman, A | 2 |
| Posadzy-Malaczynska, A | 1 |
| Rajpold, K | 1 |
| Woznicka-Leskiewicz, L | 1 |
| Marcinkowska, J | 1 |
| Xie, L | 2 |
| Frech-Tamas, F | 2 |
| Marrett, E | 1 |
| Baser, O | 1 |
| Wilson, L | 1 |
| Nair, KV | 2 |
| Saseen, JJ | 2 |
| Kandra, A | 4 |
| Palatini, P | 14 |
| Vinereanu, D | 1 |
| Dulgheru, R | 1 |
| Magda, S | 1 |
| Dragoi Galrinho, R | 1 |
| Florescu, M | 1 |
| Cinteza, M | 1 |
| Granger, C | 1 |
| Ciobanu, AO | 1 |
| Medvedev, IN | 1 |
| Briukhovetskiĭ, AG | 1 |
| Metoki, H | 3 |
| Obara, T | 3 |
| Asayama, K | 3 |
| Satoh, M | 2 |
| Hosaka, M | 2 |
| Elnagar, N | 1 |
| Miyawaki, Y | 1 |
| Kojima, I | 1 |
| Ohkubo, T | 3 |
| Imai, Y | 3 |
| Szentes, V | 1 |
| Kovács, G | 1 |
| Dézsi, CA | 1 |
| Takase, B | 1 |
| Nagata, M | 1 |
| Suzuki, H | 3 |
| Fujiwara, K | 2 |
| Frau, F | 4 |
| Zaninello, R | 5 |
| Salvi, E | 5 |
| Ortu, MF | 2 |
| Braga, D | 2 |
| Velayutham, D | 2 |
| Argiolas, G | 5 |
| Fresu, G | 2 |
| Troffa, C | 6 |
| Bulla, E | 2 |
| Bulla, P | 2 |
| Pitzoi, S | 2 |
| Piras, DA | 2 |
| Glorioso, V | 3 |
| Chittani, M | 3 |
| Bernini, G | 2 |
| Bardini, M | 2 |
| Fallo, F | 2 |
| Malatino, L | 2 |
| Stancanelli, B | 2 |
| Regolisti, G | 2 |
| Ferri, C | 4 |
| Desideri, G | 1 |
| Scioli, GA | 1 |
| Galletti, F | 2 |
| Sciacqua, A | 2 |
| Perticone, F | 2 |
| Degli Esposti, E | 3 |
| Sturani, A | 2 |
| Semplicini, A | 9 |
| Veglio, F | 2 |
| Mulatero, P | 2 |
| Williams, TA | 2 |
| Barlassina, C | 6 |
| Cusi, D | 9 |
| Glorioso, N | 9 |
| Frenkel, NJ | 1 |
| De Rooij, SE | 1 |
| Trimpert, C | 1 |
| Levi, MM | 1 |
| Deen, PM | 1 |
| van den Born, BJ | 1 |
| Chen, SH | 1 |
| Karanjia, R | 1 |
| Chevrier, RL | 1 |
| Marshall, DH | 1 |
| Argulian, E | 1 |
| Grossman, E | 6 |
| Giles, TD | 5 |
| Punzi, H | 2 |
| Weiss, RJ | 2 |
| Li, H | 1 |
| Finck, A | 1 |
| Ghushchyan, V | 1 |
| Angeloni, E | 1 |
| Vitaterna, A | 1 |
| Lombardo, P | 1 |
| Pirelli, M | 1 |
| Refice, S | 1 |
| Skoglund, PH | 1 |
| Svensson, P | 1 |
| Asp, J | 1 |
| Östergren, J | 3 |
| Sutton, G | 1 |
| Yadav, PS | 1 |
| Yadav, E | 1 |
| Verma, A | 1 |
| Amin, S | 1 |
| Lin, LL | 1 |
| Cheng, YQ | 1 |
| Su, DF | 3 |
| Liu, AJ | 1 |
| Sarin, AP | 2 |
| DiTommaso, S | 1 |
| Carpini, SD | 2 |
| Simonini, M | 1 |
| Pozzoli, S | 1 |
| Rivera, NV | 1 |
| Condorelli, G | 1 |
| Trimarco, B | 3 |
| Kaplan, NM | 12 |
| Tandon, S | 1 |
| Chowdhury, EK | 1 |
| Ademi, Z | 1 |
| Moss, JR | 1 |
| Wing, LMH | 1 |
| Schlimpert, V | 1 |
| Bhutani, J | 1 |
| Nakane, H | 1 |
| Kamouchi, M | 1 |
| Hata, J | 1 |
| Ibayashi, S | 1 |
| Kusuda, K | 1 |
| Omae, T | 1 |
| Ago, T | 1 |
| Solomennchuk, TM | 1 |
| Slaba, NA | 1 |
| Prots'ko, VV | 1 |
| Bedzaĭ, AO | 1 |
| Aoki, Y | 1 |
| Jung, HW | 1 |
| Kim, KI | 1 |
| Kang, DH | 2 |
| Ahn, Y | 2 |
| Kim, CH | 2 |
| Marques da Silva, P | 1 |
| Haag, U | 2 |
| Guest, JF | 1 |
| Brazier, JE | 1 |
| Soro, M | 1 |
| Semenkin, AA | 3 |
| Zhenatov, AB | 1 |
| Zhivilova, LA | 2 |
| Nechaeva, GI | 1 |
| Pritykina, TV | 2 |
| Chindareva, OI | 1 |
| Stroeva, TV | 1 |
| Pires, PW | 1 |
| Jackson, WF | 1 |
| Dorrance, AM | 1 |
| Menni, C | 1 |
| Amin, NB | 1 |
| Mitchell, JR | 1 |
| Lee, DS | 1 |
| Nucci, G | 1 |
| Rusnak, JM | 1 |
| Querci, F | 1 |
| Franzetti, I | 1 |
| Dario Ragonesi, P | 1 |
| Maffioli, P | 4 |
| Hubert, M | 1 |
| Kikuya, M | 2 |
| Inoue, R | 2 |
| Hirose, T | 2 |
| Arora, A | 1 |
| Jain, S | 1 |
| Khuller, GK | 1 |
| Vongpatanasin, W | 1 |
| Qiu, B | 1 |
| Du, JL | 1 |
| Deng, SB | 1 |
| Liu, YJ | 1 |
| She, Q | 1 |
| Cartoni, G | 1 |
| Stea, F | 1 |
| Magagna, A | 1 |
| Virdis, A | 1 |
| Grassi, D | 1 |
| Rhee, MY | 1 |
| Baek, SH | 1 |
| Park, SW | 1 |
| Oh, BH | 2 |
| Kim, SH | 3 |
| Kim, JJ | 1 |
| Shin, JH | 1 |
| Rim, SJ | 1 |
| Doh, JH | 1 |
| Chae, JK | 1 |
| Park, JB | 2 |
| Rump, LC | 5 |
| Reddy, YN | 1 |
| Deshmukh, AJ | 1 |
| Tu, W | 1 |
| Decker, BS | 1 |
| He, Z | 1 |
| Erdel, BL | 1 |
| Eckert, GJ | 1 |
| Hellman, RN | 1 |
| Murray, MD | 1 |
| Oates, JA | 1 |
| Pratt, JH | 3 |
| Toyoda, S | 1 |
| Inami, S | 1 |
| Kato, T | 2 |
| Tsukada, K | 1 |
| Nakamoto, A | 1 |
| Kikegawa, Y | 1 |
| Suzuki, A | 1 |
| Anraku, Y | 1 |
| Node, K | 2 |
| Inoue, T | 2 |
| Cooney, D | 1 |
| Milfred-LaForest, S | 1 |
| Rahman, M | 1 |
| Yu, D | 1 |
| Giménez-García, R | 1 |
| Machnicki, G | 1 |
| Ong, SH | 1 |
| Chen, W | 2 |
| Wei, ZJ | 1 |
| Kahler, KH | 2 |
| Cicero, AF | 4 |
| Tocci, G | 2 |
| Morant, SV | 1 |
| Caulfield, MJ | 1 |
| Vakilzadeh, N | 1 |
| Muller, ME | 1 |
| Forni, V | 2 |
| Milani, B | 1 |
| Hoffman, L | 1 |
| Piskunowicz, M | 1 |
| Maillard, M | 3 |
| Zweiacker, C | 1 |
| Pruijm, M | 1 |
| Fonseca, HA | 1 |
| Fonseca, FA | 1 |
| Lins, LC | 1 |
| Monteiro, AM | 1 |
| Brandão, SA | 1 |
| Povoa, RM | 1 |
| Juliano, L | 1 |
| Figueiredo-Neto, AM | 1 |
| Boschcov, P | 1 |
| Gidlund, M | 1 |
| Izar, MC | 1 |
| Souza, RA | 1 |
| Harrison, TN | 1 |
| Green, KR | 1 |
| Liu, IL | 1 |
| Vansomphone, SS | 1 |
| Scott, RD | 1 |
| Cheetham, TC | 1 |
| Reynolds, K | 1 |
| Mohamed, HM | 1 |
| Lamie, NT | 1 |
| Walsh, KR | 1 |
| Kuwabara, JT | 1 |
| Shim, JW | 1 |
| Wainford, RD | 1 |
| Kim, BS | 2 |
| Chung, WB | 1 |
| Guan, Z | 1 |
| Singletary, ST | 1 |
| Cha, H | 1 |
| Van Beusecum, JP | 1 |
| Cook, AK | 2 |
| Pollock, JS | 2 |
| Pollock, DM | 1 |
| Inscho, EW | 2 |
| Modesti, PA | 2 |
| Ghione, S | 1 |
| Portaluppi, F | 1 |
| Pozzilli, P | 1 |
| Arca, M | 1 |
| Calabrò, P | 1 |
| Fulgheri, PL | 1 |
| Bucci, M | 1 |
| Berra, S | 1 |
| Villani, GQ | 1 |
| Vladoianu, M | 1 |
| Popescu, E | 1 |
| Velican, VG | 1 |
| Pirvu, O | 1 |
| Kondo, K | 1 |
| Toh, R | 2 |
| Ishida, T | 2 |
| Mori, K | 1 |
| Yasuda, T | 1 |
| Hirata, K | 2 |
| Toh, N | 1 |
| Ishii, K | 3 |
| Kihara, H | 2 |
| Iwakura, K | 3 |
| Watanabe, H | 2 |
| Yoshikawa, J | 3 |
| Ito, H | 3 |
| Springer, K | 1 |
| Handley, A | 2 |
| Barger, B | 1 |
| Pareek, AK | 2 |
| Chandurkar, NB | 3 |
| Dharmadhikari, SK | 1 |
| Godbole, AV | 1 |
| Kshirsagar, PP | 1 |
| Agarwal, MA | 1 |
| Sharma, KH | 1 |
| Mathur, SL | 1 |
| Kumbla, MM | 1 |
| Sternlicht, H | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Akinyemi, JO | 1 |
| Ivy, JR | 1 |
| Oosthuyzen, W | 1 |
| Peltz, TS | 1 |
| Howarth, AR | 1 |
| Hunter, RW | 1 |
| Dhaun, N | 1 |
| Al-Dujaili, EA | 1 |
| Dear, JW | 1 |
| Flatman, PW | 2 |
| Bailey, MA | 3 |
| Rahman, A | 1 |
| Kittikulsuth, W | 1 |
| Fujisawa, Y | 1 |
| Sufiun, A | 1 |
| Rafiq, K | 1 |
| Hitomi, H | 1 |
| Nakano, D | 1 |
| Sohara, E | 1 |
| Uchida, S | 1 |
| Nishiyama, A | 2 |
| Goff, DC | 1 |
| López-Jaramillo, P | 2 |
| Xavier, D | 3 |
| Avezum, A | 2 |
| Leiter, LA | 2 |
| Piegas, LS | 2 |
| Parkhomenko, A | 2 |
| Keltai, M | 3 |
| Keltai, K | 2 |
| Chazova, I | 2 |
| Peters, RJ | 2 |
| Yusoff, K | 2 |
| Lewis, BS | 2 |
| Jansky, P | 2 |
| Khunti, K | 2 |
| Toff, WD | 2 |
| Varigos, J | 2 |
| Accini, JL | 1 |
| McKelvie, R | 2 |
| Lonn, EM | 1 |
| Molina, DI | 1 |
| Wilkinson, J | 1 |
| Torjesen, I | 1 |
| Podzolkov, VI | 3 |
| Bragina, AE | 1 |
| Zhou, HM | 1 |
| Zhong, ML | 1 |
| Wang, RH | 1 |
| Long, CL | 1 |
| Zhang, YF | 1 |
| Cui, WY | 1 |
| Bäurle, A | 1 |
| Shahin, MH | 1 |
| Rotroff, DM | 1 |
| Garrett, TJ | 1 |
| Motsinger-Reif, A | 1 |
| Frye, RF | 1 |
| Fiehn, O | 1 |
| Kaddurah-Daouk, R | 1 |
| Lin, JJ | 1 |
| Chang, HC | 1 |
| Ku, CT | 1 |
| Chen, HY | 1 |
| Eaton Md, CB | 2 |
| Simonyi, G | 1 |
| Ferenci, T | 1 |
| Alföldi, S | 1 |
| Farsang, C | 5 |
| Tschanz, MP | 1 |
| McBee, EC | 1 |
| Harrell, TE | 1 |
| Spalding, BM | 1 |
| Wyatt, CM | 1 |
| Chertow, GM | 1 |
| Fiore Md, LD | 1 |
| Komuro, I | 2 |
| Shiki, K | 2 |
| Ugai, H | 1 |
| Taniguchi, A | 2 |
| Ikeda, H | 3 |
| Kuroki, D | 2 |
| Nishimura, S | 2 |
| Ogihara, T | 4 |
| Corominas, M | 1 |
| Andrés-López, B | 1 |
| Lleonart, R | 1 |
| Hollander, R | 1 |
| Mortier, G | 1 |
| van Hoeck, K | 1 |
| Sukalo, A | 1 |
| Deljo, D | 1 |
| Krupalija, A | 1 |
| Zjajo, N | 1 |
| Kos, S | 1 |
| Curic, A | 1 |
| Divkovic, G | 1 |
| Hubjar, S | 1 |
| Smailagic, M | 1 |
| Hodzic, E | 1 |
| Marjanovic, D | 1 |
| Medjedovic, S | 1 |
| Chazova, IY | 1 |
| Barbič-Žagar, B | 1 |
| Damian, DJ | 1 |
| McNamee, R | 1 |
| Carr, M | 1 |
| Mendes, M | 1 |
| Dubourg, J | 1 |
| Blanchard, A | 1 |
| Bergerot, D | 1 |
| Courand, PY | 1 |
| Frank, M | 1 |
| Bobrie, G | 2 |
| Menard, J | 7 |
| Azizi, M | 2 |
| LeFevre, M | 1 |
| Lee, G | 1 |
| Grassi, G | 5 |
| Seravalle, G | 3 |
| Brambilla, G | 1 |
| Dell'Oro, R | 2 |
| Trevano, FQ | 2 |
| Fici, F | 1 |
| van Bortel, L | 1 |
| Fonseca, J | 1 |
| Oliveira, K | 1 |
| Cordeiro, M | 1 |
| Real, MV | 1 |
| Hwang, AY | 1 |
| Dave, C | 1 |
| Tsioufis, K | 1 |
| Tsioufis, C | 2 |
| Dimitriadis, K | 1 |
| Mantzouranis, E | 1 |
| Mani, I | 1 |
| Tousoulis, D | 1 |
| Wang, Z | 3 |
| Rizzi, F | 1 |
| Barcella, M | 1 |
| Li, Z | 1 |
| Ping, S | 1 |
| Bardeesi, ASA | 1 |
| Guo, Y | 1 |
| Zhou, Y | 3 |
| Pei, T | 1 |
| Deng, L | 1 |
| Sheng, P | 1 |
| Liu, S | 1 |
| Li, C | 1 |
| D'Avino, M | 1 |
| Sala, C | 1 |
| Vulpis, V | 2 |
| Felis, S | 1 |
| Guasti, L | 1 |
| Sarzani, R | 1 |
| Bestetti, A | 1 |
| Vanasia, M | 1 |
| Gaudio, G | 1 |
| Humalda, JK | 1 |
| Seiler-Muler, S | 1 |
| Kwakernaak, AJ | 1 |
| Vervloet, MG | 1 |
| Navis, G | 3 |
| Fliser, D | 1 |
| Heine, GH | 1 |
| de Borst, MH | 1 |
| Polfus, LM | 1 |
| Gibbs, RA | 1 |
| Metcalf, G | 1 |
| Muzny, D | 1 |
| Veeraraghavan, N | 1 |
| Grove, M | 1 |
| Shete, S | 1 |
| Wallace, S | 1 |
| Milewicz, D | 1 |
| Hanchard, N | 1 |
| Lupski, JR | 1 |
| Hashmi, SS | 1 |
| Gupta-Malhotra, M | 1 |
| Rubio-Guerra, AF | 1 |
| Garro-Almendaro, AK | 1 |
| Elizalde-Barrera, CI | 1 |
| Suarez-Cuenca, JA | 1 |
| Duran-Salgado, MB | 1 |
| Chen, Z | 1 |
| Hao, G | 1 |
| Ma, L | 3 |
| Zhu, M | 1 |
| Ferket, BS | 1 |
| Hunink, MG | 1 |
| Khanji, M | 1 |
| Agarwal, I | 1 |
| Fleischmann, KE | 1 |
| Petersen, SE | 1 |
| Asil, S | 1 |
| Atalar, E | 1 |
| Matsushima, T | 1 |
| Nakajima, H | 1 |
| Ohko, K | 1 |
| Nakajima, K | 2 |
| Sano, S | 1 |
| Chow, CK | 1 |
| Thakkar, J | 1 |
| Bennett, A | 1 |
| Hillis, G | 1 |
| Burke, M | 1 |
| Vo, K | 1 |
| Rogers, K | 1 |
| Atkins, E | 1 |
| Chou, M | 1 |
| Dehbi, HM | 1 |
| Krum, H | 2 |
| Chalmers, J | 3 |
| Nelson, M | 1 |
| Woodward, M | 1 |
| Hilmer, S | 1 |
| Cirri, M | 1 |
| Mennini, N | 1 |
| Maestrelli, F | 1 |
| Mura, P | 1 |
| Ghelardini, C | 1 |
| Di Cesare Mannelli, L | 1 |
| Xue, C | 1 |
| Zhou, C | 1 |
| Yang, B | 1 |
| Lv, J | 1 |
| Dai, B | 1 |
| Yu, S | 1 |
| Zhao, G | 1 |
| Mei, C | 1 |
| Malacco, E | 12 |
| Napoli, C | 1 |
| de Almeida, CL | 1 |
| Somensi, LB | 1 |
| Steimbach, VM | 1 |
| Delle Monache, F | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Tardif, JC | 2 |
| Curnew, GP | 1 |
| Leclerc, JM | 2 |
| Rehel, B | 2 |
| Ferguson, JM | 1 |
| Minas, J | 1 |
| Siapantas, S | 1 |
| Komesaroff, PA | 1 |
| Sudhir, K | 1 |
| Ageev, FT | 1 |
| Drobizhev, MB | 1 |
| Smirnova, MD | 1 |
| Fofanova, TV | 1 |
| Plisiuk, AG | 1 |
| Kadushkina, EB | 1 |
| Smith, DH | 4 |
| Scott, LJ | 3 |
| McCormack, PL | 1 |
| Samuel, R | 15 |
| Purkayastha, D | 16 |
| Einecke, D | 1 |
| Velazquez, EJ | 6 |
| Gupte, J | 4 |
| Staikos, L | 1 |
| Hua, TA | 5 |
| Shi, V | 6 |
| Tuomilehto, J | 19 |
| Ibsen, H | 20 |
| Aumiller, J | 1 |
| Croxtall, JD | 1 |
| Keating, GM | 3 |
| Fridley, BL | 1 |
| Chai, HS | 2 |
| Sicotte, H | 1 |
| Kocher, JP | 1 |
| Rodin, AS | 1 |
| Pettyjohn, FS | 1 |
| Coenen, PD | 1 |
| Grosso, A | 1 |
| Schrader, J | 3 |
| Lüders, S | 2 |
| Diener, HC | 1 |
| Haller, H | 2 |
| Wahle, K | 2 |
| Smolka, W | 4 |
| Jung, C | 4 |
| Bestehorn, K | 5 |
| Porthan, K | 1 |
| Viitasalo, M | 2 |
| Vaananen, H | 1 |
| Dabek, J | 1 |
| Suonsyrja, T | 4 |
| Hannila-Handelberg, T | 4 |
| Virolainen, J | 2 |
| Nieminen, MS | 4 |
| Toivonen, L | 2 |
| Oikarinen, L | 2 |
| Waeber, B | 7 |
| Mourad, JJ | 2 |
| Ekman, M | 2 |
| Bienfait-Beuzon, C | 1 |
| Jackson, J | 1 |
| Nash, DT | 5 |
| Tykarski, A | 3 |
| Baumgart, P | 7 |
| Reimund, B | 1 |
| Le Breton, S | 2 |
| Ferber, P | 5 |
| Plosker, GL | 3 |
| Saklayen, MG | 1 |
| Sun, NL | 4 |
| Zhu, JR | 3 |
| Tu, YM | 1 |
| Edwards, C | 2 |
| Schoenberger, JA | 7 |
| Ramsay, LE | 5 |
| Yeo, WW | 2 |
| Jackson, KC | 1 |
| Sheng, X | 1 |
| Nelson, RE | 1 |
| Keskinaslan, A | 1 |
| Brixner, DI | 2 |
| Gerc, V | 2 |
| Begović, B | 2 |
| Vehabović, M | 2 |
| Georgievich Voronkov, L | 1 |
| Vataman, E | 2 |
| Musić, L | 2 |
| Buksa, M | 2 |
| Kusljugić, Z | 2 |
| Baraković, F | 1 |
| Iosifovna Tchelujko, V | 1 |
| Ivanovich Dyaduk, A | 1 |
| Alekseevna Andrievskaja, S | 1 |
| Eduardovich Bagrij, A | 1 |
| Nikolaevich Polivoda, S | 1 |
| Lazarević, A | 1 |
| Knezević, B | 2 |
| Hima, F | 2 |
| Sowers, JR | 17 |
| Lastra, G | 1 |
| Rocha, R | 4 |
| Seifu, Y | 1 |
| Levy, DG | 1 |
| Feitosa, AD | 1 |
| Ribeiro, JM | 1 |
| Moriguchi, EH | 2 |
| Saraiva, JF | 1 |
| Précoma, DB | 1 |
| Ribeiro, AB | 3 |
| Amodeo, C | 1 |
| Brandão, AA | 2 |
| Guerrero, P | 1 |
| Moreira, LM | 1 |
| Bertoluci, C | 1 |
| Gus, M | 1 |
| Pavlicević, I | 1 |
| Kuzmanić, M | 1 |
| Rumboldt, M | 1 |
| Rumboldt, Z | 1 |
| Eriksson, JW | 2 |
| Jansson, PA | 2 |
| Carlberg, B | 2 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 2 |
| Schönrock, E | 3 |
| Odoj, P | 3 |
| Fan, X | 2 |
| Han, Y | 2 |
| Sun, K | 4 |
| Xin, Y | 1 |
| Bai, Y | 1 |
| Li, W | 2 |
| Yang, T | 1 |
| Song, X | 1 |
| Fu, C | 1 |
| Shi, Y | 2 |
| Hui, R | 4 |
| Velasquez, E | 1 |
| Staikos-Byrne, L | 2 |
| Chobanian, AV | 1 |
| Gatlin, M | 2 |
| Chen, SX | 1 |
| Chen, SL | 1 |
| Chen, JZ | 2 |
| Yan, XW | 1 |
| Ke, YN | 2 |
| DU, FH | 1 |
| Zhang, CZ | 1 |
| Qin, YW | 1 |
| Pu, K | 1 |
| Heagerty, AM | 3 |
| Mallion, JM | 5 |
| Hsueh, WA | 3 |
| Haffner, SM | 1 |
| Deedwania, PC | 3 |
| Fonseca, VA | 1 |
| Keeling, L | 1 |
| Kereiakes, D | 1 |
| Xu, J | 4 |
| Chavanu, KJ | 3 |
| Waverczak, W | 1 |
| Dubiel, R | 6 |
| Carter, BL | 5 |
| Basile, JN | 1 |
| Elliott, WJ | 8 |
| Grimm, RH | 6 |
| WU, SL | 7 |
| DU, X | 1 |
| XING, AJ | 1 |
| SONG, SM | 2 |
| HOU, GS | 2 |
| YU, Q | 2 |
| LIU, FS | 2 |
| WANG, GL | 2 |
| WANG, LG | 2 |
| LI, DX | 1 |
| CAO, ZX | 1 |
| QI, RP | 1 |
| Philipp, T | 8 |
| Guerediaga, J | 2 |
| Gorostidi, M | 3 |
| Smith, B | 2 |
| Weissbach, N | 1 |
| Maboudian, M | 1 |
| Botha, J | 3 |
| van Ingen, H | 1 |
| Vormfelde, SV | 1 |
| Toliat, MR | 1 |
| Nürnberg, P | 1 |
| Brockmöller, J | 1 |
| Bangalore, S | 3 |
| Flack, JM | 6 |
| Satlin, L | 1 |
| Barbier, M | 2 |
| Hilkert, R | 2 |
| Bönner, G | 5 |
| Nickenig, G | 1 |
| Simanenkov, V | 1 |
| Lembo, G | 1 |
| Rodriguez, P | 1 |
| Salko, T | 1 |
| Ritter, S | 2 |
| Feihl, F | 1 |
| Cohen, DL | 1 |
| Townsend, RR | 3 |
| Claassen, JA | 2 |
| Zhang, R | 3 |
| Fadel, S | 1 |
| Karmali, R | 1 |
| Cogan, E | 1 |
| Blumenstein, M | 1 |
| Romaszko, J | 1 |
| Calderón, A | 2 |
| Andersen, K | 2 |
| Ibram, G | 1 |
| Liu, Z | 1 |
| Minami, J | 4 |
| Furukata, S | 2 |
| Ishimitsu, T | 4 |
| Preobrazhenskiĭ, DV | 2 |
| Uzu, T | 2 |
| Sakaguchi, M | 1 |
| Yokomaku, Y | 1 |
| Kume, S | 1 |
| Kanasaki, M | 1 |
| Isshiki, K | 1 |
| Araki, SI | 1 |
| Sugiomoto, T | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Parra, D | 1 |
| Rosenstein, R | 1 |
| Strauss, MH | 1 |
| Weinstein, J | 2 |
| Newton, GE | 1 |
| Davis, BR | 1 |
| Düsing, R | 2 |
| Handrock, R | 4 |
| Tousset, E | 2 |
| Vrijens, B | 1 |
| Turnbull, F | 1 |
| Roca-Cusachs, A | 3 |
| Wenzel, RR | 2 |
| Makita, S | 1 |
| Abiko, A | 1 |
| Naganuma, Y | 1 |
| Tamada, M | 1 |
| Nakamura, M | 1 |
| Shrank, WH | 1 |
| Choudhry, NK | 1 |
| Solomon, DH | 1 |
| Snedden, TM | 1 |
| Lee, TH | 3 |
| Glynn, RJ | 5 |
| Brown, TV | 1 |
| Jolda, C | 1 |
| Spetman, M | 1 |
| Brookhart, MA | 1 |
| Schneeweiss, S | 1 |
| Avorn, J | 2 |
| Sureshkumar, KK | 1 |
| Ferrari, I | 1 |
| Davidai, G | 5 |
| Edes, I | 1 |
| Wright, JT | 9 |
| Black, HR | 10 |
| Kim, KS | 2 |
| Fan, WH | 1 |
| Kim, YD | 1 |
| Zhu, W | 1 |
| Ngau, YY | 1 |
| Tong, P | 1 |
| Santos, M | 1 |
| Lin, WH | 1 |
| Buranakitjaroen, P | 1 |
| Massaad, R | 1 |
| Smith, RD | 3 |
| Miele, C | 1 |
| Baguet, JP | 1 |
| Asmar, R | 5 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Baldwin, CM | 1 |
| Bush, C | 1 |
| Keefe, DL | 6 |
| Karlson, BW | 1 |
| Zetterstrand, S | 1 |
| Olofsson, B | 4 |
| Elmfeldt, D | 7 |
| Chiang, YT | 5 |
| Pareek, A | 2 |
| Basavanagowdappa, H | 1 |
| Zawar, S | 1 |
| Kumar, A | 1 |
| Chandurkar, N | 1 |
| Geiger, H | 1 |
| Barranco, E | 1 |
| Taylor, A | 1 |
| Xiang, Z | 1 |
| Koh-Tan, HH | 1 |
| Graham, D | 3 |
| Hamilton, CA | 2 |
| Nicoll, G | 1 |
| Fields, L | 1 |
| McBride, MW | 1 |
| Young, B | 1 |
| Lapuerta, P | 6 |
| Franklin, S | 2 |
| Ratova, LG | 3 |
| Chung, WY | 1 |
| Zo, JH | 1 |
| Kim, MA | 1 |
| Chang, HJ | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Gwak, JJ | 1 |
| Park, JS | 1 |
| Kang, HJ | 1 |
| Kim, HS | 1 |
| McAdam-Marx, C | 1 |
| Ye, X | 1 |
| Sung, JC | 1 |
| Ekinci, EI | 2 |
| Thomas, G | 2 |
| Thomas, D | 1 |
| Johnson, C | 2 |
| Macisaac, RJ | 2 |
| Houlihan, CA | 1 |
| Finch, S | 2 |
| Panagiotopoulos, S | 2 |
| O'Callaghan, C | 3 |
| Jerums, G | 3 |
| Campbell, K | 1 |
| Schmidt, S | 1 |
| Mantel, K | 1 |
| Siragy, HM | 1 |
| Weingärtner, O | 1 |
| Borthen, C | 1 |
| Oglaend, B | 1 |
| Eggebøe, T | 1 |
| Ellingsen, CL | 1 |
| Schjøtt, J | 1 |
| Abe, M | 4 |
| Okada, K | 5 |
| Maruyama, T | 3 |
| Matsumoto, K | 4 |
| Tsareva, VM | 1 |
| Khoziainova, NIu | 1 |
| Ivleva, AIa | 2 |
| Andreevskaia, EM | 1 |
| Burkov, SG | 1 |
| Zawar, SD | 1 |
| Salagre, SB | 1 |
| Karnik, ND | 1 |
| Matsui, Y | 3 |
| O'Rourke, MF | 3 |
| Ishikawa, J | 3 |
| Miyashita, H | 1 |
| Reichek, N | 3 |
| Rocha, RA | 1 |
| Hall, D | 2 |
| Kondrack, R | 1 |
| Mohiuddin, S | 1 |
| Araki, S | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| Sunagawa, K | 1 |
| Kinouchi, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Itoh, H | 1 |
| Pavithran, P | 1 |
| Prakash, ES | 1 |
| Dutta, TK | 1 |
| Madanmohan, T | 1 |
| Anderson, SD | 1 |
| Wen, S | 2 |
| Feng, H | 1 |
| Bubnova, MG | 1 |
| Oganov, RG | 2 |
| Kusumoto, K | 1 |
| Mori, M | 1 |
| Tanokashira, J | 1 |
| Totsuka, N | 1 |
| Zhou, Q | 6 |
| Champion, A | 4 |
| Schmidlin, O | 1 |
| Tanaka, M | 3 |
| Sebastian, A | 2 |
| Morris, RC | 1 |
| Franklin, SS | 4 |
| Bhaumik, A | 4 |
| Pool, JL | 8 |
| Glazer, R | 6 |
| Levy, D | 3 |
| Papst, CC | 2 |
| Handberg, EM | 2 |
| Legler, UF | 1 |
| Bailey, J | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Zineh, I | 1 |
| van Onzenoort, HA | 2 |
| Verberk, WJ | 2 |
| Kessels, AG | 2 |
| Kroon, AA | 2 |
| Neef, C | 2 |
| van der Kuy, PH | 2 |
| de Leeuw, PW | 10 |
| Deeks, ED | 2 |
| Armanini, D | 1 |
| Fiore, C | 1 |
| Nelemans, PJ | 1 |
| Poirier, L | 12 |
| Ogunyankin, KO | 1 |
| Day, AG | 1 |
| Schwertfeger, M | 1 |
| Palmer, BF | 1 |
| El-Haddad, B | 1 |
| Hammoud, D | 1 |
| Shaver, T | 1 |
| Shahouri, S | 1 |
| Westermann, D | 1 |
| Savvatis, K | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 2 |
| Crikelair, NA | 2 |
| Yen, J | 4 |
| Petrov, VI | 1 |
| Epshtein, OI | 1 |
| Sergeeva, SA | 1 |
| Bakumov, PA | 1 |
| Zernyukova, EA | 1 |
| Zabolotneva, YA | 1 |
| Kachanova, MV | 1 |
| Sabanov, LB | 1 |
| Mengden, T | 5 |
| Uen, S | 3 |
| Kita, T | 2 |
| Yokota, N | 2 |
| Ichiki, Y | 2 |
| Ayabe, T | 2 |
| Etoh, T | 2 |
| Tamaki, N | 2 |
| Kato, J | 2 |
| Eto, T | 2 |
| Kitamura, K | 2 |
| Waverczak, WF | 2 |
| Stoakes, KA | 2 |
| Zheng, S | 1 |
| Racine, N | 1 |
| Hamet, P | 1 |
| Sampalis, JS | 1 |
| Longo, N | 1 |
| Bastien, N | 1 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 4 |
| Sarafidis, PA | 1 |
| Weinberger, MH | 8 |
| Kontny, F | 1 |
| Risanger, T | 1 |
| Bye, A | 1 |
| Arnesen, Ø | 1 |
| Johansen, OE | 1 |
| Matsumoto, S | 1 |
| Karki, S | 1 |
| Revera, M | 1 |
| Giuliano, A | 1 |
| Veglia, F | 2 |
| Crepaldi, G | 2 |
| Zanchetti, A | 24 |
| Wray, DW | 1 |
| Supiano, MA | 2 |
| Houlihan, C | 1 |
| Premaratne, E | 1 |
| Hao, H | 1 |
| Agrawal, SS | 1 |
| Aggarwal, A | 1 |
| Edelman, JM | 2 |
| Sun, ZQ | 1 |
| Zheng, LQ | 1 |
| Zhang, DY | 1 |
| Zhang, XZ | 1 |
| Zhang, XG | 1 |
| Liu, SS | 1 |
| Xu, CL | 1 |
| Hu, DY | 1 |
| Sun, YX | 1 |
| Destro, M | 3 |
| Cagnoni, F | 1 |
| D'Ospina, A | 1 |
| Ricci, AR | 1 |
| Demichele, E | 1 |
| Peros, E | 1 |
| Zaninelli, A | 2 |
| Preti, P | 9 |
| Maniadakis, N | 1 |
| Fragoulakis, V | 1 |
| Papagiannopoulou, V | 1 |
| Yfantopoulos, J | 1 |
| Osmond, JM | 1 |
| Mintz, JD | 1 |
| Stepp, DW | 1 |
| Zhang, Y | 8 |
| Deng, Q | 2 |
| Liu, M | 2 |
| Kooter, AJ | 1 |
| Smulders, YM | 1 |
| Arif, AF | 1 |
| Kadam, GG | 1 |
| Joshi, C | 1 |
| Cakir, M | 1 |
| Raij, L | 4 |
| Jialal, I | 1 |
| Egan, BM | 3 |
| Ofili, EO | 5 |
| Eladari, D | 1 |
| Chambrey, R | 1 |
| Leviel, F | 1 |
| Ferreira, O | 1 |
| Mota, A | 1 |
| Morais, P | 1 |
| Cunha, AP | 1 |
| Azevedo, F | 1 |
| Kithas, PA | 1 |
| Mendis, S | 1 |
| Johnston, SC | 1 |
| Fan, W | 1 |
| Oladapo, O | 1 |
| Cameron, A | 1 |
| Faramawi, MF | 1 |
| Ambrosioni, E | 17 |
| Bombelli, M | 2 |
| Cerasola, G | 1 |
| Cipollone, F | 1 |
| Grazioli, I | 1 |
| Leprotti, C | 1 |
| Melzi, G | 1 |
| Mulè, G | 1 |
| Palasciano, G | 1 |
| Salvetti, A | 3 |
| Zheng, Z | 1 |
| Lin, S | 1 |
| Shi, H | 1 |
| Holm-Bentzen, M | 1 |
| Baszak, J | 1 |
| Melani, L | 1 |
| Schumacher, K | 1 |
| Weir, M | 2 |
| MacDonald, K | 2 |
| Lee, CS | 1 |
| Chen, HC | 1 |
| Ko, ML | 1 |
| Fidel, GE | 1 |
| Brié, H | 2 |
| Hermans, C | 2 |
| Vancayzeele, S | 2 |
| Reel, S | 1 |
| Van der Niepen, P | 1 |
| Abraham, I | 2 |
| Marazzi, G | 2 |
| Volterrani, M | 3 |
| Caminiti, G | 1 |
| Iaia, L | 1 |
| Cacciotti, L | 1 |
| Massaro, R | 1 |
| Sposato, B | 1 |
| Vitale, C | 3 |
| Mercuro, G | 1 |
| Rosano, G | 1 |
| Sellin, L | 4 |
| Hu, ZP | 1 |
| Wang, BN | 1 |
| Qian, HY | 1 |
| Wei, W | 1 |
| Neutel, J | 4 |
| Kabutoya, T | 2 |
| Bhad, P | 1 |
| Ayalasomayajula, S | 1 |
| Karan, R | 1 |
| Leon, S | 1 |
| Riviere, GJ | 1 |
| Sunkara, G | 1 |
| Jarugula, V | 2 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 2 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Kuriyama, S | 3 |
| Otsuka, Y | 2 |
| Ueda, H | 2 |
| Sugano, N | 2 |
| Yoshizawa, T | 3 |
| Yamada, T | 2 |
| Hosoya, T | 3 |
| Kinoshita, H | 1 |
| Kobayashi, K | 4 |
| Yaguramaki, T | 1 |
| Yasuda, M | 1 |
| Fujiki, K | 1 |
| Tomiyama, J | 1 |
| Koga, N | 1 |
| Yakushiji, F | 1 |
| Ortega, KC | 3 |
| Gusmão, JL | 1 |
| Pierin, AM | 1 |
| Nishiura, JL | 1 |
| Ignez, EC | 1 |
| Segre, CA | 1 |
| Ventura, CG | 1 |
| Mano, GP | 1 |
| Fontes, V | 1 |
| Cunha, FM | 1 |
| Mion, D | 3 |
| Murray, AV | 3 |
| Hoppe, UC | 2 |
| Dattani, D | 2 |
| Patel, S | 3 |
| Okano, Y | 1 |
| Yabana, M | 1 |
| Wilford Germino, F | 1 |
| Volkov, VS | 2 |
| Nilova, SA | 1 |
| Poseliugina, OB | 1 |
| Tripodi, G | 1 |
| Ferrandi, M | 3 |
| Messaggio, E | 1 |
| Macciardi, F | 2 |
| Valentini, G | 1 |
| Ferrari, P | 5 |
| Bianchi, G | 7 |
| Martinez-Martin, FJ | 1 |
| Rodriguez-Rosas, H | 1 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 1 |
| Pedrianes-Martin, P | 1 |
| Comi-Diaz, C | 1 |
| Girerd, X | 8 |
| Stegbauer, J | 2 |
| Pilu, A | 1 |
| Porteri, E | 1 |
| Belotti, E | 2 |
| Zani, F | 1 |
| Boari, GE | 1 |
| Schweizer, J | 2 |
| Ulmer, HJ | 1 |
| Benduhn, H | 1 |
| Andalib, A | 1 |
| Akhtari, S | 1 |
| Rigal, R | 1 |
| Curnew, G | 1 |
| Vaillancourt, M | 1 |
| Kribben, A | 1 |
| Aguirre Palacios, F | 1 |
| Bijarnia, M | 1 |
| Laflamme, AK | 1 |
| Baschiera, F | 2 |
| Hirose, H | 1 |
| Kawabe, H | 1 |
| Saito, I | 1 |
| Kang, KT | 1 |
| Spradley, FT | 1 |
| d'Uscio, LV | 1 |
| Katusic, ZS | 1 |
| Gasparotto Junior, A | 1 |
| Gasparotto, FM | 1 |
| Boffo, MA | 1 |
| Lourenço, EL | 1 |
| Stefanello, MÉ | 1 |
| Salvador, MJ | 1 |
| da Silva-Santos, JE | 1 |
| Marques, MC | 1 |
| Kassuya, CA | 1 |
| Han, YF | 1 |
| Fan, XH | 1 |
| Wang, XJ | 1 |
| Xue, H | 1 |
| Li, WJ | 1 |
| Wang, YB | 1 |
| Zhen, YS | 1 |
| Zhang, WL | 1 |
| Ram, CV | 8 |
| Lin, JY | 1 |
| Moens, AL | 1 |
| Yang, P | 3 |
| Niu, JQ | 1 |
| Zhao, DD | 2 |
| Makani, H | 2 |
| Benjo, A | 1 |
| Romero, J | 1 |
| Alviar, C | 1 |
| Hannan, JL | 2 |
| Blaser, MC | 1 |
| Pang, JJ | 1 |
| Adams, SM | 1 |
| Pang, SC | 1 |
| Adams, MA | 3 |
| Nemati, F | 1 |
| Rahbar-Roshandel, N | 1 |
| Hosseini, F | 1 |
| Mahmoudian, M | 1 |
| Shafiei, M | 1 |
| Palming, J | 1 |
| Renström, F | 1 |
| Johansson, A | 1 |
| Karlsson, C | 1 |
| Aggiusti, C | 1 |
| Scotti, A | 2 |
| Basile, J | 1 |
| Babazadeh, S | 1 |
| Lillestol, M | 1 |
| Yurkovic, C | 1 |
| Weitzman, R | 2 |
| Makris, T | 1 |
| Stefanadis, C | 1 |
| Nesbitt, S | 2 |
| Dorsch, MP | 1 |
| Gillespie, BW | 1 |
| Erickson, SR | 1 |
| Bleske, BE | 1 |
| Weder, AB | 2 |
| McInnes, GT | 4 |
| Kostka-Jeziorny, K | 1 |
| Uruski, P | 1 |
| Landers, B | 1 |
| Zeng, J | 1 |
| Jia, M | 1 |
| Ran, H | 1 |
| Yang, C | 1 |
| Zeng, C | 1 |
| Yamada, Y | 2 |
| Tsuboi, K | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Ohtake, M | 1 |
| Furukawa, M | 1 |
| Ueyama, J | 1 |
| Murohara, T | 3 |
| Nagata, K | 1 |
| Ndu, OO | 1 |
| Nworu, CS | 1 |
| Ehiemere, CO | 1 |
| Ndukwe, NC | 1 |
| Ochiogu, IS | 1 |
| Lai, WT | 1 |
| Park, JE | 1 |
| Dongre, N | 1 |
| Odili, AN | 2 |
| Richart, T | 1 |
| Kamdem, MK | 1 |
| Aderibigbe, A | 1 |
| Sachson, R | 1 |
| Littlejohn, T | 4 |
| Qian, C | 2 |
| Pool, J | 2 |
| Townsend, R | 2 |
| Bamias, A | 1 |
| Manios, E | 1 |
| Karadimou, A | 1 |
| Michas, F | 1 |
| Lainakis, G | 1 |
| Constantinidis, C | 1 |
| Deliveliotis, C | 1 |
| Zakopoulos, N | 3 |
| Dimopoulos, MA | 1 |
| Halpern, D | 1 |
| Circelli, M | 1 |
| Cremonesi, G | 2 |
| Yuan, J | 1 |
| Zhao, D | 2 |
| Ren, Q | 1 |
| Feng, F | 1 |
| Guan, W | 1 |
| Sakima, A | 2 |
| Ohshiro, K | 2 |
| Nakada, S | 2 |
| Yamazato, M | 2 |
| Kohagura, K | 2 |
| Nakamoto, M | 1 |
| Tana, T | 2 |
| Ohya, Y | 2 |
| Nesbitt, SD | 2 |
| Littlejohn, TJ | 1 |
| Graff, A | 3 |
| Jones, CJ | 1 |
| Yan, JH | 1 |
| Sabo, R | 1 |
| Dole, WP | 2 |
| Hu, Y | 1 |
| Tang, X | 2 |
| He, L | 1 |
| Ren, T | 1 |
| Tao, Q | 1 |
| Qin, X | 1 |
| Cao, W | 1 |
| Wu, T | 1 |
| Zhan, S | 1 |
| Li, L | 1 |
| Zhen, Y | 1 |
| Zhang, W | 1 |
| Bains, J | 1 |
| Smith, WB | 1 |
| Mitsutake, R | 3 |
| Duprez, DA | 3 |
| Weintraub, HS | 3 |
| Lerma, EV | 1 |
| Ohno, E | 1 |
| Nakano, N | 1 |
| Akashiba, A | 2 |
| Numabe, A | 2 |
| Wright, RF | 1 |
| Duprez, D | 2 |
| Kamura, A | 1 |
| Kuroki, S | 1 |
| Ishida, S | 1 |
| Iimori, K | 1 |
| Naitoh, H | 1 |
| Tamesue, S | 1 |
| Hermida, RC | 1 |
| Ayala, DE | 1 |
| Mojón, A | 1 |
| Fontao, MJ | 1 |
| Fernández, JR | 1 |
| Narkiewicz, K | 1 |
| Hong, BK | 1 |
| Lee, BK | 1 |
| Lee, SH | 1 |
| Jeon, DW | 1 |
| Kim, D | 1 |
| Park, CK | 1 |
| Jung, HO | 1 |
| Kim, BO | 1 |
| Choi, D | 1 |
| Drummond, W | 1 |
| Ramos, E | 1 |
| Baek, I | 1 |
| Jacobs, Ú | 1 |
| De Castro, MS | 1 |
| Ferreira, MB | 1 |
| Rajzer, M | 1 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 4 |
| Undas, A | 1 |
| Lins, R | 2 |
| Coen, N | 1 |
| Aerts, A | 1 |
| Shen, YM | 1 |
| Lee, C | 1 |
| Mecum, N | 1 |
| Slany, J | 1 |
| Nirnberger, G | 1 |
| Pittrow, LA | 1 |
| Khan, M | 1 |
| Khan, RA | 1 |
| Islam, F | 1 |
| Laghari, J | 1 |
| Jamali, SN | 1 |
| Walsh, SB | 1 |
| McCormick, JA | 1 |
| Fürstenberg, A | 1 |
| Yang, CL | 1 |
| Roeschel, T | 1 |
| Paliege, A | 1 |
| Howie, AJ | 1 |
| Conley, J | 1 |
| Bachmann, S | 1 |
| Unwin, RJ | 1 |
| Ellison, DH | 1 |
| Shang, D | 1 |
| Huang, F | 1 |
| Tian, G | 1 |
| Lu, W | 1 |
| Zhou, T | 1 |
| Suzuki, O | 1 |
| Ishii, H | 1 |
| Kasayuki, N | 1 |
| Nakamura, F | 1 |
| Fukuda, S | 2 |
| Neaton, JD | 2 |
| Collins, G | 1 |
| Thomas, W | 1 |
| Soliman, EZ | 1 |
| Prineas, RJ | 1 |
| Pinilla, A | 1 |
| Cano, N | 1 |
| Granados, C | 1 |
| Paez-Canro, C | 1 |
| Eslava-Schmalbach, J | 1 |
| Breitscheidel, L | 1 |
| Ehlken, B | 1 |
| Kostev, K | 1 |
| Oberdiek, MS | 1 |
| Sandberg, A | 1 |
| Gradman, AH | 4 |
| Lederballe, O | 2 |
| Kolloch, RE | 6 |
| Sacco, G | 1 |
| Manzini, S | 1 |
| Parlani, M | 1 |
| Bigioni, M | 1 |
| Shimizu, R | 1 |
| Miyazaki, M | 1 |
| Iwanaga, K | 1 |
| Kakemi, M | 1 |
| Iellamo, F | 2 |
| Spoletini, I | 1 |
| Dall'Armi, V | 1 |
| Fini, M | 1 |
| Rosenbaum, D | 2 |
| Ohno, I | 2 |
| Kawamura, T | 1 |
| Ogura, M | 1 |
| Ikeda, M | 1 |
| Ishikawa, M | 1 |
| Hayashi, F | 1 |
| Kanai, T | 1 |
| Tomonari, H | 1 |
| Soejima, M | 1 |
| Akaba, K | 1 |
| Tokudome, G | 1 |
| Endo, S | 1 |
| Fukui, A | 1 |
| Gomi, H | 1 |
| Hamaguchi, A | 1 |
| Hara, Y | 2 |
| Hayakawa, H | 1 |
| Hikida, M | 1 |
| Hirano, K | 1 |
| Horiguchi, M | 1 |
| Hosoya, M | 1 |
| Ichida, K | 1 |
| Imai, T | 1 |
| Ishii, T | 1 |
| Ishikawa, H | 1 |
| Kameda, C | 1 |
| Kasai, T | 1 |
| Kobayashi, A | 2 |
| Kobayashi, H | 1 |
| Kurashige, M | 1 |
| Kusama, Y | 1 |
| Maezawa, H | 1 |
| Maezawa, Y | 1 |
| Maruyama, Y | 1 |
| Matsuda, H | 1 |
| Matsuo, N | 1 |
| Matsuo, T | 1 |
| Miura, Y | 2 |
| Miyajima, M | 1 |
| Miyakawa, M | 1 |
| Miyazaki, Y | 1 |
| Mizuguchi, M | 1 |
| Nakao, M | 1 |
| Nokano, H | 1 |
| Ohkido, I | 1 |
| Ohtsuka, Y | 1 |
| Okamoto, H | 1 |
| Okonogi, H | 1 |
| Saikawa, H | 1 |
| Saito, H | 1 |
| Sekiguchi, C | 1 |
| Suetsugu, Y | 1 |
| Suzuki, T | 3 |
| Takahashi, Y | 2 |
| Takamizawa, S | 1 |
| Takane, K | 1 |
| Morita, T | 1 |
| Takazoe, K | 1 |
| Tanaka, H | 1 |
| Tanaka, S | 1 |
| Terawaki, H | 1 |
| Toyoshima, R | 1 |
| Tsuboi, N | 1 |
| Udagawa, T | 1 |
| Uetake, M | 1 |
| Unemura, S | 1 |
| Utsunomiya, M | 1 |
| Utsunomiya, Y | 1 |
| Yamaguchi, Y | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Yokoyama, K | 2 |
| Yonezawa, H | 1 |
| Yoshida, H | 1 |
| Yoshida, M | 1 |
| Christogiannis, LG | 1 |
| Kostapanos, MS | 1 |
| Tellis, CC | 1 |
| Milionis, HJ | 2 |
| Tselepis, AD | 1 |
| Elisaf, MS | 3 |
| Fujimori, S | 1 |
| Oka, Y | 1 |
| Ogata, N | 1 |
| Eto, K | 2 |
| Rosendorff, C | 4 |
| Littlejohn Iii, T | 1 |
| Forker, AD | 1 |
| Bhosekar, V | 1 |
| Yadao, A | 1 |
| Riem, L | 1 |
| Ferdinand, K | 3 |
| Wright, R | 1 |
| Meno, H | 2 |
| Inou, T | 2 |
| Tsuchiya, Y | 2 |
| Nakamura, Y | 3 |
| Ota, T | 2 |
| Kubara, I | 2 |
| Hester, RA | 1 |
| Celik, T | 1 |
| Yilmaz, MI | 1 |
| Dussol, B | 2 |
| Moussi-Frances, J | 2 |
| Morange, S | 2 |
| Somma-Delpero, C | 2 |
| Mundler, O | 2 |
| Berland, Y | 2 |
| Hübner, R | 1 |
| Tsuji, RL | 1 |
| Silva, GV | 1 |
| Berwanger, O | 1 |
| Mion Júnior, D | 2 |
| Wagner, F | 1 |
| Malice, MP | 1 |
| Wiegert, E | 1 |
| McGrath, HE | 1 |
| Gildea, J | 1 |
| Mitta, S | 1 |
| Van Dyck, K | 1 |
| De Lepeleire, I | 1 |
| Johnson-Levonas, AO | 1 |
| Sisk, CM | 1 |
| Fernandez, R | 3 |
| Greenwalt, DM | 1 |
| Beals, C | 1 |
| Nunes, I | 1 |
| Koc, Y | 1 |
| Mazi, E | 1 |
| Sakaci, T | 1 |
| Basturk, T | 1 |
| Damar, AB | 1 |
| Ahbap, E | 1 |
| Unsal, A | 1 |
| Borlu, F | 1 |
| Manukhin, IB | 1 |
| Markova, EV | 1 |
| Markova, LI | 1 |
| Striuk, RI | 1 |
| Trenkwalder, P | 8 |
| Yuan, JX | 1 |
| Zhao, LP | 1 |
| Sun, MJ | 1 |
| Chu, LM | 1 |
| Lu, DS | 1 |
| Kountz, DS | 1 |
| Goldman, A | 1 |
| Mikhail, J | 1 |
| Ezer, M | 1 |
| Sun, H | 1 |
| Duarte, JD | 1 |
| Tran, B | 1 |
| Aoun, J | 1 |
| Perrone, T | 1 |
| Khan, BV | 2 |
| Rahman, ST | 2 |
| Haque, T | 1 |
| Merchant, N | 1 |
| Bhaheetharan, S | 1 |
| Harris, J | 1 |
| Umar, K | 1 |
| Wahi, J | 1 |
| Judd, E | 1 |
| Jaimes, EA | 2 |
| Yang, WX | 1 |
| Zhao, ZG | 1 |
| Wang, LH | 1 |
| Yu, SJ | 1 |
| Liang, ZS | 1 |
| Hajjar, I | 1 |
| Hart, M | 1 |
| Chen, YL | 1 |
| Mack, W | 1 |
| Milberg, W | 1 |
| Chui, H | 1 |
| Lipsitz, L | 1 |
| Whaley-Connell, A | 1 |
| Arimura, T | 1 |
| Saura, H | 1 |
| Ogasawara, K | 1 |
| Kuroda, H | 1 |
| Yamashita, T | 1 |
| Kobayashi, M | 1 |
| Terasaki, K | 1 |
| Ogawa, A | 1 |
| Greathouse, MK | 1 |
| Fujiwara, W | 1 |
| Izawa, H | 1 |
| Ukai, G | 1 |
| Yokoi, H | 1 |
| Mukaide, D | 1 |
| Kinoshita, K | 1 |
| Morimoto, S | 2 |
| Ishii, J | 1 |
| Ozaki, Y | 1 |
| Nomura, M | 1 |
| Miyagawa, S | 1 |
| Yamada, H | 1 |
| Matsubara, H | 1 |
| Guthrie, R | 5 |
| Wu, ZB | 1 |
| Yu, QG | 1 |
| Sun, CX | 1 |
| Tao, CW | 1 |
| Stears, AJ | 1 |
| Woods, SH | 1 |
| Watts, MM | 1 |
| Burton, TJ | 1 |
| Graggaber, J | 1 |
| Mir, FA | 1 |
| Cheng, XW | 1 |
| Murphy, SR | 1 |
| Dahly-Vernon, AJ | 1 |
| Dunn, KM | 1 |
| Chen, CC | 1 |
| Ledbetter, SR | 1 |
| Roman, RJ | 1 |
| Peterzan, MA | 1 |
| Hardy, R | 1 |
| Chaturvedi, N | 1 |
| Hughes, AD | 2 |
| Beck, AL | 1 |
| Otto, ME | 1 |
| D'Avila, LB | 1 |
| Netto, FM | 1 |
| Armendaris, MK | 1 |
| Sposito, AC | 1 |
| Ashek, A | 1 |
| Menzies, RI | 1 |
| Mullins, LJ | 1 |
| Bellamy, CO | 1 |
| Harmar, AJ | 1 |
| Kenyon, CJ | 1 |
| Mullins, JJ | 2 |
| Sato, M | 1 |
| Hashimoto, T | 2 |
| Kamdem, MM | 1 |
| Shu, EN | 1 |
| Jolobe, OM | 1 |
| Braillon, A | 1 |
| Coler, C | 1 |
| Hoffman, MD | 1 |
| Towle, G | 1 |
| Hew-Butler, T | 1 |
| Adachi, M | 1 |
| Kinoshita, A | 1 |
| Koh, N | 1 |
| Gao, P | 2 |
| Voelker, B | 1 |
| Tzeng, YC | 1 |
| MacRae, B | 1 |
| Rickards, C | 1 |
| Lee, T | 1 |
| Lee, R | 1 |
| Lee, IT | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Sheu, WH | 1 |
| Nishimura, K | 1 |
| Nonaka, H | 1 |
| Inoue, Y | 1 |
| Kitagawa, Y | 1 |
| Suematsu, M | 1 |
| Miki, T | 1 |
| Emoto, N | 1 |
| Sigamani, A | 1 |
| Afzal, R | 1 |
| De Sando, V | 1 |
| Izzo, R | 1 |
| Vasta, A | 1 |
| Trimarco, A | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Konis, G | 1 |
| Fang, H | 1 |
| Severin, T | 1 |
| Allan, GM | 1 |
| Ivers, N | 1 |
| Padwal, RS | 1 |
| Aguirre P, F | 1 |
| Wright, M | 1 |
| Alessi, T | 1 |
| Gerhard, T | 1 |
| Delaney, JA | 1 |
| Shuster, J | 1 |
| Brumback, BA | 1 |
| Winterstein, AG | 1 |
| Friedman, GD | 1 |
| Asgari, MM | 1 |
| Warton, EM | 1 |
| Chan, J | 1 |
| Habel, LA | 1 |
| Karadsheh, F | 1 |
| Andrade, C | 1 |
| Fernandes, P | 1 |
| Stabler, SN | 1 |
| Tejani, AM | 1 |
| Huynh, F | 1 |
| Fowkes, C | 1 |
| Kakhramanova, SM | 1 |
| Christian Rump, L | 1 |
| Germino, FW | 2 |
| Song, E | 1 |
| Lund, BC | 1 |
| Lobmeyer, MT | 1 |
| Gawronski, BE | 1 |
| Liggett, SB | 1 |
| Julius, S | 5 |
| Brunner, HR | 4 |
| Schork, A | 3 |
| Takami, T | 1 |
| Kwon, BJ | 1 |
| Jang, SW | 1 |
| Choi, KY | 1 |
| Kim, DB | 1 |
| Ihm, SH | 1 |
| Kim, JH | 1 |
| Huan, Y | 1 |
| Glezer, MG | 1 |
| Saĭgitov, RT | 1 |
| Shimada, Y | 1 |
| Yamamuro, M | 1 |
| Kan, H | 1 |
| Takashio, S | 1 |
| Tayama, S | 1 |
| Kaikita, K | 1 |
| Hokimoto, S | 1 |
| Sumida, H | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 1 |
| Paneni, F | 1 |
| Passerini, J | 1 |
| Nieswandt, V | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Takagi, H | 1 |
| Mizuno, Y | 1 |
| Goto, SN | 1 |
| Umemoto, T | 1 |
| Koenig, W | 4 |
| Garcia-Puig, J | 3 |
| Uddin, A | 1 |
| Al Balushi, KA | 1 |
| Habib, JQ | 1 |
| Al-Zakwani, I | 1 |
| Dorresteijn, JA | 1 |
| Schrover, IM | 1 |
| Visseren, FL | 2 |
| Scheffer, PG | 1 |
| Oey, PL | 1 |
| Malishevskiĭ, MV | 1 |
| Hanayama, Y | 1 |
| Uchida, HA | 1 |
| Makino, H | 1 |
| Tziomalos, K | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Karagiannis, A | 1 |
| Egan, B | 2 |
| Maddury, SR | 1 |
| Pande, A | 1 |
| Haque, KM | 1 |
| Echtay, A | 1 |
| Go, L | 1 |
| Gulzar, T | 1 |
| Kadwa, M | 1 |
| Hristoskova, S | 1 |
| Lafeber, M | 1 |
| Grobbee, DE | 1 |
| Sachse, A | 2 |
| Freytag, F | 3 |
| Holwerda, NJ | 1 |
| Karlberg, BE | 8 |
| Meinicke, TW | 3 |
| Dao, HH | 1 |
| Essalihi, R | 1 |
| Graillon, JF | 1 |
| Larivière, R | 2 |
| De Champlain, J | 1 |
| Moreau, P | 1 |
| Brady, WE | 1 |
| Gazdick, LP | 1 |
| Lyle, P | 1 |
| Zeldin, RK | 1 |
| Radevski, IV | 4 |
| Valtchanova, ZP | 3 |
| Candy, GP | 4 |
| Wald, AM | 1 |
| Ngcezula, T | 1 |
| Sareli, P | 7 |
| Sharabi, Y | 1 |
| Illan, R | 1 |
| Kamari, Y | 1 |
| Cohen, H | 2 |
| Nadler, M | 1 |
| Wellington, K | 1 |
| Faulds, DM | 1 |
| Afsari, K | 1 |
| Posin, JP | 1 |
| Aurup, P | 2 |
| Edelman, J | 1 |
| Beevers, G | 1 |
| de Faire, U | 2 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 2 |
| Omvik, P | 5 |
| Snapinn, S | 1 |
| Wedel, H | 2 |
| Forette, F | 15 |
| Seux, ML | 4 |
| Babarskiene, MR | 1 |
| Babeanu, S | 2 |
| Bossini, A | 2 |
| Fagard, R | 23 |
| Gil-Extremera, B | 4 |
| Laks, T | 3 |
| Kobalava, Z | 1 |
| Sarti, C | 3 |
| Vanhanen, H | 3 |
| Webster, J | 6 |
| Yodfat, Y | 6 |
| Birkenhäger, WH | 7 |
| Fernández-Vega, F | 2 |
| Abellán, J | 1 |
| Vegazo, O | 1 |
| De Vinuesa, SG | 1 |
| Rodríguez, JC | 1 |
| Maceira, B | 1 |
| de Castro, SS | 1 |
| Nicolás, RR | 1 |
| Luño, J | 1 |
| Barassi, P | 1 |
| Minotti, E | 2 |
| Duzzi, L | 2 |
| Molinari, I | 1 |
| Klein, C | 1 |
| Mahmud, A | 1 |
| Feely, J | 1 |
| Brown, NJ | 3 |
| Kumar, S | 3 |
| Painter, CA | 1 |
| Vaughan, DE | 3 |
| Klingbeil, AU | 2 |
| John, S | 2 |
| Schneider, MP | 2 |
| Jacobi, J | 2 |
| Weidinger, G | 3 |
| Kato, N | 1 |
| Kanda, T | 1 |
| Sagara, M | 1 |
| Bos, A | 1 |
| Moriguchi, Y | 1 |
| Yamori, Y | 1 |
| Bart, BIa | 1 |
| Benevskaia, VF | 1 |
| Buval'tsev, VI | 2 |
| Boronenkov, GM | 1 |
| Zadionchenko, VS | 1 |
| Sandomirskaia, AP | 1 |
| Adasheva, TV | 1 |
| Gorbacheva, EV | 1 |
| Matveev, DV | 1 |
| Mareeva, AP | 1 |
| Morgan, TO | 4 |
| Anderson, A | 2 |
| Ruzicka, M | 1 |
| Leenen, FH | 2 |
| Angulo, E | 1 |
| Robles, NR | 1 |
| Grois, J | 1 |
| Barquero, A | 1 |
| Pérez Miranda, M | 1 |
| van der Linde, NA | 1 |
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 1 |
| Jara Chinarro, B | 1 |
| de Miguel Díez, J | 1 |
| García Satue, JL | 1 |
| Juretschke Moragues, MA | 1 |
| Serrano Iglesias, JA | 1 |
| Vegazo García, O | 1 |
| Llisterri Caro, JL | 1 |
| Jiménez Jiménez, FJ | 1 |
| Aznar Vicente, J | 1 |
| Vicente Lozano, J | 1 |
| Estiarte Navarro, R | 1 |
| Sciarrone, MT | 1 |
| Stella, P | 2 |
| Brown, M | 2 |
| Castaigne, A | 4 |
| de Leeuw, P | 10 |
| Palmer, CR | 2 |
| Rosenthal, T | 7 |
| Wagener, G | 2 |
| Weisser, B | 3 |
| Vetter, H | 9 |
| Westphal, S | 1 |
| Rading, A | 1 |
| Luley, C | 1 |
| Dierkes, J | 1 |
| Kuriato, AV | 1 |
| Geĭchenko, VP | 1 |
| Woolard, J | 1 |
| Hale, TM | 2 |
| Bushfield, TL | 1 |
| Coca, A | 5 |
| Calvo, C | 4 |
| Aranda, P | 1 |
| Luque, M | 1 |
| Marín-Iranzo, R | 1 |
| Lithell, H | 7 |
| Hansson, L | 20 |
| Skoog, I | 3 |
| Hofman, A | 3 |
| Wachtell, K | 1 |
| Papademetriou, V | 19 |
| Jern, S | 2 |
| Babadzhan, VD | 1 |
| Pérez-Castrillón, JL | 1 |
| Silva, J | 1 |
| Justo, I | 1 |
| Sanz, A | 1 |
| Martín-Luquero, M | 1 |
| Igea, R | 1 |
| Escudero, P | 1 |
| Pueyo, C | 1 |
| Díaz, C | 1 |
| Hernández, G | 1 |
| Dueñas, A | 1 |
| Mueller, O | 1 |
| Byrne, M | 1 |
| Williams, L | 1 |
| Carretta, R | 7 |
| Martinez, JF | 1 |
| Teitelbaum, I | 1 |
| Oddou, P | 1 |
| Fagan, T | 3 |
| Dickson, TZ | 1 |
| Zagrobelny, J | 1 |
| Lin, CC | 2 |
| Ritter, MA | 1 |
| Snavely, D | 2 |
| Ramjit, D | 1 |
| Shahinfar, S | 1 |
| Lo, MW | 2 |
| Reese, AM | 1 |
| Talbert, RL | 1 |
| Bussey, HI | 1 |
| Persson, M | 1 |
| Alaupovic, P | 1 |
| Svensson, A | 6 |
| Samuelsson, O | 2 |
| Della Chiesa, A | 1 |
| Pfiffner, D | 1 |
| Meier, B | 1 |
| Hess, OM | 1 |
| Plouin, PF | 4 |
| Sidorenko, BA | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Scopelliti, F | 2 |
| Facchini, A | 1 |
| Skiba, M | 1 |
| Gilbert, RE | 1 |
| Mainville, N | 1 |
| Connolly, WE | 1 |
| Hussein, O | 1 |
| Radan, A | 1 |
| Reuven, V | 1 |
| Vidt, DG | 3 |
| Fenton, C | 1 |
| HEJTMANCIK, MR | 1 |
| HERRMANN, GR | 1 |
| KROETZ, FW | 1 |
| SACKNER, MA | 1 |
| WALLACK, AA | 1 |
| BELLET, S | 1 |
| VERTES, V | 4 |
| SOPHER, M | 1 |
| MININNI, G | 1 |
| CANGI, G | 1 |
| MECIANI, L | 1 |
| BRINA, A | 1 |
| DE BLASIIS, M | 1 |
| SCALFI, L | 1 |
| JACONO, A | 1 |
| GUERRIERI, R | 1 |
| D'ANGELO, V | 1 |
| BUONINCONTI, R | 5 |
| MANDELLI, F | 1 |
| MANCINI, G | 1 |
| PARRINELLO, A | 1 |
| SCHWARTZ, G | 1 |
| STECHEL, GH | 1 |
| FISHMAN, SI | 1 |
| FANKHAUSER, A | 1 |
| BRAHMS, O | 1 |
| KUHNS, K | 1 |
| BUZZI, RM | 1 |
| SAMMARTINO, F | 1 |
| MAS, FR | 1 |
| LA ROSA, C | 1 |
| CORA, D | 1 |
| GHIOTTO, G | 1 |
| MAGGIA, A | 1 |
| CURRI, G | 1 |
| CROMWELL, HA | 1 |
| FISHBACK, DB | 4 |
| CASTOR, LH | 3 |
| GARGANO, N | 2 |
| REGOLI, D | 1 |
| BARTORELLI, C | 1 |
| GREIF, S | 1 |
| MICHL, F | 1 |
| HERBEUVAL, R | 2 |
| DUHEILLE, J | 2 |
| CUNY, C | 1 |
| HERZOG, B | 2 |
| PREZIOSI, P | 1 |
| MIELE, E | 1 |
| MARMO, E | 2 |
| RISER, M | 1 |
| GERAUD, J | 1 |
| BES, A | 1 |
| RASCOL, A | 1 |
| SAINT-MARC, JR | 1 |
| BESSOLES, P | 1 |
| ROSENBLOOM, SE | 1 |
| SHAPERA, RP | 1 |
| GOLDBLOOM, RS | 1 |
| PINCUS, J | 1 |
| SHAPIRO, AP | 3 |
| LISAN, P | 1 |
| BALABAN, SA | 1 |
| MASONI, A | 2 |
| TOMASI, AM | 2 |
| ROSSI, F | 1 |
| TERAN, A | 1 |
| UTLEY, JH | 1 |
| COPPO, JO | 1 |
| DUANE, GW | 1 |
| JANNEY, JG | 2 |
| BENEDETTI, G | 1 |
| MAZZA, F | 2 |
| BORHANI, NO | 6 |
| CIGADA, G | 1 |
| DE MINICIS, E | 1 |
| CUNY, G | 2 |
| GILGENKRANTZ, J | 1 |
| CHERRIER, F | 1 |
| DOUJAK, P | 1 |
| HUEBER, EF | 1 |
| LAGLER, P | 1 |
| THALER, H | 1 |
| FIFE, R | 1 |
| PATON, JP | 1 |
| WHYTE, WG | 1 |
| FIORE, RI | 1 |
| FREEMAN, RB | 1 |
| JENSON, WK | 1 |
| GILL, RJ | 1 |
| SMIRK, H | 1 |
| McQUEEN, EG | 1 |
| MORRISON, RB | 1 |
| SPITTEL, JA | 1 |
| GIFFORD, RW | 4 |
| ACHOR, RW | 1 |
| VERNET, A | 1 |
| SORG, D | 1 |
| WEINER, AA | 1 |
| LEVINE, J | 1 |
| RUSSO, JL | 1 |
| ZAGALA, J | 1 |
| DUCRET, S | 1 |
| FURBETTA, D | 1 |
| SANTUCCI, F | 2 |
| ALEKSANDROW, D | 1 |
| WYSZNACKA, W | 1 |
| BACZKO, A | 2 |
| BAIRD, HL | 1 |
| BREST, AN | 6 |
| ONESTI, G | 6 |
| SEKINE, G | 1 |
| SELLER, R | 1 |
| MOYER, JH | 4 |
| BRONOVETS, IN | 1 |
| CAVALCA, L | 1 |
| GILARDI, FF | 1 |
| MARINI, U | 1 |
| BERETTA, R | 2 |
| FORD, RV | 1 |
| FREGLY, MJ | 2 |
| GALLI, G | 1 |
| GIRALDI, A | 3 |
| MAINIERI, L | 2 |
| CHERIE LIGNIERE, EL | 1 |
| GLAUBITT, D | 1 |
| RAUSCH-STROOMANN, JG | 1 |
| HOBBS, LF | 2 |
| KATZ, JB | 1 |
| ROBINOW, SH | 1 |
| LINDEMAN, RD | 2 |
| BOUTHILET, GN | 1 |
| ASHLEY, WR | 1 |
| MORRIS, JR | 1 |
| NICOLAESCU, V | 1 |
| SIRBULESCU, R | 1 |
| ANGHEL, E | 1 |
| CIMPEANU, S | 1 |
| TEODORESCU, P | 1 |
| PIERRE, GD | 1 |
| CHERIE LIGNIERE, E | 2 |
| GUERCI, O | 1 |
| TENETTE, M | 1 |
| DODINOT, B | 1 |
| POPOV, NG | 1 |
| DOCHEV, D | 1 |
| TAKEUCHI, J | 1 |
| TAKEDA, T | 1 |
| UCHIDA, E | 1 |
| OKADA, R | 1 |
| SHINTANI, F | 1 |
| SCHULTZ, FB | 5 |
| SCHULTZ, J | 1 |
| HOLTZ, M | 1 |
| HAGEMANN, I | 1 |
| RAMOS, A | 1 |
| RETAN, JW | 1 |
| SAMESHIMA, H | 1 |
| SCHNIDER, U | 1 |
| VILLAMIL, MF | 1 |
| YEYATI, N | 1 |
| ENERO, MA | 1 |
| RUBIANES, C | 1 |
| TAQUINI, AC | 1 |
| WINER, BM | 2 |
| ABRAHAMSEN, AM | 1 |
| HUMERFELT, S | 1 |
| SIGSTAD, H | 1 |
| DE BENEDICTIS, KJ | 1 |
| PEPINO, AT | 1 |
| DOLLERY, CT | 9 |
| PENTECOST, BL | 1 |
| SAMAAN, NA | 1 |
| KERT, MJ | 1 |
| DASHE, AM | 1 |
| MAILMAN, RH | 1 |
| ROTH, SI | 1 |
| ZAGER, A | 1 |
| TALSO, PJ | 1 |
| CARBALLO, AJ | 1 |
| WILSON, WR | 3 |
| OKUN, R | 5 |
| TETREAULT, L | 1 |
| SAINANI, GS | 1 |
| NAWAZ, M | 1 |
| MIRONOV, P | 1 |
| VAPTSAROV, A | 1 |
| HEATH, WC | 1 |
| FREIS, ED | 43 |
| AGNEW, TM | 1 |
| IRVINE, RO | 1 |
| NORTH, JD | 1 |
| SINGER, MM | 1 |
| HOFF, HR | 1 |
| FISCH, S | 1 |
| DEGRAFF, AC | 1 |
| LIU, JF | 1 |
| LI, HY | 1 |
| TING, KS | 1 |
| DIGIESI, V | 1 |
| MORACE, G | 1 |
| SANCHETTI, P | 1 |
| FAVERO, S | 1 |
| LONGARETTI, A | 1 |
| BELSITO, F | 1 |
| SHULGA, IuD | 1 |
| LAAS, H | 1 |
| BETZIEN, G | 1 |
| BRANCHRZ, H | 1 |
| GOEMOERI, P | 1 |
| ROEDIGER, PM | 1 |
| PUSCHAK, TB | 1 |
| HUTCHISON, JC | 2 |
| QUAN, KC | 1 |
| KAHANA, L | 1 |
| SCHWARTZ, W | 1 |
| GELFAND, MD | 1 |
| CHERIELIGNIERE, EL | 1 |
| DIMARCO, N | 1 |
| PEDERSEN, J | 1 |
| LINDENEG, O | 1 |
| FISCHER, S | 1 |
| CASIROLA, G | 1 |
| TARTARA, A | 1 |
| PARRY, EH | 2 |
| YOUNG, DS | 1 |
| MONTEMARTINI, C | 2 |
| FRATTI, L | 1 |
| SEITZ, H | 1 |
| JAWORSKI, ZF | 1 |
| ARMASCRUZ, R | 1 |
| GOMEZ, R | 1 |
| MARDONES, J | 1 |
| PLAZADELOSREYES, M | 1 |
| SHELBURNE, PF | 1 |
| SASSEN, FA | 1 |
| ORGAIN, ES | 2 |
| BOETTIGER, LE | 1 |
| MALMBORG, RO | 1 |
| MICHAELI, EW | 1 |
| MIHAILESCU, VV | 1 |
| CLEJ, V | 1 |
| ENESCU, R | 1 |
| SBENGHE, S | 1 |
| KAKAVIATOS, N | 1 |
| CHUPKOVICH, V | 1 |
| FINNERTY, FA | 5 |
| PARDO, EG | 3 |
| VIDRIO, H | 3 |
| VARGAS, R | 2 |
| DELZAR, L | 1 |
| PALENCIA, AE | 2 |
| CONTI, LA | 2 |
| URRIBARRI, R | 2 |
| DELZAR, LE | 1 |
| JOHNSON, HJ | 1 |
| DINES, DE | 1 |
| GELFAND, ML | 1 |
| GARREN, MG | 1 |
| ROWAN, RL | 1 |
| CHRISTENSSON, B | 1 |
| GUSTAFSON, A | 1 |
| WESTLING, H | 1 |
| TAN, CH | 1 |
| KONG, Y | 1 |
| HAHN, R | 1 |
| HYMAN, AS | 1 |
| WOLFF, FW | 2 |
| LANGDON, RG | 1 |
| COHEN, MH | 1 |
| DOMINGUEZ, GH | 1 |
| ROWLAND, W | 1 |
| CHIN, YA | 1 |
| TSENG, KY | 1 |
| NIU, HY | 1 |
| PI, HP | 1 |
| BATTERMAN, RC | 2 |
| MOURATOFF, GJ | 1 |
| KAUFMAN, JE | 1 |
| MILLIEZ, P | 2 |
| FRITEL, D | 1 |
| REY, LP | 1 |
| SHIBATA, M | 1 |
| FUJII, R | 1 |
| KATO, K | 1 |
| IWAZU, A | 1 |
| HEIDER, C | 2 |
| SELLER, RH | 2 |
| DRACHEVA, ZN | 2 |
| TIAZHKOROB, AM | 1 |
| KUCHEROVA, LL | 1 |
| KANDRUSINA, GA | 1 |
| KLAPPER, MS | 1 |
| RICHARD, L | 1 |
| CHAZAN, JA | 1 |
| ROSEN, RJ | 1 |
| RAMIREZ-MUXO, O | 1 |
| NANAVATY, JM | 1 |
| KAMAT, GR | 1 |
| KLEINERMANN, L | 1 |
| KONSTANTINESKU, A | 1 |
| MORIN, Y | 2 |
| TURMEL, L | 2 |
| FORTIER, J | 2 |
| COLLYNS, JA | 1 |
| MACQUAIDE, DH | 1 |
| RUBANOVSKII, BR | 1 |
| BELLUSCHI, A | 1 |
| VACCHINI, V | 1 |
| KLEIN, K | 1 |
| SIEDEK, H | 1 |
| GAL, R | 1 |
| CONWAY, J | 1 |
| LEONETTI, G | 16 |
| GOSFIELD, E | 1 |
| GILLENWATER, J | 1 |
| CLARK, TE | 1 |
| CROSS, CJ | 1 |
| LURIA, MH | 1 |
| CHASE, WM | 1 |
| WELLS, AD | 1 |
| DAVIS, CC | 1 |
| SETTEL, E | 1 |
| FEDOSOV, SM | 1 |
| CARTER, FS | 1 |
| GENNARO, JF | 1 |
| GRAFZUDOHNA, P | 1 |
| PFISTERER, A | 1 |
| MANKOVSKII, NB | 1 |
| VAINSHTOK, IB | 1 |
| JOUVE, A | 2 |
| AVRIL, P | 1 |
| KOLODNY, AL | 1 |
| DABOLINS, R | 1 |
| LAROTONDA, A | 1 |
| ZUCAL, C | 1 |
| LEE, RE | 1 |
| SELIGMAN, AW | 1 |
| CLARK, MA | 1 |
| ROUSSEAU, PA | 1 |
| MARTOS, K | 1 |
| KISS, J | 1 |
| RENSCHLER, HE | 1 |
| LANTSBERG, LA | 1 |
| PINTO, IJ | 1 |
| DIVEKAR, MV | 1 |
| RAGHAVAN, P | 1 |
| MEHTA, DJ | 1 |
| SHETH, UK | 1 |
| Willenbrock, R | 1 |
| Zannad, F | 5 |
| Phillips, RA | 2 |
| Roniker, B | 1 |
| Kleiman, J | 1 |
| Krause, S | 1 |
| Burns, D | 1 |
| Williams, GH | 4 |
| Dmitriev, VV | 2 |
| Khanbalaeva, MN | 1 |
| Kotkina, TI | 1 |
| Ong, HT | 1 |
| Sinitsin, VE | 1 |
| Stukalova, OV | 1 |
| Alekseeva, NP | 1 |
| Belova, EV | 1 |
| Larin, VG | 1 |
| Akhundov, FIu | 1 |
| Krasina, GF | 1 |
| Kotliarova, LV | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Bulatov, VA | 2 |
| Son, EA | 2 |
| Os, I | 7 |
| Wing, LM | 5 |
| Arnolda, LF | 2 |
| Upton, J | 2 |
| Molloy, D | 2 |
| Kulbertus, H | 2 |
| Liu, G | 3 |
| Jiang, B | 1 |
| Gao, R | 1 |
| Chen, L | 1 |
| Su, L | 1 |
| Cohen, JD | 4 |
| Nosworthy, A | 1 |
| Ullrich, H | 1 |
| Passenberg, P | 1 |
| Agelink, MW | 1 |
| Marks, RG | 1 |
| Kowey, P | 1 |
| Cangiano, JL | 3 |
| Garcia-Barreto, D | 3 |
| Erdine, S | 1 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Parmley, WW | 1 |
| Galzerano, D | 2 |
| Tammaro, P | 1 |
| Cerciello, A | 1 |
| Breglio, R | 1 |
| Mallardo, M | 1 |
| Lama, D | 1 |
| Tuccillo, B | 1 |
| Capogrosso, P | 1 |
| Beliaev, SD | 1 |
| Zaslavskaia, RM | 4 |
| Khetagurova, LG | 1 |
| Varì, N | 1 |
| Capuano, V | 1 |
| Spagnuolo, V | 2 |
| Borgnino, C | 1 |
| Sobrino, J | 2 |
| Gómez, E | 1 |
| López-Paz, JE | 1 |
| Sierra, C | 1 |
| Bragulat, E | 1 |
| Rappert, B | 1 |
| Campo, C | 3 |
| Roldán, C | 1 |
| Alcázar, JM | 2 |
| Rodicio, JL | 6 |
| Franco, RJ | 4 |
| Goldflus, S | 1 |
| McQuitty, M | 1 |
| Rosner, MH | 1 |
| Ofor, OO | 1 |
| Márquez, E | 1 |
| Oliván, J | 2 |
| Roca Cusachs, A | 1 |
| Sanz de Castro, S | 1 |
| Pontes, C | 1 |
| Delgadillo, J | 1 |
| Makolkin, VI | 1 |
| Rollins, G | 1 |
| Degl'Innocenti, A | 1 |
| Wiklund, I | 1 |
| Landmark, K | 1 |
| Toft, I | 1 |
| Punzi, CF | 1 |
| Corradi, L | 4 |
| Fogari, E | 1 |
| Hildemann, SK | 2 |
| Fischer, HM | 2 |
| Bohlscheid, V | 2 |
| Pittrow, D | 4 |
| Hamilton, C | 1 |
| Beattie, E | 1 |
| Spiers, A | 1 |
| Santonastaso, M | 2 |
| Ambrosia, GB | 1 |
| Caiazza, A | 1 |
| Reid, JL | 3 |
| Murphy, MB | 3 |
| Seewaldt-Becker, E | 1 |
| Köster, J | 2 |
| Rinder, MR | 1 |
| Spina, RJ | 1 |
| Peterson, LR | 1 |
| Koenig, CJ | 1 |
| Florence, CR | 1 |
| Ehsani, AA | 1 |
| Murzynowski, JB | 1 |
| Thijisq, L | 1 |
| Celis, H | 5 |
| Bulpitt, CJ | 12 |
| Fletcher, AE | 8 |
| McCormack, P | 2 |
| Nachev, C | 6 |
| Rosenfeld, J | 4 |
| Fuchs, W | 1 |
| Germanò, G | 1 |
| Sanguigni, V | 1 |
| Pignatelli, P | 1 |
| Caccese, D | 1 |
| Lenti, L | 1 |
| Ragazzo, M | 1 |
| Lauro, R | 1 |
| Violi, F | 1 |
| Falconnet, C | 1 |
| Bochud, M | 1 |
| Bovet, P | 2 |
| Hess, L | 1 |
| Pechere-Bertschi, A | 1 |
| Muggli, F | 1 |
| Okoro, EO | 1 |
| Davies, AE | 1 |
| Ekman, S | 1 |
| Laragh, J | 1 |
| Mitchell, L | 1 |
| Plat, F | 2 |
| Chung, NA | 1 |
| Beevers, DG | 3 |
| Lip, G | 1 |
| Ranta, A | 1 |
| Wooten, GF | 1 |
| Gavras, I | 2 |
| Arinzon, Z | 1 |
| Alexander, P | 1 |
| Berner, Y | 1 |
| Qureshi, F | 1 |
| Fox, JC | 1 |
| Leight, K | 1 |
| Sutradhar, SC | 1 |
| Demopoulos, LA | 1 |
| Gleim, GW | 2 |
| Sáez, GT | 1 |
| Tormos, C | 1 |
| Giner, V | 1 |
| Chaves, J | 1 |
| Lozano, JV | 2 |
| Iradi, A | 1 |
| NEIBART, E | 1 |
| AARON, JJ | 1 |
| KARIMIPOUR, G | 1 |
| LEFF, W | 1 |
| NUSSBAUM, H | 1 |
| Toto, RD | 2 |
| McCullough, PA | 2 |
| Kirch, W | 6 |
| Eide, IK | 1 |
| Torjesen, PA | 1 |
| Drolsum, A | 1 |
| Babovic, A | 1 |
| Lilledahl, NP | 1 |
| Lehnert, H | 1 |
| Gröholm, T | 1 |
| Finckenberg, P | 1 |
| Palojoki, E | 1 |
| Saraste, A | 1 |
| Bäcklund, T | 1 |
| Eriksson, A | 1 |
| Laine, M | 1 |
| Mervaala, E | 1 |
| Tikkanen, I | 3 |
| Bond, MG | 5 |
| Gallus, G | 1 |
| Ventura, A | 1 |
| Baggio, G | 1 |
| Sampieri, L | 2 |
| Rubba, P | 1 |
| Sperti, G | 2 |
| Magni, A | 1 |
| Dobovisek, J | 2 |
| Planinc, D | 1 |
| Salerno, CM | 1 |
| Demopoulos, L | 1 |
| Mukherjee, R | 1 |
| Ruilope, L | 4 |
| Palmer, C | 1 |
| Rosental, T | 1 |
| Joerger, M | 1 |
| Diethelm, M | 1 |
| Denolle, T | 1 |
| Yau, C | 1 |
| Fiquet, B | 1 |
| Moulin, B | 1 |
| Herpin, D | 2 |
| Høieggen, A | 2 |
| Beckey, K | 1 |
| Schram, MT | 2 |
| van Ittersum, FJ | 2 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 2 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 2 |
| Twisk, JW | 2 |
| Stehouwer, CD | 2 |
| Lipsitz, LA | 1 |
| Gagnon, M | 1 |
| Vyas, M | 1 |
| Iloputaife, I | 1 |
| Kiely, DK | 1 |
| Sorond, F | 1 |
| Serrador, J | 1 |
| Cheng, DM | 1 |
| Babikian, V | 1 |
| Cupples, LA | 1 |
| Mougenot, N | 1 |
| Médiani, O | 1 |
| Lechat, P | 1 |
| Freundlich, M | 1 |
| Ludwig, M | 3 |
| Boydak, B | 1 |
| Nalbantgil, S | 1 |
| Yilmaz, H | 1 |
| Zoghi, M | 1 |
| Ozerkan, F | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Werner, H | 1 |
| Reed, MD | 1 |
| Colman, PG | 1 |
| Barraclough, D | 1 |
| Witkowski, S | 2 |
| Arbab-Zadeh, A | 1 |
| Prasad, A | 1 |
| Okazaki, K | 1 |
| Koren-Michowitz, M | 1 |
| Dishy, V | 1 |
| Zaidenstein, R | 2 |
| Yona, O | 1 |
| Berman, S | 2 |
| Weissgarten, J | 2 |
| Golik, A | 3 |
| Finkielman, JD | 1 |
| Iakimenko, ON | 1 |
| Gomazkov, OA | 1 |
| Ektova, TV | 1 |
| Aparina, TV | 1 |
| Dilakian, EA | 1 |
| Britov, AN | 1 |
| Heintz, D | 2 |
| Stolt, P | 2 |
| Khder, Y | 4 |
| Lee, M | 1 |
| Kim, JU | 1 |
| Song, KI | 1 |
| Choi, YS | 1 |
| Cheong, SS | 1 |
| Emeriau, JP | 2 |
| Knauf, H | 4 |
| Pujadas, JO | 2 |
| Calvo-Gomez, C | 2 |
| Abate, G | 2 |
| Pasotti, C | 3 |
| Rinaldi, A | 4 |
| Jayaram, S | 1 |
| Lahoti, S | 1 |
| Chandrasekharan, S | 1 |
| Ganesan, R | 1 |
| Muralidharan, RS | 1 |
| Mishra, AB | 1 |
| Sodhi, SS | 1 |
| Rajadhyaksha, GC | 1 |
| Jain, SD | 1 |
| Kadam, GS | 1 |
| Gawde, A | 1 |
| Desai, A | 1 |
| Meredith, PA | 1 |
| Giles, T | 1 |
| Sharma, AM | 3 |
| Minutolo, R | 1 |
| De Nicola, L | 1 |
| Zamboli, P | 1 |
| Chiodini, P | 1 |
| Signoriello, G | 1 |
| Toderico, C | 1 |
| Arfè, G | 1 |
| Boschi, G | 1 |
| Brancati, C | 1 |
| Iaccarino, P | 1 |
| Conte, G | 1 |
| Nedogoda, SV | 3 |
| Marchenko, IV | 2 |
| Chaliabi, TA | 2 |
| Tsoma, VA | 1 |
| Brel', UA | 2 |
| Prokhorova, EA | 2 |
| Kapustin, IO | 1 |
| Erhun, WO | 1 |
| Agbani, EO | 1 |
| Bolaji, EE | 1 |
| Ma, J | 1 |
| Albornoz, F | 1 |
| Yu, C | 1 |
| Byrne, DW | 1 |
| Liu, KJ | 2 |
| Wang, JJ | 1 |
| Wu, YT | 1 |
| Jing, S | 1 |
| Khosla, N | 1 |
| Chua, DY | 1 |
| Bernik, MM | 1 |
| Heimann, JC | 1 |
| Nakandakare, ER | 1 |
| Cazita, PM | 1 |
| Nunes, VS | 1 |
| Neves, MQ | 1 |
| Quintão, EC | 1 |
| Maitland-van der Zee, AH | 1 |
| Klungel, OH | 1 |
| Daley, W | 1 |
| Zelenkofske, S | 1 |
| Grant, RW | 1 |
| Singer, DE | 1 |
| Meigs, JB | 1 |
| Malliani, A | 1 |
| Montano, N | 1 |
| Krekler, M | 3 |
| Nürnberger, J | 1 |
| Daul, A | 1 |
| Muravyov, AV | 1 |
| Yakusevich, VV | 1 |
| Kabanov, AV | 1 |
| Petrochenko, AS | 1 |
| Hebert, D | 1 |
| Assouline, L | 1 |
| Knowles, SR | 1 |
| Wong, GA | 1 |
| Rahim, SA | 1 |
| Binkley, K | 1 |
| Phillips, EJ | 1 |
| Shear, NH | 1 |
| García-Estañ, J | 1 |
| Ortiz, MC | 1 |
| O'Valle, F | 1 |
| Alcaraz, A | 1 |
| Navarro, EG | 1 |
| Vargas, F | 1 |
| Atucha, NM | 1 |
| Saunders, E | 8 |
| Gerwe, M | 1 |
| Braun, M | 1 |
| Funken, C | 3 |
| Li, DQ | 1 |
| Li, HF | 1 |
| Zhao, HY | 2 |
| Westheim, AS | 1 |
| Demirci, B | 1 |
| McKeown, PP | 1 |
| Bayraktutan, U | 1 |
| Jordan, J | 2 |
| Engeli, S | 2 |
| Boschmann, M | 1 |
| Luft, FC | 2 |
| Kreuzberg, U | 1 |
| Hewkin, AC | 1 |
| Delonca, J | 1 |
| Moulin, C | 1 |
| Giacomino, A | 1 |
| Postel-Vinay, N | 1 |
| Bell, D | 1 |
| Smith, LR | 2 |
| Devine, AB | 1 |
| McHenry, EM | 1 |
| Nicholls, DP | 1 |
| McDermott, BJ | 1 |
| Smallegange, C | 1 |
| Heaton, JP | 1 |
| Agrawal, R | 1 |
| Marx, A | 1 |
| Tsoma, VV | 1 |
| Salako, LA | 6 |
| Falase, AO | 2 |
| Albert, K | 1 |
| Silfani, TN | 1 |
| Battershill, AJ | 1 |
| Nedostup, AV | 1 |
| Fedorova, VI | 1 |
| Linevich, AIu | 1 |
| Pukhal'skaia, TG | 1 |
| Toropina, GG | 1 |
| Kudrin, VS | 1 |
| Klodt, PM | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 3 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Goerdt, CJ | 1 |
| Steffensmeier, JJ | 1 |
| Phillips, BB | 1 |
| Zimmerman, MB | 1 |
| Bergus, GR | 1 |
| Hörl, W | 1 |
| Rabelink, AJ | 1 |
| Abts, M | 2 |
| Claus, V | 1 |
| Lataster, M | 1 |
| Quan, A | 1 |
| Chavanu, K | 1 |
| Merkel, J | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Spoelstra-de Man, AM | 1 |
| Kamp, O | 1 |
| Brouwer, CB | 1 |
| Falkner, B | 7 |
| Francos, G | 1 |
| Kushner, H | 1 |
| Ridker, PM | 3 |
| Danielson, E | 2 |
| Rifai, N | 1 |
| Kaşifoğlu, T | 1 |
| Yalçin, AU | 1 |
| Barbakadze, VY | 1 |
| Koblianidze, LG | 1 |
| Kipshidze, NN | 1 |
| Grim, CE | 2 |
| Grim, CM | 1 |
| Tavill, F | 1 |
| Sun, LX | 1 |
| He, WC | 1 |
| Conter, HS | 1 |
| McKay, DW | 1 |
| Reiz, RJ | 1 |
| Xie, HH | 2 |
| Shen, FM | 2 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Ewald, S | 2 |
| Golevtsova, ZSh | 1 |
| Protskiĭ, IA | 1 |
| Nazarov, AG | 1 |
| Potapov, VV | 1 |
| Leonova, MV | 1 |
| Demidova, MA | 1 |
| Tarasov, AV | 1 |
| Belousov, IuB | 1 |
| Tschöpe, R | 1 |
| Little, WC | 1 |
| Zile, MR | 1 |
| Klein, A | 1 |
| Appleton, CP | 1 |
| Kitzman, DW | 1 |
| Wesley-Farrington, DJ | 1 |
| Mittal, BV | 1 |
| Pendse, S | 1 |
| Rennke, HG | 1 |
| Singh, AK | 1 |
| Zhou, MS | 1 |
| Kedziora-Kornatowska, K | 1 |
| Czuczejko, J | 1 |
| Szewczyk-Golec, K | 1 |
| Motyl, J | 1 |
| Szadujkis-Szadurski, L | 1 |
| Kornatowski, T | 1 |
| Pawluk, H | 1 |
| Kedziora, J | 1 |
| Murwin, D | 2 |
| Koval, SE | 2 |
| Hasenfuss, G | 1 |
| Mutschler, E | 2 |
| da Silva, CA | 1 |
| Coelho, EB | 1 |
| Salgado, HC | 1 |
| Fazan, R | 1 |
| Wagstaff, AJ | 1 |
| Vaidyanathan, S | 1 |
| Valencia, J | 1 |
| Kemp, C | 1 |
| Zhao, C | 1 |
| Yeh, CM | 1 |
| Bizot, MN | 1 |
| Denouel, J | 1 |
| Dieterich, HA | 1 |
| Cai, XJ | 1 |
| Bi, XP | 1 |
| Zhao, Z | 1 |
| Goebel, M | 1 |
| Clemenz, M | 1 |
| Jiang, H | 1 |
| Han, P | 1 |
| Chu, ZX | 1 |
| Villamil, A | 1 |
| Calhoun, D | 1 |
| Schober, B | 1 |
| Hsu, H | 2 |
| Matrisciano-Dimichino, L | 1 |
| Barton, J | 2 |
| Nussberger, J | 2 |
| Mulcahy, D | 1 |
| Jensen, C | 1 |
| Dicker, P | 1 |
| Stanton, A | 1 |
| Hainer, JW | 2 |
| Sugg, J | 2 |
| Munzer, D | 1 |
| Lebel, M | 3 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Ptaszynska, A | 2 |
| Villeval'de, SV | 1 |
| Aldigier, JC | 1 |
| Januszewicz, A | 1 |
| Zidek, W | 1 |
| Chiang, Y | 1 |
| Satlin, A | 1 |
| Silfani, T | 2 |
| Walker, F | 2 |
| Bedrossian, S | 1 |
| Vahid, B | 1 |
| Un, I | 1 |
| Fimmers, R | 1 |
| Kuturu, V | 1 |
| Harris, KE | 2 |
| Greathouse, M | 1 |
| Paavonen, KJ | 2 |
| Miettinen, HE | 2 |
| Strandberg, T | 2 |
| Tilvis, R | 2 |
| Pentikäinen, PJ | 2 |
| Boye, SW | 1 |
| Weinberger, M | 1 |
| Alvarado, R | 1 |
| Huang, J | 2 |
| Quarti-Trevano, F | 1 |
| Horie, Y | 1 |
| Takeuchi, M | 1 |
| Long, RC | 1 |
| Wofford, MR | 1 |
| Harkins, KG | 1 |
| Minor, DS | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Yang, W | 1 |
| Preblick, R | 1 |
| Paar, WD | 1 |
| Thoenes, M | 2 |
| Abe, C | 1 |
| Takahashi, T | 1 |
| Kameda, T | 1 |
| Pugliatti, P | 1 |
| Patanè, S | 1 |
| Recupero, A | 1 |
| Coglitore, S | 1 |
| Di Bella, G | 1 |
| Lefebvre, J | 5 |
| Lefkowitz, M | 2 |
| Massie, B | 3 |
| Ofili, E | 1 |
| Palmieri, V | 2 |
| Pini, R | 2 |
| Chiara Cavallini, M | 1 |
| Soucek, M | 2 |
| Plachý, M | 1 |
| Poldermans, D | 1 |
| Glazes, R | 1 |
| Kargiannis, S | 1 |
| Wernsing, M | 1 |
| Kaczor, J | 1 |
| Gamboa, R | 1 |
| Fomina, I | 1 |
| Silva, KC | 1 |
| Pinto, CC | 1 |
| Biswas, SK | 1 |
| Souza, DS | 1 |
| de Faria, JB | 1 |
| de Faria, JM | 1 |
| Lancellotti, P | 1 |
| Jiang, X | 1 |
| Sheng, HH | 1 |
| Lin, G | 1 |
| Lu, XZ | 1 |
| Cheng, YL | 1 |
| Xiao, HS | 1 |
| Zhan, YY | 1 |
| Meng, X | 1 |
| Cushman, W | 1 |
| Klocke, RK | 2 |
| Landen, H | 2 |
| Müller, U | 1 |
| Gaxiola, E | 1 |
| Boccanelli, A | 1 |
| Heagerty, A | 2 |
| Krzesinski, JM | 2 |
| Rodicio, J | 1 |
| Stefenelli, T | 1 |
| Woittiez, A | 1 |
| Yang, LE | 1 |
| Leong, PK | 1 |
| McDonough, AA | 1 |
| Shargorodsky, M | 1 |
| Boaz, M | 1 |
| Davidovitz, I | 1 |
| Asherov, J | 1 |
| Gavish, D | 1 |
| Zimlichman, R | 3 |
| Tejada, T | 1 |
| Fornoni, A | 1 |
| Lenz, O | 1 |
| Schühlen, H | 1 |
| Kastrati, D | 1 |
| Maillard, MP | 1 |
| Lyle, PA | 2 |
| Kizer, JR | 1 |
| Yener, G | 1 |
| Aran, S | 1 |
| Bahceci, M | 1 |
| Ozdemir, K | 1 |
| Gultekin, F | 1 |
| Lowe, W | 1 |
| Smith, RE | 1 |
| Ashiya, M | 1 |
| Sládková, M | 1 |
| Kojsová, S | 1 |
| Jendeková, L | 1 |
| Pechánová, O | 1 |
| López, B | 1 |
| Castellano, JM | 1 |
| González, A | 1 |
| Barba, J | 1 |
| Díez, J | 1 |
| Reungjui, S | 1 |
| Roncal, CA | 1 |
| Mu, W | 1 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Nakagawa, T | 2 |
| Karara, AH | 1 |
| Hanes, V | 1 |
| Alonso, A | 1 |
| Ni, P | 1 |
| Poola, N | 1 |
| Silang, R | 1 |
| Blode, H | 1 |
| Schirmer, A | 1 |
| Paar, DW | 1 |
| Saruta, T | 1 |
| Toki, M | 1 |
| Hirayama, Y | 1 |
| Nonaka, K | 1 |
| Ubaid-Girioli, S | 1 |
| Ferreira-Melo, SE | 1 |
| Souza, LA | 1 |
| Nogueira, EA | 1 |
| Yugar-Toledo, JC | 1 |
| Moreno, H | 1 |
| Hilsmann, U | 1 |
| Neumann, G | 1 |
| Conen, D | 2 |
| Everett, BM | 2 |
| Ural, E | 1 |
| Kozdag, G | 1 |
| Kilic, T | 1 |
| Ural, D | 1 |
| Sahin, T | 1 |
| Celebi, O | 1 |
| Komsuoglu, B | 2 |
| Förster, A | 2 |
| Lipka, LJ | 1 |
| Wang, HY | 1 |
| Bell, DS | 2 |
| Fonseca, V | 1 |
| Katholi, RE | 1 |
| McGill, JB | 3 |
| Raskin, P | 4 |
| Holdbrook, FK | 1 |
| Lukas, MA | 1 |
| Iyengar, M | 1 |
| Filigheddu, F | 3 |
| Cocco, F | 1 |
| Degortes, S | 1 |
| Fadda, S | 1 |
| Pinna Parpaglia, P | 1 |
| Baraccani, C | 1 |
| Gohchi, K | 1 |
| Yatomi, Y | 1 |
| Voronkov, LG | 1 |
| Ilyash, MG | 1 |
| Ena, LM | 1 |
| Tchelujko, VI | 1 |
| Dyaduk, AI | 1 |
| Bagrij, AE | 1 |
| Andrievskaja, SA | 1 |
| Vehabović, A | 1 |
| Parhofer, KG | 1 |
| Münzel, F | 1 |
| Cox, D | 1 |
| Donovan, M | 1 |
| De Obaldia, ME | 1 |
| Zethraeus, N | 1 |
| Ström, O | 1 |
| Borgström, F | 1 |
| Kanis, JA | 1 |
| Jönsson, B | 1 |
| Chen, YY | 1 |
| Zhang, WZ | 1 |
| Wu, HY | 1 |
| Yu, ZQ | 1 |
| Zhang, FC | 1 |
| Xiang, XP | 1 |
| Shen, FR | 1 |
| Tao, J | 1 |
| Zhao, JA | 1 |
| Benetos, A | 5 |
| Cable, G | 1 |
| Liu, JQ | 1 |
| Liang, WN | 1 |
| Liu, GF | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Fitzgerald, MA | 1 |
| Constance, CM | 1 |
| Ali, MA | 1 |
| Jin, J | 1 |
| Allemann, Y | 1 |
| Fraile, B | 1 |
| Lambert, M | 1 |
| Molitch, M | 1 |
| Sarafidis, P | 1 |
| Bacher, P | 1 |
| Triposkiadis, F | 1 |
| Abate, N | 1 |
| Chen, E | 1 |
| Creager, MA | 1 |
| Galet, V | 1 |
| Jia, G | 1 |
| Lerman, A | 1 |
| Tershakovec, AM | 1 |
| Rosa, EC | 1 |
| Zanella, MT | 2 |
| Kohlmann, NE | 2 |
| Ferreira, SR | 1 |
| Plavnik, FL | 1 |
| Davis, P | 1 |
| Wojciechowski, D | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Tkacheva, ON | 1 |
| Shumbutova, AIu | 1 |
| Novikova, IM | 1 |
| Samsonenko, NS | 1 |
| Guseva, KIu | 1 |
| Eley, SL | 1 |
| Allen, CM | 1 |
| Williams, CL | 1 |
| Bukoski, RD | 1 |
| Pointer, MA | 1 |
| Cleveland, JM | 1 |
| Rolleri, RL | 1 |
| Donner, K | 1 |
| Petrova, TR | 1 |
| Oleĭnik, NI | 1 |
| Hall, CE | 6 |
| Holland, OB | 10 |
| Hall, O | 5 |
| Natangelo, R | 1 |
| Ferrario, G | 1 |
| Christensen, M | 1 |
| Galskov, A | 1 |
| Gwinup, G | 1 |
| Steinberg, T | 1 |
| Mifune, S | 1 |
| Bufalari, A | 1 |
| Meloni, G | 1 |
| Eldridge, JC | 1 |
| Strandhoy, J | 1 |
| Buckalew, VM | 1 |
| McCarron, DA | 1 |
| Jain, AK | 3 |
| McMahon, FG | 7 |
| Ryan, JR | 2 |
| Maronde, R | 1 |
| Vlachakis, N | 2 |
| Mroczek, W | 2 |
| Drayer, JI | 8 |
| Glasser, SP | 4 |
| McMahon, SG | 1 |
| Vanov, SK | 2 |
| Leibowitz, DA | 1 |
| Davies, RO | 3 |
| Irvin, JD | 5 |
| Kramsch, DK | 1 |
| Walker, JF | 6 |
| Moncloa, F | 4 |
| Sharma, JN | 4 |
| Fernandez, PG | 11 |
| Kim, BK | 10 |
| Triggle, CR | 5 |
| Freier, PA | 1 |
| Wollam, GL | 4 |
| Hall, WD | 7 |
| Unger, DJ | 2 |
| Douglas, MB | 2 |
| Bain, RP | 1 |
| Snedden, W | 5 |
| Nolan, R | 1 |
| Ko, P | 1 |
| Piryova, B | 1 |
| Girchev, R | 1 |
| Idikio, H | 4 |
| Fernandez, D | 2 |
| Gomez, HJ | 1 |
| Giese, J | 14 |
| Rasmussen, S | 9 |
| Nielsen, MD | 5 |
| Malini, PL | 3 |
| Strocchi, E | 2 |
| Magnani, B | 4 |
| Kulaga, SF | 2 |
| Kramsch, DM | 1 |
| McFate Smith, W | 1 |
| Pingeon, R | 1 |
| Lund-Johansen, P | 11 |
| Goodman, C | 2 |
| Coull, A | 2 |
| Sassano, P | 4 |
| Chatellier, G | 5 |
| Amiot, AM | 2 |
| Alhenc-Gelas, F | 3 |
| Corvol, P | 6 |
| von Manteuffel, GE | 2 |
| Ebel, H | 2 |
| Zehner, J | 3 |
| Priest, RT | 1 |
| Ricci, BA | 1 |
| Eltorai, MI | 1 |
| Brewer, DD | 1 |
| Halawa, B | 4 |
| Franz, IW | 4 |
| Leth, A | 16 |
| McNair, A | 2 |
| Christensen, NJ | 3 |
| Hoppe, HJ | 1 |
| Krüger, K | 1 |
| Rosenthal, J | 6 |
| Schrey, A | 1 |
| Eberhardt, R | 1 |
| Albertazzi, A | 1 |
| Del Rosso, G | 1 |
| Di Paolo, B | 1 |
| Spisni, C | 1 |
| Palmieri, PF | 1 |
| Cappelli, P | 1 |
| Di Vito, R | 1 |
| Teufel, W | 4 |
| Glocke, M | 4 |
| Tarkiainen, A | 1 |
| Saraste, K | 1 |
| Seppälä, T | 1 |
| Gordin, A | 5 |
| Auvinen, J | 2 |
| Bengtsson, C | 3 |
| De Cesaris, R | 3 |
| Balestrazzi, M | 1 |
| Procaccio, P | 1 |
| Dell'Orco, M | 1 |
| Nagel, W | 1 |
| Obel, AO | 2 |
| Gitau, W | 1 |
| Richter, R | 1 |
| Burris, JF | 8 |
| Miller, AJ | 1 |
| Kaplan, BM | 1 |
| Upton, MT | 1 |
| Grais, IM | 1 |
| Abrams, DL | 1 |
| Dawes, PM | 1 |
| Lemieux, G | 3 |
| L'Homme, C | 1 |
| González-Gómez, A | 1 |
| Gamio Capestany, F | 1 |
| Hernández-Cañero, A | 1 |
| Vlachakis, ND | 7 |
| Valasquez, M | 1 |
| Alexander, N | 2 |
| Maronde, RF | 8 |
| Middeke, M | 6 |
| Holzgreve, H | 10 |
| Bartsch, W | 1 |
| Häcker, W | 1 |
| Scarpelli, PT | 1 |
| Romano, S | 2 |
| Bigioli, F | 1 |
| Corti, C | 1 |
| Livi, R | 1 |
| Scarpelli, L | 1 |
| Croppi, E | 1 |
| Stinchetti, A | 1 |
| Imperiale, P | 1 |
| Rotmensch, HH | 8 |
| Rocci, ML | 2 |
| Vlasses, PH | 11 |
| Swanson, BN | 7 |
| Fedder, IL | 1 |
| Soyka, L | 1 |
| Ferguson, RK | 12 |
| Panikarskiĭ, VG | 5 |
| Wenger, TL | 1 |
| Dohrmann, ML | 1 |
| Strauss, HC | 1 |
| Conley, MJ | 1 |
| Wechsler, AS | 1 |
| Wagner, GS | 1 |
| Overlack, A | 6 |
| Stumpe, KO | 9 |
| Müller, HM | 2 |
| Kolloch, R | 4 |
| Higuchi, M | 1 |
| Heuer, LJ | 1 |
| Fletcher, R | 1 |
| Khatri, IM | 4 |
| McKibbin, JK | 1 |
| Pocock, WA | 1 |
| Barlow, JB | 1 |
| Millar, RN | 1 |
| Obel, IW | 1 |
| Ronsberg, MA | 2 |
| Cervoni, P | 3 |
| Bauer, JH | 9 |
| Helgeland, A | 10 |
| Franklin, BB | 1 |
| Chandler, T | 1 |
| Muhammad, A | 1 |
| Plappert, T | 1 |
| St John Sutton, M | 1 |
| Shkhvatsabaia, IK | 2 |
| D'iakonova, EG | 1 |
| Iurenev, AP | 1 |
| Gardin, JM | 2 |
| Lipson, JL | 1 |
| Porter, VD | 1 |
| Blumenstein, BA | 1 |
| Cotsonis, GA | 1 |
| Knudtson, ML | 1 |
| Felner, JM | 1 |
| Schlant, RC | 1 |
| Shen, JQ | 2 |
| Wang, LD | 1 |
| Carnovali, M | 2 |
| Crespi, E | 2 |
| Banderali, G | 1 |
| Missaglia, A | 2 |
| Ponti, GB | 1 |
| Weinstein, M | 1 |
| Hilewitz, H | 1 |
| Rogel, S | 2 |
| Inamoto, N | 1 |
| Nakamura, K | 1 |
| Cushman, DW | 2 |
| Ondetti, MA | 1 |
| Cheung, HS | 1 |
| Antonaccio, MJ | 2 |
| Murthy, VS | 1 |
| Rubin, B | 2 |
| Swartz, SL | 3 |
| Hollenberg, NK | 4 |
| Crantz, FR | 1 |
| Moore, TJ | 1 |
| Levine, L | 1 |
| Sasahara, AA | 1 |
| Dluhy, RG | 1 |
| Gross, DM | 1 |
| Arbegast, PT | 1 |
| Gaul, SL | 1 |
| Britt, PM | 1 |
| Weitz, D | 1 |
| Stone, CA | 1 |
| Zweifler, AJ | 1 |
| Nicholls, MG | 1 |
| Chiarini, C | 1 |
| Fusaroli, M | 1 |
| Masi, A | 1 |
| Santoro, A | 1 |
| Zuccalà, A | 1 |
| Zucchelli, P | 1 |
| Havelka, J | 1 |
| Studer, A | 2 |
| Greminger, P | 3 |
| Lüscher, T | 2 |
| Wollnik, S | 1 |
| Siegenthaler, W | 6 |
| Vetter, W | 7 |
| Mojaverian, P | 2 |
| Lai, FM | 1 |
| Tanikella, T | 1 |
| Herzlinger, H | 1 |
| Goldstein, B | 1 |
| Lee, RB | 1 |
| Molle, D | 1 |
| Labeyrie, E | 1 |
| Daveloose, D | 1 |
| Salesse, R | 1 |
| Viret, J | 1 |
| Leterrier, F | 1 |
| Smith, JB | 1 |
| Chernow, B | 1 |
| Zaloga, GP | 2 |
| Lake, CR | 3 |
| Coleman, MD | 3 |
| Ziegler, MG | 4 |
| Merrill, DG | 1 |
| Inouye, I | 1 |
| Benowitz, N | 2 |
| Simpson, P | 3 |
| Loge, D | 3 |
| Topic, N | 1 |
| Damkjaer Nielsen, M | 6 |
| Galway, AB | 4 |
| Nielsen, F | 3 |
| Jones, LB | 1 |
| Grenfell, RF | 2 |
| George, RB | 3 |
| Manocha, K | 2 |
| Burford, JG | 3 |
| Conrad, SA | 3 |
| Kinasewitz, GT | 1 |
| Friedman, BA | 1 |
| Hla, KM | 1 |
| Neidorf, BS | 1 |
| Gray, JM | 3 |
| Glazer, N | 3 |
| Gross, S | 2 |
| Cressman, MD | 1 |
| Leon, AS | 4 |
| Hunninghake, DB | 2 |
| Thind, GS | 2 |
| Mahapatra, RK | 1 |
| Johnson, A | 1 |
| Coleman, RD | 1 |
| Ohman, KP | 3 |
| Nilsson, OR | 5 |
| Wettre, S | 3 |
| Flamenbaum, V | 1 |
| Ryan, E | 1 |
| Muldowney, FP | 1 |
| Morledge, JH | 3 |
| Beling, S | 1 |
| Vukovich, RA | 3 |
| Neiss, ES | 3 |
| Zisblatt, M | 3 |
| Webb, E | 2 |
| Losi, M | 2 |
| Caruso, F | 1 |
| Schotz, WE | 1 |
| Eff, J | 1 |
| Bronstein, R | 1 |
| Plante, GE | 4 |
| Robillard, C | 1 |
| Ogilvie, R | 1 |
| Langlois, S | 1 |
| Kreeft, J | 1 |
| Montenero, AS | 1 |
| Mazzari, M | 1 |
| Schiavoni, G | 1 |
| Manzoli, U | 1 |
| Gherardi, S | 1 |
| Carr, AA | 5 |
| Pool, PE | 1 |
| Seagren, SC | 1 |
| Salel, AF | 1 |
| Friedman, B | 1 |
| Levit, SA | 1 |
| Ellis, RA | 1 |
| Light, RW | 3 |
| Chetty, KG | 1 |
| Stansbury, DW | 1 |
| Frishman, WH | 8 |
| Michelson, EL | 2 |
| Johnson, BF | 3 |
| Poland, MP | 2 |
| Bloomfield, SS | 1 |
| Lucas, CP | 2 |
| Gantt, CL | 1 |
| Medakovic, M | 3 |
| Velasquez, M | 1 |
| Shvedenko, LA | 5 |
| Parashchak, AP | 3 |
| Ryzhova, VL | 1 |
| da Cunha, GP | 1 |
| Albanesi, FM | 1 |
| Wajngarten, M | 3 |
| Cantarelli, EL | 1 |
| Amery, A | 20 |
| Beard, K | 1 |
| Birkenhäger, W | 14 |
| Bogaert, M | 2 |
| Brixko, P | 5 |
| Bulpitt, C | 12 |
| Clement, D | 10 |
| De Plaen, JF | 4 |
| Deruyettere, M | 1 |
| Kapocsi, J | 1 |
| Vajda, L | 1 |
| Varga, K | 1 |
| Malisak, Z | 1 |
| Fekete, M | 1 |
| Kunos, G | 1 |
| Smilde, JG | 1 |
| Andrén, L | 4 |
| van der Veur, E | 2 |
| ten Berge, BS | 1 |
| Donker, AJ | 2 |
| May, JF | 2 |
| Schuurman, FH | 2 |
| Wesseling, H | 1 |
| Buckert, C | 2 |
| Muhlhausler, W | 1 |
| Fratzer, U | 1 |
| Verho, M | 6 |
| McGowan, GK | 1 |
| Baker, PG | 1 |
| Kirsten, R | 1 |
| Seedat, YK | 4 |
| Hoosen, S | 2 |
| Bhigjee, AI | 2 |
| Inouye, IK | 2 |
| Massie, BM | 7 |
| Steiness, E | 2 |
| Bułanowski, Z | 1 |
| Kokot, F | 5 |
| Bolzano, K | 2 |
| Krempler, F | 1 |
| Sandhofer, F | 1 |
| Savioli, RM | 1 |
| Lima, EV | 1 |
| Estrella, LA | 1 |
| Puppi, EJ | 1 |
| Praxedes, JN | 1 |
| Nassif, M | 1 |
| Stoeber, GH | 1 |
| Del Nero Júnior, E | 1 |
| Novo, S | 5 |
| Strano, A | 4 |
| Costa, FV | 9 |
| Rames, I | 2 |
| Kristufek, V | 2 |
| Ohman, P | 3 |
| Aurell, M | 4 |
| Asplund, J | 4 |
| Conradsson, T | 1 |
| Delin, K | 1 |
| Forslund, T | 2 |
| Frithz, G | 4 |
| Herlitz, H | 3 |
| Karlberg, B | 2 |
| Blume, CD | 2 |
| Williams, RL | 4 |
| Clark, T | 1 |
| Lehtonen, A | 6 |
| Alves Filho, G | 1 |
| Santos, TC | 1 |
| Carvalho, OM | 1 |
| Guariento, ME | 1 |
| Rizzalitti, F | 1 |
| Pandhi, P | 2 |
| Wahi, PL | 2 |
| Sharma, PL | 2 |
| Spritzer, N | 3 |
| Wolmeister, H | 1 |
| Spritzer, TS | 1 |
| Maciel, R | 1 |
| Lindroos, M | 1 |
| Dean, S | 1 |
| Spencer-Mills, L | 2 |
| Sutandar, H | 1 |
| Sugeng, I | 1 |
| Utama, H | 1 |
| Suryaatmaja, M | 1 |
| Dias, GC | 1 |
| Castilho, F | 1 |
| Faria Neto, A | 1 |
| Santos Neto, FB | 1 |
| Assad, JE | 1 |
| Levigard, RM | 1 |
| MacGregor, GA | 9 |
| Banks, RA | 2 |
| Markandu, ND | 7 |
| Bayliss, J | 2 |
| Roulston, J | 1 |
| Thomas, JP | 1 |
| Thomson, WH | 1 |
| Licht, JH | 1 |
| Haley, RJ | 1 |
| Pugh, B | 1 |
| Lewis, SB | 1 |
| Koopmans, PP | 3 |
| Thien, T | 4 |
| Gribnau, FW | 3 |
| Giudicelli, JF | 2 |
| Freslon, JL | 1 |
| Richer, C | 2 |
| Sterkowicz, W | 1 |
| Vaicaitis, JS | 1 |
| Emsley, RA | 1 |
| Gledhill, RF | 1 |
| Barr, J | 1 |
| Spencer, CA | 1 |
| Chan, L | 2 |
| Oles, KS | 1 |
| Denham, JW | 1 |
| Hamilton, BP | 4 |
| Mersey, JH | 1 |
| Hamilton, J | 2 |
| Kuzbida, G | 1 |
| Pavlis, R | 1 |
| Levinson, P | 1 |
| Prcović, M | 1 |
| Stanković, M | 1 |
| Price, M | 2 |
| Johnson, E | 1 |
| Smith, M | 1 |
| Hollifield, JW | 6 |
| Madias, JE | 1 |
| Madias, NE | 1 |
| Gavras, HP | 1 |
| Dons, RF | 1 |
| Phillips, DM | 1 |
| Shear, CL | 1 |
| Houtzagers, JJ | 1 |
| Dols, DM | 1 |
| Meems, L | 1 |
| Young, JH | 2 |
| VandenBurg, MJ | 5 |
| Isitt, VL | 1 |
| Currie, WJ | 4 |
| Boyles, PW | 3 |
| Woollard, ML | 1 |
| Arr, SM | 1 |
| Wight, L | 1 |
| Kher, A | 1 |
| Fillastre, JP | 1 |
| Fourtillan, JB | 1 |
| Lefebvre, MA | 1 |
| Ingrand, I | 1 |
| Koffler, S | 1 |
| Lowenthal, DT | 5 |
| Narins, RG | 2 |
| Dorigotti, L | 1 |
| Carpi, C | 1 |
| Bertoli, G | 1 |
| Mariani, PL | 1 |
| Abman, SH | 1 |
| Warady, BA | 1 |
| Lum, GM | 1 |
| Koops, BL | 1 |
| Garrett, BN | 3 |
| Grunfeld, B | 1 |
| Gimenez, M | 1 |
| Simsolo, R | 1 |
| Mendilaharzu, F | 1 |
| Becu, L | 1 |
| Groth, H | 3 |
| Knüsel, J | 3 |
| Boerlin, HJ | 2 |
| Walger, P | 2 |
| Wehling, M | 2 |
| Kukes, VG | 2 |
| Volkov, RIu | 1 |
| Fager, G | 1 |
| Berglund, G | 7 |
| Bondjers, G | 1 |
| Lager, I | 1 |
| Olofsson, SO | 1 |
| Smith, U | 1 |
| Wiklund, O | 1 |
| Svendsen, UG | 2 |
| Dige-Petersen, H | 2 |
| Fariello, R | 4 |
| Porcellati, C | 2 |
| Innocenti, PF | 1 |
| Corea, L | 5 |
| Roncati, G | 1 |
| Burke, TJ | 1 |
| Nobles, EM | 1 |
| Wolf, PS | 1 |
| Erickson, AL | 1 |
| Noble, RE | 2 |
| Webb, EL | 1 |
| Godfrey, JC | 1 |
| Tsikulin, AE | 1 |
| Friedrich, G | 3 |
| Neus, H | 3 |
| Rüdel, H | 1 |
| von Eiff, AW | 3 |
| Johnson, JE | 1 |
| Wright, LF | 1 |
| Neerahoo, RM | 1 |
| Naidoo, K | 1 |
| Rüddel, H | 2 |
| Schulte, W | 1 |
| Schneider, H | 1 |
| Ferrara, LA | 5 |
| Siani, A | 1 |
| Strazzullo, P | 2 |
| Zborovskiĭ, EI | 1 |
| Avramenko, TV | 1 |
| Gore, RD | 1 |
| Bentivoglio, M | 2 |
| Verdecchia, P | 2 |
| Lipson, LG | 1 |
| Kochar, MS | 7 |
| Kalbfleisch, JH | 2 |
| Blumenthal, SS | 1 |
| Maierhofer, WJ | 1 |
| Lopez, LM | 4 |
| Mehta, JL | 1 |
| Ames, RP | 5 |
| Peacock, PB | 1 |
| Cooper, WD | 4 |
| Eninia, GI | 1 |
| Smeltere, ES | 1 |
| Godlevska, MA | 1 |
| Uzulinia, IP | 1 |
| Leren, P | 6 |
| Foss, OP | 1 |
| Hjermann, I | 4 |
| Holme, I | 4 |
| Lund-Larsen, PG | 1 |
| Hamdy, RC | 1 |
| Davies, A | 1 |
| Arnold, K | 1 |
| Tovey, JD | 1 |
| Saimbi, SS | 1 |
| Short, MD | 1 |
| Exton-Smith, AN | 1 |
| Tubau, JF | 4 |
| Beck, ML | 1 |
| Cline, JF | 1 |
| Hardman, JT | 1 |
| Racela, LS | 1 |
| Davis, JW | 1 |
| Evans, DH | 1 |
| Zacharias, FJ | 1 |
| Cornhill, J | 1 |
| Strykers, PH | 1 |
| Stern, RS | 1 |
| Morse, BM | 1 |
| Kozak, VP | 2 |
| Man'ko, VI | 1 |
| Bigar', PV | 2 |
| Andersson, PO | 2 |
| H-Andersen, H | 1 |
| Hagman, A | 1 |
| Henning, R | 2 |
| Traub, YM | 3 |
| Dujovny, M | 1 |
| Nelson, D | 1 |
| Deruyttere, M | 8 |
| De Schaepdryver, A | 8 |
| Dollery, C | 8 |
| Forte, J | 3 |
| Hamdy, R | 2 |
| MacFarlane, JP | 2 |
| Mutsers, A | 5 |
| O'Malley, K | 3 |
| Silvestrini, C | 1 |
| Maini, C | 1 |
| Marchesi, M | 1 |
| Mueller, G | 1 |
| Salmela, PI | 2 |
| Jounela, AJ | 8 |
| Karppanen, H | 2 |
| Beitman, RE | 1 |
| Kuzma, RJ | 1 |
| Morledge, J | 1 |
| Rolf, CN | 1 |
| Tsai, TH | 1 |
| Rabinad Estrada, E | 1 |
| Ingelmo Morin, M | 1 |
| Martinez Amenos, A | 1 |
| Alsina, J | 1 |
| Balcells Gorina, A | 1 |
| Pedrinelli, R | 2 |
| Simonini, N | 1 |
| Galassi, A | 2 |
| Ginevrino, P | 1 |
| Libretti, A | 2 |
| Morgagni, W | 1 |
| Rappelli, A | 4 |
| Parry, EE | 2 |
| Young, J | 1 |
| Arr, S | 2 |
| Gu, TH | 1 |
| Gu, DG | 1 |
| Wu, SW | 1 |
| Zhao, GS | 1 |
| Pan, XX | 1 |
| Gruppillo, P | 1 |
| Tomaini, MD | 1 |
| Brugger, P | 1 |
| Klein, G | 2 |
| Sundberg, S | 1 |
| Salo, H | 3 |
| Melamies, L | 1 |
| Lamminsivu, U | 1 |
| Nuotto, E | 1 |
| Keränen, A | 1 |
| Hitzenberger, G | 3 |
| Korn, A | 1 |
| Dorcsi, M | 1 |
| Bauer, P | 1 |
| Wohlzogen, FX | 3 |
| Román, O | 3 |
| Valenzuela, MA | 1 |
| Salazar, R | 1 |
| Steim, H | 1 |
| Knappe, J | 1 |
| Dück, KD | 2 |
| Strube, G | 1 |
| Holtz, H | 1 |
| Heinrich, J | 1 |
| Roulston, JE | 1 |
| Jones, JC | 1 |
| El-Mehairy, MM | 3 |
| Shaker, A | 3 |
| Ramadan, M | 3 |
| Hamza, S | 3 |
| Tadros, SS | 4 |
| Wenting, GJ | 1 |
| de Bruyn, JH | 1 |
| Man in't Veld, AJ | 3 |
| Woittiez, AJ | 2 |
| Derkx, FH | 2 |
| Schalekamp, MA | 6 |
| Gross, F | 1 |
| Fabris, B | 2 |
| Bellini, G | 3 |
| Tonutti, L | 1 |
| Battilana, G | 1 |
| Bianchetti, A | 1 |
| Campanacci, L | 2 |
| Affrime, MB | 3 |
| Hamstra, B | 1 |
| Struyker-Boudier, HA | 2 |
| Smits, JF | 1 |
| Kleinjans, JC | 1 |
| van Essen, H | 1 |
| Prupas, HM | 1 |
| Brown, D | 1 |
| Hornung, RS | 1 |
| Gould, BA | 1 |
| Kieso, H | 1 |
| Raftery, EB | 2 |
| Vakaliuk, PM | 2 |
| Nikulin, KE | 2 |
| Iurkevich, ST | 3 |
| Gerasimenko, NI | 1 |
| Tait, D | 1 |
| Flamenbaum, W | 3 |
| Milgrom, M | 2 |
| Artman, M | 1 |
| Boerth, RC | 1 |
| Lorimer, AR | 1 |
| Barbour, MB | 1 |
| Lawrie, TD | 1 |
| Brown, JL | 1 |
| Hagstrom, D | 1 |
| Neporadnyĭ, MD | 1 |
| Aigner, A | 1 |
| Schmidt, U | 1 |
| Danielson, M | 2 |
| Lundbäck, M | 1 |
| Slaton, PE | 2 |
| Widman, L | 2 |
| Dyckner, T | 2 |
| Wester, PO | 5 |
| De Ridder, JH | 1 |
| Marchandise, P | 1 |
| Pietrek, J | 1 |
| Srokowska, S | 1 |
| Wartenberg, W | 1 |
| Kuska, J | 1 |
| Jedrychowska, M | 1 |
| Duda, G | 1 |
| Zielińska, K | 1 |
| Wartenberg, Z | 1 |
| Kuźmiak, M | 1 |
| Lutterodt, A | 1 |
| Nattel, S | 1 |
| McLeod, PJ | 1 |
| van Brummelen, P | 6 |
| Man in 't Veld, AJ | 1 |
| Bergler, JH | 1 |
| Pennington, AC | 1 |
| Metcalfe, M | 1 |
| Koplin, JR | 4 |
| Shirinian, A | 1 |
| Burke, JF | 1 |
| Alexander, JC | 1 |
| van Soeren, F | 1 |
| Hagelund, CH | 3 |
| Tretli, S | 3 |
| Roeckel, A | 1 |
| Heidland, A | 2 |
| Distler, A | 8 |
| Lüth, B | 1 |
| Burns, DG | 1 |
| Pittaway, D | 2 |
| Horovitz, ZP | 1 |
| Odar-Cederlöf, I | 1 |
| Lins, LE | 2 |
| Tolagen, K | 1 |
| Myers, JB | 1 |
| Gillies, A | 2 |
| Waga, S | 1 |
| Hwang, IK | 1 |
| Muccilli, AC | 1 |
| Nissinen, A | 5 |
| Honkavaara, M | 1 |
| Tessman, DK | 2 |
| Kaplan, HR | 1 |
| Nekrasova, AA | 3 |
| Mergenbaeva, TK | 3 |
| Fairchild, C | 2 |
| Gomez-Sanchez, CE | 2 |
| Pörsti, P | 2 |
| Jalonen, K | 1 |
| Ryysy, L | 1 |
| Toivonen, T | 1 |
| Viherkoski, M | 1 |
| Pessina, AC | 9 |
| Casiglia, E | 1 |
| Hlede, M | 4 |
| Gava, R | 1 |
| Schwartz, FN | 1 |
| Tiffany, J | 1 |
| Röckel, A | 1 |
| Pasquel, R | 1 |
| Tribble, PW | 1 |
| Simon, A | 2 |
| Merkle, GW | 1 |
| Bader, PI | 1 |
| Creason, PL | 1 |
| Townsend, DW | 1 |
| Conn, PS | 1 |
| Lakes, MK | 1 |
| Campbell, NM | 1 |
| Manitius, J | 1 |
| Badzio, T | 1 |
| Krupa-Wojciechowska, B | 1 |
| Leary, WP | 7 |
| Reyes, AJ | 3 |
| Mimran, A | 3 |
| Targhetta, R | 1 |
| Laroche, B | 1 |
| Russell, R | 1 |
| Sova-Schultz, K | 1 |
| Wyndham, R | 1 |
| Walker, WG | 2 |
| Freis, E | 1 |
| Cospite, M | 1 |
| Ferrara, F | 1 |
| Raimondi, F | 1 |
| Lo Presti, T | 1 |
| Ballo, M | 1 |
| Milio, G | 1 |
| Meli, F | 1 |
| Dafgärd, T | 1 |
| Forsén, B | 3 |
| Lindahl, T | 1 |
| Liedholm, H | 1 |
| Ursing, D | 1 |
| Lijnen, P | 1 |
| Staessen, J | 9 |
| Vander Elst, E | 3 |
| Van Ypersele de Strihou, C | 2 |
| Wilkins, LH | 1 |
| Winternitz, SR | 1 |
| Dustan, HP | 5 |
| Nievel, JG | 1 |
| Harvard, CW | 1 |
| Aberg, H | 1 |
| Mörlin, C | 2 |
| Rhomberg, F | 1 |
| Leya, A | 1 |
| de Oliveira, JM | 1 |
| Carlier, B | 1 |
| Belleau, LJ | 1 |
| Brossard, JJ | 3 |
| Fischer, RG | 1 |
| Olerud, B | 1 |
| Luborsky, L | 1 |
| Crits-Christoph, P | 1 |
| Brady, JP | 1 |
| Kron, RE | 1 |
| Weiss, T | 1 |
| Cohen, M | 1 |
| Levy, L | 1 |
| Tarazi, RC | 6 |
| Bravo, EL | 4 |
| Walker, BR | 1 |
| Deitch, MW | 2 |
| Gold, JA | 1 |
| Levey, BA | 1 |
| Zelnick, N | 1 |
| Boner, G | 1 |
| Gonasun, LM | 5 |
| Langrall, H | 1 |
| Moser, M | 9 |
| Lunn, J | 6 |
| Campbell, N | 1 |
| Granter-Button, S | 1 |
| MacDonald, J | 1 |
| Gill, V | 1 |
| Lavenius, B | 1 |
| Lochaya, S | 2 |
| Jansiriskul, V | 1 |
| Srivorpongpan, R | 1 |
| Jiamsucson, K | 1 |
| Suvachittanont, O | 2 |
| Penman, WA | 1 |
| Smith, RG | 1 |
| Mitenko, PA | 1 |
| McKenzie, JK | 2 |
| Gobbi, A | 2 |
| Reguzzoni, G | 2 |
| Bonzi, G | 2 |
| Jaffé, G | 2 |
| Grimshaw, JJ | 2 |
| Vallé-Jones, JC | 1 |
| Warnock, JM | 1 |
| Ostapenko, TV | 1 |
| Suvorov, IuI | 1 |
| Konstantinov, EN | 1 |
| Dal Palu, C | 4 |
| Morandin, F | 1 |
| Rossi, GP | 2 |
| Ilika, VG | 1 |
| Aronow, WS | 2 |
| Gay, J | 1 |
| Hossain, M | 1 |
| McCrory, WW | 1 |
| Hellemans, J | 5 |
| Henry, JF | 3 |
| Koistinen, A | 2 |
| Laaser, U | 4 |
| Laher, M | 1 |
| Lewis, P | 1 |
| MacFarlane, J | 3 |
| Meurer, K | 1 |
| Miguel, P | 2 |
| Morris, J | 1 |
| Ohm, OJ | 1 |
| Pelemans, W | 3 |
| Perera, N | 1 |
| Verschueren, LJ | 1 |
| Willemse, P | 2 |
| Fouad, FM | 1 |
| Ponte, CD | 1 |
| Salonen, JT | 1 |
| Ylitalo, P | 1 |
| Spence, JD | 5 |
| Kumar, EB | 1 |
| Nelson, GI | 1 |
| Silke, B | 1 |
| Ahuja, RC | 1 |
| Okoli, RC | 1 |
| Taylor, SH | 1 |
| Zanozdra, NS | 2 |
| Nazarenko, VR | 2 |
| Vykhovaniuk, IV | 1 |
| Levinson, PD | 1 |
| Cassi, E | 1 |
| Colombo, A | 1 |
| De Paoli, A | 1 |
| Marciandi, C | 1 |
| Renzetti, GA | 1 |
| Sau, F | 1 |
| Raffo, M | 1 |
| Seguro, C | 1 |
| Pisano, MR | 1 |
| Pirisi, R | 1 |
| Cherchi, A | 1 |
| Mourão, AM | 1 |
| Reinert, MI | 1 |
| Peixoto, RL | 1 |
| de Moraes, CA | 1 |
| Pimentel Filho, P | 1 |
| Della Marchina, MM | 1 |
| Renzi, G | 1 |
| Serofilli, S | 1 |
| Nixon, JV | 1 |
| Kuhnert, L | 1 |
| Shchepotin, BM | 1 |
| Shchulipenko, IM | 1 |
| Prisiazhniuk, MS | 1 |
| Tsyrul'neva, NI | 1 |
| Hansen, JL | 1 |
| Swanson, LN | 1 |
| Katiukhin, VN | 1 |
| Temirov, AA | 1 |
| Churnosov, EV | 1 |
| Wong, CM | 1 |
| Tse, TF | 1 |
| Green, TP | 1 |
| Nevins, TE | 1 |
| Houser, MT | 1 |
| Sibley, R | 1 |
| Fish, AJ | 1 |
| Sinaiko, AR | 2 |
| Boehringer, K | 1 |
| Meier, A | 1 |
| Weidmann, P | 3 |
| Schiffl, H | 1 |
| Mordasini, R | 1 |
| Riesen, W | 3 |
| Jäättelä, A | 2 |
| Geisler, LS | 1 |
| Herrmann, JM | 1 |
| Hiemstra, S | 1 |
| Hoenig, B | 1 |
| Patel, KM | 1 |
| Mehta, BR | 1 |
| Robinson, BH | 1 |
| Marks, P | 1 |
| Nimalasuriya, A | 1 |
| Anderson, J | 2 |
| Valdés, G | 2 |
| Thomsen, P | 1 |
| Otipka, N | 1 |
| Durley, Y | 1 |
| Cubberley, RB | 1 |
| Thomas, S | 1 |
| Borba, P | 1 |
| Tenório, J | 1 |
| Didier, M | 1 |
| França, P | 1 |
| Santos, A | 2 |
| Schröder, HE | 1 |
| Thiele, P | 1 |
| Dombey, SL | 1 |
| Lawrence, J | 1 |
| Vlassak, W | 1 |
| Salvia, A | 1 |
| Opasich, C | 1 |
| Cobelli, F | 1 |
| Assandri, J | 1 |
| Vecchio, C | 1 |
| Maxwell, M | 1 |
| Alderman, MH | 5 |
| Prachar, H | 1 |
| Nobis, H | 1 |
| Pollak, H | 1 |
| Enenkel, W | 2 |
| Channick, BJ | 2 |
| Kessler, WB | 1 |
| Marks, AD | 2 |
| Adlin, EV | 2 |
| Goodfellow, RM | 2 |
| Westberg, B | 2 |
| Heaton, PB | 1 |
| Davì, G | 1 |
| Avellone, G | 1 |
| Fazio, M | 2 |
| Micci, S | 1 |
| Modica, R | 1 |
| Buzzetti, G | 1 |
| Darmadji, T | 1 |
| Pikir, BS | 1 |
| Yogiarto, M | 1 |
| Saleh, M | 1 |
| Brandão, AP | 1 |
| Albanesi Filho, FM | 1 |
| Tucker, RM | 1 |
| Van Den Berg, CJ | 1 |
| Knox, FG | 1 |
| Beauchemin, M | 2 |
| Vinay, P | 2 |
| Gougoux, A | 2 |
| Pedersen, TR | 1 |
| Morgan, DB | 1 |
| Davidson, C | 4 |
| Kopin, IJ | 2 |
| Penhall, RK | 1 |
| Frewin, DB | 2 |
| Rosenberg, L | 1 |
| Shapiro, S | 1 |
| Slone, D | 1 |
| Kaufman, DW | 1 |
| Miettinen, OS | 1 |
| Stolley, PD | 1 |
| Diaz, VP | 1 |
| Jarillo, MD | 1 |
| Millet, VG | 1 |
| Nadeau, J | 1 |
| Ogilvie, RI | 2 |
| Ruedy, J | 2 |
| García Sacristán, A | 1 |
| Boyden, TW | 1 |
| Nugent, CA | 3 |
| Maeda, T | 1 |
| Cybulska, I | 1 |
| Wasowska-Ciszek, T | 1 |
| Rosenfeld, JB | 3 |
| Bretza, JA | 1 |
| Novey, HS | 1 |
| Vaziri, ND | 1 |
| Warner, AS | 1 |
| Magil, AB | 1 |
| Ballon, HS | 1 |
| Cameron, EC | 1 |
| Rae, A | 1 |
| Lenz, K | 1 |
| Hannan, P | 1 |
| Blackburn, H | 1 |
| Pigato, R | 2 |
| Inui, TS | 1 |
| Carter, WB | 1 |
| Pecoraro, RE | 1 |
| Pearlman, RA | 1 |
| Dohan, JJ | 1 |
| Akhmetov, KZh | 3 |
| Teĭblium, MM | 3 |
| Gol'dberg, VA | 1 |
| Iarema, NI | 1 |
| Rudyk, BI | 1 |
| Safar, M | 5 |
| Metelitsa, VI | 10 |
| Duda, SG | 5 |
| Ostrovskaia, TP | 6 |
| Filatova, NP | 7 |
| Mukhamedzhanova, GF | 2 |
| Vygodin, VA | 5 |
| Siegrist, J | 1 |
| Broer, M | 2 |
| Rakette, S | 1 |
| Woll, EM | 1 |
| Reinfrank, J | 1 |
| Schiemann, J | 1 |
| Jones, DW | 6 |
| Sands, CD | 5 |
| Traub, O | 2 |
| Webb, RC | 3 |
| Narayan, P | 3 |
| Kokkinos, P | 1 |
| Senior, R | 1 |
| Imbs, JL | 2 |
| Bory, M | 1 |
| Amabile, G | 1 |
| Denis, B | 1 |
| De Luca, N | 2 |
| Marchegiano, R | 2 |
| Lahiri, A | 1 |
| Contard, F | 2 |
| Glukhova, M | 2 |
| Sabri, A | 1 |
| Marotte, F | 2 |
| Sartore, S | 1 |
| Narcisse, G | 2 |
| Schatz, C | 2 |
| Guez, D | 3 |
| Rappaport, L | 2 |
| Samuel, JL | 2 |
| Lumme, JA | 4 |
| Catalano, M | 1 |
| Dickstein, K | 1 |
| Aarsland, T | 1 |
| Todd, M | 1 |
| Stimpel, M | 10 |
| Pauly, NC | 2 |
| Safar, ME | 4 |
| Meyer, BH | 1 |
| Frei, M | 1 |
| Küster, L | 1 |
| Gardosch von Krosigk, PP | 1 |
| Koch, HF | 1 |
| Küppers, H | 1 |
| Guul, SJ | 1 |
| Rapeport, WG | 1 |
| Grimwood, VC | 1 |
| Korlipara, K | 1 |
| Grillage, MG | 1 |
| James, I | 1 |
| Anderton, JL | 1 |
| Selfridge, DI | 1 |
| Romero, R | 1 |
| Castellote, E | 1 |
| Ocón, J | 5 |
| Wagner, B | 2 |
| Swensen, E | 1 |
| Gjelsvik, B | 1 |
| Stensland, P | 1 |
| Stavdal, A | 1 |
| Geanon, JD | 1 |
| Perkins, TW | 1 |
| Sanders, LR | 1 |
| Gold, G | 1 |
| Fishman, P | 1 |
| Bauer, IH | 1 |
| Reams, GP | 5 |
| Lau-Sieckman, A | 1 |
| Mehnert, G | 1 |
| Soffer, BA | 1 |
| Wiens, B | 1 |
| Goldberg, AI | 5 |
| Madkour, H | 2 |
| Gadallah, M | 2 |
| Riveline, B | 2 |
| Massry, SG | 2 |
| Enríquez, R | 1 |
| Cabezuelo, JB | 1 |
| González, C | 1 |
| Lacueva, J | 1 |
| Teruel, A | 1 |
| Fernández, J | 1 |
| Arenas, MD | 1 |
| Fox, AA | 2 |
| Streckfus, CF | 2 |
| Prisant, LM | 6 |
| Adegbile, IA | 1 |
| Alemayehu, D | 3 |
| Lefkowitz, MP | 1 |
| Ajayi, AA | 3 |
| Akintomide, AO | 2 |
| Mayaudon, H | 1 |
| Chanudet, X | 1 |
| Janin, G | 1 |
| Madonna, O | 1 |
| Reaven, GM | 1 |
| Clinkingbeard, C | 1 |
| Jeppesen, J | 1 |
| Maheux, P | 1 |
| Pei, D | 1 |
| Foote, J | 1 |
| Hollenbeck, CB | 1 |
| Chen, YD | 1 |
| Santini, DL | 1 |
| Lorenzo, BJ | 1 |
| Koufis, T | 1 |
| Reidenberg, MM | 1 |
| Malamani, GD | 1 |
| Marasi, G | 1 |
| Vanasia, A | 2 |
| Villa, G | 2 |
| Dobrindt, R | 1 |
| Aulehner, R | 2 |
| Lydtin, H | 3 |
| Martina, B | 4 |
| Weinbacher, M | 4 |
| Gasser, P | 3 |
| Rhyner, K | 1 |
| Köhler, M | 2 |
| Wohler, D | 3 |
| LeBloch, Y | 1 |
| Bart, T | 2 |
| Pompeo, F | 1 |
| Gisonni, P | 1 |
| Iovino, G | 1 |
| D'Auria, F | 1 |
| Del Mastro, L | 1 |
| Simonelli, P | 1 |
| Ahaneku, JE | 6 |
| Taylor, GO | 4 |
| Agbedana, OE | 2 |
| Walker, O | 4 |
| Peleg, E | 2 |
| Carroll, J | 2 |
| Shamiss, A | 2 |
| Brunner, H | 2 |
| Irwin, R | 1 |
| Snavely, DB | 2 |
| Dobbins, TW | 1 |
| Faison, EP | 2 |
| Nelson, EB | 5 |
| Dunlay, MC | 2 |
| Pordy, RC | 2 |
| Landahl, S | 2 |
| Singer, DR | 4 |
| Cappuccio, FP | 2 |
| Miller, MA | 2 |
| Sagnella, GA | 2 |
| Klaus, D | 3 |
| Mroczek, WJ | 6 |
| Simon, JS | 1 |
| Chen, SY | 1 |
| Bryzinski, BS | 2 |
| Kirpizidis, HG | 1 |
| Papazachariou, GS | 1 |
| De Lima, MD | 1 |
| Neves, FA | 1 |
| Peterseim, U | 1 |
| von Gizycki-Nienhaus, B | 1 |
| Schattenkirchner, M | 1 |
| Meurer, M | 2 |
| Rolland, PH | 1 |
| Friggi, A | 1 |
| Barlatier, A | 1 |
| Piquet, P | 1 |
| Latrille, V | 1 |
| Faye, MM | 1 |
| Guillou, J | 2 |
| Charpiot, P | 1 |
| Bodard, H | 1 |
| Ghiringhelli, O | 1 |
| Jonsson, O | 1 |
| Sukonthasarn, A | 1 |
| Ratanaprakarn, R | 1 |
| Koanantakul, B | 1 |
| Ngam-Ukos, P | 1 |
| Tettamanti, F | 2 |
| Tettamanzi, D | 2 |
| Lusardi, P | 2 |
| Motolese, M | 5 |
| Fenichel, RR | 2 |
| Lipicky, RJ | 2 |
| Stein, GH | 4 |
| Hamilton, JH | 1 |
| Holtzman, JL | 2 |
| Kirkendall, WM | 4 |
| Abrams, A | 2 |
| Neri, G | 2 |
| Culter, R | 1 |
| Matthews, K | 2 |
| Belz, GG | 4 |
| Breithaupt, K | 2 |
| Erb, K | 2 |
| Pasic, J | 1 |
| Shapiro, D | 1 |
| Jamner, LD | 1 |
| Hui, KK | 1 |
| Lenz, T | 1 |
| Schulte, KL | 1 |
| Lilienthal, J | 1 |
| Gotzen, R | 3 |
| Genthon, R | 1 |
| Wu, AJ | 1 |
| Ship, JA | 1 |
| Brown, LJ | 1 |
| Chrysant, S | 2 |
| Kaihlanen, PM | 1 |
| Lueg, M | 2 |
| Anzalone, D | 1 |
| Agbedana, EO | 3 |
| Nakhle, G | 1 |
| Pollare, T | 4 |
| Berne, C | 3 |
| Jergas, M | 1 |
| Kosow, A | 1 |
| Uffmann, M | 1 |
| Schmutz, G | 1 |
| Böckenförde, JB | 1 |
| Glüer, CC | 1 |
| Köster, O | 1 |
| Lilja, M | 2 |
| Lumme, J | 1 |
| Hoyem, A | 1 |
| Wessel-Aas, T | 1 |
| Borrild, NJ | 1 |
| Verhaeghe, J | 1 |
| Creytens, G | 2 |
| Coupez, G | 1 |
| Van Dessel, A | 1 |
| Opsomer, M | 1 |
| Corcoran, C | 1 |
| Applegate, WB | 3 |
| Davidov, ME | 2 |
| Avanzini, F | 1 |
| Alli, C | 1 |
| Bettelli, G | 1 |
| Corso, R | 1 |
| Colombo, F | 1 |
| Mariotti, G | 1 |
| Radice, M | 1 |
| Torri, V | 1 |
| Tognoni, G | 1 |
| Canter, D | 1 |
| Frank, GJ | 1 |
| Knapp, LE | 1 |
| Phelps, M | 1 |
| Quade, M | 1 |
| Texter, M | 1 |
| Fagan, TC | 4 |
| Coulson, LR | 1 |
| DeQuattro, VL | 1 |
| Dukart, G | 1 |
| Goldberg, JD | 1 |
| Koury, K | 1 |
| Arnott, W | 2 |
| Nakai, T | 1 |
| Hiatt, RA | 1 |
| Tolan, K | 1 |
| Quesenberry, CP | 1 |
| Tsoporis, J | 1 |
| Fields, N | 1 |
| Lee, RM | 1 |
| Mora-Macià, J | 1 |
| Castellet, R | 2 |
| del Río, G | 3 |
| Boulard, JC | 1 |
| Hanslik, T | 1 |
| Alterescu, R | 1 |
| Baglin, A | 1 |
| Manoshkina, EM | 1 |
| Aĭvazian, TA | 1 |
| Kondrat'ev, VV | 1 |
| Fauvel, JP | 1 |
| Wimart, MC | 1 |
| Adolphe, AB | 1 |
| Rofman, BA | 2 |
| Brescia, D | 1 |
| Zellner, SR | 1 |
| Kool, MJ | 2 |
| Lustermans, FA | 2 |
| Breed, JG | 2 |
| Hoeks, AP | 2 |
| Van Bortel, LM | 2 |
| Simonella, C | 3 |
| Meneghetti, G | 2 |
| Chierichetti, F | 3 |
| Serena, L | 1 |
| Claroni, F | 1 |
| Fazari, G | 1 |
| Ferlin, G | 3 |
| Archambault, F | 2 |
| Stevenson, JG | 1 |
| Chideckel, EW | 1 |
| Middlemost, SJ | 1 |
| Tager, R | 1 |
| Davis, J | 1 |
| Siegel, D | 2 |
| Saliba, P | 1 |
| Haffner, S | 1 |
| Letellier, P | 1 |
| Agnes, E | 1 |
| Desche, P | 3 |
| Pirich, C | 1 |
| Banyai, M | 1 |
| Asmar, RG | 2 |
| Chaouche-Teyara, K | 1 |
| Raveau-Landon, CM | 1 |
| Bielen, E | 1 |
| Lueg, MC | 1 |
| Targum, S | 1 |
| Cardenas, P | 1 |
| Klassen, D | 1 |
| Goodfriend, TL | 2 |
| Schuna, AA | 4 |
| Young, DY | 1 |
| Peterson, CA | 1 |
| Introcaso, L | 1 |
| Santello, JL | 2 |
| Escobar, E | 1 |
| Roessler, E | 1 |
| Zarate, H | 1 |
| Medina, E | 1 |
| Carruthers, SG | 1 |
| Vint-Reed, C | 1 |
| Lever, AF | 1 |
| Brennan, PJ | 1 |
| Antikainen, R | 2 |
| Bert, P | 2 |
| Hakamäki, T | 1 |
| Feldman, RD | 1 |
| Freeman, DJ | 1 |
| Bierbrier, GS | 1 |
| Anthony, SE | 1 |
| Brown, JE | 1 |
| Ranieri, G | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Lamontanara, G | 1 |
| Fernández, M | 2 |
| Madero, R | 1 |
| González, D | 1 |
| Camacho, P | 1 |
| Villalpando, J | 1 |
| Arriaga, J | 2 |
| Vardan, S | 5 |
| Hill, NE | 4 |
| Mehrotra, KG | 3 |
| Mookherjee, S | 5 |
| Smulyan, H | 4 |
| Perry, HM | 3 |
| Benz, JR | 2 |
| Bartels, DW | 1 |
| Due, DL | 2 |
| Peng, A | 1 |
| Sirgo, M | 1 |
| Mandal, AK | 1 |
| Markert, RJ | 1 |
| Bell, RD | 1 |
| Poujol, A | 1 |
| Rimet, Y | 1 |
| Cournelle, MA | 1 |
| Cornus, P | 1 |
| Frayssinet, R | 1 |
| Zarrouk, F | 1 |
| Brusquet, Y | 1 |
| De Cort, P | 5 |
| Fletcher, A | 5 |
| Kivinen, P | 1 |
| Lehtomaki, E | 1 |
| Arriaga-Gracia, J | 1 |
| Sánchez-Garcia, JL | 1 |
| González-García, CA | 1 |
| Breitstadt, A | 4 |
| Cairns, V | 5 |
| Bauer, B | 4 |
| Bender, N | 3 |
| Priestley, C | 1 |
| Moreadith, C | 1 |
| Phillips, J | 1 |
| Koch, G | 1 |
| Bray-Desboscs, L | 1 |
| el Ghawi, R | 2 |
| Donner, M | 1 |
| Thibout, E | 1 |
| Stoltz, JF | 3 |
| Ljungman, S | 1 |
| Wikstrand, J | 3 |
| Hartford, M | 1 |
| Lindstedt, G | 1 |
| Heidbreder, D | 3 |
| Froer, KL | 3 |
| Zemel, PC | 1 |
| Nichols, FT | 1 |
| Zemel, MB | 1 |
| Thompson, WO | 1 |
| Carruthers, G | 1 |
| Dessain, P | 1 |
| Fodor, G | 1 |
| Newman, C | 1 |
| Palmer, W | 1 |
| Sim, D | 1 |
| Provencher, P | 4 |
| Reda, DJ | 8 |
| Hamburger, RJ | 1 |
| Fye, C | 1 |
| Lakshman, R | 1 |
| Gottdiener, J | 2 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Gall, MA | 2 |
| Rossing, P | 2 |
| Skøtt, P | 2 |
| Hommel, EE | 1 |
| Mathiesen, ER | 2 |
| Gerdes, LU | 2 |
| Lauritzen, M | 2 |
| Vølund, A | 2 |
| Faergeman, O | 2 |
| Beck-Nielsen, H | 2 |
| McCorvey, E | 1 |
| Culbert, JP | 1 |
| McKenney, JM | 3 |
| Proctor, JD | 1 |
| Annett, MP | 1 |
| Poulter, NR | 1 |
| Sanderson, JE | 1 |
| Thompson, AV | 1 |
| Sever, PS | 3 |
| Chang, CL | 1 |
| Furberg, CD | 6 |
| Byington, RP | 5 |
| Gibbons, ME | 2 |
| Otterstad, JE | 6 |
| Froeland, G | 5 |
| Erikssen, J | 2 |
| Romo, M | 2 |
| Hirvonen, H | 1 |
| Pitkämäki, L | 1 |
| Pynnönen, S | 1 |
| Saarinen, P | 1 |
| Lüscher, TF | 1 |
| Schubiger, JL | 1 |
| Swynghedauw, B | 1 |
| Goodrich, AL | 1 |
| Kohn, SR | 1 |
| Nadeau, A | 2 |
| Tancrède, G | 2 |
| Cook, CA | 1 |
| Champion, D | 1 |
| Wong, S | 1 |
| Jenkins, PA | 1 |
| Kong, BW | 2 |
| Gagné, C | 2 |
| Licata, G | 2 |
| Scaglione, R | 3 |
| Guillet, C | 2 |
| Capuana, G | 2 |
| Parrinello, G | 3 |
| Indovina, A | 2 |
| Lipari, R | 2 |
| Mazzola, G | 1 |
| Merlino, G | 1 |
| Slovick, DI | 1 |
| Cox, J | 3 |
| Melis, MG | 1 |
| Tonolo, G | 1 |
| Soro, A | 2 |
| Madeddu, P | 1 |
| Pazzola, A | 1 |
| Pala, F | 1 |
| Kellaway, GS | 1 |
| Oliván Martínez, J | 1 |
| Hoyos Jiménez, M | 1 |
| Miranda García, MJ | 1 |
| Justo Alpañés, E | 1 |
| Pérez Cano, R | 1 |
| Schneeweiss, A | 4 |
| Marmor, A | 3 |
| Alcocer, L | 1 |
| Campos, C | 1 |
| Bahena, JH | 1 |
| Nacaud, A | 1 |
| Parra Carillo, J | 1 |
| Weber, C | 1 |
| Lerebours, G | 1 |
| Mickalonis, L | 1 |
| Villahermosa, MT | 1 |
| Lloyd, MC | 1 |
| Kriegman, A | 1 |
| Opsahl, JA | 2 |
| Goldberg, MR | 5 |
| Katz, SA | 1 |
| Struyker Boudier, HA | 1 |
| Reneman, RS | 1 |
| Velasco-Cornejo, IF | 1 |
| Martin, LC | 2 |
| MacKay, JH | 1 |
| Arcuri, KE | 2 |
| Snapinn, SM | 1 |
| Fitzpatrick, V | 1 |
| Francischetti, EA | 1 |
| Silverberg, DS | 1 |
| Iaina, A | 1 |
| Taylor, OG | 1 |
| Behr, U | 2 |
| Tönnesmann, U | 2 |
| Gurwitz, JH | 1 |
| Everitt, DE | 1 |
| Monane, M | 1 |
| Choodnovskiy, I | 1 |
| Beaudet, MP | 1 |
| Petersen, JR | 2 |
| Drabaek, H | 1 |
| Gleerup, G | 2 |
| Mehlsen, J | 2 |
| Petersen, LJ | 1 |
| Winther, K | 2 |
| Hersh, AD | 1 |
| Kelly, JG | 1 |
| Laher, MS | 2 |
| Carmody, M | 1 |
| Doyle, GD | 1 |
| Aucott, JN | 1 |
| Pelecanos, E | 1 |
| Dombrowski, R | 1 |
| Fuehrer, SM | 1 |
| Laich, J | 1 |
| Aron, DC | 1 |
| van Bogaert, LJ | 1 |
| Bieniaszewski, L | 1 |
| O'Brien, ET | 3 |
| Jääskivi, M | 3 |
| Válek, J | 1 |
| Válková, L | 1 |
| Storková, H | 1 |
| Lapidus, L | 2 |
| Reggi, DR | 1 |
| Plesher, MM | 1 |
| Saini, RK | 2 |
| Battikha, JP | 2 |
| Breithaupt-Grögler, K | 2 |
| Leschinger, M | 2 |
| Butzer, R | 1 |
| de May, C | 1 |
| Sinn, W | 1 |
| Cozic, J | 1 |
| Grégoire, M | 1 |
| Heyrman, J | 1 |
| Stibbe, G | 1 |
| Van den Haute, M | 1 |
| Prince, M | 1 |
| Lewis, G | 1 |
| Bird, A | 1 |
| Blizard, R | 1 |
| Mann, A | 1 |
| Gonzalez, NM | 1 |
| Liebson, PR | 1 |
| Darioli, R | 1 |
| Simeon-Dubach, D | 1 |
| Wunderlin, R | 1 |
| Ganguzza, A | 2 |
| Corrao, S | 1 |
| Costa, R | 1 |
| Paternà, S | 1 |
| Cannavo, MG | 1 |
| Di Chiara, T | 1 |
| D'Aubert, MD | 1 |
| Cottone, C | 1 |
| McCrea, JB | 1 |
| Tomasko, L | 1 |
| Hsieh, JY | 1 |
| Capra, NL | 1 |
| Ignat'ev, VG | 1 |
| Pavlova, LI | 1 |
| Rumiantsev, AS | 1 |
| Pavlov, SS | 1 |
| Privalov, AN | 1 |
| Chil'tsov, VV | 1 |
| Simpson, RL | 1 |
| Toh, J | 1 |
| van Jaarsveld, BC | 1 |
| Krijnen, P | 1 |
| Pieterman, H | 1 |
| Dees, A | 1 |
| Postma, CT | 1 |
| Himmelmann, A | 1 |
| Bergbrant, A | 1 |
| Larochelle, P | 2 |
| Dey, HM | 1 |
| Soufer, R | 1 |
| Hoffer, P | 1 |
| Wackers, FJ | 1 |
| Plaschke, M | 1 |
| Oelzner, S | 1 |
| Brandstädt, A | 1 |
| Hoffmann, A | 1 |
| Persson, B | 1 |
| Ono, Y | 1 |
| Ono, H | 1 |
| Frohlich, ED | 7 |
| Skoularigis, J | 1 |
| Strugo, V | 1 |
| Chopamba, A | 1 |
| Setekge, S | 1 |
| Stewart, WH | 2 |
| Bagdade, JD | 1 |
| Buchanan, WF | 1 |
| Laflèche, A | 1 |
| Gautier, S | 1 |
| Safar, A | 1 |
| Ebner, F | 1 |
| Afolabi, MA | 1 |
| Balogun, MO | 1 |
| Adigun, AQ | 1 |
| Ajayi, OE | 1 |
| Manning, G | 1 |
| Joy, A | 1 |
| Mathias, CJ | 1 |
| McDonald, CJ | 1 |
| Millar-Craig, MW | 1 |
| Voegeli, J | 1 |
| Baumann, P | 1 |
| Hammerschmidt, R | 1 |
| Schaaf, D | 1 |
| Lohmann, FW | 1 |
| Luccioni, R | 2 |
| Di Perri, T | 2 |
| Laurandin, I | 1 |
| Brault, Y | 1 |
| Chastang, C | 2 |
| Madren, EM | 1 |
| Paran, E | 1 |
| Anson, O | 1 |
| Neumann, L | 1 |
| Le Bloch, Y | 1 |
| Himmel, W | 1 |
| Lönker, B | 1 |
| Kochen, MM | 1 |
| Sowunmi, A | 1 |
| Cléroux, J | 2 |
| Boileau, G | 1 |
| Hirawa, N | 1 |
| Kawabata, Y | 1 |
| Nagoshi, H | 1 |
| Kaneko, H | 1 |
| Gomi, T | 1 |
| Goto, A | 1 |
| Toyo-oka, T | 1 |
| Omata, M | 1 |
| Nwachuku, CE | 1 |
| Bartens, W | 1 |
| Nauck, M | 1 |
| Wanner, C | 1 |
| Franz, M | 1 |
| Hörl, WH | 1 |
| Notter, T | 2 |
| Zilles, P | 1 |
| Benz, J | 1 |
| Oshrain, C | 1 |
| Henry, D | 1 |
| Avery, C | 1 |
| Keinänen-Kiukaanniemi, S | 2 |
| Rasmusen, M | 1 |
| Pekkarinen, T | 1 |
| Pitkäjärvi, T | 3 |
| Takala, J | 1 |
| Magometschnigg, D | 3 |
| Gottdiener, JS | 3 |
| Williams, DW | 2 |
| Anderson, RJ | 1 |
| Shou, I | 3 |
| Wang, LN | 3 |
| Fukui, M | 3 |
| Tomino, Y | 3 |
| Koch, B | 3 |
| Arabidze, G | 2 |
| Grigorow, M | 1 |
| Jankulova, K | 1 |
| Kohonen-Jalonen, P | 1 |
| Lazebnic, L | 1 |
| Mantova, S | 1 |
| Kermova, P | 1 |
| Vänskä, O | 1 |
| Richter, WO | 1 |
| Schwandt, P | 2 |
| Hegner, G | 1 |
| Faust, G | 1 |
| Meilenbrock, S | 1 |
| Sullivan, J | 1 |
| Bodin, F | 1 |
| Tang, Z | 1 |
| Reisin, E | 3 |
| Hutchinson, HG | 2 |
| Anzalone, DA | 1 |
| Tuck, ML | 5 |
| Anlauf, M | 1 |
| Michaelis, J | 3 |
| Wellek, S | 3 |
| Hotnes, T | 1 |
| Dollerup, J | 2 |
| Mogensen, CE | 2 |
| Carney, S | 2 |
| Wing, L | 2 |
| Ribeiro, A | 1 |
| Kallwellis, R | 1 |
| Viskoper, RJ | 1 |
| Kobrin, I | 1 |
| Lazebnik, LB | 1 |
| Malichenko, SB | 1 |
| Serebrov, AN | 1 |
| Arabidze, GG | 2 |
| Novrit, BA | 1 |
| Siegrist, I | 1 |
| Letzel, H | 2 |
| Arens, HJ | 1 |
| Marín, P | 1 |
| Saini, R | 4 |
| Velasquez, MT | 3 |
| Striffler, JS | 1 |
| Abraham, AA | 1 |
| Michaelis, OE | 1 |
| Scalbert, E | 2 |
| Thibault, N | 1 |
| Moryleva, ON | 1 |
| Drozdov, VN | 1 |
| Moiseev, VS | 1 |
| Ol'binskaia, LI | 2 |
| Cushman, WG | 1 |
| Zachariah, PK | 1 |
| Gottdiener, PS | 1 |
| Chase, GA | 1 |
| Suzuki, S | 1 |
| Harvey, PJ | 1 |
| Bune, AJ | 5 |
| Chalmers, JP | 5 |
| Rahn, KH | 2 |
| Heesen, WF | 1 |
| Beltman, FW | 1 |
| Smit, AJ | 1 |
| de Graeff, PA | 1 |
| Havinga, TK | 1 |
| Meyboom-de Jong, B | 1 |
| Lie, KI | 1 |
| Faulhaber, HD | 1 |
| Molinero, E | 1 |
| Murga, N | 1 |
| Sagastagoitia, JD | 1 |
| Garrido, J | 3 |
| Webb, RL | 1 |
| Navarrete, AE | 1 |
| Davis, S | 1 |
| Pahor, M | 3 |
| Psaty, BM | 1 |
| Hall, DR | 1 |
| Odendaal, HJ | 1 |
| Stamatelopoulos, S | 1 |
| Moulopoulos, S | 1 |
| Tedesco, MA | 3 |
| Ratti, G | 3 |
| Aquino, D | 2 |
| Caccavale, A | 1 |
| Acitorio, M | 1 |
| Rocereto, A | 1 |
| Cosimi, R | 1 |
| Coppolino, P | 1 |
| Iarussi, D | 3 |
| Iacono, A | 3 |
| Sihm, I | 1 |
| Schroeder, AP | 1 |
| Aalkjaer, C | 1 |
| Mulvany, MJ | 1 |
| Thygesen, K | 1 |
| Pelttari, LH | 1 |
| Hietanen, EK | 1 |
| Salo, TT | 1 |
| Kataja, MJ | 1 |
| Kantola, IM | 1 |
| Roman, MJ | 1 |
| Pickering, TG | 1 |
| Keating, JO | 1 |
| Sealey, JE | 1 |
| Littlejohn, TW | 1 |
| Shephard, AM | 1 |
| Wilson, TW | 2 |
| Wright, J | 1 |
| Kassler-Taub, KB | 1 |
| Reeves, RA | 2 |
| Mas, A | 1 |
| Jordana, R | 1 |
| Vallés, J | 1 |
| Cervantes, M | 1 |
| McClennen, W | 1 |
| Wilson, T | 1 |
| Manyemba, J | 1 |
| Gadsbøll, N | 2 |
| Jensen, BH | 1 |
| Høilund-Carlsen, PF | 1 |
| Buter, H | 1 |
| Hemmelder, MH | 1 |
| de Jong, PE | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Sleight, P | 1 |
| Williams, G | 1 |
| Wittes, J | 1 |
| Fakouhi, TD | 1 |
| Drewe, J | 1 |
| Bray des Boscs, L | 1 |
| Meilhac, B | 2 |
| Montestruc, F | 1 |
| Sha, L | 1 |
| Smith, DA | 1 |
| Cleary, EW | 1 |
| Watkins, S | 1 |
| Huffman, CS | 1 |
| Dilzer, SC | 1 |
| Lasseter, KC | 2 |
| Gerhardt, G | 1 |
| Lehmann, G | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 2 |
| Fagard, RH | 3 |
| Efstratopoulos, AD | 2 |
| Petrie, JC | 2 |
| Zulli, R | 3 |
| Corbellini, C | 2 |
| Monteduro, C | 2 |
| Limongelli, G | 1 |
| di Salvo, G | 1 |
| Mennella, S | 2 |
| Meurin, P | 1 |
| Larrazet, F | 1 |
| Weber, H | 1 |
| Bourmayan, C | 1 |
| Pezza, V | 1 |
| Bernardini, F | 1 |
| Pezza, E | 1 |
| Pezza, B | 1 |
| Curione, M | 1 |
| Farthing, D | 1 |
| Fakhry, I | 1 |
| Ripley, EB | 1 |
| Ames, R | 1 |
| Nielsen, S | 1 |
| Nielsen, B | 1 |
| Conlin, PR | 1 |
| Elkins, M | 1 |
| Liss, C | 2 |
| Vrecenak, AJ | 1 |
| Barr, E | 1 |
| Craven, TE | 3 |
| Pickkers, P | 1 |
| Russel, FG | 1 |
| Smits, P | 1 |
| Gong, L | 3 |
| De Jong, MJ | 1 |
| Reed, A | 1 |
| Fitzsimmons, S | 1 |
| Anderson, NH | 1 |
| Devlin, AM | 2 |
| Morton, JJ | 1 |
| Schork, NJ | 1 |
| Brun, C | 1 |
| Rosenstock, J | 1 |
| Rossi, L | 1 |
| Lin, CS | 1 |
| MacNeil, D | 1 |
| Osbakken, M | 1 |
| DeQuattro, V | 4 |
| Hermansson, K | 1 |
| Lakshman, MR | 1 |
| Caupers, P | 1 |
| Rafik, A | 1 |
| Polónia, J | 1 |
| Dziak, GV | 1 |
| Kolomiets, SN | 1 |
| Minakov, AI | 1 |
| Fushteĭ, IM | 2 |
| Iavorskiĭ, OG | 1 |
| Bekker, VF | 1 |
| Vankhanen, VN | 1 |
| Davydova, IV | 1 |
| Zaĭtseva, VI | 1 |
| Kolesnik, TV | 1 |
| Kolomiets, VV | 1 |
| Svishchenko, EP | 1 |
| Taran, AI | 1 |
| Shlykova, NA | 1 |
| Barbich-Zhagar, B | 1 |
| Phillips, PJ | 1 |
| Tallis, GA | 1 |
| Popplewell, PY | 1 |
| Gasowski, J | 1 |
| Duggan, J | 1 |
| Rodico, JL | 1 |
| Ylitalo, A | 1 |
| Airaksinen, KE | 1 |
| Huikuri, HV | 1 |
| Luna, RL | 2 |
| Ramirez, JA | 1 |
| Batlouni, M | 1 |
| da Rocha, JC | 1 |
| Feitosa, GS | 1 |
| Castro, I | 1 |
| Chaves Júnior, Hde C | 1 |
| God, EM | 1 |
| Maia, LN | 1 |
| Raineri, AM | 1 |
| Langtry, HD | 1 |
| McClellan, KJ | 1 |
| Negrusz-Kawecka, M | 1 |
| Salo, TM | 1 |
| Kantola, I | 1 |
| Voipio-Pulkki, LM | 1 |
| Pelttari, L | 1 |
| Viikari, JS | 1 |
| Valtchanova, SP | 1 |
| Tshele, EF | 1 |
| Diamant, M | 1 |
| Vincent, HH | 1 |
| Brosnan, MJ | 1 |
| Clark, JS | 1 |
| Papademitriou, V | 1 |
| Guthrie, G | 1 |
| Sega, R | 1 |
| Giummelly, P | 1 |
| Lartaud-Idjouadiene, I | 1 |
| Marque, V | 1 |
| Niederhoffer, N | 1 |
| Chillon, JM | 2 |
| Capdeville-Atkinson, C | 2 |
| Atkinson, J | 2 |
| Kochar, M | 1 |
| Triscari, J | 1 |
| Kassler-Taub, K | 2 |
| Levine, JH | 1 |
| Zuschke, CA | 1 |
| Ripley, E | 2 |
| Hardison, JD | 1 |
| Cushing, DJ | 1 |
| Prasad, R | 1 |
| Thakur, V | 1 |
| Cook, ME | 1 |
| Wallin, JD | 1 |
| Flack, J | 2 |
| Reeves, R | 1 |
| Kimura, G | 1 |
| Lombardi, C | 1 |
| Dettori, F | 1 |
| Parpaglia, PP | 1 |
| Alibrandi, MT | 1 |
| Howe, P | 1 |
| Phillips, P | 1 |
| Theodorou, J | 1 |
| Pappas, H | 1 |
| Papagalanis, N | 1 |
| Katopodis, K | 1 |
| Kalaitzidis, R | 1 |
| Siamopoulos, KC | 1 |
| Manzo, G | 1 |
| Grieco, M | 1 |
| Rainone, AC | 1 |
| Sizova, ZhM | 1 |
| Zheleznykh, EA | 1 |
| Fitilev, SB | 1 |
| Sergeeva, TE | 1 |
| Pukhlianko, ME | 1 |
| Potapova, GN | 1 |
| King, K | 1 |
| Dieterle, T | 1 |
| Battegay, E | 1 |
| Louis, WJ | 1 |
| Mander, AG | 1 |
| Dawson, M | 1 |
| Conway, EL | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Kdher, Y | 1 |
| Le Bray Des Boses, B | 1 |
| Ghawi, RE | 1 |
| Cauchois, G | 1 |
| Gentils, M | 1 |
| Muller, S | 1 |
| Owens, P | 1 |
| Kelly, L | 1 |
| Nallen, R | 1 |
| Ryan, D | 2 |
| Fitzgerald, D | 1 |
| Fasce, E | 1 |
| Wagemann, H | 1 |
| O'Kane, KP | 1 |
| Istad, H | 1 |
| Van Mierlo, HF | 1 |
| Kraiczi, H | 1 |
| Hedner, J | 1 |
| Peker, Y | 1 |
| Grote, L | 1 |
| Huff, M | 1 |
| Barnett, PA | 1 |
| Malmqvist, K | 1 |
| Kahan, T | 3 |
| Maresca, A | 2 |
| Pauletto, P | 2 |
| Niegowska, J | 1 |
| Baiz, AQ | 1 |
| Vrijens, F | 1 |
| Bortman, G | 1 |
| Cifková, R | 1 |
| Nakov, R | 1 |
| Novozámská, E | 1 |
| Hejl, Z | 1 |
| Petrzílková, Z | 1 |
| Poledne, R | 1 |
| Stávek, P | 1 |
| Compagnone, D | 1 |
| Hlatswayo, MN | 1 |
| Schillaci, G | 1 |
| Reboldi, GP | 1 |
| Sacchi, N | 1 |
| Bruni, B | 1 |
| Benemio, G | 1 |
| Ester, A | 1 |
| Teuben, E | 1 |
| Nossent, JC | 1 |
| Boschi, S | 3 |
| Vantaggiato, G | 1 |
| Torri, C | 1 |
| Zini, I | 1 |
| Agnati, LF | 1 |
| Zoli, M | 1 |
| Biagini, G | 1 |
| Viskoper, JR | 1 |
| Antonios, TF | 1 |
| He, FJ | 1 |
| Hanon, O | 1 |
| Franconi, G | 1 |
| Baleydier, A | 1 |
| Croce, I | 1 |
| Viigimaa, M | 1 |
| Allikmets, K | 1 |
| Parik, T | 1 |
| Skards, J | 1 |
| Franken, A | 1 |
| Häss, G | 1 |
| Consoli, S | 2 |
| Safavian, A | 2 |
| Dubanchet, A | 1 |
| Ohma, KP | 1 |
| Milon, H | 3 |
| Valnes, K | 1 |
| Lehrl, S | 1 |
| Grässel, E | 1 |
| Eicke, C | 1 |
| Jelakovic, B | 1 |
| Jacovides, A | 1 |
| Bernhardi, DC | 1 |
| Cabrera, WJ | 1 |
| Watanabe, LA | 1 |
| Barragan, J | 1 |
| Matadamas, N | 1 |
| Mendiola, A | 1 |
| Woo, KS | 3 |
| Mejia, AD | 1 |
| Bunt, T | 1 |
| Dumortier, T | 1 |
| Reilly, PA | 2 |
| Fernández, G | 1 |
| González-Esteban, J | 1 |
| Schelling, A | 1 |
| Meinicke, T | 1 |
| Deichsel, G | 1 |
| Biiasilov, NS | 1 |
| Goldberg, A | 2 |
| Welch, WJ | 1 |
| Wilcox, CS | 1 |
| Su, JZ | 1 |
| Chen, SC | 1 |
| Wu, KG | 1 |
| Chen, DG | 1 |
| Rui, HB | 1 |
| Wang, XY | 1 |
| Wang, HJ | 1 |
| Voyaki, SM | 1 |
| Libhaber, E | 2 |
| Den Hond, E | 1 |
| Libhaber, C | 1 |
| Skudicky, D | 2 |
| Lin, Y | 1 |
| Kagiyama, S | 1 |
| Abe, I | 2 |
| Brouwers, AJ | 1 |
| van der Meulen, J | 1 |
| Carollo, C | 1 |
| Santipolo, N | 1 |
| Campbell, M | 1 |
| Sonkodi, S | 1 |
| Wiecek, A | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Motro, M | 1 |
| Shemesh, J | 1 |
| Gariépy, J | 1 |
| Moyse, D | 1 |
| Levenson, J | 1 |
| Levine, B | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Barbagallo, M | 1 |
| Bedigian, MP | 1 |
| Lewin, A | 1 |
| Yellen, L | 1 |
| Barbosa, JA | 1 |
| Kushnir, E | 1 |
| Gradman, A | 1 |
| Kraus, WE | 1 |
| Lester, FM | 1 |
| Alderman, M | 1 |
| Green, S | 1 |
| Espenshade, M | 1 |
| Ceesay, P | 1 |
| Alexander, J | 1 |
| Bonaduce, D | 1 |
| Bertocchi, F | 3 |
| Mann, J | 2 |
| Condorelli, M | 1 |
| Vaïsse, B | 3 |
| Ghobrial, H | 1 |
| Vaur, L | 1 |
| Poncelet, P | 1 |
| Perk, G | 1 |
| Ghanem, J | 1 |
| Aamar, S | 1 |
| Ben-Ishay, D | 1 |
| Bursztyn, M | 1 |
| Aschwanden, R | 1 |
| Sadecky, L | 1 |
| Tytus, R | 1 |
| O'Keefe, D | 1 |
| Lenis, J | 2 |
| Orchard, R | 1 |
| Martin, K | 1 |
| Nikas, S | 1 |
| Dezii, CM | 2 |
| Shabanov, VA | 1 |
| Terekhina, EV | 1 |
| Kostrov, VA | 1 |
| Puig, JG | 1 |
| Rodríguez-Pérez, JC | 1 |
| Schiffrin, EL | 1 |
| Pu, Q | 1 |
| Adam, SA | 1 |
| Rosolová, H | 1 |
| Cech, J | 1 |
| Sefrna, F | 1 |
| Sawathiparnich, P | 1 |
| Candy, G | 1 |
| Radevski, I | 1 |
| Valtchanova, Z | 1 |
| Tshele, E | 1 |
| Di, SS | 1 |
| Dorigatti, F | 1 |
| Wienen, W | 1 |
| Schierok, HJ | 1 |
| Conti, M | 1 |
| Natalizio, M | 1 |
| Madeleine, G | 1 |
| Paccaud, F | 1 |
| Verboom, CN | 1 |
| Jäger, B | 1 |
| Lauten, WB | 1 |
| Khan, QA | 1 |
| Navalkar, S | 1 |
| Parthasarathy, S | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Bhagat, K | 1 |
| Melian, EB | 1 |
| Jarvis, B | 1 |
| Iida, M | 1 |
| Adamopoulos, C | 1 |
| Argyriadis, P | 1 |
| Bean, K | 1 |
| Mazzali, M | 1 |
| Kanellis, J | 1 |
| Han, L | 1 |
| Feng, L | 1 |
| Xia, YY | 1 |
| Chen, Q | 1 |
| Gordon, KL | 1 |
| Watanabe, S | 1 |
| Lan, HY | 1 |
| Soler, J | 1 |
| Felip, A | 1 |
| Pelegrí, A | 1 |
| Mínguez, A | 1 |
| Vila, J | 1 |
| Plana, J | 1 |
| Sorof, JM | 1 |
| Cargo, P | 1 |
| Graepel, J | 1 |
| Humphrey, D | 1 |
| King, E | 1 |
| Rolf, C | 1 |
| Cunningham, RJ | 1 |
| Piazza, S | 1 |
| Di Somma, S | 2 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Chang, NC | 1 |
| Shih, CM | 1 |
| Bi, WF | 1 |
| Lai, ZY | 1 |
| Lin, MS | 1 |
| Wang, TC | 1 |
| Pyörälä, K | 2 |
| Mattila, S | 1 |
| Leirisalo, M | 1 |
| Toivonen, S | 1 |
| Schirger, A | 1 |
| Sheps, SG | 1 |
| Kohler, C | 1 |
| Berkowitz, B | 1 |
| Spector, S | 1 |
| Finch, L | 1 |
| Hicks, PE | 1 |
| Moore, RA | 1 |
| Werning, C | 1 |
| Gudbrandsson, T | 1 |
| Faupel, RP | 1 |
| Overlack, O | 1 |
| Klimm, HD | 1 |
| Andersson, O | 2 |
| Goodfellow, R | 1 |
| Dixon, GT | 1 |
| Johnson, ES | 1 |
| Kurppa, K | 1 |
| Kannas, M | 1 |
| Tiller, D | 1 |
| Horvath, J | 1 |
| Bune, A | 1 |
| Laragh, JH | 3 |
| Berthaux, P | 4 |
| Pedersen, OL | 5 |
| Mikkelsen, E | 3 |
| Johnston, CI | 3 |
| Millar, JA | 1 |
| McGrath, BP | 4 |
| Matthews, PG | 3 |
| Enger, SC | 1 |
| Gevers Leuven, JA | 1 |
| van Gent, CM | 1 |
| McAllister, RG | 1 |
| Love, DW | 1 |
| Guthrie, GP | 1 |
| Dominic, JA | 1 |
| Kotchen, TA | 2 |
| Uchida, K | 1 |
| Miyamori, I | 1 |
| Miyamoto, M | 1 |
| Takeda, R | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| De Giorgio, LA | 1 |
| Innocenti, F | 1 |
| Bartolomei, GC | 1 |
| Hill, P | 1 |
| Goldet, L | 1 |
| Mathieu, M | 1 |
| Sivertsson, R | 1 |
| Hollnagel, H | 2 |
| Kappelgaard, AM | 2 |
| Damkjaer, M | 1 |
| Turek, DM | 1 |
| Rovner, DR | 1 |
| Nemati, M | 1 |
| Kyle, MC | 3 |
| Ramirez, EA | 4 |
| Elson, L | 1 |
| Gear, AS | 1 |
| Oster, JR | 2 |
| Talmers, FN | 4 |
| Thomas, JR | 2 |
| Bryan, RK | 1 |
| Hoobler, SW | 2 |
| Rosenzweig, J | 1 |
| Weller, JM | 2 |
| Purdy, JM | 1 |
| Brooks, CS | 2 |
| Johnson, CA | 1 |
| Kotchen, JM | 1 |
| De Shaepdryver, A | 1 |
| Ernould, H | 1 |
| Kho, T | 1 |
| Meurice, J | 1 |
| Pierquin, L | 1 |
| Lederballe Pedersen, O | 1 |
| Moscovici, H | 1 |
| Occhialini, RP | 1 |
| Glitz, T | 1 |
| Pinheiro, JP | 1 |
| Shiguematsu, S | 1 |
| Lion, MF | 2 |
| Castenfors, H | 1 |
| de Carvalho, JG | 3 |
| Dunn, FG | 3 |
| Van Herick, R | 1 |
| Greenfield, R | 1 |
| Alimadadian, H | 1 |
| Burwell, D | 1 |
| Mann, W | 1 |
| Beg, M | 2 |
| Loracher, C | 1 |
| Charocopos, F | 1 |
| Rudolph, W | 1 |
| de Pasquale, C | 1 |
| Currò, F | 1 |
| Amadeo, A | 1 |
| Spotnitz, HM | 1 |
| Walter, NM | 1 |
| Suthers, MB | 1 |
| Friedman, A | 1 |
| Boel, A | 2 |
| Maling, T | 1 |
| Ohn, OH | 1 |
| Pelemans, J | 1 |
| Suchettkaye, AI | 1 |
| Willems, J | 2 |
| Kyöstilä, S | 1 |
| Kontro, J | 1 |
| Mattila, MJ | 1 |
| Araoye, MA | 2 |
| Chang, MY | 1 |
| Gillies, AH | 1 |
| Schrijver, G | 1 |
| Jaroonvesma, N | 1 |
| Charoenlarp, K | 1 |
| Zeller, JR | 1 |
| Itskovitz, HD | 3 |
| De Padua, F | 1 |
| Ohm, OT | 1 |
| Suchett-Kaye, AI | 1 |
| Miller, SA | 2 |
| Furrer, J | 1 |
| Kohvakka, A | 2 |
| Eisalo, A | 3 |
| Manninen, V | 1 |
| Clark, EC | 1 |
| Podolsky, S | 1 |
| Thompson, EJ | 1 |
| Huang, CM | 1 |
| Chock, D | 1 |
| del Greco, F | 2 |
| Armstrong, M | 1 |
| Kroc, J | 1 |
| Quintanilla, A | 1 |
| Beg, MA | 4 |
| Zuccarello, W | 1 |
| Donikian, MA | 1 |
| Ragland, R | 2 |
| Ziv, DS | 1 |
| Kuhnert, LV | 1 |
| Poindexter, C | 1 |
| Pak, CY | 1 |
| Wilhelmsson, CE | 1 |
| Vedin, JA | 1 |
| Moerlin, C | 1 |
| Vorburger, C | 1 |
| Lutterbeck, PM | 1 |
| Bolognese, J | 1 |
| Cirillo, VJ | 1 |
| Tempero, KF | 1 |
| Jennings, G | 1 |
| Bobik, A | 1 |
| Korner, P | 1 |
| Ponticelli, C | 1 |
| Lechi, A | 3 |
| Redaelli, B | 1 |
| Locatelli, F | 1 |
| Rivolta, E | 1 |
| Covi, G | 2 |
| Messa, GL | 1 |
| Pincella, G | 1 |
| Pedrini, L | 1 |
| Recchia, M | 1 |
| Gouère, P | 1 |
| Németh, M | 1 |
| Tényi, I | 1 |
| Pár, A | 1 |
| Man in't Veld, A | 1 |
| Danti, G | 1 |
| Riva, AD | 1 |
| Pedrolli, E | 1 |
| Pomari, S | 1 |
| Simpson, HW | 1 |
| Arias, F | 1 |
| Zamora, J | 1 |
| Lee, WR | 1 |
| Fox, LM | 1 |
| Slotkoff, LM | 1 |
| Mohamadi, M | 1 |
| Bivins, L | 1 |
| Becker, KL | 2 |
| Woerlee, M | 1 |
| Smith, WM | 1 |
| Dupont, P | 1 |
| Wauthier, P | 1 |
| Lamy, F | 1 |
| Han Wan, S | 1 |
| Tartagni, F | 1 |
| Pasetti, L | 1 |
| Melandri, G | 1 |
| Singer, K | 1 |
| Gomez-Sanchez, C | 1 |
| Bergis, K | 1 |
| Oviasu, VO | 1 |
| Idahosa, PE | 2 |
| Mauro, B | 1 |
| Savagnone, E | 1 |
| Alicandri, C | 3 |
| Oldoni, T | 1 |
| Muiesan, G | 8 |
| Masacci, E | 1 |
| Bobba, P | 1 |
| Croce, L | 1 |
| Ricciardi, S | 1 |
| Mussari, A | 1 |
| Bernardi, P | 2 |
| Dalla Torre, M | 1 |
| Di Benedetto, A | 1 |
| Lombardo, M | 1 |
| Engel, R | 1 |
| Nelson, W | 1 |
| Bartter, FC | 1 |
| Mullick, FG | 1 |
| McAllister, HA | 1 |
| Aschinberg, LC | 1 |
| Zeis, PM | 1 |
| Miller, RA | 1 |
| John, EG | 1 |
| Chan, LL | 1 |
| Inada, Y | 2 |
| Nishikawa, K | 2 |
| Nagaoka, A | 1 |
| Kikuchi, S | 1 |
| Morgan, T | 3 |
| Morgan, G | 1 |
| Wilson, M | 2 |
| Meurer, KA | 1 |
| Kaufmann, W | 1 |
| Corgnati, A | 1 |
| Ambrosio, G | 1 |
| Laplante, L | 4 |
| Shah, S | 1 |
| Khatri, I | 2 |
| Hull, DH | 1 |
| Wolthuis, RA | 1 |
| Triebwasser, JH | 1 |
| McAfoose, DA | 1 |
| Schröder, K | 1 |
| Teichmann, G | 2 |
| Eckermann, P | 1 |
| Jung, D | 1 |
| Hintzen, AH | 2 |
| Henquet, JW | 1 |
| Chappin, JJ | 1 |
| Slagboom, G | 1 |
| Ducrocq, MB | 1 |
| Beermann, B | 2 |
| Groschinsky-grind, M | 2 |
| Schalekamp, M | 1 |
| de Graeff, J | 1 |
| Lübke, H | 1 |
| Witzgall, H | 2 |
| Bank, N | 1 |
| Lief, PD | 1 |
| Piczon, O | 1 |
| Bech, K | 1 |
| Skovsted, L | 1 |
| Siersbaek-Nielsen, K | 1 |
| Hansen, JM | 1 |
| Yao, LL | 1 |
| Buscarini, L | 1 |
| Camarri, E | 1 |
| Camerini, F | 1 |
| Scardi, S | 1 |
| Alberti, E | 1 |
| Fontana, G | 1 |
| Forattini, C | 2 |
| Alessi, A | 1 |
| Perin, S | 2 |
| Furlanello, F | 1 |
| Vergara, G | 1 |
| Del Favero, A | 1 |
| Lenzi, S | 1 |
| Pecoraro, F | 1 |
| Baraldini, L | 1 |
| Bastagli, L | 1 |
| Malamani, V | 1 |
| Bellomo, G | 1 |
| Migone, L | 1 |
| Dal Canton, A | 1 |
| Nava, S | 1 |
| Antognetti, R | 1 |
| Passeri, M | 1 |
| Pallumeri, E | 1 |
| Piccolo, E | 1 |
| De Piccoli, B | 1 |
| Cazzin, R | 1 |
| Scarpioni, L | 1 |
| Giorgi-Pierfranceschi, D | 1 |
| Molnár, K | 1 |
| Kömíves, S | 1 |
| Kalmár, J | 1 |
| Gerzon, J | 1 |
| Kucher, E | 1 |
| Sanguigni, D | 1 |
| Benvenuti, C | 1 |
| Jefferson, JW | 1 |
| Kalin, NH | 1 |
| Rothenberg, RJ | 1 |
| Nies, AS | 2 |
| Michael, UF | 1 |
| Perez-Stable, EC | 2 |
| Korner, PI | 2 |
| Tiller, DJ | 2 |
| Steiner, JD | 1 |
| West, MJ | 3 |
| Uther, JF | 1 |
| Baumann, JC | 1 |
| Braun, HD | 1 |
| Colombi, A | 2 |
| Valmin, K | 1 |
| Hansen, T | 1 |
| Brailovsky, D | 1 |
| Horvath, JS | 1 |
| England, JD | 1 |
| Fletcher, PJ | 1 |
| Miele, N | 1 |
| Sidel'nikova, TIa | 1 |
| Bissett, JK | 1 |
| de Soyza, ND | 1 |
| Kane, JJ | 1 |
| Murphy, ML | 1 |
| Sambhi, MP | 1 |
| Eggena, P | 1 |
| Barrett, JC | 1 |
| Tuck, M | 1 |
| Wiedeman, CE | 1 |
| Thananopavarn, C | 1 |
| Brown, WJ | 1 |
| Brown, FK | 1 |
| Dunn, MI | 1 |
| Freeman, J | 1 |
| David, NA | 1 |
| Welborn, WS | 1 |
| Pierce, HI | 1 |
| Hollander, W | 1 |
| Madoff, I | 1 |
| Paddock, J | 1 |
| Kirkpatrick, B | 1 |
| Briggs, WA | 1 |
| Mutterperl, R | 1 |
| Adelman, B | 1 |
| Creditor, MA | 1 |
| Oviasu, OV | 1 |
| McFarland, KF | 1 |
| Shimizu, M | 1 |
| Yoshida, K | 1 |
| Kadokawa, T | 1 |
| Hatano, N | 1 |
| Kuwashima, J | 1 |
| Post, KD | 1 |
| Flamm, ES | 1 |
| Goodgold, A | 1 |
| Ransohoff, J | 1 |
| Brym, E | 1 |
| Wolyńczyk-Niegowska, J | 1 |
| Sznajderman, M | 1 |
| Eddleman, EE | 1 |
| Maxwell, MH | 4 |
| Iriuchijima, J | 2 |
| Numao, Y | 2 |
| Jones, AW | 1 |
| Sander, PD | 1 |
| Kampschmidt, DL | 1 |
| Mirkin, BL | 1 |
| Anderson, GH | 1 |
| Dalakos, TG | 1 |
| Elias, A | 1 |
| Tomycz, N | 1 |
| Streeten, DH | 1 |
| Piwowarska, W | 1 |
| Bielecki, A | 1 |
| Basu, J | 1 |
| Chakrabarty, K | 1 |
| Majumder, G | 1 |
| Neelakantan, C | 1 |
| Maity, AK | 1 |
| Bardhan, AK | 1 |
| Das, S | 1 |
| Ghosh, JC | 1 |
| Chhetri, MK | 1 |
| Lohmöller, G | 2 |
| Masso, M | 1 |
| Gimeno Martínez, J | 1 |
| Honorato, J | 1 |
| Lancaster, R | 1 |
| Goodwin, TJ | 1 |
| Peart, WS | 1 |
| Burge, PS | 1 |
| Montuschi, E | 1 |
| Akman, D | 1 |
| Nemes, LM | 1 |
| Aloof, S | 1 |
| Adornato, E | 1 |
| Tassone, F | 1 |
| Neller, GK | 1 |
| Dillard, B | 1 |
| Taguchi, J | 2 |
| Gunnells, JC | 1 |
| McGuffin, WL | 1 |
| Pettinger, WA | 3 |
| Schoenbaum, EE | 1 |
| Perhach, JL | 1 |
| Ferguson, HC | 1 |
| McKinney, GR | 1 |
| Dodek, A | 1 |
| Burg, JR | 1 |
| Kloster, FR | 1 |
| Matthews, G | 1 |
| Roberts, R | 1 |
| Klump, F | 1 |
| Braun, B | 1 |
| Lemke, R | 1 |
| Zöfel, P | 1 |
| Danilevicius, Z | 1 |
| Hamilton, TC | 1 |
| Dannhorn, R | 1 |
| Müller, AA | 1 |
| Romboli, L | 1 |
| Sullo, B | 1 |
| Seppia, M | 1 |
| Leumann, EP | 1 |
| Mauracher, EH | 1 |
| Rivier, JL | 1 |
| Keidan, H | 1 |
| Rosén, A | 1 |
| Fritschka, E | 1 |
| Sander, GE | 3 |
| Roffidal, LE | 2 |
| Quiroz, AC | 2 |
| Mazzu, AL | 1 |
| Phillips, JA | 1 |
| Koch, GG | 1 |
| Oksa, A | 1 |
| Stefíková, K | 1 |
| Fedelesová, V | 1 |
| Baculáková, V | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 2 |
| Foulkes, R | 1 |
| Ferrario, RG | 1 |
| Salvati, P | 1 |
| Bartholomeusz, RC | 1 |
| Gaffney, RD | 1 |
| Clampett, AD | 1 |
| Chatterton, BE | 1 |
| Barnhill, BW | 1 |
| Sadler, R | 1 |
| Weisser, K | 1 |
| Schloos, J | 1 |
| Jakob, S | 1 |
| Mühlberg, W | 1 |
| Platt, D | 1 |
| Palmer, AJ | 1 |
| Rudge, PJ | 1 |
| Andrews, CD | 1 |
| Callaghan, TS | 1 |
| Kolber-Postepska, B | 1 |
| Zebrowska-Lupina, I | 1 |
| Markiewicz, M | 1 |
| Horubała-Bielak, G | 1 |
| Ekbom, T | 1 |
| Scherstén, B | 2 |
| Curi, PR | 1 |
| Kohlmann Júnior, O | 1 |
| Leite, JB | 1 |
| Lorga, AM | 1 |
| Salomão Filho, A | 1 |
| Ferreira Filho, SR | 1 |
| Chuster, M | 1 |
| Mion Júnior, DM | 1 |
| Sampaio, M | 1 |
| Balbi, AL | 1 |
| de Mey, C | 1 |
| Stenkula, S | 1 |
| Soeyland, AK | 2 |
| Saltvedt, E | 1 |
| Calebich, S | 1 |
| Beschi, M | 1 |
| Castellano, M | 1 |
| Sideris, DA | 2 |
| Toumanidis, ST | 1 |
| Anastasiou-Nana, M | 1 |
| Kitsiou, A | 1 |
| Tsagarakis, K | 1 |
| Moulopoulos, SD | 2 |
| Miller, ST | 1 |
| Brugger, SB | 1 |
| Schnaper, HW | 5 |
| Khoury, S | 2 |
| Foster, E | 1 |
| Plehn, JF | 1 |
| Bernard, SA | 1 |
| Battinelli, NJ | 1 |
| Huntington-Coats, M | 1 |
| Apstein, CS | 1 |
| Mulè, LG | 1 |
| Stampino, CG | 1 |
| Thurston, H | 2 |
| Ratheiser, K | 1 |
| Dusleag, J | 1 |
| Seitl, K | 1 |
| Titscher, G | 1 |
| Klein, W | 1 |
| Habte, B | 1 |
| Penttila, O | 1 |
| Kanniainen, E | 1 |
| Jounela, A | 1 |
| Huikko, M | 1 |
| Tomashets, EA | 1 |
| Mazur, NA | 1 |
| Masenko, VP | 1 |
| Silagy, CA | 1 |
| McNeil, JJ | 1 |
| Stein, CM | 2 |
| Neill, P | 2 |
| Kusemamuriwo, T | 1 |
| van Zyl, A | 1 |
| Jennings, AA | 1 |
| Byrne, MJ | 1 |
| Opie, LH | 2 |
| Lartaud, I | 1 |
| Mertès, PM | 1 |
| Langley, A | 1 |
| Misra, NP | 1 |
| Verma, Y | 1 |
| Shah, JY | 1 |
| Guo, C | 1 |
| Morabito, S | 2 |
| Fabiano, M | 1 |
| Puliti, M | 1 |
| Palumbo, R | 1 |
| Marinelli, R | 1 |
| Simonetti, BM | 1 |
| Pierucci, A | 1 |
| Cooper, ME | 1 |
| Rumble, JR | 1 |
| Allen, TJ | 1 |
| O'Brien, RC | 1 |
| Doyle, AE | 1 |
| Ferroni, C | 1 |
| Collatina, S | 1 |
| Salzano, E | 1 |
| Isenring, P | 1 |
| Grose, JH | 1 |
| Weno, BL | 1 |
| Baumbach, GL | 1 |
| Heistad, DD | 1 |
| Wasenius Soeyland, AK | 1 |
| Knutsen, KM | 1 |
| Ekeli, T | 2 |
| Corder, CN | 1 |
| Alaupovic, PA | 1 |
| Price, MD | 1 |
| Furste, SS | 1 |
| Michelsen, S | 1 |
| Jung, KM | 1 |
| Kim, HJ | 1 |
| LaPalio, L | 1 |
| Glasser, S | 1 |
| Tifft, C | 1 |
| Forette, B | 2 |
| Koen, R | 1 |
| Vicaut, E | 1 |
| Hommel, E | 1 |
| Jurek, IE | 1 |
| Higgins, JT | 2 |
| McGrady, A | 1 |
| Turkkan, JS | 2 |
| Allen, RP | 1 |
| Hienz, RD | 1 |
| Illingworth, JM | 1 |
| Yoshimoto, R | 1 |
| Hashiguchi, Y | 1 |
| Dohmoto, H | 1 |
| Hosono, M | 1 |
| Iida, H | 1 |
| Fujiyoshi, T | 1 |
| Ikeda, K | 1 |
| Hayashi, Y | 1 |
| Abdon, D | 1 |
| Devissaguet, M | 1 |
| Juggi, JS | 1 |
| Lévesque, C | 1 |
| Lore, W | 1 |
| Muita, AK | 1 |
| Ogola, ES | 1 |
| Goldstein, DS | 1 |
| Miller, E | 1 |
| Pathé, M | 1 |
| Graham, RD | 1 |
| Murray, NH | 1 |
| Swaisland, AJ | 2 |
| Lang, H | 1 |
| Mulkerrins, E | 1 |
| Hosie, J | 1 |
| Connell, PA | 1 |
| Smith, RP | 1 |
| Hart, W | 1 |
| Andrejak, M | 1 |
| Santoni, JP | 2 |
| Carré, A | 1 |
| Goldstein, RJ | 1 |
| Weissel, M | 2 |
| Stanek, B | 1 |
| Flygt, G | 2 |
| Maharaj, B | 3 |
| Bannatyne, RE | 1 |
| Quay, G | 1 |
| Lopez, L | 1 |
| McCarley, D | 1 |
| Seelig, CB | 1 |
| DeForrest, JM | 1 |
| Waldron, TL | 1 |
| Harvey, C | 1 |
| Scalese, B | 1 |
| Mitch, S | 1 |
| Powell, JR | 1 |
| Petrillo, W | 1 |
| Louis, W | 1 |
| Howes, L | 1 |
| Whitworth, JA | 1 |
| Kincaid-Smith, PS | 1 |
| Fraser, I | 1 |
| Scheinkestel, C | 1 |
| MacDonald, G | 1 |
| Rallings, M | 1 |
| Djian, J | 1 |
| Roy, M | 1 |
| Lekieffre, J | 1 |
| Solomon, R | 2 |
| Weinberg, MS | 2 |
| Dubey, A | 1 |
| Canossa-Terris, M | 1 |
| Buckalew, V | 1 |
| Worthy, AJ | 1 |
| Binner, L | 3 |
| Gabrielsen, F | 1 |
| Sund, M | 3 |
| Hombach, V | 3 |
| Langdon, CG | 1 |
| Baxter, GA | 1 |
| Young, PH | 2 |
| Szlachcic, J | 2 |
| O'Kelly, B | 1 |
| Ammon, S | 1 |
| Boulet, AP | 1 |
| Chockalingam, A | 1 |
| Fodor, JG | 1 |
| Houde, M | 1 |
| Logan, AG | 2 |
| Robitaille, MN | 1 |
| Spénard, J | 1 |
| Li, XQ | 1 |
| Li, XW | 1 |
| Zhu, CX | 1 |
| Chiariello, M | 1 |
| Hulley, SB | 2 |
| Black, DM | 1 |
| Cheitlin, MD | 1 |
| Seeley, DG | 1 |
| Hearst, N | 1 |
| Fine, R | 1 |
| Chappel, C | 1 |
| Farnham, DJ | 1 |
| Levin, B | 1 |
| McCluskey, D | 1 |
| Steiner, C | 1 |
| Greenberg, S | 1 |
| Hehr, R | 2 |
| Clarke, PF | 1 |
| Kendall, R | 1 |
| Hornby, R | 1 |
| Kendall, MJ | 1 |
| Lederle, RM | 3 |
| Yedinak, KC | 1 |
| Muller, RJ | 1 |
| Lann, HD | 1 |
| Korinteli, MO | 2 |
| Pavlov, AA | 1 |
| Rykin, BA | 1 |
| Klüglich, M | 1 |
| Lucas, C | 2 |
| Jenkins, P | 2 |
| Mendels, J | 1 |
| Due, D | 1 |
| Forbes, WP | 1 |
| Sirgo, MA | 2 |
| Gurgenian, SV | 1 |
| Mikaelian, ES | 1 |
| Dzhandzhapanian, AZ | 1 |
| Babaian, AS | 1 |
| Faintuch, JJ | 1 |
| Azul, JB | 1 |
| Rocha, Ados S | 1 |
| Van Hoof, R | 1 |
| Marmor, AT | 1 |
| Franzén, P | 1 |
| Backman, R | 1 |
| Wollenberg, A | 1 |
| Mazzola, C | 3 |
| Mangiameli, S | 1 |
| Castello, C | 1 |
| Deruyterre, ML | 1 |
| Weber, RR | 1 |
| Levinzon, AM | 9 |
| Moskalenko, NP | 1 |
| Glezer, GA | 10 |
| Guivarc'h, PH | 1 |
| Soro, S | 3 |
| Grassi, A | 1 |
| Pasanisi, F | 2 |
| Chuang-Stein, C | 1 |
| Mohberg, NR | 1 |
| Sinkula, MS | 1 |
| Goldstein, G | 3 |
| White, TJ | 3 |
| Nunn, S | 3 |
| Fineberg, NS | 1 |
| Lutcavage, GJ | 1 |
| Schaberg, SJ | 1 |
| Abraham, AS | 1 |
| Brooks, BA | 1 |
| Grafstein, Y | 1 |
| Barchilon, E | 1 |
| Nubani, N | 1 |
| Eylath, U | 1 |
| Shemesh, O | 1 |
| Widmann, L | 2 |
| van der Does, R | 2 |
| Hörrmann, M | 2 |
| Machwirth, M | 2 |
| Uberbacher, HJ | 1 |
| Stienen, U | 1 |
| Dupont, AG | 1 |
| Schoors, DF | 1 |
| Venuti, RP | 1 |
| Sebastian, JL | 1 |
| McKinney, WP | 1 |
| Kaufman, J | 1 |
| Young, MJ | 1 |
| Angioni, L | 2 |
| Vaccarella, A | 2 |
| Capra, A | 2 |
| Botta, G | 3 |
| Abraham, PA | 2 |
| Bennett, WM | 1 |
| Brachfeld, N | 1 |
| Goodman, RP | 2 |
| Olsson, G | 1 |
| Warnold, I | 1 |
| Barber, H | 1 |
| Eliasson, K | 4 |
| Jastrup, B | 1 |
| Karatzas, N | 1 |
| Leer, J | 1 |
| Souchet, T | 1 |
| Delage, Y | 1 |
| Poggi, L | 2 |
| Tamburrini, LR | 1 |
| Di Monte, M | 1 |
| Sugden, AL | 1 |
| Ernst, E | 1 |
| Witkowska, M | 2 |
| Kübler, G | 1 |
| Kopel, E | 1 |
| Karolko, B | 2 |
| Gretler, DD | 1 |
| Gramelspacher, GP | 1 |
| Fumo, MT | 1 |
| Garcá Puig, J | 1 |
| Miranda, ME | 1 |
| Mateos, F | 1 |
| Herrero, E | 1 |
| Lavilla, P | 1 |
| Gil, A | 1 |
| Allen, DH | 1 |
| Puddey, IB | 1 |
| Morton, AR | 1 |
| Beilin, LJ | 2 |
| Brown, CL | 1 |
| Backhouse, CI | 3 |
| Grippat, JC | 1 |
| Haerlin, R | 1 |
| Hilgenstock, G | 1 |
| Passfall, J | 1 |
| Pessina, A | 2 |
| Pirrelli, A | 2 |
| Wurst, W | 1 |
| Mwaluko, GM | 1 |
| Kusema, T | 1 |
| Rudzite, VK | 1 |
| Vitols, AV | 2 |
| Liepinja, DJ | 1 |
| Silava, AK | 1 |
| Samuel, P | 4 |
| Cutler, R | 1 |
| Hamilton, B | 1 |
| Matthews, KP | 1 |
| Bird, AS | 1 |
| Blizard, RA | 1 |
| Mann, AH | 1 |
| Lønborg-Jensen, H | 1 |
| Leikersfeldt, G | 1 |
| Rasmussen, SL | 1 |
| Atmer, B | 1 |
| Hjalmers, S | 1 |
| Wahlqvist, I | 1 |
| Caralis, PV | 2 |
| Rathaus, M | 1 |
| Bernheim, J | 1 |
| Zevin, D | 1 |
| Levi, J | 1 |
| Mazzu, A | 1 |
| Essinger, I | 1 |
| Glassman, HN | 1 |
| Boger, RS | 1 |
| Luther, R | 1 |
| Averbukh, Z | 2 |
| Cohn, M | 1 |
| Maor, J | 1 |
| Shaked, U | 2 |
| Modai, D | 2 |
| Cinotti, G | 2 |
| Alcántara Nicolás, J | 1 |
| Cano Cano, R | 1 |
| Cano Cano, E | 1 |
| Contreras, C | 1 |
| García Galvis, JA | 1 |
| García Giralda, L | 1 |
| González Comeche, J | 1 |
| Madrid Conesa, A | 1 |
| Ramos La Torre, F | 1 |
| Sánchez Moreno, J | 1 |
| Maclean, D | 1 |
| Richardson, PJ | 3 |
| Zukowska-Szczechowska, E | 2 |
| Grzeszczak, W | 1 |
| Little, J | 1 |
| Sánchez de la Peña, S | 1 |
| Abramowitz, P | 1 |
| Tuna, N | 1 |
| Duckett, GK | 1 |
| Cheadle, B | 1 |
| Gerber, JG | 1 |
| LoVerde, M | 2 |
| Byyny, RL | 2 |
| Blumenthal, JA | 1 |
| Ekelund, LG | 1 |
| Emery, CF | 1 |
| Lipko, DS | 3 |
| Perani, G | 1 |
| Martignoni, A | 1 |
| Muggia, C | 1 |
| Ferrari, T | 1 |
| Simonich, P | 1 |
| Pompei, R | 1 |
| Marchesi, E | 1 |
| Finardi, G | 1 |
| Berioli, S | 1 |
| Conti, R | 1 |
| Osanna, RA | 1 |
| Savino, K | 1 |
| Zollino, L | 1 |
| Taylor, S | 1 |
| Bluemner, E | 1 |
| Neusy, AJ | 1 |
| Valeri, A | 1 |
| Monmany, J | 1 |
| Domingo, P | 1 |
| Gomez, JA | 1 |
| Sanz, F | 1 |
| Nolla, J | 1 |
| Jane, F | 1 |
| Sambol, NC | 1 |
| Bostrom, A | 1 |
| Shishkina, OS | 1 |
| Lundgren, H | 1 |
| Bengtsson, L | 1 |
| Merzon, AK | 1 |
| Donskova, TV | 1 |
| Shelest, IuP | 1 |
| Kelly, JL | 1 |
| Hart, LL | 1 |
| Chapman, RH | 2 |
| Landry, KM | 1 |
| Ristow, SM | 1 |
| Zaeh, D | 1 |
| Haider, B | 1 |
| Brown, P | 1 |
| Silas, E | 1 |
| Skarda, IJ | 1 |
| Liepinia, DJ | 1 |
| Voita, DU | 1 |
| Skards, JV | 1 |
| Lauler, DP | 1 |
| Weidler, DJ | 1 |
| Toth, PD | 1 |
| Spürk, P | 1 |
| Gerlach, A | 1 |
| Angelkort, B | 1 |
| Casner, PR | 1 |
| Dillon, KR | 1 |
| Croog, SH | 3 |
| Sudilovsky, A | 2 |
| Levine, S | 4 |
| Baume, RM | 1 |
| Cady, WJ | 1 |
| Notargiacomo, A | 4 |
| Fletcher, RD | 3 |
| deGrau, A | 1 |
| Foti, A | 1 |
| Kim, SJ | 1 |
| DeQuattro, E | 1 |
| Allen, J | 1 |
| Kuller, LH | 1 |
| Neaton, J | 1 |
| Luomanmäki, K | 1 |
| Hartikainen, M | 1 |
| Allen, IE | 1 |
| Pascucci, VL | 1 |
| Gennari, J | 1 |
| Goldstein, R | 1 |
| McChesney, JA | 1 |
| Mehta, J | 2 |
| Fasano, ML | 2 |
| Mancini, M | 3 |
| van der Byl, K | 3 |
| Ferder, L | 1 |
| Inserra, F | 1 |
| Medina, F | 1 |
| Péter, M | 1 |
| Balás-Eltes, A | 1 |
| Fehér, J | 1 |
| Conrad, KA | 3 |
| Simons, JA | 2 |
| Krishna, GG | 1 |
| Kontoyannis, DA | 1 |
| Diakos, A | 1 |
| Kontoyannis, SA | 1 |
| Jansen, RW | 2 |
| van Lier, HJ | 2 |
| Hoefnagels, WH | 2 |
| Billaud, E | 2 |
| Furnival, L | 1 |
| Khoshnodi, L | 1 |
| Lorenz, H | 1 |
| Zahlten, R | 1 |
| Gries, J | 1 |
| Kretzschmar, R | 1 |
| Neumann, BW | 1 |
| Heine, D | 1 |
| Shapiro, DA | 2 |
| Liss, CL | 1 |
| Lewis, JL | 1 |
| Lengerich, RA | 1 |
| Poulsen, L | 1 |
| Friberg, M | 1 |
| Noer, I | 1 |
| Krusell, L | 1 |
| Fiorentini, C | 1 |
| Guazzi, M | 1 |
| Graves, J | 1 |
| Rofman, B | 1 |
| Koehn, DK | 2 |
| Wilmoth, SK | 1 |
| Enevold, GL | 1 |
| Strickland, HL | 1 |
| Borhani, NA | 1 |
| Nunez, BD | 1 |
| Nunez, MM | 1 |
| Garavaglia, GE | 1 |
| Ventura, HO | 1 |
| Mammarella, A | 1 |
| Paoletti, V | 1 |
| Barlattani, M | 1 |
| Leone, G | 1 |
| Filippello, CP | 1 |
| Mariani, AR | 1 |
| Chrysant, C | 1 |
| Trus, J | 1 |
| Hitchcock, A | 1 |
| Nilsen, OG | 1 |
| Sellevold, OF | 1 |
| Romfo, OS | 1 |
| Smedsrud, A | 1 |
| Grynne, B | 1 |
| Williams, PE | 1 |
| Kleinbloesem, CH | 1 |
| Pasman, JW | 1 |
| Gabreëls, FJ | 1 |
| Semmekrot, B | 1 |
| Renier, WO | 1 |
| Monnens, LA | 1 |
| Winer, N | 1 |
| Kögler, P | 3 |
| Sánchez, RA | 1 |
| Traballi, CA | 1 |
| Marcó, EJ | 1 |
| Cianciulli, T | 1 |
| Giannone, CA | 1 |
| Ramiréz, AJ | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Taylor, EJ | 1 |
| Balaban, DJ | 1 |
| Abrams, WB | 1 |
| Feinberg, J | 1 |
| Oyewo, EA | 1 |
| Ladipo, GO | 1 |
| Akinsola, A | 1 |
| Grosskopf, S | 1 |
| German, R | 1 |
| Vandongen, R | 1 |
| Rogers, P | 1 |
| Gosse, P | 1 |
| Dallocchio, M | 1 |
| Gourgon, R | 1 |
| Wichmann, C | 1 |
| Zähringer, J | 1 |
| Schuster, S | 1 |
| Schoel, G | 1 |
| Buhr-Schinner, H | 1 |
| Warneke, G | 1 |
| Kandt, M | 1 |
| Haupt, A | 1 |
| Scheler, F | 1 |
| Barría, MS | 1 |
| Plubins, L | 1 |
| Rodríguez, MS | 1 |
| Alvo, M | 1 |
| Nuñez, G | 1 |
| Vega, C | 1 |
| Gonzalez, H | 1 |
| Faivovich, A | 1 |
| Gonzalez, F | 1 |
| Domic, H | 1 |
| Vasdev, S | 1 |
| Bolli, P | 2 |
| Ramanathan, KB | 2 |
| Ahmad, S | 1 |
| Lutz, LJ | 1 |
| Miilunpalo, S | 1 |
| Saarinen, R | 1 |
| Marniemi, J | 1 |
| Osterloh, I | 1 |
| Kawanishi, DT | 1 |
| Reid, CL | 1 |
| Gonzales, A | 1 |
| O'Rourke, RA | 1 |
| Rahimtoola, SH | 1 |
| Smith, SJ | 1 |
| Brouwer, RM | 1 |
| Erné, P | 1 |
| Kiowski, W | 1 |
| Bühler, FR | 2 |
| Ribstein, J | 2 |
| Friedman, RG | 1 |
| Garland, WT | 1 |
| Hollifield, J | 1 |
| Marks, A | 1 |
| Lukasik, S | 1 |
| Kawecka, M | 1 |
| Moszczyńska, J | 1 |
| Mitchell, W | 1 |
| Nicholson, JP | 1 |
| Resnick, LM | 1 |
| Stamler, R | 3 |
| Stamler, J | 3 |
| Gosch, FC | 3 |
| Berkson, DM | 3 |
| Dyer, AR | 2 |
| Hershinow, P | 3 |
| Takiyyuddin, MA | 1 |
| Cervenka, JH | 1 |
| Dinh, T | 1 |
| Witztum, JL | 1 |
| O'Connor, DT | 1 |
| Batey, DM | 2 |
| Nicolich, MJ | 1 |
| Lasser, VI | 2 |
| Jeffrey, SS | 1 |
| Lasser, NL | 2 |
| Whalen, JJ | 1 |
| Fisher, SG | 1 |
| Hamburger, R | 1 |
| Borreson, RE | 1 |
| Mezey, KC | 1 |
| Mukherji, B | 1 |
| Neal, WW | 2 |
| Taguchi, JT | 1 |
| Ozgür, O | 1 |
| Duman, EL | 1 |
| Komsuoğlu, SS | 1 |
| Brown, R | 1 |
| Schnaper, H | 3 |
| Smolens, P | 1 |
| Montijo, M | 1 |
| Michelson, E | 1 |
| Lessem, J | 1 |
| Freedman, D | 1 |
| Maroko, PR | 1 |
| McDevitt, JT | 1 |
| Fox, MJ | 1 |
| Silber, SA | 1 |
| Young, MD | 1 |
| Rockhold, FW | 2 |
| Free, SM | 1 |
| Herron, JR | 1 |
| Scherer, B | 1 |
| Lange, HH | 1 |
| Weber, PC | 1 |
| Gostick, NK | 1 |
| Mayhew, SR | 1 |
| Mukerji, D | 1 |
| Bradley, I | 1 |
| Ganvir, P | 1 |
| Shepherd, F | 1 |
| Davis, A | 1 |
| MacKay, D | 1 |
| Hopwood, AM | 1 |
| Peters, RW | 1 |
| Cheung, DG | 1 |
| Gasster, JL | 1 |
| Verhiest, W | 1 |
| Baehre, M | 1 |
| Volkers, P | 1 |
| Szmyd, L | 1 |
| Schwartz, B | 1 |
| Santucci, A | 1 |
| Botta, GF | 3 |
| Antonicelli, R | 1 |
| Raffaelli, S | 1 |
| Paciaroni, E | 2 |
| Zingaretti, P | 1 |
| Shaw, KM | 1 |
| Magenta, M | 1 |
| Noia, E | 1 |
| Renesto, E | 1 |
| Sartini, C | 1 |
| Halstenson, CE | 1 |
| Nascimento, LO | 2 |
| Lion, R | 1 |
| Pesquisadores, E | 1 |
| Ramires, JA | 1 |
| Giorgy, D | 1 |
| Mansur, AP | 1 |
| Nicolau, JC | 1 |
| Pierri, H | 1 |
| Solimene, MC | 1 |
| Beretta-Piccoli, C | 1 |
| Amstein, R | 1 |
| Bertel, O | 1 |
| Follath, F | 1 |
| Reutter, F | 1 |
| Vallotton, MB | 1 |
| Schmidt, GR | 3 |
| Gasilin, VS | 1 |
| Kruglov, VA | 1 |
| Titov, VI | 1 |
| Ushakova, TI | 1 |
| Mickiewicz, C | 1 |
| Sharoky, M | 1 |
| Perkal, M | 1 |
| Tabatznik, B | 1 |
| Cane, RC | 1 |
| Costello, K | 1 |
| Goodwin, P | 1 |
| Ooi, WL | 1 |
| Madhavan, S | 1 |
| Offen, WW | 2 |
| Dornseif, BE | 1 |
| Guy, JR | 1 |
| Fagien, S | 1 |
| Donovan, JP | 1 |
| Rubin, ML | 1 |
| Meza, N | 1 |
| López, H | 1 |
| Rosenkranz, RP | 2 |
| Hayashi, CM | 1 |
| Lakatos, I | 1 |
| McClelland, DL | 2 |
| de Divitiis, O | 1 |
| Liguori, V | 1 |
| Petitto, M | 1 |
| Magnotta, C | 1 |
| Ausiello, M | 1 |
| Natale, N | 1 |
| Brignoli, M | 1 |
| Galderisi, M | 1 |
| Lehany, AM | 1 |
| Bryan, DL | 1 |
| Cooper, LW | 1 |
| Lambert, CM | 1 |
| Woo, J | 2 |
| Kin, T | 1 |
| Vallance-Owen, J | 2 |
| Lal, SM | 1 |
| Quintanilla, AP | 1 |
| Finn, M | 1 |
| Weffer, MI | 1 |
| Iwaoka, T | 1 |
| Umeda, T | 1 |
| Strømmen, R | 2 |
| Stein, G | 1 |
| Russell, AE | 1 |
| Elliott, JM | 2 |
| Morris, MJ | 2 |
| Thorman, AD | 1 |
| Acosta, JH | 1 |
| Fairhurst, G | 2 |
| Ferreira, C | 1 |
| Kaarsalo, E | 1 |
| Silva, MC | 1 |
| Simone, A | 1 |
| Beckman, S | 1 |
| Goldberger, J | 1 |
| Sherman, D | 1 |
| Prince, MJ | 1 |
| Stuart, CA | 1 |
| Padia, M | 1 |
| Bandi, Z | 1 |
| Quay, GP | 1 |
| McCarley, DL | 1 |
| Tanabe, M | 1 |
| Kawazoe, K | 1 |
| Meany, B | 1 |
| Breckenridge, AM | 2 |
| Grimmer, SF | 1 |
| Johnston, GD | 1 |
| Kondowe, G | 1 |
| Bilo, HJ | 1 |
| Westerman, RF | 2 |
| Nicolaas-Merkus, AM | 1 |
| Franca, G | 1 |
| Cosenzi, A | 1 |
| Piemontesi, A | 1 |
| Cervi, V | 1 |
| Eggertsen, R | 1 |
| Mussi, A | 5 |
| Dornhorst, A | 1 |
| Powell, SH | 1 |
| Pensky, J | 1 |
| Sidorenko, GI | 1 |
| Pavlova, AI | 1 |
| Nechesova, TA | 1 |
| Al'khimovich, VM | 1 |
| Gaĭduk, VN | 1 |
| Lewis, JE | 1 |
| Wong, DG | 3 |
| Lindsay, RM | 1 |
| Sromovsky, JA | 1 |
| Ghosh, AK | 1 |
| Severin, E | 1 |
| Mladovan, G | 1 |
| Dyer, A | 1 |
| Lamki, L | 1 |
| Freeman, D | 1 |
| McDonald, JW | 1 |
| Blaine, EH | 1 |
| Seymour, AA | 1 |
| Marsh, EA | 1 |
| Napier, MA | 1 |
| Ruoff, G | 1 |
| Benfield, GF | 1 |
| Haffner, C | 1 |
| Harris, P | 1 |
| Stableforth, DE | 1 |
| Lindholm, L | 1 |
| Råstam, L | 1 |
| Löllgen, H | 1 |
| Upmeyer, HJ | 1 |
| Zawada, ET | 5 |
| Trost, BN | 1 |
| Claessens, J | 1 |
| Streulens, Y | 1 |
| Nelemans, F | 1 |
| Hylander, B | 3 |
| Hjemdahl, P | 2 |
| Tanskanen, A | 1 |
| Temmerman, J | 1 |
| Borgmästars, H | 1 |
| Hellebø, R | 1 |
| Walle, PO | 1 |
| Nielsen, HM | 1 |
| Nielsen, E | 1 |
| Winkel, O | 1 |
| Honoré, P | 1 |
| Wambach, G | 1 |
| Mickiewicz, CW | 1 |
| Scharf, MB | 1 |
| Mayleben, DW | 1 |
| Krug, K | 1 |
| Mollura, JL | 1 |
| Nash, J | 1 |
| Hamill, SJ | 1 |
| Waters, VV | 1 |
| De Quattro, V | 1 |
| Iureneva, AP | 1 |
| Salenko, BB | 1 |
| Khramelashvili, VV | 1 |
| Cox, DA | 1 |
| Leader, JP | 1 |
| Milson, JA | 1 |
| Singleton, W | 1 |
| Wilhelmsen, L | 1 |
| Del Prato, C | 1 |
| Triacca, R | 1 |
| Gramenzi, S | 1 |
| Astorri, E | 1 |
| Hjortdahl, P | 1 |
| von Krogh, H | 1 |
| Daae, L | 1 |
| Mohanty, PK | 2 |
| Kirkendal, WM | 1 |
| Kontos, HA | 1 |
| Malherbe, E | 1 |
| Le Hegarat, M | 1 |
| Clostre, F | 1 |
| Braquet, P | 1 |
| Kirkendall, W | 3 |
| Schaefer, EJ | 1 |
| Chin, B | 2 |
| Schoenfeld, BH | 2 |
| Lieberman, S | 2 |
| Remien, J | 1 |
| Kirzinger, S | 1 |
| Kezdi, P | 1 |
| Danopulos, D | 1 |
| Stanley, EL | 1 |
| Mullins, M | 1 |
| Lee, CC | 1 |
| Herrera-Acosta, J | 1 |
| Pérez-Grovas, H | 1 |
| Ayers, CR | 1 |
| Baker, KM | 1 |
| Weaver, BA | 1 |
| Lehman, MR | 1 |
| Gaddy, P | 2 |
| Chiou, XC | 1 |
| Owens, R | 1 |
| Wrigley, B | 1 |
| Johnson, AL | 1 |
| Price, WA | 1 |
| Wong, PC | 1 |
| Vavala, RF | 1 |
| Stump, JM | 1 |
| Pascoe, J | 1 |
| Moon, R | 1 |
| Gray, D | 1 |
| Musgrove, J | 1 |
| Hill, JF | 2 |
| Tenschert, W | 2 |
| Bongiovì, S | 1 |
| Perissinotto, F | 1 |
| Samà, B | 1 |
| Mozzato, MG | 1 |
| Robb, OJ | 1 |
| Trafford, J | 1 |
| Burgess, J | 1 |
| Magee, PF | 1 |
| Stroh, JA | 1 |
| Saltzberg, S | 1 |
| Weinberg, P | 1 |
| Shamoon, H | 1 |
| Charlap, S | 1 |
| Frishman, W | 1 |
| Mittman, N | 1 |
| Dubrow, A | 1 |
| Westerman, M | 1 |
| Crombie, A | 1 |
| Manson, P | 1 |
| McVey, D | 1 |
| Smith, MW | 1 |
| Smeeton, VJ | 1 |
| Somerton, DT | 1 |
| Reams, G | 1 |
| Cain, MD | 1 |
| Graham, JR | 1 |
| Southgate, DO | 1 |
| Parag, KB | 1 |
| Adamo, L | 1 |
| Alaimo, G | 1 |
| Boni, E | 1 |
| Mattei, A | 2 |
| Garg, LC | 1 |
| Narang, N | 1 |
| Brunelli, A | 2 |
| Brunelli, D | 1 |
| Sangiorgio, P | 2 |
| Lombardi, G | 1 |
| Mainardi, A | 1 |
| Bracchetti, D | 3 |
| Katz, LA | 2 |
| Cobbol, C | 1 |
| Grundy, S | 1 |
| van der Byl, KV | 1 |
| Leehey, DJ | 1 |
| Hartman, E | 1 |
| Bennett, JM | 1 |
| Weich, DJ | 1 |
| Schoeman, HS | 1 |
| Bope, ET | 1 |
| Adams, RC | 1 |
| Brewer, SC | 1 |
| Cairns, CB | 1 |
| Fosnaugh, NR | 1 |
| Leidheiser, PC | 1 |
| Platt, CW | 1 |
| Polsley, JS | 1 |
| Romaker, RR | 1 |
| Scarbrough, SD | 1 |
| Cugini, P | 1 |
| Di Veroli, C | 1 |
| Di Palma, L | 1 |
| Battisti, P | 1 |
| Stornello, M | 1 |
| Valvo, E | 1 |
| Scapellato, L | 1 |
| Sullivan, JM | 1 |
| Senn, N | 1 |
| Ollivier, JP | 1 |
| Abitbol, JP | 1 |
| Garay, R | 1 |
| Jiao, PH | 1 |
| Allen, JW | 1 |
| Reda, D | 1 |
| Henderson, WG | 1 |
| Lernhardt, E | 1 |
| Solt-Buzsaki, V | 1 |
| Jeunemaitre, X | 1 |
| Charru, A | 1 |
| Degoulet, P | 1 |
| Julien, J | 1 |
| Anshelevich, IuV | 1 |
| Raĭbaert, IaIa | 1 |
| Dumesh, SZ | 1 |
| Orlova, VP | 1 |
| Itskovich, VS | 1 |
| Cranfield, FR | 1 |
| Walters, EG | 1 |
| Markanday, S | 1 |
| Shelton, JR | 1 |
| Akbar, FA | 1 |
| Bayman, IW | 1 |
| Gould, SE | 1 |
| Turner, JF | 1 |
| Fidel, J | 1 |
| Glikberg, F | 1 |
| Kristinsson, A | 1 |
| Hardarson, T | 3 |
| Palsson, K | 1 |
| Petursson, MK | 1 |
| Snorrason, SP | 3 |
| Thorgeirsson, G | 1 |
| Hawkins, DW | 1 |
| Dieckmann, MR | 1 |
| Horner, RD | 1 |
| Groom, P | 1 |
| Simpson, RJ | 1 |
| Singh, B | 1 |
| Ward, DE | 1 |
| Peers, E | 1 |
| Richardson, PD | 2 |
| Bossaller, W | 2 |
| Malerczyk, V | 1 |
| Carle, WK | 1 |
| Latta, D | 1 |
| Lees, CT | 1 |
| Lough, JR | 1 |
| Pender, J | 1 |
| Ross, JR | 1 |
| Sefton, S | 1 |
| Peers, EM | 1 |
| Heinen, B | 1 |
| Ragnarsson, J | 2 |
| Wyndham, RN | 1 |
| Gimenez, L | 1 |
| Russell, RP | 2 |
| Myers, MG | 1 |
| Orlov, VM | 1 |
| Ivashchuk, AG | 1 |
| Troshina, EV | 1 |
| Iartsev, SS | 1 |
| Gorokhovskaia, GN | 1 |
| Roffidal, LC | 1 |
| Thomas, MG | 1 |
| Given, MB | 1 |
| MacCarthy, EP | 1 |
| Anderson, M | 1 |
| Eidelson, BA | 1 |
| Labreche, DG | 1 |
| Ulep, D | 1 |
| Bartels, D | 1 |
| Shionoiri, H | 1 |
| Iino, S | 2 |
| Inoue, S | 1 |
| Dunsky, MH | 2 |
| Warner, RA | 2 |
| Thurm, RH | 1 |
| Graney, WF | 1 |
| Nichola, PS | 1 |
| Saelen, A | 1 |
| Popa, V | 1 |
| Curry, C | 1 |
| Hinds, J | 1 |
| Poland, M | 1 |
| Roper, K | 1 |
| Aranda-Lara, P | 1 |
| Gras-Balaguer, X | 1 |
| Cabello, M | 1 |
| Martín-Reyes, G | 1 |
| Valera, A | 1 |
| Frutos, M | 1 |
| López de Novales, E | 1 |
| Storm, TL | 1 |
| Badskjaer, J | 1 |
| Hammer, R | 1 |
| Zhu, YC | 1 |
| Krönig, B | 1 |
| Cagli, V | 1 |
| Carotti, A | 1 |
| Innocenti, P | 1 |
| Malerba, M | 1 |
| Jueng, C | 1 |
| Halperin, AK | 2 |
| Hashimoto, F | 1 |
| Callender, K | 1 |
| Mulinari, R | 1 |
| Gavras, H | 1 |
| Reeves, RL | 1 |
| Crook, J | 1 |
| Garrett, B | 1 |
| Philip, IG | 1 |
| Qureshi, SM | 1 |
| Richards, HH | 1 |
| Sharma, SK | 1 |
| Wright, FG | 1 |
| Rowley-Jones, D | 2 |
| Cantelli, I | 1 |
| Dessurault, DL | 1 |
| Bleicher, JM | 1 |
| Plachetka, JR | 1 |
| Platt, J | 1 |
| Crawford, RJ | 1 |
| Allman, S | 1 |
| Lisi, DM | 1 |
| Salvadeo, A | 1 |
| Segagni, S | 1 |
| Moroni, G | 1 |
| Poggio, F | 1 |
| Bruner, CA | 1 |
| Irmisch, R | 1 |
| de Looze, S | 1 |
| Rangoonwala, B | 2 |
| Velasco, M | 1 |
| Morillo, J | 1 |
| Urbina, A | 1 |
| Leishman, B | 1 |
| Pasquier, M | 1 |
| Hernändez-Pieretti, O | 1 |
| Farinaro, E | 1 |
| Celentano, E | 1 |
| Gupta, RC | 1 |
| Bhan, GL | 1 |
| Nartowicz, E | 1 |
| Burduk, P | 1 |
| Karwowski, J | 1 |
| Westergren, G | 1 |
| Van Couter, A | 1 |
| Feldstein, CA | 1 |
| Ming, KS | 1 |
| Kuramoto, K | 1 |
| Meaney, E | 1 |
| Wahl, J | 1 |
| Singh, BN | 1 |
| Thoden, WR | 1 |
| Davis, TK | 1 |
| Carroll, L | 1 |
| Hui, TP | 1 |
| Krakoff, LR | 1 |
| Felton, K | 1 |
| Yeager, K | 1 |
| Wicker, P | 1 |
| Clementy, J | 2 |
| Weiner, B | 1 |
| Marwaha, R | 2 |
| Johnson, J | 2 |
| Bannon, JA | 2 |
| Thomas, CM | 1 |
| Van den Berg, RJ | 1 |
| Saunders, R | 1 |
| Hickler, R | 1 |
| Testa, MA | 2 |
| Brown, B | 1 |
| Jenkins, CD | 1 |
| Klerman, GL | 1 |
| Juustila, H | 2 |
| Kinnunen, O | 1 |
| Koistinen, P | 1 |
| Rorive, G | 1 |
| Cowling, CG | 1 |
| Mahomedy, Y | 1 |
| Melby, JC | 1 |
| Chan, LS | 1 |
| Mondal, S | 1 |
| Sharma, BK | 1 |
| Houston, MC | 1 |
| Johnston, PE | 1 |
| Jackson, G | 1 |
| Rowland, M | 1 |
| Adam, G | 1 |
| MacFarlane, E | 1 |
| Jackson, PG | 1 |
| Lee, SM | 1 |
| Koeppe, PR | 1 |
| Ruoff, GE | 1 |
| Sapir, DG | 1 |
| Vollmer, C | 1 |
| Schwebig, A | 2 |
| Mazaud, C | 1 |
| Justal, A | 1 |
| Bricaud, H | 1 |
| Creisson, C | 1 |
| Baulac, L | 2 |
| Lenfant, B | 1 |
| Rabinad, E | 1 |
| Gaya, J | 1 |
| Rivera, F | 1 |
| Ingelmo, M | 1 |
| Balcells, A | 1 |
| Andersen, H | 1 |
| Galasse, R | 1 |
| Dominguez, JR | 1 |
| de la Calle, H | 1 |
| Hurtado, A | 1 |
| Robles, RG | 1 |
| Sancho-Rof, J | 1 |
| Pitterle, ME | 1 |
| Panozzo, M | 1 |
| Ponti, G | 1 |
| Wilson, DJ | 1 |
| Solomon, RJ | 1 |
| Stillman, N | 1 |
| Sano, T | 1 |
| Weisweiler, P | 1 |
| Lischner, M | 1 |
| Lang, R | 1 |
| Jutrin, I | 1 |
| Smith, LK | 2 |
| Sowers, J | 2 |
| McCarron, D | 2 |
| Wyrzykowski, B | 3 |
| Klein, MD | 2 |
| Weiner, DA | 1 |
| Bernard, F | 1 |
| Drivet-Perrin, J | 1 |
| Sambuc, R | 1 |
| Steru, D | 1 |
| Childs, M | 1 |
| Lancrenon, S | 1 |
| Languillat, JM | 1 |
| Millet, B | 1 |
| Stephan, A | 1 |
| Pannier, BM | 1 |
| Hugue, CJ | 1 |
| Meijer, JL | 1 |
| Ardesch, HG | 1 |
| Van Rooijen, JC | 1 |
| De Bruijn, JH | 1 |
| Kayanakis, JG | 1 |
| Osterkorn, K | 1 |
| Runge, J | 1 |
| Skoutakis, VA | 1 |
| Carter, CA | 1 |
| Acchiardo, SR | 1 |
| Soltis, EE | 1 |
| Bohr, DF | 1 |
| Sabanathan, K | 1 |
| Castleden, CM | 1 |
| Adam, HK | 1 |
| Ryan, J | 1 |
| Fitzsimons, TJ | 1 |
| Cohen, N | 1 |
| Sigler, E | 1 |
| Thames, MD | 1 |
| Słowińska-Srzednicka, J | 1 |
| Zgliczyński, S | 1 |
| Tołłoczko, T | 1 |
| Jørgensen, F | 1 |
| Bredesgaard, P | 1 |
| Johansen, P | 1 |
| Torriani, A | 1 |
| Bravi, M | 1 |
| Broglia, M | 1 |
| Giuffrè, G | 1 |
| Carisdeo, V | 1 |
| Daniels, AR | 1 |
| Hughes, GS | 1 |
| Cowart, TD | 1 |
| Conradi, EC | 1 |
| Packard, RC | 1 |
| Palou Redorta, J | 1 |
| Morote Robles, J | 1 |
| Costa Pagés, J | 1 |
| Arnau de Bolós, JM | 1 |
| Tikhonov, VP | 1 |
| Umurzakov, EU | 1 |
| Ridgeway, NA | 1 |
| Ginn, DR | 1 |
| Alley, K | 1 |
| Takada, T | 1 |
| Nakata, K | 1 |
| Yamauchi, H | 1 |
| Iso, T | 1 |
| Kuznetsov, GP | 1 |
| Lebedev, PA | 1 |
| Rapacke, J | 1 |
| Thornhill, MD | 1 |
| Upton, RA | 1 |
| Blume, C | 1 |
| Clark, TS | 1 |
| Lin, E | 1 |
| Benet, LZ | 1 |
| Kurilova, LP | 2 |
| Smith, VE | 1 |
| Lubis, HR | 1 |
| Silalahi, M | 1 |
| Wu, SC | 1 |
| Secchi, MB | 1 |
| Mancarella, S | 1 |
| Bettazzi, L | 1 |
| Civelli, M | 1 |
| Cirò, A | 1 |
| Oltrona, L | 1 |
| Folli, G | 1 |
| McManus, BM | 1 |
| Blackbourne, BD | 1 |
| Roberts, WC | 1 |
| Stewart, KA | 1 |
| Schrogie, JJ | 1 |
| Delisser, O | 1 |
| Falliers, CJ | 1 |
| Vrchota, J | 1 |
| Blasucci, DJ | 1 |
| Maloy, JW | 1 |
| Hudson, L | 1 |
| Manocha, KL | 1 |
| Bobrov, VA | 1 |
| Polipova, SN | 1 |
| Ianushevskaia, TA | 1 |
| Craig, HM | 1 |
| Lynn, KL | 1 |
| Bailey, RR | 1 |
| Swainson, CP | 1 |
| Sainsbury, R | 1 |
| Low, WI | 1 |
| Nieszporek, T | 1 |
| Mleczko, Z | 1 |
| Trembecki, J | 1 |
| Brachfeld, J | 1 |
| Itskovitz, H | 1 |
| Lunn, JA | 1 |
| Cobb, SD | 1 |
| Petrulis, AS | 1 |
| Oren, A | 1 |
| Riley, LJ | 1 |
| Farooki, MS | 1 |
| Farsky, K | 1 |
| Bouchard, S | 1 |
| Lalonde, Y | 1 |
| Brookman, S | 1 |
| Fruncillo, RJ | 1 |
| Caporicci, D | 1 |
| Achilli, L | 1 |
| Pepi, R | 1 |
| Mori, A | 1 |
| Piña, C | 2 |
| Vila, R | 1 |
| Arnau, C | 1 |
| Macieira-Coelho, E | 1 |
| Garcia-Alves, M | 1 |
| Reis-Valle, A | 1 |
| O'Sullivan, J | 1 |
| Strozzi, C | 1 |
| Padula, A | 1 |
| Russo, L | 1 |
| Alfiero, R | 1 |
| Rizzo, A | 1 |
| Kocemba, J | 1 |
| Wojciechowska, M | 1 |
| Tyson, J | 1 |
| Hudson, LD | 1 |
| Chetty, K | 1 |
| Triyanond, K | 1 |
| Cutler, JA | 1 |
| Swartz, S | 1 |
| Zawada, E | 1 |
| Dols, W | 1 |
| Lucchini, M | 1 |
| Airoldi, G | 1 |
| Cagianelli, MA | 1 |
| Cortese, R | 1 |
| Diamanti, G | 1 |
| Giuntoli, F | 1 |
| Pettinà, G | 1 |
| Haimerl, F | 1 |
| Lehmann, K | 1 |
| Köpcke, W | 1 |
| Garrido Peralta, M | 1 |
| Seco Vasco, J | 1 |
| Rodríguez Alvarez, J | 1 |
| Gras, X | 1 |
| Andersen, B | 1 |
| da Silva Franco, RS | 1 |
| da Silva Franco, RJ | 1 |
| Barretti, P | 1 |
| Longo, AA | 1 |
| Spadaro, J | 1 |
| Nurnberger, JI | 1 |
| Siperstein, MD | 1 |
| Guevara, A | 1 |
| Springmann, KE | 1 |
| Drach, GW | 1 |
| Hillman, BJ | 1 |
| Fenderson, RW | 1 |
| Perry, RS | 1 |
| Mohr, JP | 1 |
| Dzúriková, V | 1 |
| Krechnáková, A | 1 |
| Szalayová, V | 1 |
| Schouten, JA | 1 |
| Hengeveld, WL | 1 |
| Korobenko, GN | 1 |
| Steele, TH | 1 |
| Gottstein, JH | 1 |
| Challoner-Hue, L | 1 |
| Lavin, PJ | 1 |
| Weissman, BM | 1 |
| Scillitani, A | 1 |
| Gagliardi, R | 1 |
| Trachewsky, D | 1 |
| Kem, DC | 1 |
| Dimitrov, D | 1 |
| Mulvihill-Wilson, J | 1 |
| Gaffney, FA | 1 |
| Graham, RM | 1 |
| Blomqvist, CG | 1 |
| Kuller, L | 1 |
| Farrier, N | 1 |
| Caggiula, A | 1 |
| Borhani, N | 1 |
| Dunkle, S | 1 |
| Mustafaev, II | 1 |
| Perova, NV | 1 |
| Postol'nikov, SF | 1 |
| Metel'skaia, VA | 1 |
| Hovell, MF | 1 |
| Geary, DC | 1 |
| Black, DR | 1 |
| Kamachi, K | 1 |
| Kirk, R | 1 |
| Elder, J | 1 |
| Scholz, W | 1 |
| Hropot, M | 1 |
| Cohen, L | 1 |
| Kitzes, R | 1 |
| Shnaider, H | 1 |
| Geerling, J | 1 |
| Markiewicz, K | 1 |
| Górski, L | 1 |
| Cholewa, M | 1 |
| Kohner, EM | 1 |
| Lowy, C | 1 |
| Schumer, B | 1 |
| Graybiel, AL | 1 |
| Sode, J | 1 |
| George, CF | 1 |
| Schweitzer, IL | 1 |
| Peters, RL | 1 |
| Siitonen, L | 1 |
| Jänne, J | 1 |
| Keyriläinen, O | 1 |
| Koskinen, P | 1 |
| Leskinen, O | 1 |
| Reinikainen, M | 1 |
| Heinze, A | 1 |
| Wessels, F | 1 |
| Paterson, JW | 2 |
| Mehbod, H | 2 |
| Swartz, CD | 2 |
| Sweet, RL | 1 |
| Sheffield, LT | 1 |
| Cole, PA | 1 |
| Tarpley, EL | 1 |
| Groover, ME | 1 |
| Fulghum, JE | 1 |
| Simpson, WG | 1 |
| O'Steen, WK | 1 |
| Hall, OS | 1 |
| Ryvkin, IA | 2 |
| Korsunskiĭ, AA | 1 |
| Pribylova, LP | 1 |
| Lobanova, LS | 1 |
| Raĭskaia, AM | 1 |
| Poblete, PF | 1 |
| Pipberger, HV | 1 |
| Demura, H | 1 |
| Fukuchi, S | 2 |
| Goto, K | 2 |
| Bourgoignie, JJ | 1 |
| Catanzaro, FJ | 1 |
| Lubbe, WF | 1 |
| Colton, T | 1 |
| Radó, JP | 1 |
| Szabó, T | 1 |
| Takó, J | 1 |
| Szántó, Z | 1 |
| Kubota, K | 1 |
| Nicholas, TE | 1 |
| Spark, RF | 2 |
| Mendelson, DJ | 1 |
| Löper, W | 1 |
| Gottlieb, TB | 1 |
| Katz, FH | 1 |
| Chidsey, CA | 1 |
| Kmoch, J | 1 |
| Svoboda, Z | 1 |
| Raper, AJ | 1 |
| Takenouchi, T | 1 |
| Nishisato, K | 1 |
| Hubert, C | 1 |
| Demanet, JC | 1 |
| Degaute, JP | 1 |
| Fichefet, JP | 1 |
| Paduart, P | 1 |
| Trompetto, G | 1 |
| Mata, O | 1 |
| Gysling, E | 1 |
| de Wurstemberger, B | 1 |
| Fletcher, HP | 1 |
| Bennett, R | 1 |
| Clark, GM | 1 |
| Troop, RC | 1 |
| Levin, DM | 1 |
| Shields, LH | 1 |
| Parijs, J | 1 |
| Joossens, JV | 1 |
| Van der Linden, L | 1 |
| Verstreken, G | 1 |
| Amery, AK | 1 |
| Leemhuis, MP | 1 |
| Struyvenberg, A | 1 |
| Jones, J | 1 |
| Douglas, JG | 1 |
| Liddle, GW | 1 |
| O'Hare, CM | 1 |
| Regan, RM | 1 |
| Vetter, G | 1 |
| Lung-Johansen, P | 1 |
| De Schaepdrijver, A | 1 |
| Heino, A | 1 |
| Munter, J | 1 |
| Erina, EV | 1 |
| Luk'ianova, ON | 1 |
| Ustinova, SE | 1 |
| Chasis, H | 1 |
| Schwartz, AB | 1 |
| Laidlaw, JC | 1 |
| Dargie, HJ | 1 |
| Kennedy, AC | 1 |
| Ward, DM | 1 |
| Boddy, K | 1 |
| King, PC | 1 |
| Pfaff, JR | 1 |
| Newberry, PD | 1 |
| Sederberg-Olsen, P | 1 |
| Acchiardo, S | 1 |
| Blatrix, C | 1 |
| Saldanha, RV | 1 |
| Veras, RO | 1 |
| de Paula e Silva, P | 1 |
| de Serro-Azul, LG | 1 |
| Carstens, E | 1 |
| Corman, LA | 1 |
| Skversky, NJ | 1 |
| Beaudry, C | 1 |
| Limas, CJ | 1 |
| Kim, KE | 1 |
| Swartz, C | 1 |
| Horwitz, D | 2 |
| Alexander, RW | 1 |
| Lovenberg, W | 1 |
| Keiser, HR | 1 |
| Haller, J | 1 |
| Degnbol, B | 2 |
| Dorph, S | 4 |
| Marner, T | 2 |
| Hesse, E | 1 |
| Lang, O | 1 |
| Lamid, S | 1 |
| Naidoo, DN | 1 |
| Kashnir, VS | 1 |
| Balizet, L | 1 |
| Lindy, S | 1 |
| Tarssanen, L | 1 |
| Galeeva, MG | 1 |
| Suzuki, Y | 2 |
| Ina, K | 1 |
| Yamagami, I | 2 |
| Ekbom, KA | 1 |
| Spach, MO | 1 |
| Bloch, R | 1 |
| Velly, J | 1 |
| Bousquet, P | 1 |
| Schwartz, J | 1 |
| Ariënsen, EJ | 1 |
| Simonis, AM | 1 |
| Keim, HJ | 1 |
| Philippi, A | 1 |
| Walter, U | 1 |
| Werner, E | 1 |
| Gandhi, MJ | 1 |
| Rao, VC | 1 |
| Kumar, B | 1 |
| Burke, GE | 1 |
| Juchems, R | 1 |
| Ammerschläger, G | 1 |
| Froment, R | 1 |
| Froment, A | 3 |
| Zech, P | 2 |
| Rantanen, I | 1 |
| Petz, E | 1 |
| Todisco, T | 1 |
| Spechtmeyer, H | 1 |
| Fischer, U | 1 |
| Fritz, KW | 2 |
| Kusus, T | 1 |
| Zöllner, N | 1 |
| Aoki, VS | 1 |
| Ikeda, T | 1 |
| Dean, G | 1 |
| Louw, S | 1 |
| Hersch, C | 1 |
| Kirsten, HO | 1 |
| Brereton, DN | 1 |
| Finnemore, L | 1 |
| Dewar, J | 1 |
| Kiesenwetter, R | 1 |
| Vaidya, PM | 1 |
| Munshi, CP | 1 |
| Sawkar, LA | 1 |
| Parikh, HM | 1 |
| Gulati, OD | 1 |
| Godfrey, BE | 1 |
| Hill, DM | 1 |
| Munro-Faure, AD | 1 |
| Sheldon, J | 1 |
| Ausubel, H | 1 |
| Levine, ML | 1 |
| Bloomfield, DK | 1 |
| Scheiber, V | 2 |
| Esch, I | 2 |
| Wilkinson, B | 1 |
| Williams, JA | 1 |
| Moldovan, T | 1 |
| Idu, SM | 1 |
| Anastasiu, R | 1 |
| Mihai, N | 1 |
| Smolenskiĭ, VS | 1 |
| Mazel', GS | 1 |
| Durand, J | 1 |
| Oulie, M | 1 |
| Kunitsa, LD | 6 |
| Nekrashevich, MI | 1 |
| Iuditskaia, VI | 1 |
| Kojima, K | 1 |
| Shinoda, M | 1 |
| Davidov, M | 1 |
| Antcliff, AC | 1 |
| Hamilton, M | 1 |
| Harpur, JE | 1 |
| Meyer, P | 1 |
| Mikhaĭlin, SE | 1 |
| Ianovskiĭ, GV | 1 |
| Onoprienko, ZV | 1 |
| Zelinskaia, NT | 1 |
| Sales, EJ | 1 |
| Villa, JJ | 1 |
| Mendez, MA | 1 |
| Munoz, JT | 1 |
| Scheib, ET | 1 |
| Jewett, JF | 1 |
| Neuvonen, PJ | 1 |
| Meneuvonen, PJ | 1 |
| Vinichuk, SM | 3 |
| Mattar, E | 1 |
| Cruz, HM | 1 |
| Cruz, J | 1 |
| Smith, RW | 1 |
| Levshteĭn, DI | 1 |
| Maslova, KK | 1 |
| Sviderskaia, NA | 1 |
| Tsessarskiĭ, AV | 1 |
| Vyshnepol'skiĭ, IuIa | 2 |
| Taylor, WR | 1 |
| Wilkinson, WH | 1 |
| de Azambuja, PL | 1 |
| Koshikawa, S | 1 |
| Sasaoka, T | 1 |
| Fiegel, G | 1 |
| Bargheer, R | 1 |
| Heindorf, M | 1 |
| Spiekerman, RE | 1 |
| Berge, KG | 1 |
| Thurber, DL | 1 |
| Gedge, SW | 1 |
| McGuckin, WF | 1 |
| Wolf, RL | 1 |
| Mendlowitz, M | 1 |
| Roboz, J | 1 |
| Styan, GP | 1 |
| Kornfeld, P | 1 |
| Weigl, A | 1 |
| Kraus, GW | 1 |
| Marchese, JR | 1 |
| Yen, SS | 1 |
| Schubert, R | 1 |
| Pasz, T | 1 |
| Enescu, I | 1 |
| Tacu, V | 1 |
| Babei, E | 1 |
| Friedman, R | 1 |
| Maebashi, M | 1 |
| Yoshinaga, K | 1 |
| Miura, K | 1 |
| Katsushima, I | 1 |
| Simonian, AT | 1 |
| Bostandzhian, OSh | 1 |
| Ronnov-Jessen, V | 1 |
| Hansen, J | 2 |
| Shilova, EN | 1 |
| Paloyan, E | 2 |
| Farland, M | 1 |
| Pickleman, JR | 2 |
| Trunova, TL | 1 |
| Vincent, M | 1 |
| Dupont, JC | 1 |
| Kern, A | 1 |
| Poletti, T | 1 |
| Mangano, D | 1 |
| Gastaldi, L | 1 |
| Buccianti, G | 1 |
| Rizzato, G | 1 |
| Marazzini, L | 1 |
| Yoshida, T | 1 |
| Eto, M | 1 |
| Duarte, CG | 1 |
| Winnacker, JL | 1 |
| Pace, A | 1 |
| Gnedkova, GL | 1 |
| Lazareva, DN | 1 |
| Gros, G | 1 |
| Dabrowska, B | 1 |
| Poplawska, W | 1 |
| Wocial, B | 1 |
| Steinbuch, HJ | 1 |
| Polak, F | 1 |
| Romanenko, VV | 1 |
| Adamenko, RIa | 1 |
| Rozgon, GI | 1 |
| Grazi, S | 1 |
| Polese, A | 1 |
| Warembourg, H | 1 |
| Jaillard, J | 1 |
| Michot, F | 1 |
| Engelman, K | 1 |
| Ambrose, IM | 1 |
| Sjoerdsma, A | 1 |
| Haslam, RM | 1 |
| Doll, R | 1 |
| Langman, MJ | 1 |
| Shawdon, HH | 1 |
| Poniecki, A | 1 |
| Pavesi, V | 1 |
| Campus, G | 1 |
| Datey, KK | 1 |
| Dalvi, CP | 1 |
| Deshmukh, SN | 1 |
| Oigaard, A | 1 |
| Priddle, WW | 1 |
| Liu, SF | 1 |
| Breithaupt, DJ | 1 |
| Grant, PG | 1 |
| Sugita, K | 1 |
| Narusawa, T | 1 |
| Niitani, H | 1 |
| Prescott, LF | 1 |
| Yasui, H | 1 |
| Vaĭngrib, LG | 1 |
| Kaeding, A | 1 |
| Schmicker, R | 1 |
| Klinkmann, H | 1 |
| Kósmider, S | 1 |
| Wojciechowski, J | 1 |
| Gjonnaess, H | 1 |
| Davidovich, NIa | 1 |
| Fedoseev, GB | 1 |
| Guseĭnov, AK | 1 |
| Lebedeva, ZG | 2 |
| Ivanov, IuM | 2 |
| Pozet, N | 1 |
| Banssillon, V | 1 |
| Traeger, J | 1 |
| Repetto, S | 1 |
| Rezzonico, A | 1 |
| Gervasini, N | 1 |
| Dickey, JM | 1 |
| Tanney, H | 1 |
| Binder, C | 1 |
| Pomerantz, HZ | 1 |
| Walsh, JA | 1 |
| Hyman, C | 1 |
| Straus, FH | 1 |
| Forland, M | 1 |
| Heimsoth, V | 1 |
| Hartmann, F | 1 |
| Tolva, D | 1 |
| Benati, E | 1 |
| Colombo, G | 1 |
| Ripka, O | 1 |
| Malis, F | 1 |
| Victor, G | 1 |
| Soproni, G | 1 |
| Conrad, H | 1 |
| Scotti, G | 1 |
| Gatti, A | 1 |
| Phillips, BM | 1 |
| Kramer, DL | 1 |
| Latotzki, H | 1 |
| Vizioli, A | 1 |
| Ceino, A | 1 |
| Cannon, PJ | 1 |
| Pistolese, M | 1 |
| Rosica, V | 1 |
| Gallo Curcio, C | 1 |
| Gombos, EA | 1 |
| Moghadam, A | 1 |
| Briggs, AH | 1 |
| Holland, WC | 1 |
| Tourniaire, A | 1 |
| Blum, J | 1 |
| Hutinel, P | 1 |
| Gallet, M | 1 |
| Mutalik, GS | 1 |
| Angelo, TL | 1 |
| Berger, E | 1 |
| Schmidt, K | 1 |
| Sappington, RF | 1 |
| Tretenhahn, W | 1 |
| Dorndorf, W | 1 |
| Lotz, W | 1 |
| Ol', IV | 1 |
| Anfossi, F | 1 |
| Guaraggi, A | 1 |
| Rossi, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #597 - Diuretic Comparison Project[NCT02185417] | Phase 3 | 13,523 participants (Actual) | Interventional | 2016-06-15 | Completed | ||
| Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide[NCT02100462] | Phase 4 | 30 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Use of Hydrochlorothiazide and the Risk of Skin Cancer[NCT04334824] | 2,953,748 participants (Actual) | Observational | 2019-05-27 | Completed | |||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination With Amiloride in Multiple Doses on Blood Pressure in Patients With Primary Hypertension: a Factorial Randomized Controlled Trial.[NCT03928145] | Phase 3 | 84 participants (Anticipated) | Interventional | 2019-11-13 | Recruiting | ||
| DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886] | Phase 4 | 28 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care[NCT01431326] | 3,520 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Effect of High-Intensity Interval Training Compared to Hydrochlorothiazide on Ambulatory Blood Pressure, Cardiovascular Health, Cognition and Mobility in Pre-Hypertensive Older Adults.[NCT04103411] | 60 participants (Anticipated) | Interventional | 2018-04-26 | Recruiting | |||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial[NCT02255253] | 1,410 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| A Cross-over Trial to Identify Patient Characteristics That Predict Blood Pressure Response to Antihypertensive Therapy in General Practice[NCT00457483] | Phase 4 | 120 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension[NCT00994617] | Phase 4 | 600 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension[NCT00846365] | Phase 3 | 1,085 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828] | Phase 3 | 153 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| The Precision Hypertension Care Study[NCT02774460] | Phase 4 | 280 participants (Actual) | Interventional | 2017-02-20 | Completed | ||
| Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension[NCT02412761] | 42 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans[NCT02742467] | Phase 4 | 702 participants (Actual) | Interventional | 2017-06-07 | Completed | ||
| Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controll[NCT02294539] | Phase 4 | 231 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension[NCT00801671] | Phase 3 | 50 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension.[NCT00327587] | Phase 3 | 2,279 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial[NCT01030458] | Phase 4 | 183 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People[NCT01259297] | Phase 3 | 2,336 participants (Actual) | Interventional | 2011-01-31 | Terminated (stopped due to Terminated early in agreement with Health Authorities for feasibility reasons) | ||
| Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091] | Phase 3 | 2,689 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium[NCT01307046] | Phase 3 | 336 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®][NCT01307033] | Phase 3 | 278 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension[NCT00241124] | Phase 4 | 1,099 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration[NCT01302691] | Phase 3 | 327 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical [NCT01299376] | Phase 3 | 286 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.[NCT03847350] | 3,250 participants (Actual) | Observational | 2015-07-01 | Completed | |||
| A Multicenter, Open-Label, Single-Arm, Free Tablet Combination, Long-Term Study to Evaluate the Safety of Nebivolol in Combination With Valsartan in Patients With Stage 1 or Stage 2 Essential Hypertension[NCT01415505] | Phase 3 | 812 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.[NCT00408512] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequa[NCT01096667] | Phase 2 | 194 participants (Actual) | Interventional | 2010-05-17 | Completed | ||
| A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Ph[NCT01258673] | Phase 3 | 263 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With[NCT00797862] | Phase 3 | 1,254 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effect of Aliskiren 300mg and Hydrochlorothiazide 25mg on Kidney Oxygenation in Patients With Stage 1 and 2 Hypertension: a BOLD-MRI Study[NCT01519635] | Phase 4 | 24 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With D[NCT01838850] | Phase 3 | 344 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Heart Outcomes Prevention Evaluation-3[NCT00468923] | Phase 4 | 12,705 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension[NCT03532620] | Phase 4 | 396 participants (Anticipated) | Interventional | 2018-08-09 | Recruiting | ||
| Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care[NCT05155137] | Phase 3 | 12,268 participants (Anticipated) | Interventional | 2021-12-20 | Recruiting | ||
| Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS)[NCT00224549] | Phase 4 | 180 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Efficacy and Safety of Canrenone as Add-on in Patients With Essential Hypertension-Italy (ESCAPE-IT)[NCT02687178] | Phase 4 | 180 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial[NCT02646397] | Phase 4 | 508 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension[NCT00273299] | Phase 3 | 607 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Valsartan 80 mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Cont[NCT00250562] | Phase 3 | 1,171 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness.[NCT00394394] | Phase 2 | 0 participants | Interventional | 2005-02-28 | Completed | ||
| Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice[NCT00631514] | Phase 4 | 88 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome[NCT00170937] | Phase 4 | 507 participants | Interventional | 2004-11-30 | Completed | ||
| A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension[NCT00430638] | Phase 4 | 278 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six W[NCT00219154] | Phase 3 | 1,125 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension[NCT00294710] | Phase 3 | 976 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension[NCT00353912] | Phase 3 | 571 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Open-label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hype[NCT00267943] | Phase 3 | 639 participants | Interventional | 2006-01-31 | Completed | ||
| An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 m[NCT00386139] | Phase 3 | 881 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy[NCT00387517] | Phase 3 | 726 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Mea[NCT00394823] | Phase 3 | 206 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance[NCT00171132] | Phase 4 | 64 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy[NCT00354991] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
| Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865] | Phase 4 | 50 participants (Actual) | Interventional | 2010-03-31 | Terminated (stopped due to The participants signed an old version of the informed consent.) | ||
| An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hyperte[NCT00219193] | Phase 3 | 641 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial[NCT01552954] | Phase 4 | 269 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)[NCT00607035] | Phase 4 | 220 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension[NCT00139555] | Phase 4 | 125 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy[NCT00304226] | Phase 4 | 1,288 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures[NCT00229242] | 38 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With [NCT00280540] | Phase 4 | 648 participants | Interventional | 2005-12-31 | Completed | ||
| A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension[NCT00403481] | Phase 4 | 192 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome[NCT00546052] | Phase 3 | 1,738 participants (Actual) | Interventional | 2005-09-01 | Completed | ||
| A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension[NCT00441350] | Phase 3 | 1,004 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Sa[NCT00386607] | Phase 3 | 601 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi[NCT00867490] | Phase 3 | 186 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Felodipine Event Reduction Study[NCT01136863] | 9,800 participants (Actual) | Interventional | 1998-04-30 | Completed | |||
| An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596] | Phase 4 | 332 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertensi[NCT00219024] | Phase 3 | 2,775 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension[NCT00760266] | Phase 4 | 451 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very [NCT00698646] | Phase 4 | 384 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 m[NCT00621153] | Phase 4 | 214 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 [NCT00219102] | Phase 3 | 336 participants | Interventional | 2005-06-30 | Completed | ||
| Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.[NCT02058875] | Phase 4 | 0 participants (Actual) | Interventional | 2014-02-28 | Withdrawn (stopped due to The study funder retracted their grant funding offer before contract signed.) | ||
| A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype[NCT00425997] | Phase 4 | 480 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.[NCT00219037] | Phase 3 | 1,955 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hype[NCT00171405] | Phase 3 | 250 participants | Interventional | 2005-06-30 | Completed | ||
| Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy[NCT00430508] | Phase 3 | 972 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy[NCT00430950] | Phase 3 | 1,011 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks[NCT01011660] | Phase 4 | 13,542 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination: A Comparison of Active and Usual Titration Regimen in the Treatment of Hypertensive Patients Insufficiently Controlled by Monotherapy[NCT00708344] | Phase 4 | 832 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)[NCT00605072] | Phase 2 | 53 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension[NCT00380289] | 66 participants | Interventional | 2006-09-30 | Recruiting | |||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction[NCT01061450] | Phase 4 | 55 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension[NCT01033071] | Phase 3 | 1,071 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Lin[NCT00926289] | Phase 4 | 894 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension[NCT00412932] | Phase 4 | 178 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension[NCT00818883] | Phase 3 | 609 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258] | Phase 4 | 999 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension[NCT00667719] | Phase 3 | 564 participants (Actual) | Interventional | 2008-06-05 | Completed | ||
| A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill[NCT01506505] | 78 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine[NCT00564057] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Genetic Epidemiology of Responses to Antihypertensives[NCT00005520] | 1,200 participants (Actual) | Observational | 1997-02-28 | Completed | |||
| Stroke Prediction Study Using a Model Based on Internet Search Queries[NCT04755959] | 450 participants (Anticipated) | Observational | 2021-02-28 | Not yet recruiting | |||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| HYZAAR Versus Ramipril Diabetic Patients[NCT00480805] | Phase 3 | 312 participants (Actual) | Interventional | 2001-08-08 | Completed | ||
| Prospective Cross-sectional Study on Prevalence of Primary Aldosteronism in Resistant Hypertension and Association With Cardiometabolic Complications[NCT04213963] | 100 participants (Anticipated) | Observational | 2011-09-01 | Recruiting | |||
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure[NCT02627196] | 1,200 participants (Anticipated) | Interventional | 2016-04-19 | Active, not recruiting | |||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Methodological Improvement in Measuring Efficacy Outcome in Antihypertensive Trials in Children[NCT01070342] | 170 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115] | Phase 3 | 493 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Randomised, Double-Blind, Placebo-Controlled, 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension[NCT00153049] | Phase 2 | 583 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.[NCT00140959] | Phase 4 | 120 participants | Interventional | 2003-02-01 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertensio[NCT00092209] | Phase 3 | 840 participants | Interventional | 2002-04-30 | Completed | ||
| An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina[NCT00360178] | Phase 3 | 198 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patien[NCT00219063] | Phase 3 | 844 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy[NCT00327145] | Phase 3 | 894 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure[NCT00289887] | Phase 3 | 261 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Efficacy and Safety of a Combination of Ramipril Plus Hydrochlorothiazide Versus the Component Monotherapies in Subjects With Essential Hypertension[NCT00355589] | Phase 3 | 0 participants | Interventional | 2006-07-31 | Completed | ||
| Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)[NCT00154271] | Phase 4 | 1,677 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| "Sub-Study Evaluating the Quality of Different Methods of Obtaining Informed Consent"[NCT00794729] | 250 participants (Anticipated) | Observational | 2008-10-16 | Completed | |||
| Once Versus Twice Daily Electrolyte Monitoring in CHF; a Study Monitoring Electrolytes in Congestive Heart Failure Patients Being Actively Diuresed in Hospital[NCT02497742] | 96 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| [NCT00000525] | Phase 3 | 233 participants (Actual) | Interventional | 1986-07-31 | Completed | ||
| Estudio RioplateNsE Sobre Telemonitoreo en hIpertensos No-controlAdos[NCT02730052] | 0 participants (Actual) | Interventional | 2016-12-31 | Withdrawn (stopped due to Centers recruited poorly) | |||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| Metabolic Phenotyping and Systems Biology in Surgery[NCT01378013] | 50 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, [NCT00348413] | 80 participants (Anticipated) | Interventional | 2003-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 4.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -33.0 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -34.1 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -26.9 |
The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 8.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -37.6 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -38.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -31.5 |
The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -14.4 | -15.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.8 | -16.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.8 | -12.1 |
The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -25.0 | -27.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -25.5 | -28.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -19.2 | -21.1 |
The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.9 | -15.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.4 | -16.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.5 | -12.0 |
The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -24.1 | -26.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -24.4 | -27.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -18.4 | -20.7 |
The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -14.2 | -15.3 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.7 | -16.6 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.7 | -12.1 |
The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -24.5 | -26.7 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -25.1 | -28.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -18.9 | -21.0 |
The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.4 | -14.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -13.3 | -15.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -9.6 | -11.8 |
The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -22.3 | -25.2 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -21.9 | -26.3 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.6 | -19.7 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.4 | -14.6 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.6 | -15.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.9 | -12.0 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -22.4 | -24.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -23.6 | -26.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.4 | -19.6 |
The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=360; n=347; n=352) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.6 | -16.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.2 | -16.5 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.4 | -12.8 |
Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or <130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 51.3 | 58.1 | 68.8 | 69.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 48.5 | 61.4 | 65.4 | 68.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 35.9 | 44.6 | 55.5 | 54.7 |
Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as <90 mm Hg for participants without diabetes or CKD or <80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 63.6 | 71.4 | 77.9 | 79.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 66.2 | 73.8 | 76.9 | 79.1 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 47.8 | 58.2 | 66.9 | 66.0 |
Percentage of participants who achieve a clinic systolic blood pressure response, defined as <140 mm Hg for participants without diabetes or CKD or <130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 60.3 | 66.1 | 76.8 | 76.0 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 57.2 | 68.9 | 73.4 | 76.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 44.9 | 52.3 | 64.9 | 64.6 |
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 69.3 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 78.4 |
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 58.7 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 73.0 |
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 80.0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 87.8 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Adverse Events | Adverse Events Leading to Discontinuation | Serious Adverse Events | Serious Adverse Events Leading to Discontinuation | Death | |
| Azilsartan Medoxomil + Chlorthalidone | 68 | 17 | 8 | 5 | 0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 58 | 15 | 9 | 4 | 1 |
For each n-of-1 trial, the preferred drug is defined as that which produces normal ambulatory blood pressure (by pediatric Ambulatory blood pressure monitoring (ABPM) standards), with the greatest magnitude of wake mean systolic BP reduction, and without unacceptable side effects. (NCT02412761)
Timeframe: The outcome of BP control and side effect tolerability will be assessed 2 weeks after starting each drug. Participants will be followed for an average of 10-12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Lisinopril | 16 |
| Amlodipine | 8 |
| Hydrochlorothiazide | 4 |
This variable gives the proportion of patients reaching blood pressure control over time (< 140 mmHg systolic and < 90 mmHg diastolic) (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 58 |
| Hydrochlorothiazide Plus Bisoprolol | 40 |
(NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 1 |
| Hydrochlorothiazide Plus Bisoprolol | 1 |
Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | mmHg (Mean) |
|---|---|
| Amlodipine Plus Valsartan | 127.2 |
| Hydrochlorothiazide Plus Bisoprolol | 134.1 |
The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | weeks (Median) |
|---|---|
| Amlodipine Plus Valsartan | 12 |
| Hydrochlorothiazide Plus Bisoprolol | 18 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) |
|---|---|
| Aliskiren Based Regimen | 11 |
| Non-Aliskiren Based Regimen | 14 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) |
|---|---|
| Aliskiren+Amlodipine/HCTZ Group | 2 |
| Placebo | 8 |
The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date. (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | Participants (Number) |
|---|---|
| Aliskiren Based Regimen | 5 |
| Non-Aliskiren Based Regimen | 9 |
Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis. (NCT01259297)
Timeframe: Baseline (BL), 6 week, 6 month and 12 month
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| change from Baseline to 6 week (n=821,867) | change from baseline to 6 month (n=730,775) | change from baseline to 12 month (n=397,399) | |
| Aliskiren Based Regimen | -5.6 | -4.9 | -4.3 |
| Non-Aliskiren Based Regimen | -3.6 | -3.5 | -3.9 |
Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis. (NCT01259297)
Timeframe: Baseline (BL), 6 week, 6 month and 12 month
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| change from Baseline to 6 week (n=821,867) | change from baseline to 6 month (n=730,775) | change from baseline to 12 month (n=397,399) | |
| Aliskiren Based Regimen | -11.9 | -10.1 | -7.7 |
| Non-Aliskiren Based Regimen | -8.02 | -6.8 | -5.8 |
"Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:~Community Cognition (maximum of scores of questions 1 to 6);~Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);~Mobility (maximum of scores of questions 11 and 12);.~Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities." (NCT01259297)
Timeframe: Baseline, End of study (209 days [median])
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Community Cognition | Instrumental Activities of daily Living (IADL) | Mobility | ADL | |
| Aliskiren Based Regimen | -0.04 | -0.06 | 0.01 | -0.09 |
| Non-Aliskiren Based Regimen | -0.05 | -0.04 | 0.00 | -0.08 |
"The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:~End-stage renal disease [ESRD] requiring dialysis or transplantation~Doubling of serum creatinine and reaching an eGFR < 45 ml/min/1.73 m^2." (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) | |
|---|---|---|
| ESRD requiring dialysis or transplantation | Doubling of creatinine & eGFR<45 ml/min/1.73 m^2 | |
| Aliskiren Based Regimen | 0 | 7 |
| Non-Aliskiren Based Regimen | 0 | 1 |
"Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).~Part II of SAGE included 2 dimensions:~Normal if the scores of all SAGE questions is 0 (i.e., No difficulty)~Mobility Only if scores of both SAGE questions 11 and 12 are 0" (NCT01259297)
Timeframe: End of study (209 days [median])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Normal | Mobility Only | |
| Aliskiren Based Regimen | 44.2 | 66.8 |
| Non-Aliskiren Based Regimen | 46.5 | 68.6 |
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm HG (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -23.0 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -23.9 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -23.8 |
| Olmesartan/Amlodipine 20mg/5mg | -20.5 |
| Olmesartan/Amlodipine 40mg/5mg | -21.2 |
| Olmesartan/Amlodipine 40mg/10mg | -22.1 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -3.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -4.1 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -2.7 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | -3.8 |
(NCT00923091)
Timeframe: Week 26 to week 54
| Intervention | mm Hg (Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25 | -11.9 |
(NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -33.2 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -33.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -35.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -35.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -36.2 |
| Olmesartan/Amlodipine 20mg/5mg | -29.9 |
| Olmesartan/Amlodipine 40mg/5mg | -30.4 |
| Olmesartan/Amlodipine 40mg/10mg | -32.8 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -5.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -6.5 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -4.5 |
| OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25 | -6.7 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 177 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 176 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 197 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 190 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 179 |
| Olmesartan/Amlodipine 20mg/5mg | 144 |
| Olmesartan/Amlodipine 40mg/5mg | 155 |
| Olmesartan/Amlodipine 40mg/10mg | 166 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | Participants (Number) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | 29 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | 47 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 63 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 137 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -8.7 |
| Losartan | -3.6 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -14.5 |
| Losartan | -5.4 |
(NCT01307046)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MK-0954A | 31.3 |
| Losartan | 26.5 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -5.3 |
| MK-0954A (L100/H12.5) | -5.0 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -6.2 |
| MK-0954A (L100/H12.5) | -8.5 |
(NCT01307033)
Timeframe: Up to 52 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5→L100/H12.5 Open Label (Period 2) | 71.0 |
| L100/H12.5→L100/H12.5 Open Label (Period 2) | 72.4 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -9.1 |
| L50 + A5 | -8.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -13.4 |
| L50 + A5 | -10.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 30.5 |
| L50 + A5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 11.6 |
| L50 + A5 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50 + A5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.6 |
| L50 + A5 | 0.6 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm (NCT01302691)
Timeframe: up to 8 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 1.2 |
| L50 + A5 | 0.0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -12.1 |
| L50/H12.5 | -6.2 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -17.7 |
| L50/H12.5 | -7.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 27.0 |
| L50/H12.5 | 29.7 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants that experienced at least 1 AE during long-term period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 70.9 |
| L50/H12.5→L50/H12.5/A5 | 66.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 12.1 |
| L50/H12.5 | 14.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the long-term reporting period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 27.7 |
| L50/H12.5→L50/H12.5/A5 | 14.3 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. the percentage of participants that experienced an SAE that assessed as possibly, probably, or definitely related to the study drug by the investigator was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 0.0 |
| L50/H12.5→L50/H12.5/A5 | 0.8 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50/H12.5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Those SAEs assessed as possibly, probably, or definitely related to the study drug during the long-term period were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 3.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week double-blind treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug discontinued during the 44 week extension due to an AE regardless of completion status were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 2.3 |
Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM). (NCT01096667)
Timeframe: 24 hours
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 136.11 |
| Ertugliflozin 1 mg | 133.13 |
| Ertugliflozin 5 mg | 135.08 |
| Ertugliflozin 25 mg | 135.59 |
| HCTZ 12.5mg | 139.55 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). (NCT01096667)
Timeframe: 24 hours
| Intervention | grams/day (Mean) |
|---|---|
| Placebo | 13.35 |
| Ertugliflozin 1 mg | 9.97 |
| Ertugliflozin 5 mg | 8.04 |
| Ertugliflozin 25 mg | 17.56 |
| HCTZ 12.5mg | 6.96 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 169.47 |
| Ertugliflozin 1 mg | 158.38 |
| Ertugliflozin 5 mg | 158.29 |
| Ertugliflozin 25 mg | 172.03 |
| HCTZ 12.5mg | 156.87 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures. (NCT01096667)
Timeframe: Baseline
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 84.89 |
| Ertugliflozin 1 mg | 83.08 |
| Ertugliflozin 5 mg | 83.79 |
| Ertugliflozin 25 mg | 83.89 |
| HCTZ 12.5mg | 84.72 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures. (NCT01096667)
Timeframe: Baseline
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 77.07 |
| Ertugliflozin 1 mg | 78.73 |
| Ertugliflozin 5 mg | 77.30 |
| Ertugliflozin 25 mg | 75.63 |
| HCTZ 12.5mg | 77.97 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures. (NCT01096667)
Timeframe: Baseline
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 135.17 |
| Ertugliflozin 1 mg | 134.23 |
| Ertugliflozin 5 mg | 137.31 |
| Ertugliflozin 25 mg | 135.25 |
| HCTZ 12.5mg | 138.07 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 2
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -5.44 |
| Ertugliflozin 1 mg | -10.98 |
| Ertugliflozin 5 mg | -22.45 |
| Ertugliflozin 25 mg | -32.03 |
| HCTZ 12.5mg | 3.21 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 4.39 |
| Ertugliflozin 1 mg | -13.70 |
| Ertugliflozin 5 mg | -30.41 |
| Ertugliflozin 25 mg | -31.03 |
| HCTZ 12.5mg | 3.79 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.30 |
| Ertugliflozin 1 mg | -0.90 |
| Ertugliflozin 5 mg | -0.75 |
| Ertugliflozin 25 mg | -2.71 |
| HCTZ 12.5mg | -2.54 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 2.34 |
| Ertugliflozin 1 mg | -1.86 |
| Ertugliflozin 5 mg | 1.22 |
| Ertugliflozin 25 mg | -1.51 |
| HCTZ 12.5mg | -0.99 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 1.24 |
| Ertugliflozin 1 mg | -2.77 |
| Ertugliflozin 5 mg | -5.92 |
| Ertugliflozin 25 mg | -4.96 |
| HCTZ 12.5mg | -3.13 |
Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.77 |
| Ertugliflozin 1 mg | -1.89 |
| Ertugliflozin 5 mg | -2.34 |
| Ertugliflozin 25 mg | -1.50 |
| HCTZ 12.5mg | -1.42 |
Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 1.00 |
| Ertugliflozin 1 mg | -1.22 |
| Ertugliflozin 5 mg | 1.07 |
| Ertugliflozin 25 mg | -1.39 |
| HCTZ 12.5mg | -0.56 |
Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF). (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.26 |
| Ertugliflozin 1 mg | -2.71 |
| Ertugliflozin 5 mg | -3.73 |
| Ertugliflozin 25 mg | -3.42 |
| HCTZ 12.5mg | -2.95 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | grams/day (Least Squares Mean) |
|---|---|
| Placebo | 4.15 |
| Ertugliflozin 1 mg | 46.33 |
| Ertugliflozin 5 mg | 64.54 |
| Ertugliflozin 25 mg | 74.49 |
| HCTZ 12.5mg | -0.48 |
Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.87 |
| Ertugliflozin 1 mg | -2.12 |
| Ertugliflozin 5 mg | -1.88 |
| Ertugliflozin 25 mg | -1.77 |
| HCTZ 12.5mg | -1.69 |
Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | 1.58 |
| Ertugliflozin 1 mg | -1.80 |
| Ertugliflozin 5 mg | 1.10 |
| Ertugliflozin 25 mg | -1.07 |
| HCTZ 12.5mg | -0.06 |
Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 0.82 |
| Ertugliflozin 1 mg | -2.88 |
| Ertugliflozin 5 mg | -3.61 |
| Ertugliflozin 25 mg | -4.17 |
| HCTZ 12.5mg | -3.10 |
Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 1.02 |
| Ertugliflozin 1 mg | -1.48 |
| Ertugliflozin 5 mg | -2.52 |
| Ertugliflozin 25 mg | -0.84 |
| HCTZ 12.5mg | -0.55 |
Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | Beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Ertugliflozin 1 mg | -0.15 |
| Ertugliflozin 5 mg | 1.43 |
| Ertugliflozin 25 mg | -1.99 |
| HCTZ 12.5mg | -1.24 |
Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | -0.29 |
| Ertugliflozin 1 mg | -2.48 |
| Ertugliflozin 5 mg | -3.47 |
| Ertugliflozin 25 mg | -2.31 |
| HCTZ 12.5mg | -2.30 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE. (NCT01096667)
Timeframe: Up to 28 days (treatment period)
| Intervention | Participants (Number) |
|---|---|
| Placebo | 0 |
| Ertugliflozin 1 mg | 0 |
| Ertugliflozin 5 mg | 0 |
| Ertugliflozin 25 mg | 1 |
| HCTZ 12.5mg | 0 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. (NCT01096667)
Timeframe: Up to 63 days (including run-in, treatment period, and follow-up)
| Intervention | Participants (Number) |
|---|---|
| Placebo | 9 |
| Ertugliflozin 1 mg | 8 |
| Ertugliflozin 5 mg | 15 |
| Ertugliflozin 25 mg | 12 |
| HCTZ 12.5mg | 10 |
Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| 24-hr | Daytime | Nighttime | |
| Ertugliflozin 1 mg | 78.67 | 81.77 | 72.05 |
| Ertugliflozin 25 mg | 80.36 | 83.59 | 73.28 |
| Ertugliflozin 5 mg | 80.18 | 83.47 | 73.05 |
| HCTZ 12.5mg | 82.66 | 85.87 | 75.76 |
| Placebo | 81.89 | 85.32 | 74.24 |
Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
| Intervention | beats per minute (Mean) | ||
|---|---|---|---|
| 24-hr | Daytime | Nighttime | |
| Ertugliflozin 1 mg | 80.74 | 83.74 | 74.44 |
| Ertugliflozin 25 mg | 79.41 | 82.18 | 73.49 |
| Ertugliflozin 5 mg | 79.68 | 82.71 | 73.16 |
| HCTZ 12.5mg | 79.08 | 81.95 | 73.03 |
| Placebo | 81.11 | 84.43 | 74.05 |
Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Daytime: 16 hours; Nighttime: 8 hours
| Intervention | mmHg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Ertugliflozin 1 mg | 136.85 | 125.15 |
| Ertugliflozin 25 mg | 139.56 | 127.13 |
| Ertugliflozin 5 mg | 138.89 | 126.37 |
| HCTZ 12.5mg | 143.32 | 131.68 |
| Placebo | 139.95 | 127.54 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -13.64 |
| Aliskiren Start-Amlodipine Add On | -13.22 |
| Amlodipine Start-Aliskiren Add On | -12.25 |
Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.96 |
| Aliskiren Start-Amlodipine Add On | -12.96 |
| Amlodipine Start-Aliskiren Add On | -11.62 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -27.37 |
| Aliskiren Start-Amlodipine Add On | -26.34 |
| Amlodipine Start-Aliskiren Add On | -25.52 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 & 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msSBP was a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -26.42 |
| Aliskiren Start-Amlodipine Add On | -25.75 |
| Amlodipine Start-Aliskiren Add On | -24.32 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.39 |
| Aliskiren Start-Amlodipine Add On | -8.37 |
| Amlodipine Start-Aliskiren Add On | -9.02 |
Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks, and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -25.34 |
| Aliskiren Start-Amlodipine Add On | -17.94 |
| Amlodipine Start-Aliskiren Add On | -19.81 |
Systolic & Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP <140 mmHg and msDBP <90 mmHg) at weeks 8, 16, 24 & 32 endpoints. (NCT00797862)
Timeframe: Baseline to week 8, 16, 24 and 32 endpoints
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Week 8 endpoint | Week 16 endpoint | Week 24 endpoint | Week 32 endpoint | |
| Aliskiren Start-Amlodipine Add On | 22.8 | 33.3 | 62.8 | 59.0 |
| Aliskiren+Amlodipine | 46.5 | 65.9 | 63.4 | 61.6 |
| Amlodipine Start-Aliskiren Add On | 25.2 | 40.9 | 57.8 | 53.4 |
Changes in R2* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney (NCT01519635)
Timeframe: week 0 vs week 8
| Intervention | 1/sec (Mean) | |
|---|---|---|
| Cortex week 0 | Cortex week 8 | |
| Aliskiren | 20.5 | 19.5 |
| Hydrochlorothiazide | 19.5 | 20.5 |
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
Change from study baseline (average of triplicate DBP measurements at the last 2 qualifying visits during placebo run-in period) in DBP to the end of 12 weeks of randomized treatment using a last observation carried forward (LOCF) approach. (NCT00430638)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo Group | -0.8 |
| Olmesartan Group | -12.1 |
The change from baseline in mean systolic blood pressure (SBP) after 12 weeks of randomized treatment was compared between the olmesartan based treatment group and the placebo treatment group. (NCT00430638)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -0.1 |
| Olmesartan Group | -22.3 |
(NCT00430638)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -21.3 | -12.5 |
The difference in the change from baseline to week 12 in seated blood pressure for females in the olmesartan group vs. the placebo group was analyzed. (NCT00430638)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -21.6 | -12.0 |
The difference in the change from baseline to week 12 in seated systolic and diastolic blood pressure for males in the olmesartan group vs. the placebo group was analyzed. (NCT00430638)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic Blood Pressure | Diastolic Blood Pressure | |
| Olmesartan vs. Placebo | -22.6 | -13.5 |
(NCT00430638)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -22.3 | -12.8 |
(NCT00430638)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -16.1 | -9.0 |
(NCT00430638)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -23.8 | -13.6 |
(NCT00430638)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -22.1 | -12.2 |
(NCT00430638)
Timeframe: Baseline to 12 months
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Olmesartan vs. Placebo | -22.5 | -13.2 |
"Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan~*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were mean of all participants on specific study week, but ∆albuminuria (week 8 - week 16) value was mean of ∆ values of 8 weeks-16 weeks in each individuals. Therefore, values of 3 patients were excluded in mean of ∆albuminuria (week 8 - week 16). That's why simple subtraction (week 8 - week 16) of values are not matched with the data." (NCT01552954)
Timeframe: changes from week 8 at week 16 (week 8 - week 16)
| Intervention | mg/day (Mean) | ||
|---|---|---|---|
| 24hr-urine albumin (8th week) | 24hr-urine albumin (16th week);n=124, 118 | Mean of ∆albuminuria (week 8-week 16); n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 483.5 | 487.3 | -0.4 |
| Intensive Education of Low-salt Diet Group | 569.9 | 417.4 | 154.0 |
The change of hemoglobin after prescription of Olmesartan (NCT01552954)
Timeframe: 0 week, 16 weeks
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin (week 0) | Hemoglobin (week 8) | Hemoglobin (week 16) | Hemoglobin changes from week 0 at week 16 | |
| Conventional Education of Low-salt Diet Group | 13.8 | 13.5 | 13.3 | 0.46 |
| Intensive Education of Low-salt Diet Group | 14.0 | 13.7 | 13.4 | 0.62 |
Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16 (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mEq/day (Mean) | ||
|---|---|---|---|
| week 8 | week 16; n=124, 118 | ∆Na excretion (week 8 - week 16);n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 155.5 | 147.1 | 9.0 |
| Intensive Education of Low-salt Diet Group | 157.4 | 122.1 | 35.4 |
Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic BP at week 8 | Systolic BP at week 16 | sBP changes from week 8 at week 16 | Diastolic BP at week 8 | Diastolic BP at week 16 | dBP changes from week 8 at week 16 | |
| Conventional Education of Low-salt Diet Group | 121.8 | 121.2 | 0.6 | 73.4 | 74.8 | -0.7 |
| Intensive Education of Low-salt Diet Group | 122.1 | 120.4 | 1.7 | 73.6 | 73.1 | 0.5 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -18.6 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -18.2 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -18.6 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -11.1 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -20.4 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 Weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study Population | -10.6 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Overall Study Population | -22.3 | -18.8 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| 4 hours | 6 hours | |
| Overall Study Population | -10.7 | -10.8 |
Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Overall Study Population | -12.0 | -10.2 |
Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -0.36 |
Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -19.17 |
Absolute change in Body Mass Index Baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Kg/m2 (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -7.3 |
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -9.84 |
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.02 |
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.04 |
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -16.95 |
Absolute change in Waist Circumference between baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | cm (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.28 |
Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.21 |
Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.49 |
Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -2.98 |
Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 1.09 |
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks (NCT00546052)
Timeframe: 52 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Achieved Target Blood Pressure | Did NOT achieve target Blood Pressure | |
| Overall Intend to Treat | 1200 | 514 |
| Overall Per Protocol | 1200 | 311 |
| Overall Total | 1200 | 538 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
| HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
| HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline | |
| HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
| HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
| HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
Reduction in Mean Trough Sitting dBP (mmHg) from Baseline (Week 0) to Week 8 (NCT00441350)
Timeframe: Eight weeks
| Intervention | mmHG (Mean) |
|---|---|
| OM 40 | -15.8 |
| OM/HCTZ 40/12.5 | -18.9 |
Reduction in trough sitting diastolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder). (NCT00441350)
Timeframe: Eight weeks
| Intervention | mmHg (Mean) |
|---|---|
| OM 40 mg Responders | -0.5 |
| OM 40 mg Non-responders | -9.3 |
| OM/HCTZ 40/12.5 mg Responders | -0.3 |
| OM/HCTZ 40/12.5 mg Non-responders | -8.0 |
Reduction in Mean Trough Sitting sBP (mmHg) from Baseline (Week 0) to Week 8 (NCT00441350)
Timeframe: Eight weeks
| Intervention | mmHG (Mean) |
|---|---|
| OM 40 | -26.5 |
| OM/HCTZ 40/12.5 | -31.9 |
Reduction in trough sitting systolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder). (NCT00441350)
Timeframe: Eight weeks
| Intervention | mmHg (Mean) |
|---|---|
| OM 40 mg Responders | -0.5 |
| OM 40 mg Non-responders | -12.4 |
| OM/HCTZ 40/12.5 mg Responders | -0.4 |
| OM/HCTZ 40/12.5 mg Non-responders | -12.1 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
(NCT00386607)
Timeframe: Baseline and Month 18
| Intervention | mmHg (Mean) |
|---|---|
| Extension Treatment | -18.3 |
(NCT00386607)
Timeframe: Baseline and Month 18
| Intervention | mmHg (Mean) |
|---|---|
| Extension Treatment | -28.8 |
(NCT00386607)
Timeframe: Month 12
| Intervention | percentage of patients (Number) |
|---|---|
| Core Treatment- Aliskiren/Valsartan & Aliskiren/Valsartan/HCTZ | 76.2 |
adverse event data obtained from both the core study and the 6 month extension study. (NCT00386607)
Timeframe: Month 18
| Intervention | percentage of patients (Number) |
|---|---|
| Core and Extension Treatment - Aliskiren/Valsartan/HCTZ | 61.6 |
(NCT00386607)
Timeframe: Month 18
| Intervention | Percentage of patients (Number) |
|---|---|
| Extension Treatment | 86.6 |
(NCT00386607)
Timeframe: Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54
| Intervention | mmHg (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 4 (Visit 6) | Week 6 (Visit 7) | Week 10 (Visit 8) | Week 14 (Visit 9) | Week 18 (Visit 10) | Week 28 (Visit 11) | Week 41 (Visit 12) | Week 54 (Visit 13) | Endpoint (value at week 54 or LOCF) | |
| Core Treatment | -7.9 | -10.8 | -11.8 | -12.5 | -13.7 | -15.0 | -15.2 | -15.2 | -14.2 | -13.4 |
(NCT00386607)
Timeframe: Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54
| Intervention | mmHg (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 4 (Visit 6) | Week 6 (Visit 7) | Week 10 (Visit 8) | Week 14 (Visit 9) | Week 18 (Visit 10) | Week 28 (Visit 11) | Week 41 (Visit 12) | Week 54 (Visit 13) | Endpoint (value at week 54 or LOCF) | |
| Core Treatment | -11.0 | -15.0 | -17.6 | -18.4 | -20.7 | -22.6 | -24.3 | -24.3 | -22.3 | -20.5 |
(NCT00386607)
Timeframe: .Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54
| Intervention | Percentage of patients (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 4 (Visit 6) | Week 6 (Visit 7) | Week 10 (Visit 8) | Week 14 (Visit 9) | Week 18 (Visit 10) | Week 28 (Visit 11) | Week 41 (Visit 12) | Week 54 (Visit 13) | Endpoint (value at week 54 or LOCF) | |
| Core Treatment | 32.8 | 45.9 | 52.4 | 60.8 | 68.7 | 76.4 | 77.9 | 78.2 | 71.7 | 66.9 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -3.12 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -5.87 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -2.81 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -9.20 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.31 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -3.33 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.27 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | 0.03 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 34.1 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 47.5 |
Normalized blood pressure was defined as a msSBP < 140 mmHg and/or a msDBP < 90 mmHg. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 33.3 |
Normalized was defined as a msSBP < 140 mm Hg and/or a msDBP < 90 mm Hg. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 44.3 |
To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of participants (Number) |
|---|---|
| Aliskiren HCTZ | 63.6 |
| Amlodipine | 62.3 |
To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of responders (Number) |
|---|---|
| Aliskiren HCTZ | 84.6 |
| Amlodipine | 90.7 |
To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 96.0 | 86.0 | -10.0 |
| Amlodipine | 95.0 | 84.0 | -11.0 |
To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 72.2 | 52.7 | -19.4 |
| Amlodipine | 73.1 | 55.1 | -18.0 |
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline to Week 8 | |
| Aliskiren HCTZ | 168.2 | 138.8 | -29.4 |
| Amlodipine | 168.1 | 139.1 | -29.0 |
(NCT00760266)
Timeframe: Baseline and Week 4
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren/HCTZ | -11.1 |
| HCTZ | -9.2 |
(NCT00760266)
Timeframe: Baseline and Week 4
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren/HCTZ | -29.6 |
| HCTZ | -22.3 |
(NCT00760266)
Timeframe: Baseline and Week 8
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| msSBP | msDBP (N = 130 , 133) | |
| Aliskiren/HCTZ | -33.2 | -13.3 |
| HCTZ | -25.7 | -10.1 |
Responders defined as mean sitting Systolic Blood Pressure < 140 mmHg or reduction of ≥ 20 mmHg from baseline (NCT00760266)
Timeframe: At 4 weeks and 8 weeks
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Week 4 | Week 8 | |
| Aliskiren/HCTZ | 73.3 | 83.1 |
| HCTZ | 55.9 | 67.6 |
Blood pressure control defined as mean sitting Systolic Blood Pressure < 140 mm Hg and mean sitting Diastolic Blood Pressure < 90 mm Hg (NCT00760266)
Timeframe: At Weeks 4 and 8
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| week 4 | week 8 | |
| Aliskiren/HCTZ | 49.8 | 62.2 |
| HCTZ | 33.3 | 39.2 |
(NCT00698646)
Timeframe: During 16 weeks
| Intervention | Weeks (Median) |
|---|---|
| Valsartan | 12.0 |
| HCTZ | 8.0 |
| Valsartan + HCTZ | 4.0 |
(NCT00698646)
Timeframe: Baseline and Week 4
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 4 | Change in MSSBP from Baseline to Week 4 | |
| HCTZ | 164.5 | 150.9 | -13.6 |
| Valsartan | 166.2 | 157.5 | -8.6 |
| Valsartan + HCTZ | 164.5 | 147.1 | -17.3 |
(NCT00698646)
Timeframe: Baseline and Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Change in MSDBP from Baseline to Week 4 | Week 8 | Change in MSDBP from Baseline to Week 8 | Week 12 | Change in MSDBP from Baseline to Week 12 | Week 16 | Change in MSDBP from Baseline to Week 16 | |
| HCTZ | 85.5 | 81.6 | -3.9 | 79.1 | -6.4 | 78.1 | -7.3 | 77.9 | -7.5 |
| Valsartan | 84.9 | 81.0 | -3.9 | 78.3 | -6.6 | 77.6 | -7.3 | 77.8 | -7.1 |
| Valsartan + HCTZ | 84.8 | 77.8 | -7.1 | 76.5 | -8.4 | 75.4 | -9.5 | 76.6 | -8.3 |
(NCT00698646)
Timeframe: Baseline and Weeks 8, 12, and 16
| Intervention | mm Hg (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Week 8 | Change in MSSBP from Baseline to Week 8 | Week 12 | Change in MSSBP from Baseline to Week 12 | Week 16 | Change in MSSBP from Baseline to Week 16 | |
| HCTZ | 164.5 | 147.4 | -17.1 | 145.1 | -19.4 | 144.9 | -19.7 |
| Valsartan | 166.2 | 150.4 | -15.7 | 148.6 | -17.5 | 148.7 | -17.5 |
| Valsartan + HCTZ | 164.5 | 144.2 | -20.2 | 142.0 | -22.5 | 143.5 | -20.9 |
Cumulative refers to achieving blood pressure goal before or at the corresponding visit. (NCT00698646)
Timeframe: Weeks 4, 8, 12 and 16
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | |
| HCTZ | 38.89 | 52.38 | 62.70 | 68.25 |
| Valsartan | 25 | 40.63 | 50 | 56.25 |
| Valsartan + HCTZ | 49.21 | 63.49 | 69.05 | 72.22 |
Cumulative refers to achieving of blood pressure control before or at the corresponding visit. (NCT00698646)
Timeframe: Weeks 4, 8, 12 and 16
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | |
| HCTZ | 37.3 | 50.79 | 61.11 | 66.67 |
| Valsartan | 25 | 40.63 | 50 | 55.47 |
| Valsartan + HCTZ | 49.21 | 63.49 | 69.05 | 72.22 |
Mean of the changed DBP from baseline after 4 weeks (NCT00621153)
Timeframe: 4 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Candesartan Cilexetil/Hydroclorozide Combination Therapy | -17.0 |
| Candesartan Cilexetil Monotherapy | -14.1 |
Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -7.2 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -5.3 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -4.1 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -2.0 |
Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -7.0 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -5.5 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -4.0 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -1.8 |
Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -7.9 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -4.5 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -4.2 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -2.3 |
Change = Week 12 - Week 8 (baseline). (NCT00430508)
Timeframe: 4 weeks, change = week 12 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -8.74 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -7.72 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -6.66 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -4.47 |
Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -11.16 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -9.13 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -8.10 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -5.66 |
Change = Week 12 - Week 8 (baseline). (NCT00430508)
Timeframe: 4 weeks, change = week 12 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -13.16 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -10.90 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -9.65 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -6.60 |
Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | -16.17 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | -13.52 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | -11.46 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | -8.85 |
Target Blood Pressure is diastolic blood pressure (dBP) < 90 mmHg and systolic blood pressure (sBP) < 140 mmHg for non-diabetics, and dBP < 80 mmHg and sBP < 130 mmHg for diabetics (NCT00430508)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| OM/HCTZ 40/25mg + 20/12.5 Matching Placebo | 59 |
| OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo | 110 |
| OM/HCTZ 20/12.5mg + 40/0 Matching Placebo | 88 |
| OM/HCTZ 40/0mg + 20/12.5 Matching Placebo | 68 |
"Change in mean trough sitting diastolic Blood Pressure between OM/HCTZ 20/25 mg vs. 40/25 mg, in those patients inadequately controlled on OM 40 mg monotherapy, after eight weeks of double blind treatment, as compared to baseline.~Change = Week 16 - Week 8 (baseline)." (NCT00430950)
Timeframe: 8 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo | -11.16 |
| OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo | -10.45 |
Change = Week 12 - Week 8 (baseline). (NCT00430950)
Timeframe: 4 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo | -9.32 |
| OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo | -8.83 |
(NCT00430950)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo | 260 |
| OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo | 255 |
Change = Week 16 - Week 8 (baseline). (NCT00430950)
Timeframe: 8 weeks
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Change from Week 8 to Wk 16 in mean 24-hr ABPM dBP | Change from Week 8 to wk16 in daytime ABPM dBP | Change from Week 8 to wk16 in nighttime ABPM dBP | Change from Week 8 to wk16 in mean 24-hr ABPM sBP | Change from Week 8 to wk16 in daytime ABPM sBP | Change from Week 8 to wk16 in nighttime ABPM sBP | |
| OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo | -7.6 | -7.7 | -7.0 | -12.0 | -12.3 | -10.7 |
| OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo | -9.2 | -9.3 | -8.6 | -14.7 | -15.0 | -13.4 |
4 weeks Change = Week 12 - Week 8 (baseline). 8 weeks Change = Week 16 - Week 8 (baseline). (NCT00430950)
Timeframe: 8 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change from baseline (Week 8) to Week 16 in sBP | Change from baseline (Week 8) to Week 12 in sBP | |
| OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo | -17.09 | -13.80 |
| OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo | -17.41 | -14.07 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
This reports the change in the least square mean from baseline to 12 months, adjusted for age (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | cm/sec (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -0.3 |
| ARB (Candesartan) | -2.85 |
| HCTZ | 0.35 |
Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | 28 |
| ARB (Candesartan) | 27 |
| HCTZ | 21 |
This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | number of digits repeated (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -0.3 |
| ARB (Candesartan) | 0.02 |
| HCTZ | -0.04 |
This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | number words remembered (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -1 |
| ARB (Candesartan) | -2 |
| HCTZ | -3 |
This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | seconds (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -14 |
| ARB (Candesartan) | 17 |
| HCTZ | 4 |
The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -19.4 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.7 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.2 |
The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -33.9 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.3 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -27.5 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -20.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -21.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.0 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -35.3 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -37.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -28.8 |
The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -17.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -18.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -14.0 |
The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -29.6 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -31.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -23.9 |
The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -19.8 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.0 |
The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -32.9 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -34.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -25.9 |
The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -20.4 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -22.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.5 |
The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -36.2 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -38.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -29.7 |
The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -42.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -44.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -37.1 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | 1 to 2 Hour (n=232; n=214; n=238) | 2 to 3 Hour (n=232; n=214; n=238) | 3 to 4 Hour (n=232; n=214; n=238) | 4 to 5 Hour (n=232; n=214; n=238) | 5 to 6 Hour (n=232; n=214; n=238) | 6 to 7 Hour (n=232; n=214; n=238) | 7 to 8 Hour (n=232; n=214; n=238) | 8 to 9 Hour (n=232; n=214; n=238) | 9 to 10 Hour (n=232; n=214; n=238) | 10 to 11 Hour (n=232; n=214; n=238) | 11 to 12 Hour (n=232; n=214; n=238) | 12 to 13 Hour (n=232; n=214; n=238) | 13 to 14 Hour (n=232; n=214; n=238) | 14 to 15 Hour (n=232; n=214; n=238) | 15 to 16 Hour (n=232; n=214; n=238) | 16 to 17 Hour (n=232; n=214; n=238) | 17 to 18 Hour (n=231; n=214; n=238) | 18 to 19 Hour (n=232; n=214; n=238) | 19 to 20 Hour (n=232; n=214; n=238) | 20 to 21 Hour (n=232; n=214; n=238) | 21 to 22 Hour (n=232; n=214; n=238) | 22 to 23 Hour (n=232; n=214; n=238) | 23 to 24 Hour (n=232; n=214; n=238) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -18.2 | -18.8 | -21.2 | -20.8 | -21.7 | -20.9 | -20.8 | -20.5 | -20.7 | -21.0 | -19.7 | -19.3 | -19.2 | -19.6 | -18.9 | -17.8 | -17.2 | -16.6 | -17.4 | -17.8 | -16.7 | -17.8 | -19.5 | -20.2 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.4 | -20.9 | -23.4 | -23.7 | -23.7 | -23.6 | -22.0 | -21.9 | -21.5 | -21.9 | -20.7 | -21.2 | -20.3 | -19.5 | -19.7 | -18.6 | -16.9 | -17.1 | -18.1 | -18.5 | -18.4 | -18.5 | -19.6 | -21.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -15.2 | -15.9 | -17.7 | -18.2 | -17.9 | -19.0 | -18.0 | -17.7 | -17.9 | -18.3 | -16.7 | -17.0 | -16.0 | -15.3 | -15.4 | -14.5 | -13.9 | -13.2 | -14.3 | -13.8 | -13.9 | -14.7 | -15.6 | -16.4 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | 1 to 2 Hour (n=232; n=214; n=238) | 2 to 3 Hour (n=232; n=214; n=238) | 3 to 4 Hour (n=232; n=214; n=238) | 4 to 5 Hour (n=232; n=214; n=238) | 5 to 6 Hour (n=232; n=214; n=238) | 6 to 7 Hour (n=232; n=214; n=238) | 7 to 8 Hour (n=232; n=214; n=238) | 8 to 9 Hour (n=232; n=214; n=238) | 9 to 10 Hour (n=232; n=214; n=238) | 10 to 11 Hour (n=232; n=214; n=238) | 11 to 12 Hour (n=232; n=214; n=238) | 12 to 13 Hour (n=232; n=214; n=238) | 13 to 14 Hour (n=232; n=214; n=238) | 14 to 15 Hour (n=232; n=214; n=238) | 15 to 16 Hour (n=232; n=214; n=238) | 16 to 17 Hour (n=232; n=214; n=238) | 17 to 18 Hour (n=231; n=214; n=238) | 18 to 19 Hour (n=232; n=214; n=238) | 19 to 20 Hour (n=232; n=214; n=238) | 20 to 21 Hour (n=232; n=214; n=238) | 21 to 22 Hour (n=232; n=214; n=238) | 22 to 23 Hour (n=232; n=214; n=238) | 23 to 24 Hour (n=232; n=214; n=238) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -33.6 | -33.4 | -36.7 | -36.6 | -36.8 | -37.2 | -36.3 | -37.2 | -37.3 | -36.9 | -36.1 | -35.2 | -34.8 | -34.1 | -33.4 | -30.9 | -29.6 | -28.5 | -29.5 | -29.7 | -28.2 | -30.6 | -32.9 | -33.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.2 | -36.4 | -39.3 | -40.3 | -40.8 | -41.2 | -38.6 | -38.5 | -38.1 | -38.0 | -37.6 | -38.2 | -36.2 | -35.3 | -35.0 | -32.9 | -31.1 | -30.8 | -31.9 | -32.5 | -31.2 | -32.8 | -34.0 | -35.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -26.8 | -27.5 | -30.0 | -29.6 | -30.1 | -31.5 | -29.8 | -29.7 | -30.5 | -30.8 | -29.4 | -29.3 | -27.7 | -26.4 | -26.2 | -25.3 | -24.5 | -23.1 | -24.3 | -23.5 | -23.0 | -24.6 | -25.9 | -26.1 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -14.9 | -17.0 | -18.8 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -15.8 | -17.7 | -20.5 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -11.7 | -13.9 | -16.4 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -34.7 | -39.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.7 | -39.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -29.7 | -33.5 |
Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 81.3 | 88.1 | 91.3 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 84.8 | 87.3 | 92.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 74.4 | 81.0 | 84.7 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 89.2 | 90.7 | 94.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 89.7 | 90.9 | 95.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 85.2 | 87.8 | 91.5 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 87.8 | 93.3 | 93.0 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 90.0 | 92.4 | 94.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 79.8 | 85.6 | 89.3 |
The DBP value at baseline was subtracted from the DBP value at Week 7. (NCT00926289)
Timeframe: Baseline and Week 7
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Telmisartan 40/80 mg | -15.4 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | -18.6 |
The SBP value at baseline was subtracted from the SBP value at Week 3. (NCT00926289)
Timeframe: Baseline and Week 3
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Telmisartan 40/80 mg | -26.5 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | -33.3 |
The SBP value at baseline was subtracted from the SBP value at Week 5. (NCT00926289)
Timeframe: Baseline and Week 5
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Telmisartan 40/80 mg | -28.6 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | -35.8 |
The SBP value at baseline was subtracted from the SBP value at Week 7. (NCT00926289)
Timeframe: Baseline and Week 7
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Telmisartan 40/80 mg | -28.5 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | -37.0 |
DBP response is defined as DBP<90 mmHg or a reduction of >= 10 mmHg (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 202 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 483 |
BP control is defined as SBP<140 mmHg and DBP < 90 mmHg and is adjusted for baseline SBP (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 99 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 318 |
BP control is defined as SBP<140 mmHg and DBP < 90 mmHg and is adjusted for baseline DBP (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 99 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 318 |
DBP control is defined as DBP<90 mmHg (NCT00926289)
Timeframe: Week 3 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 131 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 343 |
DBP control is defined as DBP<90 mmHg (NCT00926289)
Timeframe: Week 5 timepoint
| Intervention | participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 150 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 391 |
DBP control is defined as DBP<90 mmHg (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 150 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 389 |
SBP control is defined as SBP < 140 mmHg (NCT00926289)
Timeframe: Week 3 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 97 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 306 |
SBP control is defined as SBP < 140 mmHg (NCT00926289)
Timeframe: Week 5 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 119 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 355 |
SBP control is defined as SBP < 140 mmHg. (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 122 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 363 |
SBP response is defined as SBP<140 mmHg or a reduction of >= 15 mmHg (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) |
|---|---|
| Telmisartan 40/80 mg | 233 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 527 |
"BP categories comprise:~BP optimal (SBP <120 mmHg and DBP <80 mmHg)~BP normal (SBP <130 mmHg and DBP <85 mmHg but not 'optimal')~BP high normal (SBP <140 mmHg and DBP <90 mmHg but not 'normal')~Grade 1 hypertension (SBP <160 mmHg and DBP <100 mmHg but not 'high normal')~Grade 2 hypertension (SBP <180 mmHg and DBP <110 mmHg but not 'Grade 1 hypertension')~Grade 3 hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)" (NCT00926289)
Timeframe: Week 7 timepoint
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| BP optimal | BP normal | BP high normal | Grade 1 hypertension | Grade 2 hypertension | Grade 3 hypertension | |
| Telmisartan 40/80 mg | 6 | 36 | 57 | 120 | 44 | 22 |
| Telmisartan 40/80 mg + HCTZ 12.5/25 mg | 44 | 136 | 138 | 186 | 58 | 11 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study | -12.3 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Overall Study | -25.7 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Overall Study | -13.0 | -11.5 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Daytime | Nighttime | |
| Overall Study | -26.5 | -24.4 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| BP<140/90 mm Hg | SBP<140 mm Hg | DBP<90 mm Hg | |
| Overall Study | 133 | 133 | 149 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| BP<140/90 mm Hg | SBP<140 mm Hg | DBP<90 mm Hg | |
| Overall Study | 120 | 120 | 145 |
All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| BP<140/90 mm Hg | SBP<140 mm Hg | DBP<90 mm Hg | |
| Overall Study | 143 | 143 | 149 |
The change in 24-hour mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.9 | -12.6 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -14.7 | -15.2 |
The change in 24-hour mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179, n=162) | Week 10 (n=227, n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -19.9 | -22.4 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -25.7 | -26.6 |
The change in trough diastolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.6 | -12.7 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.2 | -15.1 |
The change in trough systolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179, n=162) | Week 10 (n=227, n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -18.4 | -21.4 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -25.7 | -25.6 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.1 | -12.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.4 | -15.8 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -20.2 | -22.8 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -27.0 | -27.5 |
The change in the 12-hour mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.1 | -12.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.7 | -16.0 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.3 | -11.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -12.8 | -13.8 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -18.8 | -21.1 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -21.8 | -23.8 |
The change in the 12-hour mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -20.6 | -23.2 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -27.7 | -28.0 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated including final visit relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.2 | -13.7 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.0 | -16.4 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -29.5 | -32.8 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -35.1 | -37.8 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as <90 mm Hg for participants without diabetes or chronic kidney disease or <80 mm Hg for participants with diabetes or chronic kidney disease. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 41.3 | 57.4 | 59.2 | 72.3 | 75.0 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 49.1 | 71.9 | 76.6 | 81.4 | 82.7 |
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at each week indicated, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease or <130/80 mm Hg for participants with diabetes or chronic kidney disease[GFR <60 mL/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) >200 mg albumin/g creatinine at Screening.] Systolic/diastolic blood pressure is the average of the 3 serial trough sitting systolic/diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 24.6 | 45.3 | 45.9 | 59.2 | 62.3 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 27.2 | 58.6 | 64.1 | 72.5 | 71.5 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as <140mm Hg without diabetes or chronic kidney disease or <130/mm Hg with diabetes or chronic kidney disease. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 34.1 | 54.7 | 58.2 | 65.4 | 69.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 33.2 | 68.2 | 71.9 | 79.7 | 76.9 |
(NCT00791258)
Timeframe: baseline to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 |
(NCT00791258)
Timeframe: baseline to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 84.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.8 | -16.3 | -12.5 | -13.6 | -13.0 | -12.6 | -9.4 | -10.6 | -7.6 | -8.6 | -8.0 | -7.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -21.0 | -23.2 | -17.5 | -19.6 | -18.2 | -17.9 | -13.3 | -15.0 | -11.1 | -12.3 | -11.6 | -11.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | mm Hg (Mean) | ||||
|---|---|---|---|---|---|
| 4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -8.1 | -9.1 | -11.9 | -14.6 | -14.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | mm Hg (Mean) | ||||
|---|---|---|---|---|---|
| 4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.6 | -16.6 | -21.8 | -26.0 | -26.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140/90 mm Hg, N=230 | 4 weeks: <135/80 mm Hg, N=230 | 4 weeks: <130/80 mm Hg, N=230 | 4 weeks: <120/80 mm Hg, N=230 | 8 weeks: <140/90 mm Hg, N=231 | 8 weeks: <135/80 mm Hg, N=231 | 8 weeks: <130/80 mm Hg, N=232 | 8 weeks: <120/80 mm Hg, N=232 | 12 weeks: <140/90mm Hg, N=232 | 12 weeks: <135/80 mm Hg, N=232 | 12 weeks: <130/80 mm Hg, N=232 | 12 weeks: <120/80 mm Hg, N=232 | 16 weeks: <140/90 mm Hg, N=232 | 16 weeks: <135/80 mm Hg, N=232 | 16 weeks: <130/80 mm Hg, N=232 | 16 weeks: <120/80 mm Hg, N=232 | 20 weeks: <140/90 mm Hg, N=232 | 20 weeks: <135/80 mm Hg, N=232 | 20 weeks: <130/80 mm Hg, N=232 | 20 weeks: <120/80 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 45.7 | 14.8 | 10.4 | 3.9 | 55.0 | 23.8 | 20.8 | 10.4 | 68.5 | 38.4 | 35.8 | 16.4 | 80.6 | 49.1 | 47.4 | 30.6 | 86.6 | 57.8 | 55.2 | 39.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=230 | 4 weeks: <85 mm Hg, N=230 | 4 weeks: <80 mm Hg, N=230 | 8 weeks: <90 mm Hg, N=231 | 8 weeks: <85 mm Hg, N=231 | 8 weeks: <80 mm Hg, N=231 | 12 weeks: <90 mm Hg, N=232 | 12 weeks: <85 mm Hg, N=232 | 12 weeks: <80 mm Hg, N=232 | 16 weeks: <90 mm Hg, N=232 | 16 weeks: <85 mm Hg, N=232 | 16 weeks: <80 mm Hg, N=232 | 20 weeks: <90 mm Hg, N=232 | 20 weeks: <85 mm Hg, N=232 | 20 weeks: <80 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.9 | 42.2 | 19.6 | 71.9 | 53.7 | 30.3 | 82.3 | 66.0 | 45.3 | 92.2 | 76.3 | 55.2 | 94.8 | 80.6 | 61.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=230 | 4 weeks: >10 and ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 20 mm Hg, N=230 | 4 weeks: >20 mm Hg, N=230 | 8 weeks: ≤ 10 mm Hg, N=220 | 8 weeks: >10 and ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 20 mm Hg, N=220 | 8 weeks: >20 mm Hg, N=220 | 12 weeks: ≤ 10 mm Hg, N=208 | 12 weeks: >10 and ≤15 mm Hg, N=208 | 12 weeks: >15 and ≤ 20 mm Hg, N=208 | 12 weeks: >20 mm Hg, N=208 | 16 weeks: ≤ 10 mm Hg, N=199 | 16 weeks: >10 and ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 20 mm Hg, N=199 | 16 weeks: >20 mm Hg, N=199 | 20 weeks: ≤ 10 mm Hg, N=189 | 20 weeks: >10 and ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 20 mm Hg, N=189 | 20 weeks: >20 mm Hg, N=189 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 70.0 | 17.8 | 7.9 | 4.4 | 66.8 | 15.0 | 10.9 | 7.3 | 54.8 | 21.2 | 12.0 | 12.0 | 38.7 | 19.6 | 23.1 | 18.6 | 36.0 | 19.6 | 20.6 | 23.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=230 | 4 weeks: <135 mm Hg, N=230 | 4 weeks: <130 mm Hg, N=230 | 4 weeks: <120 mm Hg, N=230 | 8 weeks: <140 mm Hg, N=231 | 8 weeks: <135 mm Hg, N=231 | 8 weeks: <130 mm Hg, N=231 | 8 weeks: <120 mm Hg, N=231 | 12 weeks: <140 mm Hg, N=232 | 12 weeks: <135 mm Hg, N=232 | 12 weeks: <130 mm Hg, N=232 | 12 weeks: <120 mm Hg, N=232 | 16 weeks: <140 mm Hg, N=232 | 16 weeks: <135 mm Hg, N=232 | 16 weeks: <130 mm Hg, N=232 | 16 weeks: <120 mm Hg, N=232 | 20 weeks: <140 mm Hg, N=232 | 20 weeks: <135 mm Hg, N=232 | 20 weeks: <130 mm Hg, N=232 | 20 weeks: <120 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.7 | 34.4 | 19.6 | 5.7 | 62.3 | 44.6 | 33.8 | 13.0 | 76.3 | 59.1 | 47.0 | 19.8 | 84.9 | 71.1 | 61.2 | 34.1 | 91.0 | 80.6 | 71.1 | 44.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 30 mm Hg, N=230 | 4 weeks: >30 and ≤ 45 mm Hg, N=230 | 4 weeks: >45 mm Hg, N=230 | 8 weeks: ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 30 mm Hg, N=220 | 8 weeks: >30 and ≤ 45 mm Hg, N=220 | 8 weeks: >45 mm Hg, N=220 | 12 weeks: ≤ 15 mm Hg, N=208 | 12 weeks: >15 and ≤ 30 mm Hg, N=208 | 12 weeks: >30 and ≤ 45 mm Hg, N=208 | 12 weeks: >45 mm Hg, N=208 | 16 weeks: ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 30 mm Hg, N=199 | 16 weeks: >30 and ≤ 45 mm Hg, N=199 | 16 weeks: >45 mm Hg, N=199 | 20 weeks: ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 30 mm Hg, N=189 | 20 weeks: >30 and ≤ 45 mm Hg, N=189 | 20 weeks: >45 mm Hg, N=189 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.0 | 32.2 | 7.4 | 0.4 | 53.6 | 38.2 | 7.3 | 0.9 | 38.9 | 41.8 | 16.4 | 2.9 | 30.7 | 37.2 | 25.1 | 7.0 | 24.3 | 37.6 | 29.6 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=128 | 4 weeks: <85 mm Hg, N=128 | 4 weeks: <80 mm Hg, N=128 | 8 weeks: <90 mm Hg, N=128 | 8 weeks: <85 mm Hg, N=128 | 8 weeks: <80 mm Hg, N=128 | 12 weeks: <90 mm Hg, N=128 | 12 weeks: <85 mm Hg, N=128 | 12 weeks: <80 mm Hg, N=128 | 16 weeks: <90 mm Hg, N=128 | 16 weeks: <85 mm Hg, N=128 | 16 weeks: <80 mm Hg, N=128 | 20 weeks: <90 mm Hg, N=128 | 20 weeks: <85 mm Hg, N=128 | 20 weeks: <80 mm Hg, N=128 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 83.6 | 69.5 | 45.3 | 89.1 | 79.7 | 60.2 | 95.3 | 87.5 | 71.1 | 96.9 | 93.0 | 82.0 | 96.9 | 93.0 | 85.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=126 | 4 weeks: >10 and ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 20 mm Hg, N=126 | 4 weeks: >20 mm Hg, N=126 | 8 weeks: ≤ 10 mm Hg, N=123 | 8 weeks: >10 and ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 20 mm Hg, N=123 | 8 weeks: >20 mm Hg, N=123 | 12 weeks: ≤ 10 mm Hg, N=120 | 12 weeks: >10 and ≤15 mm Hg, N=120 | 12 weeks: >15 and ≤ 20 mm Hg, N=120 | 12 weeks: >20 mm Hg, N=120 | 16 weeks: ≤ 10 mm Hg, N=112 | 16 weeks: >10 and ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 20 mm Hg, N=112 | 16 weeks: >20 mm Hg, N=112 | 20 weeks: ≤ 10 mm Hg, N=105 | 20 weeks: >10 and ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 20 mm Hg, N=105 | 20 weeks: >20 mm Hg, N=105 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.6 | 26.2 | 13.5 | 12.7 | 38.2 | 24.4 | 22.0 | 15.5 | 33.3 | 25.8 | 19.2 | 21.7 | 27.7 | 17.0 | 20.5 | 34.8 | 36.2 | 16.2 | 18.1 | 29.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=128 | 4 weeks: <135 mm Hg, N=128 | 4 weeks: <130 mm Hg, N=128 | 4 weeks: <120 mm Hg, N=128 | 8 weeks: <140 mm Hg, N=128 | 8 weeks: <135 mm Hg, N=128 | 8 weeks: <130 mm Hg, N=128 | 8 weeks: <120 mm Hg, N=128 | 12 weeks: <140 mm Hg, N=128 | 12 weeks: <135 mm Hg, N=128 | 12 weeks: <130 mm Hg, N=128 | 12 weeks: <120 mm Hg, N=128 | 16 weeks: <140 mm Hg, N=128 | 16 weeks: <135 mm Hg, N=128 | 16 weeks: <130 mm Hg, N=128 | 16 weeks: <120 mm Hg, N=128 | 20 weeks: <140 mm Hg, N=128 | 20 weeks: <135 mm Hg, N=128 | 20 weeks: <130 mm Hg, N=128 | 20 weeks: <120 mm Hg, N=128 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 64.8 | 51.6 | 35.2 | 11.7 | 76.6 | 67.2 | 51.6 | 25.0 | 89.1 | 78.9 | 66.4 | 38.3 | 95.3 | 89.8 | 81.3 | 47.7 | 97.7 | 93.0 | 85.9 | 51.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 30 mm Hg, N=126 | 4 weeks: >30 and ≤ 45 mm Hg, N=126 | 4 weeks: >45 mm Hg, N=126 | 8 weeks: ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 30 mm Hg, N=123 | 8 weeks: >30 and ≤ 45 mm Hg, N=123 | 8 weeks: >45 mm Hg, N=123 | 12 weeks: ≤ 15 mm Hg, N=120 | 12 weeks: >15 and ≤ 30 mm Hg, N=120 | 12 weeks: >30 and ≤ 45 mm Hg, N=120 | 12 weeks: >45 mm Hg, N=120 | 16 weeks: ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 30 mm Hg, N=112 | 16 weeks: >30 and ≤ 45 mm Hg, N=112 | 16 weeks: >45 mm Hg, N=112 | 20 weeks: ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 30 mm Hg, N=105 | 20 weeks: >30 and ≤ 45 mm Hg, N=105 | 20 weeks: >45 mm Hg, N=105 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 43.7 | 38.1 | 15.9 | 2.4 | 40.7 | 35.8 | 22.0 | 1.6 | 28.3 | 39.2 | 27.5 | 5.0 | 20.5 | 36.6 | 31.3 | 11.6 | 29.5 | 28.6 | 33.3 | 8.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=227 | 4 weeks: <85 mm Hg, N=227 | 4 weeks: <80 mm Hg, N=227 | 8 weeks: <90 mm Hg, N=227 | 8 weeks: <85 mm Hg, N=227 | 8 weeks: <80 mm Hg, N=227 | 12 weeks: <90 mm Hg, N=227 | 12 weeks: <85 mm Hg, N=227 | 12 weeks: <80 mm Hg, N=227 | 16 weeks: <90 mm Hg, N=227 | 16 weeks: <85 mm Hg, N=227 | 16 weeks: <80 mm Hg, N=227 | 20 weeks: <90 mm Hg, N=227 | 20 weeks: <85 mm Hg, N=227 | 20 weeks: <80 mm Hg, N=227 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.1 | 76.7 | 58.2 | 92.1 | 83.7 | 71.8 | 97.4 | 92.1 | 80.2 | 98.7 | 94.3 | 88.6 | 98.7 | 95.2 | 90.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=224 | 4 weeks: >10 and ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 20 mm Hg, N=224 | 4 weeks: >20 mm Hg, N=224 | 8 weeks: ≤ 10 mm Hg, N=217 | 8 weeks: >10 and ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 20 mm Hg, N=217 | 8 weeks: >20 mm Hg, N=217 | 12 weeks: ≤ 10 mm Hg, N=199 | 12 weeks: >10 and ≤15 mm Hg, N=199 | 12 weeks: >15 and ≤ 20 mm Hg, N=199 | 12 weeks: >20 mm Hg, N=199 | 16 weeks: ≤ 10 mm Hg, N=179 | 16 weeks: >10 and ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 20 mm Hg, N=179 | 16 weeks: >20 mm Hg, N=179 | 20 weeks: ≤ 10 mm Hg, N=166 | 20 weeks: >10 and ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 20 mm Hg, N=166 | 20 weeks: >20 mm Hg, N=166 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.8 | 20.5 | 9.4 | 6.3 | 57.1 | 19.8 | 14.3 | 8.8 | 45.2 | 25.1 | 15.6 | 14.1 | 27.4 | 25.1 | 22.9 | 24.6 | 34.9 | 20.5 | 24.1 | 20.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=227 | 4 weeks: <135 mm Hg, N=227 | 4 weeks: <130 mm Hg, N=227 | 4 weeks: <120 mm Hg, N=227 | 8 weeks: <140 mm Hg, N=227 | 8 weeks: <135 mm Hg, N=227 | 8 weeks: <130 mm Hg, N=227 | 8 weeks: <120 mm Hg, N=227 | 12 weeks: <140 mm Hg, N=227 | 12 weeks: <135 mm Hg, N=227 | 12 weeks: <130 mm Hg, N=227 | 12 weeks: <120 mm Hg, N=227 | 16 weeks: <140 mm Hg, N=227 | 16 weeks: <135 mm Hg, N=227 | 16 weeks: <130 mm Hg, N=227 | 16 weeks: <120 mm Hg, N=227 | 20 weeks: <140 mm Hg, N=227 | 20 weeks: <135 mm Hg, N=227 | 20 weeks: <130 mm Hg, N=227 | 20 weeks: <120 mm Hg, N=227 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 52.0 | 37.9 | 23.4 | 9.7 | 67.0 | 57.7 | 43.6 | 18.1 | 80.6 | 70.0 | 56.8 | 28.6 | 87.7 | 79.7 | 70.9 | 43.6 | 91.6 | 85.9 | 78.9 | 50.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 30 mm Hg, N=224 | 4 weeks: >30 and ≤ 45 mm Hg, N=224 | 4 weeks: >45 mm Hg, N=224 | 8 weeks: ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 30 mm Hg, N=217 | 8 weeks: >30 and ≤ 45 mm Hg, N=217 | 8 weeks: >45 mm Hg, N=217 | 12 weeks: ≤ 15 mm Hg, N=199 | 12 weeks: >15 and ≤ 30 mm Hg, N=199 | 12 weeks: >30 and ≤ 45 mm Hg, N=199 | 12 weeks: >45 mm Hg, N=199 | 16 weeks: ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 30 mm Hg, N=179 | 16 weeks: >30 and ≤ 45 mm Hg, N=179 | 16 weeks: >45 mm Hg, N=179 | 20 weeks: ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 30 mm Hg, N=166 | 20 weeks: >30 and ≤ 45 mm Hg, N=166 | 20 weeks: >45 mm Hg, N=166 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.3 | 40.2 | 11.2 | 1.3 | 42.9 | 37.8 | 16.6 | 2.8 | 26.6 | 46.7 | 24.6 | 2.0 | 17.9 | 32.4 | 39.7 | 10.1 | 14.5 | 37.4 | 38.0 | 10.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=98 | 4 weeks: <85 mm Hg, N=98 | 4 weeks: <80 mm Hg, N=98 | 8 weeks: <90 mm Hg, N=100 | 8 weeks: <85 mm Hg, N=100 | 8 weeks: <80 mm Hg, N=100 | 12 weeks: <90 mm Hg, N=100 | 12 weeks: <85 mm Hg, N=100 | 12 weeks: <80 mm Hg, N=100 | 16 weeks: <90 mm Hg, N=100 | 16 weeks: <85 mm Hg, N=100 | 16 weeks: <80 mm Hg, N=100 | 20 weeks: <90 mm Hg, N=100 | 20 weeks: <85 mm Hg, N=100 | 20 weeks: <80 mm Hg, N=100 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 66.3 | 53.1 | 34.7 | 85.0 | 70.0 | 48.0 | 92.0 | 78.0 | 62.0 | 96.0 | 90.0 | 75.0 | 96.0 | 90.0 | 75.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=98 | 4 weeks: >10 and ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 20 mm Hg, N=98 | 4 weeks: >20 mm Hg, N=98 | 8 weeks: ≤ 10 mm Hg, N=91 | 8 weeks: >10 and ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 20 mm Hg, N=91 | 8 weeks: >20 mm Hg, N=91 | 12 weeks: ≤ 10 mm Hg, N=83 | 12 weeks: >10 and ≤15 mm Hg, N=83 | 12 weeks: >15 and ≤ 20 mm Hg, N=83 | 12 weeks: >20 mm Hg, N=83 | 16 weeks: ≤ 10 mm Hg, N=75 | 16 weeks: >10 and ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 20 mm Hg, N=75 | 16 weeks: >20 mm Hg, N=75 | 20 weeks: ≤ 10 mm Hg, N=71 | 20 weeks: >10 and ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 20 mm Hg, N=71 | 20 weeks: >20 mm Hg, N=71 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 65.3 | 16.3 | 8.2 | 10.2 | 52.8 | 18.7 | 14.3 | 14.3 | 41.0 | 20.5 | 14.5 | 24.1 | 30.7 | 25.3 | 16.0 | 28.0 | 31.0 | 12.7 | 26.8 | 29.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=98 | 4 weeks: <135 mm Hg, N=98 | 4 weeks: <130 mm Hg, N=98 | 4 weeks: <120 mm Hg, N=98 | 8 weeks: <140 mm Hg, N=100 | 8 weeks: <135 mm Hg, N=100 | 8 weeks: <130 mm Hg, N=100 | 8 weeks: <120 mm Hg, N=100 | 12 weeks: <140 mm Hg, N=100 | 12 weeks: <135 mm Hg, N=100 | 12 weeks: <130 mm Hg, N=100 | 12 weeks: <120 mm Hg, N=100 | 16 weeks: <140 mm Hg, N=100 | 16 weeks: <135 mm Hg, N=100 | 16 weeks: <130 mm Hg, N=100 | 16 weeks: <120 mm Hg, N=100 | 20 weeks: <140 mm Hg, N=100 | 20 weeks: <135 mm Hg, N=100 | 20 weeks: <130 mm Hg, N=100 | 20 weeks: <120 mm Hg, N=100 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 55.1 | 39.8 | 31.6 | 10.2 | 64.0 | 51.0 | 41.0 | 15.0 | 77.0 | 67.0 | 54.0 | 30.0 | 84.0 | 77.0 | 66.0 | 37.0 | 88.0 | 83.0 | 72.0 | 41.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 30 mm Hg, N=98 | 4 weeks: >30 and ≤ 45 mm Hg, N=98 | 4 weeks: >45 mm Hg, N=98 | 8 weeks: ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 30 mm Hg, N=91 | 8 weeks: >30 and ≤ 45 mm Hg, N=91 | 8 weeks: >45 mm Hg, N=91 | 12 weeks: ≤ 15 mm Hg, N=83 | 12 weeks: >15 and ≤ 30 mm Hg, N=83 | 12 weeks: >30 and ≤ 45 mm Hg, N=83 | 12 weeks: >45 mm Hg, N=83 | 16 weeks: ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 30 mm Hg, N=75 | 16 weeks: >30 and ≤ 45 mm Hg, N=75 | 16 weeks: >45 mm Hg, N=75 | 20 weeks: ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 30 mm Hg, N=71 | 20 weeks: >30 and ≤ 45 mm Hg, N=71 | 20 weeks: >45 mm Hg, N=71 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 50.0 | 37.8 | 7.1 | 5.1 | 42.9 | 44.0 | 9.9 | 3.3 | 31.3 | 36.1 | 25.3 | 7.2 | 22.7 | 36.0 | 34.7 | 6.7 | 23.9 | 33.8 | 33.8 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=497 | 4 weeks: <85 mm Hg, N=497 | 4 weeks: <80 mm Hg, N=497 | 8 weeks: <90 mm Hg, N=497 | 8 weeks: <85 mm Hg, N=500 | 8 weeks: <80 mm Hg, N=500 | 12 weeks: <90 mm Hg, N=500 | 12 weeks: <85 mm Hg, N=500 | 12 weeks: <80 mm Hg, N=500 | 16 weeks: <90 mm Hg, N=500 | 16 weeks: <85 mm Hg, N=500 | 16 weeks: <80 mm Hg, N=500 | 20 weeks: <90 mm Hg, N=500 | 20 weeks: <85 mm Hg, N=500 | 20 weeks: <80 mm Hg, N=500 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.2 | 46.3 | 26.0 | 77.2 | 59.4 | 38.8 | 86.6 | 69.8 | 48.4 | 93.2 | 80.4 | 60.4 | 94.6 | 83.8 | 67.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=495 | 4 weeks: >10 and ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 20 mm Hg, N=495 | 4 weeks: >20 mm Hg, N=495 | 8 weeks: ≤ 10 mm Hg, N=468 | 8 weeks: >10 and ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 20 mm Hg, N=468 | 8 weeks: >20 mm Hg, N=468 | 12 weeks: ≤ 10 mm Hg, N=436 | 12 weeks: >10 and ≤15 mm Hg, N=436 | 12 weeks: >15 and ≤ 20 mm Hg, N=436 | 12 weeks: >20 mm Hg, N=436 | 16 weeks: ≤ 10 mm Hg, N=400 | 16 weeks: >10 and ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 20 mm Hg, N=400 | 16 weeks: >20 mm Hg, N=400 | 20 weeks: ≤ 10 mm Hg, N=379 | 20 weeks: >10 and ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 20 mm Hg, N=379 | 20 weeks: >20 mm Hg, N=379 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.5 | 17.8 | 8.5 | 6.3 | 59.4 | 19.9 | 13.0 | 7.7 | 48.9 | 22.5 | 16.1 | 12.6 | 33.3 | 23.0 | 19.0 | 24.8 | 31.9 | 18.7 | 22.4 | 26.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=497 | 4 weeks: <135 mm Hg, N=497 | 4 weeks: <130 mm Hg, N=497 | 4 weeks: <120 mm Hg, N=497 | 8 weeks: <140 mm Hg, N=500 | 8 weeks: <135 mm Hg, N=500 | 8 weeks: <130 mm Hg, N=500 | 8 weeks: <120 mm Hg, N=500 | 12 weeks: <140 mm Hg, N=500 | 12 weeks: <135 mm Hg, N=500 | 12 weeks: <130 mm Hg, N=500 | 12 weeks: <120 mm Hg, N=500 | 16 weeks: <140 mm Hg, N=500 | 16 weeks: <135 mm Hg, N=500 | 16 weeks: <130 mm Hg, N=500 | 16 weeks: <120 mm Hg, N=500 | 20 weeks: <140 mm Hg, N=500 | 20 weeks: <135 mm Hg, N=500 | 20 weeks: <130 mm Hg, N=500 | 20 weeks: <120 mm Hg, N=500 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.3 | 37.2 | 23.3 | 7.9 | 63.2 | 49.2 | 37.0 | 13.8 | 76.6 | 61.6 | 49.2 | 23.2 | 85.8 | 75.6 | 63.6 | 34.6 | 90.2 | 82.6 | 72.2 | 43.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 30 mm Hg, N=495 | 4 weeks: >30 and ≤ 45 mm Hg, N=495 | 4 weeks: >45 mm Hg, N=495 | 8 weeks: ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 30 mm Hg, N=468 | 8 weeks: >30 and ≤ 45 mm Hg, N=468 | 8 weeks: >45 mm Hg, N=468 | 12 weeks: ≤ 15 mm Hg, N=436 | 12 weeks: >15 and ≤ 30 mm Hg, N=436 | 12 weeks: >30 and ≤ 45 mm Hg, N=436 | 12 weeks: >45 mm Hg, N=436 | 16 weeks: ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 30 mm Hg, N=400 | 16 weeks: >30 and ≤ 45 mm Hg, N=400 | 16 weeks: >45 mm Hg, N=400 | 20 weeks: ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 30 mm Hg, N=379 | 20 weeks: >30 and ≤ 45 mm Hg, N=379 | 20 weeks: >45 mm Hg, N=379 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.0 | 35.2 | 8.5 | 0.4 | 52.4 | 35.9 | 10.3 | 1.5 | 37.8 | 42.4 | 17.4 | 2.5 | 27.8 | 36.0 | 27.5 | 8.8 | 20.6 | 37.5 | 33.3 | 8.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 95.6 | 90.4 | 79.9 | 47.2 | 98.7 | 96.1 | 84.7 | 94.3 | 89.1 | 80.3 | 73.4 | 52.4 | 45.9 | 27.5 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 97.5 | 94.5 | 70.4 | 100.0 | 97.5 | 93.0 | 99.5 | 96.0 | 92.5 | 90.5 | 75.4 | 70.4 | 55.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.2 | 79.9 | 66.4 | 28.8 | 95.6 | 83.0 | 65.5 | 86.9 | 72.9 | 61.1 | 53.3 | 31.9 | 27.9 | 13.1 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 96.5 | 93.5 | 83.9 | 51.8 | 98.5 | 92.5 | 83.9 | 95.0 | 88.4 | 81.9 | 77.4 | 56.8 | 51.3 | 33.2 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 97.8 | 94.3 | 92.6 | 74.7 | 99.6 | 98.3 | 94.8 | 97.4 | 93.4 | 90.8 | 89.1 | 77.7 | 74.2 | 62.0 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 99.5 | 97.5 | 86.4 | 99.5 | 98.5 | 96.0 | 99.0 | 98.5 | 96.0 | 95.0 | 88.9 | 85.9 | 78.9 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.5 | 75.2 | 62.0 | 33.6 | 94.7 | 83.2 | 61.1 | 86.7 | 55.8 | 49.6 | 29.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 93.8 | 87.6 | 79.7 | 47.8 | 98.2 | 89.4 | 77.0 | 92.9 | 74.3 | 69.9 | 43.4 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 73.5 | 59.0 | 47.9 | 18.8 | 86.3 | 72.7 | 48.7 | 68.4 | 40.2 | 34.2 | 16.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 89.7 | 83.8 | 69.2 | 41.0 | 91.5 | 85.5 | 69.2 | 85.5 | 64.1 | 59.8 | 36.8 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 90.0 | 75.0 | 25.0 | 100.0 | 95.0 | 75.0 | 100.0 | 70.0 | 65.0 | 20.0 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 100.0 | 95.0 | 45.0 | 100.0 | 95.0 | 95.0 | 100.0 | 95.0 | 95.0 | 40.0 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 81.3 | 69.3 | 53.0 | 31.5 | 94.4 | 80.6 | 64.3 | 78.5 | 52.7 | 43.5 | 27.9 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 91.5 | 84.5 | 71.4 | 47.4 | 98.2 | 89.8 | 78.5 | 90.5 | 71.0 | 61.5 | 44.5 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 80.8 | 69.2 | 56.0 | 26.1 | 89.7 | 76.9 | 59.0 | 76.1 | 52.6 | 46.2 | 23.1 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.3 | 87.2 | 79.5 | 47.4 | 96.6 | 89.3 | 74.8 | 90.6 | 70.1 | 65.0 | 44.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140/90 mm Hg, N=975 | 4 weeks: <135/80 mm Hg, N=975 | 4 weeks: <130/80 mm Hg, N=975 | 4 weeks: <120/80 mm Hg, N=975 | 8 weeks: <140/90 mm Hg, N=929 | 8 weeks: <135/80 mm Hg, N=929 | 8 weeks: <130/80 mm Hg, N=929 | 8 weeks: <120/80 mm Hg, N=929 | 12 weeks: <140/90 mm Hg, N=865 | 12 weeks: <135/80 mm Hg, N=865 | 12 weeks: <130/80 mm Hg, N=865 | 12 weeks: <120/80 mm Hg, N=865 | 16 weeks: <140/90mm Hg, N=797 | 16 weeks: <135/80mm Hg, N=797 | 16 weeks: <130/80mm Hg, N=797 | 16 weeks: <120/80mm Hg, N=797 | 20 weeks: <140/90 mm Hg, N=745 | 20 weeks: <135/80 mm Hg, N=745 | 20 weeks: <130/80 mm Hg, N=745 | 20 weeks: <120/80 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.1 | 23.0 | 17.3 | 7.8 | 52.4 | 29.8 | 24.8 | 11.2 | 68.1 | 40.0 | 34.3 | 17.6 | 77.8 | 51.3 | 46.2 | 28.7 | 81.3 | 55.6 | 50.1 | 28.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=975 | 4weeks: <85 mm Hg, N=975 | 4 weeks: <80 mm Hg, N=975 | 8 weeks: <90 mm Hg, N=929 | 8 weeks: <85 mm Hg, N=929 | 8 weeks: <80 mm Hg, N=929 | 12 weeks: <90 mm Hg, N=865 | 12 weeks: <85 mm Hg, N=865 | 12 weeks: <80 mm Hg, N=865 | 16 weeks: <90 mm Hg, N=797 | 16 weeks: <85 mm Hg, N=797 | 16 weeks: <80 mm Hg, N=797 | 20 weeks: <90 mm Hg, N=745 | 20 weeks: <85 mm Hg, N=745 | 20 weeks: <80 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 55.2 | 34.2 | 75.1 | 57.1 | 40.2 | 84.3 | 68.7 | 49.5 | 90.2 | 76.9 | 59.6 | 89.7 | 79.5 | 62.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=975 | 4 weeks: >10 and ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 20 mm Hg, N=975 | 4 weeks: >20 mm Hg, N=975 | 8 weeks: ≤ 10 mm Hg, N=929 | 8 weeks: >10 and ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 20 mm Hg, N=929 | 8 weeks: >20 mm Hg, N=929 | 12 weeks: ≤ 10 mm Hg, N=865 | 12 weeks: >10 and ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 20 mm Hg, N=865 | 12 weeks: >20 mm Hg, N=865 | 16 weeks: ≤ 10 mm Hg, N=797 | 16 weeks: >10 and ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 20 mm Hg, N=797 | 16 weeks: >20 mm Hg, N=797 | 20 weeks: ≤ 10 mm Hg, N=745 | 20 weeks: >10 and ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 20 mm Hg, N=745 | 20 weeks: >20 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 61.3 | 21.0 | 10.5 | 7.2 | 54.7 | 20.7 | 14.1 | 10.6 | 43.8 | 24.1 | 15.8 | 16.3 | 30.4 | 22.8 | 21.5 | 25.4 | 31.4 | 19.9 | 22.6 | 26.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=975 | 4 weeks: <135 mm Hg, N=975 | 4 weeks: <130 mm Hg, N=975 | 4 weeks: <120 mm Hg, N=975 | 8 weeks: <140 mm Hg, N=929 | 8 weeks: <135 mm Hg, N=929 | 8 weeks: <130 mm Hg, N=929 | 8 weeks: <120 mm Hg, N=929 | 12 weeks: <140 mm Hg, N=865 | 12 weeks: <135 mm Hg, N=865 | 12 weeks: <130 mm Hg, N=865 | 12 weeks: <120 mm Hg, N=865 | 16 weeks: <140 mm Hg, N=797 | 16 weeks: <135 mm Hg, N=797 | 16 weeks: <130 mm Hg, N=797 | 16 weeks: <120 mm Hg, N=797 | 20 weeks: <140 mm Hg, N=745 | 20 weeks: <135 mm Hg, N=745 | 20 weeks: <130 mm Hg, N=745 | 20 weeks: <120 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.2 | 39.8 | 25.3 | 8.9 | 57.2 | 45.9 | 35.0 | 12.9 | 72.6 | 59.0 | 45.3 | 19.4 | 80.9 | 70.3 | 58.9 | 30.9 | 84.3 | 75.2 | 64.2 | 31.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 30 mm Hg, N=975 | 4 weeks: >30 and ≤ 45 mm Hg, N=975 | 4 weeks: >45 mm Hg, N=975 | 8 weeks: ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 30 mm Hg, N=929 | 8 weeks: >30 and ≤ 45 mm Hg, N=929 | 8 weeks: >45 mm Hg, N=929 | 12 weeks: ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 30 mm Hg, N=865 | 12 weeks: >30 and ≤ 45 mm Hg, N=865 | 12 weeks: >45 mm Hg, N=865 | 16 weeks: ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 30 mm Hg, N=797 | 16 weeks: >30 and ≤ 45 mm Hg, N=797 | 16 weeks: >45 mm Hg, N=797 | 20 weeks: ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 30 mm Hg, N=745 | 20 weeks: >30 and ≤ 45 mm Hg, N=745 | 20 weeks: >45 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.4 | 36.6 | 10.5 | 1.5 | 45.8 | 37.7 | 14.3 | 2.3 | 30.5 | 43.1 | 22.4 | 3.9 | 23.2 | 35.9 | 32.0 | 8.9 | 20.4 | 36.2 | 34.0 | 9.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=454 | 4 weeks: <85 mm Hg, N=454 | 4 weeks: <80 mm Hg, N=454 | 8 weeks: <90 mm Hg, N=457 | 8 weeks: <85 mm Hg, N=457 | 8 weeks: <80 mm Hg, N=457 | 12 weeks: <90 mm Hg, N=457 | 12 weeks: <85 mm Hg, N=457 | 12 weeks: <80 mm Hg, N=457 | 16 weeks: <90 mm Hg, N=457 | 16 weeks: <85 mm Hg, N=457 | 16 weeks: <80 mm Hg, N=457 | 20 weeks: <90 mm Hg, N=457 | 20 weeks: <85 mm Hg, N=457 | 20 weeks: <80 mm Hg, N=457 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 69.6 | 53.5 | 31.9 | 82.1 | 66.1 | 43.5 | 90.4 | 76.6 | 56.5 | 94.8 | 83.2 | 65.9 | 95.4 | 86.2 | 72.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=453 | 4 weeks: >10 and ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 20 mm Hg, N=453 | 4 weeks: >20 mm Hg, N=453 | 8 weeks: ≤ 10 mm Hg, N=431 | 8 weeks: >10 and ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 20 mm Hg, N=431 | 8 weeks: >20 mm Hg, N=431 | 12 weeks: ≤ 10 mm Hg, N=402 | 12 weeks: >10 and ≤15 mm Hg, N=402 | 12 weeks: >15 and ≤ 20 mm Hg, N=402 | 12 weeks: >20 mm Hg, N=402 | 16 weeks: ≤ 10 mm Hg, N=371 | 16 weeks: >10 and ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 20 mm Hg, N=371 | 16 weeks: >20 mm Hg, N=371 | 20 weeks: ≤ 10 mm Hg, N=356 | 20 weeks: >10 and ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 20 mm Hg, N=356 | 20 weeks: >20 mm Hg, N=356 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 62.7 | 22.3 | 8.6 | 6.4 | 56.6 | 19.7 | 15.3 | 8.4 | 44.3 | 22.1 | 17.4 | 16.2 | 32.4 | 24.0 | 21.0 | 22.6 | 33.2 | 19.4 | 22.5 | 25.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=454 | 4 weeks: <135 mm Hg, N=454 | 4 weeks: <130 mm Hg, N=454 | 4 weeks: <120 mm Hg, N=454 | 8 weeks: <140 mm Hg, N=457 | 8 weeks: <135 mm Hg, N=457 | 8 weeks: <130 mm Hg, N=457 | 8 weeks: <120 mm Hg, N=457 | 12 weeks: <140 mm Hg, N=457 | 12 weeks: <135 mm Hg, N=457 | 12 weeks: <130 mm Hg, N=457 | 12 weeks: <120 mm Hg, N=457 | 16 weeks: <140 mm Hg, N=457 | 16 weeks: <135 mm Hg, N=457 | 16 weeks: <130 mm Hg, N=457 | 16 weeks: <120 mm Hg, N=457 | 20 weeks: <140 mm Hg, N=457 | 20 weeks: <135 mm Hg, N=457 | 20 weeks: <130 mm Hg, N=457 | 20 weeks: <120 mm Hg, N=457 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.4 | 41.4 | 27.1 | 7.9 | 67.6 | 54.3 | 40.9 | 16.2 | 81.4 | 67.2 | 54.1 | 27.6 | 88.8 | 80.3 | 67.0 | 39.0 | 91.5 | 85.6 | 74.8 | 47.1 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 30 mm Hg, N=453 | 4 weeks: >30 and ≤ 45 mm Hg, N=453 | 4 weeks: >45 mm Hg, N=453 | 8 weeks: ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 30 mm Hg, N=431 | 8 weeks: >30 and ≤ 45 mm Hg, N=431 | 8 weeks: >45 mm Hg, N=431 | 12 weeks: ≤ 15 mm Hg, N=402 | 12 weeks: >15 and ≤ 30 mm Hg, N=402 | 12 weeks: >30 and ≤ 45 mm Hg, N=402 | 12 weeks: >45 mm Hg, N=402 | 16 weeks: ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 30 mm Hg, N=371 | 16 weeks: >30 and ≤ 45 mm Hg, N=371 | 16 weeks: >45 mm Hg, N=371 | 20 weeks: ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 30 mm Hg, N=356 | 20 weeks: >30 and ≤ 45 mm Hg, N=356 | 20 weeks: >45 mm Hg, N=356 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.5 | 38.4 | 11.5 | 0.7 | 48.0 | 35.5 | 14.4 | 2.1 | 30.4 | 43.8 | 22.6 | 3.2 | 24.0 | 37.7 | 29.1 | 9.2 | 19.7 | 36.5 | 36.0 | 7.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=190 | 4 weeks: <85 mm Hg, N=190 | 4 weeks: <80 mm Hg, N=190 | 8 weeks: <90 mm Hg, N=190 | 8 weeks: <85 mm Hg, N=190 | 8 weeks: <80 mm Hg, N=190 | 12 weeks: <90 mm Hg, N=190 | 12 weeks: <85 mm Hg, N=190 | 12 weeks: <80 mm Hg, N=190 | 16 weeks: <90 mm Hg, N=190 | 16 weeks: <85 mm Hg, N=190 | 16 weeks: <80 mm Hg, N=190 | 20 weeks: <90 mm Hg, N=190 | 20 weeks: <85 mm Hg, N=190 | 20 weeks: <80 mm Hg, N=190 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 | 64.2 | 39.0 | 85.8 | 72.6 | 51.1 | 94.2 | 83.2 | 63.7 | 97.9 | 89.0 | 70.5 | 99.0 | 90.5 | 76.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=189 | 4 weeks: >10 and ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 20 mm Hg, N=189 | 4 weeks: >20 mm Hg, N=189 | 8 weeks: ≤ 10 mm Hg, N=181 | 8 weeks: >10 and ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 20 mm Hg, N=181 | 8 weeks: >20 mm Hg, N=181 | 12 weeks: ≤ 10 mm Hg, N=170 | 12 weeks: >10 and ≤15 mm Hg, N=170 | 12 weeks: >15 and ≤ 20 mm Hg, N=170 | 12 weeks: >20 mm Hg, N=170 | 16 weeks: ≤ 10 mm Hg, N=156 | 16 weeks: >10 and ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 20 mm Hg, N=156 | 16 weeks: >20 mm Hg, N=156 | 20 weeks: ≤ 10 mm Hg, N=150 | 20 weeks: >10 and ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 20 mm Hg, N=150 | 20 weeks: >20 mm Hg, N=150 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.7 | 16.9 | 11.6 | 3.7 | 60.8 | 20.4 | 14.9 | 3.9 | 41.2 | 32.4 | 12.9 | 13.5 | 32.7 | 26.9 | 21.8 | 18.6 | 37.3 | 18.0 | 26.0 | 18.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=190 | 4 weeks: <135 mm Hg, N=190 | 4 weeks: <130 mm Hg, N=190 | 4 weeks: <120 mm Hg, N=190 | 8 weeks: <140 mm Hg, N=190 | 8 weeks: <135 mm Hg, N=190 | 8 weeks: <130 mm Hg, N=190 | 8 weeks: <120 mm Hg, N=190 | 12 weeks: <140 mm Hg, N=190 | 12 weeks: <135 mm Hg, N=190 | 12 weeks: <130 mm Hg, N=190 | 12 weeks: <120 mm Hg, N=190 | 16 weeks: <140 mm Hg, N=190 | 16 weeks: <135 mm Hg, N=190 | 16 weeks: <130 mm Hg, N=190 | 16 weeks: <120 mm Hg, N=190 | 20 weeks: <140 mm Hg, N=190 | 20 weeks: <135 mm Hg, N=190 | 20 weeks: <130 mm Hg, N=190 | 20 weeks: <120 mm Hg, N=190 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.7 | 41.1 | 26.3 | 10.0 | 69.0 | 56.3 | 42.6 | 15.8 | 81.6 | 69.5 | 57.9 | 30.0 | 87.9 | 79.0 | 69.0 | 39.5 | 91.1 | 84.2 | 75.3 | 48.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 30 mm Hg, N=189 | 4 weeks: >30 and ≤ 45 mm Hg, N=189 | 4 weeks: >45 mm Hg, N=189 | 8 weeks: ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 30 mm Hg, N=181 | 8 weeks: >30 and ≤ 45 mm Hg, N=181 | 8 weeks: >45 mm Hg, N=181 | 12 weeks: ≤ 15 mm Hg, N=170 | 12 weeks: >15 and ≤ 30 mm Hg, N=170 | 12 weeks: >30 and ≤ 45 mm Hg, N=170 | 12 weeks: >45 mm Hg, N=170 | 16 weeks: ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 30 mm Hg, N=156 | 16 weeks: >30 and ≤ 45 mm Hg, N=156 | 16 weeks: >45 mm Hg, N=156 | 20 weeks: ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 30 mm Hg, N=150 | 20 weeks: >30 and ≤ 45 mm Hg, N=150 | 20 weeks: >45 mm Hg, N=150 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.1 | 36.0 | 7.9 | 0.0 | 54.1 | 34.3 | 11.6 | 0.0 | 35.3 | 38.2 | 22.9 | 3.5 | 28.2 | 40.4 | 26.3 | 5.1 | 26.0 | 40.0 | 26.7 | 7.3 |
(NCT00791258)
Timeframe: Baseline to 12 and 20 weeks
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 12 weeks | 20 weeks | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 84.8 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Baseline, Weeks 28 and 54 endpoint
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Baseline | Change from Baseline to Week 28 Endpoint | Change from Baseline to Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 101.8 | -20.3 | -21.8 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Baseline, Weeks 28 and 54 endpoints
| Intervention | millimeters of mercury (Mean) | ||
|---|---|---|---|
| Baseline | Change from baseline to Week 28 Endpoint | Change from Baseline to Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 166.1 | -34.2 | -37.3 |
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT00667719)
Timeframe: 54 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any Adverse Events | Serious Adverse Events | Death | |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg | 255 | 14 | 0 |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | 54 | 1 | 0 |
| Aliskiren/Hydrochlorothiazide 300/12.5 mg | 57 | 0 | 0 |
Blood pressure control was defined as having a mean sitting diastolic blood pressure <90 mmHg and a mean sitting systolic blood pressure <140 mmHg. Percentage of participants achieving the blood pressure control of < 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 69.1 | 77.1 |
Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure <90 mmHg or a >=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 91.8 | 96.6 |
Systolic blood pressure response was defined as a mean sitting systolic blood pressure <140 mmHg or a >=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 90.2 | 93.7 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.9 |
| Placebo | -7.1 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -14.1 |
| Placebo | -6.0 |
"Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -9.7 |
| Placebo | -6.9 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -16.7 |
| Placebo | -6.8 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -19.1 |
| Placebo | -6.4 |
"Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8.~A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment*week, and week*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline." (NCT00289887)
Timeframe: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan | -12.1 |
| Placebo | -6.8 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
205 reviews available for hydrochlorothiazide and Hypertension
| Article | Year |
|---|---|
Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2022 |
Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indap | 2022 |
What Dermatologists Should Know About Thiazides.
Topics: Antihypertensive Agents; Dermatologists; Humans; Hydrochlorothiazide; Hypertension; Sodium Chloride | 2022 |
Treatment of Hypertension: A Review.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2022 |
Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hydroc | 2023 |
[Which is better? Chlorthalidone or Hydrochlorothiazide].
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2023 |
The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis.
Topics: Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Melanoma; Skin Neopla | 2023 |
Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Canada; | 2023 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2019 |
Hydrochlorothiazide and squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinoma, Basal Cell; Humans; Hydrochlorothiazide | 2020 |
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2020 |
Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2021 |
Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Treatment Adherence | 2021 |
Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2021 |
Superior antihypertensive and cardioprotective effects of chlorthalidone compared with hydrochlorothiazide.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2021 |
Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Chlorthalidone; Cholesterol; Diuretics; Huma | 2017 |
Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies.
Topics: Aged; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; Drug Therapy, | 2018 |
Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Diuretics, Potassium Spari | 2018 |
Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics, Potassium Sparing; Drug Therapy, | 2018 |
Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.
Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Genome-Wide Association Study; Genome, Human; Hu | 2019 |
Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hydrochlorothiazide; Hypertension; Ra | 2019 |
[Hydrochlorothiazide and skin cancer].
Topics: Blood Pressure; Carcinoma, Basal Cell; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Skin Ne | 2019 |
Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer.
Topics: Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms; Sodium Chloride Symporter Inhibitors | 2019 |
Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients.
Topics: Age Factors; Aged; Benzimidazoles; Benzoates; Drug Combinations; Humans; Hydrochlorothiazide; Hypert | 2013 |
Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2013 |
An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2013 |
[A fixed dose combination of telmisartan, and a thiazide diuretic in the treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Diuret | 2013 |
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Chlorthal | 2013 |
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2013 |
Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Fuma | 2014 |
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2014 |
Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials, | 2014 |
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Essential Hypertension; Humans; Hydr | 2014 |
Clinical inquiry: How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?
Topics: Antihypertensive Agents; Chlorthalidone; Evidence-Based Medicine; Humans; Hydrochlorothiazide; Hyper | 2014 |
Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update.
Topics: Animals; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Captopril; Cardiovascular Dise | 2014 |
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.
Topics: Antihypertensive Agents; Bayes Theorem; Black or African American; Carrier Proteins; Cation Transpor | 2015 |
[Practice of antihypertensive treatment in diabetic patients with hypertension in Hungary].
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2014 |
Misconceptions and facts about treating hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2015 |
Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Topics: Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; I | 2015 |
Evidence-based diuretics: focus on chlorthalidone and indapamide.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indap | 2015 |
Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic.
Topics: Blood Pressure; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2015 |
Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2015 |
Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; | 2016 |
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Topics: Diuretics; Genome-Wide Association Study; Humans; Hydrochlorothiazide; Hypertension | 2017 |
[All diuretics used in the treatment of hypertension are not the same].
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indapamide | 2017 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2017 |
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2008 |
Olmesartan medoxomil: a review of its use in the management of hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Combi | 2008 |
Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimidazoles; | 2008 |
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Human | 2009 |
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.
Topics: Amides; Animals; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hydrochlorot | 2008 |
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2008 |
Irbesartan and hydrochlorothiazide association in the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2009 |
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2009 |
The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hydrochlorothiazide; | 2009 |
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2009 |
Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; H | 2009 |
Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2009 |
[Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trial | 2009 |
Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Diuretics; Drug Therapy, Combination; Humans; H | 2009 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2009 |
Eprosartan: a review of its use in hypertension.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Ma | 2009 |
Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressu | 2009 |
Rational of the use of aliskiren in hypertension and beyond.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl C | 2009 |
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2009 |
Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as | 2010 |
Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2010 |
[Identification of a new target for thiazidic diuretics in kidney].
Topics: Absorption; Amiloride; Animals; Biological Transport, Active; Blood Pressure; Drug Design; Humans; H | 2010 |
A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2010 |
Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dose-Response Relationship, Drug; | 2010 |
Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement.
Topics: Angiotensin Receptor Antagonists; Blood Pressure Determination; Cardiovascular Diseases; Case-Contro | 2010 |
Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combinations; Humans; Hydrochlo | 2010 |
Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlo | 2011 |
Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials.
Topics: Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Humans; Hydrochlorothiazide; Hyperte | 2011 |
Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2011 |
In brief: Another three-drug combination for hypertension.
Topics: Amides; Amlodipine; Animals; Drug Approval; Drug Combinations; Fumarates; Humans; Hydrochlorothiazid | 2011 |
Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hy | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2011 |
Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2011 |
Angiotensin II receptor blocker combinations: from guidelines to clinical practice.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Huma | 2012 |
Half a century of hydrochlorothiazide: facts, fads, fiction, and follies.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension | 2011 |
Polymorphisms, hypertension and thiazide diuretics.
Topics: Biomarkers, Pharmacological; Calmodulin-Binding Proteins; Diuretics; Genetic Association Studies; Ge | 2011 |
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Design; Fumarates; Humans; Hydr | 2011 |
Chlorthalidone: the forgotten diuretic.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2012 |
Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; H | 2012 |
The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Co | 2012 |
Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2012 |
Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Humans; Hyd | 2012 |
Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.
Topics: Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Chlorthalidone; Dose-Response Relation | 2012 |
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2012 |
Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2013 |
Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease.
Topics: Antihypertensive Agents; Chlorthalidone; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hy | 2012 |
Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Garlic; Humans; | 2012 |
Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Practice Guidelines as Topic; | 2012 |
Module 2: Rethinking the role of thiazide-type diuretics in the management of hypertension: which diuretic is best?
Topics: Antihypertensive Agents; Chlorthalidone; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyp | 2012 |
Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Co | 2012 |
The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Fumarates; Humans; Hydrochlorothiazi | 2012 |
Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Calcium Chann | 2012 |
Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2012 |
A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2013 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; Humans; | 2013 |
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.
Topics: Adipogenesis; Antihypertensive Agents; Black or African American; Blood Glucose; Calcium-Binding Pro | 2014 |
Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Topics: Acrylates; Age Factors; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hyp | 2002 |
Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
Topics: Antihypertensive Agents; Databases, Bibliographic; Diuretics; Drug Therapy, Combination; Humans; Hyd | 2002 |
Combination therapy as first-line treatment of arterial hypertension.
Topics: Antihypertensive Agents; Atenolol; Captopril; Diltiazem; Drug Therapy, Combination; Humans; Hydrochl | 2002 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Clinical Trials as Topic; Diure | 2003 |
[Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension].
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Dose-Response Relationship, Drug; Drug Combinati | 2003 |
Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Dose-Response Relation | 2004 |
Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Combinati | 2004 |
Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Combinati | 2003 |
[Development of combined drugs (ARB and diuretics)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Combination therapy as first-line treatment for hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 2004 |
Pharmacological and clinical profile of moexipril: a concise review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bone and Bones; Diuretic | 2004 |
Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hy | 2004 |
Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Controlled Clinical | 2004 |
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Dose-Response Relation | 2005 |
Telmisartan/hydrochlorothiazide: a new fixed dose combination.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates | 2005 |
Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.
Topics: Angiotensin II Type 1 Receptor Blockers; Diuretics; Drug Therapy, Combination; Humans; Hydrochloroth | 2005 |
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Evaluation; Humans; Hydroc | 2005 |
Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, pros
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2005 |
Telmisartan: a review of its use in the management of hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Drug | 2006 |
A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Factor | 2006 |
Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2006 |
Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.
Topics: Antihypertensive Agents; Drug Interactions; Humans; Hydrochlorothiazide; Hypertension; Tetrazoles; T | 2006 |
Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diuretics; Drug Therapy, Combina | 2006 |
[Combination therapy in contemporary strategy of treatment of arterial hypertension. Review of data on efficacy and safety of fixed combination valsartan and hydrochlorothiazide].
Topics: Angiotensin II Type 1 Receptor Blockers; Diuretics; Drug Therapy, Combination; Humans; Hydrochloroth | 2006 |
Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans | 2007 |
Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Captopril; Cardio | 2006 |
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Ad | 2006 |
Variability in response to antihypertensive drugs.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Black or African American; Blood Pressure Determi | 2007 |
[Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Co | 2007 |
Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Femal | 2007 |
Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; | 2007 |
Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Th | 2007 |
Metoprolol succinate extended release/hydrochlorothiazide combination tablets.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Delayed-Action Preparations; Drug Combinations | 2007 |
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Humans; | 2007 |
[Observational study of an AT1-antagonist].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
[Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
Topics: Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Clinical Trials as Topic; Diastole; | 2007 |
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Combinations; | 2008 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2008 |
Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.
Topics: Amides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Interact | 2008 |
Beta-blockers in the management of hypertension: focus on nebivolol.
Topics: Adrenergic beta-Antagonists; Antioxidants; Benzopyrans; Blood Pressure; Drug Synergism; Drug Therapy | 2008 |
Enalapril worldwide experience.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Cell Count; Blood Pressure; Captopril; Dipeptides; D | 1984 |
An overview of the clinical pharmacology of enalapril.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Di | 1984 |
[Current treatment of hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Clonidine; Guanethidine; Human | 1980 |
Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.
Topics: Body Fluids; Captopril; Dipeptides; Drug Evaluation; Enalapril; Glomerular Filtration Rate; Hemodyna | 1984 |
[The heart and arterial hypertension].
Topics: Blood Pressure; Cardiac Output; Cardiac Volume; Cardiomegaly; Heart; Heart Rate; Hemodynamics; Human | 1982 |
Hypertension--low cost chemotherapy.
Topics: Drug Therapy, Combination; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1983 |
Drug systems approach to hypertension.
Topics: Captopril; Clonidine; Drug Combinations; Drug Therapy, Combination; Guanethidine; Humans; Hydralazin | 1984 |
[Exertion hypertension in coronary disease and its importance in prevention and rehabilitation].
Topics: Adult; Coronary Disease; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metoprolol; Middle | 1982 |
Effects of captopril in animal models of hypertension.
Topics: Adrenal Glands; Aldosterone; Angiotensin I; Angiotensin II; Animals; Arteries; Blood Pressure; Brady | 1980 |
[Treatment of arterial hypertension in elderly patients].
Topics: Age Factors; Aged; Antihypertensive Agents; Chlorpromazine; Diazoxide; Dihydralazine; Drug Therapy, | 1981 |
Managing diuretic-induced hypokalemia in ambulatory hypertensive patients.
Topics: Aged; Ambulatory Care; Chlorthalidone; Diuretics; Food; Humans; Hydrochlorothiazide; Hypertension; H | 1982 |
Salivary function and hypertension: a review of the literature and a case report.
Topics: Humans; Hydrochlorothiazide; Hypertension; Lisinopril; Male; Middle Aged; Saliva; Secretory Rate; Xe | 1995 |
Cilazapril with adjunctive hydrochlorothiazide. Analysis of safety and efficacy in hypertensive patients not responding to cilazapril alone.
Topics: Blood Pressure; Cilazapril; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochloro | 1995 |
Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.
Topics: Acanthosis Nigricans; Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteri | 1993 |
Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.
Topics: Calcium; Chlorides; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Natriuresis | 1993 |
Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective.
Topics: Antihypertensive Agents; Diuretics; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazide; H | 1995 |
Evidence for the efficacy of low-dose diuretic monotherapy.
Topics: Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorot | 1996 |
Combination therapy with diuretics: an evolution of understanding.
Topics: Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorot | 1996 |
[Value of diuretics in hypertension].
Topics: Antihypertensive Agents; Diuretics; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazide; H | 1996 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive | 1997 |
Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Contr | 1997 |
Hyperlipidemia of diuretic therapy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cere | 1998 |
Valsartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Heart Rate; Humans; Hydrochlor | 1999 |
Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug | 2000 |
Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diure | 2002 |
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 2002 |
Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?
Topics: Amiloride; Arteriosclerosis; Calcium Channel Blockers; Cardiovascular Diseases; Diuretics; Drug Comb | 2002 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
[Importance of the continuity of anti-hypertension treatment in prevention of ischemic cardiovascular diseases: preliminary note. Controlled study of hypertensive patients treated with amiloride associated with hydrochlorothiazide and chlorthalidone].
Topics: Adult; Aged; Amiloride; Chlorthalidone; Coronary Disease; Drug Therapy, Combination; Female; Humans; | 1978 |
Elderly hypertensive patient. Epidemiologic review.
Topics: Adult; Age Factors; Aged; Cerebrovascular Disorders; Female; Humans; Hydrochlorothiazide; Hypertensi | 1978 |
Low renin hypertension.
Topics: Adult; Age Factors; Diagnosis, Differential; Female; Humans; Hydrochlorothiazide; Hyperaldosteronism | 1975 |
Drug therapy: clonidine, a new antihypertensive drug.
Topics: Blood Pressure; Brain; Clonidine; Drug Interactions; Drug Therapy, Combination; Hemodynamics; Humans | 1975 |
Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy.
Topics: Adult; Aged; Cardiovascular System; Double-Blind Method; Enalapril; Female; Heart; Heart Ventricles; | 1992 |
Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug | 1992 |
The treatment of moderate to severe hypertension with ACE inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug Therapy, Co | 1990 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Drug Combinations; | 1991 |
Hypertension in the Hispanic-American population.
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Female; Hispanic or Latino; Humans; Hydroch | 1990 |
Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Doxazosin; Humans; Hydrochlorothiazide; H | 1989 |
Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Enalapril; Female | 1985 |
Effects of atrial natriuretic factor on renal function and cyclic GMP production.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium; Cyclic GMP; Enzyme Activation; Furosemi | 1986 |
Spironolactone in the treatment of hypertension: a review.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Diureti | 1986 |
Calcium antagonists: use in hypertension evaluation of calcium antagonists in combination with diuretics.
Topics: Bendroflumethiazide; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; | 1988 |
Ethnics differences in the reactions to drugs and xenobiotics. Antihypertensive agents.
Topics: Antihypertensive Agents; Bendroflumethiazide; Black People; Clinical Trials as Topic; Diuresis; Diur | 1986 |
[Properties and indications of potassium-sparing diuretics].
Topics: Amiloride; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperaldosteronism; Hy | 1986 |
Essential hypertension: new insights and controversies in treatment with diuretics.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Coronary Disease; Diuretics; Dose-Response Relat | 1986 |
Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs.
Topics: Angina Pectoris; Biological Availability; Calcium Channel Blockers; Delayed-Action Preparations; Dil | 1987 |
Captopril and hydrochlorothiazide: rationale for their combination.
Topics: Captopril; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Metabolism | 1987 |
Effectiveness of drug therapy in hypertension: present status. A review.
Topics: Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Eye Diseases; Ganglionic Block | 1971 |
[Pharmacological properties of the hydrochlorothiazide-guanethidine association].
Topics: Animals; Blood Pressure; Catecholamines; Drug Combinations; Guanethidine; Hemodynamics; Humans; Hydr | 1972 |
The treatment of hypertension. Why, when and how.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diuretics; Female; Guanethidine; Humans; Hydralazine; Hyd | 1972 |
Significance of hypokalaemia due to diuretics.
Topics: Amiloride; Arrhythmias, Cardiac; Chlorothiazide; Diuretics; Ethacrynic Acid; Extracellular Space; Fu | 1973 |
Renin and hypertension: a review article.
Topics: Aldosterone; Humans; Hydrochlorothiazide; Hypertension; Juxtaglomerular Apparatus; Kidney Diseases; | 1973 |
[Hypertension--diuretics as antihypertensive agents].
Topics: Aged; Antihypertensive Agents; Arthritis; Benzothiadiazines; Blood Pressure; Chlorothiazide; Chlorth | 1970 |
[Side effects of antihypertensive therapy].
Topics: Acetazolamide; Antihypertensive Agents; Blood Pressure; Furosemide; Humans; Hydralazine; Hydrochloro | 1970 |
1678 trials available for hydrochlorothiazide and Hypertension
| Article | Year |
|---|---|
Propranolol-hydrochlorothiazide combination in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Femal | 1982 |
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
A Differential Response to Antihypertensive Therapy in African Men and Women: Insights From the CREOLE Trial.
Topics: Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Drug Combina | 2022 |
Influence of Hypersensitive C-Reactive Protein on the Effect of Continuous Antihypertensive Pharmacological Therapy.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Captopril; Humans; Hydrochlorothiazide; | 2022 |
Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Electronic Health Records; Human | 2022 |
Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood | 2022 |
Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Chlorthalidone; Diuretics; Double-Blind Method; Dr | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Hu | 2023 |
Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial.
Topics: Antihypertensive Agents; Bayes Theorem; Blood Pressure; Double-Blind Method; Female; Humans; Hydroch | 2023 |
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Circulating microparticles and central blood pressure according to antihypertensive strategy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cell-Derived Microparticles; Drug Therapy, Combina | 2019 |
Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Double-Blind Method; Dru | 2019 |
A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease.
Topics: Adult; Aged; Amiloride; Blood Pressure Determination; Cross-Over Studies; Diet, Sodium-Restricted; D | 2020 |
High-intensity interval training vs. hydrochlorothiazide on blood pressure, cardiovascular health and cognition: Protocol of a non-inferiority trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cognition; Drug Therapy, Combination; Equivalence Tri | 2021 |
Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy, Combination; Humans; Hydroc | 2021 |
Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: A randomized controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Therapy, C | 2021 |
A double-blind, placebo-controlled trial on the antihypertensive treatment effect of a quadruple single-pill combination.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Humans; Hyd | 2021 |
Telmisartan and hydrochlorothiazide antihypertensive treatment in high sodium intake population: a randomized double-blind trial.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hydrochlorothiazide; Hyp | 2017 |
ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2017 |
Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Humans; Hydrochlorothiazide; Hype | 2017 |
Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Dose-Respo | 2017 |
Patient characteristics do not predict the individual response to antihypertensive medication: a cross-over trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over St | 2018 |
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aldehyde Dehydrogenase 1 Family; Angiotensin-C | 2017 |
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relation | 2017 |
The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with….
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiaz | 2018 |
Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Blood Pressure Monitors | 2018 |
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Chlorthalidone; Diuretics; Double-Bli | 2018 |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Topics: Aged; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2018 |
Spironolactone is superior to hydrochlorothiazide for blood pressure control and arterial stiffness improvement: A prospective study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Monitoring; Female; Humans; Hydrochloroth | 2018 |
Rationale and design of the comparison of 3 combination therapies in lowering blood pressure in black Africans (CREOLE study): 2 × 3 factorial randomized single-blind multicenter trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Black People; Drug Com | 2018 |
Clinical efficacy and ultrasound inspection of the treatment of hypertensive heart patients with Valsartan combined with hydrochlorothiazide.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Female; | 2018 |
Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Blood | 2018 |
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Black or Afr | 2018 |
The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2019 |
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Asian People; Benzimid | 2019 |
Treating Hypertension in Children With
Topics: Academic Medical Centers; Adolescent; Amlodipine; Antihypertensive Agents; Bayes Theorem; Blood Pres | 2019 |
Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pr | 2019 |
Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Do | 2019 |
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.
Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; E | 2019 |
The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Carotid-Femoral Pulse Wave Velocity; Fema | 2019 |
Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Th | 2013 |
Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Res | 2013 |
Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2013 |
The influence of a direct renin inhibitor on the central blood pressure.
Topics: Adult; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Admin | 2013 |
A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers.
Topics: Adolescent; Adult; Amlodipine; Benzimidazoles; Benzoates; Cross-Over Studies; Drug Therapy, Combinat | 2013 |
Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calc | 2013 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Fema | 2013 |
Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Bl | 2013 |
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Coronary Artery Disease; Double-Blind Metho | 2013 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blo | 2013 |
Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2013 |
Effects of aerobic exercise and drug therapy on blood pressure and antihypertensive drugs: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure; Diur | 2013 |
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Pressure; Blo | 2013 |
Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Dem | 2013 |
Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Dr | 2013 |
Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood | 2013 |
Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diur | 2014 |
A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Blood Pressure; Dose-Response Relationship, Drug; Drug Combi | 2014 |
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Blood Pres | 2014 |
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Meth | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Hydrochlorothiazide; Hyper | 2013 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2013 |
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Drug Therapy, | 2014 |
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
Topics: Adult; Antihypertensive Agents; Benzazepines; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; | 2013 |
Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: a subgroup analysis of a randomized, double-blind, active-controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind Method | 2013 |
Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidine | 2014 |
The influence of long term hydrochlorothiazide administration on the relationship between renin-angiotensin-aldosterone system activity and plasma glucose in patients with hypertension.
Topics: Administration, Oral; Blood Glucose; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 2013 |
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agent | 2014 |
Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Captopril; Case-Control Studie | 2014 |
[Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Diu | 2013 |
TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressur | 2014 |
The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients.
Topics: Adult; Aged; Amides; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2014 |
Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dr | 2014 |
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy | 2014 |
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Hispanic or Latino; Humans; | 2014 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme In | 2015 |
Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Do | 2014 |
[Comparison pharmacoeconomics organoprotection using fixed combinations of antihypertensive drugs].
Topics: Antihypertensive Agents; Drug Therapy, Combination; Economics, Pharmaceutical; Enalapril; Female; Hu | 2014 |
Type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Com | 2014 |
A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide.
Topics: Aged; Amiloride; Antihypertensive Agents; Combined Modality Therapy; Dancing; Drug Therapy, Combinat | 2014 |
Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?
Topics: Aged; Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Drug Combinations; Drug Mo | 2015 |
Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; | 2015 |
Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; | 2014 |
[Optimization of arterial hypertension management by the use of two- and three-drugs fixed dose combinations at the daily stay department].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Da | 2014 |
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Coh | 2014 |
Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic.
Topics: Administration, Cutaneous; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Blo | 2015 |
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity.
Topics: Adult; Age Factors; Aged; Amlodipine; Blood Pressure; Body Mass Index; Dose-Response Relationship, D | 2014 |
Time of administration important? Morning versus evening dosing of valsartan.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2015 |
The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial.
Topics: Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, | 2014 |
[The use of verospiron and the degree of platelet aggregation in arterial hypertension with abdominal obesity].
Topics: Comorbidity; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Obesity, Abdom | 2014 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Differential effects of angiotensin II receptor blocker and losartan/hydrochlorothiazide combination on central blood pressure and augmentation index.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Dose-Respon | 2015 |
Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Brachial Artery; Drug Therapy, Combination; Endothelium, | 2014 |
Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Topics: Antihypertensive Agents; Benzopyrans; Drug Combinations; Ethanolamines; Female; Humans; Hydrochlorot | 2014 |
Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Topics: Antihypertensive Agents; Benzopyrans; Drug Combinations; Ethanolamines; Female; Humans; Hydrochlorot | 2014 |
Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Topics: Antihypertensive Agents; Benzopyrans; Drug Combinations; Ethanolamines; Female; Humans; Hydrochlorot | 2014 |
Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.
Topics: Antihypertensive Agents; Benzopyrans; Drug Combinations; Ethanolamines; Female; Humans; Hydrochlorot | 2014 |
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug T | 2015 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Dioxygenase | 2015 |
Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2015 |
Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Australia; Cardiovas | 2015 |
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
[Changes of twenty-four-hour profile blood pressure and its correction of patients with arterial hypertension on the background of combined antihypertensive therapy application].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Com | 2014 |
Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY study.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrochlo | 2015 |
A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2015 |
Visit-to-visit variability and seasonal variation in blood pressure: Combination of Antihypertensive Therapy in the Elderly, Multicenter Investigation (CAMUI) Trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans | 2015 |
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Drug Combinations; Female; H | 2015 |
[Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide].
Topics: Aged; Antihypertensive Agents; Biological Availability; Blood Pressure; Carbohydrate Metabolism; Del | 2014 |
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambu | 2015 |
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Be | 2015 |
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-R | 2015 |
Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 2017 |
Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; | 2015 |
Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual-Combination Therapy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Mon | 2016 |
Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2015 |
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2015 |
Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Glucose; Blood Pressure; Clinical Protocols; Diuretics; Do | 2015 |
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
Topics: Aged; Amiloride; Diuretics; Double-Blind Method; Female; Glucose Intolerance; Humans; Hydrochlorothi | 2016 |
Comparative Effect of a Renin Inhibitor and a Thiazide Diuretic on Renal Tissue Oxygenation in Hypertensive Patients.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Female; Fumarates; Humans; Hydrochlorothiazide; Hypert | 2015 |
Antihypertensive therapy increases natural immunity response in hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hydrochlorothiazi | 2015 |
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, | 2016 |
Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambula | 2016 |
Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study.
Topics: Aged; Aged, 80 and over; Amlodipine; Benzimidazoles; Benzoates; Drug Therapy, Combination; Female; H | 2016 |
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2016 |
Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
Topics: Adult; Aged; Benzimidazoles; Chlorthalidone; Cohort Studies; Dizziness; Drug Therapy, Combination; E | 2016 |
Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidon | 2016 |
Effects of aerobic dance training on blood pressure in individuals with uncontrolled hypertension on two antihypertensive drugs: a randomized clinical trial.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Combined | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2016 |
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double- | 2017 |
Treatment of Hypertension with Combination of Lisinopril/Hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosnia and Herzegovina; Drug Combinations; | 2016 |
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial.
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2017 |
Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Aged; Amiloride; Antihypertensive Agents; Ateno | 2016 |
Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Doub | 2017 |
Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Belgium; Biphenyl Compounds; Blood Pressure; Doubl | 2017 |
Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2016 |
Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2017 |
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.
Topics: Aged; Cross-Over Studies; Diabetic Nephropathies; Diet, Sodium-Restricted; Diuretics; Double-Blind M | 2016 |
Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Dose-Response Relationship, Drug; D | 2017 |
Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Beijing; Blood Pressure; Community Health Centers; | 2017 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2017 |
Mobile Device-Based Electronic Data Capture System Used in a Clinical Randomized Controlled Trial: Advantages and Challenges.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Cell Phone; Data Collection; Double-Blind | 2017 |
Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
Topics: Aged; Antihypertensive Agents; Blood Pressure; Canada; Drug Therapy, Combination; Female; Follow-Up | 2008 |
Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calci | 2008 |
[Free or fixed combination of enalapril and hypothiazide in real ambulatory practice: what is better for a patient with arterial hypertension].
Topics: Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diuretics; Dose-Response | 2008 |
Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Chi-Square D | 2008 |
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Dose-Response Relationship, | 2008 |
Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Double-Blind Method; | 2008 |
[Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; C-Reactive P | 2008 |
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Topics: Action Potentials; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cross-Over Studi | 2009 |
Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combin | 2008 |
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Doubl | 2008 |
The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; | 2008 |
Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Blood Pressure; China; Double | 2008 |
Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2008 |
Losartan with hydrochlorothiazide in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; | 1995 |
Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cough; Diuretics; | 1995 |
Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy | 2008 |
Initial combination therapy compared with monotherapy in diabetic hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressur | 2008 |
Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide.
Topics: Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2008 |
Interaction between antihypertensives and NSAIDs in primary care: a controlled trial.
Topics: Acetaminophen; Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; B | 2008 |
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |
Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Atenolol; Blood Pressure; Captopril; China; Dela | 2008 |
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Glucose; Blood Press | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
[A randomized, double-blind, double-dummy study comparing a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg to telmisartan 80 mg in Chinese hypertensive patients who failed to respond adequately to telmisartan 80 mg].
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; | 2008 |
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes | 2008 |
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressu | 2008 |
[Impact of patient compliance on the outcomes in hypertensive patients receiving hydrochlorothiazide based combination therapy with spironolactone or captopril].
Topics: Aged; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Follow-Up Studies; Huma | 2008 |
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Double-Blind Method; Dyspepsia; | 2009 |
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Double-Blind Method; Dyspepsia; | 2009 |
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Double-Blind Method; Dyspepsia; | 2009 |
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Double-Blind Method; Dyspepsia; | 2009 |
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diver
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Body Mass Index; Body Weight; Cluster Analysis; D | 2008 |
Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Black Peop | 2009 |
Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood P | 2009 |
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Be | 2008 |
Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders.
Topics: Adolescent; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Me | 2008 |
Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone.
Topics: Adult; Amides; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combinati | 2009 |
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzo | 2009 |
[Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Calcium Ch | 2009 |
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rh | 2009 |
Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combina | 2009 |
Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combina | 2009 |
Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combina | 2009 |
Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combina | 2009 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; | 2009 |
Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.
Topics: Diuretics; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hydrochlorothiazide; Hyperlipidem | 2009 |
Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
Topics: Adult; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Press | 2009 |
Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2009 |
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Di | 2009 |
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asia | 2009 |
Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel | 2009 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Topics: Amides; Antihypertensive Agents; Double-Blind Method; Fumarates; Humans; Hydrochlorothiazide; Hypert | 2009 |
A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Laboratory Tec | 2009 |
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Double-Blind Method; Drug Ther | 2009 |
A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Ther | 2009 |
Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doub | 2009 |
[Combined treatment of arterial hypertension (results of the international program CLIP-ACCORD)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2009 |
Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Chemistry, Pharmaceutical; Dose-Respons | 2009 |
Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles | 2009 |
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Topics: Adult; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Drug Administration Schedule | 2009 |
ACCOMPLISH the goal: hypertension and beyond.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2009 |
Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2009 |
Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Re | 2009 |
[The role of combination therapy in the treatment of arterial hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diuretics; Drug C | 2009 |
[Preventive pharmacotherapy in arterial hypertension: problems of clinical assessment of drugs in women].
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Del | 2009 |
Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; H | 2009 |
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aorta; Azetidinecarboxylic Acid; Blood Pressure; Calc | 2009 |
Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; | 2009 |
Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatinine; Dose-Response Relationsh | 2009 |
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diure | 2009 |
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S | 2009 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bi | 2009 |
Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2009 |
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Double-Blin | 2010 |
Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Humans; Hydrochlorothiazid | 2010 |
Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydr | 2009 |
Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2010 |
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Co | 2009 |
Pharmacodynamics of kardos administered as monotherapy and in combination with hypothiazide and enalapril in grade I-II arterial hypertension.
Topics: Antibodies; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; H | 2009 |
One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors.
Topics: Aged; Antihypertensive Agents; Asian People; Drug Therapy, Combination; Female; Humans; Hydrochlorot | 2010 |
Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2010 |
A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glu | 2010 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Double- | 2010 |
Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2010 |
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blo | 2010 |
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure Determination; Drug Therapy, | 2010 |
Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.
Topics: Aged; Aldosterone; Blood Pressure; Body Composition; Catecholamines; Diuretics; Female; Heart Rate; | 2010 |
Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Doubl | 2010 |
Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antihypertensive Agents; Area Under Curve; B | 2010 |
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
[Analysis of therapeutic effects of rural patients with hypertension by combination administration of low dosage of hydrochlorothiazide and nitrendipine].
Topics: Aged; Antihypertensive Agents; Case-Control Studies; China; Drug Therapy, Combination; Female; Human | 2010 |
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.
Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzi | 2011 |
Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Drug Combinations; F | 2009 |
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass | 2010 |
Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dizziness; Double-Blind Method; Drug Therapy, Combina | 2010 |
Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension.
Topics: Age Factors; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure Monitoring, Ambulato | 2010 |
Cardiovascular risk management and its impact on hypertension control in primary care in low-resource settings: a cluster-randomized trial.
Topics: Adult; Aged; Algorithms; Antihypertensive Agents; Cardiovascular Diseases; China; Cluster Analysis; | 2010 |
Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Topics: Acrylates; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Age | 2010 |
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
Topics: Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2010 |
Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, mult
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; D | 2010 |
Cardiovascular events during differing hypertension therapies in patients with diabetes.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2010 |
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Body Mas | 2010 |
Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Belgium; Blood Pressure; Fe | 2011 |
Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2010 |
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2010 |
Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Blood Glucose; Drug Therapy, Combination; Ethanolamines; | 2010 |
Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2010 |
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Algorithms; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2010 |
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
Topics: Adolescent; Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Dose | 2011 |
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2010 |
How to avoid discontinuation of antihypertensive treatment: The experience in São Paulo, Brazil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Calcium Channel Blockers | 2010 |
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 2010 |
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amides; Antihypertensive Agents; Drug Combinations; Drug | 2010 |
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; D | 2010 |
Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Topics: Androstanols; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Female; Genetic | 2010 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination | 2011 |
Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Endothelial Cells; Female; Humans; Hydroch | 2011 |
Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Topics: Adult; Aged; Algorithms; Amides; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2011 |
Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blin | 2010 |
Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects.
Topics: Adiponectin; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Glucose; Blood P | 2011 |
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure Moni | 2011 |
Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Blood Pressure; China; Cytochrome P-450 CYP11B2; | 2011 |
Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients.
Topics: Adipose Tissue; Amyloid; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Gene E | 2011 |
Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Brachial Artery; Calcium Channel Blockers; Endothelium, Vascul | 2011 |
Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Felodip | 2011 |
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study.
Topics: Age Factors; Aged; Amides; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Body Mass | 2011 |
Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients.
Topics: Adult; Aged; Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; | 2011 |
Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Fe | 2011 |
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black Peop | 2011 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, | 2011 |
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach | 2011 |
Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Combina | 2011 |
A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor B | 2011 |
Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Topics: Administration, Oral; Adolescent; Adult; Amides; Analysis of Variance; Antihypertensive Agents; Bloo | 2012 |
Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Topics: Administration, Oral; Adolescent; Adult; Amides; Analysis of Variance; Antihypertensive Agents; Bloo | 2012 |
Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Topics: Administration, Oral; Adolescent; Adult; Amides; Analysis of Variance; Antihypertensive Agents; Bloo | 2012 |
Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Topics: Administration, Oral; Adolescent; Adult; Amides; Analysis of Variance; Antihypertensive Agents; Bloo | 2012 |
Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; China; Dihydralazine; D | 2011 |
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Doub | 2011 |
Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2011 |
Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, T | 2011 |
Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA
Topics: Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Dose-Respons | 2011 |
Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhy | 2011 |
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Drug Therapy, Combination; Electrocardiography; F | 2012 |
Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood Pressu | 2011 |
Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 1; Diabet | 2011 |
Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Coagulation; Female; Fibrin; Humans; H | 2012 |
Cardiovascular risk stratification and antihypertensive therapy according to guidelines in the outpatient setting.
Topics: Age Factors; Aged; Ambulatory Care; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compo | 2011 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodiu | 2011 |
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Met | 2011 |
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co | 2011 |
Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2012 |
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Combined Modality Therapy; Diuretics | 2011 |
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, | 2011 |
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, | 2011 |
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, | 2011 |
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, | 2011 |
Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Benzopyrans; | 2012 |
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Drug Ther | 2012 |
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressu | 2012 |
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressu | 2012 |
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressu | 2012 |
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressu | 2012 |
Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cholesterol; Female; Humans; Hydrochlorothiazide; | 2013 |
Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hydrochlo | 2011 |
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Dru | 2011 |
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Topics: Amides; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2011 |
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressur | 2011 |
Antihypertensive efficacy of the losartan/hydrochlorothiazide combination and its effect on plasma B-type natriuretic peptide in hypertensive patients uncontrolled by angiotensin II type 1 receptor antagonist-based therapy: a multicentre prospective obser
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Humans; Hyd | 2012 |
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2012 |
A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease.
Topics: Aged; Anthropology; Biological Availability; Blood Pressure; Chronic Disease; Diet Records; Diuretic | 2012 |
Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Blood Pre | 2011 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyd | 2012 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; G-Protein-Coupled Receptor Kinase 4; Huma | 2012 |
Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.
Topics: Age Factors; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Double | 2012 |
Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzi | 2012 |
Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug-Related Side Effects and Adve | 2011 |
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2012 |
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Benzopyrans; Black or African American; Dose-Respons | 2012 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2012 |
Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.
Topics: Age Factors; Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Cognition; Cogn | 2012 |
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2012 |
Does a combination pill of antihypertensive drugs improve medication adherence in Japanese? A randomized controlled trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2012 |
Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2013 |
Long-term antihypertensive efficacy of losartan/hydrochlorothiazide combination therapy on home blood pressure control.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pre | 2012 |
[Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients].
Topics: Aged; Amlodipine; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hy | 2012 |
A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension.
Topics: Adult; Aged; Amiloride; Atenolol; Blood Glucose; Blood Pressure Determination; Cross-Over Studies; D | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind M | 2012 |
Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A | 2012 |
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretic
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Blood Press | 2012 |
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretic
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Blood Press | 2012 |
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretic
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Blood Press | 2012 |
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretic
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Blood Press | 2012 |
Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Brazi | 2012 |
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Black or African | 2012 |
The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Drug Combinations; | 2012 |
Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients.
Topics: Administration, Oral; Adult; Africa South of the Sahara; Aged; Amlodipine; Amlodipine, Valsartan Dru | 2012 |
Change in high-sensitive cardiac troponin T on hypertensive treatment.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2013 |
Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.
Topics: Aged; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure Monitoring, Ambulatory; Dihy | 2012 |
Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Chan | 2012 |
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Black People; Blood Pressure; Chlorth | 2012 |
Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2012 |
Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agent | 2012 |
Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diure | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian People; Blood Pressure; Circa | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc | 2012 |
Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Double-Blind Method; Drug Therapy, C | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; F | 2012 |
Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Diastole; Double-Blind Method; Drug Th | 2012 |
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Confounding Factors, Epidemiologic; Coronary Artery D | 2012 |
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Adult; Aged; Aging; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Bloo | 2012 |
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressu | 2012 |
[Series: Clinical study from Japan and its reflections morning hypertension and angiotensin receptor blocker/hydrochlorothiazide combination therapy study--MAPPY study].
Topics: Aged; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 2012 |
Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Th | 2012 |
Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; China; Double-Blind Method; | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2012 |
Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2013 |
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydroch | 2012 |
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Topics: Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Female; Genetic Loci; Genetic Predi | 2012 |
[Effectiveness and safety of losartan and its combination with hydrochlorothiazide in patients with hypertension: in result study].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Diur | 2012 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-B | 2012 |
Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.
Topics: Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biological Availability; Blood Pressure; D | 2012 |
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca | 2013 |
Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial.
Topics: Cross-Over Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydrochlo | 2013 |
Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2012 |
Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2013 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; | 2014 |
Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; | 2002 |
A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essent
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pre | 2002 |
Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension.
Topics: Adult; Aged; Analysis of Variance; Black People; Blood Pressure Determination; Dose-Response Relatio | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
[Arterial hypertension in elderly individuals].
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; | 2002 |
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Dementia; Double-Blind Method; Drug Therapy | 2002 |
Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2002 |
Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diastole; Diuretics; Doubl | 2002 |
Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction.
Topics: Aged; Angiotensin II; Antihypertensive Agents; Aorta; Blood Pressure; Brachial Artery; Cross-Over St | 2002 |
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Blood Pressure; Diast | 2002 |
Different drug classes have variable effects on blood pressure depending on the time of day.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circ | 2003 |
[Comparison of the antihypertensive activity of fosinopril and irbesartan].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood P | 2002 |
[Antihypertensive treatment and prevention of dementia].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dementia; Diur | 1999 |
Effect of AT1 receptor blockade on endothelial function in essential hypertension.
Topics: Acetylcholine; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coho | 2003 |
Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects.
Topics: Angiotensin II; Antihypertensive Agents; Diuresis; Diuretics; Drug Synergism; Drug Therapy, Combinat | 2003 |
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopri | 2003 |
[Effectiveness of combined therapy at set doses in a cohort of hypertense patients not controlled by single therapy].
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Drug Therapy, Combination; Female; Humans; H | 2003 |
ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy.
Topics: Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Diuretics; Female; Genetic Mar | 2003 |
Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).
Topics: Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular D | 2003 |
[Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy, | 2003 |
Antihypertensive treatment and homocysteine concentrations.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular D | 2003 |
[Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Dose- | 2003 |
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2003 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2003 |
Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bone Density; Calcium; Enalapril; Female; Homeosta | 2003 |
Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 2003 |
Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Combinati | 2003 |
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment.
Topics: Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; | 2003 |
A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diuretics; Enalapril; Follow-Up Stud | 2003 |
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Topics: Antihypertensive Agents; Apolipoproteins; Atenolol; Blood Glucose; Blood Pressure; Drug Therapy, Com | 2003 |
Sexual activity in hypertensive men.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Coitus; Diuretics; Drug Therapy, Combination; Humans | 2003 |
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; | 2003 |
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2003 |
Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studie | 2003 |
A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Australia; Diuretics; Enalapril; | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
[Co-renitek treatment of patients with moderate and severe forms of hypertensive disease].
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2003 |
Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension.
Topics: Adult; Analysis of Variance; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiac Output; | 2003 |
Candesartan and hydrochlorothiazide in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Australia; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressu | 2003 |
A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; China; Double-Blind Method; Drug T | 2003 |
Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response | 2003 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2004 |
A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blocke | 2003 |
Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Drug Combinatio | 2003 |
Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cholesterol; Do | 2003 |
Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brazil; Double-Blind Method | 2003 |
Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Do | 2004 |
[Efficacy of losartan potassium and its combination with hydrochlorothiazide in hypertensive disease. Focus on the state of microcirculation].
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Forearm; Hemodynamics; Huma | 2003 |
Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2004 |
Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2004 |
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dihydropyridine | 2004 |
Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2004 |
Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 2004 |
Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults.
Topics: Aged; Angiotensins; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Compo | 2004 |
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Dihydrop | 2004 |
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, | 2004 |
Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood P | 2004 |
Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Blood Pressure Monito | 2004 |
Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Guidel | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Endotheliu | 2004 |
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chi-Square Distribution; Diabetes | 2004 |
Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Atenolol; Be | 2004 |
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Di | 2004 |
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents | 2004 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; C | 2004 |
Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydro | 2004 |
Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Diuretics; Drug Therapy, Co | 2004 |
Effects of nifedipine GITS and diuretics in isolated systolic hypertension--a subanalysis of the INSIGHT study.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocker | 2004 |
A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.
Topics: Adult; Aged; Chlorides; Cross-Over Studies; Diuretics; Double-Blind Method; Furosemide; Humans; Hydr | 2005 |
Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determinati | 2004 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Flow Velocity; Blood P | 2005 |
Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Flow Velocity; Blood P | 2005 |
Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Flow Velocity; Blood P | 2005 |
Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Flow Velocity; Blood P | 2005 |
The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch | 2004 |
The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.
Topics: Antihypertensive Agents; Creatinine; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; | 2005 |
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Human | 2005 |
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2005 |
Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Antihypertensive Agents; Antioxidants; C-Reactive Protein; Carba | 2005 |
Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Antihypertensive Agents; Double-Blind Met | 2005 |
Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug | 2005 |
Assessment of efficacy, safety and tolerability of fixed dose combination of telmisartan 40mg and hydrochlorothiazide 12.5mg in adult Indian patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2004 |
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, | 2005 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
[Comparison of noliprel and caposide efficacy in patients with arterial hypertension of high risk].
Topics: Antihypertensive Agents; Captopril; Cardiomegaly; Female; Heart Ventricles; Humans; Hydrochlorothiaz | 2005 |
Positive benefits of a pharmacist-managed hypertension clinic in Nigeria.
Topics: Aged; Amiloride; Antihypertensive Agents; Community Health Centers; Counseling; Diuretics; Drug Moni | 2005 |
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Topics: Adult; Cross-Over Studies; Diuretics; Double-Blind Method; Electrolytes; Female; Fibrinolysis; Hemod | 2005 |
[The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; China; Drug Combinations; Huma | 2005 |
Effects of hydrochlorothiazide and propranolol treatment on chylomicron metabolism in hypertensive objects.
Topics: Adult; Aged; Antihypertensive Agents; Cholesterol Esters; Chylomicrons; Female; Hemodynamics; Humans | 2005 |
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects.
Topics: Adult; Black or African American; Blood Glucose; Blood Pressure; Cholesterol; Diuretics; Female; Gen | 2005 |
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Black People; Blood Pressure; Calc | 2005 |
The effect of diuretics on red blood cell microrheological parameters in female hypertensive patients.
Topics: Blood Viscosity; Diuretics; Erythrocyte Aggregation; Erythrocytes; Female; Furosemide; Hematologic T | 2005 |
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri
Topics: Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochloro | 2005 |
The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensi | 2005 |
Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2005 |
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2005 |
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzo | 2005 |
[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Ch | 2005 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2005 |
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2005 |
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2006 |
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2006 |
[Comparative efficacy of fixed dose combinations of enalapril with hydrochlorothiazide and captopril with hydrochlorothiazide in patients with high risk hypertension].
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cos | 2005 |
[Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diuretics; Dose-Re | 2005 |
Clinical evaluation of moduretic in the treatment of arterial hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Diuretics; Drug Combinations; Female; Hospitals, Un | 1973 |
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blo | 2006 |
[Anxiodepressive and neuromediatory disorders in hypertensive patients. Effects of cypramil therapy].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Anxiety; Citalopram; | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Chlortha | 2006 |
Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Double-Blind Method; Drug | 2006 |
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
Topics: Antihypertensive Agents; Biphenyl Compounds; Black People; Blood Pressure; Drug Combinations; Female | 2006 |
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Compliance | 2006 |
Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2006 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Topics: Amiloride; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Fibrinolysis; Huma | 2006 |
The Republic of Georgia High Blood Pressure Control Program.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Education, Profession | 2006 |
Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure Determin | 2004 |
Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Double-Blind Method; Drug Therapy, Combin | 2006 |
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diastole; Diuretics; Double-Blind Method; Echocardiography, | 2006 |
Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Catalase; Diuretics; Drug The | 2006 |
Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure De | 2006 |
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzo | 2006 |
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2006 |
Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial.
Topics: Amlodipine; C-Reactive Protein; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Interl | 2006 |
[The effects of antidepressant treatment on efficacy of antihypertensive therapy in elderly hypertension].
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Bloo | 2006 |
[The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bisoprolol; Drug Combinations; Humans; Hydrochloro | 2006 |
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Topics: Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
Topics: Adult; Aged; Aged, 80 and over; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2007 |
Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bl | 2006 |
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double- | 2006 |
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doub | 2007 |
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Dose-Response Relationship, Drug | 2007 |
Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Drug Therapy, Combination; | 2007 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method | 2007 |
Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes.
Topics: Blood Vessels; Calcium Channel Blockers; Case-Control Studies; Dihydropyridines; Diuretics; Female; | 2006 |
Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; | 2007 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administr | 2007 |
Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Com | 2007 |
Impact of losartan on stroke risk in hypertensive patients in primary care.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dr | 2007 |
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; | 2007 |
[The FEVER (Felodipine EVEnt Reduction) trial; a randomised, double-blind, placebo-controlled trial in Chinese hypertensive patients].
Topics: Aged; Calcium Channel Blockers; China; Diuretics; Double-Blind Method; Felodipine; Female; Humans; H | 2007 |
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind | 2007 |
[Possibilities of using indices of vascular wall function as markers of negative metabolic effects of treatment with thiazide diuretics in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Endothelium, Vascular; Female; Humans; Hydroch | 2007 |
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug Therapy | 2007 |
Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Confidence Intervals; Coronary Artery Disease; Femal | 2007 |
Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Double-Bl | 2007 |
[Intensive blood pressure reduction in patients with increased cardiovascular risk with high-dose combination therapy of 160 mg valsartan plus 25 mg hydrochlorothiazide. Results of the MACHT II observational study].
Topics: Antihypertensive Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combina | 2007 |
Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diuretics; | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; | 2007 |
Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2007 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Topics: Aged; Aldosterone; Androstenes; Antihypertensive Agents; Area Under Curve; Biological Availability; | 2007 |
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; | 2007 |
Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Drug Therapy, Combination; Fema | 2007 |
Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biph | 2007 |
Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination.
Topics: Benzimidazoles; Biphenyl Compounds; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyperten | 2007 |
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Epidemiologic Methods; | 2008 |
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pres | 2008 |
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Diastole; Drug-Related Side Effec | 2007 |
[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients].
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydr | 2007 |
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2007 |
Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Diureti | 2007 |
Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlor | 2007 |
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2007 |
Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diureti | 2007 |
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2007 |
[Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China].
Topics: Adult; Aged; Antihypertensive Agents; China; Delayed-Action Preparations; Drug Therapy, Combination; | 2007 |
Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes Mellitu | 2008 |
Possible association of ACE gene I/D polymorphism with blood pressure--lowering response to hydrochlorothiazide.
Topics: Aged; Alleles; Antihypertensive Agents; Female; Genetic Predisposition to Disease; Genotype; Humans; | 2007 |
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; | 2008 |
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Topics: Administration, Oral; Adult; Amides; Antihypertensive Agents; Blood Pressure; Double-Blind Method; D | 2008 |
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2008 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2008 |
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2008 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Co | 2008 |
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination | 2008 |
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.
Topics: Adult; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon | 2008 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Diuretics; D | 2008 |
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Calcium; Cross-Over Studies; | 2008 |
Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diure | 2008 |
Endocrinologic effects of antihypertensive therapy with guanabenz or hydrochlorothiazide.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Endocrine System Diseases; Female; Glucag | 1984 |
Step-one antihypertensive therapy: a comparison of a centrally acting agent and a diuretic.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Diureti | 1984 |
Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method | 1984 |
Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension.
Topics: Adult; Black People; Blood Pressure; Dipeptides; Dopamine; Dose-Response Relationship, Drug; Double- | 1984 |
Left ventricular changes after chronic therapy with enalapril maleate in moderate to severe hypertensive patients.
Topics: Adult; Blood Pressure; Cardiomegaly; Chlorides; Creatinine; Diastole; Dipeptides; Double-Blind Metho | 1984 |
Long-term antihypertensive, metabolic and cellular effects of enalapril.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Enalapril; E | 1984 |
The efficacy and safety of enalapril in moderate to severe essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Clinical Trials as | 1984 |
Overall tolerance and safety of enalapril.
Topics: Captopril; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Com | 1984 |
A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Dih | 1984 |
A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Black or African American; Blood Pressure; Clinical Trials as Top | 1984 |
[Combination therapy of arterial hypertension].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Diuretics; | 1980 |
[Advantages of hypertension therapy with the once daily administration of a combination of beta-blocker and diuretic. Experiences with the self-measurement of blood pressure].
Topics: Blood Pressure Determination; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydro | 1981 |
[The advantage of hypertension therapy with a once-daily beta-blocker-diuretic combination].
Topics: Blood Pressure; Drug Administration Schedule; Drug Combinations; Female; Heart Rate; Humans; Hydroch | 1981 |
A controlled study of the antihypertensive effect of carteolol, a new beta-adrenergic receptor blocking drug, in combination with hydrochlorothiazide and amiloride.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Carteo | 1981 |
Seven years on a selective beta-blocker - metoprolol. A long-term study of women with arterial hypertension.
Topics: Adrenergic beta-Antagonists; Alprenolol; Clinical Trials as Topic; Drug Therapy, Combination; Female | 1981 |
[Intraindividual comparison between 1 tablet BM 02.004 and 1 tablet of torrat twice daily in the long-term treatment of hypertension].
Topics: Administration, Oral; Adult; Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertens | 1981 |
Comparison of the antihypertensive effect of metipranolol, butizide and torrat in Kenyan Africans.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Drug Combinatio | 1981 |
Diuretic or beta-blocker as first-line treatment for mild hypertension?
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Diuretics; Double-Blind Method; Humans; Hydro | 1982 |
Thiazide or beta-blocker for hypertension?
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Propranolo | 1983 |
The treatment of hypertension with indapamide alone or in combination with other drugs.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; | 1983 |
[Blood pressure during isometric and dynamic exercise under long-term antihypertensive treatment with beta receptor blockaders and diuretics].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Diuretics; E | 1983 |
Therapy of mild hypertension: an overview.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Cardiovascular D | 1984 |
[Therapeutic equivalent of a single and divided daily dose of 2 Tri-Torrat coated tablets].
Topics: Clinical Trials as Topic; Dihydralazine; Double-Blind Method; Drug Combinations; Female; Humans; Hyd | 1984 |
Single-agent and combination therapy of essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aldosterone; Blood Pressure; Diuretics; Drug Therapy | 1984 |
Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aldosterone; Blood Pressure; Drug Therapy, Combination; Female; | 1984 |
Veterans Administration cooperative study on nadolol as monotherapy and in combination with a diuretic.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Bendroflumethiazide; Clinical Trials as Topic; Diure | 1984 |
Time course of regression of left ventricular hypertrophy in treated hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Cardiomegaly; Clinical Trials as Topic; Drug Therapy, Combination; Echo | 1983 |
Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Drug Eruptions; Drug Therapy, Combination; Humans; | 1984 |
[Use of SQ 14225 in the treatment of essential arterial hypertension].
Topics: Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topi | 1981 |
Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Clini | 1982 |
A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Dipeptides; Enal | 1982 |
Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Epop | 1983 |
Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Dip | 1984 |
The renin-angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment-resistant hypertension.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Blo | 1984 |
An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension.
Topics: Adult; Antihypertensive Agents; Clinical Trials as Topic; Dipeptides; Drug Therapy, Combination; Ena | 1984 |
Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Volume; Body Fluids; Clinical Trials as Topic; Dipept | 1984 |
Double-blind study of guanabenz acetate in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Double-Blind Me | 1983 |
Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Exercise | 1983 |
Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1983 |
Controversies in hypertension: mild hypertension, isolated systolic hypertension, and the choice of a step one drug.
Topics: Adult; Aged; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; | 1983 |
A multiclinic double-blind comparison of timolol and hydrochlorothiazide alone and in combination in th e treatment of essential hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fem | 1983 |
Captopril, aldosterone and urinary kallikrein in primary hypertension.
Topics: Aldosterone; Angiotensin II; Captopril; Humans; Hydrochlorothiazide; Hypertension; Kallikreins; Prol | 1983 |
Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system.
Topics: Blood Pressure; Clinical Trials as Topic; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Mal | 1983 |
Use of angiotensin I to II converting enzyme inhibitor S.Q. 14225 (captopril), in moderate essential hypertension.
Topics: Adult; Captopril; Clinical Trials as Topic; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; | 1983 |
Clinical efficacy and safety of indapamide in essential hypertension.
Topics: Adult; Aged; Animals; Clinical Trials as Topic; Diuretics; Double-Blind Method; Electrolytes; Humans | 1983 |
Long-term experience with indapamide.
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Humans; Hydrochloroth | 1983 |
Multi-centre clinical investigation of indapamide in the United States: a review.
Topics: Antihypertensive Agents; Biological Availability; Clinical Trials as Topic; Diuretics; Drug Therapy, | 1983 |
Indapamide in the treatment of essential arterial hypertension: results of a controlled study.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Electrolytes; Femal | 1983 |
Indapamide versus hydrochlorothiazide in essential hypertension: measurement of peripheral resistance using plethysmography.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Epinephrine; | 1983 |
Indoramin as second step therapy in the management of benign essential hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothia | 1983 |
Mild hypertension.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Propranolo | 1983 |
Separation of essential hypertensive patients based on blood pressure responses after the withdrawal of antihypertensive agents by step-wise discriminant analysis.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Bl | 1983 |
Clinical hemodynamic profile of trimazosin in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Exercise Test; | 1983 |
United States experience with oxprenolol in hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hy | 1983 |
Clinical responses to oxprenolol in the elderly.
Topics: Aged; Aging; Clinical Trials as Topic; Drug Therapy, Combination; Drug Tolerance; Humans; Hydrochlor | 1983 |
Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Forced Expiratory Volume; Humans | 1983 |
Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Step II treatment with labetalol for essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; H | 1983 |
Hemodynamic effect of lofexidine with a diuretic in hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Clonidine; Drug Therapy, Combination; Epinephrine; | 1983 |
[Treatment of hypertensive patients with adelphan-esidrex].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; F | 1983 |
[Treatment of arterial hypertension with a combination of hydrochlorothiazide and hydrochloride amiloride].
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Humans; | 1983 |
The progress of patients in the European Working Party on Hypertension in the Elderly trial.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fema | 1983 |
Reversal by naloxone of the antihypertensive action of clonidine: involvement of the sympathetic nervous system.
Topics: Adult; Blood Pressure; Clonidine; Drug Therapy, Combination; Epinephrine; Heart Rate; Hemodynamics; | 1984 |
Comparison of the antihypertensive effect of a double dose of metoprolol versus the addition of hydrochlorothiazide to metoprolol.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Hea | 1983 |
Captopril or atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Synergism; Drug The | 1983 |
Hydrochlorothiazide and bendroflumethiazide in low doses--a comparative trial.
Topics: Adult; Aged; Bendroflumethiazide; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Bl | 1984 |
Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Half-Life; Humans; Hydrochlorothi | 1984 |
A double-blind multicentre study of piretanide and hydrochlorothiazide in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Human | 1984 |
Treatment of essential hypertension with beta-blocker plus diuretic: a study of 1402 patients treated by general practitioners with acebutolol 200 mg combined with hydrochlorothiazide 12.5 mg ('Secadrex') once daily for 3 months.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Dru | 1984 |
The effects of piretanide on catecholamine metabolism, plasma renin activity and serum aldosterone: a double-blind pilot comparison against hydrochlorothiazide in patients with essential hypertension.
Topics: Aged; Aldosterone; Blood Pressure; Catecholamines; Diuretics; Dopamine; Double-Blind Method; Female; | 1984 |
Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Hydrochlor | 1984 |
Clinical experience with rate-controlled delivery of antihypertensive therapy by a transdermal system.
Topics: Administration, Oral; Blood Pressure; Clinical Trials as Topic; Clonidine; Drug Therapy, Combination | 1984 |
[A combination of methyldopa, hydrochlorothiazide and amiloride in the treatment of essential hypertension].
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Creatinine; Drug Combinations; Fem | 1984 |
[Controlled clinical study on the effects of acebutolol in comparison with hydrochlorothiazide in the aged hypertensive].
Topics: Acebutolol; Aged; Blood Pressure; Clinical Trials as Topic; Heart Rate; Humans; Hydrochlorothiazide; | 1983 |
Captopril and oxprenolol in a fixed combination with thiazide diuretics: comparison of their antihypertensive efficacy and metabolic effects.
Topics: Adult; Blood Pressure; Captopril; Chlorthalidone; Cholesterol; Clinical Trials as Topic; Creatinine; | 1984 |
[Effect of different saluretics on carbohydrate metabolism and blood pressure behavior in diabetics].
Topics: Acetazolamide; Aged; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Chronic Disease; Clinic | 1984 |
A long-term follow-up of patients with essential hypertension treated with captopril.
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Female; Follow-Up Studies; Hemodynamics; Humans; H | 1984 |
Advantages of diuretics.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hyperten | 1984 |
A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure; Clinical Trials as Topic; Dose-Res | 1984 |
Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; | 1984 |
[Treatment of mild and moderate arterial hypertension with low doses of captopril].
Topics: Adult; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Female; Human | 1984 |
A randomized double-blind clinical trial of xipamid and hydrochlorothiazide in essential hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Humans; Hydrochlorothiazid | 1984 |
[Captopril in mild or moderate systemic arterial hypertension].
Topics: Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydr | 1984 |
Timolol and a hydrochlorothiazide-amiloride combination in the treatment of essential hypertension in young and middle-aged patients: a comparative study with once-daily administration.
Topics: Adult; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart | 1984 |
Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Drug | 1984 |
The efficacy and acceptability of the combination of acebutolol and hydrochlorothiazide in the treatment of essential hypertension.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Humans | 1984 |
[Efficacy and safety of captopril in low doses, alone or combined with diuretics, in the treatment of mild or moderate arterial hypertension].
Topics: Aged; Blood Pressure; Captopril; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Fem | 1984 |
[Efficacy and safety of low doses of captopril, alone or combined with diuretics in the treatment of mild or moderate hypertension].
Topics: Adult; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart | 1984 |
Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker.
Topics: Acebutolol; Adult; Body Weight; Chlorides; Clinical Trials as Topic; Dose-Response Relationship, Dru | 1983 |
Comparison of thiazides and amiloride in treatment of moderate hypertension.
Topics: Adult; Aged; Amiloride; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; H | 1983 |
Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Pressure; Drug Interactions; Female; Humans; Hydrochlor | 1984 |
Nonarrhythmogenicity of diuretic-induced hypokalemia. Its evidence in patients with uncomplicated hypertension.
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Hydrochlorothiazide; Hyperte | 1984 |
Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Drug Administration Schedule; Drug Combinations; Female; Hea | 1984 |
Efficacy and tolerance of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol, taken before or after food, in the treatment of hypertension.
Topics: Adult; Aged; Amiloride; Drug Combinations; Female; Food; Humans; Hydrochlorothiazide; Hypertension; | 1984 |
Effects of antihypertensive drugs on cognitive function in adolescents.
Topics: Adolescent; Antihypertensive Agents; Clonidine; Cognition; Female; Humans; Hydrochlorothiazide; Hype | 1984 |
Effect of pindolol on potassium homeostasis in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Drug Combinations; Female; Homeostasis; Humans; Hydrochlorothiazide; Hy | 1984 |
Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients.
Topics: Adult; Aged; Amiloride; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 1983 |
Indapamide in the stepped-care treatment of obese hypertensive patients.
Topics: Adult; Aged; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; | 1983 |
The influence of beta blockers on cardiovascular reactivity and Type A behavior pattern in hypertensives.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Heart Rate; Humans | 1983 |
Biochemical changes in black and Indian hypertensive patients on diuretic therapy.
Topics: Adult; Amiloride; Blood Glucose; Blood Pressure; Chlorthalidone; Creatinine; Diuretics; Drug Therapy | 1983 |
A comparison of timolol plus hydrochlorothiazide plus amiloride and methyldopa in essential hypertension in Black Africans.
Topics: Adult; Amiloride; Antihypertensive Agents; Black People; Drug Combinations; Female; Humans; Hydrochl | 1983 |
[The effect of beta receptor blockers and diuretics on blood pressure reactivity].
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochlor | 1983 |
Long term treatment with tienilic acid or thiazides: comparison of antihypertensive and metabolic effects.
Topics: Adult; Amiloride; Blood Pressure; Female; Glycolates; Humans; Hydrochlorothiazide; Hypertension; Liv | 1983 |
Serum cholesterol during treatment of hypertension with diuretic drugs.
Topics: Chlorthalidone; Cholesterol; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Male; Random Allo | 1984 |
Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Weight; Drug Therapy, Combination; Fasting; Huma | 1984 |
Hydrochlorothiazide/triamterene combination: once daily in the treatment of hypertension.
Topics: Adult; Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1984 |
Potassium sparing by amiloride during thiazide therapy in hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 1984 |
Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents.
Topics: Adult; Aged; Black People; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hy | 1982 |
Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Heart Rate; | 1982 |
Influence of anti-hypertensive therapy on serum cholesterol in elderly hypertensive patients. Results of trial by the European Working Party on High blood pressure in the Elderly (EWPHE).
Topics: Aged; Aging; Blood Pressure; Cholesterol; Clinical Trials as Topic; Europe; Female; Follow-Up Studie | 1982 |
[Double-blind controlled study of the therapeutic effectiveness and tolerance of the guabenxan-bemetizid combination as compared with guanethidine-hydrochlorothiazide in arterial hypertension in the aged].
Topics: Aged; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Combinations | 1982 |
Double-blind comparison of dihydralazine and prazosin in hypertensive patients on the diuretic-reserpine regimen.
Topics: Adult; Aged; Clinical Trials as Topic; Dihydralazine; Double-Blind Method; Female; Humans; Hydralazi | 1981 |
Comparative efficacy and safety of lofexidine and clonidine given alone or concomitantly with hydrochlorothiazide in hypertensive outpatients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Clonidine; Double-Bl | 1982 |
Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.
Topics: Blood; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hy | 1982 |
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Rate; Hum | 1982 |
Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.
Topics: Black People; Blood Pressure; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyp | 1982 |
Multicenter evaluation of mepindolol and of mepindolol plus hydrochlorothiazide in essential hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate; Humans; Hyd | 1982 |
Comparison of timolol/hydrochlorothiazide/amiloride ('Moducren') with cyclopenthiazide/potassium in mild to moderate hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Cyclopent | 1982 |
[Clinical study of a new hypotensive drug association].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyper | 1982 |
Effect of low dose diuretics on plasma and blood cell electrolytes, plasma uric acid and blood glucose.
Topics: Adult; Amiloride; Blood Glucose; Clinical Trials as Topic; Diuretics; Double-Blind Method; Electroly | 1982 |
[Controlled randomized double-blind study for the comparison of the treatment of patients with essential hypertension with homeopathic and with pharmacologically effective drugs].
Topics: Amiloride; Blood Pressure; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Combinatio | 1982 |
[Guanfacine in primary arterial hypertension: a long-term open clinical study].
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1982 |
[Average time prognosis of hypertension in qualitatively different treatment protocols].
Topics: Aged; Blood Pressure; Dihydralazine; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperte | 1980 |
Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol.
Topics: Adult; Aged; Aldosterone; Body Weight; Captopril; Clinical Trials as Topic; Drug Therapy, Combinatio | 1982 |
Long-term treatment of essential hypertension with Nadolol and Hydrochlorothiazide: a two-year follow-up.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Lon | 1982 |
The use of clonidine monotherapy in adolescent hypertension.
Topics: Adolescent; Adult; Blood Pressure; Clonidine; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; | 1983 |
R-wave amplitude change during aerobic exercise in hypertensive adolescents after treatment.
Topics: Adolescent; Adult; Aerobiosis; Blood Pressure; Clonidine; Electrocardiography; Exercise Test; Female | 1983 |
A general practice study of timolol/hydrochlorothiazide/amiloride ('Moducren'), a new therapy for hypertension, and the doctor's influence on management.
Topics: Adult; Aged; Amiloride; Blood Pressure; Drug Combinations; Family Practice; Female; Humans; Hydrochl | 1983 |
Response of thiazide-induced hypokalemia to amiloride.
Topics: Aldosterone; Amiloride; Bicarbonates; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypert | 1983 |
An evaluation of the effect on resting and exercise blood pressure of some first line treatments in hypertension.
Topics: Adult; Blood Pressure Determination; Drug Combinations; Exercise Test; Female; Humans; Hydrochloroth | 1983 |
The influence of physicians' instructions on the outcome of antihypertensive therapy.
Topics: Adult; Aged; Amiloride; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1983 |
Lofexidine, a new, antihypertensive imidazoline derivative. Clinical profile of action with single-drug treatment and in combination with hydrochlorothiazide.
Topics: Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Clonidine; Drug Combinations; Fema | 1982 |
Effect of moduretic and aldactone on electrolytes in skeletal muscle in patients on long-term diuretic therapy.
Topics: Cardiomyopathies; Humans; Hydrochlorothiazide; Hypertension; Magnesium; Muscles; Potassium; Spironol | 1982 |
Duration of antihypertensive effect of a single daily dose of hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; | 1980 |
Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders.
Topics: Adult; Aldosterone; Blood Volume; Body Weight; Diuresis; Hemodynamics; Humans; Hydrochlorothiazide; | 1980 |
Informed consent: how much does the patient understand?
Topics: Adult; Clinical Trials as Topic; Comprehension; Consent Forms; Double-Blind Method; Educational Meas | 1980 |
The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone.
Topics: Adult; Aged; Amiloride; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; | 1980 |
[Clinical trials with hypertensive patients in general practice].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertensi | 1980 |
Antihypertensive effect of guanfacine: a double-blind cross-over trial compared with clonidine.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To | 1980 |
Combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A multicentre trial.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Drug Evaluation | 1980 |
The treatment of mild to moderate essential hypertension with tienilic acid (ticrynafen).
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Glycolates; Heart Rate; Humans; Hydrochloroth | 1980 |
Evaluation of a fixed combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A long-term multicentre trial.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Diastole; Drug Combinations; Femal | 1980 |
Urinary zinc excretion during treatment with different diuretics.
Topics: Adult; Aged; Bendroflumethiazide; Bumetanide; Chlorthalidone; Clinical Trials as Topic; Diuretics; F | 1980 |
Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.
Topics: Adult; Blood Pressure; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Drug T | 1980 |
Timolol and hydrochlorothiazide-amiloride in primary hypertension.
Topics: Adult; Amiloride; Blood Pressure; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; F | 1980 |
Effect of tienilic acid and amiloride in healthy volunteers and in hypertensives with normal renal function.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Therap | 1980 |
Multiclinic evaluation of the antihypertensive effect of a methyldopa, hydrochlorothiazine, and amiloride combination.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinat | 1980 |
Clinical evaluation of the antihypertensive effect of metoprolol in combination with hydrochlorothiazide and hydralazine in an unselected hypertensive population.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cholesterol; Clinical Trials as Topic; Drug Therapy, | 1980 |
Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1981 |
Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hypertension. A controlled long-term study with reference to initial plasma renin activity.
Topics: Adult; Aldosterone; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinat | 1981 |
Effect of guanabenz and hydrochlorothiazide on blood pressure and plasma renin activity.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Female; Guanabenz; Guanidines; Humans; Hydro | 1981 |
Antihypertensive action of drug combination: Timolol, hydralazine, hydrochlorothiazide and triamterene.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydralazine | 1981 |
[Double-blind cross-over study of the anti-hypertensive effectiveness of mepindolol, hydrochlorothiazide and their combination].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyd | 1981 |
Timolol maleate and hydrochlorothiazide in control of essential hypertension: use of a fixed combination for once-a-day administration.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydro | 1981 |
Hypotensive effects of xipamide in essential hypertension. Crossover comparison with hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Electrolytes; Female; Humans; Hydr | 1981 |
Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.
Topics: Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertens | 1981 |
Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blin | 1981 |
The patient with mild to moderate essential hypertension: peripheral renin activity and a comparative drug study.
Topics: Adult; Age Factors; Blood Pressure; Chlorothiazide; Clinical Trials as Topic; Double-Blind Method; D | 1981 |
Antihypertensive and metabolic effects of a combination of hydrochlorothiazide and amiloride.
Topics: Adult; Aged; Amiloride; Blood Proteins; Blood Urea Nitrogen; Cholesterol; Clinical Trials as Topic; | 1981 |
[Comparative study between prazosin and methyldopa in essential arterial hypertension: results of a parallel, randomized double-blind trial].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamic | 1980 |
[Current state of the treatment of arterial hypertension].
Topics: Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Heart Failure; Humans; Hydralazine | 1980 |
Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up S | 1981 |
Antihypertensive effect and tolerability of two fixed combination of metoprolol and hydrochlorothiazide followed by a long-term tolerance study with one combination.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Combinations; Female; Follow-Up Studies; Hum | 1981 |
Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hyperten | 1981 |
Lofexidine and clonidine in moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Therapy, | 1981 |
Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Heart | 1981 |
Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension.
Topics: Adult; Blood Pressure; Captopril; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Ag | 1981 |
[Treatment of benign essential hypertension with an association of spironolactone and thiabutazide: an open multicenter study in general practice (author's transl)].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Fem | 1981 |
[Verapamil-hydrochlorothiazide vs. metoprolol-hydrochlorothiazide. Trial in hypertensive patients].
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertensio | 1981 |
Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension.
Topics: Acebutolol; Adult; Aldosterone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina | 1982 |
Hydrochlorothiazide and nadolol in the treatment of hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydroc | 1982 |
Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia.
Topics: Adult; Body Weight; Clinical Trials as Topic; Diuretics; Drug Combinations; Female; Furosemide; Huma | 1982 |
Evaluation of guanabenz added to hydrochlorothiazide therapy in hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Therap | 1982 |
Adverse reactions to pindolol administration.
Topics: Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hyperten | 1982 |
Responses to captopril and hydrochlorothiazide in black patients with hypertension.
Topics: Adult; Black People; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Femal | 1982 |
Methyldopa in the elderly hypertensive.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; | 1982 |
Potassium conservation with amiloride/hydrochlorothiazide ("Moduret') in thiazide-induced hypokalaemia in hypertension.
Topics: Amiloride; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; | 1982 |
A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fem | 1982 |
Antihypertensive effects of metoprolol and reserpine-hydrochlorothiazide.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hy | 1982 |
Pilot study of antihypertensive treatment in the elderly.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorot | 1982 |
Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide.
Topics: Acebutolol; Adult; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Female; Heart Rate; H | 1982 |
Do all diuretics have equal hypotensive efficacy?
Topics: Adult; Aged; Amiloride; Blood Pressure; Cyclopenthiazide; Diuretics; Drug Combinations; Female; Huma | 1982 |
Antihypertensive therapy in patients above age 60 with systolic hypertension. A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE).
Topics: Aged; Blood Glucose; Blood Pressure; Creatinine; Drug Therapy, Combination; Electrolytes; Female; Hu | 1982 |
Effectiveness of centrally acting drugs and diuretics in adolescent hypertension.
Topics: Adolescent; Blood Pressure; Clonidine; Double-Blind Method; Drug Evaluation; Female; Humans; Hydroch | 1982 |
Antihypertensive, saluretic and hypokalaemic effects of cyclothiazide in comparison with hydrochlorthiazide with amiloride supplement.
Topics: Adult; Amiloride; Antihypertensive Agents; Benzothiadiazines; Drug Therapy, Combination; Humans; Hyd | 1982 |
Effects of beta-blockers on type-A coronary-prone behaviour.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Humans; Hydrochlorothiazide; Hypertension; Ma | 1982 |
[The effect of hydrochlorothiazide/amiloride alone or in combination with alpha-methyldopa on serum lipoproteins].
Topics: Adult; Amiloride; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Lipi | 1981 |
Moderate sodium restriction and various diuretics in the treatment of hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diet, Sodium-Restricted; Diuretics; | 1981 |
Fixed combination of sotalol and hydrochlorothiazide in the treatment of uncomplicated hypertension.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hu | 1981 |
Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients.
Topics: Black People; Blood Glucose; Blood Pressure; Body Weight; Humans; Hydrochlorothiazide; Hypertension; | 1981 |
[Propranolol, triamteren and hydrochlorothiazide in fixed combinations in the treatment of hypertension (author's transl)].
Topics: Adolescent; Adult; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Heart Rate; Human | 1981 |
Antihypertensive effect of oral timolol maleate and hydrochlorothiazide once daily compared with hydrochlorothiazide once daily.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; | 1981 |
Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Furosemide; Heart Rate; | 1981 |
[Effects of metoprolol and a combination of metoprolol and hydrochlorothiazide on arterial tension values in hypertensive patients at rest and following exertion. Crossed double-blind study].
Topics: Adult; Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metoprolol; | 1981 |
[Hypertension treated with hydrochlorothiazide/amilorid and timolol maleate].
Topics: Adult; Amiloride; Blood Pressure; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazid | 1980 |
Reserpine, hydrochlorothiazide and pituitary-gonadal hormones in hypertensive patients.
Topics: Adult; Aged; Erectile Dysfunction; Gonadal Steroid Hormones; Humans; Hydrochlorothiazide; Hypertensi | 1980 |
Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial.
Topics: Adult; Chlorthalidone; Cholesterol; Cholesterol, Dietary; Double-Blind Method; Humans; Hydrochloroth | 1981 |
Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carotid Arteries; Di | 1995 |
[The effect of long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents on the quality of life in patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working
Topics: Adult; Antihypertensive Agents; Azerbaijan; Captopril; Humans; Hydrochlorothiazide; Hypertension; Ma | 1995 |
[Effectiveness and tolerance of combined verapamil retard and hydrochlorothiazide. Results of a double-blind, randomized study].
Topics: Adult; Aged; Antihypertensive Agents; Austria; Delayed-Action Preparations; Double-Blind Method; Fem | 1995 |
Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Doxazosi | 1993 |
Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes.
Topics: Analysis of Variance; Antihypertensive Agents; Cardiac Complexes, Premature; Diltiazem; Echocardiogr | 1994 |
Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; France; Humans; Hydro | 1993 |
Left ventricular mass, serum electrolyte levels and cardiac arrhythmias in patients with mild hypertension treated with cilazapril or hydrochlorothiazide.
Topics: Cardiac Complexes, Premature; Cilazapril; Double-Blind Method; Echocardiography; Electrocardiography | 1993 |
Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Dr | 1993 |
Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroch | 1994 |
Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. Investigator Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Female; Human | 1994 |
Double-blind comparison of the efficacy and safety of trandolapril 2 mg and hydrochlorothiazide 25 mg in patients with mild-to-moderate essential hypertension. Investigator Study Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Drug Therapy, Combina | 1994 |
Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Double-Blind Met | 1994 |
The efficacy and tolerability of enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistent to enalapril monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 1995 |
The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension.
Topics: Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Bendroflumethiazide; Diu | 1995 |
Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1995 |
Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
Topics: Aldosterone; Angiotensin II; Biphenyl Compounds; Blood Pressure; Creatinine; Drug Combinations; Fema | 1995 |
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diast | 1995 |
Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension.
Topics: Body Weight; Creatinine; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hypertensi | 1995 |
Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Delayed-Action Preparat | 1995 |
Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Bisoprolol; Blood Pressure; Double-Blind Method; Drug | 1995 |
The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.
Topics: Amlodipine; Blood Pressure; Drug Tolerance; Female; Heart Rate; Humans; Hydrochlorothiazide; Hyperte | 1995 |
[Comparison of the efficacy of enalapril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in mild-to-moderate arterial hypertension by ambulatory measurement of blood pressure].
Topics: Adult; Aged; Ambulatory Care; Blood Pressure Determination; Captopril; Double-Blind Method; Enalapri | 1995 |
Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.
Topics: Administration, Oral; Blood Glucose; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hydroc | 1995 |
[The long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents of patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working group of the Multicenter Captopr
Topics: Adult; Azerbaijan; Captopril; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1995 |
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressur | 1995 |
Antihypertensive treatment with felodipine but not with a diuretic reduces episodes of myocardial ischaemia in elderly patients with hypertension.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Felodipine; Female; Hemodyn | 1994 |
Efficacy and tolerability of 5 mg of cilazapril plus 12.5 mg of hydrochlorothiazide in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cilazap | 1994 |
Nail fold capillaroscopy and echocardiography in mild-to-moderate hypertension treated with cilazapril plus hydrochlorothiazide: first results.
Topics: Administration, Oral; Adult; Blood Flow Velocity; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1994 |
[Effects of antihypertensive treatment on carotid vascular changes].
Topics: Aged; Antihypertensive Agents; Blood Circulation; Blood Pressure; Calcium Channel Blockers; Carotid | 1994 |
Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Bod | 1994 |
Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cough; Double-Blind Method; Femal | 1994 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
[Good quality of life of older patients with hypertension. Equally good effect of felodipine and hydrochlorothiazide].
Topics: Aged; Double-Blind Method; Felodipine; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Qual | 1995 |
Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide.
Topics: Aged; Blood Pressure; Captopril; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydrochlor | 1995 |
First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension.
Topics: Aged; Bisoprolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hy | 1995 |
Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study.
Topics: Blood Pressure; Blood Pressure Determination; Double-Blind Method; Drug Therapy, Combination; Echoca | 1995 |
The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enalapril; Female; Glycated Hemo | 1995 |
[The antihypertensive effects of the lisinopril-hydrochlorothiazide combination (Zestoretic) in elderly hypertensive patients. The results of a multicenter study. The Italian Zestoretic Study Group].
Topics: Aged; Aged, 80 and over; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyp | 1994 |
Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. A double-blind placebo-controlled multicenter study of factorial design.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cilazapril; Dose-Response Relationship, Drug; Dou | 1994 |
Relationship between change in erythrocyte sodium and antihypertensive response to enalapril.
Topics: Adult; Enalapril; Erythrocytes; Humans; Hydrochlorothiazide; Hypertension; Male; Matched-Pair Analys | 1994 |
Efficacy and acceptability of perindopril in essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female | 1994 |
Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of benazepril 20 mg plus hydrochlorothiazide 25 mg fixed combination as compared to captopril 50 mg [corrected] plus hydrochlorothiazide 25 mg fixed combination in treating mild to mod
Topics: Administration, Oral; Adult; Analysis of Variance; Antihypertensive Agents; Benzazepines; Blood Pres | 1994 |
Fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension: evaluation by 24-hour non invasive ambulatory blood pressure monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Benzazepines; Blood Pressure Monitoring, Ambulatory; Circadian | 1994 |
One year experience of elderly hypertensive patients with isradipine therapy.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide | 1994 |
Long-term efficacy and safety of moexipril in the treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Bli | 1994 |
Review of studies on the clinical pharmacodynamics of cilazapril.
Topics: Administration, Oral; Aged; Angiotensin I; Blood Pressure; Captopril; Cardiac Output; Cilazapril; Cr | 1994 |
Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 1994 |
Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Female; | 1994 |
Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.
Topics: Blood Pressure; Diltiazem; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazi | 1994 |
Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method | 1994 |
Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cough; Double-Blind Method; Fema | 1994 |
Long-term metabolic effects of antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Glucose; Captopril; Cholesterol, H | 1994 |
[The effect of a low-dose hydrochlorothiazide therapy on the bone mineral content of the axial and peripheral skeleton].
Topics: Absorptiometry, Photon; Aged; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; | 1994 |
Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects.
Topics: Adolescent; Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1994 |
Efficacy and safety of rilmenidine in elderly patients--comparison with hydrochlorothiazide. The Belgian Multicentre Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Hydrochlorothia | 1994 |
Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Choles | 1994 |
Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidon | 1994 |
Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril Investigator Group.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug | 1994 |
A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
Topics: Bisoprolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochl | 1994 |
Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Apolipoproteins; Benzopyrans; Blood Pressure; Dose | 1994 |
[The effect of monotherapy with nifedipine and hydrochlorothiazide on the psychological characteristics and quality of life of hypertension patients].
Topics: Adult; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nifedipine; Psychological Tests | 1993 |
Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group.
Topics: Blood Pressure; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiaz | 1994 |
Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydr | 1993 |
Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial (PROTECT).
Topics: Adult; Antihypertensive Agents; Arteries; Clinical Protocols; Double-Blind Method; Europe; Female; H | 1993 |
Combination therapy versus monotherapy in hypertensive patients: an Italian multicentre study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; | 1993 |
Effect of perindopril and amiloride/hydrochlorothiazide on haemodynamics and vessel wall properties of large arteries.
Topics: Adult; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Arteries; Double-Blind Method; Female; H | 1993 |
Effects of fosinopril and hydrochlorothiazide on cerebral perfusion in uncomplicated essential hypertension.
Topics: Blood Pressure; Cerebrovascular Circulation; Double-Blind Method; Female; Fosinopril; Humans; Hydroc | 1993 |
Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzopyrans; Blood Pressure Monitors; Double-Blind | 1994 |
Evaluation of cilazapril versus captopril in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Captopril; Cilazapril; Drug Therapy, Combination; Female; Humans; Hydro | 1994 |
Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients.
Topics: Adult; Black People; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Enalapril; Ex | 1994 |
MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group.
Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi | 1994 |
Glucose and insulin levels during diuretic therapy in hypertensive men.
Topics: Adult; Aged; Blood Glucose; Chlorthalidone; Diuretics; Electrolytes; Humans; Hydrochlorothiazide; Hy | 1994 |
Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; | 1994 |
[Antihypertensive effectiveness of enalapril and hydrochlorothiazide as a combination drug].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Enalapril; Female; Humans; | 1993 |
Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension.
Topics: Adult; Aged; Brachial Artery; Carotid Arteries; Double-Blind Method; Felodipine; Female; Hemodynamic | 1993 |
Response of ambulatory blood pressure to antihypertensive therapy guided by clinic pressure.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Drug Therapy, Combination; | 1993 |
A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension.
Topics: Bisoprolol; Blood Pressure Monitors; Drug Combinations; Female; Hemodynamics; Humans; Hydrochlorothi | 1993 |
Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diastole; Double-Blind Method; Female; Humans; Hydro | 1993 |
[Systolic hypertension in the elderly: Chinese trial (Syst-China)--second interim report].
Topics: Captopril; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1993 |
Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Canada; Delayed-Action Preparations; Double-Blind Method; | 1993 |
MRC trial of treatment in elderly hypertensives.
Topics: Aged; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; H | 1993 |
Antihypertensive therapy in elderly patients with isolated systolic hypertension: third progress report of the Syst-Eur trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Diastole; Double-Blind | 1993 |
Beta-adrenergic responsiveness is regulated selectively in hypertension.
Topics: Adult; Blood Pressure; Diet, Sodium-Restricted; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1993 |
Glucose and lipid metabolism in essential hypertension: effects of diuretics and ACE-inhibitors.
Topics: Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Female; Humans; Hydrochlorothiazide; Hypert | 1993 |
Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Fosinopril; Humans; Hydrochloro | 1994 |
Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorothiazide; | 1994 |
Nitrendipine in older patients with isolated systolic hypertension: second progress report on the SYST-EUR trial.
Topics: Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Follow-Up S | 1993 |
The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide.
Topics: Adult; Analysis of Variance; Arterioles; Cardiac Output; Double-Blind Method; Enalapril; Hand; Hemod | 1993 |
Nicardipine or propranolol combined with hydrochlorothiazide in patients with essential hypertension.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hy | 1993 |
APTH--a trial on ambulatory blood pressure monitoring and treatment of hypertension: objectives and protocol.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitors; Dipeptid | 1993 |
Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; M | 1993 |
Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Platelets; Blood Pressure; Blood Viscos | 1993 |
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension--Part 2: An open long-term study of efficacy and safety.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperte | 1993 |
Carotid plaque associations among hypertensive patients.
Topics: Aged; Arteriosclerosis; Carotid Stenosis; Female; Georgia; Humans; Hydrochlorothiazide; Hypertension | 1993 |
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos | 1993 |
Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Dru | 1993 |
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Captopril; Cloni | 1993 |
[The effect of captopril, metoprolol and hydrochlorothiazide therapy in patients with non-insulin-dependent diabetes (NIDDM) and primary hypertension. A double-blind, randomized cross-over study].
Topics: Aged; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evaluation; Female; Humans; Hy | 1993 |
Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients.
Topics: Aged; Cognition; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; | 1993 |
Comparison of nifedipine and propranolol as second line agent for hypertension in black Kenyans.
Topics: Adult; Aged; Black People; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Humans; H | 1993 |
Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study.
Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi | 1993 |
Left ventricular end-diastolic dimensions measured at the P wave and Q wave during a randomized, double-blind one-year follow-up study comparing the effect of atenolol vs. hydrochlorothiazide + amiloride on blood pressure in men with mild to moderate hype
Topics: Adult; Amiloride; Atenolol; Diastole; Double-Blind Method; Drug Therapy, Combination; Echocardiograp | 1993 |
Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1993 |
Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women.
Topics: Adult; Aged; Black People; Blood Glucose; Cholesterol; Creatinine; Double-Blind Method; Female; Home | 1993 |
Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension.
Topics: Adolescent; Adult; Age Factors; Aged; Apolipoproteins; Captopril; Cholesterol; Dose-Response Relatio | 1993 |
Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Creatinine; Double-Blind Method; Female; Glomerular | 1993 |
SYST-EUR multicentre trial on the treatment of isolated systolic hypertension in the elderly: first interim report.
Topics: Aged; Aging; Blood Pressure; Circadian Rhythm; Cognition; Dementia, Vascular; Double-Blind Method; D | 1993 |
Different sensitivity to hydrochlorothiazide and to potassium-canrenoate among essential hypertensive patients.
Topics: Blood Pressure; Canrenoic Acid; Double-Blind Method; Drug Resistance; Female; Humans; Hydrochlorothi | 1993 |
A comparison of the efficacy of cilazapril versus cilazapril plus hydrochlorothiazide in patients with mild to moderate essential hypertension. Inhibace General Practice Study Group.
Topics: Adolescent; Adult; Aged; Cilazapril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 1993 |
[Double blind comparative randomized study of the efficacy of celiprolol versus amiloride-hydrochlorothiazide in mild to moderate AHT].
Topics: Adult; Amiloride; Celiprolol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroc | 1993 |
[Acute and chronic modification by cilazapril in comparison with hydrochlorothiazide on diastole heart function in hypertensive patients].
Topics: Aged; Cilazapril; Diastole; Double-Blind Method; Echocardiography; Female; Gated Blood-Pool Imaging; | 1993 |
[Changes in the left ventricular mass, wall tension and left atrial filling in long-term antihypertensive therapy. A comparative study with cilazapril and a thiazide diuretic].
Topics: Aged; Blood Pressure; Cardiac Volume; Cilazapril; Diastole; Double-Blind Method; Echocardiography; F | 1993 |
Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Press | 1995 |
Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 1996 |
[Comparison of metabolic and hemodynamic effects of hydrochlorothiazide in monotherapy and in association with lisinopril. An Italian multicenter study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Met | 1995 |
Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.
Topics: Antihypertensive Agents; Biphenyl Compounds; Double-Blind Method; Female; Humans; Hydrochlorothiazid | 1995 |
The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients.
Topics: Adult; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Arteries; Blood Pressure; Compliance; Di | 1995 |
[Efficacy and tolerability of the captopril and hydrochlorothiazide combination in the treatment of mild to moderate hypertension. Multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Captopril; Drug | 1995 |
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug | 1996 |
Losartan potassium as initial therapy in patients with severe hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Biphen | 1995 |
Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 1995 |
ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 1995 |
Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Body Mass Index; Cholesterol; Choles | 1995 |
The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Antihyperten | 1996 |
ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Flow Velocity; Blood | 1996 |
Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Diuretics; Drug Therapy, | 1996 |
Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hydro | 1996 |
[Glycemia increases during treatment of hypertension. 13 years' experience in the treatment of middle-aged men, randomized for treatment with beta blockers and diuretics].
Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Diuretics; Humans; Hydrochlorothiazide; | 1996 |
Antihypertensive drugs and glucose metabolism: a comparison between a diuretic and felodipine, a new calcium antagonist, when added to a beta-blocker in non-diabetic hypertensive women.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Drug The | 1994 |
Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1996 |
Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Cilazapril; D | 1996 |
Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Belgium; Blood Pressure; Double-Blind Method; Drug | 1996 |
A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population.
Topics: Aged; Amiloride; Antihypertensive Agents; Atenolol; Cognition Disorders; Dementia; Drug Combinations | 1996 |
Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind | 1996 |
Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Ag | 1995 |
Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cilazapril; Double-B | 1995 |
Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diuretics; Drug Interactions | 1995 |
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Asthenia; Biphenyl Compounds; Blood Pressure; Controlled Clinical Tr | 1996 |
'Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiography; Antihypertensive Agents; Atenolol; Drug Resistance | 1996 |
Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combination; | 1996 |
Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diur | 1996 |
Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Volume; Calcium Channel Bloc | 1996 |
Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters.
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; D | 1996 |
Correlations between subjective compliance, objective compliance, and factors determining compliance in geriatric hypertensive patients treated with triamterene and hydrochlorothiazide.
Topics: Age Factors; Aged; Aged, 80 and over; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; | 1996 |
Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood | 1996 |
Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Blood Pressure Monitoring, Ambul | 1995 |
Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; | 1996 |
Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Capt | 1996 |
Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension.
Topics: Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diureti | 1996 |
INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment.
Topics: Aged; Aged, 80 and over; Amiloride; Calcium Channel Blockers; Delayed-Action Preparations; Diuretics | 1996 |
Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension.
Topics: Aged; Alpha-Globulins; Angiotensin-Converting Enzyme Inhibitors; Blood Platelets; Diuretics; Double- | 1996 |
A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Delaye | 1996 |
Double-blind, parallel, comparative multicentre study of a new combination of diltiazem and hydrochlorothiazide with individual components in patients with mild or moderate hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 1996 |
Effect of hydrochlorothiazide therapy on cardiac arrhythmias in African-American men with systemic hypertension and moderate to severe left ventricular hypertrophy.
Topics: Black or African American; Diuretics; Echocardiography; Electrocardiography; Electrocardiography, Am | 1996 |
Monitoring antihypertensive therapy through blood pressure measurements taken casually, at rest, during exercise, and under outpatient conditions.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitors; Circadian Rhythm; Dose-Response Relationshi | 1996 |
An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Captopril; Double-Blind Method; Dr | 1995 |
The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood | 1996 |
Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cross-Ov | 1996 |
Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Creatinine; Cr | 1996 |
Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 1995 |
Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug | 1997 |
[Combination antihypertensive therapy in patients with an increased risk profile].
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 1996 |
Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combi | 1997 |
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1997 |
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1997 |
Effects of lisinopril or lisinopril/hydrochlorothiazide compared with adjusting of previous medication and intensifying non-pharmacological treatment in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Female; Health Education; Humans; Hydroch | 1997 |
Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhib | 1997 |
Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; D | 1997 |
Therapy in old patients with isolated systolic hypertension: fourth progress report on the Syst-Eur trial.
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Enalapril; Humans; Hy | 1997 |
The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 1997 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agent | 1997 |
Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monit | 1997 |
Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Fema | 1997 |
Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
Topics: Adult; Aged; Benzimidazoles; Calcium Channel Blockers; Diuretics; Double-Blind Method; Drug Therapy, | 1997 |
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; | 1997 |
Physical performance is preserved after regression of left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combin | 1997 |
The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diu | 1997 |
[The Multicenter Captopril and the Quality of Life Study: the effect of antihypertensive agents from the basic groups on the quality of life of patients in different populations. The working group of the Multicenter Captopril and the Quality of Life Study
Topics: Antihypertensive Agents; Azerbaijan; Captopril; Demography; Humans; Hydrochlorothiazide; Hypertensio | 1996 |
Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 1997 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive | 1997 |
Management of hypertension: the role of combination therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diab | 1997 |
[Fosinorm in the treatment of essential hypertension with a metabolic syndrome].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Diuretics; Drug | 1997 |
[The treatment of mild and moderate arterial hypertension with enalapril. A multicenter study of enap and enap-HL in Russia].
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretic | 1997 |
Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; E | 1997 |
Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1997 |
Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aorta; Blood Pressure; Cross-Over Studies; Dihydro | 1997 |
[The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 1998 |
Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Diastole; Diuretics; | 1998 |
[Results of the SYST-EUR study. Isolated systolic hypertension and calcium antagonists].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Double- | 1997 |
Treatment of diastolic dysfunction in hypertensive patients without left ventricular hypertrophy.
Topics: Adult; Aged; Amiloride; Anti-Arrhythmia Agents; Antihypertensive Agents; Diuretics; Drug Therapy, Co | 1998 |
The addition of a diuretic to anti-hypertensive therapy for early severe hypertension in pregnancy.
Topics: Adult; Amiloride; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Therapy, Combination; | 1998 |
Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study.
Topics: Adrenergic beta-Antagonists; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1997 |
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diur | 1998 |
[The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothi | 1998 |
Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens.
Topics: Adult; Amiloride; Antihypertensive Agents; Arteries; Buttocks; Calcium Channel Blockers; Diuretics; | 1998 |
Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; | 1998 |
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am | 1998 |
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Dose-Response Relation | 1998 |
Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Diuretics; Double-Blind Method; Drug Administr | 1998 |
A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Delayed-Action Preparation | 1997 |
Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dose-Response Relation | 1998 |
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Choleste | 1998 |
Divergent cardiac response to exercise in essential hypertension vs. normotension and the effect of enalapril.
Topics: Adult; Antihypertensive Agents; Cardiac Output; Cardiac Volume; Drug Therapy, Combination; Enalapril | 1998 |
Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Capillaries; | 1998 |
Calcium antagonists and thiazide diuretics have opposite effects on blood rheology and radial artery compliance in arterial hypertension: a randomized double-blind study.
Topics: Antihypertensive Agents; Blood Pressure; Blood Viscosity; Calcium Channel Blockers; Compliance; Diur | 1998 |
Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am | 1998 |
Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Topics: Area Under Curve; Blood Pressure; Cross-Over Studies; Diuretics; Double-Blind Method; Female; Heart | 1998 |
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Dru | 1998 |
Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Re | 1998 |
Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-Action Prepa | 1998 |
Effects of losartan on hypertension and left ventricular mass: a long-term study.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hype | 1998 |
Study of supplemental oral l-arginine in hypertensives treated with enalapril + hydrochlorothiazide.
Topics: Administration, Oral; Antihypertensive Agents; Arginine; Drug Therapy, Combination; Enalapril; Femal | 1998 |
Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diuretics; Double | 1998 |
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.
Topics: Aged; Aging; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug | 1998 |
Isradipine in prediabetic hypertensive subjects.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis | 1998 |
The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastol | 1998 |
Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Captopril; | 1998 |
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Dizziness; Dose-Response Relationship, Drug; Double- | 1998 |
Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Arm; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Br | 1999 |
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Demography; Drug Therapy, | 1998 |
Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks.
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Bisoprolol; Black People; Chi-Squar | 1999 |
Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.
Topics: Administration, Oral; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 1999 |
Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Captopri | 1999 |
[The additional efficacy of the nifedipine-diuretic combination depends on the potency of the drug administered first and not the sequence of administration. A double blind study in salt-sensitive black hypertensives].
Topics: Adult; Antihypertensive Agents; Black People; Calcium Channel Blockers; Cross-Over Studies; Diuretic | 1999 |
[Treatment of mild and moderate hypertension with enalapril (multicenter study of enap and enap N in Ukraine)].
Topics: Administration, Oral; Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; D | 1999 |
Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies.
Topics: Amlodipine; Bisoprolol; Double-Blind Method; Drug Therapy, Combination; Enalapril; Humans; Hydrochlo | 1998 |
Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Determination; Calcium Channel Bloc | 1999 |
Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension.
Topics: Aged; Antihypertensive Agents; Baroreflex; Blood Pressure; Double-Blind Method; Drug Therapy, Combin | 1999 |
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
Topics: Arteriosclerosis; Blood Glucose; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Artery D | 1997 |
Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Captopril; Double-Blind Method; Drug Therapy, Com | 1998 |
[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Drug Combinations; Female; Follow-Up Studies; Huma | 1998 |
[Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Captopril; Diuretics; Drug Combina | 1998 |
The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1999 |
Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Carb | 1999 |
Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am | 1999 |
Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cough; | 1999 |
Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1997 |
Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 1999 |
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Topics: Acrylates; Administration, Oral; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Enala | 1999 |
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Double-Blind Method; Drug Co | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug | 1999 |
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 1999 |
Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs.
Topics: Acetaminophen; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1999 |
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Double-Blind Method; D | 1999 |
Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diuretics; Female; Heart Rate; Huma | 1999 |
The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 1999 |
Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy, C | 1999 |
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Demography; Double-Blind Method; | 1999 |
Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Cognition; Diuretics; Double | 1999 |
[Antihypertensive efficacy, tolerance and safety of lisinopril (sinopril) and captopril (capoten) in patients with mild and moderate arterial hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diuretics; Drug Hypersensitivit | 1999 |
Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Asian People; Blood Pressure; Captopril; Cardiovasc | 2000 |
Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery.
Topics: Aged; Aging; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cogniti | 1999 |
Influence of a calcium antagonist on blood rheology and arterial compliance in hypertension: comparison with a thiazide diuretic.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Compliance; Cross-Sectional Studies; Diuretics; D | 1999 |
Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide--a randomized controlled trial.
Topics: Antihypertensive Agents; Blood Platelets; Blood Pressure; Diuretics; Double-Blind Method; Drug Thera | 2000 |
Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2000 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Apolipoproteins B; Blood Pressure; Cholesterol; Di | 2000 |
Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Cerebral perfusion in hypertensives with carotid artery stenosis: a comparative study of lacidipine and hydrochlorothiazide.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Carotid Stenosis; Cerebrovascular Circulation; Dihydr | 2000 |
The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure | 2000 |
Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Antihypertensive effect of low-dose hydrochlorothiazide alone or in combination with quinapril in black patients with mild to moderate hypertension.
Topics: Antihypertensive Agents; Black People; Blood Pressure; Drug Therapy, Combination; Echocardiography; | 2000 |
Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pres | 2000 |
Diuretic therapy in Afrocaribbeans with uncomplicated essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Caribbean Region; Cost-Benefit Analysis; Diu | 2000 |
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Calcium Channel Blockers; Chemistry, Ph | 2000 |
Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.
Topics: Aldosterone; Amlodipine; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2000 |
[The estimation of cardiovascular risk in hypertensive patients is not modified by management of the hypertension].
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Drug C | 2000 |
Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: comparison with enalapril. Tasosartan Study Group.
Topics: Analysis of Variance; Angiotensin II; Antihypertensive Agents; Blood Pressure; Double-Blind Method; | 2000 |
Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Blood Pressure Monitoring | 2000 |
Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimida | 2000 |
[Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study].
Topics: Aged; Amiloride; Blood Viscosity; Brain; Cognition Disorders; Dementia; Double-Blind Method; Drug Th | 2000 |
[Cognition disorders and dementia--new end-organ damage in hypertension].
Topics: Aged; Amiloride; Cognition Disorders; Dementia; Double-Blind Method; Felodipine; Humans; Hydrochloro | 2000 |
Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2000 |
Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2001 |
A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Humans; H | 2001 |
Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Benzim | 2001 |
Treatment of hypertension in the very old.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2000 |
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic.
Topics: Adult; Age Factors; Aldosterone; Alleles; Antihypertensive Agents; Blood Pressure; Diuretics; Female | 2001 |
[Capozide-50 alone and in combination with melatonin in therapy of hypertension].
Topics: Antioxidants; Blood Pressure; Captopril; Circadian Rhythm; Drug Administration Schedule; Drug Combin | 2000 |
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Ther | 2001 |
Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Topics: Aged; Antihypertensive Agents; Creatinine; Diabetes Complications; Double-Blind Method; Enalapril; E | 2001 |
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe | 2001 |
Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2001 |
Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2001 |
Cerebral perfusion in hypertensive patients: effects of lacidipine and hydrochlorothiazide.
Topics: Adult; Aged; Antihypertensive Agents; Carotid Stenosis; Cerebrovascular Circulation; Dihydropyridine | 2000 |
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weigh | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.
Topics: Aged; Amiloride; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Coronary Artery Disease; Di | 2001 |
Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arter | 2001 |
Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2001 |
Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Topics: Acrylates; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Canada; Diuretic | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Black People | 2001 |
Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans | 2001 |
Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension.
Topics: Antihypertensive Agents; Black or African American; Double-Blind Method; Drug Therapy, Combination; | 2001 |
A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2001 |
[Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind M | 2001 |
Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Clonidine; Diastole; Dilt | 2001 |
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressur | 2001 |
Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Canada; Dose-Respon | 2001 |
[Changes in blood rheological properties in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Blood; Blood Viscosity; Calcium Channel Blockers; Diuretics; Drug Thera | 2001 |
Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study.
Topics: Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double- | 2001 |
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihyper | 2002 |
Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Femal | 2001 |
[Effectiveness and tolerance of fosinopril in the treatment of arterial hypertension of mild and medium severity].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diuretics; Drug T | 2001 |
Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diuretics; Do | 2002 |
Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Body Mass Index; Calcium Cha | 2002 |
Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2002 |
Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT).
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Blood Pressure Determination; Blood Pre | 2002 |
Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Topics: Acrylates; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; | 2002 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive | 2001 |
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 2002 |
Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Bisoprolol; Blood Pressure; Child; Diuretics; Dose-Response | 2002 |
Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Captopril; Double-Bli | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Data Interpretation, Statistical; Dose-Response Rela | 2002 |
[The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide].
Topics: Adrenergic beta-Antagonists; Adult; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combina | 1976 |
Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1977 |
Treatment of arterial hypertension with tienilic acid, a new diuretic with uricosuric properties.
Topics: Adult; Blood Pressure; Blood Urea Nitrogen; Calcium; Clinical Trials as Topic; Diuretics; Double-Bli | 1978 |
Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bendroflumethiazide; Chlorthalidone; Diuretics; | 1979 |
Diuretics, beta-blockers or both as treatment for essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Blood Pressure; Drug Therapy, Combination; Fe | 1979 |
Tienilic acid in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1979 |
Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Blood Pressure Determination; Clinical Trials as | 1976 |
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Female; Follow-Up Studies; Glucose Tolerance Test; Hu | 1978 |
Beta-blockers and uric-acid excretion.
Topics: Amiloride; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Propanolamines; Pyr | 1978 |
Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.
Topics: Adult; Aged; Angiotensin I; Angiotensin II; Blood Pressure; Bradykinin; Captopril; Drug Synergism; F | 1979 |
HDL-cholesterol in antihypertensive treatment. The Oslo Study.
Topics: Adult; Antihypertensive Agents; Cholesterol; Humans; Hydrochlorothiazide; Hypertension; Lipoproteins | 1979 |
Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Clinical Trials as Topic; Humans; Hydrochlorothiazi | 1979 |
Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; B | 1979 |
Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Antihypertensive Agents; Cats; Clinical Trial | 1975 |
Results of a national therapeutic trial conducted in 10,000 hypertensive patients by 2000 general practitioners.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Drug Tolerance; Female; Heart Rate; Humans; Hydroch | 1978 |
Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; H | 1977 |
Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Diureti | 1977 |
Multiclinic controlled trial of bethanidine and guanethidine in severe hypertension.
Topics: Bethanidine; Clinical Trials as Topic; Guanethidine; Guanidines; Humans; Hydrochlorothiazide; Hypert | 1977 |
Propranolol in the treatment of essential hypertension.
Topics: Adolescent; Adult; Blood Pressure; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combinati | 1977 |
Effect of minoxidil on blood pressure and hemodynamics in severe hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Drug Therapy, Combinat | 1977 |
Diuretic therapies in low renin and normal renin essential hypertension.
Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Combinations | 1977 |
Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly.
Topics: Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Female; Humans; Hydrochloro | 1977 |
[Treatment of mild to moderate essential arterial hypertension with timolol alone and in combination with hydrochlorothiazide + amiloride. A multicenter, double-blind, cross-over study].
Topics: Amiloride; Clinical Trials as Topic; Creatinine; Double-Blind Method; Drug Evaluation; Drug Therapy, | 1977 |
[Double-blind study of the treatment of essential arterial hypertension with timolol and hydrochlorothiazide separately or in combination].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combina | 1977 |
Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1977 |
Antihypertensive effect and serum potassium homeostasis: comparison of hydrochlorothiazide and spironolactone alone and in combination.
Topics: Adult; Aged; Blood Urea Nitrogen; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combi | 1977 |
Ticrynafen: a novel uricosuric antihypertensive natriuretic agent.
Topics: Blood Pressure; Blood Urea Nitrogen; Blood Volume; Body Weight; Clinical Trials as Topic; Creatinine | 1978 |
Effect of timolol plus hydrochlorothiazide plus hydralazine on essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Humans; Hydr | 1978 |
Ticrynafen and hydrochlorothiazide in hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethacrynic Acid; Humans; Hydro | 1978 |
Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; C | 1978 |
[Therapy of severe hypertension with minoxidil, beta blockers and diuretics--long term results].
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination | 1977 |
A comparison between spironolactone and hydrochlorothiazide with and without alpha-methyldopa in the treatment of hypertension.
Topics: Adult; Angiotensin II; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1978 |
Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High blood pressure in Elderly (EWPHE).
Topics: Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Double-Blind Method; Europe | 1978 |
Antihypertensive drug combinations: prazosin, hydrochlorothiazide and clonidine.
Topics: Blood Pressure Determination; Clinical Trials as Topic; Clonidine; Drug Combinations; Drug Evaluatio | 1977 |
Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Furosemide; Humans; Hydrochlorothiazide; Hype | 1978 |
[Antihypertensive effect of a fixed beta-receptor blockader-diuretic combination during a single daily administration].
Topics: Adult; Amiloride; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hyperten | 1978 |
A double-blind comparison of the effects of hydrochlorothiazide and tienylic acid (a diuretic with uricosuric properties) in hypertension.
Topics: Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Body Weight; Carbon Dioxide; Chlorides; Clinical T | 1978 |
Hydrochlorothiazide and spironolactone in hypertension.
Topics: Adult; Aldosterone; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Cr | 1979 |
Pindolol: a potent beta-adrenergic blocking agent in the treatment of hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; | 1978 |
Prazosin in hypertension with and without methyldopa.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochl | 1979 |
Antihypertensive therapy in patients above age 60 years (Fourth Interim report of the European Working Party on High Blood pressure in Elderly: EWPHE).
Topics: Aged; Aging; Blood Glucose; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Doubl | 1978 |
Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Glyco | 1979 |
[Experiences with a new hypouricemic diuretic (tienilic acid): comparison with hydrochlorothiazide].
Topics: Adult; Clinical Trials as Topic; Diuretics; Female; Glycolates; Heart Arrest; Humans; Hydrochlorothi | 1978 |
Maintenance of potassium balance during diuretic therapy.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Drug Therapy, | 1979 |
Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Glycolates; Humans; Hydroc | 1979 |
Double-blind comparison of hydrochlorothiazide plus triameterene therapy versus chlorthalidone therapy in hypertension.
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-B | 1979 |
Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic.
Topics: Amiloride; Clinical Trials as Topic; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combina | 1979 |
Antihypertensive and hemodynamic effects of ticrynafen compared with hydrochlorothiazide.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Bl | 1979 |
Renal function during ticrynafen therapy.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hydrochlorothia | 1979 |
Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients.
Topics: Adult; Aged; Black or African American; Clinical Trials as Topic; Female; Furosemide; Humans; Hydroc | 1979 |
A double-blind comparison of a novel indanone diuretic (MK-196) with hydrochlorothiazide in the treatment of essential hypertension.
Topics: Adult; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide | 1979 |
A double-blind study of tienilic acid with two year follow-up of patients with mild to moderate essential hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Glycolates; Humans; Hydroch | 1979 |
Long-term usage of tienilic acid in essential hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Glycolates; Humans; Hydrochlorothiazide; Hyper | 1979 |
Safety of tienilic acid.
Topics: Clinical Trials as Topic; Glycolates; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Kidn | 1979 |
Double-blind assessment of tienilic acid in essential hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Glycolates | 1979 |
The hypouricaemic effect of tienilic acid: experience in patients with hyperuricaemia.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Drug A | 1979 |
Comparison of effectiveness of timolol administered once a day and twice a day in the control of blood pressure in essential hypertension.
Topics: Adult; Ambulatory Care; Amiloride; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Fe | 1979 |
Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension.
Topics: Adult; Aging; Amiloride; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Heart Rat | 1979 |
Multicentre comparative trial of tienilic acid and hydrochlorothiazide in hypertensive patients.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Glucose; Clinical Trials as Topic; Electrolytes; Fe | 1979 |
Nepresol in the treatment of hypertension of major severity.
Topics: Adult; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Drug Therapy, Comb | 1979 |
An evaluation of tienilic acid, a new diuretic uricosuric agent, in the therapy of arterial hypertension.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Cholesterol; Clinical Trials as Topic; Creat | 1979 |
Effects of antihypertensive therapy on cardiovascular response to exercise.
Topics: Adult; Blood Pressure; Diastole; Heart Rate; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension | 1979 |
Comparative effects of ticrynafen and hydrochlorothiazide on blood pressure, renal function, serum uric acid and electrolytes, and body fluid spaces in hypertensive man.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Fluid Compartments; Diuretics; Humans; Hydrochl | 1979 |
Double blind clinical study of tienilic acid and hydrochlorothiazide in primary arterial hypertension.
Topics: Adult; Aged; Blood Pressure; Diuretics; Double-Blind Method; Female; Glycolates; Humans; Hydrochloro | 1979 |
Role of renin classification for diuretic treatment of black hypertensive patients.
Topics: Adult; Aged; Black or African American; Blood Pressure; Female; Furosemide; Humans; Hydrochlorothiaz | 1979 |
[Tienilic acid in the treatment of arterial hypertension and congestive cardiac insufficiency].
Topics: Adult; Aged; Diuresis; Drug Evaluation; Female; Glycolates; Heart Failure; Humans; Hydrochlorothiazi | 1979 |
A simplified approach to the treatment of hypertension.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1977 |
[Whether treatment of hypertension in elderly patients is necessary: a European study (author's transl)].
Topics: Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Follow-Up Studies | 1978 |
[Haemiton compositum in the ambulatory therapy of hypertension].
Topics: Adult; Ambulatory Care; Aniline Compounds; Drug Combinations; Female; Humans; Hydrochlorothiazide; H | 1978 |
Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Glucose Tolerance Test; Humans; H | 1978 |
[Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].
Topics: Anxiety; Bradycardia; Dihydralazine; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydroch | 1978 |
Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine.
Topics: Body Weight; Clinical Trials as Topic; Drug Resistance; Evaluation Studies as Topic; Female; Guaneth | 1976 |
A comparison of debrisoquine and methyldopa in hypertension.
Topics: Adult; Clinical Trials as Topic; Debrisoquin; Female; Humans; Hydrochlorothiazide; Hypertension; Iso | 1976 |
Antihypertensive effects of oxprenolol and propranolol.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hydrochlorot | 1976 |
Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Depression, Chemical; Drug Therapy, Combination; Fe | 1976 |
[Potassium-saving saluretic treatment of hypertension and edematous heart decompensation with Moduretik].
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Drug Combinations; Edema, Cardiac; Female; Heart F | 1976 |
Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.
Topics: Clinical Trials as Topic; Dihydralazine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Syn | 1975 |
Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide.
Topics: Adult; Bicarbonates; Blood Pressure; Body Weight; Clinical Trials as Topic; Diuresis; Dose-Response | 1975 |
Comparison of metoprolol as hydrochlorothiazide and antihypertensive agents.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart | 1976 |
The use of timolol maleate alone and with diuretic in the treatment of essential hypertension.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Dru | 1976 |
Quantitative effects of timolol and hydrochlorothiazide on blood pressure, heart rate and plasma renin activity: results of a double-blind factorial trial in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart R | 1976 |
Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study.
Topics: Adult; Amiloride; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate; Humans; H | 1976 |
Antihypertensive drugs in combination: Effects of methyldopa on thiazide-induced changes in renal hemodynamics and plasma renin activity.
Topics: Adult; Blood Pressure; Chlorothiazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1975 |
A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensives.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1976 |
Comparison of guanethidine and methyldopa in essential hypertension: a controlled study.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Guanethidine; Humans; Hydrochlorothiazide; | 1975 |
The use of guanethidine and hydrochlorothiazide in the long-term treatment of essential hypertension.
Topics: Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gu | 1975 |
Moderate hypertension: treatment with guanethidine and methyldopa.
Topics: Adult; Body Weight; Clinical Trials as Topic; Drug Administration Schedule; Female; Guanethidine; Hu | 1975 |
Comparison of multiple and combination tablet drug therapy in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug C | 1975 |
Patient compliance for antihypertensive medication: the usefulness of urine assays.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; | 1976 |
Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety.
Topics: Double-Blind Method; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Mal | 1977 |
[Triamterene in the treatment of hypertension with hydrochlorothiazide and propranolol (author's transl)].
Topics: Acid-Base Equilibrium; Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; | 1977 |
Efficacy of an antihypertensive agent. Comparison of methyldopa and hydrochlorothiazide in combination and singly.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Drug Tolerance; Fe | 1975 |
Partial versus complete control of blood pressure in the prevention of hypertensive complications.
Topics: Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up St | 1975 |
Comparisons of once-daily nilvadipine with enalapril and diuretic in patients with essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug The | 1992 |
Comparative effects of nitrendipine and hydrochlorothiazide on calciotropic hormones and bone density in hypertensive patients.
Topics: Aged; Aged, 80 and over; Blood Pressure; Bone Density; Calcitonin; Calcium; Double-Blind Method; Fem | 1992 |
[Systolic hypertension in the elderly: Chinese trial (syst-China). Interim report].
Topics: Age Factors; Aged; Blood Pressure; Captopril; China; Female; Follow-Up Studies; Humans; Hydrochlorot | 1992 |
Metabolic effects of enalapril in the treatment of essential hypertension.
Topics: Adult; Aged; Drug Therapy, Combination; Enalapril; Female; Glucose Tolerance Test; Humans; Hydrochlo | 1992 |
A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance in essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Enalapril; Fe | 1992 |
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; | 1992 |
The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Pressure; Creatinine; Enalapril; Enalaprilat; F | 1992 |
Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Double-Blind Method; Drug Therapy, Combination; Fe | 1992 |
[Effect of hydrochlorothiazide on various components of the kinin system and plasma renin activity in patients with arterial hypertension treated with captopril].
Topics: Adult; Blood Pressure; Captopril; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroch | 1992 |
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system.
Topics: Blood Pressure; Cardiovascular System; Double-Blind Method; Electrocardiography; Enalaprilat; Hemody | 1992 |
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Echocardiography; Enalapril; Heart; Humans; Hydroc | 1992 |
Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study.
Topics: Aged; Aged, 80 and over; Amiloride; Atenolol; Double-Blind Method; Drug Therapy, Combination; Female | 1992 |
[Captopril in mild and moderate arterial hypertension resistant to diuretic therapy. A multicenter study].
Topics: Adolescent; Adult; Aged; Blood Pressure; Captopril; Drug Resistance; Drug Therapy, Combination; Fema | 1992 |
[An open comparative study of captopril + hydrochlorothiazide versus chlorthalidone for the treatment of mild and moderate primary hypertension].
Topics: Adolescent; Adult; Aged; Blood Pressure; Captopril; Chi-Square Distribution; Chlorthalidone; Drug Th | 1992 |
Aortic compliance in hypertension--effects of cilazapril and hydrochlorothiazide can be distinguished.
Topics: Aged; Aorta; Cilazapril; Compliance; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; | 1992 |
Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment.
Topics: Adult; Antihypertensive Agents; Arterioles; Child; Double-Blind Method; Echocardiography; Enalapril; | 1992 |
Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men.
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Cardiac Output; Drug Combinations; Heart Rate; Hemodynam | 1992 |
The circadian profile of extrasystolic arrhythmia: its relationship to heart rate and blood pressure.
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Blood Pressure; Blood Pressure Monitors; Cardiac Complexe | 1992 |
Syst-Eur--a multicenter trial on the treatment of isolated systolic hypertension in the elderly: first interim report.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Double- | 1992 |
MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group.
Topics: Antihypertensive Agents; Arteriosclerosis; Dihydropyridines; Double-Blind Method; Female; Humans; Hy | 1992 |
Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: randomized controlled trial versus hydrochlorothiazide.
Topics: Adult; Double-Blind Method; Female; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Kidney; | 1992 |
Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug | 1992 |
A "lipo-protective" effect of a fixed combination of captopril and hydrochlorothiazide in antihypertensive therapy.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Cho | 1992 |
The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Enalapril; Ethiopia; Female; Humans; Hydrochl | 1992 |
A comparative study of nicardipine and pindolol as second-line treatments in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; N | 1992 |
[The efficacy of nitrendipine in patients with stable arterial hypertension. The data from a cooperative study in the USSR. The Working Group for the Cooperative Study of Nitrendipine].
Topics: Adult; Chi-Square Distribution; Drug Tolerance; Humans; Hydrochlorothiazide; Hypertension; Lipids; M | 1992 |
Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitors; Double-Blin | 1992 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
Antihypertensive effects of low doses of hydrochlorothiazide in hypertensive black Zimbabweans.
Topics: Adult; Aged; Black People; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 1992 |
Effects of therapy on renal impairment in essential hypertension.
Topics: Adult; Aged; Amiloride; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtratio | 1992 |
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1--A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Tolerance; Female; Heart R | 1992 |
[SYST-EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report].
Topics: Aged; Aged, 80 and over; Blood Pressure; Drug Therapy, Combination; Enalapril; Europe; Female; Human | 1992 |
Trials in elderly patients with isolated systolic hypertension.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Enalapril; Humans; Hydrochlorothiazide; Hypert | 1992 |
Changes in left ventricular dimensions and systolic function in 100 mildly hypertensive men during one year's treatment with atenolol vs. hydrochlorothiazide and amiloride (Moduretic): a double-blind, randomized study.
Topics: Adult; Aged; Atenolol; Cardiomegaly; Double-Blind Method; Echocardiography; Humans; Hydrochlorothiaz | 1992 |
Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Gua | 1992 |
Are there differences in the blood-pressure-lowering effect of atenolol vs. hydrochlorothiazide + amiloride (Moduretic) when assessed by standard clinic recordings vs. 24-h ambulatory monitoring?
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Blood Pressure Determination; Double-Blind Method; Drug | 1992 |
Effect of phenylpropanolamine hydrochloride on blood pressure in Korean patients with hypertension controlled by hydrochlorothiazide.
Topics: Administration, Oral; Aged; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hydroch | 1992 |
Safety and efficacy of metoprolol in the treatment of hypertension in the elderly.
Topics: Age Factors; Aged; Blood Pressure; Clinical Protocols; Diastole; Drug Therapy, Combination; Female; | 1992 |
Efficacy and safety of quinapril in the elderly hypertensive patient.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Press | 1992 |
Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension.
Topics: Aged; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; | 1992 |
Lipid profile in 100 men with moderate hypertension treated for 1 year with atenolol or hydrochlorothiazide plus amiloride: a double-blind, randomized study.
Topics: Adult; Amiloride; Apoproteins; Atenolol; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyp | 1992 |
Ambulatory blood pressure monitoring for the assessment of nicardipine as a third drug in severe essential hypertension.
Topics: Adult; Aged; Ambulatory Care; Blood Pressure Determination; Capsules; Captopril; Delayed-Action Prep | 1992 |
Introduction to lisinopril-hydrochlorothiazide combination.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Drug Combinations; En | 1991 |
Lisinopril-hydrochlorothiazide combination vs lisinopril for the treatment of hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Drug Com | 1991 |
Controlling hypertension: lisinopril-hydrochlorothiazide vs captopril-hydrochlorothiazide. An Italian multicentre study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Combinations; Ena | 1991 |
Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Double-Blind Metho | 1991 |
The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Chromatography, High Pressure Liquid; Drug Combinat | 1991 |
The results of a large multicentre study comparing low-dose lisinopril-hydrochlorothiazide with the monocomponents.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Drug Com | 1991 |
The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Dru | 1991 |
Lisinopril-hydrochlorothiazide combination compared with the monocomponents in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Meth | 1991 |
A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhib | 1991 |
The treatment of moderate to severe hypertension with ACE inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug Therapy, Co | 1990 |
Felodipine is more effective than hydrochlorothiazide when added to a beta-blocker in treating elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Body Weight; Double-Blind Method; Drug Therapy, C | 1990 |
Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans.
Topics: Adult; Africa; Black People; Blood Pressure; Double-Blind Method; Felodipine; Female; Heart Rate; Hu | 1990 |
Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combination; | 1990 |
Efficacy and tolerance of sustained-release diltiazem 300 mg and a diuretic in the elderly.
Topics: Aged; Aging; Blood Pressure; Delayed-Action Preparations; Diltiazem; Drug Tolerance; Female; Heart R | 1990 |
The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group.
Topics: Adult; Aged; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Dihydropyridines; Double- | 1991 |
Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Catecholamines; Delayed-Action Preparations; Double-Blind | 1991 |
A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Humans; Hydroc | 1991 |
Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1991 |
Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Captopril; Double-Bli | 1991 |
Treatment of mild-to-moderate hypertension: comparison between a calcium-channel blocker and a potassium-sparing diuretic.
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Diltiazem; Diuretics; Double-Blind Method; Drug A | 1991 |
Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochloroth | 1991 |
A double-blind comparison of the efficacy and safety of lacidipine and hydrochlorothiazide in essential hypertension. The Southern Italy Lacidipine Study Group.
Topics: Administration, Oral; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Double-Blind Metho | 1991 |
Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Chlorthalidone; Double-Blind Method; Electrocardi | 1992 |
Antihypertensive and metabolic effects of single and combined atenolol regimens.
Topics: Atenolol; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug | 1992 |
Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Press | 1991 |
Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; | 1991 |
Captopril and hydrochlorthiazide--a safe antihypertensive for use in general practice?
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart R | 1991 |
[Fixed drug combination of ACE inhibitor plus diuretic. Results of an open multicenter study for the treatment of hypertension].
Topics: Adult; Blood Pressure; Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertensi | 1991 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
[Screening of single doses of the main antihypertensive drugs at rest and during various exercise tests in patients with hypertension].
Topics: Adult; Blood Pressure; Drug Evaluation; Exercise; Exercise Test; Humans; Hydrochlorothiazide; Hypert | 1991 |
[The results of the comparative study of nadolol, propranolol, prazosin and hydrochlorothiazide in patients with arterial hypertension in a 12-month stepped-plan treatment (cooperative research). The Working Group of the Cooperative Program to Study New P
Topics: Adult; Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nadolol; Prazos | 1991 |
The results of the comparative study of nadolol, propranolol, prazosin and hydrochlorothiazide in patients with arterial hypertension in a 12-month stepped-plan treatment (cooperative research). The Working Group of the Cooperative Program to Study New Pr
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1991 |
Comparative effects of converting enzyme inhibition and conventional therapy in hypertensive non-insulin dependent diabetics with normal renal function.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Drug T | 1991 |
The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients.
Topics: Black People; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Fe | 1991 |
[Mononuclear magnesium in elderly hypertensive patients treated with thiazide].
Topics: Aged; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Leukocytes, Mononuclear; Ma | 1991 |
Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Aged; Cardiomegaly; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Electro | 1991 |
MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data.
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Carotid Arteries; Diuretics; | 1991 |
Comparative evaluation of the effect of afterload- and preload-reducing drugs on diastolic cardiac function in hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilazapril; Double-Blind Method; Gated Blood-Pool Imaging; | 1991 |
Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Female; Fosino | 1991 |
Comparison of the effects on blood pressure and left ventricular hypertrophy of lacidipine and hydrochlorothiazide in hypertensive patients.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Dihydropyridines; Double-Blind Method; Heart | 1991 |
Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly.
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Hydro | 1991 |
[Value of isometric and dynamic exercise tests with standard drug doses for selecting long-term antihypertensive treatment with vasodilators, adrenergic beta blockaders and diuretics].
Topics: Adult; Exercise; Exercise Test; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nifedi | 1991 |
A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide.
Topics: Blood Pressure; Body Weight; Double-Blind Method; Female; Heart Rate; Humans; Hydrochlorothiazide; H | 1991 |
Once vs twice daily administration of a fixed combination of captopril plus hydrochlorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination.
Topics: Adult; Aged; Blood Pressure; Captopril; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1991 |
Ketanserin and hydrochlorothiazide in the treatment of arterial hypertension.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hyperten | 1991 |
Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Department of Veterans Affairs Cooperative Study Group on Ant
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Humans; Hydrochlorothiazide; Hypertension; | 1991 |
Long-term effect of nifedipine and hydrochlorothiazide on blood pressure and sodium homeostasis at varying levels of salt intake in mildly hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Female; Homeostasis; Humans; Hydrochlorothiazide; | 1991 |
Effects of hydrochlorothiazide, diltiazem and enalapril on mononuclear cell sodium and magnesium levels in systemic hypertension.
Topics: Aged; Diltiazem; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Leukocytes, Mononucle | 1991 |
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Choleste | 1990 |
Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Blood Pressure; Carbazoles; C | 1990 |
The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Clinical Trials as Topic; Diure | 1990 |
The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group.
Topics: Adrenergic beta-Antagonists; Adult; Ankle; Blood Pressure; Body Weight; Double-Blind Method; Drug Ad | 1990 |
Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population.
Topics: Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Cough; Cross-Sectional Studies; Humans; H | 1991 |
Captopril versus captopril plus hydrochlorothiazide for essential hypertension in Koreans.
Topics: Antihypertensive Agents; Captopril; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochl | 1991 |
Treatment of hypertension in the elderly: effects on blood pressure, heart rate, and physical fitness.
Topics: Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Captopril; Female; Heart Rate; Hemodynamic | 1991 |
Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly.
Topics: Aged; Depression; Double-Blind Method; Drug Therapy, Combination; Europe; Gout; Humans; Hydrochlorot | 1991 |
Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Aged; Creatinine; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Hydrochlor | 1991 |
The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Aged; Arthritis, Gouty; Blood Glucose; Cardiovascular Diseases; Cholesterol; Creatinine; Drug Therap | 1991 |
The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Black People; Blood Pressure; D | 1991 |
Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study.
Topics: Adult; Arteriosclerosis; Bendroflumethiazide; Death, Sudden; Diuretics; Follow-Up Studies; Humans; H | 1991 |
[Comparative study of enalapril, hydrochlorothiazide and their combination in the treatment of essential hypertension].
Topics: Adult; Aged; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension | 1991 |
[Captopril and hydrochlorothiazide for the treatment of arterial hypertension in the elderly].
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Captopril; Drug Therapy, Combination; Female | 1991 |
Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Double-Blind Metho | 1991 |
Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combina | 1991 |
Influence of diuretic therapy on the clonidine suppression test.
Topics: Adult; Amiloride; Clonidine; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazide; Hy | 1991 |
Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Diuretics; Double-Blind Method; Female; Humans; Hydrochlor | 1991 |
Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Humans; Hy | 1991 |
Well-being and its measurement in hypertension. A randomized, double-blind cross-over comparison of 5 mg clopamide with 25 mg hydrochlorothiazide. Hunter Hypertension Research Group.
Topics: Adult; Aged; Clopamide; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Qualit | 1991 |
A controlled study of the effects of aerobic exercise on antihypertensive drug requirements of essential hypertensive patients in the general practice setting.
Topics: Adolescent; Adult; Blood Pressure; Captopril; Exercise Therapy; Female; Humans; Hydrochlorothiazide; | 1991 |
The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Drug The | 1990 |
Concomitant considerations in long-term antihypertensive treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy | 1990 |
Clinical aspects of antihypertensive therapy with urapidil. Comparison with hydrochlorothiazide.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Tolerance; Female; Heart Rate; Hu | 1990 |
Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination | 1990 |
Symptoms and well-being during antihypertensive treatment with thiazide diuretics.
Topics: Aged; Blood Pressure; Diuretics; Double-Blind Method; Female; Health Status; Humans; Hydrochlorothia | 1990 |
Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Clopamide; Dihydroer | 1990 |
Effect of isradipine, a new calcium antagonist on the lipid profile in patients with hypertension.
Topics: Antihypertensive Agents; Apolipoproteins; Calcium Channel Blockers; Cholesterol; Double-Blind Method | 1990 |
Multicenter comparison of once- and twice-daily isradipine to hydrochlorothiazide for the treatment of hypertension in elderly patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administ | 1990 |
Comparative evaluation of the acute and chronic effects of cilazapril and hydrochlorothiazide on diastolic cardiac function in hypertensive patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cilazapril; Diastole; Double-Blind M | 1990 |
Comparison of long-term hemodynamic effects at rest and during exercise of lisinopril plus sodium restriction versus hydrochlorothiazide in essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Combined Modality Therapy; Diet, Sodium-Restricted; Enalap | 1990 |
Treating hypertension in the older person: an evaluation of the association of blood pressure level and its reduction with cognitive performance.
Topics: Aged; Amiloride; Blood Pressure; Cognition; Cohort Studies; Female; Follow-Up Studies; Humans; Hydro | 1990 |
Is a high serum cholesterol level associated with longer survival in elderly hypertensives?
Topics: Aged; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 1990 |
Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100 mg and hydrochlorothiazide (HCT) 12.5 mg in comparison with the fixed combination of metoprolol and HCT.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combina | 1990 |
Treatment of hypertension by enalapril and hydrochlorothiazide separately and together: a multicenter study.
Topics: Adult; Aged; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Human | 1990 |
Comparison of effects of nitrendipine versus hydrochlorothiazide on left ventricular structure and function and neurohumoral status in systemic hypertension.
Topics: Aged; Blood Pressure; Double-Blind Method; Echocardiography; Female; Heart; Humans; Hydrochlorothiaz | 1990 |
Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study.
Topics: Blood Pressure; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Enalapril; Female; | 1990 |
[Captopril in single doses in the treatment mild-moderated arterial hypertension].
Topics: Adult; Aged; Captopril; Clinical Protocols; Diastole; Drug Evaluation; Drug Therapy, Combination; Hu | 1990 |
[Role of a beta adrenergic blocking agent nadolol (corgard) in prevention of arterial hypertension: a 6-month treatment (cooperative study)].
Topics: Adult; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Mult | 1990 |
Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison.
Topics: Adolescent; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Enalapril; | 1990 |
[Effect of adrenergic beta receptor blockaders and thiazide diuretics on gastric acid and gastrin secretion in patients with essential hypertension].
Topics: Adult; Antacids; Depression, Chemical; Female; Gastric Acid; Gastrins; Humans; Hydrochlorothiazide; | 1990 |
Longitudinal chronobiologic blood pressure monitoring for assessing the need and timing of antihypertensive treatment.
Topics: Antihypertensive Agents; Blood Pressure; Chronobiology Phenomena; Circadian Rhythm; Drug Administrat | 1990 |
Hypertension in the elderly: a study of a combination of atenolol, hydrochlorothiazide and amiloride hydrochloride.
Topics: Aged; Amiloride; Atenolol; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 1990 |
The antihypertensive efficacy of hydrochlorothiazide is not prostacyclin dependent.
Topics: Adult; Aged; Blood Pressure; Body Weight; Double-Blind Method; Epoprostenol; Female; Humans; Hydroch | 1990 |
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril.
Topics: Analysis of Variance; Atenolol; Blood Pressure; Cognition; Depression; Diuretics; Double-Blind Metho | 1990 |
[Comparative study of the hypotensive action of monotherapy using hydrochlorothiazide and its combination with triamterene and amiloride and their effect on hemodynamics at rest and during exercise therapy].
Topics: Amiloride; Drug Therapy, Combination; Exercise; Exercise Test; Hemodynamics; Humans; Hydrochlorothia | 1990 |
[Therapy of moderate hypertension with the calcium antagonist nitrendipine in combination with beta receptor blocker or diuretic].
Topics: Acebutolol; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 1990 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide | 1990 |
Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Doub | 1990 |
Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1990 |
Long-term effects of pindolol and a thiazide diuretic on plasma lipids and blood pressure in patients with essential hypertension.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1990 |
Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins.
Topics: Cholesterol; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Met | 1990 |
Effect of hydrochlorothiazide 25 mg/day on essential hypertension.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; | 1990 |
Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Double-Blind Method; Felodipine; Female; Glucose Tolerance T | 1990 |
Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study.
Topics: Aged; Aging; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Administration Schedule; Drug | 1990 |
Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study.
Topics: Activities of Daily Living; Affect; Aged; Antihypertensive Agents; Behavior; Cognition; Drug Therapy | 1990 |
Efficacy and safety of combinations of nitrendipine, atenolol, and hydrochlorothiazide in black hypertensive patients.
Topics: Atenolol; Black People; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension | 1990 |
Interaction of enalapril with sodium restriction, diuretics, and slow-channel calcium-blocking drugs.
Topics: Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Drug Interactions; Drug Synergis | 1990 |
Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Female; Heart Rate; Humans; Hydrochlorothiazide; | 1990 |
A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide.
Topics: Adult; Aged; Antihypertensive Agents; Biological Availability; Blood Pressure; Drug Combinations; Fe | 1990 |
Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Double-Blind | 1990 |
An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy.
Topics: Adult; Analysis of Variance; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Drug Thera | 1990 |
Comparison of the effect of indoramin and prazosin on blood pressure and lipid profiles in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Human | 1986 |
Antihypertensive effects of indoramin and prazosin in combination with hydrochlorothiazide.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Heart Rate | 1986 |
A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Therap | 1986 |
Antihypertensive therapy with indoramin in the elderly.
Topics: Age Factors; Aged; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Comb | 1986 |
Endocrine and vascular responses in hypertensive patients to long-term treatment with diltiazem.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Body Weight; Diltiazem; Dinoprostone; Endocrine Glands; | 1987 |
Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical T | 1987 |
Antihypertensive efficacy of the combination of ketanserin + thiazide in hypertensives older than 50 years.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Dizziness; Drug Therapy, Combination; Female; Humans | 1987 |
Comparative antihypertensive effects of ketanserin and a ketanserin-hydrochlorothiazide combination administered once daily.
Topics: Blood Pressure; Drug Therapy, Combination; Erectile Dysfunction; Fatigue; Heart Rate; Humans; Hydroc | 1987 |
Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension.
Topics: Cardiac Complexes, Premature; Cardiomegaly; Clinical Trials as Topic; Electrocardiography; Humans; H | 1988 |
Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertens | 1987 |
Long-term open evaluation of amlodipine versus hydrochlorothiazide in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hydro | 1988 |
Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as To | 1988 |
Prolonged calcium channel blocker therapy of hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hy | 1988 |
Antihypertensive therapy with nitrendipine: comparison with hydrochlorothiazide and propranolol.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hydrochl | 1988 |
Effects of nitrendipine and hydrochlorothiazide on postprandial blood pressure reduction and carbohydrate metabolism in hypertensive patients over 70 years of age.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Metho | 1988 |
Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone.
Topics: Angiotensinogen; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Humans; H | 1989 |
Moderate sodium restriction, angiotensin converting enzyme inhibition, and thiazide diuretic in the management of essential hypertension.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Diet, So | 1989 |
An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure | 1989 |
The effect of potassium and potassium plus magnesium supplementation on ventricular extrasystoles in mild hypertensives treated with hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Cardiac Complexes, Premature; Double-Blind Method; Drug Therapy, Combin | 1989 |
Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension.
Topics: Blood Pressure; Cardiac Complexes, Premature; Catecholamines; Double-Blind Method; Electrocardiograp | 1989 |
Enalapril and hydrochlorothiazide as antihypertensive agents in the elderly.
Topics: Aged; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1987 |
Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Body Weight; Double-Blind Method; Female; Heart Rate; Humans | 1989 |
[Perindopril: first-line treatment of arterial hypertension].
Topics: Adolescent; Adult; Aged; Amiloride; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials as | 1989 |
Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 1989 |
[Multicenter, double-blind study comparing rilmenidine 1 mg and hydrochlorothiazide 25 mg in 244 patients].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Fe | 1989 |
Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Therapy | 1989 |
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Clinical Trials as Topic | 1989 |
[Efficacy and tolerability of captopril-hydrochlorothiazide vs amiloride-hydrochlorothiazide combination in mild to moderate arterial hypertension].
Topics: Aged; Amiloride; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination | 1989 |
Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide.
Topics: Alanine Transaminase; Amlodipine; Aspartate Aminotransferases; Calcium Channel Blockers; Cholesterol | 1989 |
Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cilazapril; Double-Blind Method; Dr | 1989 |
Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Sched | 1989 |
Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Multicentre Study Group.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cilazapril; Femal | 1989 |
Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cilazapril; Drug Combinations; Female; Humans; Hydro | 1989 |
Diuretic therapy and exercise in patients with systemic hypertension.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Catecholamines; Combined Modality Therapy; Double-Blind Method; | 1989 |
Enalapril and hydrochlorothiazide in hypertensive Africans.
Topics: Adult; Age Factors; Aged; Black People; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorot | 1989 |
A randomised double blind comparison of enalapril versus hydrochlorothiazide in elderly hypertensives.
Topics: Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Enalapril; Humans; Hydrochlorothiazide | 1989 |
ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; D | 1989 |
[Modification of blood coagulation by antihypertensive therapy? Effect of enalapril and hydrochlorothiazide on blood coagulation parameters in patients with essential hypertension].
Topics: Adult; Aged; Aged, 80 and over; Blood Coagulation Tests; Enalapril; Humans; Hydrochlorothiazide; Hyp | 1989 |
[24-hour blood pressure behavior in patients with untreated and treated hypertension in comparison with normotensive patients].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Drug Ther | 1989 |
[Regression of left heart hypertrophy in hypertensive patients as a result of antihypertensive therapy].
Topics: Acebutolol; Adult; Antihypertensive Agents; Atenolol; Cardiac Output; Cardiac Volume; Cardiomegaly; | 1989 |
Bevantolol attenuates thiazide stimulated renin secretion and catecholamine release in diuretic resistant hypertensives.
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Adult; Catecholamines; Drug Therapy, Combination; Femal | 1989 |
Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Cholesterol; Coronary Disease; Double-B | 1989 |
The safety of amlodipine.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; D | 1989 |
Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.
Topics: Black People; Blood Glucose; Blood Pressure; Captopril; Cholesterol; Drug Therapy, Combination; Fema | 1985 |
Captopril and hydrochlorothiazide in the fixed combination multicenter trial.
Topics: Adult; Blood Pressure; Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertensi | 1985 |
Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects metabolic values and intracellular electrolytes.
Topics: Adult; Aged; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Female; Heart | 1985 |
Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine.
Topics: Blood Pressure; Body Weight; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hype | 1985 |
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Captopril | 1985 |
Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide.
Topics: Adult; Aged; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Magnesium; Middle Aged; Patient | 1989 |
Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine.
Topics: Aged; Blood Chemical Analysis; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female | 1989 |
Efficacy and safety of triamterene/hydrochlorothiazide combinations in mild systemic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combina | 1989 |
Initial antihypertensive drug therapy--a comparison of alpha-blocker (prazosin) and diuretic (hydrochlorothiazide). Brief summary of a randomized, controlled trial.
Topics: Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; | 1989 |
Selective alpha-blockade versus angiotensin-converting enzyme inhibition as initial antihypertensive therapy. Effects on circulating lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Captopril; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combinati | 1989 |
Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients.
Topics: Adult; Aged; Black People; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydrochlorothia | 1989 |
Definition of the effective dose of the converting-enzyme inhibitor benazepril.
Topics: Benzazepines; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Bli | 1989 |
Effects of reduction in drugs or dosage after long-term control of systemic hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Clonidine; Drug Administration Schedule; Follow-U | 1989 |
The effect of chronic antihypertensive therapy on the index of left ventricular mass in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Cardiac Volume; Clinical Trials as Topic; Echocardiography | 1989 |
Nicardipine and hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Heart | 1989 |
Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Captopril; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hy | 1989 |
Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weigh | 1989 |
Does hormone analysis predict the antihypertensive response of basic medical treatment?
Topics: Adolescent; Adult; Aldosterone; Clinical Trials as Topic; Dinoprost; Dinoprostone; Female; Humans; H | 1989 |
A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the General Practitioner Hypertension Study Group.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Hum | 1989 |
Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Drug Administratio | 1989 |
A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.
Topics: Blood Glucose; Blood Pressure; Captopril; Double-Blind Method; Female; Heart Rate; Humans; Hydrochlo | 1989 |
Comparison of two combined diuretics in the treatment of essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Clinical Trials as Topic; Diuretics; Double-Blind Method; | 1989 |
[Treatment of hypertension with hydrochlorothiazide and pindolol--good for the lipid pattern].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Ma | 1989 |
[Assessment of tolerability and antihypertensive efficacy of aceplus mite (captopril (CPT) 50 mg + hydrochlorothiazide (HCTZ) 15 mg): a double-blind study vs. HCTZ in diabetic hypertensive patients. A report on three treatments].
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Diabetes Complications; Double-Blind Method; Drug | 1989 |
[Evaluation of the efficacy and tolerability of a fixed dose combination of captopril (CPT) 50 mg and hydrochlorothiazide (HCTZ) 15 mg in the elderly].
Topics: Aged; Aged, 80 and over; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 1989 |
[Hypotensive effect of hydrochlorothiazide and its combination with triamterene].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Humans; Hydroc | 1989 |
Hypertension in diabetes: effect of indapamide on glucose tolerance in diabetic hypertensive patients.
Topics: Clinical Trials as Topic; Diabetes Complications; Diuretics; Double-Blind Method; Humans; Hydrochlor | 1989 |
Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therap | 1989 |
Influence of zofenopril and low doses of hydrochlorothiazide on plasma lipoproteins in patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins; Captopril; Doubl | 1989 |
Results of clinical trials regarding the efficacy of treating hypertension.
Topics: Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Stud | 1989 |
[Treatment of mild and moderate hypertension with the use of captopril alone or combined with hydrochlorothiazide. A multicenter study].
Topics: Adolescent; Adult; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; F | 1989 |
[Efficacy of captopril in the treatment of mild and moderate hypertension in patients over 60 years of age].
Topics: Aged; Aged, 80 and over; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combinat | 1989 |
Antihypertensive efficacy and influence on physical activity of three different treatments in elderly hypertensive patients.
Topics: Aged; Amiloride; Antihypertensive Agents; Captopril; Drug Evaluation; Drug Therapy, Combination; Dru | 1989 |
[Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Atenolol; Blood Pressure; Drug Therapy, Combination; Fema | 1989 |
Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product.
Topics: Adolescent; Adult; Aged; Blood Pressure; Chromatography, High Pressure Liquid; Drug Combinations; El | 1989 |
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Guanidines | 1989 |
[Hemodynamic effects of hydrochlorothiazide, propranolol and a combination of pindolol and clopamide in patients with essential hypertension].
Topics: Clopamide; Drug Combinations; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Pindolol; Pro | 1989 |
Effort blood pressure control in the course of antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Exercise Test; Female; Humans; | 1989 |
The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide.
Topics: Adult; Aged; Blood Pressure; Dinoprostone; Double-Blind Method; Drug Administration Schedule; Electr | 1989 |
A single-blind, randomized, cross-over study of angiotensin-converting enzyme inhibitor and triamterene and hydrochlorothiazide in the treatment of mild to moderate hypertension in the elderly.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Clinical Trials as Topic; | 1987 |
[Definition and consequences of blocking the renin-angiotensin system by converting enzyme inhibition].
Topics: Adult; Aged; Aldosterone; Blood Pressure; Drug Administration Schedule; Enalapril; Female; Humans; H | 1987 |
[Enalapril, atenolol and hydrochlorothiazide in mild or moderate hypertension. A comparative multicenter trial in general practice in Norway].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Enala | 1987 |
Comparison of enalapril and thiazide diuretics in the elderly hypertensive patient.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Evaluation; Enalapril; Female; Humans; Hydrochlor | 1987 |
Combined action of enalapril or timolol with hydrochlorothiazide plus amiloride in hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination | 1987 |
Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions.
Topics: Angiotensin II; Atenolol; Atrial Natriuretic Factor; Double-Blind Method; Drug Therapy, Combination; | 1987 |
Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1988 |
Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1988 |
Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1987 |
Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Dou | 1988 |
Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Enalapril; Humans; Hydrochlorothiazide; Hyperte | 1988 |
Lisinopril in essential hypertension: a six month comparative study with nifedipine.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blin | 1987 |
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide.
Topics: Adult; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enalapril; Female; Humans; Hy | 1985 |
Modifications of intra- and extracellular sodium and potassium. A possible mechanism for the antihypertensive action of captopril and hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; H | 1985 |
Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Drug Thera | 1985 |
Comparison of acebutolol and hydrochlorothiazide in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Double-Blind Method; Female; Humans; Hydrochlo | 1985 |
Effects of age and race on clinical response to acebutolol in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Black People; Clinical Trials as | 1985 |
Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group.
Topics: Administration, Oral; Adult; Aged; Aging; Analysis of Variance; Blood Pressure; Clinical Trials as T | 1985 |
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Actuarial Analysis; Aged; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic | 1985 |
Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide.
Topics: Amiloride; Clinical Trials as Topic; Crystallization; Drug Therapy, Combination; Female; Humans; Hyd | 1985 |
Treating the older hypertensive: beta-blocker or diuretic?
Topics: Adrenergic beta-Antagonists; Aged; Amiloride; Atenolol; Blood Pressure; Diuretics; Double-Blind Meth | 1985 |
Coronary heart disease and treatment of hypertension. Some Oslo Study data.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Glucose; Carbohydrate | 1986 |
Initial antihypertensive drug therapy: alpha blocker or diuretic. Interim report of a randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Cholesterol; Clinical Trials as Topic; Diuretics; Female; Human | 1986 |
Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1986 |
Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio | 1985 |
Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.
Topics: 6-Ketoprostaglandin F1 alpha; Adrenergic beta-Antagonists; Adult; Amiloride; Anti-Inflammatory Agent | 1986 |
Comparative trials of terazosin with other antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combina | 1986 |
Oslo Hypertension Study.
Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Cholesterol, HDL; Coronary Disease; Follow-Up Stu | 1986 |
Enalapril, atenolol, and hydrochlorothiazide in hypertension.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Enalapril; Humans; Hydrochlorothiazide; Hyp | 1986 |
Captopril versus hydrochlorothiazide/triamterene in mild-to-moderate hypertension in the elderly.
Topics: Aged; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Combinations; Humans; Hydro | 1986 |
Metoprolol or hydrochlorothiazide in patients with hypertension aged 60-75 years. With special reference to assessment of compliance. Hunter Hypertension Research Group.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hydrochlorothia | 1986 |
Swedish trial in old patients with hypertension. A prospective multicentre study in Swedish primary health care.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiloride; Atenolol; Clinical Trials as Topic; | 1986 |
[Double-blind comparison of fixed combination preparations of a beta blocker and a diuretic and beta blocker, a diuretic and hydralazine in patients with coronary heart disease and arterial hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Amiloride; Clinical Trials as Topic; Coronary Disease; Double-Bli | 1986 |
Renal hemodynamic changes after beta-blocker-diuretic combination therapy in azotemic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Drug Therapy, Combination; Glomerular Filtration Rate; Hum | 1986 |
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Met | 1987 |
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials | 1987 |
Responses to mental stress and physical provocations before and during long term treatment of hypertensive patients with beta-adrenoceptor blockers or hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cyclic AMP; Epinephrine; Female; Glycerol; Heart | 1987 |
Comparison of hydrochlorothiazide and slow release furosemide as adjuvant therapy to beta-blockers in the treatment of moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Dou | 1987 |
Felodipine versus hydrochlorothiazide as an addition to a beta-blocker in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fel | 1987 |
Clinical evaluation of felodipine in hypertensive patients previously treated with a triple drug regimen.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Felodipine; Humans; | 1987 |
Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study.
Topics: Adrenergic beta-Antagonists; Adult; Amiloride; Bisoprolol; Blood Pressure; Double-Blind Method; Drug | 1987 |
[Lowering blood pressure effectively. Enalapril and hydrochlorothiazide in fixed combination and mild and moderate hypertension--results of a multicenter study].
Topics: Blood Pressure; Clinical Trials as Topic; Enalapril; Humans; Hydrochlorothiazide; Hypertension | 1988 |
Comparative effects of prazosin and hydrochlorothiazide on sexual function in hypertensive men.
Topics: Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Male; Penile Erection; Prazosin; Sleep, R | 1989 |
The long-term antihypertensive effects of prazosin and atenolol.
Topics: Atenolol; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertensi | 1989 |
Effects of antihypertensive therapy on blood pressure control, cognition, and reactivity. A placebo-controlled comparison of prazosin, propranolol, and hydrochlorothiazide.
Topics: Antihypertensive Agents; Blood Pressure; Cognition; Heart Rate; Humans; Hydrochlorothiazide; Hyperte | 1989 |
Nitrendipine versus hydrochlorothiazide in hypertensive patients over 70 years of age.
Topics: Aged; Body Weight; Double-Blind Method; Female; Heart Rate; Hemodynamics; Humans; Hydrochlorothiazid | 1989 |
The antihypertensive effects of doxazosin: a clinical overview.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cholesterol | 1986 |
QRS-amplitudes during antihypertensive treatment: a comparison between beta-blocker and thiazide diuretic regimens.
Topics: Adult; Aged; Blood Pressure; Cardiomegaly; Clinical Trials as Topic; Coronary Disease; Electrocardio | 1986 |
Treatment of essential hypertension with PN 200-110 (isradipine).
Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Drug Therap | 1987 |
A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart | 1987 |
Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study.
Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Heart Rate; Humans; Hydrochlorot | 1988 |
Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension.
Topics: Adult; Aged; Apolipoproteins; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hydroch | 1988 |
Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans.
Topics: Adult; Antihypertensive Agents; Black People; Blood Pressure; Clinical Trials as Topic; Dipeptides; | 1985 |
Enalapril maleate versus captopril. A comparison of the hormonal and antihypertensive effects.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Captopril; | 1985 |
Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition.
Topics: Body Fluids; Clinical Trials as Topic; Diuresis; Double-Blind Method; Drug Evaluation; Drug Therapy, | 1985 |
Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Enalapril; Female; Humans; Hydrochlorothiazide; Hyp | 1985 |
Angiotensin converting enzyme inhibitors and quality of life: the European trial.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, | 1985 |
Converting enzyme inhibition in mild and moderate essential hypertension. I. Acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Brad | 1985 |
Converting enzyme inhibition in mild and moderate essential hypertension. II.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Captopril; Female; Glom | 1986 |
[Predictability and prevention of hypokalemia induced by hydrochlorothiazide].
Topics: Clinical Trials as Topic; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Random | 1985 |
Humoral effects of long-term oral enalapril therapy.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Blood Pressure; Blood Specimen Collection; Clinic | 1986 |
Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Body Fluids; Clinical Trials as Topic; Double-Blind Method; Drug | 1986 |
Enalapril in moderate to severe hypertension: a comparison with atenolol.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Creatinine; Drug Evaluation; Drug Therapy, Combin | 1986 |
Is low-dose hydrochlorothiazide effective?
Topics: Acebutolol; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enala | 1986 |
Combination therapy with enalapril and hydrochlorothiazide: optimal dose, renin response, and prostaglandin excretion.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dinoprost; Dino | 1986 |
Renal function and hemodynamics during treatment with enalapril in primary hypertension.
Topics: Double-Blind Method; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hydro | 1986 |
Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Enal | 1986 |
A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Black People; Blood Pressure; Clinical Trials as | 1987 |
Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients.
Topics: Adult; Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Kinetics; Ma | 1987 |
Metabolic and blood pressure effects of angiotensin converting enzyme inhibitors in mild-to-moderate American hypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Humans; Hydrochlorothiazide; Hy | 1987 |
[Double-blind comparative study of the efficacy of metoprolol and hydrochlorothiazide in the elderly hypertensive. Italian results of an international multicenter study].
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertensi | 1988 |
Treating black hypertensives with capozide.
Topics: Black People; Blood Pressure; Blood Urea Nitrogen; Captopril; Clinical Trials as Topic; Creatinine; | 1988 |
Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Gua | 1988 |
Volume (weight) loss and blood pressure response following thiazide diuretics.
Topics: Black People; Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazi | 1988 |
A comparison of captopril and atenolol in addition to hydrochlorothiazide for the treatment of hypertension.
Topics: Adult; Atenolol; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination | 1988 |
Comparison of diltiazem and hydrochlorothiazide for treatment of patients 60 years of age or older with systemic hypertension.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Electrocardiography; | 1988 |
Initial antihypertensive drug therapy. Final report of a randomized, controlled trial comparing alpha-blocker and diuretic.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Femal | 1988 |
Double-blind study comparing indoramin and propranolol in the treatment of black patients with hypertension.
Topics: Adult; Amiloride; Black People; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug | 1988 |
Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combina | 1988 |
[Effect of various diuretic doses on hemodynamics in patients with hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Dose-Response Relation | 1988 |
Multicenter private practice comparison of tripamide and hydrochlorothiazide in the treatment of hypertension.
Topics: Antihypertensive Agents; Family Practice; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles | 1988 |
Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1988 |
[Comparison of the antihypertensive effectiveness of captopril in combination with various doses of hydrochlorothiazide].
Topics: Adult; Aged; Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1988 |
[Antihypertensive effects of captopril, hydrochlorothiazide, alone or in combination, with different categories of essential hypertensive patients].
Topics: Biological Transport; Captopril; Drug Therapy, Combination; Erythrocytes; Humans; Hydrochlorothiazid | 1988 |
Cigarette smoking interferes with treatment of hypertension.
Topics: Adult; Bendroflumethiazide; Black People; Double-Blind Method; Humans; Hydrochlorothiazide; Hyperten | 1988 |
Dose response to hydrochlorothiazide in hypertensives receiving a calcium channel blocker.
Topics: Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 1988 |
A comparative study of Spiroprop and Moducren in the treatment of mild to moderate hypertension in general practice.
Topics: Adolescent; Amiloride; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothiazi | 1988 |
Comparative study of ketanserin and hydrochlorothiazide in essential hypertension. Janssen Research Group.
Topics: Blood Pressure; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Ketanserin; Random Allocation | 1988 |
Calcium antagonists: use in hypertension evaluation of calcium antagonists in combination with diuretics.
Topics: Bendroflumethiazide; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; | 1988 |
Additive effects of moderate dietary salt reduction and captopril in hypertension.
Topics: Adult; Aged; Captopril; Clinical Trials as Topic; Diet, Sodium-Restricted; Drug Therapy, Combination | 1988 |
Diuretics and hypertension in black adults.
Topics: Adult; Black People; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazid | 1988 |
A double-blind comparison of felodipine and hydrochlorothiazide added to metoprolol to control hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dizziness; Double-Bl | 1988 |
Serum selenium levels in diuretic-treated hypertensives: a double-blind trial of piretanide against hydrochlorothiazide plus amiloride.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Diuretics; Double-Blind Method; Humans; Hydrochlor | 1988 |
A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1988 |
Serum trace-element levels in piretanide-treated hypertensives: a double-blind trial against hydrochlorothiazide plus amiloride.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Diuretics; Double-Blind Method; Humans; Hydrochlor | 1987 |
Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker.
Topics: Aged; Amiloride; Arrhythmias, Cardiac; Bendroflumethiazide; Clinical Trials as Topic; Drug Combinati | 1987 |
Hydrochlorothiazide with or without amiloride for hypertension in the elderly. A dose-titration study.
Topics: Aged; Aged, 80 and over; Amiloride; Blood Pressure; Clinical Trials as Topic; Dose-Response Relation | 1987 |
[Experience with using sinepress in hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Dihydroergotoxine; Drug Combinations | 1987 |
Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension.
Topics: Blood Pressure; Catecholamines; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Fem | 1987 |
Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide.
Topics: Adult; Age Factors; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Drug Resistance; Drug | 1987 |
Twenty-four-hour blood pressure monitoring in the evaluation of once daily treatment of essential hypertension.
Topics: Blood Pressure Determination; Captopril; Clinical Trials as Topic; Drug Administration Schedule; Dru | 1987 |
Comparative effects of nicardipine hydrochloride and hydrochlorothiazide in the treatment of mild to moderate hypertension: a double-blind parallel study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hyp | 1986 |
Captopril-related (and -induced?) asthma.
Topics: Asthma; Captopril; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Humans; H | 1987 |
Labetalol compared with propranolol in the treatment of black hypertensive patients.
Topics: Adolescent; Adult; Aged; Black People; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1987 |
Tiapamil and hydrochlorothiazide: a double-blind comparison of two antihypertensive agents.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Met | 1987 |
Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's
Topics: Adult; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydrochlorothi | 1987 |
Oslo study: treatment of mild hypertension. A five-year controlled drug study.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; | 1987 |
[Clinical significance of using captopril compounds treating primary hypertension].
Topics: Adult; Captopril; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Humans; Hydrochl | 1987 |
Felodipine versus Moduretic. A double-blind parallel-group multicentre study.
Topics: Adult; Amiloride; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Me | 1987 |
Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study.
Topics: Aged; Captopril; Double-Blind Method; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; | 1987 |
Nifedipine GITS and hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparation | 1987 |
Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Evalua | 1987 |
A comparison of a hydrochlorothiazide plus triamterene combination (Dyazide) and atenolol in the treatment of patients with mild hypertension: a multicentre study in general practice.
Topics: Adult; Aged; Atenolol; Drug Combinations; Family Practice; Female; Humans; Hydrochlorothiazide; Hype | 1987 |
Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide.
Topics: Aged; Blood Pressure; Diuretics; Drug Evaluation; Drug Tolerance; Humans; Hydrochlorothiazide; Hyper | 1988 |
An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Amiloride; Drug Combinations; Electrocardiography; Female; Furosemide; Heart Rate; Huma | 1988 |
Diltiazem compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Diltiazem; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hy | 1988 |
Amiloride prevents thiazide-induced intracellular potassium and magnesium losses.
Topics: Aged; Amiloride; Blood Pressure; Body Water; Body Weight; Drug Combinations; Female; Heart Failure; | 1988 |
Lack of effect of piretanide (a potassium-stable diuretic) on serum magnesium.
Topics: Amiloride; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1987 |
Blood pressure during a combination of ketanserin and hydrochlorothiazide.
Topics: Aged; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Ketanser | 1987 |
Treatment of elderly hypertensives with beta-blocker/thiazide combination.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Drug Combinations; Humans | 1987 |
Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fema | 1986 |
Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Hear | 1986 |
Initial antihypertensive therapy. Comparison of prazosin and hydrochlorothiazide.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Fem | 1986 |
Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension.
Topics: Administration, Oral; Aged; Amiloride; Analysis of Variance; Blood Glucose; Blood Pressure; Body Wei | 1986 |
The influence of pindolol and hydrochlorothiazide on blood pressure, and plasma renin and plasma lipid levels.
Topics: Adult; Aged; Blood Pressure; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Drug Admini | 1986 |
The PACT study: post-marketing surveillance in 47,465 patients treated with Maxzide (triamterene/hydrochlorothiazide). An interim report.
Topics: Age Factors; Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Female; Humans; H | 1986 |
The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diuresis; Double-Blind Method; Drug Interacti | 1986 |
Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Amiloride; Angiotensin II; Blood Pressure; Clinical Trials as Topic; Drug | 1986 |
The effects of thiazide diuretics upon plasma lipoproteins.
Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLD | 1986 |
The effects of antihypertensive therapy on the quality of life.
Topics: Adult; Aged; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Humans; Hydro | 1986 |
Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy | 1986 |
Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients.
Topics: Aged; Amiloride; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; H | 1986 |
Antihypertensive therapy with triamterene-hydrochlorothiazide vs amiloride-hydrochlorothiazide. Comparison of effects on urinary prostaglandin E2 excretion.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dinoprostone; Drug Com | 1986 |
Ethnics differences in the reactions to drugs and xenobiotics. Antihypertensive agents.
Topics: Antihypertensive Agents; Bendroflumethiazide; Black People; Clinical Trials as Topic; Diuresis; Diur | 1986 |
Antihypertensive effects of acebutolol plus hydrochlorothiazide and hydrochlorothiazide alone in black patients.
Topics: Acebutolol; Adult; Black People; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; H | 1986 |
Selected mechanisms of diuretic-induced electrolyte changes.
Topics: Aldosterone; Amiloride; Clinical Trials as Topic; Diuresis; Diuretics; Double-Blind Method; Humans; | 1986 |
Role of diuretics in treatment of essential hypertension.
Topics: Clinical Trials as Topic; Diuretics; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; | 1986 |
Hypokalemia in thiazide-treated systemic hypertension.
Topics: Aldosterone; Amiloride; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothia | 1986 |
Placebo controlled double-blind randomised cross-over trial of atenolol, hydrochlorothiazide and amiloride, and the combination (Kalten) in patients over 60 years of age.
Topics: Aged; Amiloride; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; D | 1986 |
Effect of tripamide on glucose tolerance in patients with hypertension.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Ty | 1986 |
Low-dose captopril in mild to moderate geriatric hypertension.
Topics: Age Factors; Aged; Black or African American; Blood Pressure; Captopril; Clinical Trials as Topic; D | 1986 |
Comparison and additivity of nitrendipine and hydrochlorothiazide in systemic hypertension.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydr | 1986 |
Comparative study of the efficacy and tolerance of capozide and moduretic administered in a single daily dose for the treatment of chronic moderate arterial hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Pressure; Captopril; Double-Blind Method; Drug Combination | 1986 |
Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study.
Topics: Aged; Blood Pressure; Captopril; Clinical Trials as Topic; Creatinine; Double-Blind Method; Drug Com | 1986 |
Neurohormonal responses to antihypertensive treatment with captopril or hydrochlorothiazide.
Topics: Adult; Aldosterone; Blood Pressure; Captopril; Dopamine; Female; Humans; Hydrochlorothiazide; Hypert | 1986 |
Efficacy of captopril and hydrochlorothiazide administered once a day.
Topics: Blood Pressure; Captopril; Clinical Trials as Topic; Drug Combinations; Female; Heart Rate; Humans; | 1986 |
Influence of captopril on intracellular ions--a possible mode of action.
Topics: Adult; Blood Pressure; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertensi | 1986 |
Once-daily treatment of essential hypertension with captopril.
Topics: Adolescent; Adult; Blood Pressure; Captopril; Double-Blind Method; Drug Evaluation; Drug Therapy, Co | 1986 |
Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial.
Topics: Adult; Atenolol; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Humans; | 1987 |
Atenolol vs. amiloride-hydrochlorothiazide in the treatment of mild to moderate hypertension: a double-blind, crossover, placebo-controlled study.
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Dru | 1987 |
Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension.
Topics: Adult; Age Factors; Clinical Trials as Topic; Delayed-Action Preparations; Diltiazem; Double-Blind M | 1987 |
The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Clinical Trials as Topic; Creatinine; Diclofenac; Drug The | 1987 |
Specific patient challenge: the elderly hypertensive patient.
Topics: Aged; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hemodynamics; Humans; | 1987 |
Amiloride with or without salbutamol versus placebo: effects on lipoproteins in hypertensive patients treated with timolol-hydrochlorothiazide.
Topics: Albuterol; Amiloride; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazi | 1986 |
Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combin | 1987 |
Comparison of once and twice daily administration of captopril plus hydrochlorothiazide on 24 h blood pressure levels.
Topics: Blood Pressure; Captopril; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Drug | 1987 |
Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension.
Topics: Captopril; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation | 1987 |
Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension.
Topics: Adult; Aged; Captopril; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Sche | 1987 |
Comparative study of once-daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension.
Topics: Adult; Aged; Captopril; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Humans; Hyd | 1987 |
Captopril in combination with hydrochlorothiazide: comparative efficacy vs perceived best therapy.
Topics: Captopril; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; Ma | 1987 |
Therapeutic assessment of Slow-K and K-tab potassium chloride formulations in hypertensive patients treated with thiazide diuretics.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hydrochlorothiaz | 1987 |
Effects of hydrochlorothiazide and diltiazem on reflex vasoconstriction in hypertension.
Topics: Adult; Blood Pressure; Diltiazem; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Low | 1987 |
The effects of bendroflumethiazide/potassium chloride versus hydrochlorothiazide/amiloride on blood pressure and serum electrolytes in patients with mild to moderate hypertension seen in general practice.
Topics: Adult; Aged; Amiloride; Bendroflumethiazide; Blood Pressure; Drug Therapy, Combination; Electrolytes | 1986 |
Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs.
Topics: Adult; Amiloride; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Double-Blin | 1987 |
Hydrochlorothiazide and triamterene with sustained-release oxprenolol in the treatment of hypertension.
Topics: Aged; Creatinine; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kidn | 1986 |
A comparative study of two beta-blocker-diuretic combinations in the treatment of hypertension.
Topics: Acebutolol; Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertensio | 1986 |
Cardiac arrhythmias in hypertensive outpatients on various diuretics. Correlation between incidence and serum potassium and magnesium levels.
Topics: Adult; Arrhythmias, Cardiac; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hype | 1986 |
Beta-blocker versus diuretic for control of the blood pressure response to stress in hypertensive patients.
Topics: Adult; Amiloride; Atenolol; Chronic Disease; Drug Combinations; Female; Heart Rate; Humans; Hydrochl | 1986 |
The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hydr | 1985 |
Blood pressure lowering and potassium conservation by triamterene-hydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1985 |
Step 1 1/2 therapy for the treatment of hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diuretics; Drug Combinations; Female; Humans; Hyd | 1985 |
Crossover comparison of captopril and propranolol as step 2 agents in hypertension.
Topics: Adult; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochloro | 1985 |
Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level.
Topics: Adolescent; Adult; Age Factors; Aged; Amiloride; Blood Pressure; Body Weight; Clinical Trials as Top | 1985 |
Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug A | 1985 |
Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Dose-Response Relationship, Drug; Dru | 1985 |
Long-term effects of captopril and atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combi | 1985 |
Hypertension in the elderly.
Topics: Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hype | 1985 |
[Comparison of hypotensive effectiveness of propranolol and atenolol in combined treatment of primary hypertension].
Topics: Adult; Atenolol; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1985 |
Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazid | 1985 |
Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity.
Topics: Adolescent; Adult; Aged; Asthma; Clinical Trials as Topic; Drug Evaluation; Female; Forced Expirator | 1985 |
Antihypertensive and hypokalemic effects of isobutyl hydrochlorothiazide alone and in combination with spironolactone.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Therapy, Combi | 1985 |
Drug treatment trials in hypertension: a review.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Coro | 1985 |
Diuretics versus calcium-channel blockers in systemic hypertension: a preliminary multicenter experience with hydrochlorothiazide and sustained-release diltiazem.
Topics: Aged; Benzazepines; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Diltiazem | 1985 |
Antihypertensive efficacy of two low dosages of hydrochlorothiazide in patients treated with captopril.
Topics: Adult; Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 1985 |
Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: a double-blind comparison with a combination of hydrochlorothiazide and amiloride.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fe | 1985 |
Multicentre comparison of the antihypertensive effect of acebutolol and hydrochlorothiazide in uncomplicated mild-moderate hypertension in the elderly.
Topics: Acebutolol; Aged; Blood Pressure; Clinical Trials as Topic; Heart Rate; Humans; Hydrochlorothiazide; | 1985 |
[Treatment of essential hypertension with a potassium-sparing diuretic combination. Results of a German multicenter study with Moduretic].
Topics: Adult; Aged; Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Germany | 1985 |
[Multicenter study of the efficacy of 3 antihypertensive regimens: captopril + hydrochlorothiazide, oxprenolol + hydrochlorothiazide, and alphamethyldopa + hydrochlorothiazide].
Topics: Adult; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate; Humans; H | 1985 |
Hydrochlorothiazide and potassium chloride in comparison with hydrochlorothiazide and amiloride in the treatment of mild hypertension.
Topics: Adult; Aged; Amiloride; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Met | 1985 |
Comparison of cyclothiazide and hydrochlorthiazide in hypertension. Effects of different doses of diuretics.
Topics: Adult; Antihypertensive Agents; Benzothiadiazines; Blood Glucose; Blood Pressure; Clinical Trials as | 1985 |
[Treatment of arterial hypertension with a combination metoprolol-hydrochlorothiazide].
Topics: Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hy | 1985 |
Improvement of the lipid profile during long-term administration of pindolol and hydrochlorothiazide in patients with hypertension.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydrochl | 1986 |
Prazosin once or twice daily?
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1985 |
Cross-over study of muzolimine and hydrochlorothiazide-amiloride in hypertensive patients.
Topics: Adult; Amiloride; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertensi | 1985 |
[Clinical evaluation of penbutolol (Hoe, 893 d) (beta adrenergic blockader), alone and in combination with hydrochlorothiazide, in the treatment of arterial hypertension. I: Effect on arterial hypertension. Comparative study of 2 parallel groups with cros
Topics: Adult; Drug Evaluation; Drug Therapy, Combination; Heart Rate; Humans; Hydrochlorothiazide; Hyperten | 1985 |
Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action.
Topics: Adult; Drug Therapy, Combination; Exercise Test; Female; Hemodynamics; Humans; Hydralazine; Hydrochl | 1985 |
[Change in the spectrum of lipids and apoproteins A1 and B as affected by hypothiazide and pratsiol in patients with hypertension].
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydrochloro | 1985 |
Comparative effects of diltiazem and hydrochlorothiazide in blacks with systemic hypertension.
Topics: Adult; Aged; Benzazepines; Black or African American; Blood Pressure; Delayed-Action Preparations; D | 1985 |
Effect of diuretic therapy on glucose tolerance in hypertensive patients.
Topics: Age Factors; Blood Glucose; Body Weight; Diabetes Mellitus; Diuretics; Ethacrynic Acid; Fasting; Fat | 1971 |
Diuretics, potassium depletion, and carbohydrate intolerance.
Topics: Benzothiadiazines; Carbohydrate Metabolism; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Po | 1971 |
Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia.
Topics: Adult; Aged; Amiloride; Blood Pressure; Body Weight; Diuretics; Drug Therapy, Combination; Female; H | 1973 |
Hydralazine and beta-adrenergic blockade in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combinat | 1974 |
[Therapy of essential hypertension using a new beta-receptor blockader (timolol maleate) combined with hydrochlorothiazide].
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, | 1974 |
Effect of propranolol in mild hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Midd | 1966 |
Effects of hydrochlorothiazide in hypertensive patients and the need for potassium supplementation.
Topics: Adult; Aged; Blood Pressure; Body Weight; Carbon Dioxide; Chlorides; Clinical Trials as Topic; Human | 1973 |
Study of a new antihypertensive (guanabenz).
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Evaluation; Ele | 1974 |
Controlled trial of guanethidine and methyldopa in moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Guanethidi | 1974 |
[Hemodynamic effects of long-term saluretic therapy of hypertension].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diuretics; Female; Hemodynamics; Humans; Hydrochl | 1974 |
Effect of treatment on morbidity in hypertension. Veterans Administration Cooperative Study on Antihypertensive Agents. Effect on the electrocardiogram.
Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiomegaly; Clinical Trials as Topi | 1973 |
Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together.
Topics: Angiotensin II; Antihypertensive Agents; Blood Pressure Determination; Blood Volume Determination; C | 1968 |
Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.
Topics: Adult; Age Factors; Aged; Aneurysm; Atrial Fibrillation; Blood Glucose; Blood Pressure; Cerebrovascu | 1972 |
One-tablet combination drug therapy in the treatment of hypertension.
Topics: Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Dosage Forms; Drug Com | 1972 |
Duration of therapy necessary for antihypertensive effect with a combination tablet.
Topics: Adult; Aged; Barbiturates; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrochlorot | 1972 |
Moderate sodium restriction and diuretics in the treatment of hypertension.
Topics: Adult; Body Weight; Clinical Trials as Topic; Diet, Sodium-Restricted; Female; Humans; Hydrochloroth | 1973 |
Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; | 1974 |
Low-renin hypertension. Restoration of normotension and renin responsiveness.
Topics: Administration, Oral; Clinical Trials as Topic; Diet; Drug Therapy, Combination; Furosemide; Humans; | 1974 |
[Clinical testing of a new potassium-saving diuretic for the treatment of hypertension].
Topics: Aged; Amiloride; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Diuretics; Drug | 1973 |
Hypotensive effect of oxprenolol in mild hypertension: a co-operative controlled study.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Drug Interactions; Drug Synergism; F | 1973 |
Haemodynamic changes in long-term therapy of essential hypertension: a comparative study of diuretics, alpha-methyldopa and clonidine.
Topics: Adult; Cardiac Output; Chlorthalidone; Clinical Trials as Topic; Clonidine; Diuretics; Heart Rate; H | 1973 |
European working party on high blood pressure in elderly (EWPHE): organization of a double-blind multicentre trial on antihypertensive therapy in elderly patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Belgium; Cardiovascular Diseases; Clinical Trials as Top | 1973 |
The effect of alprenolol in elderly patients with raised blood pressure.
Topics: Aged; Alprenolol; Ambulatory Care; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparat | 1974 |
Appraisal of antihypertensive drug therapy.
Topics: Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Diabetes Comp | 1974 |
Partial reduction of blood pressure and prevention of complications in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Follow-U | 1974 |
Dosage of potassium chloride elixir to correct thiazide-induced hypokalemia.
Topics: Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Male; Plac | 1974 |
Hypertension: a challenge in preventive medicine.
Topics: Age Factors; Attitude to Health; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disea | 1974 |
Total body potassium in long-term Lasix therapy.
Topics: Aldosterone; Clinical Trials as Topic; Diuresis; Furosemide; Humans; Hydrochlorothiazide; Hypertensi | 1974 |
Reserpine, hydralazine, hydrochlorothiazide combination (Ser-AP-ES) in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Computers; Drug Combinations; Humans; Hydrala | 1972 |
The effect of different diuretics on elevated blood pressure and serum potassium.
Topics: Adult; Aged; Amides; Bicarbonates; Blood Pressure; Chlorides; Clopamide; Creatinine; Depression, Che | 1973 |
Hypertension: effectiveness of two drugs.
Topics: Antihypertensive Agents; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Enzyme Therapy; Hum | 1967 |
Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.
Topics: Adult; Aged; Blood Pressure Determination; Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 1967 |
[Hemodynamics after intravenous administration of guanethidine, reserpine and hydrochlorothiazide].
Topics: Adult; Blood Pressure; Cardiac Output; Dye Dilution Technique; Guanethidine; Hemodynamics; Humans; H | 1967 |
Effect of amiloride hydrochloride (MK-870) on blood pressure, serum electrolytes, and glucose tolerance in patients with mild hypertension.
Topics: Adult; Blood Pressure; Chlorides; Clinical Trials as Topic; Diuretics; Drug Synergism; Female; Gluco | 1968 |
The combination of guanethidine and hydrochlorothiazide in the treatment of arterial hypertension with and without renal failure.
Topics: Adult; Analysis of Variance; Blood Pressure; Clinical Trials as Topic; Creatine; Drug Synergism; Fem | 1968 |
[Clinical methods on the demonstration of the action of antihypertensive agents].
Topics: Antihypertensive Agents; Cardiovascular System; Clinical Trials as Topic; Electrocardiography; Endoc | 1969 |
[Betanidine as a component of a combination therapy in severe hypertension].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Synergism; Guanethidine; Humans; Hydrochloro | 1969 |
[Saluretic treatment of hypertension and uric acid level in serum. Clinical test of a combination of hydrochlorothiazide and probenecid].
Topics: Adult; Aged; Alanine Transaminase; Blood Glucose; Blood Pressure; Blood Protein Electrophoresis; Bod | 1969 |
Hydralazine and methyldopa in thiazide-treated hypertensive patients.
Topics: Black People; Clinical Trials as Topic; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertensi | 1970 |
A double-blind trial in hypertension comparing Baycaron (FBA 1500), hydrochlorothiazide and placebo.
Topics: Black People; Blood Pressure; Blood Urea Nitrogen; Body Weight; Clinical Trials as Topic; Furans; Hu | 1971 |
A clinical trial of alpha-methyldopa (Aldomet) and hydrochlorthiazide (Dichlotride) alone and in combination in hypertension.
Topics: Adult; Clinical Trials as Topic; Drug Interactions; Female; Humans; Hydrochlorothiazide; Hypertensio | 1971 |
A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Blood Proteins; Carbon Dioxide; Clinical Trials as Topic; Female; Furos | 1971 |
A double-blind evaluation of the therapeutic efficacy of salutensin versus hydropres-50 in essential hypertension.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hydroflumethiazide; Hypertensi | 1970 |
[Design and evaluation of a clinical study comparing combinations of antihypertensive agents].
Topics: Analysis of Variance; Antihypertensive Agents; Biometry; Blood Pressure; Clinical Trials as Topic; C | 1971 |
[Controlled clinical study of the blood pressure lowering effect of a rauwolfia-saluretic combination, with and without addition of an adrenolytic agent].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Clopamide; Diuretics; Ergoloid Me | 1971 |
Amiloride hydrochloride combined with hydrochlorothiazide in the control of hypertension and plasma potassium levels.
Topics: Alanine Transaminase; Amiloride; Aspartate Aminotransferases; Diuretics; Drug Combinations; Humans; | 1972 |
[Treatment of the hypertensive patient. Value of Amiloride during saldiuretic treatment].
Topics: Adult; Amiloride; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Kidney | 1972 |
Effect of treatment on morbidity and mortality in hypertension.
Topics: Age Factors; Black or African American; Blood Pressure; Humans; Hydralazine; Hydrochlorothiazide; Hy | 1971 |
Comparison of ethacrynic acid and hydrochlorothiazide in hypertension.
Topics: Aged; Ethacrynic Acid; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Middle Age | 1971 |
[Medical treatment of arterial hypertension].
Topics: Antihypertensive Agents; Diuretics; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Mi | 1971 |
[Comparative clinical experimental studies with pure alpha-methyldopa and in combination with hydrochlorothiazide].
Topics: Clinical Trials as Topic; Humans; Hydrochlorothiazide; Hypertension; Hypertension, Malignant; Methyl | 1965 |
Hypertensive treatment with veratrum alkaloids and thiazides alone and in combination.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Midd | 1966 |
Clinical study of the antihypertensive effects of debrisoquin sulfate in combination with hydrochlorothiazide.
Topics: Adult; Aged; Amidines; Antihypertensive Agents; Clinical Trials as Topic; Female; Humans; Hydrochlor | 1966 |
Potassium-sparing effects of triamterene in the treatment of hypertension.
Topics: Adult; Aged; Blood Gas Analysis; Blood Glucose; Chlorides; Chlorothiazide; Clinical Trials as Topic; | 1966 |
Treatment of hypertension with spironolactone. Double-blind study.
Topics: Clinical Trials as Topic; Humans; Hydrochlorothiazide; Hypertension; Spironolactone | 1966 |
Prophylactic use of hydrochlorothiazide in pregnancy.
Topics: Clinical Trials as Topic; Female; Humans; Hydrochlorothiazide; Hypertension; Infant Mortality; Infan | 1966 |
[Comparative mass studies on alpha-methyldopa (Presinol), Sali-Presinol and Cyclazenine in hypertensives of various origin].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Guanine; Humans; Hydrochlorothiazide; Hypertension; H | 1965 |
Hemodynamic changes in long-term diuretic therapy of essential hypertension. A comparative study of chlorthalidone, polythiazide and hydrochlorothiazide.
Topics: Adult; Blood Pressure; Blood Volume; Cardiac Output; Chlorthalidone; Electrolytes; Heart Rate; Human | 1970 |
[Effects of different diuretics on increased blood pressure and serum potassium].
Topics: Adult; Aged; Clopamide; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle A | 1971 |
Amiloride hydrochloride in hypertensive patients.
Topics: Bicarbonates; Blood Pressure; Chlorides; Depression, Chemical; Diuretics; Drug Synergism; Guanidines | 1968 |
Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone.
Topics: Adult; Aged; Body Weight; Female; Glycyrrhiza; Humans; Hydrochlorothiazide; Hypertension; Male; Midd | 1968 |
Metabolic and hypotensive effects of ethacrynic acid. Comparative study with hydrochlorothiazide.
Topics: Analysis of Variance; Aspartate Aminotransferases; Blood Glucose; Blood Pressure; Blood Urea Nitroge | 1968 |
Long-term effect of probenecid on diuretic-induced hyperuricemia.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Pressure Determination; Body Weight; Chlorthalidone; Hum | 1966 |
1479 other studies available for hydrochlorothiazide and Hypertension
| Article | Year |
|---|---|
N2-(4-Substituted-2,6-dichlorophenyl)-N1,N1-dimethylformamidines as antihypertensive and diuretic agents.
Topics: Amidines; Animals; Antihypertensive Agents; Blood Pressure; Chemical Phenomena; Chemistry; Chloroben | 1984 |
2-(Aminomethyl)phenols, a new class of saluretic agents. 2. Synthesis and pharmacological properties of the 5-aza isostere of 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenol.
Topics: Animals; Blood Pressure; Chemical Phenomena; Chemistry; Diuretics; Dogs; Electrolytes; Hypertension; | 1981 |
Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.
Topics: Animals; Disease Models, Animal; Dogs; ERG1 Potassium Channel; Half-Life; Hypertension; Potassium Ch | 2017 |
Diuretic and Renal Protective Effect of Kaempferol 3-
Topics: Animals; Antioxidants; Bauhinia; Calcium; Chlorides; Cyclooxygenase Inhibitors; Diuretics; Hypertens | 2020 |
Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Connective Tissue Growth Factor; Fib | 2021 |
Plasma metabolomic profiles associated with hypertension and blood pressure in response to thiazide diuretics.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochloroth | 2022 |
Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Dermatitis, Contact; Diuretics; Drug Th | 2021 |
Management of American Heart Association/American College of Cardiology-Defined Stage 2 Hypertension by Cardiologists in India.
Topics: American Heart Association; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiologists; Card | 2022 |
Characterization of Potassium-Induced Natriuresis in Hypertensive Postmenopausal Women During Both Low and High Sodium Intake.
Topics: Female; Humans; Hydrochlorothiazide; Hypertension; Natriuresis; Postmenopause; Potassium; Sodium; So | 2022 |
Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia.
Topics: Antihypertensive Agents; Cardiology; Drug Combinations; Germany; Humans; Hydrochlorothiazide; Hypert | 2023 |
Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999-2018.
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hype | 2023 |
Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2022 |
The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hydrochloroth | 2023 |
Prediction and evaluation of combination pharmacotherapy using natural language processing, machine learning and patient electronic health records.
Topics: Digoxin; Drug Combinations; Electronic Health Records; Humans; Hydrochlorothiazide; Hypertension; Ma | 2022 |
Differentiation of hydrochlorothiazide-induced dermatitis from stasis dermatitis.
Topics: Dermatitis, Phototoxic; Eczema; Exanthema; Female; Humans; Hydrochlorothiazide; Hypertension; Leg De | 2022 |
Hydrochlorothiazide Versus Chlorthalidone: What Is the Difference?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2022 |
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Humans; Hydrochl | 2022 |
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension | 2022 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Awareness and Counseling Among Dermatologists of the Association Between Hydrochlorothiazide and Nonmelanoma Skin Cancer: Barriers and Opportunities.
Topics: Antihypertensive Agents; Cross-Sectional Studies; Dermatologists; Humans; Hydrochlorothiazide; Hyper | 2023 |
The 'cold case' of chlortalidone vs. hydrochlorothiazide in hypertension closed by the diuretic comparison project?
Topics: Blood Pressure; Chlorthalidone; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; H | 2023 |
Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study.
Topics: Aged; Cohort Studies; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Retrospect | 2023 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 y.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ethnicity; Humans; Hydroch | 2023 |
Oat Beta-Glucan Alone and in Combination with Hydrochlorothiazide Lowers High Blood Pressure in Male but Not Female Spontaneously Hypertensive Rats.
Topics: Angiotensin II; Animals; beta-Glucans; Blood Pressure; Female; Heart Diseases; Hydrochlorothiazide; | 2023 |
Importance of accounting for timing of time-varying exposures in association studies: Hydrochlorothiazide and non-melanoma skin cancer.
Topics: Aged; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Incidence; Ontario; Skin N | 2023 |
Concurrent exercise training induces additional benefits to hydrochlorothiazide: Evidence for an improvement of autonomic control and oxidative stress in a model of hypertension and postmenopause.
Topics: Animals; Baroreflex; Blood Pressure; Female; Heart Rate; Hexamethonium; Hydrochlorothiazide; Hyperte | 2023 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Fem | 2023 |
Chlorthalidone No Better Than Hydrochlorothiazide for Hypertension.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
[Chlorthalidone or hydrochlorothiazide as the first choice in the treatment of people with hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Association of urinary sodium/potassium ratio with structural and functional vascular changes in non-diabetic hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; C-Reactive Protein; Carotid-Femoral Pulse | 2019 |
A High Throughput HPLC-MS/MS Method for Antihypertensive Drugs Determination in Plasma and Its Application on Pharmacokinetic Interaction Study with Shuxuetong Injection in Rats.
Topics: Animals; Antihypertensive Agents; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; High- | 2019 |
Comparative effectiveness of combination treatment for hypertension in black Africans.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Calcium | 2020 |
Enalapril protect human lymphocytes from genotoxicity of Hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Chromosomes, Human; Drug Synergism; Drug Therapy, Combination; Enala | 2019 |
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mi | 2020 |
Comments on "Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study".
Topics: Asian People; Case-Control Studies; Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms | 2020 |
Sequential Drug-Induced Severe Hyponatremia in a Minimally Symptomatic, 81-Year-Old Patient.
Topics: Aged, 80 and over; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Salin | 2020 |
Comment on "Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea".
Topics: Humans; Hydrochlorothiazide; Hypertension; Republic of Korea; Retrospective Studies; Skin Neoplasms | 2020 |
Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Calcium; Calcium Gluconate; Coronav | 2020 |
Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, An | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension-Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Response to comment on "Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea".
Topics: Humans; Hydrochlorothiazide; Hypertension; Republic of Korea; Retrospective Studies; Skin Neoplasms | 2020 |
Clinical efficacy of various anti-hypertensive regimens in hypertensive women of Punjab; a longitudinal cohort study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Diuretics; | 2020 |
Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, | 2021 |
Effects of cyanidin 3-
Topics: Animals; Anthocyanins; Cytokines; Hydrochlorothiazide; Hypertension; Immunologic Memory; Immunopheno | 2020 |
Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.
Topics: Adolescent; Age Factors; Area Under Curve; Child; Child, Preschool; Computer Simulation; Diuretics; | 2021 |
Hydrochlorothiazide Associated with Risk of Skin Cancer.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Skin Neoplasms | 2020 |
"Dear Doctor" Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription.
Topics: Antihypertensive Agents; Drug Labeling; Hand; Humans; Hydrochlorothiazide; Hypertension; Prescriptio | 2020 |
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Desoxycorticosterone Acetate; Dis | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyper | 2021 |
Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2021 |
Multiple Mechanisms are Involved in Salt-Sensitive Hypertension-Induced Renal Injury and Interstitial Fibrosis.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Fibrosis; Hydrochlorothiazide; Hypert | 2017 |
The Case | Hypomagnesemia with knee pain.
Topics: Aged; Arthrocentesis; Chondrocalcinosis; Humans; Hydrochlorothiazide; Hypertension; Knee Joint; Magn | 2017 |
Association of obstructive sleep apnea with arterial stiffness and nondipping blood pressure in patients with hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2017 |
Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2017 |
Chemical composition and diuretic, natriuretic and kaliuretic effects of extracts of Mimosa bimucronata (DC.) Kuntze leaves and its majority constituent methyl gallate in rats.
Topics: Administration, Oral; Animals; Atropine; Cell Line; Disease Models, Animal; Diuretics; Gallic Acid; | 2017 |
Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Moni | 2018 |
Hydrochlorothiazide.
Topics: Diuretics; Drug Prescriptions; Humans; Hydrochlorothiazide; Hypertension; Medicine in the Arts; Pris | 2017 |
Long-term safety of different antihypertensive regimens: The risk of unfair comparisons.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combi | 2018 |
Prolonged diuretic and saluretic effect of nothofagin isolated from Leandra dasytricha (A. Gray) Cogn. leaves in normotensive and hypertensive rats: Role of antioxidant system and renal protection.
Topics: Animals; Antioxidants; Chalcones; Diuretics; Hydrochlorothiazide; Hypertension; Kidney; Male; Melast | 2018 |
The role of distal tubule and collecting duct sodium reabsorption in sunitinib-induced hypertension.
Topics: Amiloride; Animals; Antihypertensive Agents; Arterial Pressure; Epithelial Sodium Channel Blockers; | 2018 |
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2018 |
[Hydrochlorothiazide and skin cancer].
Topics: Carcinoma; Diuretics; Evidence-Based Medicine; Humans; Hydrochlorothiazide; Hypertension; Skin Neopl | 2018 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; F | 2018 |
Thiazide diuretics-associated skin rash.
Topics: Antihypertensive Agents; Drug Eruptions; Exanthema; Humans; Hydrochlorothiazide; Hypertension; Male; | 2018 |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study.
Topics: Age Distribution; Aged; Aged, 80 and over; Carcinoma, Merkel Cell; Case-Control Studies; Denmark; Do | 2019 |
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
Topics: Antihypertensive Agents; Atenolol; Brazil; Captopril; Cell Survival; Cells, Cultured; DNA Damage; Do | 2018 |
Diuretics and left ventricular hypertrophy regression: The relationship that we commonly forget.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hyper | 2018 |
Which thiazide to choose-A "dynamic" question with a mundane answer?
Topics: Blood Pressure Monitoring, Ambulatory; Carbonic Anhydrases; Chlorthalidone; Diuretics; Endothelium; | 2018 |
Fractal properties and morphological investigation of Nano hydrochlorothiazide is used to treat hypertension.
Topics: Antihypertensive Agents; Fractals; Hydrochlorothiazide; Hypertension; Microscopy, Electron, Scanning | 2018 |
Reliable and easy-to-use LC-MS/MS-method for simultaneous determination of the antihypertensives metoprolol, amlodipine, canrenone and hydrochlorothiazide in patients with therapy-refractory arterial hypertension.
Topics: Amlodipine; Antihypertensive Agents; Canrenone; Carbon Isotopes; Chromatography, High Pressure Liqui | 2019 |
In persistent hypertension, low-dose triple-pill therapy increased the likelihood of achieving target BP at 6 mo.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Sri Lanka | 2018 |
Interventricular vessel of the heart and diuretics.
Topics: Chlorthalidone; Diuretics; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, | 2019 |
The expanding saga of hydrochlorothiazide and skin cancer.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrochlorothiazide; | 2019 |
[Arterial hypertension : novelties in 2018].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; Hype | 2019 |
Zinc deficiency induces hypertension by promoting renal Na
Topics: Animals; Blood Pressure; Cells, Cultured; Chelating Agents; Diet; Ethylenediamines; Hydrochlorothiaz | 2019 |
Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Risk Assessment; Risk Factors; S | 2019 |
A Novel Frameshift Mutation of SCNN1G Causing Liddle Syndrome with Normokalemia.
Topics: Adolescent; Aged; Amiloride; Antihypertensive Agents; Biomarkers; Blood Pressure; Child; Drug Combin | 2019 |
A persistent dyspnea induced by hydrochlorothiazide.
Topics: Antihypertensive Agents; Dyspnea; Female; Humans; Hydrochlorothiazide; Hypertension; Middle Aged | 2019 |
In black Africans with hypertension, amlodipine-based therapy vs perindopril-hydrochlorothiazide improved BP control.
Topics: Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Humans; Hydrochlorothiazide; Hype | 2019 |
Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2019 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
[Telangiectasia during amlodipine therapy].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Drug Substitution; Drug T | 2013 |
Obesity and hypertension: It's about more than the numbers.
Topics: Antihypertensive Agents; Chlorthalidone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2013 |
Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Cost of Illness; Drug Combinations; Dr | 2013 |
Toward a personalized chronotherapy of high blood pressure and a circadian overswing.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2013 |
Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Follow-Up Studies; Hospitalization; Humans; Hydrochlo | 2013 |
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
Topics: Adult; Age Factors; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bla | 2013 |
Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2013 |
Beneficial effects of nebivolol and hydrochlorothiazide combination in spontaneously hypertensive rats.
Topics: Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Benzopyrans; Blood Pressure; Drinki | 2013 |
Impact of antihypertensive medication adherence on blood pressure control in hypertension: the COMFORT study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazid | 2013 |
[Hypertension. Goal: achieving target blood pressure with only 1 pill daily].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Germany; Humans; Hydrochlorothiazide; Hypert | 2013 |
Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
Topics: Adult; Aged; Ambulatory Care; Amides; Antihypertensive Agents; Blood Pressure; Cohort Studies; Drug | 2013 |
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chromosomes, Human, Pair 17; Diuretics; Fe | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Drugs for treating hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drugs, Generic; Humans; Hydrochlorothia | 2013 |
Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Calcium; Chlorthalidone; Creatin | 2013 |
Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED.
Topics: Acute Disease; Administration, Oral; Drug Therapy, Combination; Emergency Service, Hospital; Female; | 2013 |
Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Austria; Blood Pressure; Diu | 2013 |
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Topics: Aged; Antihypertensive Agents; Black or African American; Case-Control Studies; Coronary Artery Dise | 2013 |
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hype | 2014 |
Factors associated with changes in retinal microcirculation after antihypertensive treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Arterioles; Benzimidazoles; | 2014 |
Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relatio | 2013 |
Commentary in support of a highly effective hypertension treatment algorithm.
Topics: Adult; Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Ther | 2013 |
Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide?
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2014 |
Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioles; Blood Pressure | 2014 |
Single-pill combination of telmisartan and hydrochlorothiazide: studies and pooled analyses of earlier hypertension treatment.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzo | 2014 |
ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2014 |
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Co | 2014 |
Hypertension and edema in the aged. Comparison of hydrochlorothiazide and a hydrochlorothiazide-syrosingopine combination.
Topics: Aged; Aged, 80 and over; Chlorothiazide; Edema; Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pres | 2014 |
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Topics: Adult; Antihypertensive Agents; Black or African American; Diuretics; Female; Genome-Wide Associatio | 2014 |
Pharmacokinetic-pharmacodynamic model of the antihypertensive interaction between telmisartan and hydrochlorothiazide in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Interactions; Drug | 2014 |
Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population.
Topics: Aged; Antihypertensive Agents; Asian People; Case-Control Studies; Child; Chrysanthemum; Clonidine; | 2014 |
Genetic predictors of thiazide-induced serum potassium changes in nondiabetic hypertensive patients.
Topics: Adult; Aged; Female; Genotype; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Male; Middle | 2014 |
Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Essential Hyper | 2014 |
Effects of a combination of losartan and hydrochlorothiazide in patients with hypertension and a history of heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2014 |
Characterization and evaluation of multi-component crystals of hydrochlorothiazide.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Crystallization; Female; Hydrochlorothiazide; Hype | 2014 |
Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diuretics; Fasting; Female; Follow-Up Stu | 2014 |
Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2015 |
Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure.
Topics: Age Factors; Animals; Antihypertensive Agents; Blood Pressure; Cytokines; Disease Models, Animal; Fe | 2014 |
[Hypertension. Guidelines recommend fixed combinations].
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Guideline Adheren | 2014 |
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, | 2014 |
Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Amlodipine; Animals; Atropine; Enalapril; | 2014 |
Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension.
Topics: Aged; Amides; Antihypertensive Agents; Arterial Pressure; Biomarkers; Cells, Cultured; Diabetes Mell | 2015 |
Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asia; Bloo | 2014 |
Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.
Topics: Animals; Collagen; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Diabetic Nephropathies; | 2015 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; | 2014 |
Therapeutic impact of the single fixed-dose combination with a high-dose angiotensin-receptor blocker and a low-dose thiazide diuretic in the management of hypertension: awaiting further accumulation of clinical evidence.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Female; Humans; Hydroch | 2014 |
A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combi | 2014 |
Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cohort Studies; Diuretics; Fem | 2014 |
Antihypertensive effectiveness of combination therapy with losartan/hydrochlorothiazide for 'real world' management of isolated systolic hypertension.
Topics: Adult; Aged; Cross-Sectional Studies; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypert | 2015 |
Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium-Calmodulin-Dependent Protein | 2014 |
Thiazide-induced hyponatraemia is associated with increased water intake and impaired urea-mediated water excretion at low plasma antidiuretic hormone and urine aquaporin-2.
Topics: Aged; Aged, 80 and over; Aquaporin 2; Drinking; Electrolytes; Female; Humans; Hydrochlorothiazide; H | 2015 |
Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia.
Topics: Aged; Antihypertensive Agents; Diagnosis, Differential; Female; Glaucoma, Angle-Closure; Headache; H | 2014 |
Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Drug; Electroni | 2015 |
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dihydropyridines; Do | 2015 |
Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Austria; | 2015 |
Development, characterization, and pharmacodynamic evaluation of hydrochlorothiazide loaded self-nanoemulsifying drug delivery systems.
Topics: Administration, Oral; Animals; Biological Availability; Drug Delivery Systems; Drug Stability; Emuls | 2014 |
Long-term treatment of clonidine, atenolol, amlodipine and dihydrochlorothiazide, but not enalapril, impairs the sexual function in male spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Clonidine; Drug Administration Schedule; Enalapril; Hydr | 2015 |
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperten | 2015 |
Indapamide: is it the better diuretic for hypertension?
Topics: Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Potassium | 2015 |
[Optimizing antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2015 |
Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.
Topics: Animals; Antihypertensive Agents; Arterioles; Calcium; Calcium Channel Blockers; Calcium Channels, L | 2015 |
Blood pressure pharmacogenomics: gazing into a misty crystal ball.
Topics: Antihypertensive Agents; DNA-Binding Proteins; Humans; Hydrochlorothiazide; Hypertension; Male; Memb | 2015 |
[Fixed combination improves compliance].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Drug Combinations; Humans; Hydrochlorothiazide; | 2015 |
Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2015 |
Hydrochlorothiazide--Teaching an Old Drug New Tricks.
Topics: Humans; Hydrochlorothiazide; Hypertension | 2015 |
Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension.
Topics: Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Comb | 2016 |
The pharmacokinetic-pharmacodynamic model of telmisartan and hydrochlorothiazide on blood pressure and plasma potassium after long-term administration in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Determin | 2015 |
Hyperpigmentation Induced by Combination Therapy With Telmisartan-Hydrochlorothiazide.
Topics: Aged; Benzimidazoles; Benzoates; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiaz | 2016 |
Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Cohort Studies; Drug Combinations; Fem | 2015 |
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
Topics: Albuminuria; Animals; Blood Pressure; Drug Combinations; Furosemide; Hydrochlorothiazide; Hypertensi | 2016 |
Automated Outreach for Cardiovascular-Related Medication Refill Reminders.
Topics: Aged; Cardiovascular Diseases; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethyl | 2016 |
Hypertension subtypes modify metabolic response to thiazide diuretics.
Topics: Adiponectin; Adult; Antihypertensive Agents; Arginine; Asian People; Blood Glucose; China; Cholester | 2016 |
Application and validation of superior spectrophotometric methods for simultaneous determination of ternary mixture used for hypertension management.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Combinations; Hydrochlorothiazi | 2016 |
Norepinephrine-evoked salt-sensitive hypertension requires impaired renal sodium chloride cotransporter activity in Sprague-Dawley rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease M | 2016 |
Pentosan polysulfate preserves renal microvascular P2X1 receptor reactivity and autoregulatory behavior in DOCA-salt hypertensive rats.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Arterioles; Bloo | 2016 |
Chlorthalidone vs. Hydrochlorothiazide for Treatment of Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Evidence-Base | 2015 |
Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Female; Humans; Hydrochloroth | 2016 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
Glucocorticoids Induce Nondipping Blood Pressure by Activating the Thiazide-Sensitive Cotransporter.
Topics: Animals; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Corticosterone; Disease Mod | 2016 |
Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
Topics: Administration, Oral; Animals; Blood Pressure; Diuretics; Furosemide; Hydrochlorothiazide; Hypertens | 2016 |
More HOPE for Prevention with Statins.
Topics: Antihypertensive Agents; Benzimidazoles; Cardiovascular Diseases; Female; Humans; Hydrochlorothiazid | 2016 |
Blood pressure lowering does not reduce risk of cardiovascular events in patients at intermediate risk.
Topics: Antihypertensive Agents; Benzimidazoles; Cardiovascular Diseases; Female; Humans; Hydrochlorothiazid | 2016 |
[The Strategy of Indapamide Retard Use in the Prevention of the Early Vascular Aging Syndrome].
Topics: Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indapamide | 2015 |
Synergisms of cardiovascular effects between iptakalim and amlodipine, hydrochlorothiazide or propranolol in anesthetized rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Heart Rate; Hydrochlor | 2015 |
[Effective blood pressure control with a fixed combination].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; M | 2016 |
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Antihypertensive Agents; Blood Pressure Monitoring, Ambu | 2016 |
Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hydr | 2016 |
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hydrochlorothiazide; Hypertensi | 2016 |
Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hungary; Hydrochlorothiazide | 2016 |
Efficacy of Low-Dose Chlorthalidone Versus Hydrochlorothiazide Remains Ambiguous.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2016 |
Reply: Efficacy of Low-Dose Chlorthalidone Versus Hydrochlorothiazide Remains Ambiguous.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2016 |
Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Humans; Hydrochlorothiazide; Hyper | 2016 |
Chlorthalidone Versus Hydrochlorothiazide: A New Kind of Veterans Affairs Cooperative Study.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Randomized Contr | 2016 |
Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Dou | 2017 |
Severe adverse drug reactions induced by hydrochlorothiazide: A persistent old problem.
Topics: Aged; Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydr | 2016 |
Hyperkalemia in young children: blood pressure checked?
Topics: Child; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Incidental Findin | 2016 |
Copeptin is increased in resistant hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Co | 2016 |
In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hydrochlorothiazide; Hypertension; Rosuvas | 2016 |
Posterior reversible encephalopathy syndrome: A case report.
Topics: Amiloride; Antihypertensive Agents; Child; Diagnosis, Differential; Diagnostic Imaging; Diuretics; E | 2019 |
Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Determinati | 2016 |
Role of nifedipine and hydrochlorothiazide in MAPK activation and vascular smooth muscle cell proliferation and apoptosis.
Topics: Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MA | 2017 |
Whole-exome sequencing reveals an inherited R566X mutation of the epithelial sodium channel β-subunit in a case of early-onset phenotype of Liddle syndrome.
Topics: Adult; Aldosterone; Alleles; Amiloride; Child, Preschool; Epithelial Sodium Channels; Exome; Exome S | 2016 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
Chlorothiazide-induced photoaggravation of psoriatic lesion during narrowband ultraviolet B treatment in a case of psoriasis vulgaris.
Topics: Aged; Disease Progression; Drug Combinations; Female; Ficusin; Humans; Hydrochlorothiazide; Hyperten | 2017 |
Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Cyclodextrins; Dela | 2017 |
Diuretic, natriuretic and potassium-sparing effect of nothofagin isolated from Leandra dasytricha (A. Gray) Cogn. leaves in normotensive and hypertensive rats.
Topics: Animals; Antioxidants; Cell Line; Chalcones; Diuretics, Potassium Sparing; Hydrochlorothiazide; Hype | 2017 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
[Amlodipine is the better partner].
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; | 2008 |
[Unexpected study data for treatment of hypertension. Combination therapy with a diuretic not imperative].
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Cause of Death; Drug Com | 2008 |
Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Humans; Hy | 2008 |
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.
Topics: Adult; Black People; Blood Pressure Determination; Case-Control Studies; Chromosomes, Human, Pair 12 | 2008 |
Angiotensin II type 1 receptor blocker combined with hydrochlorothiazide for the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dose-Response Relationship, Drug; | 2008 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; Franc | 2008 |
Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; | 2008 |
Aliskiren/hydrochlorothiazide (Tekturna HCT) for hypertension.
Topics: Adult; Amides; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Fumarates; H | 2008 |
Which diuretic should be used for the treatment of hypertension?
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Practice Patterns, Physicians'; Randomize | 2008 |
Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug T | 2008 |
Aliskiren for hypertension in adults.
Topics: Adult; Amides; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug C | 2008 |
Based treatment algorithm for essencial hypertension with olmesartan medoxomil.
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2008 |
Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bl | 2008 |
Does it matter how hypertension is controlled?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2008 |
Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Dizziness; D | 2009 |
All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Chlorthalidone; Diuretics; Humans; Hydrochlorothi | 2009 |
Using diuretics in practice--one opinion.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2008 |
Atrial natriuretic peptide polymorphisms, hydrochlorothiazide and urinary potassium excretion.
Topics: Adolescent; Adult; Animals; Atrial Natriuretic Factor; Diuretics; DNA; Genotype; Humans; Hydrochloro | 2010 |
Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?
Topics: Amides; Antihypertensive Agents; Benchmarking; Fumarates; Humans; Hydrochlorothiazide; Hypertension | 2009 |
[The ACCOMPLISH trial: are results really unexpected?].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Diuret | 2009 |
Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Diuret | 2009 |
Cerebral vasomotor reactivity before and after blood pressure reduction in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; F | 2009 |
Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatremia.
Topics: Aged; Diuretics; Drinking; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Hyponatrem | 2009 |
Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: observational, prospective study in primary care.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Complications; Drug Therapy, Com | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood P | 2009 |
Hypertension: an ACCOMPLISHED regimen for hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium Channel Blo | 2009 |
Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.
Topics: Amides; Antihypertensive Agents; Blood Pressure; Drug Combinations; Fumarates; Humans; Hydrochloroth | 2009 |
Triple fixed-dose combination therapy: back to the past.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Drug Therapy, Combination; Humans; Hy | 2009 |
Exforge HCT.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2009 |
Renal and vascular glutathione S-transferase mu is not affected by pharmacological intervention to reduce systolic blood pressure.
Topics: Acetylcysteine; Animals; Glutathione Transferase; Humans; Hydrochlorothiazide; Hypertension; Imidazo | 2009 |
Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.
Topics: Aged; Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Blood Pressure; Body Mas | 2009 |
[Hyponatremia, rhabdomyolysis and encephalopathy after taking hydrochlorothiazide and tea].
Topics: Antihypertensive Agents; Beverages; Brain Diseases; Diuretics; Drinking; Female; Humans; Hydrochloro | 2009 |
Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
[67-year-old patient with abdominal pain and pronounced peritonitis].
Topics: Abdominal Pain; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2009 |
Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2009 |
A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension.
Topics: Aged; Alleles; Biomarkers; Case-Control Studies; Diuretics; Endosomal Sorting Complexes Required for | 2009 |
The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide.
Topics: Aged; Chlorthalidone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans | 2009 |
Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Brain; El | 2009 |
Effect of antihypertensive drug therapy on short-term heart rate variability in newly diagnosed essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Arrhythmia, Sinus; Atenolol; Enalapril; Female; Heart Ra | 2010 |
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Glucose; Female; Humans; Hydrochlorothiazide | 2009 |
[Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program].
Topics: Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle A | 2009 |
Selective chloride loading is pressor in the stroke-prone spontaneously hypertensive rat despite hydrochlorothiazide-induced natriuresis.
Topics: Animal Feed; Animals; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorides; Diuretics; D | 2010 |
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2009 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2009 |
Choice of diuretic therapy and reconsideration for aldosterone receptors blockers.
Topics: Aldosterone; Blood Pressure; Chlorthalidone; Diuretics; Dose-Response Relationship, Drug; Humans; Hy | 2010 |
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2009 |
Malignancy-associated multicentric reticulohistiocytosis.
Topics: Antihypertensive Agents; Antineoplastic Agents; Arthralgia; Atenolol; Combined Modality Therapy; Dru | 2011 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pres | 2010 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2010 |
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2010 |
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2011 |
Preventing increased blood pressure in the obese Zucker rat improves severity of stroke.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diet, Sodiu | 2010 |
[Chlorthalidone better than hydrochlorothiazide in hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Treatment Outcom | 2010 |
Significant hyperkalemia and hyponatremia secondary to telmisartan/hydrochlorothiazide treatment.
Topics: Aged; Benzimidazoles; Benzoates; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; Hyp | 2010 |
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Drug Combinations; Drug Eruption | 2010 |
Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Benzopyrans; Blood Pressure; Diabetes | 2010 |
Aliskiren + hydrochlorothiazide.
Topics: Amides; Antihypertensive Agents; Drug Combinations; Fumarates; Humans; Hydrochlorothiazide; Hyperten | 2010 |
Cushing's syndrome with uncontrolled hypertension, occasional hypokalemia, and two pregnancies.
Topics: Adrenalectomy; Adrenocortical Adenoma; Adult; Antihypertensive Agents; Cushing Syndrome; Dexamethaso | 2010 |
Tribenzor for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Dr | 2010 |
Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients?
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Monitoring, Ambula | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Managing hypertensive patients with gout who take thiazide.
Topics: Adult; Aged; Diuretics; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 2010 |
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2011 |
Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: case series of 40 patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothia | 2011 |
[Effects of combination therapy with losartan/hydrochlorothiazide on the relationships between base blood pressure, autonomic function, and health-related QOL].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autonomic Nervous System; Bl | 2010 |
[Syndrome of hypovolemia in patients with arterial hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Volume; Drug Therapy, Combination; Female; Hum | 2010 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2012 |
Antihypertensive therapy increases tetrahydrobiopterin levels and NO/cGMP signaling in small arteries of angiotensin II-infused hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biopterins; Cyclic GMP; GTP Cyclohydrolase; Hydral | 2011 |
Diuretic and potassium-sparing effect of isoquercitrin-an active flavonoid of Tropaeolum majus L.
Topics: Animals; Diuretics; Dose-Response Relationship, Drug; Hydrochlorothiazide; Hypertension; Male; Phyto | 2011 |
Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Clinical Trials as Topic | 2011 |
Tetrahydrobiopterin and hypertension: more than an emigrating story.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biopterins; Drug Therapy, Combination; Humans; Hyd | 2011 |
Impact of hypertension, aging, and antihypertensive treatment on the morphology of the pudendal artery.
Topics: Age Factors; Aging; Animals; Antihypertensive Agents; Apomorphine; Enalapril; Endothelium, Vascular; | 2011 |
Looking forward to new hypertension guidelines.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hydrochlorothiazide; Hypertension; Meta-An | 2011 |
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Capto | 2011 |
The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Comorbidity; Drug Therapy, Com | 2011 |
Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2011 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes | 2011 |
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2011 |
Hypertension: meta-analyses: first-rank evidence or second-hand information?
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Evidence-Based Medic | 2011 |
Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Dr | 2011 |
Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrochlorothiazide in experimental animals.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Herb-Drug Interactions; Hibiscus; | 2011 |
Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Asia; Asian People; Dose-Response Relationship, Drug; Drug Therapy, | 2011 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyr | 2011 |
Gout.
Topics: Allopurinol; Antihypertensive Agents; Gout; Gout Suppressants; Humans; Hydrochlorothiazide; Hyperten | 2011 |
Gender-specific association between ACE gene I/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Blood Pressure; Female; Gene Frequency; Genotype | 2011 |
Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Packaging; Humans; Hydrochlorothiazide; | 2011 |
Managing erectile dysfunction in hypertensive patients.
Topics: Amides; Antihypertensive Agents; Benzopyrans; Chlorthalidone; Ethanolamines; Fumarates; Humans; Hydr | 2011 |
Hypertension associated polymorphisms in WNK1/WNK4 are not associated with hydrochlorothiazide response.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Case-Control Studies; China; Diuretics; Female | 2011 |
Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension.
Topics: Aged; Blood Pressure; Body Weight; Diastole; Dose-Response Relationship, Drug; Female; Follow-Up Stu | 2012 |
Antihypertensive treatment using an angiotensin receptor blocker and a thiazide diuretic improves patients' quality of life: the Saga Challenge Antihypertensive Study (S-CATS).
Topics: Age Factors; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Chemical | 2011 |
The influence of cognition, anxiety and psychiatric disorders over treatment adherence in uncontrolled hypertensive patients.
Topics: Aged; Antihypertensive Agents; Anxiety; Cognition; Cohort Studies; Female; Humans; Hydrochlorothiazi | 2011 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Huma | 2011 |
Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascul | 2011 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Respons | 2011 |
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Topics: Analysis of Variance; Animals; Bendroflumethiazide; Calcineurin Inhibitors; Calcium; Cell Line; Chlo | 2011 |
Simultaneous determination of nitrendipine and hydrochlorothiazide in spontaneously hypertensive rat plasma using HPLC with on-line solid-phase extraction.
Topics: Animals; Area Under Curve; Chromatography, High Pressure Liquid; Drug Stability; Hydrochlorothiazide | 2011 |
Effects of an angiotensin 2 receptor blocker plus diuretic combination drug in chronic heart failure complicated by hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men.
Topics: Adult; Alleles; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Moni | 2012 |
Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Electrocardiography; Humans; Hydrochlorothiazide | 2011 |
Inequalities in prescription of hydrochlorothiazide for diabetic hypertensive patients in Colombia.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Colombia; Cross-Sectional Studies; Di | 2011 |
Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany.
Topics: Aged; Antihypertensive Agents; Drug Costs; Female; Germany; Humans; Hydrochlorothiazide; Hypertensio | 2012 |
Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study).
Topics: Aged; Blood Pressure; Drug Combinations; Drug Substitution; Female; Humans; Hydrochlorothiazide; Hyp | 2011 |
Combined antihypertensive and cardioprotective effects of nebivolol and hydrochlorothiazide in spontaneous hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzopyrans; Blood Pressure; Diuretics; Drug Therap | 2011 |
Seasonal variability of blood pressure in California.
Topics: Aged; Antihypertensive Agents; Blood Pressure; California; Dose-Response Relationship, Drug; Drug Co | 2011 |
The pharmacokinetic-pharmacodynamic assessment of the hypotensive effect after coadministration of losartan and hydrochlorothiazide in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Hydrochlorothiazide; Hypertension; Losa | 2012 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug | 2012 |
Why are we still using hydrochlorothiazide?
Topics: Antihypertensive Agents; Diabetes Mellitus; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hy | 2011 |
[EFFECTIVE data. New effectiveness dimensions in antihypertensive combination therapy].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topi | 2011 |
[Focus on compliance. Rapid goal attainment in hypertension].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relations | 2011 |
The beneficial effects of nebivolol on endothelial functions in arterial hypertension.
Topics: Benzopyrans; Biphenyl Compounds; Blood Pressure; Ethanolamines; Female; Humans; Hydrochlorothiazide; | 2012 |
An economic evaluation of antihypertensive therapies based on clinical trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination | 2012 |
Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2011 |
[Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Chronic Disease; Dose-Response Relations | 2012 |
[High blood pressure in the morning].
Topics: Benzimidazoles; Benzoates; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Delayed-Action P | 2011 |
[Effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide].
Topics: Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP11B2; Female; Humans; Hydrochlorothiazi | 2012 |
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
Topics: Adult; Antihypertensive Agents; Atenolol; Black or African American; Blood Pressure; Chromosomes, Hu | 2013 |
Control of hypertension in rats using volatile components of leaves of Taxus chinensis var. mairei.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; B | 2012 |
The kaliuretic impact of cicletanine compared to hydrochlorothiazide.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Male; Natriuresis; Potassium; Pr | 2012 |
Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Occlusive Di | 2012 |
Revival of beta-blockers in arterial hypertension.
Topics: Benzopyrans; Biphenyl Compounds; Blood Pressure; Ethanolamines; Female; Humans; Hydrochlorothiazide; | 2013 |
Effects of potassium-sparing versus thiazide diuretics on glucose tolerance: new data on an old topic.
Topics: Amiloride; Atenolol; Blood Glucose; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 2012 |
Guidelines for use of diuretics: a view from a member of JNC 7.
Topics: Chlorthalidone; Consensus Development Conferences as Topic; Diuretics; Dose-Response Relationship, D | 2012 |
Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and renin-angiotensin-aldosterone blockade.
Topics: Blood Pressure; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Kidney Diseases; Male | 2012 |
Impact of the combination of an angiotensin II receptor blocker and low-dose hydrochlorothiazide on patients with morning hypertension.
Topics: Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male | 2012 |
Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.
Topics: Acute Kidney Injury; Animals; Antibodies, Anti-Idiotypic; Antihypertensive Agents; Blood Pressure; C | 2012 |
Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.
Topics: Azetidinecarboxylic Acid; Blood Pressure; Dihydropyridines; Female; Humans; Hydrochlorothiazide; Hyp | 2012 |
Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP1A1; Hydrochlo | 2012 |
[Hypertension: improved therapy adherence after switch to a fixed drug combinations].
Topics: Amlodipine; Antihypertensive Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2012 |
A reappraisal of chlorthalidone also is required.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension | 2012 |
Can selection bias in trials allow hydrochlorothiazide to be banned?
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension | 2012 |
Hyponatremia in an 85-year-old hiker: when depletion plus dilution produces delirium.
Topics: Age Factors; Aged, 80 and over; Antihypertensive Agents; Arginine Vasopressin; Delirium; Drinking; E | 2012 |
Clinical efficacy and safety of losartan/hydrochlorothiazide combination therapy.
Topics: Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male | 2012 |
A recipe for reducing blood pressure variability: adding blood flow to the mix.
Topics: Azetidinecarboxylic Acid; Blood Pressure; Dihydropyridines; Female; Humans; Hydrochlorothiazide; Hyp | 2012 |
Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?
Topics: Aged; Antihypertensive Agents; Blood Glucose; Diuretics; Dose-Response Relationship, Drug; Drug Ther | 2012 |
Ask the doctor. I am a 47-year-old man with diabetes being treated with insulin and high blood pressure treated with lisinopril and low-dose hydrochlorothiazide (HCTZ). I have read that HCTZ can actually cause diabetes. My physician says not to worry abou
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hydrochlorothiazide; Hypertension; Lisin | 2012 |
Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2012 |
Best thiazide diuretic for hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2012 |
Antihypertensive drugs and lip cancer in non-Hispanic whites.
Topics: Adult; Aged; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Lip Neoplas | 2012 |
Do angiotensin receptor blockers really hold promise for the improvement of cognitive functioning?
Topics: Benzimidazoles; Cognition; Cognition Disorders; Female; Humans; Hydrochlorothiazide; Hypertension; L | 2012 |
[The efficacy of lysinopril (and/or its combination with hydrochlorothiazide) in patients with essential hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlo | 2012 |
The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans.
Topics: Aged; Blood Pressure; Chlorthalidone; Cohort Studies; Comparative Effectiveness Research; Female; Hu | 2012 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C-Reactive | 2012 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2).
Topics: Adolescent; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Anti | 2013 |
Effects of a fixed combination of losartan with hydrochlorothiazide on glucose tolerance in hypertensive patients uncontrolled with angiotensin ii receptor blockers alone.
Topics: Aged; Angiotensin Receptor Antagonists; Drug Combinations; Female; Glucose Tolerance Test; Humans; H | 2013 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2013 |
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Topics: Diuretics; Endothelium, Vascular; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Obesity; | 2013 |
Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting.
Topics: Adult; Amides; Antihypertensive Agents; Asian People; Drug Combinations; Female; Fumarates; Humans; | 2013 |
Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2013 |
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Arteries; Biphenyl Compounds; Calcinosis; Collage | 2002 |
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; | 2002 |
Diuretic induced hyponatraemia in elderly hypertensive women.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; | 2002 |
[Despite antihypertensive medication every 4th patient has elevated blood pressure values in the morning].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; | 2002 |
Central pontine myelinolysis.
Topics: Adult; Alcoholic Intoxication; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hyperte | 2002 |
PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats.
Topics: Androstanols; Animals; Blood Pressure; Diuresis; Hydrochlorothiazide; Hypertension; Kidney; Rats; So | 2002 |
Proposition of a feasible protocol to evaluate salt sensitivity in a population-based setting.
Topics: Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Diet; Feasibility Studies; Femal | 2002 |
[Experience of the use of nebivolol in the treatment of hypertension in postmenopausal women].
Topics: Analysis of Variance; Antihypertensive Agents; Benzopyrans; Drug Therapy, Combination; Ethanolamines | 2002 |
[Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Benzopyrans; Blood Pressure; Blood Viscosity; Data Interpretat | 2002 |
[Acute non-cardiogenic pulmonary edema secondary to hydrochlorothiazide therapy].
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diarrhea; Diuretic | 2003 |
[High dose sartan plus thiazide. Power duo in hypertension].
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrochlorothi | 2003 |
[Effect of combined therapy with enalapril maleate and hypothiazide on the structuro-functional status of erythrocyte membranes in hypertensive patients].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Enalapril; Erythrocyte M | 2003 |
Persistent lowering of arterial pressure after continuous and intermittent therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug The | 2003 |
[High dose sartan plus diuretic. More power in hypertension and its sequelae].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; | 2003 |
[Hemodynamics and cell membrane effects of angiotensin II receptor antagonists in treatment of hypertension].
Topics: Adenosine Triphosphatases; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive | 2003 |
[Therapy of hypertension. Pulse pressure must also be reduced].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure | 2003 |
Angiotensin-converting-enzyme inhibitors and diuretics for hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chlorthalidone; Coronary Disease; | 2003 |
Acute visual loss after initiation of antihypertensive therapy: case report.
Topics: Acute Disease; Antihypertensive Agents; Blindness; Blood Pressure; Drug Therapy, Combination; Fosino | 2003 |
Effect of cilazapril with or without low dose thiazide on LDL peroxidation in [correction of peroxidationin] hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Biomarkers; Blo | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
The effects of Su-5879 (esidrix) in congestive heart failure and hypertension: a clinical evaluation.
Topics: Acetazolamide; Heart Failure; Humans; Hydrochlorothiazide; Hypertension | 1959 |
The diuretic effects of hydrochlorothiazide in congestive heart failure, cirrhosis, chronic renal disease and hypertension: preliminary report based on a study of 28 cases.
Topics: Acetazolamide; Diuretics; Edema; Heart Failure; Hydrochlorothiazide; Hypertension; Kidney Failure, C | 1959 |
Clinical studies on hydrochlorothiazide; antihypertensive and metabolic effects.
Topics: Acetazolamide; Antihypertensive Agents; Biomedical Research; Heart Failure; Hydrochlorothiazide; Hyp | 1959 |
[Hydrochlorothiazide in the treatment of arterial hypertension; preliminary clinical study].
Topics: Acetazolamide; Humans; Hydrochlorothiazide; Hypertension | 1959 |
[Dihydrochlorothiazide (esidrex) as diuretic & as hypotensive drug].
Topics: Acetazolamide; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 1959 |
[Hydrochlorothiazide in the treatment of arterial hypertension].
Topics: Acetazolamide; Humans; Hydrochlorothiazide; Hypertension | 1959 |
[Treatment of arterial hypertension with hydrochlorothiazide].
Topics: Acetazolamide; Humans; Hydrochlorothiazide; Hypertension | 1959 |
[Carbethoxysyringoyl methylreserpate alone and with dihydrochlorothiazide in therapy of arterial hypertension].
Topics: Acetazolamide; Hydrochlorothiazide; Hypertension; Reserpine | 1959 |
Clinical therapeutic evaluation of hydrochlorothiazide (hydrodiuril).
Topics: Acetazolamide; Coronary Disease; Diuretics; Heart Diseases; Humans; Hydrochlorothiazide; Hypertensio | 1959 |
[Treatment of hypertension with hydrochlorothiazide].
Topics: Acetazolamide; Hydrochlorothiazide; Hypertension | 1959 |
[Hydrochlorothiazide in clinical practice].
Topics: Chlorothiazide; Coronary Disease; Diuretics; Hydrochlorothiazide; Hypertension; Kidney Diseases; Liv | 1960 |
[Effects of intravenous administration of hydrochlorothiazide on renal hemodynamics and excretion of electrolytes in hypertensive patients].
Topics: Administration, Intravenous; Chlorothiazide; Electrolytes; Hemodynamics; Hydrochlorothiazide; Hypert | 1960 |
Control of hypertension with hydrochlorothiazide and deserpidine.
Topics: Alkaloids; Chlorothiazide; Hydrochlorothiazide; Hypertension; Hypnotics and Sedatives; Rauwolfia; Re | 1961 |
The use of chlorothiazide or hydrochlorothiazide with reserpine in the office treatment of hypertension.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Reserpine | 1961 |
[Alterations of electrolyte equilibrium induced by prolonged treatment with hydrochlorothiazide and their relation to the hypotensive action of saluretic drugs].
Topics: Chlorothiazide; Diuretics; Electrolytes; Hydrochlorothiazide; Hypertension; Hypotension; Water-Elect | 1961 |
[The therapy of hypertension with hydrochlorothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
[Modifications of renal function in the course of treatment of arterial hypertension by hydrochlorothiazide-reserpine association].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Kidney; Reserpine; Urinary Tract Physiological Ph | 1961 |
[Behavior of some hypertensive responses in the dog treated in a subacute manner with hydrochlorothiazide].
Topics: Animals; Blood Physiological Phenomena; Blood Pressure; Blood Pressure Determination; Chlorothiazide | 1961 |
[Treatment of arterial hypertension with hydrochlorothiazide].
Topics: Hydrochlorothiazide; Hypertension | 1961 |
Technic of controlled drug assay. II. Comparison of chlorothiazide, hydrochlorothiazide and a placebo in the hypertensive patient.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1961 |
Hydrochlorothiazide and syrosingopine in the control of hypertension.
Topics: Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
[The antihypertensive activity of benzothiodiazinic diuretics in clinical application. Experience with hydrochlorothiazide].
Topics: Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 1960 |
[Treatment of arterial hypertension with a combination of reserpine-dihydralazine-hydrochlorothiazide].
Topics: Antihypertensive Agents; Chlorothiazide; Dihydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
Chlorothiazide and hydrochlorothiazide. A clinical comparative study.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1961 |
[Hydrochlorothiazide in arterial hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
Chlorothiazide and hydrochlorothiazide: a comparative study of their hypotensive, saluretic and hyperuricemic action.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Hypotension | 1960 |
[Hydrochlorothiazide in the treatment of the hypertensive edemo-nephrotic syndrome].
Topics: Chlorothiazide; Edema; Female; Humans; Hydrochlorothiazide; Hypertension; Nephrotic Syndrome; Pregna | 1960 |
[Hydrochlorothiazide in the treatment of arterial hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
[Clinical experiences in the therapy of hypertension with hydrochlorothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
The treatment of hypertension with hydrochlorothiazide: a comparison with reserpine.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
[Various pharmacological and therapeutic considerations on chlorothiazide and hydrochlorothiazide in the treatment of arterial hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1959 |
Hydrochlorothiazide used alone and with other hypotensive agents in the treatment of arterial hypertension: a preliminary report.
Topics: Antihypertensive Agents; Chlorothiazide; Hydrochlorothiazide; Hypertension | 1959 |
Chlorothiazide and hydrochlorothiazide in management of hypertension.
Topics: Chlorothiazide; Disease Management; Hydrochlorothiazide; Hypertension | 1960 |
Treatment of hypertension with hydrochlorothiazide as the sole antihypertensive agent.
Topics: Antihypertensive Agents; Chlorothiazide; Foot; Hydrochlorothiazide; Hypertension | 1959 |
[Results of the ambulatory treatment of edemas and arterial hypertension with hydrochlorothiazide].
Topics: Chlorothiazide; Edema; Hydrochlorothiazide; Hypertension | 1960 |
Treatment of congestive heart failure and hypertension: clinical experience with hydrochlorothiazide.
Topics: Chlorothiazide; Heart Failure; Hydrochlorothiazide; Hypertension | 1960 |
[Adelphan esidrex in medical practice].
Topics: Chlorothiazide; Drug Combinations; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
[Treatment of severe essential arterial hypertension with combined reserpine and hydrochlorothiazide].
Topics: Antihypertensive Agents; Chlorothiazide; Essential Hypertension; Hydrochlorothiazide; Hypertension; | 1960 |
[Studies on the mechanism of hypotensive effects of diuril. III. Effect of hydrochlorothiazide on the electrolyte content in arterial walls and skeletal muscles in rats with experimental hypertension].
Topics: Animals; Aorta; Arteries; Chlorothiazide; Electrolytes; Humans; Hydrochlorothiazide; Hypertension; M | 1961 |
Hypertension and edema in the aged: observations on the use of a meprobamate-hydrochlorothiazide combination.
Topics: Aged; Aged, 80 and over; Chlorothiazide; Edema; Edetic Acid; Hydrochlorothiazide; Hypertension; Mepr | 1961 |
Meprobamate alone and in combination with hydrochlorothiazide in the treatment of essential hypertension.
Topics: Chlorothiazide; Essential Hypertension; Hydrochlorothiazide; Hypertension; Meprobamate | 1962 |
[Treatment of hypertension with reserpine in combination with hypothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
[Plasmatic, urinary and tissular water-electrolyte changes in dogs with hypertension induced by baroceptive deafferentation, treated with hydrochlorothiazide].
Topics: Animals; Chlorothiazide; Dogs; Electrolytes; Hydrochlorothiazide; Hypertension; Neurosurgical Proced | 1961 |
Treatment of hypertension with guanethidine and hydrochlorothiazide.
Topics: Chlorothiazide; Guanethidine; Hydrochlorothiazide; Hypertension | 1961 |
Effect of chlorothiazide and hydrochlorothiazide on blood pressure and thyroid activity of hypertensive rats.
Topics: Animals; Blood Pressure; Blood Pressure Determination; Chlorothiazide; Humans; Hydrochlorothiazide; | 1961 |
[Reserpine-hydrazinophthalazine-hydrochlorothiazide combination in the treatment of hypertension].
Topics: Chlorothiazide; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
[Renal hemodynamic variations induced by dihydrochlorothiazide alone and associated with hypotensive agents in subjects with arterial hypertension].
Topics: Antihypertensive Agents; Chlorothiazide; Hemodynamics; Hydrochlorothiazide; Hypertension; Kidney | 1962 |
[Magnesium, calcium and phosphorus balances in essential hypertension and heart insufficiency in the treatment with hydrochlorothiazide].
Topics: Calcium, Dietary; Chlorothiazide; Essential Hypertension; Heart Failure; Humans; Hydrochlorothiazide | 1962 |
The use of Serpasil-Esidrix in the management of mild and moderate hypertension.
Topics: Disease Management; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
Comparison of short term metabolic effects of hydroflumethiazide and hydrochlorothiazide.
Topics: Chlorothiazide; Heart Failure; Humans; Hydrochlorothiazide; Hydroflumethiazide; Hypertension; Ions; | 1962 |
Effect of hydrochlorothiazide-reserpine therapy on cerebral function in elderly hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Psychological Tests; Reserpine | 1963 |
[Comparative study of the effectiveness of drug therapy in hypertensive disease].
Topics: Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine; Vasodilator Agents | 1963 |
A comparative study of Su 8341 and hydrochlorothiazide in hypertensive patients.
Topics: Benzothiadiazines; Humans; Hydrochlorothiazide; Hypertension | 1963 |
[The renal hemodynamics of hypertensive subjects treated with mecamylamine associated with reserpine and dihydrochlorothiazide].
Topics: Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Kidney; Kidney Function Tests; Mecamylamine | 1963 |
[Treatment of hypertension in aged subjects by the reserpine-hydrochlorothiazide-dihydrazinophthalazine combination].
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1963 |
A broad ranged antihypertensive combination (Ser-Ap-Es).
Topics: Antihypertensive Agents; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1963 |
Effective hypertension therapy with least side effects: observations on mebutamate and hydrochlorothiazide.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Antipsychotic Agents; Carbamates; Humans; Hydrochlorot | 1963 |
[Treatment of hypertension with 2 new preparations].
Topics: Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
Vascular lesions in experimental renal hypertension, with special reference to effect of hypotensive treatment.
Topics: Arteries; Cerebral Hemorrhage; Coronary Vessels; Guanethidine; Humans; Hydralazine; Hydrochlorothiaz | 1963 |
A new triple combination tablet for anti-hypertensive therapy.
Topics: Antihypertensive Agents; Hydrazines; Hydrochlorothiazide; Hypertension; Reserpine; Tablets | 1963 |
The evaluation of hypertensive drugs.
Topics: Cardiovascular Agents; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
[The effect of prolonged administration of hydrochlorothiazide on the development of experimental renal hypertension and on electrolyte metabolism in rats].
Topics: Animals; Chlorides; Electrolytes; Hydrochlorothiazide; Hypertension; Hypertension, Renal; Kidney; Po | 1963 |
A comparative evaluation of two antihypertensive preparations.
Topics: Antihypertensive Agents; Benzothiadiazines; Heterocyclic Compounds, 2-Ring; Hydrochlorothiazide; Hyp | 1963 |
[Clinical use of behyd in urology].
Topics: Humans; Hydrochlorothiazide; Hypertension; Urology | 1962 |
[Combined treatment of hypertension with guanethidine-chlorothiazide derivatives (Ismelin-Esidrex and Ismelin-Navidrex)].
Topics: Chlorothiazide; Cyclopenthiazide; Dexamethasone; Guanethidine; Humans; Hydrochlorothiazide; Hyperten | 1962 |
Effect of long-term treatment with hydrochlorothiazide on water and electrolytes of muscle in hypertensive subjects.
Topics: Electrolytes; Humans; Hydrochlorothiazide; Hypertension; Muscles; Potassium; Sodium; Sodium, Dietary | 1963 |
The antihypertensive mechanisms of salt depletion induced by hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorothiazide; Hydrochlorothiazide; Hypertension; Hyponatremia; Sodium; So | 1961 |
Combined guanethidine and hydrochlorothiazide therapy in hypertension.
Topics: Guanethidine; Hydrochlorothiazide; Hypertension | 1963 |
Comparison of two preparations for treating hypertension and edema in the aged.
Topics: Antihypertensive Agents; Edema; Geriatrics; Humans; Hydrochlorothiazide; Hypertension; Meprobamate; | 1962 |
Drug-induced diabetes.
Topics: Benzothiadiazines; Diabetes Mellitus; Humans; Hydrochlorothiazide; Hypertension | 1962 |
A long-term study of combined guanethidine and hydrochlorothiazide therapy in the management of hypertension.
Topics: Guanethidine; Humans; Hydrochlorothiazide; Hypertension | 1962 |
Combined therapy of hypertensive disease with a derivative of rauwolfia and hydrochlorothiazide.
Topics: Alkaloids; Chlorothiazide; Hydrochlorothiazide; Hypertension; Hypnotics and Sedatives; Psychotherapy | 1962 |
METHYLDOPA AND HYDROCHLOROTHIAZIDE IN PRIMARY HYPERTENSION: CONTROLLED CLINICAL TRIAL OF DRUGS SINGLY AND IN COMBINATION.
Topics: Antihypertensive Agents; Essential Hypertension; Humans; Hydrochlorothiazide; Hypertension; Methyldo | 1963 |
TREATMENT OF HYPERTENSION WITH GUANETHIDINE.
Topics: Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Mecamylamine; Toxicology | 1963 |
[CURRENT THERAPY OF HYPERTENSION].
Topics: Antihypertensive Agents; Benzothiadiazines; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; | 1963 |
TRIAMTERENE WITH HYDROCHLOROTHIAZIDE IN THE TREATMENT OF HYPERTENSION.
Topics: Diuretics; Hydrochlorothiazide; Hypertension; Hypokalemia; Potassium; Pterins; Sodium; Sodium, Dieta | 1963 |
METHYLDOPA AND HYDROCHLOROTHIAZIDE COMPARED WITH RESERPINE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Methyldopa; Placebos; Reserpine | 1963 |
RED BLOOD CELL POTASSIUM; THERAPEUTIC IMPLICATIONS.
Topics: Anemia; Anemia, Hypochromic; Blood Platelets; Digitalis Glycosides; Diuretics; Erythrocytes; Fludroc | 1964 |
[EFFECTS OF 6 DRUGS ON THE PRODUCTION OF RENAL HYPERTENSION IN RATS].
Topics: Alkaloids; Bretylium Compounds; Hydrochlorothiazide; Hypertension; Hypertension, Renal; Pharmacology | 1962 |
[GUSTATORY ACUITY FOR SALTY FLAVOR AND SALIVARY ELECTROLYTE CONCENTRATION].
Topics: Addison Disease; Cerebrovascular Disorders; Chlorides; Cushing Syndrome; Flavoring Agents; Heart Fai | 1963 |
[CLINICAL STUDY OF A NEW COMPLEX HYPOTENSIVE DRUG COMBINATION].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Cerebrovascular Disorders; Coronary Disease; | 1963 |
[CLINICAL RESEARCH WITH A COMPOUND HYPOTENSIVE PREPARATION (MEBUTAMATE + 1-4 DIHYDRAZINOPHTHALAZINE + DIHYDROCHLOROTHIAZIDE + POTASSIUM)].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Humans; Hydralazine; Hydrochlorothiazide; Hyp | 1963 |
[APPLICATION OF HYPOTHIAZIDE IN CHRONIC KIDNEY DISEASES].
Topics: Acute Kidney Injury; Blood Chemical Analysis; Glomerulonephritis; Hydrochlorothiazide; Hypertension; | 1963 |
[ON THE ANTIHYPERTENSIVE EFFECT OF THE SUBSTANCES ISOBUTYLHYDROCHLOROTHIAZIDE, SPIRONOLACTONE AND TRIAMTERENE ACTING ON ELECTROLYTES].
Topics: Antihypertensive Agents; Diuretics; Electrolytes; Geriatrics; Humans; Hydrochlorothiazide; Hypertens | 1963 |
[SOME PRINCIPLES OF DRUG THERAPY IN HYPERTENSION].
Topics: Antihypertensive Agents; Ganglionic Blockers; Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1963 |
HYPERTENSION CONTROL; MEBUTAMATE AND HYDROCHLOROTHIAZIDE.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Carbamates; Geriatrics; Hydrochlorothiazide; Hypertens | 1964 |
CLINICAL EXPERIENCE WITH THE DIURETIC EFFECTS OF TRIAMTERENE ALONE AND COMBINED WITH HYDROCHLOROTHIAZIDE.
Topics: Arteriosclerosis; Body Weight; Diuretics; Heart Failure; Hydrochlorothiazide; Hypertension; Potassiu | 1964 |
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates; | 1964 |
THE HYPERGLYCEMIC EFFECT OF HYPOTENSIVE DRUGS.
Topics: Antihypertensive Agents; Benzothiadiazines; Black People; Blood Glucose; Diazoxide; Guanethidine; Hu | 1964 |
[ACTION OF ALPHA-METHYLDOPA IN COMBINATION WITH DIHYDROCHLOROTHIAZIDE ON RENAL HEMODYNAMICS IN HYPERTENSIVE SUBJECTS].
Topics: Antihypertensive Agents; Arteriosclerosis; Blood Circulation; Diuresis; Hemodynamics; Humans; Hydroc | 1963 |
[ACUTE MALIGNANT HYPERTENSION WITH SECONDARY ALDOSTERONISM. A CASE IN A 31-YEAR-OLD MAN WITH CONGENITAL UNILATERAL RENAL HYPOPLASIA].
Topics: Alkalosis; Antihypertensive Agents; Blood Chemical Analysis; Congenital Abnormalities; Guanethidine; | 1964 |
[ON THE ACTION OF TRIAMTERENE ON SALIDIURESIS CAUSED BY HYDROCHLOROTHIAZIDE].
Topics: Ascites; Diuresis; Diuretics; Edema; Heart Failure; Hepatitis; Hydrochlorothiazide; Hypertension; Hy | 1963 |
DIURETIC AND HYPOTENSIVE PROPERTIES OF ETHACRYNIC ACID: A COMPARISON WITH HYDROCHLOROTHIAZIDE.
Topics: Biomedical Research; Blood Pressure; Blood Pressure Determination; Chlorides; Diuretics; Ethacrynic | 1964 |
[THE ASSOCIATION OF ALPHA-METHYL-DOPA WITH DIHYDROCHLOROTHIAZIDE IN THE THERAPY OF ARTERIAL HYPERTENSION].
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Methyldopa | 1964 |
EFFECT OF HYDROCHLOROTHIAZIDE ON SERUM AND URINARY CALCIUM AND URINARY CITRATE.
Topics: Acetazolamide; Benzothiadiazines; Blood Chemical Analysis; Body Fluids; Calcium; Calcium, Dietary; C | 1964 |
[NATRIURETIC DRUGS].
Topics: Acetazolamide; Aldosterone; Ascites; Chlorothiazide; Dexamethasone; Diabetes Insipidus; Diuresis; Di | 1963 |
GUANETHIDINE IN COMBINATION WITH HYDRALAZINE AND WITH HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Blood Pressure Determination; Guanethidine; Hydralazine; Hydrochlorothiazide; Hypertension; Toxicolo | 1964 |
[SEVERE NEUROLOGICAL SIDE-EFFECTS IN HYPOTENSION THERAPY].
Topics: Amobarbital; Antihypertensive Agents; Arteriosclerosis; Chlorothiazide; Chlorthalidone; Guanethidine | 1964 |
[CONSIDERATIONS ON THE RENAL SIDE-EFFECTS DURING TREATMENT OF ARTERIAL HYPERTENSION].
Topics: Bretylium Compounds; Chlorothiazide; Guanethidine; Hydralazine; Hydrochlorothiazide; Hypertension; K | 1964 |
COMPARISON OF ALPHA-METHYLDOPA WITH STANDARD ANTIHYPERTENSIVE THERAPY IN MAN.
Topics: Antihypertensive Agents; Blood Pressure Determination; Guanethidine; Humans; Hydralazine; Hydrochlor | 1964 |
[CONTRIBUTION TO THE STUDY OF EXPERIMENTAL MODELS OF ARTERIAL HYPERTENSION].
Topics: Animals; Chlorisondamine; Classification; Cortisone; Dogs; Ganglionic Blockers; Hydrochlorothiazide; | 1964 |
[ACTION OF ALPHA-METHYLDOPA, ALONE AND COMBINED WITH HYDROCHLOROTHIAZIDE, IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION].
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Methyldopa | 1964 |
[ALPHA-METHYLDOPA, ALPHA-METHYLDOPA AND HYDROCHLOROTHIAZIDE, AND A PLACEBO IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION: "DOUBLE-BLIND" TEST].
Topics: Antihypertensive Agents; Biomedical Research; Blindness; Double-Blind Method; Hydrochlorothiazide; H | 1964 |
LONG TERM THERAPY WITH GUANETHIDINE AND ASSOCIATED ANTIHYPERTENSIVE DRUGS.
Topics: Antihypertensive Agents; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reser | 1964 |
MANAGEMENT OF HYPERTENSION IN AMBULANT PATIENTS.
Topics: Barbiturates; Disease Management; Geriatrics; Hydrochlorothiazide; Hypertension; Reserpine | 1964 |
POLYARTERITIS NODOSA. REPORT OF A PATIENT RECEIVING LONG-TERM ANTICOAGULANT THERAPY.
Topics: Anticoagulants; Biopsy; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Guanethidin | 1964 |
ACUTE ANURIA ASSOCIATED WITH CHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE THERAPY: RECOVERY.
Topics: Acute Kidney Injury; Anuria; Chlorothiazide; Diabetes Mellitus; Digoxin; Geriatrics; Gout; Hydrochlo | 1964 |
THE EFFECT OF SALURETICS ON PULSE RATE, BLOOD PRESSURE AND ELECTROCARDIOGRAM DURING EXERCISE IN NORMAL SUBJECTS.
Topics: Aspirin; Biomedical Research; Blood; Blood Pressure; Blood Pressure Determination; Chlorides; Chlort | 1964 |
COMBINATION DRUG THERAPY OF HYPERTENSION.
Topics: Drug Therapy; Drug Therapy, Combination; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Res | 1964 |
THE CARDIAC ATHLETE. RECENT STUDIES IN SPORTS MEDICINE.
Topics: Athletes; Atrial Fibrillation; Classification; Exercise Test; Heart; Heart Diseases; Humans; Hydroch | 1964 |
CONJOINT CLINIC ON DRUGS AND DIABETES.
Topics: Adrenalectomy; Antihypertensive Agents; Benzothiadiazines; Biomedical Research; Blood; Blood Glucose | 1964 |
PROLONGED CARDIOGENIC SHOCK WITH RECOVERY.
Topics: Angina Pectoris; Coronary Disease; Digoxin; Electrocardiography; Hydrochlorothiazide; Hypercholester | 1964 |
USE OF SER-AP-ES FOR HYPERTENSION.
Topics: Biomedical Research; Drug Therapy; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1964 |
A NEW HYPOTENSIVE DRUG COMBINATION (GUANETHIDINE-HYDROCHLOROTHIAZIDE).
Topics: Biomedical Research; Drug Combinations; Drug Therapy; Geriatrics; Guanethidine; Hydrochlorothiazide; | 1964 |
[THE BLOOD PRESSURE RESPONSES OF NORMOTENSIVE AND HYPERTENSIVE DOGS TO NORADRENALINE AND METHACHOLINE DURING THE ADMINISTRATION OF HYPOTENSIVE DRUGS].
Topics: Blood Pressure; Dogs; Hydrochlorothiazide; Hypertension; Methacholine Chloride; Methacholine Compoun | 1964 |
TREATMENT OF HYPERTENSION WITH COMBINATION OF ALKAVERVIR AND EPITHIAZIDE.
Topics: Benzothiadiazines; Biomedical Research; Blood Pressure Determination; Drug Therapy; Humans; Hydrochl | 1964 |
SUSTAINED HYPERTENSION IN DOGS FOLLOWING CHRONIC ADMINISTRATION OF GANGLIONIC BLOCKING AGENTS.
Topics: Animals; Blood Pressure; Chlorisondamine; Dogs; Ganglionic Blockers; Hydrochlorothiazide; Hypertensi | 1964 |
[CLINICAL TRIAL OF A HYPOTENSIVE DRUG: 3,4-DIHYDROXY-D-L-PHENYLALANINE OR METHYLDOPA].
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Eye Manifestations; Humans; Hydrochlorothia | 1964 |
[CLINICAL EXPERIENCE OF 2,4,7-TRIAMINO-6-PHENYLPTERIDINE THERAPY UPON LONG TERM AND COMPOUND ADMINISTRATION WITH OTHER AGENTS].
Topics: Adolescent; Biomedical Research; Chlorthalidone; Diuretics; Drug Therapy; Edema; Geriatrics; Hydroch | 1964 |
COMPARATIVE EFFECTIVENESS OF PARGYLINE AS AN ANTIHYPERTENSIVE AGENT.
Topics: Antihypertensive Agents; Biomedical Research; Drug Therapy; Guanethidine; Hemodynamics; Humans; Hydr | 1964 |
[USE OF RESERPINE ASSCIATED WITH HYPOTHIAZIDE IN THE TREATMENT OF CEREBRAL FORMS OF HYPERTENSION].
Topics: Cerebrovascular Disorders; Drug Therapy; Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1964 |
THE USE OF METHYLDOPA IN HYPERTENSION.
Topics: Aspartate Aminotransferases; Biomedical Research; Blood; Blood Urea Nitrogen; Chlorothiazide; Drug T | 1964 |
SMALL-BOWEL ULCERS WITH THAIZIDE AND POTASSIUM.
Topics: Coronary Disease; Diuretics; Hydrochlorothiazide; Hypertension; Ileum; Intestinal Diseases; Potassiu | 1965 |
MAGNESIUM METABOLISM IN HYPERTENSION.
Topics: Biomedical Research; Blood Chemical Analysis; Blood Pressure; Blood Pressure Determination; Blood Ur | 1965 |
CLINICAL EXPERIENCES WITH HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF UNCOMPLICATED, UNTREATED, ESSENTIAL HYPERTENSION.
Topics: Disease Management; Drug Therapy; Essential Hypertension; Humans; Hydrochlorothiazide; Hypertension | 1964 |
[THE EFFECT OF DIURETIC PREPARATIONS (THIAZIDE) ON INTRA- AND EXTRACELLULAR POTASSIUM IN EDEMA-FREE PATIENTS].
Topics: Chlorothiazide; Diuretics; Drug Therapy; Edema; Heart Block; Humans; Hydrochlorothiazide; Hypertensi | 1964 |
METHYLDOPA: CLINICAL STUDIES IN ARTERIAL HYPERTENSION.
Topics: Cardiac Output; Chemical and Drug Induced Liver Injury; Drug Therapy; Hemodynamics; Hepatitis; Human | 1964 |
TRIAMTERENE: CLINICAL STUDIES IN ARTERIAL HYPERTENSION.
Topics: Blood Volume; Cardiac Output; Drug Therapy; Dye Dilution Technique; Hemodynamics; Humans; Hydrochlor | 1965 |
HYPOKALEMIC ALKALOSIS WITH ADRENAL TUMOR: A CASE REPORT. CONN'S SYNDROME OR DRUG-INDUCED HYPOKALEMIC ALKALOSIS.
Topics: Adenoma; Adrenal Gland Neoplasms; Alkalosis; Drug Therapy; Humans; Hydrochlorothiazide; Hyperaldoste | 1965 |
[HYPOTHIAZIDE THERAPY OF HYPERTENSION AND POSSIBILITIES OF ITS PROLONGED USE].
Topics: Antihypertensive Agents; Drug Therapy; Electrocardiography; Geriatrics; Hydrochlorothiazide; Hyperte | 1964 |
[CLINICAL EVALUATION OF A PHARMACOLOGIC ASSOCIATION WITH HYPOTENSIVE ACTION].
Topics: Antihypertensive Agents; Biomedical Research; Carbamates; Drug Therapy; Electric Impedance; Humans; | 1964 |
FLUORESCEIN CIRCULATION TIME AND TREATMENT IN HYPERTENSION.
Topics: Blood Circulation Time; Drug Therapy; Fluorescein; Fluoresceins; Hydrochlorothiazide; Hypertension; | 1965 |
[TREATMENT OF HYPERTENSION WITH ALPHA-METHYL-DOPA AND HYDROCHLOROTHIAZIDE].
Topics: Adolescent; Drug Therapy; Humans; Hydrochlorothiazide; Hypertension; Methyldopa | 1965 |
TREATING DIFFICULT-TO-MANAGE EDEMATOUS HYPERTENSIVE PATIENTS WITH HYDROCHLOROTHIAZIDE.
Topics: Disease Management; Drug Therapy; Edema; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; T | 1965 |
HYPOTENSIVE EFFECT OF ETHACRYNIC ACID.
Topics: Biomedical Research; Blood Chemical Analysis; Diet, Sodium-Restricted; Diuretics; Drug Therapy; Etha | 1965 |
SIX-MONTH DOUBLE-BLIND STUDY OF BENZOTHIADIAZINE DRUG EFFECTS ON HYPERTENSION AND SELECTED BLOOD CHEMISTRIES.
Topics: Bendroflumethiazide; Biomedical Research; Blood Chemical Analysis; Double-Blind Method; Drug Therapy | 1965 |
CLINICAL EFFECTIVENESS OF FOUR HYPOTENSIVE PREPARATIONS.
Topics: Barbiturates; Biomedical Research; Drug Therapy; Hydrochlorothiazide; Hypertension; Reserpine; Treat | 1965 |
TREATMENT OF HYPERTENSION WITH DEBRISOQUIN SULFATE (DECLINAX).
Topics: Antihypertensive Agents; Biomedical Research; Debrisoquin; Drug Therapy; Hydrochlorothiazide; Hypert | 1965 |
MANAGING THE HYPERTENSIVE OUT PATIENT WITH THE RAUWOLFIA-THIAZIDE PREPARATION.
Topics: Alkaloids; Hydrochlorothiazide; Hypertension; Outpatients; Rauwolfia; Reserpine; Thiazides; Toxicolo | 1965 |
FURTHER EXPERIENCE WITH SPIRONOLACTONE-HYDRO-CHLOROTHIAZIDE (ALDACTAZIDE-A) IN THE LONG-TERM TREATMENT OF REFRACTORY CARDIAC EDEMA.
Topics: Arteriosclerosis; Chlorothiazide; Coronary Disease; Drug Combinations; Drug Therapy; Edema; Edema, C | 1965 |
[DATA ON THE TREATMENT OF HYPERTENSIVE PATIENTS WITH HYPOTHIAZIDE].
Topics: Drug Therapy; Humans; Hydrochlorothiazide; Hypertension | 1964 |
COMPARATIVE EFFICACY OF MEBUTAMATE COMBINED WITH HYDROCHLOROTHIAZIDE IN ESSENTIAL HYPERTENSION.
Topics: Antihypertensive Agents; Carbamates; Drug Therapy; Essential Hypertension; Hydrochlorothiazide; Hype | 1965 |
EFFECT OF THIAZIDES ON METACORTICOID HYPERTENSION AND ON THYROID ACTIVITY OF RATS.
Topics: Adrenal Glands; Chlorothiazide; Desoxycorticosterone; Heart; Humans; Hydrochlorothiazide; Hypertensi | 1965 |
[HIGH BLOOD PRESSURE THERAPY WITHOUT RESERPINE? A CONTRIBUTION TO THE THERAPY OF HYPERTENSION].
Topics: Alkaloids; Drug Therapy; Humans; Hydrochlorothiazide; Hypertension; Potassium Chloride; Rauwolfia; R | 1965 |
[TREATMENT OF AGED PATIENTS WITH CEREBRAL FORMS OF HYPERTENSION WITH HYPOTHIAZIDE AND RESERPINE].
Topics: Cerebrovascular Disorders; Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1965 |
[Ambulatory treatment by hydrochlorothiazide of arterial hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
Potentiating the hypotensive effect of hydrochlorothiazide with syrosingopine.
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Reserpine | 1960 |
[Hypotensive action of hydrochlorothiazide in the treatment of arterial hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension; Hypotension | 1960 |
A comparison of the side effects and antihypertensive potency of chlorothiazide and hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
[Results of dihydrochlorothiazide therapy of ambulatory hypertonic patients].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1959 |
[Observations on the therapy of hypertension with hydrochlorothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1960 |
[Use of hypothiazide in the treatment of hypertension].
Topics: Chlorothiazide; Hydrochlorothiazide; Hypertension | 1962 |
Clinical trials with hydrochlorothiazide.
Topics: Chlorothiazide; Heart Failure; Hydrochlorothiazide; Hypertension | 1962 |
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide.
Topics: Adult; Blood Pressure; Calmodulin-Binding Proteins; Diuretics; Female; Gene Frequency; Genotype; Hum | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
[Therapy of patients with arterial hypertension with fixed dose combination of losartan and hydrochlorothiazide. Effect on 24 hour blood pressure and left-ventricular hypertrophy].
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochl | 2003 |
[The use of nebivolol in menopausal women with hypertension].
Topics: Age Factors; Antihypertensive Agents; Benzopyrans; Diuretics; Drug Therapy, Combination; Ethanolamin | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
Images in clinical medicine. Hypokalemia.
Topics: Adult; Amiloride; Diuretics; Drug Combinations; Electrocardiography; Humans; Hydrochlorothiazide; Hy | 2003 |
[Episodes of depression with attempted suicide after taking valsartan with hydrochlorothiazide].
Topics: Adult; Antihypertensive Agents; Depression; Drug Therapy, Combination; Female; Humans; Hydrochloroth | 2003 |
[Fast to the blood pressure goal. Lengthy dose adjustments harm compliance].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Diuretics; Dr | 2003 |
[Optimization of sanatorium treatment of patients with essential hypertension stage II by chronotherapy].
Topics: Adult; Aged; Antihypertensive Agents; Balneology; Chronotherapy; Circadian Rhythm; Diuretics; Echoca | 2003 |
[Therapy of hypertension. Cost conscious prevention of complications].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Cost Sa | 2003 |
[Health care too costly? Saving more than 10 million euros in 2 months!].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost Savings; Drug Combinations; | 2003 |
Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Depression; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; H | 2004 |
Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination | 2004 |
[From the beginning -- a strong-acting and well tolerable antihypertensive agent. The recipe against constant change].
Topics: Antihypertensive Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 2003 |
Calcium antagonist and beta blocker regimens found equally effective in hypertensive patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; Di | 2004 |
[Can hydrochlorothiazide and chlorthalidone be compared in the treatment of hypertension?].
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Sodiu | 2004 |
[Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Delayed-Action Prepar | 2003 |
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba | 2004 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
[Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Drug Combinations | 2003 |
Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2004 |
Sponsorship of educational programmes in Nigerian medical and pharmacy schools by pharmaceutical companies: possible risk implication for public health.
Topics: Advertising; Conflict of Interest; Drug Industry; Education, Medical; Education, Pharmacy; Financial | 2001 |
Hyponatremia due to an additive effect of carbamazepine and thiazide diuretics.
Topics: Anticonvulsants; Carbamazepine; Comorbidity; Diuretics; Drug Interactions; Epilepsy, Complex Partial | 2004 |
Hydrochlorothiazide induced hepato-cholestatic liver injury.
Topics: Aged; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Di | 2004 |
The world wide web.
Topics: Aged; Antihypertensive Agents; Drug Combinations; Enalapril; Family Practice; Humans; Hydrochlorothi | 2004 |
[First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Combinations; Huma | 2004 |
[New combination of high dosage sartan and 25 mg HCT. Systolic blood pressure lowered by 21 mmHg].
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2004 |
[Therapy of hypertension. Pulse pressure must also be reduced].
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hydrochlorothiazide; Hyp | 2004 |
TREATMENT OF HYPERTENSION WITH GUANETHIDINE AND HYDROCHLOROTHIAZIDE.
Topics: Drug Therapy; Geriatrics; Guanethidine; Hydrochlorothiazide; Hypertension | 1964 |
Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; A | 2004 |
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2004 |
[Lethal polypharmacy in a patient with arterial hypertension].
Topics: Aged; Aged, 80 and over; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2004 |
Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Automation; Blood Pressure; | 2004 |
Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats.
Topics: Animals; Bisoprolol; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug T | 2005 |
A novel epithelial sodium channel beta-subunit mutation associated with hypertensive Liddle syndrome.
Topics: Amiloride; Amino Acid Substitution; Base Sequence; Child, Preschool; Diuretics; Drug Therapy, Combin | 2005 |
[Lethal polypharmacy in a patient with arterial hypertension--re the article from DMW 50/2004].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2005 |
Cyclical Cushing's disease causing recurrent oedema and knee effusions.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Diuretics; Drug Therapy, Combination; Edema; Enalapril | 2005 |
Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity?
Topics: Adult; Antihypertensive Agents; Baroreflex; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2005 |
The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Drug Therapy, Combinatio | 2005 |
[Level of endothelial vasodilatation and activity of angiotensin converting enzyme as criterion of efficacy of therapy in patients with mild and moderate hypertension].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Brachial Artery; Diuret | 2005 |
[Good blood pressure control even in overweight patients].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2005 |
Management of hypertension in patients with CKD: differences between primary and tertiary care settings.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2005 |
[Association of polymorphisms in ACE and CYP11B2 genes with antihypertensive effects of hydrochlorothiazide].
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP11B2; Female; Humans; Hydrochlorothiazide; Hyper | 2005 |
Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
Topics: Adult; Aging; Antihypertensive Agents; Atenolol; Case-Control Studies; Cohort Studies; Drug Prescrip | 2005 |
Antihypertensive treatment and sympathetic excitation.
Topics: Antihypertensive Agents; Baroreflex; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2005 |
[A patient with severe hyperkalaemia -- an emergency after RALES].
Topics: Acute Kidney Injury; Adrenergic beta-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2005 |
Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction.
Topics: Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Middle Aged | 2005 |
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
Topics: Adult; Biological Transport; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Epithe | 2005 |
Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Diuretics; Drug Therap | 2006 |
[Association of polymorphism in alpha-adducin gene with antihypertensive effect of Hydrochlorothiazide].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins | 2005 |
More heat to support aggressive blood pressure lowering: the FEVER study.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Felodipine; Humans; Hy | 2005 |
Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; B | 2005 |
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chi-Square Distribution; Coronary Disea | 2005 |
Differential expression of components of the cardiomyocyte adrenomedullin/intermedin receptor system following blood pressure reduction in nitric oxide-deficient hypertension.
Topics: Adrenomedullin; Animals; Body Weight; Hydralazine; Hydrochlorothiazide; Hypertension; Intracellular | 2006 |
Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Apomorphine; Blood Pressure; Enalapril; Hydralazine; Hydroc | 2006 |
Hypertension in the oncology setting.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2005 |
[Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: the MACHT Observational Study.
Topics: Aged; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazid | 2006 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cholesterol; Cholesterol, LDL; Female; Glucose | 2006 |
[Chronic effects of low-dose hydrochlorothiazide in patients with mild to moderate essential hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertens | 2006 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2006 |
[Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension].
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Brachial Artery; Endothelium, Vascular | 2006 |
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Delayed-Action Preparations; | 2006 |
[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compo | 2006 |
Hematuria in a patient with class IV lupus nephritis.
Topics: Antihypertensive Agents; Biopsy; Cyclophosphamide; El Salvador; Female; Follow-Up Studies; Glomerula | 2006 |
Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blo | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Aut | 2006 |
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Topics: Adolescent; Adult; Amides; Amlodipine; Antihypertensive Agents; Drug Interactions; Drug Therapy, Com | 2006 |
Synergism of hydrochlorothiazide and nitrendipine on reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Hydrochlorothiazide; Hypertension; | 2006 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
A case of fatal necrotizing pancreatitis: complication of hydrochlorothiazide and lisinopril therapy.
Topics: Antihypertensive Agents; Fatal Outcome; Humans; Hydrochlorothiazide; Hypertension; Lisinopril; Male; | 2007 |
[Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure De | 2007 |
Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension.
Topics: Adaptation, Physiological; Adult; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure | 2007 |
Hepatocellular necrosis associated with labetalol.
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Inj | 2007 |
Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2007 |
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Comp | 2007 |
Pharmacological washout for the correct evaluation of the head-up tilt testing.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Diagnostic Errors; Drug Therapy, Combination; | 2008 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Diabetic Retinopathy; Drug C | 2007 |
Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment.
Topics: Aged; Angiotensinogen; Cytochrome P-450 CYP11B2; Female; Genotype; Humans; Hydrochlorothiazide; Hype | 2007 |
[Successful high dosage fixed combination. 7 of 10 patients achieve target blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2006 |
[Treatment of hypertension in daily practice. Current results of a postmarketing surveillance study with telmisartan].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Drug Therapy, Combi | 2007 |
[Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)].
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hydroch | 2006 |
Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug The | 2007 |
Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance.
Topics: Arteries; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Elasticity; Female; Glucose Intolera | 2007 |
Antihypertensive therapies.
Topics: Amides; Antihypertensive Agents; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials | 2007 |
Chronic and acute effects of different antihypertensive drugs on femoral artery relaxation of L-NAME hypertensive rats.
Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pre | 2007 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |
BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2007 |
The effect of Ramadan fasting on ambulatory blood pressure in hypertensive patients using combination drug therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2008 |
[Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Confidence Intervals; D | 2007 |
Conceptual basis and methodology of the SOPHIA study.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Clinical Trials as Topic | 2007 |
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antihypertensive Agents; Bone Density Conservation Agents; Cos | 2008 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Hyponatremia associated with SSRI use in a 65-year-old woman.
Topics: Depressive Disorder; Diuretics; Drug Monitoring; Drug Synergism; Dyslipidemias; Female; Humans; Hydr | 2008 |
Clinical predictors of the response to short-term thiazide treatment in nondiabetic essential hypertensives.
Topics: Adult; Chi-Square Distribution; Diuretics; Female; Heart Rate; Humans; Hydrochlorothiazide; Hyperten | 2008 |
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Ant | 2008 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Topics: Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Drug Combinations | 2008 |
[Clinical assessment of metabolic effects of antihypertensive therapy].
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Gl | 2008 |
Action of thiazide on renal interstitial calcium.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium; Diuretics; Extracellular Fluid; Hydrochlo | 2008 |
[Lipoproteinase activity, heparin and basophil blood levels in patients with hypertension, and the effect of depressin therapy on these indices].
Topics: Antihypertensive Agents; Basophils; Benzimidazoles; Female; Heparin; Humans; Hydrochlorothiazide; Hy | 1966 |
Evolution of adrenal regeneration hypertension in rats with actively regenerating or fully regenerated glands.
Topics: Adrenal Glands; Aging; Animals; Blood Pressure; Body Weight; Diet; Drinking; Female; Heart; Hydrochl | 1967 |
Benign and malignant hypertension after adrenal enucleation in the rat. Relationship to salt intake, response to hydrochlorothiazide, and similarity to essential hypertension.
Topics: Adrenalectomy; Animals; Hydrochlorothiazide; Hypertension; Hypertension, Malignant; Postoperative Co | 1967 |
[Contribution to anti-hypertensive therapy with a drug combination].
Topics: Aged; Carbamates; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1967 |
[Exchangeable potassium in normal persons and patients with arterial hypertension. With reference to the importance of diuretic therapy].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Spiron | 1967 |
Further study of the sustained hypertension produced by chronic administration of mecamylamine.
Topics: Animals; Blood Pressure; Dogs; Female; Heart Rate; Hydrochlorothiazide; Hypertension; Male; Mecamyla | 1967 |
Acute and chronic influence of diazoxide on adrenal-regeneration hypertension.
Topics: Adrenal Glands; Animals; Blood Pressure; Blood Vessels; Diazoxide; Drinking; Female; Hydrochlorothia | 1967 |
Differential response to thiazides and spironolactone in primary aldosteronism.
Topics: Adult; Alkalosis; Blood Pressure; Diagnosis, Differential; Humans; Hydrochlorothiazide; Hyperaldoste | 1967 |
[Electrolyte metabolism in hypertension].
Topics: Adult; Aged; Aldosterone; Animals; Catecholamines; Diet; Female; Food; Humans; Hydrochlorothiazide; | 1967 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heart Rate | 1984 |
The calcium channel blocker nitrendipine in single- and multiple-agent antihypertensive regimens: preliminary report of a multicenter study.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Calcium Channel Blockers; Drug Therapy, Combi | 1984 |
Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Dipeptid | 1984 |
Converting enzyme activity in regulation of blood pressure and kidney function. A review.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Drug T | 1984 |
The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Diet, Sodium-Restricted; Dipeptides; | 1984 |
Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide.
Topics: Animals; Blood Pressure; Cardiomegaly; Diet, Sodium-Restricted; Dipeptides; Enalapril; Hydrochloroth | 1983 |
Biochemical monitoring of vasoactive peptides during angiotensin converting enzyme inhibition.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Captopril; Cros | 1983 |
Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Body Fluids; Body Weight; Cardiac Output; Drug Therapy, Combination; En | 1984 |
Effect of antihypertensive therapy on left ventricular function and myocardial perfusion at rest and during exercise.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Circulation; Enalapril; Female; Heart | 1984 |
Low-dose diuretic and beta adrenoceptor blocker in essential hypertension.
Topics: Adrenergic beta-Antagonists; Aldosterone; Analysis of Variance; Black People; Blood Pressure; Diuret | 1980 |
Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Amiloride; Antihypertensive Agents; Blood Pressure; | 1980 |
Angiotensin II blockade during combined thiazide-beta-blocker treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aldosterone; Angiotensin II; Drug Interactions; Female; Humans; | 1980 |
[Beta blockader treatment in ambulatory hypertension care. A multicentric long-term study].
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Bupranolol; Female; Humans; Hydrochlorothiazide | 1980 |
[The antihypertensive effect of a fixed combination of beta receptor blockaders and diuretics on the resting and exertion blood pressure of patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Amiloride; Diuretics; Drug Combinations; Female; Humans; Hydroch | 1980 |
[Physiopathological basis for a tailored management of essential hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Amiloride; Drug Combinations; Female; Humans; Hydrochlorothiazid | 1981 |
[A new drug combination: metipranolol with butizide in the treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Diuretics; Drug Combinations; Fem | 1981 |
[Antihypertensive therapy in pregnancy].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clonidine; Female; Humans; Hydralazine; Hydro | 1982 |
Treadmill exercise testing in hypertensive patients treated with hydrochlorothiazide and beta-blocking drugs.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Drug Therapy, Combination; Exercise Test; Female | 1983 |
Thiazide or beta-blocker for hypertension.
Topics: Black People; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazide; Hypertension; Propranol | 1983 |
Modification of blood pressure and systolic time intervals by diuretics and beta-blockers in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Diuretics; Female; Furosemide; Heart R | 1983 |
Medroxalol combined with hydrochlorothiazide in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Pressure; Catecholamines; Drug Ther | 1983 |
Assessment of optimal dose of diuretic associated with fixed dose of beta-blocking: a new experimental model based on multiple sampling of blood pressure performed by self-measurements.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Blood Pressure Determination; Diuretics; Drug Th | 1984 |
[Combined treatment of hypertension patients].
Topics: Adolescent; Adult; Antihypertensive Agents; Clonidine; Drug Combinations; Drug Evaluation; Drug Ther | 1984 |
Hypersensitive carotid sinus syndrome manifested as cough syncope.
Topics: Blood Pressure; Bradycardia; Cardiac Pacing, Artificial; Carotid Sinus; Cough; Denervation; Electroc | 1980 |
Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems.
Topics: Adult; Aprotinin; Creatinine; Diuretics; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertensi | 1982 |
[Interaction between antihypertensive and antirheumatic agents].
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Aprotinin; Captopril; Dogs; Drug Antagon | 1983 |
Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias.
Topics: Adult; Aged; Ambulatory Care; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiac Complexes, Prem | 1983 |
Sotalol, hypokalaemia, syncope, and torsade de pointes.
Topics: Adult; Aged; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; Female; H | 1984 |
Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aprotinin; Captopril; Dipeptides; Drug Synergism; | 1984 |
The impact on serum lipids of combinations of diuretics and beta-blockers and of beta-blockers alone.
Topics: Adrenergic beta-Antagonists; Cholesterol, HDL; Diuretics; Drug Therapy, Combination; Humans; Hydroch | 1984 |
Reversal of left ventricular hypertrophy by antihypertensive therapy.
Topics: Antihypertensive Agents; Cardiomegaly; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazid | 1982 |
[Hemodynamic mechanism of the hypotensive action of diuretics and their effect on myocardial hypertrophy in the process of long-term treatment of hypertension].
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Diuretics; Drug Evaluation; Furosemide; Heart; Hemodyn | 1982 |
Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR): oxprenolol versus hydrochlorothiazide.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Heart Ventricles; Hydrochlorothiazide; Hypertens | 1983 |
Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Drug Therapy, Combi | 1983 |
[Combined effect of hydrochlorothiazide and atenolol in antihypertensive therapy of 42 patients].
Topics: Adult; Atenolol; Blood Pressure; Drug Therapy, Combination; Electrolytes; Heart Rate; Humans; Hydroc | 1983 |
[Efficacy of the association of atenolol with an amiloride-hydrochlorothiazide combination in the treatment of persistent arterial hypertension].
Topics: Adult; Aged; Amiloride; Atenolol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydr | 1984 |
The effect of single-dose methyldopa and diuretic on BP and left ventricular mass.
Topics: Adult; Aged; Amiloride; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; Echocardiography; F | 1984 |
Porokeratosis of Mibelli: benzylhydrochlorothiazide-induced new lesions accompanied by eosinophilic spongiosis.
Topics: Aged; Drug Eruptions; Eosinophilia; Humans; Hydrochlorothiazide; Hypertension; Keratosis; Male; Skin | 1984 |
Inhibitors of angiotensin-converting enzyme.
Topics: Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Binding Sites; Binding, Competitiv | 1980 |
Endocrine profile in the long-term phase of converting-enzyme inhibition.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diet, Sodiu | 1980 |
Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
Topics: Administration, Oral; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyperten | 1981 |
Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension.
Topics: Administration, Oral; Adult; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Comb | 1981 |
Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Creatinine; Dose-R | 1982 |
Studies on the mechanism of the enhancement of the antihypertensive activity of captopril by a diuretic in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Blood Pressure; Captopril; Drug Synergism; Heart Rate; Hydrochlorothiazide; | 1982 |
[Mechanism of action of benzothiadiazides in arterial hypertension: the energetic theory].
Topics: Adenylyl Cyclase Inhibitors; Animals; Chlorthalidone; Columbidae; Cyclic AMP; Diuretics; Energy Meta | 1982 |
Effect of antihypertensive therapy on sympathetic nervous system activity in patients with essential hypertension.
Topics: Antihypertensive Agents; Captopril; Clonidine; Guanethidine; Humans; Hydrochlorothiazide; Hypertensi | 1984 |
Monotherapy in mild to moderate hypertension: comparison of hydrochlorothiazide, propranolol and prazosin.
Topics: Adult; Aged; Blood Pressure; Erythrocytes; Female; Heart; Heart Rate; Humans; Hydrochlorothiazide; H | 1984 |
Captopril in mild and moderate essential hypertension: physiological and biochemical monitoring.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Captopril; Drug Therapy | 1983 |
Low-dose captopril titration in patients with moderate-to-severe hypertension treated with diuretics.
Topics: Adult; Aged; Blood Pressure; Captopril; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1983 |
Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide.
Topics: Aged; Benzazepines; Blood Pressure; Diltiazem; Epinephrine; Female; Heart Rate; Heart Ventricles; Hu | 1984 |
Thiazide-induced potassium loss not prevented by beta blockade.
Topics: Aldosterone; Amiloride; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1984 |
[Effect of hydrochlothiazide on the secretion and urinary excretion of insulin in patients with hypertension].
Topics: Adult; Humans; Hydrochlorothiazide; Hypertension; Insulin; Insulin Secretion; Middle Aged | 1984 |
[Antihypertensive effect of captopril in patients with mild or moderate systemic arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 1984 |
Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension.
Topics: Administration, Oral; Blood Pressure; Captopril; Drug Evaluation; Drug Synergism; Drug Therapy, Comb | 1984 |
Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; C-Peptide; Creatinine; Fatty Acids, Nonesterified; Femal | 1984 |
Combined captopril and hydrochlorothiazide therapy in severe hypertension: long-term haemodynamic changes at rest and during exercise.
Topics: Adult; Aged; Blood Glucose; Body Weight; Captopril; Cardiac Output; Creatinine; Diastole; Drug Thera | 1984 |
Beta blockers and flat dose response to thiazide in hypertension.
Topics: Acebutolol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrochlorothiazide | 1983 |
Comparison of thiazides and amiloride in treatment of moderate hypertension.
Topics: Amiloride; Blood Glucose; Humans; Hydrochlorothiazide; Hypertension; Pyrazines | 1983 |
Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost.
Topics: Blood Pressure; Chlorthalidone; Cost-Benefit Analysis; Diuretics; Female; Furosemide; Humans; Hydroc | 1983 |
[Antihypertensives and the prevention of development of genetic hypertension in the hypertensive SHR rat].
Topics: Animals; Antihypertensive Agents; Atenolol; Captopril; Cardiomegaly; Dihydralazine; Dose-Response Re | 1980 |
[Case of recurrent ventricular fibrillation caused by iatrogenic hypokalemia].
Topics: Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Iatrogenic Disease; Midd | 1984 |
Methyldopa: an agent for the treatment of older patients with isolated systolic hypertension.
Topics: Aged; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1984 |
Thiazides, compulsive water drinking and hyponatraemic encephalopathy.
Topics: Brain Diseases; Compulsive Behavior; Drinking; Female; Humans; Hydrochlorothiazide; Hypertension; Hy | 1984 |
Oral potassium chloride and amiloride in hydrochlorothiazide-induced potassium loss.
Topics: Administration, Oral; Adult; Aldosterone; Amiloride; Biological Availability; Creatinine; Drug Evalu | 1984 |
Hyponatremia induced by thiazide-like diuretics in the elderly.
Topics: Aged; Diuretics; Edema; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Monitoring, | 1984 |
Withdrawal phenomena in subjects with essential hypertension on clonidine or tiamenidine.
Topics: Adult; Blood Pressure; Clonidine; Epinephrine; Humans; Hydrochlorothiazide; Hypertension; Male; Midd | 1984 |
[Experience in the treatment of increased blood pressure with a combination of dihydroergotoxine, reserpine and hydrochlorothiazide].
Topics: Adult; Aged; Dihydroergotoxine; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Middle | 1984 |
Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension.
Topics: Blood Pressure; Body Weight; Creatinine; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Mid | 1984 |
Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension.
Topics: Adult; Arrhythmias, Cardiac; Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Magnesium; M | 1984 |
Exercise-induced hypoglycemia following propranolol in a patient after gastric fundoplication surgery.
Topics: Adult; Blood Glucose; Gastric Fundus; Humans; Hydrochlorothiazide; Hypertension; Hypoglycemia; Male; | 1984 |
Provider continuity and control of hypertension.
Topics: California; Continuity of Patient Care; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1984 |
Slow-release metoprolol, hydrochlorothiazide and hydralazine in stepwise treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Fo | 1984 |
Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly.
Topics: Aged; Aging; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperte | 1984 |
Pharmacokinetics of a fixed combination of sotalol and hydrochlorothiazide in hypertensive patients with moderate renal insufficiency.
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Kidney Diseases; Kinetics; Sotalol | 1984 |
Mild hypertension: a therapeutic dilemma.
Topics: Adult; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Humans; Hydrochlorothiazi | 1984 |
Effects of pildralazine alone and in combination on severe hypertension and cerebrovascular lesions in saline-drinking spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Drug Therapy, Combination; Female; Hydrochloroth | 1984 |
Systemic hypertension in infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Infant; In | 1984 |
Urinary kallikrein in hypertension secondary to hemolytic uremic syndrome: response to diuretic stimulus.
Topics: Adolescent; Amiloride; Child; Child, Preschool; Drug Combinations; Female; Hemolytic-Uremic Syndrome | 1984 |
Clonidine through the skin in the treatment of essential hypertension: is it practical?
Topics: Administration, Topical; Adult; Blood Pressure; Clonidine; Drug Hypersensitivity; Drug Therapy, Comb | 1983 |
[Effect of hypothiazide on carbohydrate tolerance in long-term treatment of hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Female; Glucose Tolerance Test; Humans; Hydroch | 1983 |
Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide.
Topics: Adipose Tissue; Apolipoproteins; Blood Glucose; Catecholamines; Fatty Acids; Humans; Hydrochlorothia | 1983 |
[Multi-centric study for the evaluation of the antihypertensive efficacy of hydrochlorothiazide and spironolactone association: comparison between 2 dosages schemes].
Topics: Adolescent; Adult; Aged; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Hum | 1983 |
Effect of indapamide on volume-dependent hypertension, renal haemodynamics, solute excretion and proximal nephron fractional reabsorption in the dog.
Topics: Animals; Blood Pressure; Chlorides; Diuretics; Dogs; Dose-Response Relationship, Drug; Electrolytes; | 1983 |
[Mental changes in hypertensive patients during long-term ambulatory treatment].
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Clonidine; Diuretics; Female; Humans; Hydrochloroth | 1983 |
[Potassium, magnesium and zinc concentrations in the serum, granulocytes and lymphocytes of patients with arterial hypertension treated with hydrochlorothiazide].
Topics: Adult; Granulocytes; Humans; Hydrochlorothiazide; Hypertension; Leukocytes; Lymphocytes; Magnesium; | 1983 |
Thiazide-induced hyponatremia.
Topics: Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Middle Aged; Neu | 1983 |
[Current aspects of hypertension treatment. Symposium 10 years Moduretic, Budapest 9-12 June 1983].
Topics: Amiloride; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Pyrazines | 1983 |
[Self-control of blood pressure for the purpose of increasing the effectiveness of ambulatory treatment of arterial hypertension].
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Clonidine; Diuretics; Follow-Up Stu | 1983 |
Safety and efficacy of a three-drug regimen for the treatment of hypertension: hydrochlorothiazide, propranolol, and guanadrel.
Topics: Adult; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gua | 1983 |
[Clonidine transdermal therapeutic system in essential hypertension: effect and tolerance].
Topics: Adult; Body Weight; Clonidine; Dermatitis, Contact; Drug Tolerance; Female; Heart Rate; Humans; Hydr | 1983 |
Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients.
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Drug Resistance; Female; Humans; Hydr | 1983 |
Treatment of hypertension in diabetic men: problems with sexual dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Erectile Dysfunction; Humans; Hydroc | 1984 |
Prazosin versus propranolol plus prazosin: a comparison in diuretic-treated hypertensive patients.
Topics: Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Hydrochlorothiazide; Hypertensi | 1984 |
Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Clonidine; Dose-Response Relationship, Drug; Doubl | 1984 |
Do elderly patients respond differently to treatment with Moducren?
Topics: Adult; Age Factors; Aged; Amiloride; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyperte | 1984 |
[Characteristics of the action of gemiton, adelfan and dopegit on cerebral circulation in arterial hypertension].
Topics: Aged; Antihypertensive Agents; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disea | 1984 |
The short-term effects of reducing elevated blood pressure in elderly patients with propranolol and dyazide.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiac Output; Cerebrovascular Circulation; Cognitio | 1984 |
Failure of antihypertensive therapy with diuretic, beta-blocking and calcium channel-blocking drugs to consistently reverse left ventricular diastolic filling abnormalities.
Topics: Benzazepines; Blood Pressure; Cardiac Volume; Diltiazem; Female; Heart; Heart Rate; Heart Ventricles | 1984 |
Fatal intravascular immune hemolysis induced by hydrochlorothiazide.
Topics: Anemia, Hemolytic; Antibodies; Drug Interactions; Drug Therapy, Combination; Hemolysis; Humans; Hydr | 1984 |
Diuretic regimens in essential hypertension.
Topics: Furosemide; Humans; Hydrochlorothiazide; Hypertension | 1984 |
Hyponatremia induced by a combination of amiloride and hydrochlorothiazide.
Topics: Aged; Amiloride; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; | 1984 |
[Use of adelphan-esidrex with hypertension patients].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Drug Evaluation; Electrocardiography; Femal | 1984 |
The use of a single combination tablet containing a beta blocker and a diuretic in patients uncontrolled on either alone.
Topics: Amiloride; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Ti | 1984 |
Cerebral blood flow changes with diuretic therapy in elderly subjects with systolic hypertension.
Topics: Aged; Angiotensin II; Blood Pressure; Cerebrovascular Circulation; Humans; Hydrochlorothiazide; Hype | 1982 |
Captopril in essential hypertension.
Topics: Adult; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochloro | 1982 |
Long-term experience of captopril in the treatment of primary (essential) hypertension.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1982 |
The renin-angiotensin-aldosterone system and blood pressure during oxprenolol treatment in hypertensive patients pretreated with diuretics.
Topics: Adult; Aldosterone; Amiloride; Blood Pressure; Body Weight; Diuretics; Drug Combinations; Female; Hu | 1982 |
[Effect of captopril on blood pressure in various types of hypertensive rats].
Topics: Animals; Blood Pressure; Captopril; Female; Hydrochlorothiazide; Hypertension; Male; Proline; Rats | 1982 |
[Reliable lowering of blood pressure with one tablet of Moducrin daily (author's transl)].
Topics: Amiloride; Blood Pressure; Circadian Rhythm; Drug Combinations; Drug Evaluation; Humans; Hydrochloro | 1980 |
Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin.
Topics: Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; H | 1982 |
[25 years of hypertension therapy with diuretics].
Topics: Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Sulfonamides | 1982 |
Baroreflex function after therapy withdrawal in patients with essential hypertension.
Topics: Adult; Amiloride; Blood Pressure; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1983 |
Hemodynamic actions of diuretic agents.
Topics: Animals; Blood Pressure; Chlorthalidone; Diuretics; Furosemide; Heart Rate; Hemodynamics; Hydrochlor | 1983 |
Acute idiosyncratic reaction to hydrochlorothiazide ingestion.
Topics: Adult; Female; Humans; Hydrochlorothiazide; Hypertension; Leukopenia; Pulmonary Edema; Thrombocytope | 1983 |
[Therapy of hypertension with timolol, hydrochlorothiazide and amiloride].
Topics: Amiloride; Humans; Hydrochlorothiazide; Hypertension; Propanolamines; Pyrazines; Timolol | 1983 |
[Hemodynamic indicators, phase structure of the systole of the left and right heart ventricles and the state of pulmonary circulation and microcirculation in patients with hypertension treated with adelphane-esindex].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Female; Heart Ventricles; Hemodynamics; Hum | 1983 |
Metabolic consequences of antihypertensive therapy.
Topics: Antihypertensive Agents; Blood Glucose; Carbohydrate Metabolism; Hormones; Humans; Hydrochlorothiazi | 1983 |
Clonidine poisoning. A complex problem.
Topics: Apnea; Bradycardia; Child, Preschool; Clonidine; Dopamine; Female; Fluid Therapy; Gastric Lavage; Hu | 1983 |
Antihypertensive and metabolic effects of hydrochlorothiazide, amiloride-hydrochlorothiazide, and timolol.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; | 1983 |
[Changes in the hemodynamic indices of hypertension patients].
Topics: Adult; Aged; Antihypertensive Agents; Chronic Disease; Drug Combinations; Drug Evaluation; Female; H | 1983 |
[Comparison of the effects of 2 different diuretics in the treatment of hypertension in diabetics].
Topics: Acetazolamide; Aged; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Femal | 1983 |
Withdrawal of antihypertensive drugs in mild hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Female; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1981 |
Thiazide diuretics, hypokalemia and cardiac arrhythmias.
Topics: Adult; Arrhythmias, Cardiac; Diuretics; Female; Heart Ventricles; Humans; Hydrochlorothiazide; Hyper | 1981 |
Preliminary clinical trial with a new hypotensive, guanabenz, in a group of hypertensive patients.
Topics: Aged; Amiloride; Blood Pressure; Drug Evaluation; Drug Tolerance; Female; Guanabenz; Guanidines; Hum | 1980 |
25-hydroxyvitamin D in patients with essential hypertension.
Topics: 25-Hydroxyvitamin D 2; Adult; Air Pollutants; Alkaline Phosphatase; Calcium; Ergocalciferols; Female | 1981 |
Captopril in severe treatment-resistant hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Captopril; Female; Furosemide; Heart Rate; Humans; Hydralaz | 1980 |
Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension.
Topics: Adult; Aldosterone; Extracellular Space; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male | 1980 |
Acute and chronic renal effects of guanfacine in essential and renal hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Electrolytes; Glomer | 1980 |
Metoprolol in diabetes mellitus: effect on glucose homeostasis.
Topics: Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Female; Glucagon; Homeostasis; Human | 1980 |
Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system.
Topics: Angiotensin II; Animals; Captopril; Cardiovascular Agents; Clonidine; Dose-Response Relationship, Dr | 1981 |
[Functional state of the renin-angiotensin system in the diuretic therapy of hypertension].
Topics: Adult; Angiotensin II; Blood Pressure; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Male; | 1981 |
Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays.
Topics: Angiotensinogen; Angiotensins; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hy | 1981 |
[Treatment of "therapy-resistant" forms of hypertension with captopril].
Topics: Ambulatory Care; Antihypertensive Agents; Captopril; Diuretics; Drug Resistance; Furosemide; Humans; | 1981 |
[Levels of cholesterol, triglycerides, uric acid and glucose following prolonged treatment of hypertension with low and normal renin activity with hydrochlorothiazide].
Topics: Adult; Blood Glucose; Cholesterol; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Renin; Tr | 1981 |
[Captopril in treatment-resistant hypertension (author's transl)].
Topics: Adult; Captopril; Diastole; Drug Combinations; Female; Furosemide; Humans; Hydralazine; Hydrochlorot | 1980 |
[Effect of captopril in essential hypertension (author's transl)].
Topics: Adult; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochloro | 1981 |
[Antihypertensive effects of timolol and of the combination timolol, amiloride and hydrochlorothiazide].
Topics: Adult; Amiloride; Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochloro | 1981 |
Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension.
Topics: Adult; Aldosterone; Angiotensins; Diuretics; Electrolytes; Female; Humans; Hydrochlorothiazide; Hype | 1981 |
Comparison of the effects of captopril, diuretic and their combination in low- and normal-renin essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Captopril; Drug Evaluation; Drug Therapy, Combination; Humans; H | 1982 |
Captopril in the treatment of moderate to severe hypertension. A long-term study.
Topics: Adult; Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazi | 1981 |
Clinical use of captopril. Illustrative cases.
Topics: Adult; Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Failure; Humans; Hy | 1982 |
Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.
Topics: Aldosterone; Blood Pressure; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hype | 1982 |
Behavioral versus pharmacological treatments for essential hypertension--a needed comparison.
Topics: Adult; Behavior Therapy; Biofeedback, Psychology; Blood Pressure; Drug Therapy, Combination; Humans; | 1982 |
Studies on the mechanism of the synergistic antihypertensive activity of captopril and hydrochlorothiazide following acute administration in spontaneously hypertensive rats.
Topics: Animals; Captopril; Drug Synergism; Drug Therapy, Combination; Hydrochlorothiazide; Hypertension; Hy | 1982 |
[The renin-aldosterone system in the diagnosis of essential hypertension].
Topics: Adult; Aldosterone; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Renin | 1982 |
[Hypotensive effect of saluretics].
Topics: Antihypertensive Agents; Diuretics; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydr | 1982 |
A comparative study of Moducren and Moduretic and their effect on plasma potassium in essential hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Body Weight; Drug Combinations; Female; Heart Rate; | 1982 |
[Continuous long-term treatment with diuretics of hypertension and the status of the renin-angiotensin-aldosterone system].
Topics: Adult; Blood Pressure; Diuretics; Drug Evaluation; Furosemide; Humans; Hydrochlorothiazide; Hyperten | 1982 |
Intravenous labetalol in severe hypertension.
Topics: Administration, Oral; Amiloride; Ethanolamines; Hydrochlorothiazide; Hypertension; Infusions, Parent | 1982 |
[Changes In myocardial contractile function and microcirculation in hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Conjunctiva; Drug Combinations; Dru | 1982 |
Changes in ventricular septal thickness during diuretic therapy.
Topics: Adult; Aged; Blood Pressure; Body Weight; Diuretics; Echocardiography; Heart Rate; Heart Septum; Hea | 1982 |
Essential hypertension in childhood.
Topics: Adolescent; Child; Diet, Sodium-Restricted; Electrocardiography; Humans; Hydrochlorothiazide; Hypert | 1982 |
Prolonged normotension following cessation of therapy in uncomplicated essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlo | 1982 |
Relation of cardiovascular response to the hypotensive effect of metoprolol.
Topics: Adult; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Furosemide; Heart Rate; He | 1982 |
A suspected case of thiazide-induced hyponatremia.
Topics: Aged; Body Water; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Male; Sodium C | 1982 |
Effects of antihypertensive agents on blood velocity: implications for atherogenesis.
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Flow Velocity; Blood Pressure; Female; | 1982 |
Circulatory dose-response effects of hydrochlorothiazide at rest and during dynamic exercise in essential hypertension.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Heart Rate; Hemodynamics; Humans; Hydrochlo | 1982 |
[Individualization of hypotensive therapy].
Topics: Adult; Antihypertensive Agents; Drug Evaluation; Drug Therapy, Combination; Guanethidine; Hemodynami | 1982 |
Persistence of normal BP after withdrawal of drug treatment in mild hypertension.
Topics: Blood Pressure; Drug Administration Schedule; Furosemide; Humans; Hydrochlorothiazide; Hypertension; | 1982 |
[Treatment of hypertensive states with a combination of alpha-methyldopa and a diuretic].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypert | 1982 |
[Effect of antihypertensive therapy on oxygen consumption of the myocardium. I. Hydrochlorothiazide and chlorthalidone].
Topics: Adult; Chlorthalidone; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; M | 1981 |
[Oral verapamil combined with a diuretic in the treatment of slight and moderate arterial hypertension].
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1982 |
[Diuretic therapy in the aged. A clinical comparison between two diuretic compounds].
Topics: Aged; Amiloride; Diuretics; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlorothiazide; | 1981 |
Diuretic-induced ventricular ectopic activity.
Topics: Adult; Arrhythmias, Cardiac; Electrocardiography; Exercise Test; Heart Ventricles; Humans; Hydrochlo | 1981 |
[Adelphan-esidrex in the treatment of hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Female; Hemodynamics; Humans; Hydralazine; | 1980 |
[Effect of hypotensive agents in combination with oxygen on hemocoagulation in hypertension].
Topics: Adult; Antihypertensive Agents; Blood Coagulation; Female; Guanethidine; Humans; Hydrochlorothiazide | 1980 |
[Comprehensive use of clofelin and triampur compositum in treating hypertension].
Topics: Adult; Antihypertensive Agents; Clonidine; Drug Combinations; Female; Humans; Hydrochlorothiazide; H | 1981 |
Case study: Drug interference in clinical chemistry.
Topics: Aspartate Aminotransferases; Blood Glucose; Chemical and Drug Induced Liver Injury; Clinical Enzyme | 1981 |
[Determination of the criteria for selecting the optimal obsidan and hypothiazide treatment regimen in hypertension based on mathematical modelling data].
Topics: Adult; Drug Therapy, Combination; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Mathemati | 1981 |
Comparison of the metabolic and antihypertensive properties of tienilic acid and hydrochlorothiazide.
Topics: Adult; Aged; Double-Blind Method; Female; Glycolates; Humans; Hydrochlorothiazide; Hypertension; Mal | 1981 |
Renal failure as a complication of acute antihypertensive therapy.
Topics: Acute Kidney Injury; Antihypertensive Agents; Biopsy, Needle; Blood Pressure; Child, Preschool; Crea | 1981 |
[Hypertension therapy in the aged. Possibilities and chances of success].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Child; Drug Therapy, Combination; Female; Humans; | 1981 |
[Selection of hypertensive patients for long-term diuretic therapy].
Topics: Adult; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1981 |
Triamterene nephrolithiasis complicating dyazide therapy.
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Kidney Calculi; Male; Middle Aged; Tri | 1981 |
Lithium toxicity induced by triamterene-hydrochlorothiazide.
Topics: Bipolar Disorder; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; H | 1980 |
The glucose tolerance test in hypertensive patients treated long term with thiazide diuretics.
Topics: Diabetes Mellitus; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Risk | 1981 |
[Treatment of moderate and severe hypertension with minoxidil (author's transl)].
Topics: Creatinine; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mino | 1981 |
[Comparative study of the association of propranolol-chlorthalidone and the fixed combination of timolol-hydrochlorothiazide-amiloride in the treatment of arterial hypertension].
Topics: Amiloride; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug Therapy, Combination; Humans; Hy | 1981 |
[Comparative studies on combination treatment of chronic hypertension].
Topics: Adult; Blood Pressure; Dihydralazine; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypert | 1981 |
[Effects of metoprolol and of the combination of metoprolol and hydrochlorothiazide arterial hypertension patients].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Met | 1980 |
[The syndrome of hypertension of effort in the rehabilitation of patients with recent myocardial infarct. Problems of drug therapy].
Topics: Amiloride; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperten | 1980 |
[Long-term antihypertensive treatment with prazosin in combination with a diuretic].
Topics: Adult; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Hyp | 1980 |
[Control of arterial hypertension at the work site of the patient: retrospective review of prazosin and propanolol].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Occupational Heal | 1980 |
[The combined use of alpha-methyldopa and butizide in the treatment of arterial hypertension].
Topics: Adult; Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; | 1981 |
[Moducrin--a new combined preparation in the treatment of hypertension (author's transl)].
Topics: Adult; Amiloride; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hydroc | 1981 |
A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension.
Topics: Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1981 |
The treatment of high blood pressure in the elderly: a multi-centre evaluation of a fixed combination of metoprolol and hydrochlorothiazide ("Co-Betaloc") in general practice.
Topics: Age Factors; Aged; Blood Pressure; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazid | 1981 |
Negotiation as an integral part of the physician's clinical reasoning.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Child; Child, Preschool; Clinical Competence; Dec | 1981 |
The use of acebutolol with hydrochlorothiazide in hypertension.
Topics: Acebutolol; Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; | 1981 |
[Treatment of arterial hypertension: comparative study of atenolol + chlorthalidone vs. timolol maleate-hydrochlorthiazide-amiloride association].
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1981 |
Experiences with metoprolol Durules, a slow-release formulation in hypertension.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Drug Therapy, Combination; Female; Heart Rate; H | 1980 |
Diuretics: role of sodium balance.
Topics: Acute Kidney Injury; Adult; Calcium; Diet, Sodium-Restricted; Diuretics; Furosemide; Humans; Hydroch | 1980 |
Hypokalemia during the treatment of arterial hypertension with diuretics.
Topics: Adult; Aged; Bicarbonates; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertens | 1980 |
Hypokalaemia and diuretics: an analysis of publications.
Topics: Chlorothiazide; Chlorthalidone; Coronary Disease; Diuretics; Dose-Response Relationship, Drug; Furos | 1980 |
Fenfluramine potentiation of antihypertensive effects of thiazides.
Topics: Antihypertensive Agents; Blood Pressure; Body Weight; Drug Synergism; Drug Therapy, Combination; Fen | 1980 |
Plasma potassium levels in hypertensive patients receiving fixed-combination diuretic therapy.
Topics: Adult; Aged; Amiloride; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension | 1980 |
Thiazides and acute cholecystitis.
Topics: Acute Disease; Adult; Aged; Cardiovascular Diseases; Chlorothiazide; Cholecystitis; Diuretics; Hospi | 1980 |
A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Chemical Analysis; Blood Pressure; Body Weight; Drug Thera | 1980 |
Acebutolol and hydrochlorothiazide in essential hypertension.
Topics: Acebutolol; Adult; Aged; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hydrochlor | 1980 |
[Combined action of oxprenolol, hydrochlorothiazide and hydralazine in rats with metacorticoid induced hypertension].
Topics: Animals; Desoxycorticosterone; Drug Evaluation; Drug Therapy, Combination; Hydralazine; Hydrochlorot | 1980 |
[Treatment of arterial hypertension in old age].
Topics: Age Factors; Aged; Allopurinol; Antihypertensive Agents; Blood Pressure; Clonidine; Drug Therapy, Co | 1980 |
[Comparative evaluation of the anti-hypertensive effect of moduretic and thiazides].
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Diuretics; Drug Combinations; Female; Humans; Hydro | 1980 |
[Treatment of hypertension with clofelin and adelfan-esidrex].
Topics: Adolescent; Adult; Antihypertensive Agents; Clonidine; Dihydralazine; Drug Combinations; Drug Therap | 1980 |
Hypertension: a complication of danazol therapy.
Topics: Adult; Blood Pressure; Body Weight; Danazol; Humans; Hydrochlorothiazide; Hypertension; Male; Pregna | 1980 |
Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases.
Topics: Aged; Biopsy; Drug Combinations; Drug Synergism; Female; Humans; Hydrochlorothiazide; Hypertension; | 1980 |
[Alpha-methyldopa and renal function in arterial hypertension].
Topics: Antihypertensive Agents; Clonidine; Dihydralazine; Humans; Hydrochlorothiazide; Hypertension; Hypert | 1980 |
Variations in patient compliance with common long-term drugs.
Topics: Angina Pectoris; Blood Pressure; Drug Therapy; Humans; Hydrochlorothiazide; Hypertension; Patient Co | 1980 |
[Chronosensitivity to adelphane-esidrex and sinepres and effectiveness of treatment of patients with hypertension].
Topics: Antihypertensive Agents; Dihydralazine; Dihydroergotoxine; Drug Combinations; Female; Hemodynamics; | 1995 |
[Chrono-pharmacodynamic effects of sinepres in patients with hypertension].
Topics: Antihypertensive Agents; Dihydroergotoxine; Drug Combinations; Hemodynamics; Humans; Hydrochlorothia | 1995 |
[The lipid peroxidation indices of hypertension patients undergoing combined therapy with anaprilin, korinfar and hypothiazide].
Topics: Adult; Antihypertensive Agents; Antioxidants; Drug Evaluation; Drug Therapy, Combination; Female; Hu | 1995 |
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |
Comparative effects of indapamide and hydrochlorothiazide on cardiac hypertrophy and vascular smooth-muscle phenotype in the stroke-prone, spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Cardiomegaly; Coronary Vessels; Hydrochlorothiazide; Hypertension; Indapami | 1993 |
[Treatment of hypertension--change to the expensive!].
Topics: Amiloride; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Information Services; Humans; | 1995 |
Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide.
Topics: Acute Disease; Anterior Eye Segment; Antihypertensive Agents; Choroid Diseases; Drug Hypersensitivit | 1995 |
Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene.
Topics: Acute Kidney Injury; Catecholamines; Cytokines; Eicosanoids; Hormones; Hydrochlorothiazide; Hyperten | 1995 |
Hypertension: special concerns in managing the older patient.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Cerebrovascular D | 1995 |
[Lowering blood pressure in an obese patient with long-term hypertension. Using a fixed combination of enalapril/hydrochlorothiazide].
Topics: Drug Combinations; Enalapril; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Mi | 1995 |
Granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride.
Topics: Acute Kidney Injury; Aged; Amiloride; Female; Granuloma; Humans; Hydrochlorothiazide; Hypertension; | 1995 |
Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adult; Cortisone; Creatinine; Humans; Hydrochlorothiazide; Hy | 1995 |
Effects of moduretic on plasma lipid and lipoprotein levels in hypertensive African patients.
Topics: Aged; Amiloride; Blood Pressure; Body Weight; Diet; Drug Combinations; Female; Humans; Hydrochloroth | 1993 |
[Treatment of hypertension with a fixed calcium antagonist-diuretic combination. Observations from treatment of 5,595 patients].
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up | 1995 |
Urapidil compared with diuretics in the treatment of mild-to-moderate essential hypertensive patients: effects on glucose metabolism, insulin sensitivity, and lipid profile.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Female; Glucose; Humans; Hydrochlorothiazide; Hypert | 1994 |
[Gout tophi and Heberden nodules in hyperuricemia].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Female; Fingers; Gout; Hand Deformities, Acquired; Humans | 1994 |
Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations.
Topics: Animals; Blood Vessels; Captopril; Caseins; Diet; Drug Combinations; Hemorheology; Hindlimb; Homocys | 1995 |
Combination products as first-line pharmacotherapy.
Topics: Betaxolol; Bisoprolol; Chlorthalidone; Drug Approval; Drug Combinations; Humans; Hydrochlorothiazide | 1994 |
Combination products as first-line pharmacotherapy.
Topics: Captopril; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension | 1995 |
Hostility and the response to diuretic in mild-to-moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Femal | 1994 |
Stimulated parotid salivary flow rates in normotensive, hypertensive, and hydrochlorothiazide-medicated.
Topics: Aged; Analysis of Variance; Baltimore; Black People; Case-Control Studies; Citrates; Citric Acid; El | 1994 |
Lack of effect of hydrocholorthiazide on total cholesterol.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cholesterol; Female; Humans; Hydrochlorothiazi | 1994 |
Remembering the lessons of basic pharmacology.
Topics: Bisoprolol; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrochlorothiazide; Hypert | 1994 |
Effect of diazoxide on serum and tissue electrolyte levels in rats with deoxycorticosterone acetate-induced hypertension.
Topics: Animals; Aorta; Blood Pressure; Calcium; Desoxycorticosterone; Diazoxide; Electrolytes; Hydrochlorot | 1994 |
Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA).
Topics: Body Mass Index; California; Carcinoma, Renal Cell; Case-Control Studies; Diuretics; Dose-Response R | 1994 |
Ziac for hypertension.
Topics: Bisoprolol; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension | 1994 |
Effects of the arterial vasodilator minoxidil on cardiovascular structure and sympathetic activity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Blood Volume; Cardiomegaly; Heart; Heart Ventricles; Hydrochlorothiazide; H | 1993 |
[Relationship of the renin-angiotensin-aldosterone system with auricular natriuretic factor in its response to the action of thiazide diuretics and to nifedipine, a sustained-release calcium antagonist].
Topics: Aldosterone; Amiloride; Animals; Ants; Blood Pressure; Delayed-Action Preparations; Female; Heart Ra | 1994 |
[Symptomatic hypercalcemia after vitamin D-thiazide diuretics combination. Two cases in elderly women].
Topics: Aged; Aged, 80 and over; Benzothiadiazines; Diuretics; Drug Therapy, Combination; Female; Humans; Hy | 1994 |
[Pharmacological properties and therapeutic use of the standard combination of hydrochlorothiazide (12.5 mg) and lisinopril (20 mg)].
Topics: Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Lisinopril | 1993 |
Effect of canrenone and hydrochlorothiazide on the development of hypertension in rat models of genetic hypertension.
Topics: Animals; Biological Factors; Blood Pressure; Canrenone; Cardenolides; Digoxin; Disease Models, Anima | 1993 |
[A preliminary study of insulin resistance in essential hypertension, simple obesity and acromegaly].
Topics: Acromegaly; Adult; Blood Glucose; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorot | 1993 |
[Evaluation of efficacy of the enalapril-hydrochlorothiazide combination by ambulatory blood pressure monitoring in essential hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Electrocardiography, Ambulatory; Enalapril; | 1993 |
[Treatment of mild hypertension with captopril and captopril with hydrochlorothiazide. Impact on blood pressure values and quality of life].
Topics: Adult; Aged; Blood Pressure; Captopril; Clinical Protocols; Female; Heart Rate; Humans; Hydrochlorot | 1993 |
Baroreflex function during 45-degree passive head-up tilt before and after long-term thiazide therapy in the elderly with systolic systemic hypertension.
Topics: Aged; Baroreflex; Humans; Hydrochlorothiazide; Hypertension; Male; Posture; Systole; Time Factors | 1994 |
A relationship between blood pressure control, hematocrit level, and renal function in treated essential hypertension.
Topics: Black or African American; Black People; Blood Pressure; Blood Urea Nitrogen; Creatinine; Hematocrit | 1993 |
[Dwarfism, arterial hypertension and hyperkalemic acidosis corrected with thiazides. A case of type II pseudohypoaldosteronism].
Topics: Acidosis, Renal Tubular; Child; Dwarfism; Female; Humans; Hydrochlorothiazide; Hyperkalemia; Hyperte | 1993 |
Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.
Topics: Aging; Albuminuria; Case-Control Studies; Drug Therapy, Combination; Follow-Up Studies; Glomerular F | 1993 |
Hemodynamic response to orthostatic stress in the elderly with systolic systemic hypertension before and after long-term thiazide therapy.
Topics: Aged; Cardiac Output; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Po | 1993 |
Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats.
Topics: Animals; Antihypertensive Agents; Cholesterol; Drug Therapy, Combination; Enalapril; Hydralazine; Hy | 1993 |
Effect of cilazapril on lipids.
Topics: Adult; Cilazapril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Lip | 1993 |
Antihypertensive efficacy of cilazapril in general practice: assessment by ambulatory blood pressure monitoring.
Topics: Adult; Blood Pressure Determination; Cilazapril; Drug Therapy, Combination; Family Practice; Female; | 1993 |
Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Cardiomegaly; Coronary Vessels; Drug Evaluation, Preclinical; Fibrosis; Hyd | 1993 |
Hydrochlorothiazide-induced lupus erythematosus: a new variant?
Topics: Aged; Antibodies, Antinuclear; Female; Humans; Hydrochlorothiazide; Hypercalcemia; Hypertension; Lup | 1993 |
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1995 |
[Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Exercis | 1996 |
Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system.
Topics: Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Female; Health Education; Hospitals, Veter | 1996 |
Hypertension management guidelines.
Topics: Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Practice Guidelines as Topic; Pr | 1996 |
[The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Captopril; Delayed-Action Preparations; Drug Combinations; Dru | 1996 |
Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Diuretics; Hemodynamics; Hydrochlorothiazide; Hypertension; Kidney | 1996 |
A new antihypertensive strategy for black patients: low-dose multimechanism therapy.
Topics: Antihypertensive Agents; Bisoprolol; Black or African American; Clinical Trials as Topic; Drug Thera | 1996 |
Application of response surface methodology and factorial designs to clinical trials for drug combination development.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Diltiazem; Drug | 1996 |
Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Angiotensin-Convert | 1996 |
Inappropriate secretion of antidiuretic hormone and SSRIs.
Topics: Aged; Bipolar Disorder; Citalopram; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; | 1996 |
Biochemical changes during moduretic treatment of hypertension in African patients.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Glucose; Blood Proteins; Calcium; Chlorides; | 1995 |
Vascular events during antihypertensive treatment.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Stenosis; Diuret | 1996 |
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
Topics: Adolescent; Adult; Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pr | 1996 |
[Relevance of general practitioner's prescriptions for hospital pharmacotherapy. A survey of hospital physicians].
Topics: Aged; Attitude of Health Personnel; Captopril; Data Interpretation, Statistical; Diabetes Mellitus; | 1996 |
[Drug of the month. Maxsoten].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Drug Combinations; Humans; Hydroch | 1996 |
A new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Creatinine; Eicosanoids; Hydrochlorot | 1995 |
Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Diuretics; Endothe | 1997 |
[Therapy of hypertension in general practice with Renitec and Co-Renitec--analysis of an administration study].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Drug Combinations; Enalapril; Fema | 1996 |
Effects of benidipine hydrochloride on antioxidant enzyme activity in stroke-prone spontaneous hypertensive rats (SHR-SP).
Topics: Animals; Antioxidants; Blood Pressure; Calcium Channel Blockers; Catalase; Cerebrovascular Disorders | 1997 |
Lack of effect of a diuretic added to diltiazem.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Diltiazem; Diur | 1997 |
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Captopril; Catalase; Diabetes Mellitu | 1997 |
[Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
Topics: Aged; Antihypertensive Agents; Cognition; Diabetes Mellitus, Type 2; Diuretics; Drug Evaluation; Dru | 1997 |
[Pulmonary edema associated with the ingestion of hydrochlorothiazide].
Topics: Acute Disease; Aged; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Mid | 1996 |
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Type | 1997 |
Strengths and weaknesses of drug trials without controls.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, | 1997 |
Effects of antihypertensive drugs on antioxidant enzyme activities and renal function in stroke-prone spontaneously hypertensive rats.
Topics: Acetylglucosaminidase; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1997 |
[Compliance of the hypertensive patient in medical practice--analysis of an observation study. 2].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Combinations; Enalapril; Hum | 1997 |
Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR).
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Heart Rate; Hydrochloro | 1998 |
Treatment of hypertensive patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Recurrent hydrochlorothiazide-induced pulmonary edema.
Topics: Aged; Antihypertensive Agents; Drug Hypersensitivity; Female; Hemodynamics; Humans; Hydrochlorothiaz | 1998 |
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diet, Sodium-Restricted; Diuretics; | 1998 |
[Iatrogenic acute renal failure caused by overdosage of flecainide acetate].
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-In | 1998 |
Simple method for determination of hydrochlorothiazide in human urine by high performance liquid chromatography utilizing narrowbore chromatography.
Topics: Black People; Chromatography, High Pressure Liquid; Diuretics; Female; Humans; Hydrochlorothiazide; | 1998 |
Thiazide-induced vasodilation in humans is mediated by potassium channel activation.
Topics: Antihypertensive Agents; Blood Pressure; Carrier Proteins; Dose-Response Relationship, Drug; Humans; | 1998 |
Emergency! Hyponatremia.
Topics: Aged; Diuretics; Emergencies; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Sodiu | 1998 |
A recent article in the Harvard Heart Letter mentioned that the diuretic hydrochlorothiazide could cause impotence. My doctor has me on this medication. While it hasn't caused me any problems yet, I'm wondering what are the chances that it will?
Topics: Diuretics; Erectile Dysfunction; Humans; Hydrochlorothiazide; Hypertension; Male; Sodium Chloride Sy | 1999 |
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Cell Nucleus; Diastole; DNA; | 1999 |
Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 1999 |
Could this be a drug side effect?
Topics: Aged; Amiloride; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyd | 1999 |
[Studies of lymphocyte membrane transport of sodium in patients with essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biological Transport; Cell Membrane Permeability; | 1999 |
Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive A | 1999 |
Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats.
Topics: Age Factors; Aging; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 1999 |
The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study.
Topics: Aged; Alleles; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Case-Control St | 1999 |
By the way, doctor... I am 87 and have been taking blood pressure medications for years. In the past, side effects were a problem, but for about the last year I've done very well taking valsartan (Diovan) and hydrochlorothiazide (Esidrex). Now My blood pr
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Systole | 2000 |
Racial differences in response to acute dosing with hydrochlorothiazide.
Topics: Adult; Aldosterone; Black People; Blood Pressure; Circadian Rhythm; Diuretics; Dose-Response Relatio | 2000 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
[Antihypertensive efficacy of monotherapy in increasing doses versus therapy associated in low doses].
Topics: Antihypertensive Agents; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Losar | 1999 |
Protective effects of delapril combined with indapamide or hydrochlorothiazide in spontaneously hypertensive stroke-prone rats: a comparative dose-response analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Diuretics; Dose-Resp | 2000 |
Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study.
Topics: Age Factors; Aged; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitoring, | 2000 |
AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2001 |
['Licorice hypertension' also caused by licorice tea].
Topics: Adult; Antihypertensive Agents; Diagnostic Errors; Female; Food-Drug Interactions; Glycyrrhiza; Huma | 2001 |
Perindopril + indapamide: new preparation. Simple trick.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Top | 1999 |
The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2001 |
Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.
Topics: Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperten | 2001 |
[Management of essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2000 |
[Report of experiences. Walk in the woods by a retiree without leg edema].
Topics: Benzimidazoles; Biphenyl Compounds; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Jo | 2001 |
A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Combinations; Dru | 2001 |
A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Combinations; Dru | 2000 |
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Forecastin | 2002 |
Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diuret | 2001 |
alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives.
Topics: Alleles; Amino Acid Substitution; Antihypertensive Agents; Biological Transport; Blood Pressure; Cal | 2002 |
Monitoring one-year compliance to antihypertension medication in the Seychelles.
Topics: Adult; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cross-Sectional Studies; Drug Monitor | 2002 |
Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
Topics: Acrylates; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Chemoki | 2002 |
[Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Drug Administration Schedule; Drug Ther | 2002 |
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Topics: Administration, Oral; Allopurinol; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Con | 2002 |
Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; D | 2002 |
The effect of guanethidine and hydrochlorothiazide on blood pressure and vascular tyrosine hydroxylase activity in the spontaneously hypertensive rat.
Topics: Adrenal Glands; Animals; Blood Pressure; Blood Vessels; Catecholamines; Depression, Chemical; Drug I | 1977 |
Changes in vascular reactivity in experimental hypertensive animals following treatment with indapamide.
Topics: Animals; Blood Pressure; Brain; Cats; Desoxycorticosterone; Diuretics; Hydrochlorothiazide; Hyperten | 1977 |
[Results of a study with the antihypertensive agent Torrat].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlor | 1978 |
[Metabolic effects of a fixed combination (betablocker plus saluretic) in long-term treatment of arterial hypertension (author's transl)].
Topics: Adult; Blood Glucose; Blood Pressure; Cholesterol; Drug Combinations; Female; Humans; Hydrochlorothi | 1979 |
Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Femal | 1979 |
[Treatment of arterial hypertension with torrat in general practice].
Topics: Drug Combinations; Drug Evaluation; Humans; Hydrochlorothiazide; Hypertension; Metipranolol; Potassi | 1979 |
[Antihypertensive therapy with a fixed combination of beta receptor blockers and diuretics].
Topics: Adrenergic beta-Antagonists; Adult; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazid | 1979 |
Dangerous antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension | 1979 |
Treatment of hypertension: state of the art in 1979.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Glycolates; Humans; Hydrochlorothiazide; Hypertension; | 1979 |
Efficacy of antihypertensive drugs.
Topics: Antihypertensive Agents; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Evaluatio | 1976 |
Letter: Timolol, hydrochlorothiazide, blood-pressure, and renin in essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Humans; Hydrochl | 1976 |
Beta-blockade, renin and blood-pressure.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Drug Synergism; Humans; Hydrochlorothiazide; Hypertensi | 1977 |
Peripheral beta-receptor responsiveness in patients with essential hypertension.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Female; Furosemide; Humans; Hydrochlorothia | 1979 |
Reduced response of plasma aldosterone to acute ACTH stimulation during long-term treatment with spironolactone in essential hypertension.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Blood Pressure; Humans; Hydrochlorothiazide; Hydroc | 1979 |
[Antihypertensive effectiveness and tolerability of a combination of methyldopa and hydrochlorothiazide with and without potassium supplementation].
Topics: Adult; Aged; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Hydrochlorothiazide; Hyperte | 1979 |
Acid-activated renin responses to hydrochlorothiazide, propranol and indomethacin.
Topics: Adult; Aldosterone; Blood Pressure; Enzyme Activation; Humans; Hydrochlorothiazide; Hypertension; In | 1978 |
Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes.
Topics: Adult; Cholesterol; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1978 |
Primary hypertension refractory to triple drug treatment - a study on central and peripheral hemodynamics.
Topics: Bendroflumethiazide; Drug Therapy, Combination; Hemodynamics; Humans; Hydralazine; Hydrochlorothiazi | 1979 |
Renin angiotensin system and sympathetic nerve activity in mild essential hypertension. The functional significance of angiotensin II in untreated and thiazide treated hypertensive patients.
Topics: Adult; Aldosterone; Angiotensin II; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1979 |
Angiotensin II blockade during combined thiazide-beta-adrenoreceptor-blocker treatment.
Topics: Adult; Angiotensin II; Atenolol; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; | 1979 |
Haemodynamics during long-term thiazide treatment in essential hypertension: differences between responders and non-responders.
Topics: Adult; Aldosterone; Blood Pressure; Cardiac Output; Heart Rate; Humans; Hydrochlorothiazide; Hyperte | 1979 |
Hydrochlorothiazide diuresis in healthy man: review of the circadian mediation.
Topics: Chlorides; Circadian Rhythm; Climate; Diuresis; Humans; Hydrochlorothiazide; Hypertension; Kidney; M | 1979 |
Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension.
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Fetal Growth Retardation; Fetus; Growth; Hu | 1979 |
Effect of thiazides on serum calcium.
Topics: Adult; Aged; Calcium; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Magnesium; Male; Middle | 1979 |
Renin-angiotensin system in mild essential hypertension. The functional significance of angiotensin II in untreated and thiazide-treated hypertensive patients.
Topics: Adult; Angiotensin II; Diuretics; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Mal | 1979 |
Long-term versus short-term effects of hydrochlorothiazide on renal haemodynamics in essential hypertension.
Topics: Adult; Blood Pressure; Blood Volume; Body Weight; Glomerular Filtration Rate; Hemodynamics; Humans; | 1979 |
Diuretics and cholesterol elevation.
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Polythia | 1979 |
Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients.
Topics: Adult; Blood Pressure; Dopamine beta-Hydroxylase; Heart Rate; Humans; Hydrochlorothiazide; Hypertens | 1979 |
[Use of Adelphan-Esidrex in treating hypertension].
Topics: Adult; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Midd | 1979 |
Effects of metoprolol on blood pressure and plasma renin activity in thiazide-resistant hypertensive patients.
Topics: Adult; Blood Pressure; Creatinine; Drug Resistance; Female; Heart Rate; Humans; Hydrochlorothiazide; | 1979 |
Total body potassium and long-term treatment with amiloride HCL and/or hydrochlorothiazide.
Topics: Amiloride; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Potassium; Pyrazine | 1979 |
Relative costs of ticrynafen and thiazides.
Topics: Costs and Cost Analysis; Glycolates; Humans; Hydrochlorothiazide; Hypertension; Ticrynafen | 1979 |
Antihypertensive and renal effects of tienilic acid.
Topics: Glycolates; Humans; Hydrochlorothiazide; Hypertension; Kidney; Male; Potassium; Ticrynafen; Uric Aci | 1979 |
[Results of a field study with Moducrin in 12596 hypertensive patients].
Topics: Amiloride; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; Ma | 1979 |
A fixed combination of metoprolol and hydrochlorothiazide for hypertension: a multi-centre study.
Topics: Adult; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1979 |
Open clinical evaluation of prazosin in hypertensive Nigerians.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1979 |
[The combination of propranolol, hydrochlorothiazide and spironolactone in the treatment of essential arterial hypertension].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1979 |
[The combination of hydrochlorothiazide, amiloride and alpha-methyldopa in the treatment of arterial hypertension. Clinical evaluation of a multicentric study].
Topics: Amiloride; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methy | 1979 |
Rhythmometry gauges treatment of mesor-hypertension in the seventh and eight decades of life.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Drug Combinations; Humans; Hyd | 1979 |
Myocarditis associated with methyldopa therapy.
Topics: Adult; Aged; Death, Sudden; Drug Hypersensitivity; Female; Humans; Hydrochlorothiazide; Hypertension | 1977 |
Essential hypertension in childhood.
Topics: Adolescent; Age Factors; Blood Pressure; Child; Female; Humans; Hydrochlorothiazide; Hypertension; M | 1977 |
Comparison of the hypotensive and diuretic effects of 1,4-dimorpholino-7-phenylpyrido[3,4]pyridazine (DS-511) and hydrochlorothiazide in Doca, renal and spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Diuretics; Hydrochlorothiazide; Hypertension; Hyperte | 1977 |
Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Drug Therapy, Combination; Humans; Hydrochlorothiaz | 1978 |
[Long-term treatment of arterial hypertension with propranolol. Combination with diuretics and dihydrazinophthalazine].
Topics: Adult; Dihydralazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydro | 1978 |
[Comparison of timolol, hydrochlorothiazide and timolol-hydrochlorothiazide combination: study in 21 patients with mild to moderate essential arterial hypertension].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1978 |
Mechanism of antihypertensive effect of thiazide diuretics.
Topics: Antihypertensive Agents; Body Weight; Diuretics; Extracellular Space; Hematocrit; Hemodynamics; Huma | 1978 |
Treatment of hypertension in aviators: a clinical trial with Aldactazide.
Topics: Adult; Aerospace Medicine; Blood Volume; Drug Combinations; Electrolytes; Humans; Hydrochlorothiazid | 1978 |
[Effect of oxygen cocktail on the cardiohemodynamics in complex treatment of hypertension].
Topics: Adult; Antihypertensive Agents; Coronary Circulation; Drug Therapy, Combination; Female; Guanethidin | 1978 |
Concomitant administration of timolol and hydrochlorothiazide/amiloride in hypertensive patients. Results of a titration study.
Topics: Adult; Aged; Amiloride; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension | 1978 |
Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension.
Topics: Acebutolol; Adult; Aldosterone; Amiloride; Blood Pressure; Dose-Response Relationship, Drug; Drug Th | 1978 |
Effectiveness of twice-daily dosage of methyldopa in essential hypertension.
Topics: Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Midd | 1978 |
Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Humans; Hydrochlorothiazid | 1978 |
Use of diuretics in treatment of hypertension secondary to renal disease.
Topics: Adult; Aldosterone; Antihypertensive Agents; Creatinine; Female; Furosemide; Humans; Hydrochlorothia | 1978 |
Influence of thiazides on thyroid parameters in man.
Topics: Adult; Bendroflumethiazide; Diuretics; Female; Humans; Hydrochlorothiazide; Hydroflumethiazide; Hype | 1978 |
Leukocyte intracellular cations in hypertension: Effect of antihypertensive drugs.
Topics: Adult; Antihypertensive Agents; Electrolytes; Humans; Hydralazine; Hydrochlorothiazide; Hypertension | 1978 |
[Long-term treatment of hypertension with the combination of hydrochlorothiazine and amiloride. Results of a multi-center study of 277 patients].
Topics: Adult; Aged; Amiloride; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrochlorothiaz | 1978 |
The use of the drug combination of hypothiazide+Visken+Halidor in hypertension.
Topics: Adult; Bencyclane; Cycloheptanes; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hy | 1978 |
[Indications and results of an additional differentiated pharmacotherapy of obesity].
Topics: Adolescent; Adult; Aged; Biguanides; Diabetes Mellitus; Diet, Reducing; Female; Furosemide; Humans; | 1978 |
[Comparison of spironolactone and amiloride combined with hydrochlorothiazide in the treatment of slight or moderate hypertension].
Topics: Amiloride; Blood Glucose; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1978 |
Serum lithium levels and long-term diuretic use.
Topics: Adult; Drug Interactions; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Kidney Tubu | 1979 |
[Long-term ambulatory treatment of patients with hypertensive disease].
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Benzimidazoles; Drug Evaluation; Follow-Up Studies; | 1975 |
Electrophysiology of atropine.
Topics: Adult; Aged; Atrioventricular Node; Atropine; Bundle of His; Bundle-Branch Block; Cardiac Catheteriz | 1975 |
A circulating renin activator in essential hypertension.
Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Contraceptives, Oral; Diuretics; Enzyme Ac | 1975 |
Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta.
Topics: Animals; Aortic Coarctation; Arteriosclerosis; Blood Pressure; Body Weight; Cholesterol, Dietary; Co | 1976 |
Variability in effect of low doses of prozosin in hypertensive Nigerians.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combin | 1976 |
Changes in the fasting blood sugar after hydrochlorothiazide and potassium supplementation.
Topics: Adult; Blood Glucose; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 1977 |
7-chloro-3-(4-methyl-1-piperazinyl)-4H-1,2,4-benzothiadiazine-1,1-dioxide, a new antihypertensive agent.
Topics: Animals; Antihypertensive Agents; Benzothiadiazines; Blood Pressure; Carbohydrate Metabolism; Depres | 1977 |
Ruptured intracranial aneurysms. Case morbidity and mortality.
Topics: Adult; Aged; Aminocaproic Acid; Cerebral Hemorrhage; Humans; Hydrochlorothiazide; Hypertension; Intr | 1977 |
[Evaluation of hypotensive effects of clonidine].
Topics: Adult; Blood Pressure; Clonidine; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Ag | 1977 |
Elevated blood pressure in the young adult.
Topics: Adult; Age Factors; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Patient Care Planning; R | 1977 |
Hypotensive effects of pentobarbital and diuretics on sympathectomized spontaneously hypertensive rats.
Topics: Abdomen; Animals; Blood Pressure; Hydrochlorothiazide; Hydroflumethiazide; Hypertension; Pentobarbit | 1977 |
The effect of norepinephrine on aortic 42K turnover during deoxycorticosterone acetate hypertension and antihypertensive therapy in the rat.
Topics: Animals; Antihypertensive Agents; Aorta; Arteries; Desoxycorticosterone; Dose-Response Relationship, | 1977 |
Management of severe childhood hypertension with minoxidil: a controlled clinical study.
Topics: Adolescent; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Humans; Hydrochlorothiazide | 1977 |
Diuretic therapy and response of essential hypertension to saralasin.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperte | 1977 |
[Moduretic in ambulatory treatment of hypertension].
Topics: Adult; Amiloride; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertens | 1977 |
Antihypertensive and haemodynamic effects of clonidine-hydrochlorothiazide combination.
Topics: Adolescent; Adult; Clonidine; Drug Combinations; Female; Hemodynamics; Humans; Hydrochlorothiazide; | 1977 |
Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders.
Topics: Adult; Female; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Posture; | 1977 |
Office management of hypertension.
Topics: Antihypertensive Agents; Diuretics; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; Hyperten | 1976 |
Proceedings: Hypertension in SHR after abdominal sympathectomy.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hydrochlorothiazide; Hydroflumethiazide; Hypertensi | 1976 |
[Prolonged clinical study of the LA, 313-B-xanthinol niacinate pentosan sulfonate ester combination in various forms of hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Evaluation; Female; Hu | 1976 |
The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperte | 1976 |
Long-term effects of an amiloride/hydrochlorothiazide combination ('Moduretic') on electrolyte balance.
Topics: Adult; Aged; Amiloride; Drug Combinations; Electrolytes; Female; Humans; Hydrochlorothiazide; Hypert | 1976 |
Dyazide composition.
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Male; Triamterene | 1976 |
Stimulation of renin secretion by various methods: optional results with hydrochlorothiazide.
Topics: Adult; Aged; Diazoxide; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1976 |
[Combination of amiloride chlorhydrate and hydrochlorothiazide in the ambulatory treatment of mild and moderate hypertension].
Topics: Adult; Ambulatory Care; Amiloride; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochloroth | 1976 |
[Changes in kidney function during hypotensive treatment].
Topics: Adult; Aged; Clonidine; Dihydralazine; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazid | 1976 |
Effects of diuretics on lipid metabolism in patients with essential hypertension.
Topics: Adult; Blood Glucose; Cholesterol; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; | 1976 |
Detection and treatment of hypertension at the work site.
Topics: Aged; Allied Health Personnel; Costs and Cost Analysis; Delivery of Health Care; Female; Humans; Hyd | 1975 |
Evaluation of antihypertensive agents in the stress-induced hypertensive rat.
Topics: Animals; Antihypertensive Agents; Chlorisondamine; Disease Models, Animal; Drug Evaluation, Preclini | 1975 |
Systolic time intervals in chronic hypertension: Alterations and response to treatment.
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Heart; Heart Diseases; Heart Function Tests | 1975 |
Sodium restriction and thiazide diuretics in the treatment of hypertension.
Topics: Amiloride; Bicarbonates; Body Weight; Chlorothiazide; Diet, Sodium-Restricted; Diuretics; Humans; Hy | 1975 |
[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Body Weight; Butanes; Female; Furosemide; Huma | 1975 |
How far should blood pressure be lowered in treating hypertension.
Topics: Blood Pressure; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Reserpine | 1975 |
Editorial: Hypertension is worth treating.
Topics: Blood Pressure; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydralazine; Hydrochlorothiazide | 1975 |
Influence of anti-hypertensive drug treatment on vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Female; Hydralazine; Hydrochlorothiazide; Hyperten | 1975 |
Spironolactone, a reassessment.
Topics: Diuresis; Drug Combinations; Humans; Hydrochlorothiazide; Hyperaldosteronism; Hypertension; Hypokale | 1975 |
[Treatment of hypertension with propranolol in combination with other antihypertensive agents].
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydrochlorot | 1975 |
[Ambulatory treatment of arterial hypertension urinary the new combination "saluretic and beta-sympatholytic"].
Topics: Chemical Phenomena; Chemistry; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; | 1975 |
[Treatment of arterial hypertension with an association of drugs in low dosage].
Topics: Adult; Aged; Drug Administration Schedule; Drug Combinations; Female; Guanethidine; Humans; Hydrochl | 1975 |
Low renin essential hypertension in a child.
Topics: Aldosterone; Child; Circadian Rhythm; Dexamethasone; Humans; Hydrochlorothiazide; Hydrocortisone; Hy | 1976 |
[Treatment of essential hypertension with Transicor 80 and Esidrex K under medical practice conditions].
Topics: Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Oxprenolol | 1976 |
Letter: Impotence during antihypertensive treatment.
Topics: Adult; Erectile Dysfunction; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male | 1976 |
Changes in the ratio of plasma to intersitiial fluid volume during long-term antihypertensive therapy.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Extracellular Space; Female; Humans; Hydrochloro | 1976 |
Absorption, metabolism, and excretion of hydrochlorothiazide.
Topics: Adult; Erythrocytes; Feces; Humans; Hydrochlorothiazide; Hypertension; Intestinal Absorption; Male; | 1976 |
The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology.
Topics: Analysis of Variance; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method | 1992 |
Diuretic induced hyponatraemia in the elderly.
Topics: Aged; Diagnosis, Differential; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; H | 1992 |
Differences in ouabain-induced natriuresis between isolated kidneys of Milan hypertensive and normotensive rats.
Topics: Animals; Glomerular Filtration Rate; Hydrochlorothiazide; Hypertension; Kidney; Natriuresis; Ouabain | 1992 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg | 1992 |
Regression of left ventricular hypertrophy in "previously untreated" hypertensive blacks after 6 months of blood pressure reduction with alpha- and beta-adrenergic blockade and thiazide therapy.
Topics: Adult; Aged; Black People; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; Echocardiography | 1992 |
[The dynamics of the concentration of atrial natriuretic factor depending on changes in the arterial pressure level in patients with arterial hypertension].
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Captopril; Chronic Disease; Humans; Hydrochl | 1992 |
Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Cholesterol, Dietary; Coronary Disease; Electrocardi | 1992 |
Chronic antihypertensive treatment with captopril plus hydrochlorothiazide improves aortic distensibility in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Captopril; Decerebra | 1992 |
Enalapril in hypertension.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazi | 1992 |
[Potassium canrenoate and the combination of potassium canrenoate-butizide in the therapy of light to moderate arterial hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Canrenoic Acid; Diuretics; Drug Evaluation; Drug The | 1992 |
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Gluco | 1992 |
[Efficacy and tolerability of a preconstituted combination of captopril 50 mg + hydrochlorothiazide 25 mg in aged subjects with isolated systolic hypertension].
Topics: Aged; Aged, 80 and over; Captopril; Drug Combinations; Drug Tolerance; Female; Humans; Hydrochloroth | 1992 |
Endocrine sodium and volume regulation in familial hyperkalemia with hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Family; Female; Humans; Hydrochloroth | 1992 |
Effect of antihypertensive treatment on focal cerebral infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain; C | 1992 |
Interaction of biofeedback-assisted relaxation and diuretic in treatment of essential hypertension.
Topics: Adult; Antihypertensive Agents; Biofeedback, Psychology; Combined Modality Therapy; Drug Combination | 1992 |
Chronic hydrochlorothiazide and verapamil effects on motor activity in hypertensive baboons.
Topics: Animals; Blood Pressure; Drug Interactions; Hydrochlorothiazide; Hypertension; Male; Motor Activity; | 1992 |
Effects of a new dihydropyridine derivative, FRC-8653, on blood pressure in conscious spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Dihydropyridines; Heart Rate; | 1992 |
Diuretics, potassium, and ventricular arrhythmias.
Topics: Adolescent; Aged; Arrhythmias, Cardiac; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hypoka | 1992 |
Interaction between an angiotensin converting enzyme inhibitor, perindopril, and a thiazide diuretic in the spontaneously hypertensive rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dose-Response Relationship, Drug; | 1992 |
The efficacy and tolerability of enalapril--hydrochlorothiazide combination as a first line therapy in black patients with mild to moderate arterial hypertension: a clinical study in Kenya.
Topics: Adult; Aged; Drug Therapy, Combination; Drug Tolerance; Enalapril; Female; Humans; Hydrochlorothiazi | 1992 |
Stress and sodium hypertension in baboons: neuroendocrine and pharmacotherapeutic assessments.
Topics: Animals; Atenolol; Atrial Natriuretic Factor; Creatinine; Dopamine; Epinephrine; Hydrochlorothiazide | 1991 |
Hypertension: control by combination. Focus on lisinopril-hydrochlorothiazide. Proceeding of a meeting. Reykjavik, Iceland, 2-3 July 1991.
Topics: Antihypertensive Agents; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Li | 1991 |
Review of international safety data for lisinopril-hydrochlorothiazide combination treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; | 1991 |
Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Thera | 1990 |
Magnesium deficiency in two hypertensive patient groups.
Topics: Antihypertensive Agents; Cardiac Complexes, Premature; Drug Evaluation; Female; Humans; Hydrochlorot | 1990 |
Blood pressure lowering and renal hemodynamic effects of fosinopril in conscious animal models.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Dogs; Female; Fosinopril; He | 1990 |
The diurnal rhythm of plasma potassium: relationship to diuretic therapy.
Topics: Adult; Aldosterone; Amiloride; Animals; Blood Pressure; Circadian Rhythm; Cricetinae; Diuretics; Ele | 1991 |
Influence of therapy on silent ischemia and ventricular arrhythmias in hypertensive patients.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Electrocardiography, Ambulatory | 1991 |
[Experimental study on the treatment of hypertension with combined traditional Chinese and Western medicine].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Atrial Natriuretic Factor; Cyclic AMP; Cyclic GMP; Drugs, | 1991 |
[Reserpine and reserpine-containing preparations in hypertension?].
Topics: Diuretics; Drug Therapy, Combination; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Propra | 1992 |
Thiazide diuretics and polydipsia in schizophrenic patients.
Topics: Adult; Drinking Behavior; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Male; Schizophren | 1991 |
[Side effects of long-term drug therapy of patients with uncomplicated arterial hypertension in a polyclinic].
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Clonidine; Dose-Response Relati | 1991 |
Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing.
Topics: Blood Pressure; Captopril; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration S | 1991 |
Efficacy of intravenous verapamil in arterial hypertension refractory to three-step antihypertensive therapy.
Topics: Adult; Antihypertensive Agents; Clonidine; Echocardiography; Female; Hemodynamics; Humans; Hydrochlo | 1991 |
[Thiazide diuretic-induced subacute cutaneous lupus erythematosus].
Topics: Aged; Antibodies, Antinuclear; Complement C3; Drug Combinations; Drug Eruptions; Female; Fluorescent | 1991 |
[Effects of adelphan-esidrex on hemodynamic indexes at rest and character of their changes during exercise tests].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Exercise Test; Female; Hemodynamics; Humans | 1991 |
Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Therapy, C | 1991 |
Bilateral submandibular sialolithiasis and concurrent sialadenitis: a case report.
Topics: Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Methyldopa; Salivary Duct Calculi; Salivary | 1991 |
[Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?].
Topics: Acebutolol; Adult; Coronary Disease; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male | 1991 |
Increased blood kynurenine level as a factor inhibiting the therapeutic effect of antihypertensive agents in combined long-term treatment of essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiac Volume; Cardiomegaly; Clonidine; Drug Therap | 1990 |
Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Circadian Rhythm; Drug Therapy, Combinatio | 1990 |
Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.
Topics: Adult; Aged; Aldosterone; Dipeptides; Dose-Response Relationship, Drug; Female; Humans; Hydrochlorot | 1990 |
Effect of diuretics on captopril-induced urinary zinc excretion.
Topics: Adult; Captopril; Creatinine; Drug Therapy, Combination; Female; Furosemide; Humans; Hydrochlorothia | 1990 |
Longterm effects of captopril and hydrochlorothiazide on glucose metabolism in the hypertensive patient.
Topics: Blood Glucose; Captopril; Humans; Hydrochlorothiazide; Hypertension; Insulin; Lipids | 1990 |
[Report on treatment with captopril and hydrochlorothiazide combination. Comprehensive therapy of hypertension].
Topics: Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1990 |
Metabolic effects of the combination of captopril and hydrochlorothiazide in hypertensive subjects.
Topics: Adult; Aged; Blood Pressure; Captopril; Diastole; Drug Therapy, Combination; Female; Humans; Hydroch | 1990 |
[The effect of visken and hypothiazide on the indices of the central and renal hemodynamics in patients with atherosclerotic hypertension].
Topics: Aged; Arteriosclerosis; Drug Evaluation; Female; Hemodynamics; Humans; Hydrochlorothiazide; Hyperten | 1990 |
[Comparative study of potassium-sparing effects of triamterene and amiloride in the treatment with hydrochlorothiazide].
Topics: Amiloride; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Potassium Deficienc | 1990 |
Hydrochlorothiazide dosage in hypertension.
Topics: Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Risk Factors | 1990 |
Angiotensin converting enzyme inhibitors in modern treatment of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Humans; Hydrochlorothiazide; Hypertension; Vascular Resist | 1990 |
Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; L | 1990 |
Haemodynamic resistance of forearm vessels during prolonged drug treatment of essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clonidine; Drug Therapy, Combination | 1990 |
European experience with spironolactone and thiazide diuretic as antihypertensive therapy.
Topics: Diuretics; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; | 1990 |
[Arterial hypertension and hemorheology: the effects of triamterene and hydrochlorothiazide].
Topics: Adult; Aged; Blood Chemical Analysis; Blood Viscosity; Drug Therapy, Combination; Erythrocyte Aggreg | 1990 |
[Hydrochlorothiazide and amiloride in hypertension].
Topics: Amiloride; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1990 |
Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomegaly; Diuretics; Echocardio | 1985 |
Effects of exercise on blood pressure, plasma catecholamines, potassium and the electrocardiogram after diuretic and neural-blocking therapy for moderate hypertension.
Topics: Blood Pressure; Cardiac Complexes, Premature; Catecholamines; Cholesterol; Drug Therapy, Combination | 1985 |
Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomegaly; Catecholamines; Chlorthalid | 1986 |
Safety aspects of long-term antihypertensive therapy (10 years) with clonidine.
Topics: Adult; Blood Pressure; Cardiomegaly; Cholesterol; Clonidine; Drug Therapy, Combination; Electrocardi | 1987 |
The influence of hydrochlorothiazide and tripamide on serum and urinary amylase.
Topics: Adult; Amylases; Body Weight; Creatinine; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indo | 1988 |
Hemodynamic consequences of diuretic-induced hypokalemia.
Topics: Adult; Cardiac Complexes, Premature; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Hypoka | 1988 |
Antihypertensive treatment for the management of premature ventricular complexes. Pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Blood Pressure; Cardiac Complexe | 1988 |
Long-term efficacy and safety of nitrendipine in severe essential hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Mi | 1988 |
Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Dihydralazine; Heart; H | 1989 |
Captopril and hydrochlorothiazide combined: Acezide/Capozide.
Topics: Captopril; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Male | 1989 |
Predictors of left ventricular hypertrophy in patients with essential hypertension.
Topics: Blood Pressure; Cardiomegaly; Echocardiography; Electrocardiography; Female; Humans; Hydrochlorothia | 1989 |
Detection and monitoring of asymptomatic atherosclerosis in clinical trials.
Topics: Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Humans; Hydro | 1989 |
Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias.
Topics: Adult; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiomegaly; Death, Sudden; Electrocardiogra | 1989 |
Hyperkalemic periodic paralysis in Gordon's syndrome: a possible defect in atrial natriuretic peptide function.
Topics: Adolescent; Atrial Natriuretic Factor; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Male | 1989 |
Long-term evaluation of cilazapril in severe hypertension. Assessment of left ventricular and renal function.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Cilazapril; Diastole; Dr | 1989 |
The antihypertensive response to lisinopril: the effect of age in a predominantly black population.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Black | 1989 |
[Enalapril in essential arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazi | 1989 |
Erythrocyte cation transport in obesity, hypertension, and during antihypertensive drug therapy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Cations; Erythrocytes | 1989 |
Response of blood pressure, cardiac output, peripheral resistance, and exercise performance to substitution of calcium blocker for beta-blocker plus thiazide diuretic therapy in patients with both systemic hypertension and mild stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; | 1989 |
Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Creatinine; Dipeptides; | 1985 |
Effect of pindolol on changes in serum lipids induced by hydrochlorthiazide.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydrochlorothiazide; Hyperte | 1989 |
[Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension].
Topics: Age Factors; Aged; Humans; Hydrochlorothiazide; Hypertension; Magnesium Deficiency; Male; Potassium | 1989 |
[Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension].
Topics: Adult; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Hydrochlorothiazide; Hype | 1989 |
Hydrochlorothiazide is not additive to verapamil in treating essential hypertension.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1989 |
Assessing duration of antihypertensive effects with whole-day blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Captopril; Drug Administration Schedule; Drug Co | 1989 |
Association of systemic hypertension and diabetes mellitus with cataract extraction. A case-control study.
Topics: Aged; Cataract Extraction; Cohort Studies; Diabetes Complications; Digoxin; Female; Furosemide; Huma | 1989 |
[Captopril and hydrochlorothiazide combined in the treatment of mild-to-moderate hypertension. Evaluation of sugar and lipid metabolism in a long-term study].
Topics: Adult; Aged; Blood Glucose; Captopril; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hu | 1989 |
Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males.
Topics: Administration, Cutaneous; Aged; Blood Pressure; Clonidine; Heart Rate; Humans; Hydrochlorothiazide; | 1989 |
[Moderate arterial hypertension during its natural course and in drug correction].
Topics: Blood Pressure; Cause of Death; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1989 |
Hyperkalemia in diabetes mellitus. Effect of a triamterene-hydrochlorothiazide combination.
Topics: Diabetes Complications; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyperkalemia; Hypert | 1989 |
Treatment-induced blood pressure reduction and the risk of myocardial infarction.
Topics: Blood Pressure; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Middle A | 1989 |
Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.
Topics: Adult; Female; Graves Disease; Humans; Hydrochlorothiazide; Hypertension; Injections, Intravenous; M | 1989 |
Diuretic effects of an ACE inhibitor, RS-10085, and hydrochlorothiazide in the spontaneously hypertensive rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dose-Response Relationship, Drug; Drug | 1989 |
Chronic diuretic effects of subcutaneous hydrochlorothiazide in the spontaneously hypertensive rat; validation of a simple model for chronic diuretic assessment.
Topics: Animals; Disease Models, Animal; Diuretics; Hydrochlorothiazide; Hypertension; Injections, Subcutane | 1989 |
Renal protective effect of strict blood pressure control with enalapril therapy.
Topics: Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Humans; Hydrochloro | 1987 |
Effect of treatment with hydrochlorothiazide on the red cell Na,K-adenosine triphosphatase in men with hypertension.
Topics: Adult; Erythrocytes; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Ouabain; Potassiu | 1987 |
(Na+ + K+) ATPase inhibitors and intracellular electrolytes in essential hypertension.
Topics: Humans; Hydrochlorothiazide; Hypertension; Leukocytes; Male; Potassium; Potassium Chloride; Renin; S | 1987 |
[Enalapril, atenolol and hydrochlorothiazide in mild and moderate hypertension].
Topics: Atenolol; Enalapril; Humans; Hydrochlorothiazide; Hypertension | 1988 |
Antihypertensive action of a new angiotensin converting enzyme inhibitor, (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetr ahy dro-1,5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Dogs; En | 1988 |
Effects of enalapril with and without hydrochlorothiazide in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Enalapril; Female; Glycated Hemoglobin; Hu | 1988 |
[Efficacy of angiotensin-converting enzyme inhibitors in the therapy of arterial hypertension in the aged].
Topics: Age Factors; Aged; Drug Evaluation; Drug Therapy, Combination; Enalapril; Humans; Hydrochlorothiazid | 1988 |
Long term metabolic effects of enalapril alone or in combination with hydrochlorothiazide.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertensio | 1987 |
[Value of combination therapy with Tensobon].
Topics: Blood Pressure; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Pro | 1985 |
[Optimization of hypotensive therapy in hospitals].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Circulation; Clonidine; Drug C | 1985 |
[A beta blockader-diuretic combination in long-term anti-hypertensive therapy. Undesirable effects on blood potassium].
Topics: Adrenergic beta-Antagonists; Adult; Chlorthalidone; Drug Therapy, Combination; Female; Follow-Up Stu | 1985 |
Problems with the use of diuretics in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Coronary Disease; Diuretics; Female; Humans; Hydrochlor | 1986 |
Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug.
Topics: Amiloride; Diagnosis, Differential; Drug Combinations; Drug Interactions; Female; Humans; Hydrochlor | 1986 |
Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cholesterol; Cholesterol, HDL; Female; Humans; Hydrochloro | 1987 |
[Effective combination in the therapy of hypertension. Prof. Dr. H. Brunner, Lausanne, elaborates on the advantages of a combination ACE inhibitor].
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hy | 1988 |
Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide)
Topics: Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1989 |
Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: case report.
Topics: Adult; Ampicillin; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydrochlorothiazide; Hype | 1989 |
[Left ventricular hypertrophy and neural tonus in hypertension: differences in the action of diuretics and relaxation therapy].
Topics: Adult; Aged; Blood Pressure; California; Cardiomegaly; Diuretics; Drug Therapy, Combination; Epineph | 1986 |
[Clinical and therapeutic experience in elderly patients with arterial hypertension].
Topics: Aged; Amiloride; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1987 |
Comparison of cicletanine with other antihypertensive drugs in SHR-SP models.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Diuresis; Di | 1988 |
Adrenergic hyposensitivity during long-term diuretic therapy--a possible explanation for the antihypertensive effect of diuretics?
Topics: Adult; Aged; Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Kinetics | 1985 |
Mechanism of diuretic-induced hypopotassemia in human hypertension.
Topics: Calcium; Erythrocyte Membrane; Erythrocytes; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; | 1985 |
Modulation of right and left ventricular wall thicknesses in experimental hypertension.
Topics: Animals; Cardiomegaly; Enalapril; Hydrochlorothiazide; Hypertension; Rats; Sodium Chloride | 1985 |
Enalapril in essential hypertension.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Catecholamines; Enalapril; Female | 1985 |
Hemodynamic and renal function in essential hypertension during treatment with enalapril.
Topics: Adult; Aged; Body Fluids; Drug Therapy, Combination; Enalapril; Hemodynamics; Humans; Hydrochlorothi | 1985 |
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
Topics: Animals; Enalapril; Glomerular Filtration Rate; Glomerular Mesangium; Glomerulonephritis; Glomerulos | 1985 |
Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood | 1985 |
[Diuretic-resistant hypertension. Effect of an additional daily single dose of a ACE inhibitor].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cholinesterase Inhibitor | 1985 |
Rest and exercise hemodynamic and adrenergic responses to enalapril, hydrochlorothiazide, and combination treatment in patients with systemic hypertension.
Topics: Adult; Aged; Drug Therapy, Combination; Enalapril; Epinephrine; Female; Heart Rate; Humans; Hydrochl | 1985 |
Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis.
Topics: Acute Kidney Injury; Captopril; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Hypert | 1985 |
Long-term effects of enalapril monotherapy and enalapril/hydrochlorothiazide combination therapy on blood pressure, renal function, and body fluid composition.
Topics: Adult; Aged; Blood Pressure; Body Fluids; Drug Therapy, Combination; Electrolytes; Enalapril; Glomer | 1986 |
Once daily enalapril in general practice patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazi | 1986 |
Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic.
Topics: Adult; Aldosterone; Blood Pressure; Captopril; Drug Therapy, Combination; Enalapril; Female; Furosem | 1986 |
[Clinical experience with enalapril in the treatment of essential mild-moderate arterial hypertension].
Topics: Adult; Cold Temperature; Drug Therapy, Combination; Enalapril; Exercise Test; Female; Humans; Hydroc | 1986 |
[Combination of enalapril with diuretics in the treatment of arterial hypertension].
Topics: Atenolol; Drug Therapy, Combination; Enalapril; Humans; Hydrochlorothiazide; Hypertension | 1986 |
Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron.
Topics: Animals; Ca(2+) Mg(2+)-ATPase; Creatinine; Hydrochlorothiazide; Hypertension; Male; Nephrons; Potass | 1987 |
[Chronobiological study of the antihypertensive effect of captopril-hydrochlorothiazide combination administered in a single low dose].
Topics: Adult; Aged; Captopril; Circadian Rhythm; Drug Combinations; Drug Evaluation; Female; Humans; Hydroc | 1988 |
[The effectiveness and duration of antihypertensive action of captopril 50 mg. + hydrochlorothiazide 25 mg. (CAP + HCTZ)].
Topics: Adult; Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1988 |
[Combination captopril-hydrochlorothiazide in a single dose for treatment of essential arterial hypertension].
Topics: Captopril; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1988 |
Elevated blood pressure during pregnancy.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Me | 1986 |
Diuretics and calcium antagonists in hypertension.
Topics: Bendroflumethiazide; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1988 |
[Transdermal clonidine: a new therapeutic approach in essential hypertension?].
Topics: Administration, Topical; Adult; Aged; Blood Pressure; Clonidine; Drug Eruptions; Drug Therapy, Combi | 1985 |
[Comparison on antihypertensive and cardiac effects of guanadrel and propranolol].
Topics: Antihypertensive Agents; Blood Pressure; Female; Guanidines; Hemodynamics; Humans; Hydrochlorothiazi | 1985 |
Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Therapy, Combination; Female; Follow-Up | 1988 |
[Combined antihypertensive pharmacotherapy].
Topics: Adult; Antihypertensive Agents; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Femal | 1988 |
[Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
Topics: Adult; Canrenoic Acid; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1988 |
Rebound hypertension after discontinuation of transdermal clonidine.
Topics: Administration, Cutaneous; Blood Pressure; Clonidine; Humans; Hydrochlorothiazide; Hypertension; Mal | 1988 |
The effect of a single daily low dose of methyldopa and K+ sparing diuretic on blood pressure in the elderly.
Topics: Aged; Aged, 80 and over; Amiloride; Blood Pressure; Drug Administration Schedule; Drug Therapy, Comb | 1988 |
Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril).
Topics: Adult; Aged; Aging; Bendroflumethiazide; Black People; Blood Pressure; Captopril; Dose-Response Rela | 1988 |
Influence of renin levels on the treatment of essential hypertension with thiazide diuretics.
Topics: Adolescent; Adult; Blood Pressure; Chlorothiazide; Diuretics; Female; Humans; Hydrochlorothiazide; H | 1987 |
Glucose metabolism during captopril mono- and combination therapy in diabetic hypertensive patients: a multiclinic trial.
Topics: Blood Glucose; Captopril; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucose Tolerance Te | 1987 |
Effect of one year of thiazide therapy on plasma volume, renin, aldosterone, lipids and urinary metanephrines in systolic hypertension of elderly patients.
Topics: Aged; Aldosterone; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Lipids; Metanephrin | 1987 |
[Treatment of essential arterial hypertension in the elderly with low-dose captopril and hydrochlorothiazide. Long-term study].
Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1987 |
[Preliminary evaluation of the therapeutic efficacy of a combination of captopril 50 mg + hydrochlorothiazide 25 mg (Aceplus 50/25)].
Topics: Adult; Captopril; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Male | 1987 |
Metoprolol and hydrochlorothiazide in the treatment of elderly hypertensive patients. A Dutch multicentre trial. The Dutch Investigators Group for the Study of Antihypertensive Treatment in the Elderly.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertens | 1988 |
Labetalol in the treatment of elderly patients with mild essential hypertension.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochloro | 1988 |
Hydrochlorothiazide with or without amiloride for hypertension in the elderly.
Topics: Aged; Amiloride; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1988 |
[Validity of a fixed atenolol/hydrochlorothiazide/amiloride combination (100/25/2.5 mg) in the therapy of essential arterial hypertension].
Topics: Adolescent; Adult; Amiloride; Atenolol; Drug Evaluation; Drug Therapy, Combination; Female; Follow-U | 1988 |
Effect of antihypertensive therapy on a vascular change in genetically hypertensive rats.
Topics: Animals; Arteries; Blood Pressure; Hydralazine; Hydrochlorothiazide; Hypertension; In Vitro Techniqu | 1987 |
Antihypertensive properties of tiapamil (RO 11-1781)--a new calcium antagonist--in patients with mild and moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Evaluation | 1987 |
[Nifedipine in the emergency and chronic treatment of arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Drug Therapy, Combination; Em | 1987 |
Reactivity to mental stress and cold provocation during long-term treatment with metoprolol, propranolol or hydrochlorothiazide.
Topics: Adult; Blood Pressure; Catecholamines; Cold Temperature; Humans; Hydrochlorothiazide; Hypertension; | 1986 |
The antihypertensive action of hydrochlorothiazide and renal prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Blood Pressure; Creatinine; Drug Evaluation; Epoprostenol; Fema | 1986 |
Diuretic treatment alters clonidine suppression of plasma norepinephrine.
Topics: Administration, Oral; Amiloride; Blood Glucose; Blood Pressure; Body Weight; Clonidine; Drug Interac | 1986 |
Low-dose captopril alone and in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1986 |
[Effect of hydrochlorothiazide treatment on the secretion of insulin, glucagon and pancreatic polypeptide in patients with arterial hypertension].
Topics: Adult; Female; Glucagon; Humans; Hydrochlorothiazide; Hypertension; Insulin; Insulin Secretion; Male | 1986 |
Efficacy of low dose captopril once daily in diuretic resistant hypertension.
Topics: Adult; Blood Pressure; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertensi | 1986 |
Effect of converting enzyme inhibitors in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Captopril; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug T | 1986 |
Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, aldosterone, urinary metanephrines and response to thiazide therapy.
Topics: Aged; Aged, 80 and over; Aldosterone; Epinephrine; Hemodynamics; Humans; Hydrochlorothiazide; Hypert | 1986 |
Serum potassium concentrations after initiation of captopril therapy.
Topics: Aged; Antihypertensive Agents; Captopril; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; | 1986 |
[Validity and effectiveness of a pre-constituted captopril-hydrochlorothiazide combination in a single daily dose].
Topics: Adult; Aged; Captopril; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydrochloro | 1986 |
Thiazide induced hypotension: the role of plasma volume reduction and the urinary kallikrein system.
Topics: Aldosterone; Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Kallikreins; Ma | 1986 |
Differential structural responses of small resistance vessels to antihypertensive therapy.
Topics: Animals; Antihypertensive Agents; Blood Vessels; Captopril; Hindlimb; Hydralazine; Hydrochlorothiazi | 1987 |
[Effect of long-term hydrochlorothiazide treatment on blood pressure and plasma volume in patients with normal and low-renin arterial hypertension].
Topics: Adult; Blood Pressure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Plasma Volume; | 1986 |
Captopril + hydrochlorothiazide 24 h ambulatory monitoring effects.
Topics: Adult; Aged; Ambulatory Care; Blood Pressure; Captopril; Drug Combinations; Female; Humans; Hydrochl | 1987 |
[Efficacy of a graded plan for long-term prevention using antihypertensive drugs. Work Group for the Cooperative Study for the Testing of New Preparations for the Prevention of Arterial Hypertension (CSPPAH)].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Diastole; Drug Therapy, Combination; Heart Rate; Hum | 1987 |
Vascular reactivity in the spontaneously hypertensive stroke-prone rat. Effect of antihypertensive treatment.
Topics: Animals; Blood Pressure; Calcium; Cerebrovascular Disorders; Female; Femoral Artery; Hydralazine; Hy | 1987 |
A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.
Topics: Adult; Aged; Aging; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Heart Rate; Humans; Hydr | 1987 |
Hydrochlorothiazide-amiloride causes excessive urinary zinc excretion.
Topics: Adult; Amiloride; Creatinine; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1987 |
[Hemodynamic mechanisms of the hypotensive effect of hypothiazide and oxodolin].
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Hemodynamics; Humans; Hydrochlorothiazide; Hypertens | 1987 |
[Differential diagnosis of hypercalcemic crisis associated with hypokalemia, adenoma of the parathyroid, thyroid adenomatosis, thyrotoxicosis and arterial hypertension treated with hydrochlorothiazide].
Topics: Adenoma; Diagnosis, Differential; Female; Humans; Hydrochlorothiazide; Hypercalcemia; Hypertension; | 1987 |
[Evaluation of the effect of long-term treatment with hydrochlorothiazide on the activity of the renin-angiotensin-aldosterone system, sodium metabolism and renal function in patients with primary arterial hypertension].
Topics: Humans; Hydrochlorothiazide; Hypertension; Kidney; Renin-Angiotensin System; Sodium | 1987 |
Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion.
Topics: Acute Disease; Combined Modality Therapy; Emergencies; Female; Humans; Hydrochlorothiazide; Hyperten | 1987 |
Comparison of sustained release verapamil and hydrochlorothiazide in hypertension--effect on blood pressure and metabolic variables.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cholesterol; Delayed-Action Preparations; Female; Humans | 1987 |
[Penbutolol and arterial hypertension].
Topics: Blood Pressure; Diabetes Complications; Dihydralazine; Drug Therapy, Combination; Female; Humans; Hy | 1987 |
Efficacy of verapamil--hydrochlorothiazide-spironolactone therapy in hypertensive black patients.
Topics: Adult; Aged; Black People; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1987 |
Propranolol ... not guilty.
Topics: Drug Combinations; Headache; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Propranol | 1987 |
[Effect of long-term hydrochlorothiazide treatment on the hemodynamics of patients with primary arterial hypertension].
Topics: Adult; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Time Factors | 1987 |
[Impotence caused by hydrochlorothiazide].
Topics: Erectile Dysfunction; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1986 |
[Effect of diuretics on serum lipids in hypertension].
Topics: Adult; Aged; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Lipids; | 1986 |
Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Heart Ventricles; Humans; Hydrochlorothiazid | 1986 |
Outpatient conversion of treatment to potassium-sparing diuretics.
Topics: Adult; Aged; Ambulatory Care; Amiloride; Antihypertensive Agents; Diuretics; Drug Combinations; Drug | 1986 |
[Combined effect of (2R, 4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarbo xyl ic acid (SA446) with hydrochlorothiazide or propranolol on development of hypertension in spontaneously hypertensive rats (SHR) by long-term administration].
Topics: 3-Mercaptopropionic Acid; Animals; Antihypertensive Agents; Diuresis; Hydrochlorothiazide; Hypertens | 1986 |
[Relation between the hypotensive effect of triampur and its pharmacokinetics in patients with hypertension].
Topics: Adolescent; Adult; Antihypertensive Agents; Drug Combinations; Female; Half-Life; Humans; Hydrochlor | 1986 |
Hypertension therapy.
Topics: Aged; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Triamte | 1986 |
Clinical efficacy and cost comparison of an amiloride-hydrochlorothiazide combination versus hydrochlorothiazide and wax-matrix potassium supplement in the treatment of essential hypertension.
Topics: Adult; Aged; Amiloride; Blood Pressure; Cost Control; Drug Combinations; Drug Evaluation; Humans; Hy | 1986 |
Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
Topics: Absorption; Adult; Aged; Aging; Biological Availability; Creatinine; Humans; Hydrochlorothiazide; Hy | 1986 |
[Effect of hypothiazide and furosemide on different types of metabolism in arterial hypertension].
Topics: Blood Glucose; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Lipoproteins; Potassium; Uric | 1986 |
Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Echocardiography; Female; Heart Rate; Heart Ventri | 1986 |
Fatal water intoxication, schizophrenia, and diuretic therapy for systemic hypertension.
Topics: Adult; Humans; Hydrochlorothiazide; Hypertension; Male; Schizophrenia; Water Intoxication | 1987 |
Postmarketing study of timolol-hydrochlorothiazide antihypertensive therapy.
Topics: Adolescent; Adult; Aged; Dizziness; Drug Combinations; Fatigue; Female; Humans; Hydrochlorothiazide; | 1985 |
The use of labetalol for the treatment of hypertension in patients with reversible airway obstruction.
Topics: Airway Resistance; Asthma; Bronchitis; Forced Expiratory Flow Rates; Forced Expiratory Volume; Human | 1985 |
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment].
Topics: Adult; Asthma; Bronchitis; Chronic Disease; Drug Therapy, Combination; Female; Hemodynamics; Humans; | 1985 |
Accuracy of indirect measures of medication compliance in hypertension.
Topics: Blood Pressure Determination; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Hyp | 1985 |
Renal failure with potassium-sparing diuretics.
Topics: Acute Kidney Injury; Aged; Amiloride; Anti-Inflammatory Agents; Blood Volume; Diuretics; Drug Synerg | 1985 |
[Effect of antihypertensive treatment on the secretion of corticotropin, prolactin, growth hormone and cortisol].
Topics: Adult; Humans; Hydrochlorothiazide; Hydrocortisone; Hypertension; Male; Middle Aged; Pituitary Hormo | 1985 |
[Clinical and diagnostic evaluation of the treatment of systemic arterial hypertension with captopril and hydrochlorothiazide].
Topics: Adult; Captopril; Drug Evaluation; Drug Therapy, Combination; Echocardiography; Electrocardiography; | 1985 |
[Clinical evaluation of penbutolol (Hoe 893d) (beta adrenergic blocker), alone and in combination with hydrochlorothiazide, in the treatment of arterial hypertension. II. Effect on plasma electrolytes, renal function, plasma renin and aldosterone activity
Topics: Aldosterone; Antihypertensive Agents; Drug Therapy, Combination; Electrolytes; Humans; Hydrochloroth | 1985 |
Essential hypertension: a metabolic cause? A hypothesis.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Calcium; Captopril; Female; Humans; Hydrochlorothiazide; H | 1985 |
[Ergometric evaluation of effects of captopril in hypertensive patients with exertion-induced angina].
Topics: Aged; Angina Pectoris; Captopril; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldop | 1985 |
Comparison of low-dose captopril and propranolol as second-line drugs in mild and moderate hypertension.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 1985 |
Diuretic-induced lithium toxicity presenting as mania.
Topics: Bipolar Disorder; Diagnosis, Differential; Female; Humans; Hydrochlorothiazide; Hypertension; Kineti | 1985 |
Type II diabetes: some problems in diagnosis and treatment.
Topics: Blood Glucose; Chlorpropamide; Confusion; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; | 1985 |
Management of isolated systolic hypertension in the elderly.
Topics: Adult; Aged; Aging; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Cardiac Output; Hemody | 1986 |
Triamterene stones and computerized axial tomography.
Topics: Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kidney Calculi; Kidney | 1986 |
Treatment of hypertension in the elderly.
Topics: Aged; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Guanabenz; Heart Rate; Humans; Hyd | 1986 |
Salt substitute as potassium replacement in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Diet; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia | 1986 |
Lacunar stroke.
Topics: Adult; Blood Pressure; Brain; Cerebrovascular Disorders; Diagnosis, Differential; Hemiplegia; Humans | 1986 |
Serial measurements of systolic time intervals during treatment with hydrochlorothiazide alone and combined with other antihypertensive agents.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Electrocardiography; Humans; Hydralazine; Hydroc | 1985 |
[Combination of methyldopa and diuretics in the treatment of hypertensive disease].
Topics: Aged; Amiloride; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1985 |
[Hypotensive effect and tolerability of a short course of treatment with prazosin (pratsiol) and hydralazine (apressin) in a cooperative study of new drugs for the prevention of arterial hypertension].
Topics: Adult; Drug Therapy, Combination; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Midd | 1985 |
[Side effects of treatment of arterial hypertension with hypothiazide].
Topics: Adult; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hyperlipidemias; Hypertension; | 1985 |
Function of the isolated spontaneously hypertensive rat kidney after blood pressure reduction.
Topics: Animals; Blood Pressure; Diazoxide; Drug Evaluation, Preclinical; Hydralazine; Hydrochlorothiazide; | 1985 |
'Bell's palsy' in accelerated hypertension.
Topics: Adult; Drug Therapy, Combination; Facial Paralysis; Female; Furosemide; Humans; Hydrochlorothiazide; | 1985 |
[Prevention of hypokalemia in the diuretic treatment of hypertensives].
Topics: Aged; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Hypok | 1985 |
Antihypertensive effect of riboflavin analogues in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Flavins; Hydrochlorothiazide; Hypertension; Male; Min | 1985 |
[Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide].
Topics: Adult; Blood Pressure; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; | 1985 |
Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial.
Topics: Adult; Blood Pressure; California; Chlorthalidone; Coronary Disease; Diet; Epidemiologic Methods; Hu | 1985 |
Experimental analysis of adherence counseling: implications for hypertension management.
Topics: Adult; Behavior Therapy; Blood Pressure; Body Weight; Counseling; Follow-Up Studies; Humans; Hydroch | 1985 |
Na+-K+ cotransport and hypertension. Effect of piretanide and hydrochlorothiazide on red blood cell sodium concentration in acutely salt-loaded hypertensive and normotensive rats.
Topics: Animals; Biological Transport; Diuretics; Erythrocytes; Hydrochlorothiazide; Hypertension; Male; Pot | 1985 |
The myth of long-term thiazide-induced magnesium deficiency.
Topics: Bone and Bones; Erythrocytes; Humans; Hydrochlorothiazide; Hypertension; Kidney Calculi; Lymphocytes | 1985 |
[Hypertension in the elderly].
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochloroth | 1985 |
Post-exertion changes in left ventricular systolic time intervals in patients with primary hypertension treated with hydrochlorothiazide, binazine, and propranolol.
Topics: Adult; Aged; Female; Heart Ventricles; Humans; Hydrazines; Hydrochlorothiazide; Hypertension; Male; | 1985 |
Results of treatment of hypertension.
Topics: Acute Kidney Injury; Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Female; Hum | 1971 |
Which diuretic for hypertension?
Topics: Blood Pressure Determination; Diuretics; Furosemide; Humans; Hydrochlorothiazide; Hypertension | 1972 |
Acute submassive hepatic necrosis due to methyldopa. A case demonstrating possible initiation of chronic liver disease.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biopsy, Needle; Chemical and Drug Induced Liver I | 1974 |
The effect of prolonged thiazide administration on thyroid function.
Topics: Blood Proteins; Electrolytes; Humans; Hydrochlorothiazide; Hypertension; Iodine; Iodine Radioisotope | 1967 |
When a drug is the culprit.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clofibrate; Depression; Drug-Related Side Effect | 1973 |
Myocardial infarction after exercise-induced electrocardiographic changes in a patient with variant angina pectoris.
Topics: Amitriptyline; Angina Pectoris; Arteriosclerosis; Catheterization; Diabetes Complications; Electroca | 1974 |
Arterial hypertension--northwest Florida public health survey. II. Diagnosis and treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Chlorothiazide; Diuretics | 1974 |
Hormone influenced hypertension in the male rat. Effect of hydrochlorothiazide.
Topics: 5-Hydroxytryptophan; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Ce | 1969 |
[Initial results of the activity of the Angiocardiological Center in Kolomna].
Topics: Adolescent; Adult; Coronary Disease; Diabetes Complications; Female; Heparin; Humans; Hydrochlorothi | 1971 |
A clinical study of Co-hydroDiuril a combination of an antikaliuretic (amiloride) and hydrochlorothiazide.
Topics: Adult; Aged; Amiloride; Blood Pressure; Blood Urea Nitrogen; Body Weight; Diuretics; Drug Combinatio | 1972 |
The vascular reactivity to vasoactive substances and the electrolyte contents in arterial walls.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Arteries; Blood Pressure; Carbon Tetrachloride | 1965 |
Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Female; Humans; Hydrochlorothiazide; Hypertens | 1968 |
Transitory primary aldosteronism-like condition.
Topics: Aged; Angiotensin II; Chlorides; Diuretics; Female; Heart Diseases; Humans; Hydrochlorothiazide; Hyp | 1968 |
[Study on the renin-angiotensin-aldosterone system. Effects of sodium restriction and postural changes on plasma renin activity and fluctuation in urinary aldosterone].
Topics: Aldosterone; Angiotensin II; Blood Pressure; Chromatography, Thin Layer; Diet, Sodium-Restricted; Hu | 1969 |
Responses of mean arterial pressure to pressor agents and diuretics in renal hypertensive and salt hypertensive rats.
Topics: Anesthesia, General; Angiotensin II; Animals; Arteries; Autonomic Nerve Block; Blood Pressure; Desox | 1971 |
Low renin hypertension and the adrenal cortex.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aldosterone; Angiotensin II; Blood Pressure; Cor | 1972 |
Effects of two anti-hypertensive drugs.
Topics: Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1966 |
[Use, association and contraindications of hypotensive drugs].
Topics: Antihypertensive Agents; Blood Pressure; Coronary Disease; Diuretics; Furosemide; Ganglionic Blocker | 1969 |
Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Body Weight; Cardiac Output; Female; Fu | 1972 |
Beta-blocking therapy: Propranolol.
Topics: Cardiac Output; Central Nervous System; Drug Therapy, Combination; Furosemide; Humans; Hydralazine; | 1974 |
Office management of hypertension.
Topics: Adult; Aged; Ambulatory Care; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Guan | 1974 |
[Thiazide saluretics and glucose tolerance in patients with hypertension].
Topics: Blood Glucose; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Potassium Chloride | 1974 |
Red blood cell potassium as a measure of body potassium in thiazide-treated patients with essential hypertension.
Topics: Depression, Chemical; Drug Therapy, Combination; Erythrocytes; Female; Hematocrit; Humans; Hydrochlo | 1974 |
Practical office management of chronic hypertension.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Guanethidine; Humans; Hydralazine; Hydrochloroth | 1974 |
Plasma aldosterone in essential hypertension with low renin activity.
Topics: Aldosterone; Body Weight; Corticosterone; Cushing Syndrome; Furosemide; Humans; Hydrochlorothiazide; | 1974 |
Tolerance and side-effects of the association hydrochlorothiazide-amiloride in long-term treatment of arterial hypertension.
Topics: Adult; Aged; Amiloride; Calcium; Creatinine; Drug Combinations; Drug Tolerance; Humans; Hydrochlorot | 1974 |
[Guanethidine-hydrochlorothiazide combination in the treatment of arterial hypertension].
Topics: Adult; Aged; Drug Combinations; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Mal | 1974 |
[Treatment of arterial hypertension with the hypotensive agent LA-313 B].
Topics: Adult; Aged; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middl | 1974 |
[Effects of combined treatment with hydrochlorothiazide and oxprenolol on arterial pressure and activity of plasma renin. Preliminary results].
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; H | 1974 |
[Effects of spironolactone and hydrochlorothiazide on blood pressure levels and blood potassium. Controlled studies on hypertensive patients].
Topics: Adult; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassi | 1974 |
The use of parameters-following in a therapeutics course.
Topics: Curriculum; Education, Pharmacy, Graduate; Humans; Hydrochlorothiazide; Hypertension; Methyldopa; Mo | 1974 |
Some aspects of the use of Moduretic in the treatment of patients with mild hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Diuretics; Female; Humans; Hydrochlorothiazide; Hyp | 1973 |
[Changes of cardiac output in the treatment with saluretics].
Topics: Blood Volume Determination; Cardiac Output; Cardiac Volume; Clopamide; Dye Dilution Technique; Furos | 1973 |
[Is essential hypertension still a disease entity? Definition of hyporeninemic hypertension].
Topics: Aldosterone; Amiloride; Chlorthalidone; Diagnosis, Differential; Drug Combinations; Humans; Hydrochl | 1974 |
Effect of hydrochlorothiazide on +G Z tolerance in normotensives.
Topics: Adaptation, Physiological; Aerospace Medicine; Canada; Gravitation; Heart Rate; Humans; Hydrochlorot | 1972 |
The effect of triamterene on plasma and extracellular fluid volume and blood pressure in ten thiazide-treated hypokalemic patients with essential hypertension.
Topics: Adult; Blood Pressure; Blood Volume; Drug Interactions; Extracellular Space; Female; Humans; Hydroch | 1972 |
[Therapy of arterial hypertension using a drug combination. Clinical and pharmacological considerations].
Topics: Adult; Drug Combinations; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1972 |
Clinical efficacy of fixed combinations of saluretic agents and potassium in sustained release form for the treatment of arterial hypertension.
Topics: Blood Pressure; Chlorides; Chlorthalidone; Creatinine; Delayed-Action Preparations; Drug Combination | 1972 |
Similar effects of hydrochlorothiazide and spironolactone on plasma renin activity in essential hypertension.
Topics: Adult; Blood Pressure; Blood Volume; Evaluation Studies as Topic; Humans; Hydrochlorothiazide; Hyper | 1972 |
[Diuretic treatment of arterial hypertension. Value of potassium sparing].
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Diuretics; Female; Humans; Hydrochlorothiazide; Hyp | 1972 |
[Use of alpha-methyldopa and alpha-methyldopa combined with hydrochlorothiazide in hypertensive patients in ambulatory treatment: comparative study].
Topics: Ambulatory Care; Blood Pressure; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; | 1972 |
[Antihypertensive agents].
Topics: Acetazolamide; Antihypertensive Agents; Bis-Trimethylammonium Compounds; Bretylium Compounds; Chlori | 1972 |
Methyldopa-hydrochlorothiazide therapy in hypertensive geriatric patients.
Topics: Aged; Blood Pressure; Coombs Test; Diabetic Nephropathies; Drug Combinations; Female; Hemoglobinomet | 1973 |
Severe allergic pneumonitis from hydrochlorothiazide.
Topics: Acute Disease; Adult; Drug Hypersensitivity; Humans; Hydrochlorothiazide; Hypertension; Male; Pneumo | 1973 |
Minoxidil in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Evaluation Studies as Topic; Female; Follow-Up Studi | 1973 |
Problems in therapy for the hypertensive patient.
Topics: Antihypertensive Agents; Blood Pressure; Carotid Sinus; Diuretics; Electric Stimulation; Ethacrynic | 1973 |
How to treat arterial hypertension.
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Cooperative Behavior; Diazoxide; Diuretics; | 1973 |
Volume-dependent essential and steroid hypertension.
Topics: Adult; Aged; Aldosterone; Diet, Sodium-Restricted; Female; Follow-Up Studies; Humans; Hydrochlorothi | 1973 |
Human serum dopamine- -hydroxylase. Relationship to hypertension and sympathetic activity.
Topics: Adrenal Gland Neoplasms; Adult; Amphetamine; Blood Flow Velocity; Blood Pressure; Dopamine beta-Hydr | 1973 |
[Therapy of EPH gestosis].
Topics: Chlorthalidone; Diazepam; Diet Therapy; Eclampsia; Edema; Female; Furosemide; Guanethidine; Humans; | 1973 |
[Evaluation of antihypertensive therapy with Adelphan-Esidrex by clinical and psychometric parameters].
Topics: Adult; Aged; Blood Pressure; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothiazide; Hy | 1973 |
Drug failure in reducing pressor effect of isometric handgrip stress test in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Electrocardiogra | 1973 |
A comparison of moduretic and hydrochlorothiazide in the treatment of hypertension in African patients.
Topics: Adult; Aged; Amiloride; Blood Pressure; Diuretics; Electrolytes; Female; Humans; Hydrochlorothiazide | 1973 |
Evaluation of amiloride combined with hydrochlorothiazide (Moduretic) in the treatment of hypertension.
Topics: Adult; Aged; Amiloride; Benzothiadiazines; Diuretics; Drug Combinations; Female; Guanethidine; Human | 1973 |
[Electrolyte metabolism in patients with hypertensive disease treated with hyparez].
Topics: Adult; Aged; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothi | 1973 |
Recurrent parathyroid adenoma. Association with prolonged thiazide administration.
Topics: Adenoma; Calcium; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Neoplasm Recurrence, | 1973 |
Fluorescein circulation time and the treatment of hypertension in the aged.
Topics: Adult; Age Factors; Aged; Blood Circulation Time; Blood Pressure; Carbamates; Ethacrynic Acid; Femal | 1973 |
Serum calcium and phosphorus in patients treated with thiazides and furosemide.
Topics: Adult; Aged; Calcium; Chlorothiazide; Depression, Chemical; Female; Furosemide; Heart Failure; Human | 1973 |
[Active and passive long-term therapy of hypertension with special reference to complex drug therapy and new ways of ambulatory care].
Topics: Cardanolides; Health Education; Heterocyclic Compounds; Humans; Hydrochlorothiazide; Hypertension; O | 1973 |
[Change in the blood and urine content of calcium, magnesium and inorganic phosphorus in hypertension during treatment with hypothiazide and magnesium sulfate].
Topics: Adult; Calcium; Humans; Hydrochlorothiazide; Hypertension; Magnesium; Magnesium Sulfate; Middle Aged | 1973 |
[Pharmacological studies on diuretics. 6. Actions of various diuretics on experimental nephrotic rats].
Topics: Acetazolamide; Aminophylline; Animals; Diuresis; Diuretics; Ethacrynic Acid; Furosemide; Glycosides; | 1973 |
Scotoma due to arterial hypotension.
Topics: Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Male; Middle Aged; Scotoma; Sy | 1973 |
Hypertension: challenge in preventive medicine.
Topics: Aged; Aneurysm; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therap | 1973 |
[Apparent cure of arterial hypertension].
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Female; Guanethidine; Humans; Hydrochlorothiazide | 1974 |
[Combination therapy in the treatment of hypertension; possibilities and limitations].
Topics: Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Minoxidil; Propanil; Synapses | 1974 |
[Exchangeable sodium, total-body potassium, plasma volume, and hypotensive effect of various diuretics in patients with essential hypertension and low plasma renin level (author's transl)].
Topics: Adolescent; Adult; Amiloride; Blood Pressure; Blood Volume; Body Surface Area; Diuretics; Female; Hu | 1974 |
Propranalol--hydrochlorothiazide in systemic hypertension.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1974 |
[Respective roles of hemodynamic or humoral factors and of hypotensive or salidiuretic drugs in the development of essential hypertension].
Topics: Adult; Chlorthalidone; Diet, Sodium-Restricted; Electrocardiography; Guanethidine; Humans; Hydrochlo | 1965 |
Treatment of hypertension with Ser-Ap-Es.
Topics: Adult; Aged; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Rese | 1967 |
Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide.
Topics: Adult; Extracellular Space; Female; Follow-Up Studies; Hematocrit; Humans; Hydrochlorothiazide; Hype | 1970 |
A gastrointestinal problem.
Topics: Abdomen; Humans; Hydrochlorothiazide; Hypertension; Ileum; Intestinal Diseases; Intestinal Obstructi | 1972 |
Muscle and red cell electrolytes in essential hypertension; correlation with digital vascular reactivity; the effects of hydrochlorothiazide.
Topics: Biopsy; Blood Pressure; Blood Vessels; Calorimetry; Chlorides; Erythrocytes; Fingers; Humans; Hydroc | 1972 |
[Origin and treatment of arterial hypertension in middle and old age].
Topics: Aged; Benzimidazoles; Coronary Disease; Humans; Hydrochlorothiazide; Hypertension; Intracranial Arte | 1972 |
[Treatment of arterial hypertension in general medicine].
Topics: Adult; Age Factors; Aged; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1972 |
[The state of the coagulation and anticoagulation systems of the blood in patients undergoing hypothiazide treatment for hypertension].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1972 |
Dependence of arterial pressure on intravascular volume in treated hypertensive patients.
Topics: Adult; Aged; Arteries; Blood Pressure; Female; Furosemide; Guanethidine; Humans; Hydrazines; Hydroch | 1972 |
[Diuretics. 5. Effects of single or combined administration of diuretics in normal or spontaneously hypertensive rats].
Topics: Acetazolamide; Aminophylline; Animals; Chlorides; Diuretics; Drug Synergism; Hydrochlorothiazide; Hy | 1972 |
Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clonidine; District of Columbia; Diuretics; Female; Fol | 1972 |
Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity.
Topics: Adult; Blood Pressure; Body Weight; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1972 |
[Functional condition of the adrenal cortex in hypertensive disease during treatment].
Topics: Adrenal Glands; Benzimidazoles; Chlorpromazine; Humans; Hydrochlorothiazide; Hypertension; Parasympa | 1972 |
[Hemodynamic changes in hypertensive disease during treatment with isobarin and hypothiazide].
Topics: Guanethidine; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension | 1972 |
[Treatment of essential and nephrogenic hypertension using alpha-methyldopa and alpha-methyldopa+hydrochlorothiazide. Comparative study].
Topics: Administration, Oral; Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertension, | 1971 |
Committee on Maternal Welfare. Staphylococcal bronchopneumonia.
Topics: Bronchopneumonia; Female; Humans; Hydrochlorothiazide; Hypertension; Pregnancy; Pregnancy Complicati | 1971 |
Influence of diuretics and diazoxide on ions and vascular reactivity in normotensive and spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium; Diazoxide; Ethacrynic Acid; Furosemide; Hematocrit; Hydrochlorothi | 1971 |
Effects of hydrochlorothiazide, furosemide and ethacrynic acid on pinealectomy-induced hypertension in rats.
Topics: Aldosterone; Animals; Blood Pressure; Ethacrynic Acid; Furosemide; Hydrochlorothiazide; Hypertension | 1971 |
[Use of thiazides in treating patients with hypertension accompanied by neurological disorders].
Topics: Humans; Hydrochlorothiazide; Hypertension; Nervous System Diseases | 1971 |
[Evaluation of the antihypertensive action of methyldopa alone or in combination with hydrochlorothiazide].
Topics: Administration, Oral; Adult; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Female; Hum | 1971 |
Hypertension and oral contraception.
Topics: Adolescent; Adult; Blood Pressure; Blood Pressure Determination; Contraceptives, Oral; Estrogens; Fe | 1971 |
[On experience in organizing the mass detection and treatment of hypertensive patients at industrial plants of Moscow].
Topics: Female; Humans; Hydrochlorothiazide; Hypertension; Male; Occupational Medicine; Reserpine | 1967 |
Treatment of hypertension with combination therapy.
Topics: Adult; Aged; Drug Compounding; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male | 1967 |
Drug-induced hyperuricemia prevented by probenecid.
Topics: Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Probenecid; | 1971 |
[Combined hormone treatment in arterial hypertension].
Topics: Adult; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Testosterone | 1967 |
Clinical evaluations of a combined application of amiloride (MK-870) and thiazide.
Topics: Adult; Blood Pressure; Diuretics; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; | 1969 |
Treatment of hypertension with hydrochlorothiazide and spironolactone.
Topics: Blood Pressure; Blood Urea Nitrogen; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Potass | 1969 |
[Maximum consumption of oxygen and work capacity in patients with essential arterial hypertension after treatment].
Topics: Adolescent; Adult; Disability Evaluation; Exercise Test; Female; Heart; Humans; Hydralazine; Hydroch | 1969 |
Suppressed plasma renin activity in in hypertensive patients--its evaluation for the diagnosis of primary aldosteronism.
Topics: Aldosterone; Cushing Syndrome; Diet, Sodium-Restricted; Glomerulonephritis; Humans; Hydrochlorothiaz | 1969 |
[Effect of hypothiazide on carbohydrate metabolism in patients with diabetes mellitus and hypertension].
Topics: Carbohydrate Metabolism; Diabetes Complications; Humans; Hydrochlorothiazide; Hypertension | 1969 |
Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide.
Topics: Adult; Aged; Blood Volume; Body Weight; Chromium Isotopes; Extracellular Space; Female; Guanethidine | 1969 |
[Ismelin and depressin in the treatment of patients with hypertension].
Topics: Benzimidazoles; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Parasympatholytics; Pentoba | 1969 |
[Arterial pressure changes in patients with essential hypertension following a long-term, continuous administration of dihydrochlorothiazide].
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1969 |
Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration.
Topics: Adult; Antihypertensive Agents; Calcium; Chlorothiazide; Female; Humans; Hydrochlorothiazide; Hyperp | 1969 |
[Effect of Hypothiazide on the phase structure of heart contraction in patients with hypertension].
Topics: Adult; Aged; Electrocardiography; Heart; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Mus | 1969 |
[Relationship between hypotensive and diuretic-saluretic action of hypothiazide in patients with hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Chlorides; Diuresis; Humans; Hydrochlorothiazide; Hypertension | 1969 |
[Study of habituation during long-term antihypertension therapy].
Topics: Drug Synergism; Drug Tolerance; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Mal | 1969 |
[Hyperparathyroidism caused by thiazides].
Topics: Antihypertensive Agents; Chlorothiazide; Humans; Hydrochlorothiazide; Hyperparathyroidism; Hypertens | 1970 |
Debrisoquin in the therapy of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Quinol | 1970 |
Report of the panels on cardiovascular drugs from the drug efficacy study.
Topics: Angina Pectoris; Cardiovascular Diseases; Chlorothiazide; Digitalis Glycosides; Drug Industry; Drug | 1970 |
[Clinical trial of the hypotensive action of the association of furosemide and reserpine].
Topics: Adult; Aged; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Reser | 1970 |
[Anti-hypertensive therapy in geriatrics].
Topics: Age Factors; Aged; Antihypertensive Agents; Carbamates; Drug Synergism; Female; Humans; Hydrazines; | 1970 |
[Changes in plasma and extracellular volume during long-term hydrochlorthiazide treatment of patients with essential hypertension].
Topics: Adult; Extracellular Space; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Pl | 1970 |
[Some aspects of renal metabolism of citric acid].
Topics: Adult; Age Factors; Aged; Chlorthalidone; Citrates; Heart Failure; Humans; Hydrochlorothiazide; Hype | 1970 |
[Saluretic-diuretic and hypotensive effect of hypothiazide in hypertension].
Topics: Adult; Aged; Diuretics; Electrolytes; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Natriu | 1970 |
[Vascular responses to noradrenaline in patients with essential hypertension].
Topics: Blood Flow Velocity; Blood Pressure; Blood Vessels; Female; Heart Rate; Humans; Hydrochlorothiazide; | 1970 |
[Plasma renin activity in hypertensive and non-hypertensive patients and its clinical significance].
Topics: Addison Disease; Adolescent; Adult; Aged; Aortic Diseases; Biological Assay; Blood Pressure; Blood U | 1970 |
Thiazide-induced hypercalcemia.
Topics: Adult; Blood Proteins; Calcium; Humans; Hydrochlorothiazide; Hypercalcemia; Hypertension; Male; Phos | 1971 |
[Effect of hypothiazide and reserpine on the intracellular and extracellular potassium and sodium correlation during the treatment of hypertensive disease].
Topics: Adult; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Potassium; R | 1971 |
Relationship of sodium and potassium intake to blood pressure.
Topics: Blood Pressure; Body Weight; Edema; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Potassiu | 1971 |
[Circulating blood volume in patients treated for a long time with hydrochlorothiazide].
Topics: Adult; Aged; Blood Volume Determination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mi | 1967 |
[Results of combined therapy (Adelphan-Esidrix and Ismelin) in severe hypertension].
Topics: Antihypertensive Agents; Drug Synergism; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; Hyp | 1967 |
[The inhibitory effect of phenylbutazone on lowered blood pressure produced by antihypertensives in hypertensive patients].
Topics: Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Phenylbutazone | 1967 |
[On the problem of the effect of hypothiazide on the potassium content of blood plasma in patients with hypertension].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Male; Middle Aged; Wate | 1967 |
[The effect of hypothiazide on the electrolyte metabolism of patients with hypertension].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Water-Electrolyte | 1967 |
[Comparative evaluation of hypotensive effect of ismelin and thiazides in the patients with hypertension].
Topics: Adult; Antihypertensive Agents; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Mal | 1967 |
[Effect of depression on temporal arterial pressure in hypertension].
Topics: Adult; Benzimidazoles; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Midd | 1967 |
[Fibrinolysis in patients with hypertension before and after therapy].
Topics: Adolescent; Adult; Aged; Benzimidazoles; Fibrinolysis; Humans; Hydrochlorothiazide; Hypertension; Mi | 1967 |
[Hypotensive effect of the association of hydrochlorothiazide and ethacrynic acid. Study of the relations between sodium depletion and blood pressure levels].
Topics: Diet, Sodium-Restricted; Ethacrynic Acid; Humans; Hydrochlorothiazide; Hypertension | 1967 |
[Clinical trial of L652 in the treatment of arterial hypertension: 50 cases].
Topics: Diuretics; Drug Synergism; Ethylamines; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1967 |
[Experiences with the treatment of hypertension with a combination of guanethidine and hydrochlorothiazide (Esimil)].
Topics: Adult; Drug Synergism; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; | 1967 |
Further evaluation of the tyramine test for pheochromocytoma.
Topics: Adult; Catecholamines; Diagnosis, Differential; Female; Glucagon; Histamine; Humans; Hydrochlorothia | 1968 |
[Polythiazide and hypothiazide with reserpine in treatment of arterial hypertension].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Polythiazide; Res | 1968 |
Influence of hydrochlorothiazide on fluid consumption, blood pressure, and organ changes in rats subjected to hypersalimentation or augmented hypersalimentation.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drinking; Hydrochlorothiazide; Hypertension; Hyper | 1968 |
[Results of hypotensive treatment in a hospital environment].
Topics: Adult; Aged; Arteriosclerosis; Carbamates; Female; Humans; Hydralazine; Hydrochlorothiazide; Hyperte | 1968 |
Management of severe hypertension with a combination of Adelphane-Esidrex and guanethidine sulphate (Ismelin).
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Female; Guanethidine; Humans; Hydralazine; Hydroch | 1968 |
[Effect of triamterene on serum potassium and serum creatinine in long-term treatment with thiazides].
Topics: Creatinine; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Polythiazide; Potassium; Triamte | 1968 |
Hydrochlorothiazide in the treatment of hypertension. The effects on blood volume, exchangeable sodium and blood pressure.
Topics: Aged; Albumins; Blood Pressure; Blood Pressure Determination; Blood Volume; Blood Volume Determinati | 1968 |
[Course of hypertension and temporary disability while undergoing a course of hypotensive therapy conducted without interruption of work].
Topics: Adult; Aged; Ambulatory Care; Disability Evaluation; Female; Humans; Hydrochlorothiazide; Hypertensi | 1968 |
[Treatment of hypertensive patients with Isobarin in combination with hypothiazide].
Topics: Adult; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 1968 |
Amelioration of high blood pressure in the elderly.
Topics: Age Factors; Aged; Animals; Antihypertensive Agents; Chlorothiazide; Female; Humans; Hydrochlorothia | 1968 |
[Case of primary aldosteronism--considerations on the thiazide screening test].
Topics: Adrenal Gland Neoplasms; Electrocardiography; Humans; Hydrochlorothiazide; Hyperaldosteronism; Hyper | 1968 |
The role of catecholamines in circulatory regulation on the chronic congestive heart failure. Clinical study of the urinary catecholamine excretion in the patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathies; Catecholamines; Coronary Disease; Digital | 1968 |
[Isobarin (ismelin) in combination with depressin and pyrilene in the treatment of hypertensive states].
Topics: Adult; Benzimidazoles; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male; Middle | 1968 |
[The level of sodium in blood plasma and urine in patients with hypertension during therapy with hypothiazide].
Topics: Adult; Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Natriuresis; Sodi | 1968 |
[On therapy with Triampur compositum].
Topics: Blood Urea Nitrogen; Drug Synergism; Humans; Hydrochlorothiazide; Hypertension; Potassium; Sodium; T | 1968 |
[The influence of hydrochlorothiazide on various serum kations and their excretion in essential hypertension].
Topics: Adult; Alkaline Phosphatase; Calcium; Copper; Electrolytes; Enzymes; Female; Humans; Hydrochlorothia | 1968 |
[Effect of hypotensive substances (hypothiazide, guanetidine, alpha-methyldopa) on basic hemodynamic indices].
Topics: Blood Pressure; Blood Volume; Cardiac Output; Cardiovascular System; Guanethidine; Hematocrit; Hemod | 1968 |
Thiazide treatment in pregnancy with special reference to maternal and foetal electrolytes.
Topics: Adolescent; Adult; Blood Chemical Analysis; Chlorides; Diuretics; Edema; Female; Humans; Hydrochloro | 1968 |
[Changes in external respiration in patients with hypertensive disease under the influence of treatment].
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Female; Humans; Hydrochlorothiazide; Hypertension; M | 1968 |
[Effect of depression on the arterial pressure in the central retinal artery in patients with hypertensive disease].
Topics: Antihypertensive Agents; Benzimidazoles; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Pa | 1968 |
[Hemodynamics changes during treatment of hypertensive patients with reserpine and Depressin].
Topics: Adult; Aged; Ballistocardiography; Benzimidazoles; Blood Pressure; Cardiac Output; Electrocardiograp | 1968 |
[Objectives and methods in therapy of essential arterial hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Ethacrynic Acid; Guanethidine; Humans; Hydralazi | 1968 |
[Results obtained in the treament of arterial hypertension b the alpha-methyl-dopa with hydrochlorothiazide combination].
Topics: Adolescent; Adult; Aged; Dihydroxyphenylalanine; Humans; Hydrochlorothiazide; Hypertension; Middle A | 1968 |
[Considerations on ambulatory therapy in a group of hypertensive patients].
Topics: Adult; Aged; Ambulatory Care; Carbamates; Female; Guanethidine; Humans; Hydralazine; Hydrochlorothia | 1969 |
Potassium loss with thiazide therapy.
Topics: Aldosterone; Blood Gas Analysis; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Natriuresi | 1969 |
Essential hypertension--effective therapy in private practice.
Topics: Adult; Aged; Antihypertensive Agents; Drug Synergism; Female; Humans; Hydralazine; Hydrochlorothiazi | 1969 |
Evaluation of the hypotensive effect of beta-adrenergic blockade in hypertension.
Topics: Adult; Aged; Amino Alcohols; Cardiac Output; Dyspnea; Female; Humans; Hydrochlorothiazide; Hypertens | 1969 |
Hypotensive drug therapy in the management of hypertension.
Topics: Antihypertensive Agents; Guanethidine; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Methy | 1969 |
Venous distensibility in essential hypertension.
Topics: Adult; Female; Forearm; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; M | 1969 |
Thiazide-induced parathyroid stimulation.
Topics: Animals; Dogs; Hydrochlorothiazide; Hypercalcemia; Hypertension; Male; Organ Size; Parathyroid Gland | 1969 |
[Studies on uric acid metabolism disorders following administration of saluretics].
Topics: Chlorothiazide; Chlorthalidone; Ethacrynic Acid; Furosemide; Humans; Hydrochlorothiazide; Hydroflume | 1965 |
[Hypotensive activity of alpha-methyl-dopa alone and combined with dihydrochloro-thiazide].
Topics: Adult; Aged; Arteriosclerosis; Drug Synergism; Female; Humans; Hydrochlorothiazide; Hypertension; Ma | 1965 |
[Changes in renal hemodynamics and mineral metabolism following the administration of hydrochlorothiazide in normotensive and hypertensive persons].
Topics: Humans; Hydrochlorothiazide; Hypertension; Kidney; Renal Artery; Water-Electrolyte Balance | 1965 |
Effect of adelphane and esidrex on the maximum daily dose of ismelin.
Topics: Adult; Antihypertensive Agents; Female; Guanethidine; Humans; Hydrochlorothiazide; Hypertension; Mal | 1965 |
[The detection and supervision of patients suffering from hypertension in a rural practice].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Female; Humans; Hungary; Hydrochlorothiazide; Hype | 1965 |
[The physical capacity of hypertensive subjects before and after antihypertension therapy].
Topics: Antihypertensive Agents; Disability Evaluation; Diuretics; Female; Humans; Hydrochlorothiazide; Hype | 1965 |
[Hemodynamic changes in depressin treatment of reserpine-resistant forms of arterial hypertension].
Topics: Adult; Benzimidazoles; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Parasym | 1965 |
[Effects of the prolonged administration of triamterene in arterial hypertensive patients].
Topics: Humans; Hydrochlorothiazide; Hypertension; Triamterene | 1963 |
[Modifications of blood uric acid and urinary uric acid induced by treatment with hydrochlorothiazide in aged subjects].
Topics: Aged; Blood; Heart Diseases; Humans; Hydrochlorothiazide; Hypertension; In Vitro Techniques; Uric Ac | 1965 |
Method for the evaluation of antihypertensive agents, including thiazide-type compounds.
Topics: Animals; Antihypertensive Agents; Chemistry, Pharmaceutical; Dogs; Hydrochlorothiazide; Hypertension | 1965 |
[Problems of essential hypertension].
Topics: Blood Circulation; Blood Pressure Determination; Blood Vessels; Diet, Sodium-Restricted; Germany, Ea | 1965 |
[Clinical trials of a new antihypertensive drug association in aged subjects. Behavior of the electrolyte pattern].
Topics: Aged; Carbamates; Electrolytes; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Potassium Ch | 1966 |
Relation between potassium balance and aldosterone secretion in normal subjects and in patients with hypertensive or renal tubular disease.
Topics: Acidosis, Renal Tubular; Adrenal Gland Neoplasms; Adult; Aldosterone; Ethacrynic Acid; Female; Human | 1966 |
[Thiazide diuretics and changes in carbohydrate metabolism. Clinical study of 30 cases].
Topics: Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Glucose Tolerance Test; Humans; Hydrochlo | 1966 |
Effects of MK-870 in normal subjects and hypertensive patients.
Topics: Adult; Aged; Amidines; Blood Urea Nitrogen; Creatine; Diuretics; Humans; Hydrochlorothiazide; Hypert | 1966 |
Drug therapy in hypertension.
Topics: Humans; Hydrochlorothiazide; Hypertension; Reserpine | 1966 |
[Treatment of arterial hypertension with an alpha-methyldopa-hydrochlorothiazide combination].
Topics: Adolescent; Adult; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Middle Aged | 1966 |
A comparative clinical study of hydrochlorothiazide and chlorthalidone in oedema states.
Topics: Adolescent; Adult; Chlorthalidone; Edema; Female; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1966 |
[Geriatric contribution to the treatment of hypertension (excluding reserpine)].
Topics: Aged; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Phytotherapy; Plants, Medicinal; Pota | 1966 |
Drug control of diuretic-induced hyperuricemia.
Topics: Blood; Chlorothiazide; Humans; Hydrochlorothiazide; Hypertension; Probenecid; Sulfonamides; Uric Aci | 1966 |
Prevention and reversal of adrenal-regeneration hypertension with hydrochlorothiazide.
Topics: Adrenal Glands; Adrenalectomy; Animals; Female; Hydrochlorothiazide; Hypertension; Nephrectomy; Orga | 1966 |
The drug management of mild hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1966 |
[The treatment of hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Child; Child, Preschool; Coronar | 1966 |
[Primary hyperaldosteronism (Conn's syndrome)].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Diet; Female; Humans; Hydrochlorothiazide; Hyperaldosteronis | 1966 |
[Phase analysis of heart action in patients with hypertension during treatment with Depressin].
Topics: Adult; Aged; Benzimidazoles; Electrocardiography; Heart; Humans; Hydrochlorothiazide; Hypertension; | 1966 |
[On the antihypertensive activity of some drugs alone or in various associations].
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Carbamates; Female; Humans; Hydrazines; Hydr | 1966 |